<SEC-DOCUMENT>0001654954-17-011495.txt : 20171211
<SEC-HEADER>0001654954-17-011495.hdr.sgml : 20171211
<ACCEPTANCE-DATETIME>20171211163619
ACCESSION NUMBER:		0001654954-17-011495
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20171211
DATE AS OF CHANGE:		20171211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		171249876

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>cvm_10k.htm
<DESCRIPTION>AMENDMENT NO. 2 ON FORM 10-K
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%; height: 8px; border-top: solid 4px #000000; border-bottom: 1px solid #000000"><!--style header--><br></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"> <font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">FORM
10-K/A</font> </div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px;">(Amendment
2)<br></font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">SECURITIES AND
EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Washington, D.C.
20549</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Mark
One)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(X)&#xA0;&#xA0;</font><font style="font-size: 13px; font-family: Times New Roman">ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For the fiscal year
ended September 30, 2016.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">OR</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(&#xA0;&#xA0;)</font>
<font style="font-size: 13px; font-family: Times New Roman">TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For the transition
period from _________ to __________.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Commission file
number 1-11889</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: auto; margin-right: auto;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; margin-left: auto; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td colspan="3" style="text-indent: 0px; width: 95%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
</td>
</tr><tr>
<td colspan="3" style="text-indent: 0px; width: 95%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Exact name of
registrant as specified in its charter)</font></div>
</td>
</tr><tr>
<td colspan="3" style="width: 95%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">COLORADO</font></div>
</td>
<td style="width: 5%; padding-bottom: 2px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">84-0916344<font id="TAB2" style="letter-spacing: 3pt; color: black">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(State or other
jurisdiction of incorporation or organization)</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(I.R.S. Employer
Identification No.)</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">8229 Boone Blvd.,
Suite 802</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Vienna,
Virginia</font></div>
</td>
<td style="width: 5%; padding-bottom: 2px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">22182</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Address of
principal executive offices)</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Zip
Code)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Registrant's
telephone number, including area code: (703) 506-9460</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities
registered pursuant to Section 12(b) of the Act: None</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities
registered pursuant to Section 12(g) of the Act:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Common Stock, $.01 par
value</font></font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Series S Warrants</font></font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Title of
Class)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined
in Rule 405 of the Securities
Act.&#xA0;&#xA0;[&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. [&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days.&#xA0;&#xA0;&#xA0;&#xA0;Yes
[X]&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No
[&#xA0;&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (&#xA7;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was
required to submit and post such
files).&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Yes&#xA0;&#xA0;[X]
No&#xA0;&#xA0;[ ]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein,&#xA0;&#xA0;and will not be
contained,&#xA0;&#xA0;to the best of
Registrant's&#xA0;&#xA0;knowledge,&#xA0;&#xA0;in definitive proxy
or information&#xA0;&#xA0;statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K.
[X]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &#x201C;large accelerated
filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller
reporting company&#x201D; in Rule 12b-2 of the Exchange
Act.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Large accelerated
filer&#xA0;&#xA0;[
]&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accelerated
filer&#xA0;&#xA0;[ X]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Non-accelerated
filer&#xA0;&#xA0;[ ]&#xA0;&#xA0;&#xA0;(Do not check if a smaller
reporting
company)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Smaller reporting company&#xA0;&#xA0;[ ]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act):&#xA0;&#xA0;[&#xA0;&#xA0;]
Yes&#xA0;&#xA0;&#xA0;[X] No</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The aggregate
market value of the voting stock held by non-affiliates of the
Registrant, based upon the closing sale price of the
registrant&#x2019;s common stock on March 31, 2016, as quoted on the
NYSE MKT, was $60,807,407.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">As of December 9,
2016, the Registrant had 7,548,976 issued
and outstanding shares of common stock.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Documents
Incorporated by Reference:&#xA0;&#xA0;&#xA0;None</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%; height: 8px; border-top: solid 1px #000000; border-bottom: 4px solid #000000"><!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #ffffff"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">EXPLANATORY
NOTE</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In <font style="color: #000000">October 2008, the Company entered into an
agreement whereby the Company leased a building owned by a third
party. The Company accounted for the arrangement as an operating
lease under ASC 840,</font> <font style="font-style: italic; color: #000000">Accounting for
Leases</font><font style="color: #000000">.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">I</font>n November 2017, the Company <font style="color: #000000">determined that the lease should have been treated
as a financing obligation rather than an operating
lease.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">Accordingly, this amended 10-K is
filed to correct the manner in which the Company accounted for the
lease. See</font> <font style="text-decoration: underline; color: #000000; font-size: 13px">Note
17. Restatement, in the financial statements enclosed
herein,</font> <font style="color: #000000; font-size: 13px">for
further information.</font></font><br></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
addition:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="display: table; margin-left: 72px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"> <font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">&#x25CF;</font>&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">per
share data, including earnings per share amounts, in this amended
10-K have been adjusted to reflect a 1 for 25 reverse stock split
which became effective on the NYSE American on June 15,
2017;</font> </div>
</div>
</div>
<div style="display: table; margin-left: 72px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"> <font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">&#x25CF;</font>&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">management&#x2019;s
report on internal control over financial reporting and its
conclusion on disclosure controls and procedures have been revised
to address the material weaknesses in internal control over
financial reporting; and</font> </div>
</div>
</div>
<div style="display: table; margin-left: 72px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"> <font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">&#x25CF;</font>&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
opinion of BDO USA, LLP on the effectiveness of the Company&#x2019;s
internal control over financial reporting as of September 30, 2016
has been amended.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Except
for the above, no other information included in the 10-K report
filed on December 15, 2016 is amended by this Form
10-K/A.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">PART
I</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
ITEM 1. BUSINESS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI is focused
on finding the best way to activate the immune system to fight
cancer and infectious diseases. Its lead investigational therapy
Multikine&#xAE; (Leukocyte Interleukin, Injection) is currently in
a pivotal Phase 3 clinical trial involving head and neck cancer,
for which CEL-SCI has received Orphan Drug Status from the U.S.
FDA. If the primary endpoint of this global study is achieved, the
results will be used to support applications to regulatory agencies
around the world for worldwide commercial marketing approvals as a
first line cancer therapy. Additional clinical indications for
Multikine include cervical dysplasia in HIV/HPV co-infected women,
for which a Phase 1 study was successfully concluded; and the
treatment of peri-anal warts in HIV/HPV co-infected men and
women.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
immune therapy, Multikine, is being used in a different way than
immune therapy is usually used. It is administered locally to treat
local tumors or infections and it is given before any other therapy
has been administered.<font style="color: #404040">&#xA0;</font>For
example, <font style="color: #404040">i</font>n the Phase 3
clinical trial, Multikine is given locally at the site of the tumor
as a first line of treatment before surgery, radiation and/or
chemotherapy because that is when the immune system is thought to
be strongest. The goal is to help the intact immune system kill the
micro metastases that usually cause recurrence of the cancer. In
short, CEL-SCI believes that local administration and
administration before weakening of the immune system by
chemotherapy and radiation will result in higher efficacy with less
or no toxicity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
focus on HPV is not the development of an antiviral against HPV in
the general population. Instead it is the development of an
immunotherapy to be used in patients who are immune-suppressed by
diseases such as HIV and are therefore less able or unable to
control HPV and its resultant diseases. This group of patients has
no viable treatments available to them and there are, to
CEL-SCI&#x2019;s knowledge, no competitors at the current time. HPV
is also relevant to the head and neck cancer Phase 3 study since it
is now known that HPV is a cause of head and neck cancer. Multikine
was shown to kill HPV in an earlier study of HIV infected women
with cervical dysplasia.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI is also
investigating a different peptide-based immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized
patients and as a vaccine (CEL-2000 and CEL-4000) for Rheumatoid
Arthritis (currently in preclinical testing) using its LEAPS
technology platform. The investigational immunotherapy
LEAPS-H1N1-DC treatment involves non-changing regions of H1N1
Pandemic Flu (www.jci.org/articles/view/67550), Avian Flu (H5N1),
and the Spanish Flu, as CEL-SCI scientists are very concerned about
the possible emergence of a new more virulent hybrid virus through
the combination of H1N1 and Avian Flu, or possibly Spanish
Flu.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI Corporation
was formed as a Colorado corporation in 1983. CEL-SCI&#x2019;s
principal office is located at 8229 Boone Boulevard, Suite 802,
Vienna, VA 22182. CEL-SCI&#x2019;s telephone number is 703-506-9460
and its website is www.cel-sci.com. CEL-SCI does not incorporate
the information on its website into this report, and you should not
consider it part of this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI makes its
electronic filings with the Securities and Exchange Commission
(SEC), including its annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K and amendments to these
reports available on its website free of charge as soon as
practicable after they are filed or furnished to the
SEC.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;S
PRODUCTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI is
dedicated to research and development directed at improving the
treatment of cancer and other diseases by using the immune system,
the body&#x2019;s natural defense system. CEL-SCI is currently
focused on the development of the following product candidates and
technologies:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 60px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px; font-family: Times New Roman">1)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Multikine,
an<font style="color: #57575b">&#xA0;</font>investigational<font style="color: #57575b">&#xA0;</font>immunotherapy under development for
the potential treatment of certain head and neck cancers, and anal
warts or cervical dysplasia in human immunodeficiency virus, or
HIV, and human papillomavirus, or HPV, co-infected
patients;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 60px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px; font-family: Times New Roman">2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology, or LEAPS, with two
investigational therapies, LEAPS-H1N1-DC, a product candidate under
development for the potential treatment of pandemic influenza in
hospitalized patients, and CEL-2000 and CEL-4000, vaccine product
candidates under development for the potential treatment of
rheumatoid arthritis.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following chart
depicts our product candidates, their indications and their current
stage of development:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_10k000.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
MULTIKINE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
lead investigational therapy, Multikine, is currently being
developed as a potential therapeutic agent directed at using the
immune system to produce an anti-tumor immune response. Data from
Phase 1 and Phase 2 clinical trials suggest that Multikine
simulates the activities of a healthy person&#x2019;s immune system,
enabling it to use the body&#x2019;s own anti-tumor immune response.
Multikine is the trademark that CEL-SCI has registered for this
investigational therapy, and this proprietary name is subject to
review by the U.S. Food and Drug Administration, or FDA, in
connection with CEL-SCI&#x2019;s future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved for sale, barter or exchange by the FDA or any other
regulatory agency, such as the European Medicine Agency, or EMA.
Neither has its safety or efficacy been established for any
use.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Multikine is an
immunotherapy product candidate comprised of a patented defined
mixture of 14 human natural cytokines and is manufactured in a
proprietary manner in CEL-SCI&#x2019;s manufacturing facility.
CEL-SCI spent over 10 years and more than $80 million developing
and validating the manufacturing process for Multikine. The
pro-inflammatory cytokine mixture includes interleukins,
interferons, chemokines and colony-stimulating factors, which
contain elements of the body&#x2019;s natural mix of defenses
against cancer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Multikine is
designed to be used in a different way than immune therapy is
normally used. It is designed to be administered locally to treat
local tumors before any other therapy has been administered. For
example, in the Phase 3 clinical trial, Multikine is injected
locally at the site of the tumor and near the adjacent draining
lymph nodes as a first line of treatment before surgery, radiation
and/or chemotherapy because that is when the immune system is
thought to be strongest. The goal is to help the intact immune
system recognize and kill the micro metastases that usually cause
recurrence of the cancer. In short, CEL-SCI believes that local
administration and administration before weakening of the immune
system by chemotherapy and radiation will result in better
anti-tumor response than if Multikine were administered as a
second- or later-line therapy. In clinical studies of Multikine,
administration of the investigational therapy to head and neck
cancer patients has demonstrated the potential for less or no
appreciable toxicity</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_10k001.jpg"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; color: #000000; font-size: 13px; font-family: Times New Roman">
Source: Adapted from Timar et al., Journal of Clinical Oncology
23(15) May 20, 2005</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The first
indication CEL-SCI is pursuing for its investigational drug product
candidate Multikine is an indication for the neoadjuvant therapy in
patients with squamous cell carcinoma of the head and neck, or
SCCHN (hereafter also referred to as advanced primary head and neck
cancer). As detailed below, the Phase 3 Clinical trial of the
Multikine investigational drug as neoadjuvant therapy in SCCHN is
currently on Partial Clinical Hold by the US FDA. SCCHN is a type
of head and neck cancer, and CEL-SCI believes that, in the
aggregate, there is a large, unmet medical need among head and neck
cancer patients. CEL-SCI believes the last FDA approval of a
therapy indicated for the treatment of advanced primary head and
neck cancer was over 50 years ago. In the aggregate, head and neck
cancer represents about 6% of the world&#x2019;s cancer cases, with
approximately over 650,000 patients diagnosed worldwide each year,
and nearly 60,000 patients diagnosed annually in the United States.
Multikine investigational immunotherapy was granted Orphan Drug
designation for neoadjuvant therapy in patients with SCCHN by the
FDA in the United States.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Status of Phase 3
Clinical Trial</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Following
submissions to regulatory authorities in 24 countries around the
world, including the FDA in the United States, a global Phase 3
clinical trial of the investigational Multikine therapy as a
potential neoadjuvant therapy in patients with SCCHN was initially
commenced in late 2010. This clinical trial is currently on Partial
Clinical Hold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">This trial is
currently primarily under the management of two clinical research
organizations, or CROs: ICON Inc. (who acquired Aptiv Solutions,
Inc., one of the two CROs), or ICON, and Ergomed Clinical Research
Limited, or Ergomed. Ergomed is responsible for new patient
enrollment and the clinical study management of the various study
sites, although enrollment of new patients has been on hold since
the Company received verbal notice of FDA&#x2019;s Partial Clinical
Hold on September 26, 2016. The following chart reflects the number
of patients enrolled per month from the point at which the study
management was transferred to the new CROs and the enrolment since
then and until the FDA put the study on Partial Clinical
Hold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_10k002.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The Phase 3 study
was designed with the objective that, if the study endpoint, which
is an improvement in overall survival of the subjects treated with
the Multikine treatment regimen plus the current standard of care
(SOC) as compared to subjects treated with the current SOC only, is
satisfied, the study results are expected to be used to support
applications that the Company plans to submit to regulatory
agencies in order to seek commercial marketing approvals for
Multikine in major markets around the world. This assessment can
only be made when a certain number of deaths have occurred in these
two main comparator groups of the study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">5</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The primary
endpoint for the original protocol for this Phase 3 head and neck
cancer study required that a 10% increase in overall survival be
obtained in the Multikine group which also is administered CIZ (CIZ
= low dose (non-chemotherapeutic) of cyclophosphamide, indomethacin
and Zinc-multivitamins) all of which are thought to enhance
Multikine activity), plus Standard of Care (Surgery + Radiotherapy
or Chemoradiotherapy) arm of the study over the Control comparator
(Standard of Care alone) arm. As the study originally was designed,
the final determination of whether this endpoint had been
successfully reached could only be determined when 298 events
(deaths) had occurred in the combined comparator arms of the study.
Under the original study design, the plan was to enroll 880
patients in order to be able to have 784 evaluable patients for the
per-protocol analysis.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In August 2016,
CEL-SCI announced that the currently available data from the
Clinical Study reflected that the accumulation of deaths in the
study was lower than that which was anticipated based on reported
literature at the Phase 3 study&#x2019;s inception. If the number of
deaths continued to be accumulated at the current rate, it had been
determined that it would take longer than originally planned to
complete the study. To minimize this eventuality, CEL-SCI decided
it would be necessary to enroll up to 1,273 patients to have 1,146
evaluable patients. There were also other changes in the protocol,
such as the required number of deaths (394) and the required
increase in overall survival (6.5%) in favor of the Multikine
comparator arm. With this increased patient enrollment, CEL-SCI
expected a corresponding increase in the number of deaths, and, if
this plan were implemented, the study could be completed in a more
timely manner. As required by law and in order to be able to
implement the plan, CEL-SCI submitted an amendment to the existing
Phase 3 protocol for its head and neck cancer study to multiple
regulatory agencies in the countries abroad where the Phase 3 study
is being conducted as well as to the FDA to allow for this
expansion in patient enrolment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;On September
26, 2016, CEL-SCI received verbal notice from the FDA that the
Phase 3 clinical trial in advanced primary head and neck cancer has
been placed on clinical hold. At such time, enrollment in the Phase
3 study was 928 patients. On October 21, 2016, CEL-SCI received a
Partial Clinical Hold letter from the FDA and on November 21, 2016,
CEL-SCI submitted a response to the FDA&#x2019;s Partial Clinical
Hold letter.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In its partial
clinical hold letter, FDA identified the following specific
deficiencies: a) FDA stated that there is an unreasonable and
significant risk of illness or injury to human subjects and cited
among other things the absence of prompt reports by us to the FDA
of IDMC recommendations to close the study entirely (made in spring
of 2014) or at least to close it to accrual of new patients (made
in spring of 2016); b) FDA stated that the investigator brochure is
misleading, erroneous, and materially incomplete; and c) FDA stated
that the plan or protocol is deficient in design to meet its stated
objectives. In its partial clinical hold letter, FDA also
identified the information needed to resolve these deficiencies. In
addition, FDA&#x2019;s partial clinical hold letter included two
requests relating to quality information regarding our
investigational final drug product, which were noted by FDA as
non-hold issues. CEL-SCI believes that its response submitted to
FDA on November 18, 2016, addressed each of the deficiencies
identified by FDA including detailing our belief that, under the
applicable FDA guidance, there was no obligation to report the
cited IDMC recommendations to the FDA at the time they were issued,
and it also requested a face-to-face meeting with FDA, and outlined
our commitment to diligently work with FDA in an effort to have the
partial clinical hold for the study lifted.</font> <font style="font-size: 13px; font-family: Times New Roman">On December 8,
2016, the FDA advised CEL-SCI that the agency was denying CEL-SCI's
request for a meeting at this time because FDA's review of
CEL-SCI's November 17, 2016 response was ongoing. CEL-SCI was also
advised that it will be receiving a letter addressing CEL-SCI's
response by December 18, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Throughout the
course of the Phase 3 study, an Independent Data Monitoring
Committee, or IDMC, has met periodically to review safety data from
the Phase 3 study, and the IDMC is expected to continue doing so
throughout the remainder of the Phase 3 study. At various points in
the study at which the IDMC has completed review of the safety data
and has issued recommendations, it has recommended that the Phase 3
study may continue, although on two occasions the IDMC has issued
recommendations that would have closed the study entirely (spring
of 2014) or at least closed it to accrual of new patients (spring
of 2016). On one occasion, in the spring of 2014, the IDMC made a
recommendation that the study be closed for safety and efficacy
reasons. However, following review of additional information
submitted by us, the IDMC recommended that the study may continue.
In the spring of 2016, with close to 800 patients enrolled, the
IDMC made a recommendation that enrollment in the Phase 3 study
should stop, but that patients already enrolled in the study should
continue treatment and follow-up. CEL-</font><font style="font-size: 13px; font-family: Times New Roman">SCI responded to
this letter and indicated it would address the remaining three
requests (generally relating to study design considerations) that
were not part of the IDMC recommendation in a follow-up
correspondence.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">6</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">However, before
CEL-SCI could provide our follow-up response to the remaining three
requests, the IDMC sent another letter (a) indicating that our
initial letter responding to the IDMC recommendation was
unresponsive and (b) also indicating that the IDMC was deeply
concerned about patient safety in the trial based on its review of
cumulative data. The IDMC's initial letter in the spring of 2016
did not mention that the IDMC was concerned about safety. Instead,
the initial letter in the spring of 2016 noted that the study
should be closed to further accrual, and that patients who had been
randomized may continue treatment and should be followed. The
statement that patients who had been randomized may continue
treatment suggested to us that safety was not an issue. Because no
safety concern had been raised by the IDMC since the spring of
2014, when, after further communications with CEL-SCI, the IDMC
issued its recommendation that the study should proceed, CEL-SCI
believed based on the entirety of the course of correspondence with
the IDMC that acute safety was not an issue underlying the IDMC's
recommendation to halt accrual in the spring of 2016. As noted
above, all other correspondence to CEL-SCI from the IDMC from study
initiation through September 2015, with the exception of the
recommendation in spring 2014, stated that the IDMC recommends
&#x201C;the study may continue". CEL-SCI responded to the
IDMC&#x2019;s recommendation in spring of 2016 with a statistical
analysis showing that more patients were needed in order to
complete the study in a reasonable amount of follow-up time, since
the observed death rate in the study was lower than that which was
predicted from the literature at the onset of the study.
Subsequently a protocol amendment was prepared based on the
analysis provided to the IDMC and submitted to FDA in July 2016,
and a copy was then sent to the IDMC in response to its request for
a copy of the submission. To date, CEL-SCI has not received a
response from the IDMC regarding this protocol amendment. However,
two months after the amendment was submitted to FDA, FDA placed the
protocol on partial clinical hold. CEL-SCI expects to work through
the concerns raised by the IDMC while CEL-SCI works through the
partial hold with FDA. Ultimately, the decision as to whether
CEL-SCI&#x2019;s drug product candidate is safe and effective can
only be made by FDA and/or by other regulatory authorities based
upon an assessment of all of the data from an entire drug
development program submitted as part of an application for
marketing approval. As detailed elsewhere in this document, whether
the partial clinical hold is lifted or not, the current Phase 3
clinical study for CEL-SCI&#x2019;s investigational drug may or may
not be able to be used as the pivotal study supporting a marketing
application in the United States, and, if not, at least one
entirely new Phase 3 pivotal study would need to be conducted to
provide the pivotal study supporting a marketing application in the
United States.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI estimates
that the total remaining cash cost of the Phase 3 clinical trial,
excluding any costs that will be paid by CEL-SCI's partners, would
be approximately $12.1 million after September 30, 2016. This
&#xED;s based on the executed contract costs with the CROs only and
does not include other related costs, e.g. the manufacturing of the
drug. Should the FDA allow the amended protocol filed with them to
proceed, which requires an enrollment of up to 1,273 subjects, the
remaining cost of the Phase 3 clinical trial will be higher than
currently estimated. This is in addition to the approximately $34.5
million that CEL-SCI already had spent on the trial as of September
30, 2016. This estimate is based on information currently available
under the contracts with the CROs responsible for managing the
Phase 3 clinical trial. This number may be affected by the rate of
any future patient enrollment, rate of death accumulation in the
study, foreign currency exchange rates, and many other factors,
some of which cannot be foreseen today. It is therefore possible
that the cost of the Phase 3 clinical trial will be higher than
currently estimated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Follow-Up Analysis of Overall Survival in Phase 2
Patients</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">Prior to starting
the Phase 3 study, CEL-SCI had tested Multikine in over 200
patients. The following is a summary of results from
CEL-SCI&#x2019;s last Phase 2 study conducted with Multikine. This
study employed the same treatment protocol as is being followed in
CEL-SCI&#x2019;s Phase 3 study:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Reported potential for improved
survival:</font> In a follow-up analysis of the Phase 2 clinical
study population, which used the same dosage and treatment regimen
as is being used in the Phase 3 study, head and neck cancer
patients with locally advanced primary disease who received the
investigational therapy Multikine as first-line investigational
therapy, followed by surgery and radiotherapy, were reported by the
clinical investigators to have had a 63.2% overall survival, or OS,
rate at a median of 3.33 years from surgery. This percentage of OS
was arrived at as follows: of the 21 subjects enrolled in the Phase
2 study, the consent for the survival follow-up portion of the
study was received from 19 subjects. OS was calculated using the
entire treatment population that consented to the follow-up portion
of the study (19 subjects), including two subjects who, as later
determined by three pathologists blinded to the study, did not have
oral squamous cell carcinoma, or OSCC. These two subjects were thus
not evaluable per the protocol and were not included in the
pathology portion of the study for purposes of calculating the
complete response rate, as described below, but were included in
the OS calculation. The overall survival rate of subjects receiving
the investigational therapy in this study was compared to the
overall survival rate that was calculated based upon a review of 55
clinical trials conducted in the same cancer population (with a
total of 7,294 patients studied), and reported in the peer reviewed
scientific literature between 1987 and 2007. Review of this
literature showed an approximate survival rate of 47.5% at 3.5
years from treatment. Therefore, the results of CEL-SCI's final
Phase 2 study were considered to be potentially favorable in terms
of overall survival recognizing the limitations of this early-phase
study. It should be noted that an earlier investigational therapy
Multikine study appears to lend support to the overall survival
findings described above - Feinmesser et al Arch Otolaryngol. Surg.
2003. However, no definitive conclusions can be drawn from these
data about the potential efficacy or safety profile of this
investigational therapy. Moreover, further research is required,
and these results must be confirmed in the Phase 3 clinical trial
of this investigational therapy that is currently in progress.
Subject to completion of that Phase 3 clinical trial and the
FDA&#x2019;s review and acceptance of CEL-SCI's entire data set on
this investigational therapy, CEL-SCI believes that these
early-stage clinical trial results indicate the potential for the
Multikine product candidate to become a treatment for advanced
primary head and neck cancer, if approved.</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">8</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Reported average of 50% reduction in tumor
cells in Phase 2 trials (based on 19 patients evaluable by
pathology, having OSCC):</font> The clinical investigators who
administered the three week Multikine treatment regimen used in the
Phase 2 study reported that, as was determined in a controlled
pathology study, Multikine administration appeared to have caused,
on average, the disappearance of about half of the cancer cells
present at surgery (as determined by histopathology assessing the
area of Stroma/Tumor (Mean+/- Standard Error of the Mean of the
number of cells counted per filed)) even before the start of
standard therapy, which normally includes surgery, radiation and
chemotherapy (Timar et al JCO 2005).</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Reported 10.5% complete response in the final
Phase 2 trial (based on 19 patients evaluable by pathology, having
OSCC):</font> The clinical investigators who administered the
three-week Multikine investigational treatment regimen used in the
Phase 2 study reported that, as was determined in a controlled
pathology study, the tumor apparently was no longer present (as
determined by histopathology) in approximately 10.5% of evaluable
patients with OSCC (Timar et al JCO 2005). In the original study,
21 subjects received Multikine, two of which were later excluded,
as subsequent analysis by three pathologists blinded to the study
revealed that these two patients did not have OSCC. Two subjects in
this study had a complete response, leaving a reported complete
response rate of two out of 19 assessable subjects with OSCC (or
10.5%) (Timar et al JCO 2005).</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Adverse events reported in clinical
trials:</font> In clinical trials conducted to date with the
Multikine investigational therapy, adverse events which have been
reported by the clinical investigators as possibly or probably
related to Multikine administration included pain at the injection
site, local minor bleeding and edema at the injection site,
diarrhea, headache, nausea, and constipation<font style="font-weight: bold">.</font></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Subsequently, an
analysis on the 21 subjects originally treated with Multikine in
the study to evaluate overall survival was conducted, as described
above. In connection with the follow-up portion of the study for
overall survival, <font style="color: #000000">CEL-SCI</font> also
conducted an unreported post-hoc analysis of complete response rate
in the study population, which included subjects who provided
consent for the follow-up and who also had OSCC. Two of the 21
subjects did not re-consent for follow-up, and two of the remaining
19 subjects were excluded from the post-hoc complete response rate
analysis as they had previously been determined by pathology
analysis to not have OSCC. The two complete responders with OSCC
both consented to the follow-up study. Therefore, the post-hoc
analysis of complete response was based on a calculation of the two
complete responders out of 17 evaluable subjects who consented to
the follow-up analysis and who also had OSCC (or
11.8%).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">9</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Furthermore,
CEL-SCI reported an overall response rate of 42.1% based on the
number of evaluable patients who experienced a favorable response
to the treatment, including those who experienced minor, major and
complete responses. Out of the 19 evaluable patients, two
experienced a complete response, two experienced a major response,
and four experienced a minor response to treatment. Thus,
<font style="color: #000000">CEL-SCI</font> calculated the number
of patients experiencing a favorable response as eight patients out
of 19 (or 42.1%) (Timar et al, JCO 2005).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The clinical
significance of these and other data, to date, from the multiple
Multikine clinical trials is not yet known. These preliminary
clinical data do suggest the potential to demonstrate a possible
improvement in the clinical outcome for patients treated with
Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Peri-Anal Warts and Cervical Dysplasia in HIV/HPV Co-Infected
Patients</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">HPV is a very
common sexually transmitted disease in the United States and other
parts of the world. It can lead to cancer of the cervix, penis,
anus, esophagus and head and neck. Our focus in HPV, however, is
not on developing an antiviral for the potential treatment or
prevention of HPV in the general population. Instead, the focus is
on developing an immunotherapy product candidate designed to be
administered to patients who are immune-suppressed by other
diseases, such as HIV, and who are therefore less able or unable to
control HPV and its resultant or co-morbid diseases. Such patients
have limited treatment options available to them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">One condition that
is commonly associated with both HIV and HPV is the occurrence of
anal intraepithelial dysplasia, or AIN, and anal and genital warts.
The incidence of AIN in HIV-infected people is estimated to be
about 25%. The incidence of anal HPV infection in HIV-infected men
who have sex with men, or MSM, is estimated to be as high as 95%.
In the aggregate, the United States and Europe have about 875,000
HIV-infected patients with AIN (assuming AIN prevalence of
approximately 25% of the aggregate HIV-infected population).
Persistent HPV infection in the anal region is thought to be
responsible for up to 80% of anal cancers, and men and women who
are HIV positive have a 30-fold increase in their risk of anal
cancer. Persistent HPV infection can also be a precursor to
cervical cancer, as well as certain head and neck
cancers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In October 2013,
<font style="color: #000000">CEL-SCI</font> signed a cooperative
research and development agreement, or CRADA, with the U.S. Naval
Medical Center, San Diego, or the USNMC. Pursuant to this
agreement, the USNMC was to conduct a Phase 1 study, approved by
the Human Subjects Institutional Review Board, of CEL-SCI&#x2019;s
investigational immunotherapy, Multikine, in HIV/HPV co-infected
men and women with peri-anal warts. The purpose of this study was
to evaluate the safety and clinical impact of Multikine as a
potential treatment of peri-anal warts and assess its effect on AIN
in HIV/HPV co-infected men and women.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In July 2015,
CEL-SCI added a clinical site at the University of California, San
Francisco, or UCSF, and Key Opinion Leader, or KOL, to the ongoing
Phase 1 study. In August 2016, the U.S. Navy discontinued this
Phase 1 study because of difficulties in enrolling patients. UCSF
is continuing with the study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In October 2013,
<font style="color: #000000">CEL-SCI</font> entered into a
co-development and profit sharing agreement with Ergomed for
development of Multikine as a potential treatment of HIV/HPV
co-infected men and women with peri-anal warts. This agreement is
supporting the development of Multikine with UCSF.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The treatment
regimen for this Phase 1 study of up to 15 HIV/HPV co-infected
patient volunteers with peri-anal warts, being conducted by doctors
at UCSF, is identical to the regimen that was used in an earlier
Institutional Review Board-approved Multikine Phase 1 study in
HIV/HPV co-infected patients, which was conducted at the University
of Maryland. In that study, the Multikine investigational therapy
was administered to HIV/HPV co-infected women with cervical
dysplasia, resulting in visual and histological evidence of
clearance of lesions in three out of the eight
subjects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Furthermore, in
this earlier Phase 1 study, the number of HPV viral sub-types in
three volunteer subjects tested were reduced post-treatment with
Multikine, as opposed to pre-treatment, as determined by in situ
polymerase chain reaction performed on tissue biopsy collected
before and after Multikine treatment. As reported by the
investigators in the earlier study, the study volunteers, except
one subject volunteer, all appeared to tolerate the treatment with
no reported serious adverse events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Development Agreements for Multikine</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">In August 2008,
CEL-SCI signed an agreement with Teva Pharmaceutical Industries
Ltd., or Teva, that gives Teva the exclusive right and license to
market, distribute and sell Multikine in Israel and Turkey for
treatment of head and neck cancer, if approved. The agreement
terminates on a country-by-country basis 10 years after the product
launch in each country or upon a material breach or upon bankruptcy
of either party. The agreement will automatically extend for
additional two year terms unless either party gives notice of its
intent not to extend the agreement. If CEL-SCI develops Multikine
for other oncology indications and Teva indicates a desire to
participate, the parties have agreed to negotiate in good faith
with respect to Teva&#x2019;s participation and contribution in
future clinical trials.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">Teva has agreed to
use all reasonable efforts to obtain regulatory approval to market
and sell Multikine in its territory at its own cost and expense.
Pursuant to the agreement, it is CEL-SCI&#x2019;s responsibility to
supply Multikine and Teva&#x2019;s responsibility to sell Multikine,
if approved. Net sales will be divided 50/50 between the two
parties. Teva also initially agreed to fund certain activities
relating to the conduct of a clinical trial in Israel as part of
the global Phase 3 trial for Multikine. In January 2012, pursuant
to an assignment and assumption agreement between CEL-SCI, Teva and
GCP Clinical Studies Ltd., or GCP, Teva transferred all of its
rights and obligations concerning the Phase III trial in Israel to
GCP. GCP is now operating the Phase 3 trial in Israel pursuant to a
service agreement with CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">In July 2011,
Serbia and Croatia were added to Teva&#x2019;s territory, pursuant
to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o.,
or PLIVA, an affiliate of Teva&#x2019;s, subject to similar terms as
described above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">In consideration
for the rights granted by CEL-SCI to PLIVA under the joinder
agreement, CEL-SCI will be paid by PLIVA (in U.S.
dollars):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">$100,000 upon EMA
grant of Marketing Authorization for Multikine;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">$50,000 upon
Croatia&#x2019;s grant of reimbursement status for Multikine in
Croatia; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">$50,000 upon
Serbia&#x2019;s grant of reimbursement status for Multikine in
Serbia.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">11</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">In November 2000,
CEL-SCI signed an agreement with Orient Europharma Co., Ltd., or
Orient Europharma, of Taiwan, which agreement was amended in
October 2008 and again in June 2010. Pursuant to this agreement, as
amended, Orient Europharma has the exclusive marketing and
distribution rights to Multikine, if approved, for head and neck
cancer, naso-pharyngeal cancer and potentially cervical cancer
indications in Taiwan, Singapore, Malaysia, Hong Kong, the
Philippines, South Korea, Australia and New Zealand. CEL-SCI has
granted Orient Europharma the first right of negotiation with
respect to Thailand and China.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">The agreement
requires Orient Europharma to fund 10% of the cost of the clinical
trials needed to obtain marketing approvals in these countries for
head and neck cancer, naso-pharyngeal cancer and potentially
cervical cancer. Orient Europharma has signed ten centers in
Taiwan, four centers in Malaysia, three centers in Philippines and
one center in Thailand to enroll patients as part of the Phase 3
Multikine clinical trial and has made further financial
contributions towards the cost of the Phase 3 clinical
trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">If Multikine is
approved for sale, Orient Europharma will purchase Multikine from
CEL-SCI for 35% of the gross selling price in each
country.<font style="font-weight: bold">&#xA0;</font>Orient
Europharma is obligated to use the same diligent efforts to
develop, register, market, sell and distribute Multikine in the
territory as with its own products or other licensed
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">The agreement will
terminate on a country-by-country basis 15 years after the product
approval for Multikine in each country, at which point the
agreement will be automatically extended for successive two year
periods, unless either party gives notice of its intent not to
extend the agreement. The agreement may also be terminated upon
bankruptcy of either party or material misrepresentations that are
not cured within 60 days. If the agreement ends before the 15 year
term through no fault of either party, CEL-SCI will reimburse
Orient Europharma for a prorated part of Orient Europhorma&#x2019;s
costs towards the clinical trials of Multikine. If Orient
Europharma fails to make certain minimum purchases of Multikine
during the term of the agreement, Orient Europhorma&#x2019;s rights
to the territory will become non-exclusive.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has a
licensing agreement with Byron Biopharma LLC, or Byron, under which
CEL-SCI granted Byron an exclusive license to market and distribute
Multikine in the Republic of South Africa, if approved. This
license will terminate 20 years after marketing approval in South
Africa or after bankruptcy or uncured material breach. After the
20-year period has expired, the agreement will be automatically
extended for successive two year periods, unless either party gives
notice of its intent not to extend the agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 120px"><font style="font-size: 13px; font-family: Times New Roman">Pursuant to the
agreement, Byron will be responsible for registering Multikine in
South Africa. If Multikine is approved for sale in South Africa,
CEL-SCI will be responsible for manufacturing the product, while
Byron will be responsible for sales in South Africa. Sales revenues
will be divided between CEL-SCI and Byron. CEL-SCI will be paid
fifty (50%) percent of the net sales of Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 120px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">12</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
INTELLECTUAL PROPERTY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">Patents and other
proprietary rights are essential to CEL-SCI&#x2019;s business.
CEL-SCI files patent applications to protect its technologies,
inventions and improvements to its inventions that CEL-SCI
considers important to the development of its business. CEL-SCI
files for patent registration in the United States and in key
foreign markets. CEL-SCI&#x2019;S intellectual property portfolio
covers its proprietary technologies, including Multikine and LEAPS,
by multiple issued patents and pending patent
applications.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">Multikine is
protected by a US patent, which is a composition-of-matter patent
issued in May 2005 that, in its current format, expires in 2024.
Additional composition-of-matter patents for Multikine have been
issued in Germany (issued in June 2011 and currently set to expire
in 2025), China (issued in May 2011 and currently set to expire in
2024), Japan (issued in November 2012 and currently set to expire
in 2025), and two in Europe (issued in September 2015 and May 2016
both currently set to expire in 2025).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has one
patent applications pending in Europe for Multikine, which, if
issued, would extend protection through 2026, subject to any
potential patent term extensions. In addition to the patents and
applications that offer certain protections for Multikine, the
method of manufacture for Multikine, a complex biological product,
is held by CEL-SCI as trade secret.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">LEAPS is protected
by patents in the United States issued in February 2006, April
2007, and August 2007. The LEAPS patents, which expire in 2021,
2022 and 2021, respectively, include overlapping claims, with
composition of both matter (new chemical entity), process and
methods-of-use, to maximize and extend the coverage in their
current format. Additional patent applications are pending in the
United States and Europe that could offer protection through
2034.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has six
patent applications pending in the United States and one in Europe
for LEAPS, which, if issued, would extend protection through 2034,
subject to any potential patent term extensions. One pending U.S.
application is a joint application with Northeast Ohio Medical
University (&#x201C;Neoucom&#x201D;). If granted, CEL-SCI will share
the ability to use the patent, unless CEL-SCI licenses the rights
to the patent application and any ensuing patent from
Neoucom.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px"><font style="font-size: 13px; font-family: Times New Roman">As of December 1,
2016, there were no contested proceedings and/or third party claims
with respect to CEL-SCI&#x2019;s patents or patent
applications.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
MANUFACTURING FACILITY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Before starting the
Phase 3 clinical trial, CEL-SCI needed to build a dedicated
manufacturing facility to produce Multikine. This facility has been
completed and validated, and has produced multiple clinical lots
for the Phase 3 clinical trial. The facility has also passed review
by a European Union Qualified Person on several
occasions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
lease on the manufacturing facility expires on October 31,
2028.&#xA0;CEL-SCI completed validation of its new manufacturing
facility in January 2010. The state-of-the-art facility is being
used to manufacture Multikine for CEL-SCI&#x2019;s Phase 3 clinical
trial. In addition to using this facility to manufacture Multikine,
CEL-SCI, only if the facility is not being used for Multikine, may
offer the use of the facility as a service to pharmaceutical
companies and others, particularly those that need to &#x201C;fill
and finish&#x201D; their drugs in a cold environment (4 degrees
Celsius, or approximately 39 degrees Fahrenheit). Fill and finish
is the process of filling injectable drugs in a sterile manner and
is a key part of the manufacturing process for many medicines.
However, priority will always be given to Multikine as management
considers the Multikine supply to the clinical studies and
preparation for a final marketing approval to be more important
than offering fill and finish services. See Item 2 of this report
for more information concerning the terms of this
lease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">13</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
LEAPS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
patented T-cell Modulation Process, referred to as LEAPS (Ligand
Epitope Antigen Presentation System), uses
&#x201C;heteroconjugates&#x201D; to direct the body to choose a
specific immune response. LEAPS is designed to stimulate the human
immune system to more effectively fight bacterial, viral and
parasitic infections as well as autoimmune, allergies,
transplantation rejection and cancer, when it cannot do so on its
own. Administered like a vaccine, LEAPS combines T-cell binding
ligands with small, disease associated, peptide antigens and may
provide a new method to treat and prevent certain
diseases.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The ability to
generate a specific immune response is important because many
diseases are often not combated effectively due to the body&#x2019;s
selection of the &#x201C;inappropriate&#x201D; immune response. The
capability to specifically reprogram an immune response may offer a
more effective approach than existing vaccines and drugs in
attacking an underlying disease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On July 15, 2014
CEL-SCI announced that it has been awarded a Phase 1 Small Business
Innovation Research (SBIR) grant in the amount of $225,000 from the
National Institute of Arthritis Muscoskeletal and Skin Diseases,
which is part of the National Institutes of Health. The grant is
funding the further development of CEL-SCI&#x2019;s LEAPS technology
as a potential treatment for rheumatoid arthritis, an autoimmune
disease of the joints. The work is being conducted at Rush
University Medical Center in Chicago, Illinois in the laboratories
of Tibor Glant, MD, Ph.D., The Jorge O. Galante Professor of
Orthopedic Surgery; Katalin Mikecz, MD, Ph.D. Professor of
Orthopedic Surgery &amp; Biochemistry; and Allison Finnegan, Ph.D.
Professor of Medicine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">With the support of
the SBIR grant, CEL-SCI is developing two new drug candidates,
CEL-2000 and CEL-4000, as potential rheumatoid arthritis
therapeutic vaccines. The data from animal studies using the
CEL-2000 treatment vaccine demonstrated that it could be used as an
effective treatment against rheumatoid arthritis with fewer
administrations than those required by other anti-rheumatoid
arthritis treatments currently on the market for arthritic
conditions associated with the Th17 signature cytokine TNF-&#xA0; .
The data for CEL-4000 indicates it could be effective against
rheumatoid arthritis cases where a Th1 signature cytokine (IFN-c)
is dominant. CEL-2000 and CEL-4000 have the potential to be a more
disease-specific therapy, significantly less expensive, act at an
earlier step in the disease process than current therapies and may
be useful in patients not responding to existing rheumatoid
arthritis therapies. CEL-SCI believes this represents a large unmet
medical need in the rheumatoid arthritis market.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On November 14,
2016, CEL-SCI announced new preclinical data that demonstrate its
investigational new drug candidate CEL-4000 has the potential for
use as a therapeutic vaccine to treat rheumatoid arthritis. This
efficacy study was supported in part by the SBIR Phase I Grant and
was conducted in collaboration with Drs. Katalin Mikecz and Tibor
Glant, and their research team at Rush University Medical Center in
Chicago, IL.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">14</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In March 2015,
CEL-SCI and its collaborators published a review article on vaccine
therapies for rheumatoid arthritis based in part on work supported
by the SBIR grant. The article is entitled &#x201C;Rheumatoid
arthritis vaccine therapies: perspectives and lessons from
therapeutic Ligand Epitope Antigen Presentation System vaccines for
models of rheumatoid arthritis&#x201D; and was published in Expert
Rev. Vaccines 1 - 18 and can be found at
http://www.ncbi.nlm.nih.gov/ pubmed/25787143.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In August 2012, Dr.
Zimmerman, CEL-SCI&#x2019;s Senior Vice President of Research,
Cellular Immunology, gave a Keynote presentation at the OMICS 2nd
International Conference on Vaccines and Vaccinations in Chicago.
This presentation showed how the LEAPS peptides administered
altered only select cytokines specific for each disease model,
thereby improving the status of the test animals and even
preventing death and morbidity. These results support the growing
body of evidence that provides for its mode of action by a common
format in these unrelated conditions by regulation of Th1 (e.g.,
IL12 and IFN-c) and their action on reducing TNF-&#xA0; and other
inflammatory cytokines as well as regulation of antibodies to these
disease associated antigens. This was also illustrated by a
schematic model showing how these pathways interact and result in
the overall effect of protection and regulation of cytokines in a
beneficial manner.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In February 2010,
CEL-SCI announced that its CEL-2000 vaccine demonstrated that it
was able to block the progression of rheumatoid arthritis in a
mouse model, where a Th17 signature cytokine (TNF-&#xA0; ) is
dominant. The results were published in the scientific
peer-reviewed Journal of International Immunopharmacology (online
edition) in an article titled &#x201C;CEL-2000: A Therapeutic
Vaccine for Rheumatoid Arthritis Arrests Disease Development and
Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen
Type II Induced Arthritis in the DBA Mouse Model&#x201D; Int
Immunopharmacol. 2010 Apr; 10(4):412-21 http://www.
ncbi.nlm.nih.gov/pubmed/20074669.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Using the LEAPS
technology, CEL-SCI has created a potential peptide treatment for
H1N1 (swine flu) hospitalized patients.&#xA0; This LEAPS flu
treatment is designed to focus on the conserved, non-changing
epitopes of the different strains of Type A Influenza viruses
(H1N1, H5N1, H3N1, etc.), including &#x201C;swine&#x201D;,
&#x201C;avian or bird&#x201D;, and &#x201C;Spanish Influenza&#x201D;,
in order to minimize the chance of viral &#x201C;escape by
mutations&#x201D; from immune recognition. Therefore one should
think of this treatment not really as an H1N1 treatment, but as a
potential pandemic flu treatment. CEL-SCI&#x2019;s LEAPS flu
treatment contains epitopes known to be associated with immune
protection against influenza in animal models.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In September 2009,
the U.S. FDA advised CEL-SCI that it could proceed with its first
clinical trial to evaluate the effect of LEAPS-H1N1 treatment on
the white blood cells of hospitalized H1N1 patients. This followed
an expedited initial review of CEL-SCI's regulatory submission for
this study proposal.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In November 2009,
CEL-SCI announced that The Johns Hopkins University School of
Medicine had given clearance for CEL-SCI&#x2019;s first clinical
study to proceed using LEAPS-H1N1.&#xA0;&#xA0; Soon after the start
of the study, the number of hospitalized H1N1 patients dramatically
declined and the study was unable to complete the enrollment of
patients.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">15</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Additional work on
this treatment for the pandemic flu is being pursued in
collaboration with the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health, USA.
In May 2011 NIAID scientists presented data at the Keystone
Conference on &#x201C;Pathogenesis of Influenza: Virus-Host
Interactions&#x201D; in Hong Kong, China, showing the positive
results of efficacy studies in mice of LEAPS H1N1 activated
dendritic cells (DCs) to treat the H1N1 virus. Scientists at the
NIAID found that H1N1-infected mice treated with LEAPS-H1N1 DCs
showed a survival advantage over mice treated with control DCs. The
work was performed in collaboration with scientists led by Kanta
Subbarao, M.D., Chief of the Emerging Respiratory Diseases Section
in NIAID&#x2019;s Division of Intramural Research, part of the
National Institutes of Health, USA.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In July 2013,
CEL-SCI announced the publication of the results of influenza
studies by researchers from the NIAID in the Journal of Clinical
Investigation (<font style="text-decoration: underline">www.jci.org/articles/view/67550</font>).
The studies described in the publication show that when
CEL-SCI&#x2019;s investigational J-LEAPS Influenza Virus treatments
were used &#x201C;in vitro&#x201D; to activate DCs, these activated
DCs, when injected into influenza infected mice, arrested the
progression of lethal influenza virus infection in these mice. The
work was performed in the laboratory of Dr. Subbarao.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Even though the
various LEAPS drug candidates have not yet been given to humans,
they have been tested in vitro with human cells. They have induced
similar cytokine responses that were seen in these animal models,
which may indicate that the LEAPS technology might translate to
humans. The LEAPS candidates have demonstrated protection against
lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as
a prophylactic or therapeutic agent in animals. They have also
shown some level of efficacy in animals in two autoimmune
conditions, curtailing and sometimes preventing disease progression
in arthritis and myocarditis animal models. CEL-SCI&#x2019;s belief
is that the LEAPS technology may be a significant alternative to
the vaccines currently available on the market for these
diseases.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">None of the LEAPS
investigational products have been approved for sale, barter or
exchange by the FDA or any other regulatory agency for any use to
treat disease in animals or humans. The safety or efficacy of these
products has not been established for any use. Lastly, no
definitive conclusions can be drawn from the early-phase,
preclinical-trials data involving these investigational products.
Before obtaining marketing approval from the FDA in the United
States, and by comparable agencies in most foreign countries, these
product candidates must undergo rigorous preclinical and clinical
testing which is costly and time consuming and subject to
unanticipated delays. There can be no assurance that these
approvals will be granted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
1B. RISK FACTORS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The risks described
below could adversely affect the price of CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">16</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Risks Related to CEL-SCI</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CEL-SCI
has identified a material weakness in its internal control over
financial reporting which could, if not remediated, result in
material misstatements in CEL-SCI&#x2019;s financial
statements.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
management is responsible for establishing and maintaining adequate
internal control over our financial reporting, as defined in Rule
13a-15(f) under the Exchange Act. CEL-SCI&#x2019;s management
identified a material weakness in the internal control over
financial reporting as of September 30, 2016. A material weakness
is a deficiency, or a combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the company&#x2019;s
annual or interim financial statements will not be prevented or
detected on a timely basis.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI discovered
an error in the way it accounted for the lease for its
manufacturing facility. The accounting error was determined to be a
material weakness in CEL-SCI&#x2019;s internal control over
financial reporting as of September 30, 2016 relating to
CEL-SCI&#x2019;s financial close process for non-routine
transactions including the accounting for leases and the assessment
of impairment of long-lived assets. The errors were identified
during the course of the preparation of its financial statements
and other financial data for its fiscal year ended September 30,
2017, as well as its assessment of its disclosure controls and
procedures and internal control over financial reporting as of the
date.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">If the remedial
measures CEL-SCI has begun implementing that are designed to
address this material weakness are insufficient to address this
material weakness, or if additional material weaknesses or
significant deficiencies in CEL-SCI&#x2019;s internal control are
discovered or occur in the future, the financial statements may
contain material misstatements and CEL-SCI could be required to
restate the financial results.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s Phase 3 Study has been placed on partial clinical
hold by the FDA</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
received a partial clinical hold letter from FDA stating that its
Phase 3 study had been placed on clinical hold, precluding CEL-SCI
from continuing the study except that patients enrolled prior to
September 26, 2016 may continue to receive protocol-specified
treatment at the discretion of the treating physician with written
confirmation of their consent to remain on study after receiving an
updated informed consent document. The FDA&#x2019;s partial clinical
hold letter identified the following specific deficiencies: there
is an unreasonable and significant risk of illness or injury to
human subjects; the investigator brochure is misleading, erroneous,
and materially incomplete; and that the plan or protocol is
deficient in design to meet its stated objectives. In its partial
clinical hold letter, the FDA also identified the information
needed to resolve these deficiencies. Although CEL-SCI believes it
addressed each of the deficiencies identified by the FDA in its
November 17, 2016 response to the FDA, CEL-SCI nevertheless
requested a face-to-face meeting with the FDA. On December 8, 2016,
the FDA advised CEL-SCI that the agency was denying CEL-SCI&#x2019;s
request for a meeting at this time because FDA&#x2019;s review of
CEL-SCI&#x2019;s November 17, 2016 response was ongoing. CEL-SCI was
also advised that it will be receiving a letter addressing
CEL-SCI&#x2019;s response by December 18, 2016. CEL-SCI will not be
able to enroll any additional patients in the Phase 3 study unless
FDA lifts the clinical hold. In addition, in the spring of 2016,
the IDMC recommended to CEL-SCI that new patient enrollment should
stop in the Phase 3 study, but patients already on study should
continue to be treated and followed. CEL-SCI expects to work
through the concerns raised by the IDMC while CEL-SCI works through
the partial hold with FDA. However, if the clinical hold is not
removed or if it is determined that the study has been compromised
or if the IDMC does not allow enrollment to continue, the study may
be terminated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI has incurred significant losses since inception, and
CEL-SCI anticipates that it will continue to incur significant
losses for the foreseeable future and may never achieve or maintain
profitability.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
has a history of net losses, expects to incur substantial losses
and have negative operating cash flow for the foreseeable future,
and may never achieve or maintain profitability.&#xA0;&#xA0;Since
the date of its formation and through September 30, 2016, CEL-SCI
incurred net losses of approximately $286 million. CEL-SCI has
relied principally upon the proceeds from the public and private
sales of its securities to finance its activities to date. To date,
CEL-SCI has not commercialized any products or generated any
revenue from the sale of products, and CEL-SCI does not expect to
generate any product revenue for the foreseeable future. CEL-SCI
does not know whether or when it will generate product revenue or
become profitable.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
is heavily dependent on the success of Multikine which is under
clinical development. CEL-SCI cannot be certain that Multikine will
receive regulatory approval or be successfully commercialized even
if CEL-SCI receives regulatory approval. On September 26, 2016, FDA
placed CEL-SCI&#x2019;s Phase 3 clinical trial for Multikine on
partial clinical hold. CEL-SCI will not be able to enroll any
additional patients in the Phase 3 clinical trial unless FDA
removes the clinical hold. In addition, prior to FDA&#x2019;s
issuance of the partial clinical hold, CEL-SCI was discussing with
its Independent Data Monitoring Committee issues related to
enrollment of additional patients in trial. Multikine is the only
product candidate in late-stage clinical development, and
CEL-SCI&#x2019;s business currently depends heavily on its
successful development, regulatory approval and commercialization.
CEL-SCI has no drug products for sale currently and may never be
able to develop approved and marketable drug products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">17</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Even
if CEL-SCI succeeds in developing and commercializing one or more
of its product candidates, CEL-SCI expects to continue to incur
significant operating and capital expenditures as
CEL-SCI:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">continues
to undertake preclinical development and clinical trials for
product candidates;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">seeks
regulatory approvals for product candidates;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">implements
additional internal systems and infrastructure.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">To
become and remain profitable, CEL-SCI must succeed in developing
and commercializing product candidates which must generate
significant revenue. This will require CEL-SCI to be successful in
a range of challenging activities, including completing preclinical
testing and clinical trials of its product candidates, discovering
or acquiring additional product candidates, obtaining regulatory
approval for these product candidates and manufacturing, marketing
and selling any products for which CEL-SCI may obtain regulatory
approval. CEL-SCI is only in the preliminary stages of most of
these activities. CEL-SCI may never succeed in these activities
and, even if CEL-SCI does, may never generate revenue that is
significant enough to achieve profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Even
if CEL-SCI does achieve profitability, it may not be able to
sustain or increase profitability on a quarterly or annual basis.
The failure to become and remain profitable could depress the value
of CEL-SCI and could impair its ability to raise capital, expand
its business, maintain research and development efforts, diversify
product offerings or even continue in operation. A decline in the
value of CEL-SCI could cause its stockholders to lose all or part
of their investment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
CEL-SCI will require substantial additional capital to remain in
operation. A failure to obtain this necessary capital when needed
could force CEL-SCI to delay, limit, reduce or terminate the
product candidates&#x2019; development or commercialization
efforts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">As
of September 30, 2016, CEL-SCI had cash and cash equivalents of
$2.9 million.&#xA0;&#xA0;CEL-SCI believes that it will continue to
expend substantial resources for the foreseeable future developing
Multikine, LEAPS and any other product candidates or technologies
that it may develop or acquire. These expenditures will include
costs associated with research and development, potentially
obtaining regulatory approvals and having the products
manufactured, as well as marketing and selling products approved
for sale, if any. In addition, other unanticipated costs may arise.
Because the outcome of the current and anticipated clinical trials
is highly uncertain, CEL-SCI cannot reasonably estimate the actual
amounts necessary to successfully complete the development and
commercialization of the product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
future capital requirements depend on many factors,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
rate of progress of, results of and cost of completing Phase 3
clinical development of Multikine for the treatment of certain head
and neck cancers;</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">18</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
results of the applications to and meetings with the FDA, the EMA
and other regulatory authorities and the consequential effect on
operating costs;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">assuming
favorable Phase 3 clinical results, the cost, timing and outcome of
the efforts to obtain marketing approval for Multikine in the
United States, Europe and in other jurisdictions, including the
preparation and filing of regulatory submissions for Multikine with
the FDA, the EMA and other regulatory authorities;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
scope, progress, results and costs of additional preclinical,
clinical, or other studies for additional indications for
Multikine, LEAPS and other product candidates and technologies that
CEL-SCI may develop or acquire;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
timing of, and the costs involved in, obtaining regulatory
approvals for LEAPS if clinical studies are
successful;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
cost and timing of future commercialization activities for the
products, if any of the product candidates are approved for
marketing, including product manufacturing, marketing, sales and
distribution costs;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
revenue, if any, received from commercial sales of the product
candidates for which CEL-SCI receives marketing
approval;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
cost of having the product candidates manufactured for clinical
trials and in preparation for commercialization;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
ability to establish and maintain strategic collaborations,
licensing or other arrangements and the financial terms of such
agreements;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
costs involved in preparing, filing and prosecuting patent
applications and maintaining, defending and enforcing its
intellectual property rights, including litigation costs, and the
outcome of such litigation; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
extent to which CEL-SCI acquires or in-licenses other products or
technologies.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Based
on the current operating plan, and absent any future financings or
strategic partnerships, CEL-SCI believes that its existing cash and
cash equivalents and investments will be sufficient to fund the
projected operating expenses and capital expenditure requirements
into the second quarter of fiscal year 2017. However,
CEL-SCI&#x2019;s operating plan may change as a result of many
factors currently unknown to CEL-SCI, and CEL-SCI may need
additional funds sooner than planned. Additional funds may not be
available when CEL-SCI needs them on terms that are acceptable to
CEL-SCI, or at all. If adequate funds are not available to CEL-SCI
on a timely basis, CEL-SCI may be required to delay, limit, reduce
or terminate preclinical studies, clinical trials or other
development activities for Multikine, LEAPS, or any other product
candidates or technologies that CEL-SCI develops or acquires, or
delay, limit, reduce or terminate its sales and marketing
capabilities or other activities that may be necessary to
commercialize its product candidates. Due to recurring losses from
operations and future liquidity needs, there is substantial doubt
about CEL-SCI&#x2019;s ability to continue as a going concern
without additional capital becoming available. The doubt about
CEL-SCI&#x2019;s ability to continue as a going concern could have
an adverse impact on CEL-SCI&#x2019;s ability to execute its
business plan, result in the reluctance on the part of certain
suppliers to do business with CEL-SCI, or adversely affect
CEL-SCI&#x2019;s ability to raise additional debt or equity
capital.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">19</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
The costs of the product candidates development and clinical trials
are difficult to estimate and will be very high for many years,
preventing CEL-SCI from making a profit for the foreseeable future,
if ever.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Clinical
and other studies necessary to obtain approval of a new drug can be
time consuming and costly, especially in the United States, but
also in foreign countries. The estimates of the costs associated
with future clinical trials and research may be substantially lower
than what CEL-SCI actually experiences. It is impossible to predict
what CEL-SCI will face in the development of a product candidate,
such as Multikine. The purpose of clinical trials is to provide
both CEL-SCI and regulatory authorities with safety and efficacy
data in humans. It is relatively common to revise a trial or add
subjects to a trial in progress. The difficult and often complex
steps necessary to obtain regulatory approval, especially that of
the FDA and the EMA, involve significant costs and may require
several years to complete. CEL-SCI expects that it will need
substantial additional financing over an extended period of time in
order to fund the costs of future clinical trials, related
research, and general and administrative expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
extent of the clinical trials and research programs are primarily
based upon the amount of capital available to CEL-SCI and the
extent to which CEL-SCI receives regulatory approvals for clinical
trials. CEL-SCI has established estimates of the future costs of
the Phase 3 clinical trial for Multikine, but, as explained above,
the estimates may not prove correct.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
An adverse determination in any current or future lawsuits or
arbitration proceedings to which CEL-SCI is a party could have a
material adverse effect on CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">CEL-SCI is currently involved in a pending
arbitration proceeding,&#xA0;</font><font style="font-style: italic; color: #000000">CEL-SCI Corporation v.
inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet
GmbH (f/k/a PharmaNet AG)</font><font style="color: #000000">.
CEL-SCI initiated the proceedings against inVentiv Health Clinical,
LLC, or inVentiv, the former third-party CRO, and is seeking
payment for damages related to inVentiv&#x2019;s prior involvement
in the Phase 3 clinical trial of Multikine. The arbitration claim,
initiated under the Commercial Rules of the American Arbitration
Association, alleges (i) breach of contract, (ii) fraud in the
inducement, and (iii) common law fraud. Currently, CEL-SCI is
seeking at least $50 million in damages in its amended statement of
claim.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
an amended statement of claim, CEL-SCI asserted the claims set
forth above as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against CEL-SCI for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for the alleged use of inVentiv&#x2019;s name in
connection with publications and promotions in violation of the
parties&#x2019; contract; (iii) opportunistic breach, restitution
and unjust enrichment, seeking at least $20 million in disgorgement
of alleged unjust profits allegedly made by CEL-SCI as a result of
the purported breaches referenced in subsection (ii); and (iv)
defamation, seeking at least $1 million in damages for allegedly
defamatory statements made about inVentiv. CEL-SCI believes
inVentiv&#x2019;s counterclaims are meritless and intends to
vigorously defend against them. However, if such defense is
unsuccessful, and inVentiv successfully asserts any of its
counterclaims, such an adverse determination could have a material
adverse effect on CEL-SCI&#x2019;s business, results, financial
condition and liquidity.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">20</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In October 2015
CEL-SCI signed an arbitration funding agreement with a company
established by Lake Whillans Litigation Finance, LLC, a firm
specializing in funding litigation expenses. Pursuant to the
agreement, an affiliate of Lake Whillans provides CEL-SCI with up
to $5 million in funding for litigation expenses to support its
arbitration claims against inVentiv. The funding is available to
CEL-SCI to fund the expenses of the ongoing arbitration and will
only be repaid if CEL-SCI receives proceeds from the
arbitration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
arbitration hearing on the merits began on September 26,
2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Additionally,
CEL-SCI may also be the target of claims asserting violations of
securities fraud and derivative actions, or other litigation or
arbitration proceedings in the future. Any future litigation could
result in substantial costs and divert management&#x2019;s attention
and resources. These lawsuits or arbitration proceedings may result
in large judgments or settlements against CEL-SCI, any of which
could have a material adverse effect on its business, operating
results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI has received a subpoena from the Securities and Exchange
Commission.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
has received subpoenas from the Securities and Exchange Commission,
which is conducting a non-public, private investigation relating to
certain of CEL-SCI&#x2019;s private and public financings as well as
reports, articles and other publications prepared by third parties
concerning CEL-SCI, the pending arbitration between CEL-SCI and
CEL-SCI&#x2019;s former CRO, inVentiv Health, and CEL-SCI&#x2019;s
Phase 3 clinical trial. This is the first SEC investigation
involving CEL-SCI. While CEL-SCI is confident that it has the
appropriate policies and procedures in place to ensure compliance
with all SEC rules and regulations, CEL-SCI cannot predict when the
SEC will conclude its investigation or the outcome of the
investigation. CEL-SCI is cooperating fully with the SEC in this
matter.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
Compliance with changing regulations concerning corporate
governance and public disclosure may result in additional
expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Changing
laws, regulations and standards relating to corporate governance
and public disclosure may create uncertainty regarding compliance
matters. New or changed laws, regulations and standards are subject
to varying interpretations in many cases. As a result, their
application in practice may evolve over time. CEL-SCI is committed
to maintaining high standards of corporate governance and public
disclosure. Complying with evolving interpretations of new or
changing legal requirements may cause CEL-SCI to incur higher costs
as CEL-SCI revises current practices, policies and procedures, and
may divert management time and attention from potential
revenue-generating activities to compliance matters. If the efforts
to comply with new or changed laws, regulations and standards
differ from the activities intended by regulatory or governing
bodies due to ambiguities related to practice, CEL-SCI&#x2019;s
reputation may also be harmed. Further, CEL-SCI&#x2019;s board
members, chief executive officer, and other executive officers
could face an increased risk of personal liability in connection
with the performance of their duties. As a result, CEL-SCI may have
difficulty attracting and retaining qualified board members and
executive officers, which could harm its business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">21</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
CEL-SCI has not established a definite plan for the marketing of
Multikine, if approved.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
has not established a definitive plan for marketing nor has CEL-SCI
established a price structure for any of its product candidates, if
approved. However, CEL-SCI intends, if it is in a position to do
so, to sell Multikine itself in certain markets where it is
approved, and or to enter into written marketing agreements with
various third parties with established sales forces in such
markets.&#xA0;&#xA0;The sales forces in turn would, CEL-SCI
believes, focus on selling Multikine to targeted cancer centers,
physicians and clinics involved in the treatment of head and neck
cancer. CEL-SCI has already licensed future sales of Multikine, if
approved, to three companies: Teva Pharmaceuticals in Israel,
Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore,
Hong Kong, Malaysia, South Korea, the Philippines, Australia and
New Zealand; and Byron BioPharma, LLC in South
Africa.&#xA0;&#xA0;CEL-SCI believes that these companies will have
the resources to market Multikine appropriately in their respective
territories, if approved, but there is no guarantee that they
will.&#xA0;&#xA0;There is no assurance that CEL-SCI will be able to
find qualified third-party partners to market its products in other
areas, on terms that are favorable to CEL-SCI, or at
all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
may encounter problems, delays and additional expenses in
developing marketing plans with third parties. In addition, even if
Multikine, if approved, is cost-effective and demonstrated to
increase overall patient survival, CEL-SCI may experience other
limitations involving the proposed sale of Multikine, such as
uncertainty of third-party coverage and reimbursement. There is no
assurance that CEL-SCI can successfully market Multikine, if
approved, or any other product candidates it may
develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI hopes to expand its clinical development capabilities in
the future, and any difficulties hiring or retaining key personnel
or managing this growth could disrupt its operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
is highly dependent on the principal members of its management and
development staff. If the Phase 3 Multikine clinical trial is
successful, CEL-SCI expects to expand its clinical development and
manufacturing capabilities, which will involve hiring additional
employees. Future growth will require CEL-SCI to continue to
implement and improve its managerial, operational and financial
systems and continue to retain, recruit and train additional
qualified personnel, which may impose a strain on its
administrative and its operational infrastructure. The competition
for qualified personnel in the biopharmaceutical field is intense.
CEL-SCI is highly dependent on its ability to attract, retain and
motivate highly qualified management and specialized personnel
required for clinical development. Due to limited resources,
CEL-SCI may not be able to manage effectively the expansion of its
operations or recruit and train additional qualified
personnel.&#xA0;&#xA0;If CEL-SCI is unable to retain key personnel
or manage its future growth effectively, CEL-SCI may not be able to
implement its business plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">22</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
If product liability or patient injury lawsuits are brought against
CEL-SCI, CEL-SCI may incur substantial liabilities and may be
required to limit clinical testing or future commercialization of
Multikine or its other product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
faces an inherent risk of product liability as a result of the
clinical testing of Multikine and other product candidates, and
will face an even greater risk if CEL-SCI commercializes any of its
product candidates. For example, CEL-SCI may be sued if its
Multikine or LEAPS product candidates, or any other future product
candidates, allegedly cause injury or are found to be otherwise
unsuitable during clinical testing, manufacturing or, if approved,
marketing or sale. Any such product liability claims may include
allegations of defects in manufacturing, defects in design, a
failure to warn of dangers inherent in the product candidate,
negligence, strict liability and a breach of warranties. Claims
could also be asserted under state consumer protection
acts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Furthermore,
Multikine is made, in part, from components of human blood. There
are inherent risks associated with products that involve human
blood such as possible contamination with viruses, including
hepatitis or HIV. Any possible contamination could cause injuries
to patients who receive contaminated Multikine, or could require
CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI
to possible financial losses, lawsuits and harm to its
business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
CEL-SCI cannot successfully defend itself against product liability
claims, CEL-SCI may incur substantial liabilities or be required to
limit or cease the clinical testing or commercialization of its
product candidates, if approved. Even a successful defense would
require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result
in:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">decreased
demand for Multikine or other product candidates, if
approved;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">injury
to CEL-SCI&#x2019;s reputation;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">withdrawal
of existing, or failure to enroll additional, clinical trial
participants;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">costs
to defend any related litigation;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">a
diversion of management&#x2019;s time and resources;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">substantial
monetary awards to trial participants or patients;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
candidate recalls, withdrawals or labeling, marketing or
promotional restrictions;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">loss
of revenue;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">inability
to commercialize Multikine or other product candidates;
and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">a
decline in the price of CEL-SCI&#x2019;s common stock.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Although
CEL-SCI has product liability insurance for Multikine in the amount
of $5.0 million, the successful prosecution of a product liability
case against CEL-SCI could have a materially adverse effect upon
its business if the amount of any judgment exceeds the insurance
coverage. Any claim that may be brought against CEL-SCI could
result in a court judgment or settlement in an amount that is not
covered, in whole or in part, by CEL-SCI&#x2019;s insurance or that
is in excess of the limits of the insurance coverage.
CEL-SCI&#x2019;s insurance policies also have various exclusions,
and CEL-SCI may be subject to a claim for which CEL-SCI has no
coverage. CEL-SCI may have to pay any amounts awarded by a court or
negotiated in a settlement that exceed the coverage limitations or
that are not covered by its insurance, and CEL-SCI may not have, or
be able to obtain, sufficient capital to pay such
amounts.&#xA0;&#xA0;CEL-SCI commenced the Phase 3 clinical trial
for Multikine in December 2010. Although no claims have been
brought to date, participants in the clinical trials could bring
civil actions against CEL-SCI for any unanticipated harmful effects
allegedly arising from the use of Multikine or any other product
candidate that CEL-SCI may attempt to develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">23</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s commercial success depends, in part, upon attaining
significant market acceptance of its product candidates, if
approved, among physicians, patients, healthcare payors and major
operators of cancer clinics.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Even
if CEL-SCI obtains regulatory approval for its product candidates,
any resulting product may not gain market acceptance among
physicians, healthcare payors, patients and the medical community,
which are critical to commercial success. Market acceptance of any
product candidate for which CEL-SCI receives approval depends on a
number of factors, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
efficacy and safety as demonstrated in clinical
trials;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
timing of market introduction of such product candidate as well as
competitive products;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
clinical indications for which the drug is approved;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
approval, availability, market acceptance and reimbursement for the
companion diagnostic;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">acceptance
by physicians, major operators of cancer clinics and patients of
the drug as a safe and effective treatment;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
potential and perceived advantages of a product candidate over
alternative treatments, especially with respect to patient subsets
that are targeted with a product candidate;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
safety of a product candidate seen in a broader patient group,
including its use outside the approved indications;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
cost of treatment in relation to alternative
treatments;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
availability of adequate reimbursement and pricing by third-party
payors and government authorities;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">relative
convenience and ease of administration;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
prevalence and severity of adverse side effects; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
effectiveness of sales and marketing efforts.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
CEL-SCI&#x2019;s product candidates are approved but fail to achieve
an adequate level of acceptance by physicians, healthcare payors
and patients, CEL-SCI will not be able to generate significant
revenues, and CEL-SCI may not become or remain
profitable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">24</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
Our Independent Registered Public Accountants have included in its
report on our financial statements a paragraph stating that we may
be unable to continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">As
a result of our recurring losses from operations, our independent
registered public accounting firm, BDO USA, LLP, has issued a
report in connection with their audit of our financial statements
for the year ended September 30, 2016, that included an explanatory
paragraph referring to our recurring losses from operations and
expressing substantial doubt in our ability to continue as a going
concern without additional capital becoming available. The doubt
about our ability to continue as a going concern could have an
adverse impact on our ability to execute our business plan, result
in the reluctance on the part of certain suppliers to do business
with us, or adversely affect our ability to raise additional debt
or equity capital.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Risks Related to Government Approvals</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s product candidates must undergo rigorous
preclinical and clinical testing and regulatory approvals, which
could be costly and time-consuming and subject CEL-SCI to
unanticipated delays or prevent CEL-SCI from marketing any
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
product candidates are subject to premarket approval from the FDA
in the United States, the EMA in the European Union, and by
comparable agencies in most foreign countries before they can be
sold. Before obtaining marketing approval, these product candidates
must undergo costly and time consuming preclinical and clinical
testing which could subject CEL-SCI to unanticipated delays and may
prevent CEL-SCI from marketing the product candidates. There can be
no assurance that such approvals will be granted on a timely basis,
if at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Clinical
testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical
studies and early clinical trials of the product candidates may not
be predictive of the results of later-stage clinical trials. A
number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of
efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. CEL-SCI&#x2019;s current and future
clinical trials may not be successful.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Although
CEL-SCI is involved in Phase 1 and Phase 3 clinical trials for
Multikine, CEL-SCI may experience delays in the clinical trials and
CEL-SCI does not know whether the clinical trials will need to be
redesigned, enroll patients on a timely basis or be completed on
schedule, if at all. Clinical trials can be delayed for a variety
of reasons, including delays related to:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
availability of financial resources needed to commence and complete
the planned trials;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">obtaining
regulatory approval to commence a trial;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">suspending
enrollment in clinical trials, as in the case of the partial
clinical hold issued by FDA related to our Phase 3 clinical trial
for Multikine;</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">25</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">reaching
agreement on acceptable terms with prospective contract research
organizations, or CROs, and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">obtaining
Institutional Review Board, or IRB, approval at each clinical trial
site;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">recruiting
suitable patients to participate in a trial;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">having
patients complete a trial or return for post-treatment
follow-up;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">clinical
trial sites deviating from trial protocol or dropping out of a
trial;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">adding
new clinical trial sites; or</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">manufacturing
sufficient quantities of the product candidate for use in clinical
trials.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Patient
enrollment, a significant factor in the timing of clinical trials,
is affected by many factors including the competence of the CRO
running the study, size and nature of the patient population, the
proximity of patients to clinical sites, the eligibility criteria
for the trial, the design of the clinical trial, competing clinical
trials and clinicians' and patients' perceptions as to the
potential advantages of the drug being studied in relation to other
available therapies, including any new drugs that may be approved
for the indications CEL-SCI is investigating. Furthermore, CEL-SCI
relies on CROs and clinical trial sites to ensure the proper and
timely conduct of the clinical trials and while CEL-SCI has
agreements governing their committed activities, CEL-SCI has
limited influence over their actual performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">On
October 31, 2013, CEL-SCI commenced arbitration proceedings against
inVentiv Health Clinical, LLC, or inVentiv, its former clinical
research organization (CRO). The arbitration claim, initiated under
the Commercial Rules of the American Arbitration Association,
alleges (i) breach of contract, (ii) fraud in the inducement, and
(iii) common law fraud. Currently, CEL-SCI is seeking at least $50
million in damages in its amended statement of claim.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against us for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for CEL-SCI alleged use of inVentiv&#x2019;s name
in connection with publications and promotions in violation of the
parties&#x2019; contract; (iii) opportunistic breach, restitution
and unjust enrichment, seeking at least $20 million in disgorgement
of alleged unjust profits allegedly made by CEL-SCI as a result of
the purported breaches referenced in subsection (ii); and (iv)
defamation, seeking at least $1 million in damages for allegedly
defamatory statements made about inVentiv.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">26</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Should
CEL-SCI&#x2019;s allegations be found to be true, regulatory
authorities may rule the data collected by that the former CRO
unusable in support of our marketing applications. Even if
CEL-SCI&#x2019;s allegations are not found to be true, regulatory
authorities may rule the data collected by that former CRO unusable
in support of our marketing applications. In either case, CEL-SCI
has proposed to enroll approximately 125 additional subjects in its
Phase 3 study beyond the study design that was in place prior to
FDA&#x2019;s imposition of a partial clinical hold on the study, but
those additional subjects can only be enrolled if the partial
clinical hold is lifted. The need to enroll those additional
patients will cause additional delays in our clinical testing and
development program, and there is no guarantee that the partial
clinical hold will be lifted, that if the partial clinical hold is
lifted the study will be in a position that additional patients can
be recruited and enrolled, or that CEL-SCI can successfully enroll
the additional patients necessary to complete the study if the
clinical hold is lifted. Currently, the Phase 3 study has been
placed on partial clinical hold by FDA. In its partial clinical
hold letter, FDA identified the following specific deficiencies: a)
FDA stated that there is an unreasonable and significant risk of
illness or injury to human subjects; b) FDA stated that the
investigator brochure is misleading, erroneous, and materially
incomplete; and c) FDA stated that the plan or protocol is
deficient in design to meet its stated objectives. In its partial
clinical hold letter, FDA also identified the information needed to
resolve these deficiencies. In CEL-SCI&#x2019;s response submitted
to FDA on November 18, 2016, CEL-SCI believes it addressed each of
the deficiencies identified by FDA, requested a face-to-face
meeting with FDA, and detailed its commitment to diligently work
with FDA in an effort to have the partial clinical hold for the
study lifted.</font> <font style="font-size: 13px; font-family: Times New Roman">On December 8,
2016, the FDA advised CEL-SCI that the agency was denying CEL-SCI's
request for a meeting at this time because FDA's review of
CEL-SCI's November 17, 2016 response was ongoing. CEL-SCI was also
advised that it will be receiving a letter addressing CEL-SCI's
response by December 18, 2016.</font> <font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
the partial clinical hold is not ever lifted, the Phase 3 study
will not be able to be completed to its prespecified endpoints in a
timely manner, if at all, and, if the Phase 3 study cannot be
completed to its prespecified endpoints, the study would not be
able to be used as the pivotal study supporting a marketing
application in the United States, and at least one entirely new
Phase 3 pivotal study would need to be conducted to provide the
pivotal study supporting a marketing application in the United
States. Even if the partial clinical hold is lifted, if it is not
lifted in a timely fashion, the nature and duration of the partial
clinical hold could irreparably harm the data from the Phase 3
study such that it may no longer be able to be used as the pivotal
study supporting a marketing application in the United States. Even
if the partial clinical hold is lifted in a timely fashion, it
remains possible that the regulatory authorities could determine
that the Phase 3 study is not sufficient to be used as a single
pivotal study supporting a marketing application in the United
States. In either of these latter circumstances, at least one
entirely new Phase 3 pivotal study would need to be conducted to
provide the pivotal study supporting a marketing application in the
United States. If there is a need to conduct an additional Phase 3
pivotal study, any such requirement would have significant and
severe material consequences for CEL-SCI and could impact its
ability to continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">CEL-SCI could also encounter significant delays
and/or need to terminate a development program for a product
candidate if physicians encounter unresolved ethical issues
associated with enrolling patients in clinical trials of the
product candidates in addition to existing treatments that have
established safety and efficacy profiles. Further, a clinical trial
may be suspended or terminated by CEL-SCI, one or more of the IRBs
for the institutions in which such trials are being conducted, by
CEL-SCI upon a final recommendation by the Independent Data
Monitoring Committee, or IDMC, with which CEL-SCI agrees for such
trial, or by FDA or other regulatory authorities due to a number of
factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or the clinical protocols,
as a result of inspection of the clinical trial operations or trial
site(s) by FDA or other regulatory authorities, the imposition of a
clinical hold</font>&#xA0;<font style="color: #000000">or partial
clinical hold such as the partial clinical hold currently imposed
by FDA on the Phase 3 study of our investigational drug Multikine
as detailed elsewhere in this prospectus supplement, unforeseen
safety issues or adverse side effects, failure to demonstrate a
benefit from using a product candidate, changes in governmental
regulations or administrative actions or lack of adequate funding
to continue the clinical trial. The occurrence of any one or more
of these events would have significant and severe material
consequences for us and could impact our ability to continue as an
ongoing concern.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">27</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
CEL-SCI experiences termination of, or delays in the completion of,
any clinical trial of its product candidates, the commercial
prospects for the product candidates will be harmed, and the
ability to generate product revenues will be delayed. In addition,
any delays in completing the clinical trials will increase the
costs, slow the product development and approval process and
jeopardize the ability to commence product sales and generate
revenues. Any of these occurrences may harm CEL-SCI&#x2019;s
business, prospects, financial condition and results of operations
significantly. Many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also
ultimately lead to a delay or the denial of regulatory approval for
the product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
cannot be certain when or under what conditions it will undertake
future clinical trials.&#xA0;&#xA0;A variety of issues may delay
the Phase 3 clinical trial for Multikine, such as patients in the
Phase 3 clinical trial dying at a slower rate than projected and
the existing partial clinical hold, or preclinical and early
clinical trials for the other product candidates.&#xA0;&#xA0;For
example, early trials, or the plans for later trials, may not
satisfy the requirements of regulatory authorities, such as the
FDA. CEL-SCI may fail to find subjects willing to enroll in the
trials. CEL-SCI manufactures Multikine in its manufacturing
facility, but relies on third-party vendors to manage the trial
process and other activities, and these vendors may fail to meet
appropriate standards.&#xA0;&#xA0;Accordingly, the clinical trials
relating to the product candidates may not be completed on
schedule, the FDA or foreign regulatory agencies may order CEL-SCI
to stop or modify research, or these agencies may not ultimately
approve any of the product candidates for commercial sale. Varying
interpretations of the data obtained from pre-clinical and clinical
testing could delay, limit or prevent regulatory approval of the
product candidates. The data collected from the clinical trials may
not be sufficient to support regulatory approval of the various
product candidates, including Multikine. The failure to adequately
demonstrate the safety and efficacy of any of the product
candidates would delay or prevent regulatory approval of the
product candidates in the United States, which could prevent
CEL-SCI from achieving profitability. Although CEL-SCI had positive
results in the Phase 2 trials for Multikine, those results were for
a very small sample set, and CEL-SCI will not know how Multikine
will perform in a larger set of subjects until CEL-SCI is well
into, or completes, the Phase 3 clinical trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
development and testing of product candidates and the process of
obtaining regulatory approvals and the subsequent compliance with
appropriate federal, state, local and foreign statutes and
regulations require the expenditure of substantial time and
financial resources.&#xA0;&#xA0;Failure to comply with the
applicable U.S. requirements at any time during the product
development process, approval process or after approval, may
subject an applicant to administrative or judicial sanctions. FDA
sanctions could include, among other actions, refusal to approve
pending applications, withdrawal of an approval, a clinical hold,
termination of the Phase 3 study, warning letters, product recalls
or withdrawals from the market, product seizures, total or partial
suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or
civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on
CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
requirements governing the conduct of clinical trials,
manufacturing and marketing of the product candidates, including
Multikine, outside the United States vary from country to country.
Foreign approvals may take longer to obtain than FDA approvals and
can require, among other things, additional testing and different
trial designs. Foreign regulatory approval processes include all of
the risks associated with the FDA approval process. Some of those
agencies also must approve prices for products approved for
marketing. Approval of a product by the FDA or the EMA does not
ensure approval of the same product by the health authorities of
other countries. In addition, changes in regulatory requirements
for product approval in any country during the clinical trial
process and regulatory agency review of each submitted new
application may cause delays or rejections.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">28</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
has only limited experience in filing and pursuing applications
necessary to gain regulatory approvals.&#xA0;&#xA0;The lack of
experience may impede the ability to obtain timely approvals from
regulatory agencies, if at all. CEL-SCI will not be able to
commercialize Multikine and other product candidates until CEL-SCI
has obtained regulatory approval.&#xA0;&#xA0;In addition,
regulatory authorities may also limit the types of patients to
which CEL-SCI or its third-party partners may market Multikine or
the other product candidates. Any failure to obtain or any delay in
obtaining required regulatory approvals may adversely affect
CEL-SCI&#x2019;s or its third-party partners&#x2019; ability to
successfully market the product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Even if CEL-SCI obtains regulatory approval for its investigational
products, CEL-SCI will be subject to stringent, ongoing government
regulation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
CEL-SCI&#x2019;s investigational products receive regulatory
approval, either in the United States or internationally, those
products will be subject to limitations on the approved indicated
uses for which the product may be marketed or to the conditions of
approval, and may contain requirements for potentially costly
post-marketing testing, including Phase&#xA0;4 clinical trials, and
surveillance of the safety and efficacy of the investigational
products.&#xA0;&#xA0;CEL-SCI will continue to be subject to
extensive regulatory requirements. These regulations are
wide-ranging and govern, among other things:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
design, development and manufacture;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
application and use</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">adverse
drug experience;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
advertising and promotion;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
manufacturing, including good manufacturing practices</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">record
keeping requirements;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">registration
and listing of the establishments and products with the FDA, EMA
and other state and national agencies;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">product
storage and shipping;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">drug
sampling and distribution requirements;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">electronic
record and signature requirements; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">labeling
changes or modifications.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">29</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
and any of its third-party manufacturers or suppliers must
continually adhere to federal regulations setting forth
requirements, known as current, Good Manufacturing Practices, or
cGMPs, and their foreign equivalents, which are enforced by the
FDA, the EMA and other national regulatory bodies through their
facilities inspection programs. If the facilities, or the
facilities of the contract manufacturers or suppliers, cannot pass
a pre-approval plant inspection or fail such inspections in the
future, the FDA, EMA or other national regulators will not approve
the marketing applications for the product candidates, or may
withdraw any prior approval. In complying with cGMP and foreign
regulatory requirements, CEL-SCI and any of its potential
third-party manufacturers or suppliers will be obligated to expend
time, money and effort in production, record-keeping and quality
control to ensure that the product candidates meet applicable
specifications and other requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
CEL-SCI does not comply with regulatory requirements at any stage,
whether before or after marketing approval is obtained, CEL-SCI may
be subject to, among other things, license suspension or
revocation, criminal prosecution, seizure, injunction, fines, be
forced to remove a product from the market or experience other
adverse consequences, including restrictions or delays in obtaining
regulatory marketing approval for such products or for other
product candidates for which CEL-SCI seeks
approval.&#xA0;&#xA0;This could materially harm CEL-SCI&#x2019;s
financial results, reputation and stock price. Additionally,
CEL-SCI may not be able to obtain the labeling claims necessary or
desirable for product promotion. If CEL-SCI or other parties
identify adverse effects after any of the products are on the
market, or if manufacturing problems occur, regulatory approval may
be suspended or withdrawn. CEL-SCI may be required to reformulate
products, conduct additional clinical trials, make changes in
product labeling or indications of use, or submit additional
marketing applications to support any changes.&#xA0;&#xA0;If
CEL-SCI encounters any of the foregoing problems, its business and
results of operations will be harmed and the market price of its
common stock may decline.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
FDA and other governmental authorities&#x2019; policies may change
and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of CEL-SCI&#x2019;s
product candidates. If CEL-SCI is slow or unable to adapt to
changes in existing requirements or the adoption of new
requirements or policies, or if CEL-SCI is not able to maintain
regulatory compliance, CEL-SCI may lose any marketing approval that
it may have obtained, which would adversely affect its business,
prospects and ability to achieve or sustain
profitability.&#xA0;&#xA0;CEL-SCI cannot predict the extent of
adverse government regulations which might arise from future
legislative or administrative action. Without government approval,
CEL-SCI will be unable to sell any of its product
candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s product candidates may cause undesirable side
effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following
marketing approval, if any.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Undesirable
side effects caused by the product candidates could cause CEL-SCI
or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label or the delay or
denial of regulatory approval by the FDA or other comparable
foreign authorities. Results of the clinical trials could reveal a
high and unacceptable severity and/or prevalence of these or other
side effects. In such an event, the trials could be suspended or
terminated and the FDA or comparable foreign regulatory authorities
could order CEL-SCI to cease further development of, or deny
approval of, the product candidates for any or all targeted
indications. The drug-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. Any of these
occurrences may harm CEL-SCI&#x2019;s business, financial condition
and prospects significantly.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">30</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Additionally,
if one or more of the product candidates receives marketing
approval, and CEL-SCI or others later identify undesirable side
effects caused by such products, a number of potentially
significant negative consequences could result,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">regulatory
authorities may withdraw approvals of such product;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">regulatory
authorities may require additional warnings on the
label;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
may be required to create a medication guide outlining the risks of
such side effects for distribution to patients;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
could be sued and held liable for harm caused to patients;
and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
reputation may suffer.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Any
of these events could prevent CEL-SCI from achieving or maintaining
market acceptance of a particular product candidate, if approved,
and could significantly harm its business, results of operations
and prospects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI relies on third parties to conduct its preclinical and
clinical trials. If these third parties do not successfully carry
out their contractual duties and meet regulatory requirements, or
meet expected deadlines, CEL-SCI may not be able to obtain
regulatory approval for or commercialize the product candidates and
its business could be substantially harmed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
has relied upon and plans to continue to rely upon third-party CROs
to prepare for, conduct, monitor and manage data for its ongoing
preclinical and clinical programs. CEL-SCI relies on these parties
for all aspects of the execution of its preclinical studies and
clinical trials, and although CEL-SCI diligently oversees and
carefully manages the CROs, CEL-SCI directly controls only certain
aspects of their activities and relies upon them to provide timely,
complete, and accurate reports on the conduct of the studies.
Although such third parties provide support and represent CEL-SCI
for regulatory purposes in the context of the clinical trials,
ultimately CEL-SCI is responsible for ensuring that each of the
studies is conducted in accordance with the applicable protocol,
legal, regulatory, and scientific standards, and the reliance on
the CROs does not relieve CEL-SCI of its regulatory
responsibilities. CEL-SCI and the CROs acting on CEL-SCI&#x2019;s
behalf as well as principal investigators and trial sites are
required to comply with Good Clinical Practice, or GCP, and other
applicable requirements, which are implemented through regulations
and guidelines enforced by the FDA, the Competent Authorities of
the Member States of the European Economic Area, or EEA, and
comparable foreign regulatory authorities for all of the products
in clinical development. Regulatory authorities enforce these GCPs
through periodic inspections of trial sponsors, principal
investigators, and trial sites. If CEL-SCI or any of the CROs fail
to comply with applicable GCPs or other applicable regulations, the
clinical data generated in the clinical trials may be determined to
be unreliable and CEL-SCI may therefore need to enroll additional
subjects in the clinical trials, or the FDA, EMA or comparable
foreign regulatory authorities may require CEL-SCI to perform an
additional clinical trial or trials before approving the marketing
applications. Moreover, if CEL-SCI or any of the CROs, principal
investigators, or trial sites, fail to comply with applicable
regulatory and GCP requirements, then CEL-SCI, the CROs, principal
investigators, or trial sites may be subject to enforcement
actions, such as fines, warning letters, untitled letters, clinical
holds, civil or criminal penalties, and/or injunctions. CEL-SCI
cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of the
clinical trials comply with GCP regulations. In addition, the
clinical trials must be conducted with product produced under GMP
regulations. The failure to comply with these regulations may
require CEL-SCI to delay or repeat clinical trials, which would
delay the regulatory approval process.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">31</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">For
example, CEL-SCI is currently involved in a dispute with the former
CRO relating to the conduct of the Phase 3 study where CEL-SCI
alleges (i) breach of contract, (ii) fraud in the inducement and
(iii) fraud. In connection with this dispute, CEL-SCI has alleged
that the CRO failed to properly select, monitor and supervise the
study sites and principal investigators, ensure proper enrollment
of subjects, and ensure strict compliance with the Phase 3 trial
protocol and GCP and other applicable regulatory requirements.
Should CEL-SCI&#x2019;s allegations be found to be true regulatory
authorities may rule the data collected by that former CRO unusable
in support of the marketing applications. This would result in
CEL-SCI having to enroll approximately 125 additional subjects in
the Phase 3 study beyond its current plans, which could cause
additional delays in the clinical testing and development program.
Currently the Phase 3 study is on partial clinical
hold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
any of the relationships with the third-party CROs terminate,
CEL-SCI may not be able to enter into arrangements with alternative
CROs or to do so on commercially reasonable terms. In addition, the
CROs are not CEL-SCI&#x2019;s employees, and except for remedies
available to CEL-SCI under the agreements with such CROs, CEL-SCI
cannot control whether or not they devote sufficient time and
resources to the on-going clinical, nonclinical and preclinical
programs. If CROs do not successfully fulfill their regulatory
obligations, carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the
quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to the clinical protocols, regulatory
requirements or for other reasons, the clinical trials may be
extended, delayed or terminated, and CEL-SCI may not be able to
obtain regulatory approval for or successfully commercialize the
product candidates. As a result, CEL-SCI&#x2019;s results of
operations and the commercial prospects for the product candidates
would be harmed, the costs could increase and the ability to
generate revenues could be delayed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Switching
or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result,
delays may occur, which can materially impact CEL-SCI&#x2019;s
ability to meet the desired clinical development timelines. Though
CEL-SCI diligently oversees and carefully manages its relationships
with the CROs, there can be no assurance that CEL-SCI will not
encounter similar challenges or delays in clinical development in
the future or that these delays or challenges will not have a
material adverse impact on CEL-SCI&#x2019;s business, financial
condition and prospects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">32</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI has obtained orphan drug designation from the FDA for
Multikine for neoadjuvant, or primary, therapy in patients with
squamous cell carcinoma of the head and neck, but CEL-SCI may be
unable to maintain the benefits associated with orphan drug
designation, including the potential for market
exclusivity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a
drug or biologic intended to treat a rare disease or condition,
which is defined as one occurring in a patient population of fewer
than 200,000 in the United States, or a patient population greater
than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug or biologic will
be recovered from sales in the United States. In the United States,
orphan drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial
costs, tax advantages and user-fee waivers. In addition, if a
product that has orphan drug designation subsequently receives the
first FDA approval for the disease for which it has such
designation, the product is entitled to orphan drug exclusivity,
which means that the FDA may not approve any other applications,
including a full Biologics License Application, or BLA, to market
the same biologic for the same indication for seven years, except
in limited circumstances, such as a showing of clinical superiority
to the product with orphan drug exclusivity or where the
manufacturer is unable to assure sufficient product
quantity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Even
though CEL-SCI has received orphan drug designation for Multikine
for the treatment of squamous cell carcinoma of the head and neck,
CEL-SCI may not be the first to obtain marketing approval of a
product for the orphan-designated indication due to the
uncertainties associated with developing pharmaceutical products.
In addition, exclusive marketing rights in the United States may be
limited if CEL-SCI seeks approval for an indication broader than
the orphan-designated indication, or may be lost if the FDA later
determines that the request for designation was materially
defective or if CEL-SCI is unable to assure sufficient quantities
of the product to meet the needs of patients with the rare disease
or condition. Further, even if CEL-SCI obtains orphan drug
exclusivity for a product candidate, that exclusivity may not
effectively protect the product candidate from competition because
different drugs with different active moieties can be approved for
the same condition. Even after an orphan product is approved, the
FDA can subsequently approve another drug with the same active
moiety for the same condition if the FDA concludes that the later
drug is safer, more effective, or makes a major contribution to
patient care. Orphan drug designation neither shortens the
development time or regulatory review time of a drug nor gives the
drug any advantage in the regulatory review or approval
process.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
The current and future relationships with healthcare professionals,
principal investigators, consultants, customers (actual and
potential) and third-party payors in the United States and
elsewhere may be subject, directly or indirectly, to applicable
healthcare laws and regulations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Healthcare
providers, physicians and third-party payors in the United States
and elsewhere will play a primary role in the recommendation and
prescription of any drug candidates for which CEL-SCI obtains
marketing approval. The current and future arrangements with
healthcare professionals, principal investigators, consultants,
customers (actual and potential) and third-party payors may expose
CEL-SCI to broadly applicable healthcare laws, including, without
limitation:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
federal Anti-Kickback Statute, which prohibits, among other things,
persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in
cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which
payment may be made, in whole or in part, under federal and state
healthcare programs such as Medicare and Medicaid. A person or
entity does not need to have actual knowledge of the statute or
specific intent to violate it to have committed a violation. In
addition, the Affordable Care Act provides that the government may
assert that a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the False Claims
Act;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">33</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">federal
civil and criminal false claims laws, including the federal False
Claims Act, which impose criminal and civil penalties, including
civil whistleblower actions, against individuals or entities for,
among other things, knowingly presenting, or causing to be
presented, to the federal government, including the Medicare and
Medicaid programs, claims for payment that are false or fraudulent
or making a false statement to avoid, decrease or conceal an
obligation to pay money to the federal government;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
civil monetary penalties statute, which imposes penalties against
any person or entity who, among other things, is determined to have
presented or caused to be presented a claim to a federal health
program that the person knows or should know is for an item or
service that was not provided as claimed or is false or
fraudulent;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, which created new federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or
obtain, by means of false or fraudulent pretenses, representations
or promises, any of the money or property owned by, or under the
custody or control of, any healthcare benefit program, regardless
of the payor (e.g., public or private), knowingly and willfully
embezzling or stealing from a health care benefit program,
willfully obstructing a criminal investigation of a healthcare
offense and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items or services relating to
healthcare matters. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it to have
committed a violation;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">HIPAA,
as amended by the Health Information Technology for Economic and
Clinical Health Act of 2009, or HITECH, and their respective
implementing regulations, which impose obligations on covered
entities, including healthcare providers, health plans, and
healthcare clearinghouses, as well as their respective business
associates that create, receive, maintain or transmit individually
identifiable health information for or on behalf of a covered
entity, with respect to safeguarding the privacy, security and
transmission of individually identifiable health
information;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
federal Physician Payments Sunshine Act and its implementing
regulations, which imposed annual reporting requirements for
certain manufacturers of drugs, devices, biologicals and medical
supplies for payments and &#x201C;transfers of value&#x201D; provided
to physicians and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family
members; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">analogous
state and foreign laws, such as state anti-kickback and false
claims laws, which may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers;
state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#x2019;s voluntary compliance guidelines and
the relevant compliance guidance promulgated by the federal
government or otherwise restrict payments that may be made to
healthcare providers; state and foreign laws that require drug
manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or
marketing expenditures; and state and foreign laws governing the
privacy and security of health information in certain
circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating
compliance efforts.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">34</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Efforts
to ensure that the future business arrangements with third parties
will comply with applicable healthcare laws and regulations may
involve substantial costs. It is possible that governmental
authorities will conclude that the business practices may not
comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws. If
CEL-SCI&#x2019;s operations are found to be in violation of any of
these laws or any other governmental regulations, CEL-SCI may be
subject to significant civil, criminal and administrative
penalties, including, without limitation, damages, fines,
imprisonment, exclusion from participation in government healthcare
programs, such as Medicare and Medicaid, and the curtailment or
restructuring of the operations, all of which could significantly
harm CEL-SCI&#x2019;s business. If any of the physicians or other
healthcare providers or entities with whom CEL-SCI expects to do
business, including current and future collaborators, are found not
to be in compliance with applicable laws, they may be subject to
criminal, civil or administrative sanctions, including exclusions
from participation in government healthcare programs, which could
also adversely affect CEL-SCI&#x2019;s business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Failure to obtain or maintain adequate coverage and reimbursement
for the product candidates, if approved, could limit the ability to
market those products and decrease CEL-SCI&#x2019;s ability to
generate revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Sales
of CEL-SCI&#x2019;s product candidates will depend substantially,
both domestically and abroad, on the extent to which the costs of
the product candidates will be paid by health maintenance, managed
care, pharmacy benefit, and similar healthcare management
organizations, or reimbursed by government authorities, private
health insurers and other third-party payors. CEL-SCI anticipates
that government authorities and other third-party payors will
continue efforts to contain healthcare costs by limiting the
coverage and reimbursement levels for new drugs. If coverage and
reimbursement are not available, or are available only to limited
levels, CEL-SCI may not be able to successfully commercialize its
product candidates. Even if coverage is provided, the approved
reimbursement amount may not be high enough to allow CEL-SCI to
establish or maintain pricing sufficient to realize a return on its
investment. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and
reimbursement for the product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">35</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Healthcare legislative reform measures may have a material adverse
effect on CEL-SCI&#x2019;s business and results of
operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
the United States, there have been and continue to be a number of
legislative initiatives to contain healthcare costs that may result
in more limited coverage or downward pressure on the price CEL-SCI
may otherwise receive for its product candidates. For example, in
March 2010, the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act, or
collectively, the Affordable Care Act, was passed, which
substantially changes the way health care is financed by both
governmental and private insurers, and significantly impacts the
U.S. pharmaceutical industry. The Affordable Care Act, among other
things, addressed a new methodology by which rebates owed by
manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or
injected, increased the minimum Medicaid rebates owed by
manufacturers under the Medicaid Drug Rebate Program and extended
the rebate program to individuals enrolled in Medicaid managed care
organizations, established annual fees and taxes on manufacturers
of certain branded prescription drugs, and established the Center
for Medicare and Medicaid Innovation with broad authority to test
and implement new payment models under Medicare and Medicaid, which
are designed to reduce expenditures while preserving and enhancing
quality of care.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
addition, other legislative changes have been proposed and adopted
in the United States since the Affordable Care Act was enacted. On
August 2, 2011, the Budget Control Act of 2011 among other things,
created measures for spending reductions by Congress. A Joint
Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby
triggering the legislation's automatic reduction to several
government programs. This includes aggregate reductions of Medicare
payments to providers of 2% per fiscal year, which went into effect
in April 2013 and, due to subsequent legislative amendments to the
statute, will remain in effect through 2024 unless additional
Congressional action is taken. On January 2, 2013, President Obama
signed into law the American Taxpayer Relief Act of 2012, which,
among other things, further reduced Medicare payments to several
providers, including hospitals, imaging centers and cancer
treatment centers. On April 16, 2015, President Obama signed into
law the Medicare Access and CHIP Reauthorization Act of 2015, or
MACRA. Among other things, MACRA creates incentives for physicians
to participate in alternative payment models under Medicare that
emphasize quality and value in place of the traditional,
volume-based fee-for-service program. CEL-SCI expects that
additional state and federal healthcare reform measures will be
adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and
services, which could result in reduced demand for its product
candidates or additional pricing pressures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Foreign governments often impose strict price controls, which may
adversely affect CEL-SCI&#x2019;s future profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
intends to seek approval to market Multikine in both the United
States and foreign jurisdictions. If CEL-SCI obtains approval in
one or more foreign jurisdictions, CEL-SCI will be subject to rules
and regulations in those jurisdictions relating to Multikine. In
some foreign countries, particularly in the European Union,
prescription drug pricing is subject to governmental control. In
these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval
for a drug candidate. Coverage and reimbursement decisions in one
foreign jurisdiction may impact decisions in other countries. To
obtain reimbursement or pricing approval in some countries, CEL-SCI
may be required to conduct clinical trials that demonstrate the
product candidate is more effective than current treatments and
that compare the cost-effectiveness of Multikine to other available
therapies. If reimbursement of Multikine is unavailable or limited
in scope or amount, or if pricing is set at unsatisfactory levels,
CEL-SCI may be unable to achieve or sustain
profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">36</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Risks Related to Intellectual Property</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI may not be able to achieve or maintain a competitive
position, and other technological developments may result in its
proprietary technologies becoming uneconomical or
obsolete.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
is involved in a biomedical field that is undergoing rapid and
significant technological change. The pace of change continues to
accelerate.&#xA0;&#xA0;The successful development of product
candidates from the compounds, compositions and processes, through
research financed by CEL-SCI, or as a result of possible
third-party licensing arrangements with pharmaceutical or other
companies, is not assured.&#xA0;&#xA0;CEL-SCI may fail to apply for
patents on important technologies or product candidates in a timely
fashion, or at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Many
companies are working on drugs designed to cure or treat cancer or
cure and treat viruses, such as HPV or H1N1.&#xA0;&#xA0;Many of
these companies have financial, research and development, and
marketing resources, which are much greater than CEL-SCI&#x2019;s,
and are capable of providing significant long-term competition
either by establishing in-house research groups or by forming
collaborative ventures with other entities. In addition, smaller
companies and non-profit institutions are active in research
relating to cancer and infectious diseases.&#xA0;&#xA0;The future
market share of Multikine or the other product candidates, if
approved, will be reduced or eliminated if the competitors develop
and obtain approval for products that are safer or more effective
than CEL-SCI&#x2019;S product candidates.&#xA0;&#xA0;Moreover, the
patent positions of pharmaceutical companies are highly uncertain
and involve complex legal and factual questions for which important
legal principles are often evolving and remain unresolved. As a
result, the validity and enforceability of patents cannot be
predicted with certainty. In addition, CEL-SCI does not know
whether:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
was the first to make the inventions covered by each of its issued
patents and pending patent applications;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
was the first to file patent applications for these
inventions;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">others
will independently develop similar or alternative technologies or
duplicate any of the technologies;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">any
of the pending patent applications will result in issued
patents;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">any
of the patents will be valid or enforceable;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">any
patents issued to CEL-SCI or the collaboration partners will
provide CEL-SCI with any competitive advantages, or will be
challenged by third parties;</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">37</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
will be able to develop additional proprietary technologies that
are patentable;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
U.S. government will exercise any of its statutory rights to
CEL-SCI&#x2019;s intellectual property that was developed with
government funding; or</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">its
business may infringe the patents or other proprietary rights of
others.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s patents might not protect its technology from
competitors, in which case CEL-SCI may not have any advantage over
competitors in selling any products that CEL-SCI may
develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
commercial success will depend in part on its ability to obtain
additional patents and protect its existing patent position, as
well as its ability to maintain adequate intellectual property
protection for the technologies, product candidates, and any future
products in the United States and other countries. If CEL-SCI does
not adequately protect its technology, product candidates and
future products, competitors may be able to use or practice them
and erode or negate any competitive advantage CEL-SCI may have,
which could harm CEL-SCI&#x2019;s business and ability to achieve
profitability. The laws of some foreign countries do not protect
the proprietary rights to the same extent or in the same manner as
U.S. laws, and CEL-SCI may encounter significant problems in
protecting and defending its proprietary rights in these countries.
CEL-SCI will be able to protect its proprietary rights from
unauthorized use by third parties only to the extent that its
proprietary technologies, product candidates and any future
products are covered by valid and enforceable patents or are
effectively maintained as trade secrets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Certain
aspects of CEL-SCI&#x2019;s technologies are covered by U.S. and
foreign patents. In addition, CEL-SCI has a number of new patent
applications pending. There is no assurance that the applications
still pending or which may be filed in the future will result in
the issuance of any patents. Furthermore, there is no assurance as
to the breadth and degree of protection any issued patents might
afford CEL-SCI. Disputes may arise between CEL-SCI and others as to
the scope and validity of these or other patents. Any defense of
the patents could prove costly and time consuming and there can be
no assurance that CEL-SCI will be in a position, or will deem it
advisable, to carry on such a defense.&#xA0;&#xA0;A suit for patent
infringement could result in increasing costs, delaying or halting
development, or even forcing CEL-SCI to abandon a product
candidate.&#xA0;&#xA0;Other private and public concerns, including
universities, may have filed applications for, may have been
issued, or may obtain additional patents and other proprietary
rights to technology potentially useful or necessary to CEL-SCI.
CEL-SCI is not currently aware of any such patents, but the scope
and validity of such patents, if any, and the cost and availability
of such rights are impossible to predict.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Much of CEL-SCI&#x2019;s intellectual property is protected as trade
secrets or confidential know-how, not as a patent.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
considers proprietary trade secrets and/or confidential know-how
and unpatented know-how to be important to its
business.&#xA0;&#xA0;Much of the intellectual property pertains to
CEL-SCI&#x2019;S manufacturing system, certain aspects of which may
not be suitable for patent filings and must be protected as trade
secrets and/or confidential know-how.&#xA0;&#xA0;This type of
information must be protected diligently by CEL-SCI to protect its
disclosure to competitors, since legal protections after disclosure
may be minimal or non-existent.&#xA0;&#xA0;Accordingly, much of the
value of this intellectual property is dependent upon the ability
of CEL-SCI to keep the trade secrets and know-how
confidential.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">38</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">To
protect this type of information against disclosure or
appropriation by competitors, CEL-SCI&#x2019;s policy is to require
its employees, consultants, contractors and advisors to enter into
confidentiality agreements with CEL-SCI. However, current or former
employees, consultants, contractors and advisers may
unintentionally or willfully disclose the confidential information
to competitors, and confidentiality agreements may not provide an
adequate remedy in the event of unauthorized disclosure of
confidential information. Enforcing a claim that a third party
obtained illegally, and is using, trade secrets and/or confidential
know-how is expensive, time consuming and unpredictable. The
enforceability of confidentiality agreements may vary from
jurisdiction to jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
addition, in some cases a regulator considering the application for
product candidate approval may require the disclosure of some or
all of the proprietary information.&#xA0;&#xA0;In such a case,
CEL-SCI must decide whether to disclose the information or forego
approval in a particular country.&#xA0;&#xA0;If CEL-SCI is unable
to market its product candidates in key countries, CEL-SCI&#x2019;s
opportunities and value may suffer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Failure
to obtain or maintain trade secrets and/or confidential know-how
trade protection could adversely affect CEL-SCI&#x2019;S competitive
position. Moreover, competitors may independently develop
substantially equivalent proprietary information and may even apply
for patent protection in respect of the same. If successful in
obtaining such patent protection, competitors could limit the use
of such trade secrets and/or confidential know-how.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI may be subject to claims challenging the inventorship or
ownership of its patents and other intellectual
property.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
may also be subject to claims that former employees, collaborators
or other third parties have an ownership interest in its patents or
other intellectual property. CEL-SCI may be subject to ownership
disputes in the future arising, for example, from conflicting
obligations of consultants or others who are involved in developing
the product candidates. Litigation may be necessary to defend
against these and other claims challenging inventorship or
ownership. If CEL-SCI fails in defending any such claims, in
addition to paying monetary damages, CEL-SCI may lose valuable
intellectual property rights, such as exclusive ownership of, or
right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on its business. Even if CEL-SCI is
successful in defending against such claims, litigation could
result in substantial costs and be a distraction to CEL-SCI&#x2019;s
management and employees.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Risks Related to CEL-SCI&#x2019;s common stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
You may experience future dilution as a result of future equity
offerings or other equity issuances.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
expects that significant additional capital will be needed in the
future to continue its planned operations. To raise additional
capital, CEL-SCI may in the future offer additional shares of its
common stock or other securities convertible into or exchangeable
for the common stock.&#xA0;&#xA0;&#xA0;&#xA0;To the extent CEL-SCI
raises additional capital by issuing equity securities, the
stockholders may experience substantial dilution. These sales may
result in material dilution to CEL-SCI&#x2019;s existing
stockholders and new investors could gain rights superior to
existing stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">39</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s outstanding options and warrants may adversely
affect the trading price of its common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="color: #000000; font-size: 13px; font-family: Times New Roman">As
of September 30, 2016, there were outstanding warrants and options
which allow the holders to purchase 3,442,383 shares
that may be issued upon the exercise of outstanding warrants, with
a weighted average exercise price of $24.25 per share,
and 343,571 shares that may be issued upon the
exercise of outstanding options, with a weighted average exercise
price of $59.25 per share. The outstanding options and
warrants could adversely affect the ability of CEL-SCI to obtain
future financing or engage in certain mergers or other
transactions, since the holders of options and warrants can be
expected to exercise them at a time when CEL-SCI may be able to
obtain additional capital through a new offering of securities on
terms more favorable to CEL-SCI than the terms of the outstanding
options and warrants.&#xA0; For the life of the options and
warrants, the holders have the opportunity to profit from a rise in
the market price of its common stock without assuming the risk of
ownership.&#xA0; The issuance of shares upon the exercise of
outstanding options and warrants will also dilute the ownership
interests of CEL-SCI&#x2019;s existing stockholders.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
CEL-SCI&#x2019;s ability to utilize its net operating loss
carryforwards and certain other tax attributes may be
limited.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">Under Section 382 of the Internal Revenue Code of
1986, as amended, if a corporation undergoes an &#x201C;ownership
change&#x201D; (generally defined as a greater than 50% change (by
value) in its equity ownership over a three-year period), the
corporation&#x2019;s ability to use its pre-change net operating
loss carryforwards and other pre-change tax attributes to offset
its post-change income may be limited. Taking into account the
public offerings and other transactions, CEL-SCI may have triggered
an &#x201C;ownership change&#x201D; limitation. In addition, CEL-SCI
may experience ownership changes in the future as a result of
subsequent shifts in its stock ownership, some of which are outside
its control. As a result, the ability to use the pre-change net
operating loss carryforwards and other pre-change tax attributes to
offset U.S. federal taxable income may be subject to limitations,
which could result in increased tax liability to
CEL-SCI</font><font style="font-weight: bold; color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Since CEL-SCI does not intend to pay dividends on its common stock,
any potential return to investors will result only from any
increases in the price of its common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">At
the present time, CEL-SCI intends to use available funds to finance
its operations. Accordingly, while payment of dividends rests
within the discretion of its board of directors, no common stock
dividends have been declared or paid by CEL-SCI and it has no
intention of paying any common stock dividends in the foreseeable
future. Additionally, any future debt financing arrangement may
contain terms prohibiting or limiting the amount of dividends that
may be declared or paid on CEL-SCI&#x2019;s common
stock.&#xA0;&#xA0;Any return to CEL-SCI&#x2019;s shareholders will
therefore be limited to appreciation in the price of its common
stock, which may never occur.&#xA0;&#xA0;If CEL-SCI&#x2019;s stock
price does not increase, CEL-SCI&#x2019;S shareholders are unlikely
to receive any return on their investments in CEL-SCI&#x2019;s
common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">40</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
The price of CEL-SCI&#x2019;s common stock has been volatile and is
likely to continue to be volatile, which could result in
substantial losses for CEL-SCI&#x2019;s shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
stock price has been, and is likely to continue to be, volatile. As
a result of this volatility, CEL-SCI&#x2019;s shareholders may not
be able to sell their shares at or above its current market price.
The market price for CEL-SCI&#x2019;s common stock may be influenced
by many factors, including:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">actual
or anticipated fluctuations in CEL-SCI&#x2019;s financial condition
and operating results;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">actual
or anticipated changes in CEL-SCI&#x2019;s growth rate relative to
competitors;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">competition
from existing products or new products or product candidates that
may emerge;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">development
of new technologies that may address the markets and may make
CEL-SCI&#x2019;s technology less attractive;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">changes
in physician, hospital or healthcare provider practices that may
make CEL-SCI&#x2019;s product candidates less useful;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">announcements
by CEL-SCI, its partners or competitors of significant
acquisitions, strategic partnerships, joint ventures,
collaborations or capital commitments;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">developments
or disputes concerning patent applications, issued patents or other
proprietary rights;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
recruitment or departure of key personnel;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">failure
to meet or exceed financial estimates and projections of the
investment community or that CEL-SCI provides to the
public;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">actual
or anticipated changes in estimates as to financial results,
development timelines or recommendations by securities
analysts;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">variations
in its financial results or those of companies that are perceived
to be similar to CEL-SCI;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">changes
to coverage and reimbursement levels by commercial third-party
payors and government payors, including Medicare, and any
announcements relating to reimbursement levels;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">general
economic, industry and market conditions; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
other factors described in this &#x201C;Risk Factors&#x201D;
section.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI
has been advised that it is not in compliance with certain
continued listing standards of the NYSE MKT.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On December 9,
2016, CEL-SCI received a letter from the NYSE MKT, its current
listing exchange, which advised CEL-SCI that, based upon its June
30, 2016 10-Q report, CEL-SCI was noncompliant with certain
continued listing standards of the NYSE MKT. CEL-SCI can maintain
its listing by submitting a plan of compliance by January 9, 2017.
This plan must advise of actions CEL-SCI has taken or will take to
regain compliance with the continued listing standards by June 11,
2018. CEL-SCI intends to submit such a plan by January 9, 2017. If
the plan is not acceptable, or CEL-SCI does not make sufficient
progress under the plan to reestablish compliance by June 11, 2018,
the staff of the exchange may initiate proceedings to delist
CEL-SCI&#x2019;s securities from the NYSE MKT. CEL-SCI may appeal a
delisting determination in accordance with the rules of the
exchange.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In addition, the
NYSE MKT will not normally remove the securities of an issuer which
is otherwise below the stockholders&#x2019; equity criteria noted
above if the issuer has a market capitalization of at least $50
million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The letter from the
NYSE MKT has no current effect on the listing of CEL-SCI&#x2019;s
securities on the exchange.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
Under its amended bylaws, stockholders that initiate certain
proceedings may be obligated to reimburse CEL-SCI and its officers
and directors for all fees, costs and expenses incurred in
connection with such proceedings if the claim proves
unsuccessful.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">On
February 18, 2015, CEL-SCI adopted new bylaws which include a
fee-shifting provision in Article X for stockholder claims. Article
X provides that in the event any stockholder initiates or asserts a
claim against CEL-SCI, or any of its officers or directors,
including any derivative claim or claim purportedly filed on
CEL-SCI&#x2019;s behalf, and the stockholder does not obtain a
judgment on the merits that substantially achieves, in substance
and amount, the full remedy sought, then the stockholder will be
obligated to reimburse CEL-SCI and any of its officers or directors
named in the action, for all fees, costs and expenses of every kind
and description that CEL-SCI or its officers or directors may incur
in connection with the claim.&#xA0;&#xA0;In adopting Article X, it
is the intent that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">41</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">all
actions, including federal securities law claims, would be subject
to Article X;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
phrase &#x201C;a judgment on the merits&#x201D; means the
determination by a court of competent jurisdiction on the matters
submitted to the court;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">the
phrase &#x201C;substantially achieves, in both substance and
amount&#x201D; means the plaintiffs in the action would be awarded
at least 90% of the relief sought;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">only
persons who were stockholders at the time an action was brought
would be subject to Article X; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">only
the directors or officers named in the action would be allowed to
recover.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
fee-shifting provision contained in Article X of the bylaws is not
limited to specific types of actions, but is rather potentially
applicable to the fullest extent permitted by law. Fee-shifting
bylaws are relatively new and untested. The case law and potential
legislative action on fee-shifting bylaws are evolving and there
exists considerable uncertainty regarding the validity of, and
potential judicial and legislative responses to, such bylaws. For
example, it is unclear whether the ability to invoke the
fee-shifting bylaw in connection with claims under the federal
securities laws would be pre-empted by federal law. Similarly, it
is unclear how courts might apply the standard that a claiming
stockholder must obtain a judgment that substantially achieves, in
substance and amount, the full remedy sought. The application of
the fee-shifting bylaw in connection with such claims, if any, will
depend in part on future developments of the law. CEL-SCI cannot
assure its shareholders that CEL-SCI will or will not invoke the
fee-shifting bylaw in any particular dispute. In addition, given
the unsettled state of the law related to fee-shifting bylaws, such
as CEL-SCI&#x2019;s, CEL-SCI may incur significant additional costs
associated with resolving disputes with respect to such bylaw,
which could adversely affect its business and financial
condition.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">If
a stockholder that brings any such claim, suit, action or
proceeding is unable to obtain the required judgment, the
attorneys&#x2019; fees and other litigation expenses that might be
shifted to a claiming stockholder are potentially significant. This
fee-shifting bylaw, therefore, may dissuade or discourage
stockholders (and their attorneys) from initiating lawsuits or
claims against CEL-SCI or its directors and officers.&#xA0;In
addition, it may impact the fees, contingency or otherwise,
required by potential plaintiffs&#x2019; attorneys to represent the
stockholders or otherwise discourage plaintiffs&#x2019; attorneys
from representing the stockholders at all. As a result, this bylaw
may limit the ability of stockholders to affect the management and
direction of CEL-SCI, particularly through litigation or the threat
of litigation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
The provision of the amended bylaws requiring exclusive venue in
the U.S. District Court for Delaware for certain types of lawsuits
may have the effect of discouraging lawsuits against CEL-SCI and
its directors and officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Article
X of CEL-SCI&#x2019;s amended bylaws provides that stockholder
claims brought against CEL-SCI, or its officers or directors,
including any derivative claim or claim purportedly filed on
CEL-SCI&#x2019;s behalf, must be brought in the U.S. District Court
for the district of Delaware and that with respect to any such
claim, the laws of Delaware will apply.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">42</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
exclusive forum provision may limit a stockholder&#x2019;s ability
to bring a claim in a judicial forum the stockholder finds
favorable for disputes with CEL-SCI or its directors or officers,
and may have the effect of discouraging lawsuits with respect to
claims that may benefit CEL-SCI or the stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
1B. <font style="text-decoration: underline">UNRESOLVED SEC
COMMENTS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">None</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
2. <font style="text-decoration: underline">PROPERTIES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI leases
office space at 8229 Boone Blvd., Suite 802, Vienna, Virginia at a
monthly rental of approximately $8,000. The lease on the office
space expires on June 30, 2020. CEL-SCI believes this arrangement
is adequate for the conduct of its present business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has a
17,900 square foot laboratory located in Baltimore, Maryland. The
laboratory is leased by CEL-SCI at a cost of approximately $11,000
per month. The laboratory lease expires on February 28,
2022.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">In August 2007,
CEL-SCI leased a building near Baltimore, Maryland (the San
Tomas lease). The building, which consists of approximately
73,000 square feet, has been remodeled in accordance with
CEL-SCI&#x2019;s specifications so that it can be used by CEL-SCI to
manufacture Multikine for CEL-SCI&#x2019;s Phase 3 clinical trial
and sales of the drug if approved by the FDA. The lease expires on
October 31, 2028 and required annual base rent payments of
approximately $1.6 million during the twelve months ending
September 30, 2016. The annual base rent escalates each year at 3%
beginning on November 1st. CEL-SCI is also required to pay all real
and personal property taxes, insurance premiums, maintenance
expenses, repair costs and utilities, which were approximately
$42,000 per month as of September 30, 2016. The lease allows
CEL-SCI, at its election, to extend the lease for two ten-year
periods or to purchase the building at the end of the 20-year
lease. The Company is not the legal owner of the
manufacturing building, but is deemed to be the owner for the
accounting purposes based on the accounting guidance for
build-to-suit leases under ASC 840-40-55. The lease required
CEL-SCI to pay $3,150,000 towards the remodeling costs, which is
being recouped by reductions in the annual base rent of $303,228
beginning in fiscal year 2014. In August 2011, CEL-SCI was required
to deposit $1,670,917, the equivalent of one year of base rent. The
$1,670,917 was required to be deposited when the amount of
CEL-SCI&#x2019;s cash had dropped below the amount stipulated in the
lease and is included in non-current assets at September 30,
2016.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
3. <font style="text-decoration: underline">LEGAL
PROCEEDINGS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;CEL-SCI is
currently involved in a pending arbitration proceeding, CEL-SCI
Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC)
and PharmaNet GmbH (f/k/a PharmaNet AG). CEL-SCI initiated the
proceedings against inVentiv Health Clinical LLC, or inVentiv,
CEL-SCI&#x2019;s former third-party CRO, and is seeking payment for
damages related to inVentiv&#x2019;s prior involvement in the Phase
3 clinical trial of Multikine. The arbitration claim, initiated
under the Commercial Rules of the American Arbitration Association,
alleges (i) breach of contract, (ii) fraud in the inducement, and
(iii) common law fraud. <font style="color: #000000">Currently,
CEL-SCI seeks at least $50 million in damages in its amended
statement of claim.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">43</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In an amended
statement of claim, CEL-SCI asserted the claims set forth above as
well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In connection with
the pending arbitration proceedings, inVentiv has asserted
counterclaims against CEL-SCI for (i) breach of contract, seeking
at least $2 million in damages for services allegedly performed by
inVentiv; (ii) breach of contract, seeking at least $1 million in
damages for CEL-SCI&#x2019;s alleged use of inVentiv&#x2019;s name in
connection with publications and promotions in violation of the
parties&#x2019; contract; (iii) opportunistic breach, restitution
and unjust enrichment, seeking at least $20 million in disgorgement
of alleged unjust profits allegedly made by CEL-SCI as a result of
the purported breaches referenced in subsection (ii); and (iv)
defamation, seeking at least $1 million in damages for allegedly
defamatory statements made about inVentiv. CEL-SCI believes
inVentiv&#x2019;s counterclaims are meritless. However, if inVentiv
successfully asserts any of its counterclaims, such an adverse
determination could have a material adverse effect on
CEL-SCI&#x2019;s business, results, financial condition and
liquidity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In October 2015,
CEL-SCI signed an arbitration funding agreement with a company
established by Lake Whillans Litigation Finance, LLC, a firm
specializing in funding litigation expenses. Pursuant to the
agreement, an affiliate of Lake Whillans provides CEL-SCI with
funding for litigation expenses to support its arbitration claims
against inVentiv. The funding is available to CEL-SCI to fund the
expenses of the ongoing arbitration and will only be repaid when
CEL-SCI receives proceeds from the arbitration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The arbitration
hearing on the merits (the &#x201C;trial&#x201D;) began on September
26, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
4.&#xA0;<font style="text-decoration: underline">MINE SAFETY
DISCLOSURES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Not
applicable.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
5. <font style="text-decoration: underline">MARKET FOR CEL-SCI'S
COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">As of September 30,
2016 there were approximately 1,000 record holders of
CEL-SCI&#x2019;s common stock. CEL-SCI&#x2019;s common stock is
traded on the NYSE American under the symbol
&#x201C;CVM&#x201D;.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">44</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Shown below are the
range of high and low quotations for CEL-SCI&#x2019;s common stock
for the periods indicated as reported on the NYSE
American. The market quotations have been
adjusted for a 1 for 25 reverse stock split which became effective
on the NYSE American on June 15, 2017 reflect inter-dealer
prices, without retail mark-up, mark-down or commissions and may
not necessarily represent actual transactions.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman">Quarter
Ending</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">High</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Low</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">12/31/14</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">22.75<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13.50<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">3/31/15</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">30.75<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14.75<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">6/30/15</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14.75<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">9/30/15</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">12/31/15</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18.75<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">3/31/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16.50<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">6/30/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">9/30/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13.50<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6.00<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Holders of common
stock are entitled to receive dividends as may be declared by
CEL-SCI&#x2019;s Board of Directors out of legally available funds
and, in the event of liquidation, to share pro rata in any
distribution of CEL-SCI&#x2019;s assets after payment of
liabilities. CEL-SCI&#x2019;s Board of Directors is not obligated to
declare a dividend. CEL-SCI has not paid any dividends on its
common stock and CEL-SCI does not have any current plans to pay any
common stock dividends.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The provisions in
CEL-SCI&#x2019;s Articles of Incorporation relating to
CEL-SCI&#x2019;s preferred stock allow CEL-SCI&#x2019;s directors to
issue preferred stock with rights to multiple votes per share and
dividend rights which would have priority over any dividends paid
with respect to CEL-SCI&#x2019;s common stock. The issuance of
preferred stock with such rights may make more difficult the
removal of management even if such removal would be considered
beneficial to shareholders generally, and will have the effect of
limiting shareholder participation in certain transactions such as
mergers or tender offers if such transactions are not favored by
incumbent management.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The market price of
CEL-SCI&#x2019;s common stock, as well as the securities of other
biopharmaceutical and biotechnology companies, have historically
been highly volatile, and the market has from time to time
experienced significant price and volume fluctuations that are
unrelated to the operating performance of particular companies.
Factors such as fluctuations in CEL-SCI&#x2019;s operating results,
announcements of technological innovations or new therapeutic
products by CEL-SCI or its competitors, governmental regulation,
developments in patent or other proprietary rights, public concern
as to the safety of products which may be developed by CEL-SCI or
other biotechnology and pharmaceutical companies, and general
market conditions may have a significant effect on the market price
of CEL-SCI&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
graph below matches the cumulative 5-year total return of holders
of CEL-SCI&#x2019;s common stock with the cumulative total returns
of the NYSE MTK Composite index and the RDG MicroCap Biotechnology
index. The graph assumes that the value of an investment in
CEL-SCI's common stock and in each of the indexes (including
reinvestment of dividends) was $100 on September 30, 2011 and
tracks it through September 30, 2016.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
stock price performance included in this graph is not necessarily
indicative of future stock price performance.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">45</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_10k003.jpg"></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: bottom; width: 26%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/11</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/12</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/13</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/14</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/15</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-top: solid 1px #000; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
9/16</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 26%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 26%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
CEL-SCI Corporation</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
100.00</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
94.52</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
46.58</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
24.98</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
16.44</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
8.36</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 26%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
NYSE MKT Composite</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
100.00</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
123.99</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
127.59</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
148.86</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
129.94</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
145.53</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 26%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
RDG MicroCap Biotechnology</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
100.00</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
166.25</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
182.33</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
136.22</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
97.34</font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
52.30</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">46</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">
ITEM 6.</font> SELECTED FINANCIAL DATA</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">The following
selected historical consolidated financial
data:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 84px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">reflect a 1 for 25
reverse stock split which became effective on the NYSE American on
June 15, 2017,</font> </div>
</div>
</div>
<div style="margin-left: 84px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">reflect the
restatement to the Company&#x2019;s financial statements as further
explained in Note 17, in the financial statements enclosed herein,
and</font> </div>
</div>
</div>
<div style="margin-left: 84px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">are qualified by
reference to, and should be read in conjunction with the
consolidated financial statements and the related notes thereto,
appearing elsewhere in this report, as well as Item 7 of this
report.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr style="">
<td rowspan="1" style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="5" rowspan="1" style="vertical-align: bottom; width: 65%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 2%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 96%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">(Restated)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 2%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="text-decoration: underline"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Statements
of Operations</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2014</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2013</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2012</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Grant
revenue and other</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">285,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">657,377</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">264,033</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">159,583</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">254,610</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
expenses:</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,191,750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,266,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,027,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,908,007</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">General
and administrative</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,486,501</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,855,775</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,665,558</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,093,738</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,683,045</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Gain
on derivative instruments</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">282,616</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">248,767</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,750,666</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,911,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on debt extinguishment</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
income (expense), net</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,879,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,964,221</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,933,732</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,932,272</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,017,719</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(9,143,485</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(15,442,478</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="3" style="vertical-align: bottom; width: 61%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; Issuance of additional shares due to reset
provision&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,117,447</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(250,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Modification
of warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(59,531</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(325,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Inducement
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,593,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss available to common shareholders</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(28,470,126</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,203,016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(17,611,098</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2.37</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(10.51</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(12.10</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(7.60</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(17.48</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2.37</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(10.51</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(12.21</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(16.47</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(19.38</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="">
<td colspan="2" style="vertical-align: bottom; width: 48%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; Weighted average common shares
outstanding&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
and diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,300,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,352,185</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,211,178</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,007,346</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">47</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="text-decoration: underline"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Balance
Sheets</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2014</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2013</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2012</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Working
capital (deficit)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,446,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,639,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,952,002</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,632,087</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,877,670</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
assets</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,553,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">32,104,603</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,457,326</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,655,921</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Derivative
instruments (a)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,394,934</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,686,587</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,505,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">433,024</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,983,690</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,565,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,315,972</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,320,790</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,430,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,329,124</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stockholders'
(deficit) equity</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,783,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,026,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,326,797</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 12px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;(a)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Included in total
liabilities.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI's net loss
available to common shareholders for each fiscal quarter during the
two years ended September 30, 2016 were:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Net
income (loss) per share</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman">Quarter-
(Restated)<br></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Net
income (loss)</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Basic</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Diluted</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">12/31/15</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">2,332,734</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">0.53</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">0.53</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">3/31/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(8,855,530</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(1.87</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(1.87</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">6/30/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(3,861,606</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(0.78</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(0.78</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">9/30/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(1,128,090</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(0.21</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(0.21</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td colspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">12/31/14</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(7,846,983</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(2.68</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(3.42</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">3/31/2015</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(12,559,695</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(4.14</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(4.14</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">6/30/2015</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(4,413,593</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(1.32</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(1.62</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">9/30/2015</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(9,871,939</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(2.54</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(2.54</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 348px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Variances in
quarterly gains and losses for the quarters presented are caused by
the changes in the fair value of outstanding warrants accounted for
as derivatives each quarter.&#xA0; These changes in the fair value
of the warrants are recorded on the statements of
operations.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">48</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
7.&#xA0; <font style="text-decoration: underline">MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following
discussion should be read in conjunction with the financial
statements and the related notes thereto appearing elsewhere in
this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
lead investigational therapy, Multikine, is cleared for a Phase 3
clinical trial in advanced primary head and neck cancer. It has
received a go-ahead by the U.S. FDA as well as twenty-three other
countries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On September 26,
2016, CEL-SCI received verbal notice from the FDA that the Phase 3
clinical trial in advanced primary head and neck cancer has been
placed on clinical hold. Pursuant to this communication from FDA,
patients currently receiving study treatments can continue to
receive treatment, and patients already enrolled in the study will
continue to be followed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On October 21,
2016, CEL-SCI issued a press release stating the following:
&#x201C;following up on our press release issued on September 26,
2016, we have received the Partial Clinical Hold letter from the
U.S. Food and Drug Administration (FDA). &#xA0;On November 21,
2016, CEL-SCI announced that it had submitted a response to
FDA&#x2019;s Partial Clinical Hold letter referenced
above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI also owns
and is developing a pre-clinical technology called
LEAPS.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">All of
CEL-SCI&#x2019;s projects are under development. As a result,
CEL-SCI cannot predict when it will be able to generate any revenue
from the sale of any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Since inception,
CEL-SCI has financed its operations through the issuance of equity
securities, convertible notes, loans and certain research grants.
CEL-SCI&#x2019;s expenses will likely exceed its revenues as it
continues the development of Multikine and brings other drug
candidates into clinical trials. Until such time as CEL-SCI becomes
profitable, any or all of these financing vehicles or others may be
utilized to assist CEL-SCI&#x2019;s capital
requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Correction of an Error</font> </div>
<div> <font style="font-family: Times New Roman; font-size: 10">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">The historical
financial information in this report have been restated. In
November 2017, the Company discovered an error in the way it
accounted for the operating lease for its manufacturing facility.
In <font style="color: #000000">October 2008, the Company entered
into a lease arrangement whereby the Company leased a building
owned by a third party, but to which the owner made tenant-directed
improvements. Upon commencement of the lease, the Company accounted
for the arrangement as an operating lease under ASC 840,</font>
<font style="font-style: italic; color: #000000">Accounting for
Leases</font><font style="color: #000000">, whereby the total
minimum lease payment obligations under the leases were recognized
as monthly rent expense on a straight-line basis over the term of
the lease. The cost of the tenant improvements incurred were
capitalized as deferred rent and amortized over the 20-year lease
term.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In November 2017, it was determined that because
the terms of the original lease agreement required the Company to
be responsible for possible cost overruns, if there were any, but
of which there were none, the Company was deemed to be the owner of
the leased building for accounting purposes only under ASC
840-40-55. In addition to the costs it incurred and capitalized for
the tenant improvements, the Company should have reflected an asset
on its balance sheet for the costs paid by the lessor to purchase
the building and improve it, as well as a corresponding liability.
Upon completion of the improvements, the Company did not meet the
&#x201C;sale-leaseback&#x201D; criteria under ASC 840-40-25,</font>
<font style="font-style: italic; color: #000000">Accounting for
Leases, Sale-Leaseback Transactions</font> <font style="color: #000000">due to the Company&#x2019;s significant continuing
involvement with the facility which is considered to be other than
a normal leaseback as defined in ASC 840-40-25 and therefore should
have treated the lease as a financing obligation and the asset and
corresponding liability should not be
derecognized.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
correction to the historical financial statements to apply ASC
840-40-25 does not affect the total cash payments the Company has
made or is obligated to make under the lease agreement, nor does it
change the total expense to be recognized over the lease term.
However, the timing and nature of expense is different under this
treatment as compared to operating lease treatment. Specifically,
the Company should have recognized depreciation, expense on the
asset it is deemed to own and interest expense on the associated
lease financing obligation, instead of rental
expense.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">The accompanying
Management's Discussion and Analysis of Financial Condition and
Results of Operations gives effect to the restatement adjustments
made to the previously reported financial statements for the years
ended September 30, 2016, 2015, and 2014. For additional
information and a detailed discussion of the restatement, see Note
17 of the financial statements included in this
Report.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">49</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Results of Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Fiscal 2016</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2016, grant and other income decreased by
approximately $372,000 compared to the year ended September 30,
2015. The decrease is primarily due to the timing of drug shipments
to supply the Company&#x2019;s partner in Taiwan and the grant
income earned by the Company&#x2019;s Small Business Innovation
Research (SBIR) grant during fiscal year 2016 compared to fiscal
year 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2016, research and development expenses
decreased by approximately $1.7 million compared to the year ended
September 30, 2015. The Company is continuing the Phase 3 clinical
trial subject to the partial clinical hold and research and
development fluctuates based on the activity level of the clinical
trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2016, general and administrative expenses
decreased by approximately $7.4 million, compared to the year ended
September 30, 2015. Major components of the decrease are 1) Lake
Whillans Litigation Finance took over payment of legal fees which
were about $4.4 million in fiscal year 2015 in the arbitrations
against the former CRO that used to run the Company's Phase 3
trial, 2) a $2.8 million decrease in share-based employee
compensation costs, which relates to the timing vesting for the
incentive stock bonus plan and 3) other miscellaneous decreases
netting to approximately $200,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, 2016 and 2015, CEL-SCI recorded a derivative
gain of approximately $14.0 million and $283,000, respectively.
This variation was the result of the change in fair value of the
derivative liabilities during the period which was caused by
fluctuations in the share price of CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Net interest income
(expense) decreased approximately $85,000 during the
year ended September 30, 2016 compared to the year ended September
30, 2015, primarily due to an approximate $124,000 reduction in
interest expense on the related party loan, which was paid off in
January 2016, offset by an approximate $35,000 increase in
interest expense on the lease liability.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Fiscal 2015</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2015, grant and other income increased by
approximately $393,000 compared to the year ended September 30,
2014. The increase is primarily due to the timing of drug shipments
to supply the Company&#x2019;s partner in Taiwan and the grant
income earned by the Company&#x2019;s Small Business Innovation
Research (SBIR) grant during fiscal year 2015 compared to fiscal
year 2014.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2015, research and development expenses
increased by approximately $3.9 million compared to the year ended
September 30, 2014. CEL-SCI is continuing the Phase 3 clinical
trial and research and development fluctuates based on the activity
level of the clinical trial. In fiscal year 2015, CEL-SCI received
clearance from seven new countries for the Phase 3 clinical trial,
and enrolled 305 patients in fiscal year 2015 vs 142 in fiscal year
2014.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2015, general and administrative expenses
increased by approximately $3.2 million, compared to
the year ended September 30, 2014. This increase is primarily due
to an increase of approximately $2.0 million of equity based
compensation costs for restricted stock granted, increased legal
fees of approximately $1.8 million relating to arbitration with the
Company&#x2019;s former CRO, as discussed in Item 3 above, and an
increase of approximately $220,000 in fees for professional
services. These increases were offset by a decrease of
approximately $788,000 in employee compensation, primarily due to a
decrease in the number of stock options issued and vested in 2015
compared to 2014.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, 2015 and 2014, CEL-SCI recorded a derivative
gain of approximately $283,000 and $249,000, respectively. This
variation was the result of the change in fair value of the
derivative liabilities during the period which resulted from
relative consistencies in the share price of CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">50</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Interest expense
increased by approximately $30,000 during
the year ended September 30, 2015 compared to the year ended
September 30, 2014, and consisted primarily of approximately
$37,000 in increased interest expense on the lease
liability, offset by a reduction of the interest on the loan
from CEL-SCI&#x2019;s former president. Effective July 7, 2015, the
interest rate on the related party loan was reduced from 15% to
9%. Additionally, the modifications of the loan from
de Clara Trust were determined to be substantive, resulting in an
extinguishment loss of approximately $620,000 during
2015.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Research and Development Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the five
years ended September 30, 2016, CEL-SCI&#x2019;s research and
development efforts involved Multikine and LEAPS. The table below
shows the research and development expenses associated with each
project during this five-year period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td colspan="6" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 1%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 98%; font-size: 11px;">(Restated)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 1%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2014</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2013</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2012</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">MULTIKINE</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,054,474</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,697,940</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,891,411</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,650,239</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,516,929</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LEAPS</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">390,908</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">493,810</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">374,778</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">377,485</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">391,078</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,191,750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,266,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,027,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,908,007</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In January 2007,
CEL-SCI received a &#x201C;no objection&#x201D; letter from the FDA
indicating that it could proceed with Phase 3 trials with Multikine
in head and neck cancer patients.&#xA0;&#xA0;CEL-SCI had previously
received a &#x201C;no objection&#x201D; letter from the Canadian
Biologics and Genetic Therapies Directorate which enabled CEL-SCI
to begin its Phase 3 clinical trial in
Canada.&#xA0;&#xA0;Subsequently, CEL-SCI received similar
authorizations from twenty-three other regulators.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
Phase 3 clinical trial began in December 2010 after the completion
and validation of CEL-SCI&#x2019;s dedicated manufacturing
facility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">As explained in
Item 1 of this report, as of November 30, 2016, CEL-SCI was
involved in pre-clinical studies with respect to its LEAPS
technology. As with Multikine, CEL-SCI does not know what obstacles
it will encounter in future pre-clinical and clinical studies
involving its LEAPS technology. Consequently, CEL-SCI cannot
predict with any certainty the funds required for future research
and clinical trials and the timing of future research and
development projects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Clinical and other
studies necessary to obtain regulatory approval of a new drug
involve significant costs and require several years to complete.
The extent of CEL-SCI&#x2019;s clinical trials and research programs
are primarily based upon the amount of capital available to CEL-SCI
and the extent to which CEL-SCI has received regulatory approvals
for clinical trials. The inability of CEL-SCI to conduct clinical
trials or research, whether due to a lack of capital or regulatory
approval, will prevent CEL-SCI from completing the studies and
research required to obtain regulatory approval for any products
which CEL-SCI is developing. Without regulatory approval, CEL-SCI
will be unable to sell any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On September 26,
2016, CEL-SCI received verbal notice from the FDA that the Phase 3
clinical trial in advanced primary head and neck cancer has been
placed on clinical hold. Pursuant to this communication from FDA,
patients currently receiving study treatments can continue to
receive treatment, and patients already enrolled in the study will
continue to be followed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">51</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On October 21,
2016, CEL-SCI issued a press release stating the following:
&#x201C;following up on our press release issued on September 26,
2016, we have received the Partial Clinical Hold letter from the
U.S. Food and Drug Administration (FDA). On November 21, 2016,
CEL-SCI announced that it had submitted a response to FDA&#x2019;s
Partial Clinical Hold letter referenced above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has had
only limited revenues from operations since its inception in March
1983.&#xA0;&#xA0;CEL-SCI has relied upon capital generated from the
public and private offerings of its common stock and convertible
notes.&#xA0;&#xA0;In addition, CEL-SCI has utilized short-term
loans to meet its capital requirements.&#xA0;&#xA0;Capital raised
by CEL-SCI has been used to acquire an exclusive worldwide license
to use, and later purchase, certain patented and unpatented
proprietary technology and know-how relating to the human
immunological defense system and for clinical
trials.&#xA0;&#xA0;Capital has also been used for patent
applications, debt repayment, research and development,
administrative costs, and the construction of CEL-SCI&#x2019;s
laboratory facilities.&#xA0;&#xA0;CEL-SCI does not anticipate
realizing significant revenues until it enters into licensing
arrangements regarding its technology and know-how or until it
receives regulatory approval to sell its products (which could take
a number of years). As a result, CEL-SCI has been dependent upon
the proceeds from the sale of its securities to meet all of its
liquidity and capital requirements and anticipates having to do so
in the future. During fiscal year 2016 and 2015, CEL-SCI raised net
proceeds of approximately $21.4 million and $21.1 million,
respectively, through the sale of stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">CEL-SCI estimates
the total cash cost of the Phase 3 clinical trial, with the
exception of the parts that will be paid by its licensees, Teva
Pharmaceuticals and Orient Europharma, to be approximately
$12.1 million going forward.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In August 2007,
CEL-SCI leased a building near Baltimore, Maryland. The building,
which consists of approximately 73,000 square feet, has been
remodeled in accordance with CEL-SCI&#x2019;s specifications so that
it can be used by CEL-SCI to manufacture Multikine for
CEL-SCI&#x2019;s Phase III clinical trials and sales of the drug if
approved by the FDA. The lease expires on October 31, 2028, and
required annual base rent payments of approximately $1.6 million
during the twelve months ended September 30, 2016. See Item 2 of
this report for more information concerning the terms of this
lease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">In January 2014,
CEL-SCI offered to the investors to extend the outstanding Series N
warrants by one year and allow for cashless exercise in exchange
for cancelling the reset provision in the warrant agreement. One of
the investors accepted this offer. In March 2014,
4,272 Series N Warrants were exercised. On October 28,
2014, the remaining Series N warrants were transferred to the de
Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is
the trustee and a beneficiary. On June 29, 2015, concurrently with
the modification of the note payable held by the de Clara Trust,
CEL-SCI extended the expiration date of the Series N warrants to
August 18, 2017. As of September 30, 2016, the remaining
113,785 Series N warrants entitle the holders to
purchase one share of CEL-SCI's common stock at a price of
$13.18 per share at any time prior to August 18,
2017.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">52</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
January 13, 2016, CEL-SCI repaid the note payable to the de Clara
Trust, the balance of which was $1,105,989, including principal and
interest. At the same time the Company sold 120,000
shares of its common stock and 120,000 Series X
warrants to the de Clara Trust for $1,110,000. Each warrant allows
the de Clara Trust to purchase one share of the Company's common
stock at a price of $9.25 per share at any time on or
before January 13, 2021.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2013, CEL-SCI sold 713,043 shares of its
common stock, plus 819,000 Series S warrants, in an
underwritten offering. The net proceeds to CEL-SCI from the sale of
the shares and warrants were approximately $16.4 million, after
deducting the underwriting discount. The Series S warrants may be
exercised at any time on or before October 11, 2018 at a price of
$31.25 per share.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
December 2013, CEL-SCI sold 209,524 shares of its
common stock and Series S warrants, in an underwritten offering.
The net proceeds to CEL-SCI from the sale of the shares and Series
S warrants were approximately $2.7 million, after deducting the
underwriting discount. The Series S warrants may be exercised at
any time on or before October 11, 2018 at a price of
$31.25 per share.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
February 2014, the S warrants began trading on the NYSE MKT under
the ticker symbol &#x201C;CVM WS&#x201D;. As of September 30, 2016,
83,551 Series S Warrants had been exercised. The
remaining 1,037,120 Series S warrants entitle the
holders to purchase one share of CEL-SCI's common stock at a price
of $31.25 per share.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
April 2014, CEL-SCI sold 285,129 shares of common
stock, plus 71,282 Series T warrants, in an
underwritten offering. The net proceeds to CEL-SCI from the sale of
the stock and warrants were approximately $9.23 million. The Series
T warrants had an exercise price of $39.50 and expired
on October 17, 2014. CEL-SCI also issued 17,821 Series
U warrants to the underwriters for this offering. The Series U
warrants may be exercised beginning October 17, 2014 at a price of
$43.75 per share and expire on October 17, 2017. As of
September 30, 2016, none of the Series U warrants had been
exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2014, CEL-SCI sold 315,789 shares of common
stock, plus 78,947 Series S warrants in an
underwritten public offering. The net proceeds to CEL-SCI from the
sale of the stock and warrants were approximately $5.5 million. The
warrants are immediately exercisable, expire October 11, 2018 and
have an exercise price of $31.25.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Additionally, in
October 2014, CEL-SCI sold 52,800 shares of common
stock, plus 13,200 Series S warrants in a registered
direct offering. The net proceeds to CEL-SCI from the sale of the
stock and warrants were approximately $941,000. The warrants are
immediately exercisable, expire October 11, 2018 and have an
exercise price of $31.25.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On May
28, 2015, CEL-SCI sold 810,127 shares of common stock,
plus 810,127 Series V warrants, in an underwritten
public offering. The common stock and Series V warrants were sold
at a combined per unit price of $19.75 for net
proceeds of approximately $14.7 million. The Series V warrants are
immediately exercisable at a price of $19.75 and
expire on May 28, 2020. As of September 30, 2016, none of the
Series V warrants had been exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, the Company closed an underwritten public
offering of 688,930 shares of common stock and
688,930 Series W warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $16.75 for net proceeds of approximately
$10.5 million, net of underwriting discounts and commissions and
offering expenses. The Series W warrants are immediately
exercisable at a price of $16.75 and expire on October
28, 2020. As of September 30, 2016, none of the Series W warrants
had been exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">53</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">In
January 2016, the Company sold 120,000 shares of its
common stock and 120,000 Series X warrants to the de
Clara Trust for approximately $1.1 million, as noted above. The de
Clara Trust is controlled by Geert Kersten, the Company's Chief
Executive Officer and a director. Each Series X warrant allows the
de Clara Trust to purchase one share of the Company's common stock
at a price of $9.25 per share at any time on or before
January 13, 2021. As of September 30, 2016, none of the Series X
warrants had been exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
February 2016, the Company sold 52,000 shares of its
common stock and 26,000 Series Y warrants to a private
investor for $624,000. Each Series Y warrant allows the holder to
purchase one share of the Company's common stock at a price of
$12.00 per share at any time on or before February 15,
2021. As of September 30, 2016, none of the Series Y warrants had
been exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, the Company closed a registered direct offering of
400,000 shares of common stock and
264,000 Series Z warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $12.50 for net proceeds of approximately
$4.6 million, net of placement agent&#x2019;s commissions and
offering expenses. The Series Z warrants may be exercised at any
time on or after November 23, 2016 and on or before November 23,
2021 at a price of $13.75 per share. The Company also
issued 20,000 Series ZZ warrants to the placement
agent as part of its compensation. The Series ZZ warrants may be
exercised at any time on or after November 23, 2016 and on or
before May 18, 2021 at a price of $13.75 per share. As
of September 30, 2016, none of the Series Z and ZZ warrants had
been exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On August 26, 2016, the Company closed a
registered direct offering of&#xA0;400,000 shares of
common stock and Series AA warrants to purchase up to
40,000 shares of common stock. Each share of common
stock was sold together with a Series AA warrant to purchase
one-half of a share of common stock for the combined purchase price
of $12.50. Each warrant can be exercised at any time
after February 22, 2017 and on or before February 22, 2022 at a
price of $13.75 per share.</font> The Company also
issued 16,000 Series BB warrants to the placement
agent as part of its compensation. The Series BB warrants may be
exercised at any time on or after February 22, 2017 and on or
before August 22, 2021 at a price of $13.75 per share.
The Company received proceeds from the sale of Series AA and Series
BB shares and warrants of approximately $4.5 million, net of
placement agent&#x2019;s commissions and offering expenses. As of
September 30, 2016, none of the Series AA and BB warrants had been
exercised.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 8, 2016, the Company sold 1,360,960 shares of
common stock and warrants to purchase common stock at a price of
$3.13 in a public offering. The warrants consist of
680,480 Series CC warrants to purchase
680,480 shares of common stock, 1,360,960
Series DD warrants to purchase 1,360,960 shares of
common stock and 1,360,960 Series EE warrants to
purchase 1,360,960 shares of common stock. The Series
CC warrants are immediately exercisable, expire in five-years and
have an exercise price of $5.00 per share. The Series
DD warrants are immediately exercisable, expire in six-months and
have an exercise price of $4.50 per share. The Series
EE warrants are immediately exercisable, expire in nine-months and
have an exercise price of $4.50 per share. In
addition, the Company issued 68,048 Series FF warrants
to purchase 68,048 shares of common stock to the
placement agent. The FF warrants are exercisable at any time on or
after June 8, 2017 and expire on December 1, 2021 and have an
exercise price $3.91. The net proceeds to CEL-SCI from
this offering was approximately $3.8 million, excluding any future
proceeds that may be received from the exercise of the
warrants.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Inventory decreased
by approximately $393,000 at September 30, 2016 as compared to
September 30, 2015, due to the timing of supplies purchased and
used in the manufacturing of Multikine for the Phase 3 clinical
trial. In addition, receivables increased by approximately
$307,000, primarily due to the timing of payments reimbursed under
the litigation funding arrangement noted above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">54</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2016, CEL-SCI&#x2019;s cash decreased by
approximately $2.8 million. Significant components of this decrease
include: 1) net cash used in operating activities of approximately
$23.1 million, 2) expenditures for equipment and patents of
approximately $34,000, 3) the approximate $1.1 million repayment of
the related party loan, and 4) the payment of approximately $8,000
in capital lease obligations offset by approximately $21.4 in
proceeds from the sale of stock and warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Future Capital Requirements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Other than funding
operating losses, funding its research and development program, and
making required lease payments, CEL-SCI does not have any material
capital commitments. As of September 30, 2016, material contractual
obligations, consisting of operating lease payments,
excluding payments under the San Tomas lease, are as
follows:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">243,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">251,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">258,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">238,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">163,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">69,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="margin-left:0px;padding-bottom:4px;"><font style="font-family: Times New Roman; font-size: 13px">Total minimum
lease payments:<br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,222,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Future minimum
lease payments under the San Tomas lease as of September 30, 2016
are as follows:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Years ending
September 30,</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,687,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,747,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,808,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,872,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,937,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">15,762,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Total future
minimum lease obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,813,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Less imputed
interest on financing obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(11,802,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 4px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Net present value
of lease financing obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,011,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: -12px; margin-right: 0px; text-indent: 60px"><font style="font-size: 13px; font-family: Times New Roman">For information on
employment contracts, see Item 11 of this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Further, CEL-SCI
has contingent obligations with vendors for work that will be
completed in relation to the Phase 3 trial. The timing of these
obligations cannot be determined at this time.</font> <font style="font-size: 13px; font-family: Times New Roman">CEL-SCI estimates
that the total remaining cash cost of the Phase 3 clinical trial,
excluding any costs that will be paid by CEL-SCI's partners, would
be approximately $12.1 million after September 30, 2016. This
&#xED;s based on the executed contract costs with the CROs only and
does not include other related costs, e.g. the manufacturing of the
drug.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI will need
to raise additional funds, either through the exercise of
outstanding warrants/options, through a debt or equity financing or
a partnering arrangement, to complete the Phase 3 trial and bring
Multikine to market. The ability of CEL-SCI to complete the
necessary clinical trials and obtain FDA approval for the sale of
products to be developed on a commercial basis is uncertain.
&#xA0;In general, CEL-SCI believes that it will be able to raise
sufficient capital in fiscal year 2017 to continue operations
through December 2017. However, it is possible that CEL-SCI will
not be able to generate enough cash to continue operations at its
current level. CEL-SCI's registered independent public accounting
firm has issued an audit opinion that includes an explanatory
paragraph that expresses substantial doubt about CEL-SCI&#x2019;s
ability to continue as a going concern mainly due to continued
losses from operations and future liquidity needs of CEL-SCI.
CEL-SCI&#x2019;s management has engaged in fundraising for over 20
years and believes that the manner in which it is proceeding will
produce the best possible outcome for the shareholders. There can
be no assurances that CEL-SCI will be successful in raising
additional funds.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Clinical and other
studies necessary to obtain regulatory approval of a new drug
involve significant costs and require several years to complete.
The extent of CEL-SCI&#x2019;s clinical trials and research programs
are primarily based upon the amount of capital available to CEL-SCI
and the extent to which CEL-SCI has received regulatory approvals
for clinical trials. The inability of CEL-SCI to conduct clinical
trials or research, whether due to a lack of capital or regulatory
approval, will prevent CEL-SCI from completing the studies and
research required to obtain regulatory approval for any products
which CEL-SCI is developing. Without regulatory approval, CEL-SCI
will be unable to sell any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">55</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In the absence of
revenues, CEL-SCI will be required to raise additional funds
through the sale of securities, debt financing or other
arrangements in order to continue with its research efforts.
However, there can be no assurance that such financing will be
available or be available on favorable terms. Ultimately, CEL-SCI
must complete the development of its products, obtain appropriate
regulatory approvals and obtain sufficient revenues to support its
cost structure.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Since all of
CEL-SCI&#x2019;s projects are under development, CEL-SCI cannot
predict with any certainty the funds required for future research
and clinical trials, the timing of future research and development
projects, or<font style="color: #ff0000">&#xA0;</font>when it will
be able to generate any revenue from the sale of any of its
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI's cash flow
and earnings are subject to fluctuations due to changes in interest
rates on its bank accounts, and, to an immaterial extent, foreign
currency exchange rates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Critical Accounting Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI's
significant accounting policies are more fully described in Note 1
to the financial statements included as part of this report.
However, certain accounting policies are particularly important to
the portrayal of CEL-SCI&#x2019;s financial position and results of
operations and require the application of significant judgments by
management. As a result, the financial statements are subject to an
inherent degree of uncertainty. In applying those policies,
management uses its judgment to determine the appropriate
assumptions to be used in the determination of certain estimates.
These estimates are based on CEL-SCI's historical experience, terms
of existing contracts, observance of trends in the industry and
information available from outside sources, as appropriate.
CEL-SCI&#x2019;s significant accounting policies
include:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Stock Options and Warrants</font> &#x2013;
Compensation cost is measured at fair value as of the grant date in
accordance with the provisions of ASC 718. The fair value of the
stock options is calculated using the Black-Scholes option pricing
model. The Black-Scholes model requires various judgmental
assumptions including volatility, forfeiture rates and expected
option life. The stock-based compensation cost is recognized on the
accelerated method as expense over the requisite service or vesting
period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Options to
non-employees are accounted for in accordance with ASC 505-50,
&#x201C;<font style="font-style: italic">Equity-Based Payments to
Non-Employees</font>.&#x201D; Accordingly, compensation cost is
recognized when goods or services are received and is measured
using the Black-Scholes valuation model. The Black-Scholes model
requires CEL-SCI&#x2019;s management to make assumptions regarding
the fair value of the options at the date of grant and the expected
life of the options.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Asset Valuations and Review for Potential
Impairments</font> - CEL-SCI reviews its fixed assets, intangibles
and deferred rent every fiscal quarter. This review requires that
CEL-SCI make assumptions regarding the value of these assets and
the changes in circumstances that would affect the carrying value
of these assets. If such analysis indicates that a possible
impairment may exist, CEL-SCI is then required to estimate the fair
value of the asset and, as deemed appropriate, expense all or a
portion of the asset. The determination of fair value includes
numerous uncertainties, such as the impact of competition on future
value. CEL-SCI believes that it has made reasonable estimates and
judgments in determining whether its long-lived assets have been
impaired; however, if there is a material change in the assumptions
used in its determination of fair values or if there is a material
change in economic conditions or circumstances influencing fair
value, CEL-SCI could be required to recognize certain impairment
charges in the future. As a result of the reviews, no changes in
asset values were required.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">56</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Derivative Instruments&#x2014;</font>CEL-SCI
enters into financing arrangements that consist of freestanding
derivative instruments or hybrid instruments that contain embedded
derivative features. CEL-SCI accounts for these arrangements in
accordance with ASC 815, &#x201C;<font style="font-style: italic">Accounting for Derivative Instruments and
Hedging Activities</font>, as well as related interpretations of
these standards. In accordance with accounting principles generally
accepted in the United States (&#x201C;GAAP&#x201D;), derivative
instruments and hybrid instruments are recognized as either assets
or liabilities in the statement of financial position and are
measured at fair value with gains or losses recognized in earnings
or other comprehensive income depending on the nature of the
derivative or hybrid instruments. Embedded derivatives that are not
clearly and closely related to the host contract are bifurcated and
recognized at fair value with changes in fair value recognized as
either a gain or loss in earnings if they can be reliably measured.
When the fair value of embedded derivative features cannot be
reliably measured, CEL-SCI measures and reports the entire hybrid
instrument at fair value with changes in fair value recognized as
either a gain or loss in earnings. CEL-SCI determines the fair
value of derivative instruments and hybrid instruments based on
available market data using appropriate valuation models, giving
consideration to all of the rights and obligations of each
instrument and precluding the use of &#x201C;blockage&#x201D;
discounts or premiums in determining the fair value of a large
block of financial instruments. Fair value under these conditions
does not necessarily represent fair value determined using
valuation standards that give consideration to blockage discounts
and other factors that may be considered by market participants in
establishing fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET
RISKS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Market risk is the
potential change in an instrument's value caused by, for example,
fluctuations in interest and currency exchange rates. CEL-SCI
enters into financing arrangements that are, or include,
freestanding derivative instruments or that are, or include, hybrid
instruments that contain embedded derivative features. CEL-SCI does
not enter into derivative instruments for trading purposes.
Additional information is presented in the notes to the financial
statements. The fair value of these instruments is affected
primarily by volatility of the trading prices of CEL-SCI&#x2019;s
common stock. For three years ended September 30, 2016, CEL-SCI
recognized gains of $14,013,726, $282,616, and $248,767,
respectively, resulting from changes in fair value of derivative
instruments. CEL-SCI has exposure to risks associated with foreign
exchange rate changes because some of the expenses related to the
Phase 3 trial are transacted in a foreign currency. The interest
risk on investments on September 30, 2016 was considered immaterial
due to the fact that the interest rates at that time were nominal
at best and CEL-SCI keeps its cash and cash equivalents in short
term maturities.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">57</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">See the financial
statements included with this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Not
applicable</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
9A. CONTROLS AND PROCEDURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Under the direction
and with the participation of CEL-SCI&#x2019;s management, including
CEL-SCI&#x2019;s Chief Executive Officer and Chief Financial
Officer, CEL-SCI carried out an evaluation of the effectiveness of
the design and operation of its disclosure controls and procedures
as of September 30, 2016. CEL-SCI maintains disclosure controls and
procedures that are designed to ensure that information required to
be disclosed in its periodic reports with the Securities and
Exchange Commission is recorded, processed, summarized and reported
within the time periods specified in the SEC&#x2019;s rules and
regulations, and that such information is accumulated and
communicated to CEL-SCI&#x2019;s management, including its principal
executive officer and principal financial officer, as appropriate,
to allow timely decisions regarding required disclosure.
CEL-SCI&#x2019;s disclosure controls and procedures are designed to
provide a reasonable level of assurance of reaching its desired
disclosure control objectives. Previously based on
this evaluation, CEL-SCI&#x2019;s Chief Executive and Principal
Financial Officer has concluded that CEL-SCI&#x2019;s disclosure
controls were effective as of September 30, 2016. However,
due to the material weaknesses in internal control over financial
reporting described below, CEl-SCI's Chief Executive Officer and
Principal Financial Officer concluded that CEL-SCI's disclosure
controls and procedures were not effective as of September 30,
2016.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Management&#x2019;s
Report on Internal Control Over Financial Reporting</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
management is responsible for establishing and maintaining adequate
internal control over financial reporting and for the assessment of
the effectiveness of internal control over financial reporting. As
defined by the Securities and Exchange Commission, internal control
over financial reporting is a process designed by, or under the
supervision of CEL-SCI&#x2019;s&#xA0;principal executive officer and
principal financial officer&#xA0;and implemented by CEL-SCI&#x2019;s
Board of Directors, management and other personnel, to provide
reasonable assurance regarding the reliability of financial
reporting and the preparation of CEL-SCI&#x2019;s financial
statements in accordance with U.S. generally accepted accounting
principles.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Because of its
inherent limitations, internal control over financial reporting may
not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or
procedures may deteriorate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Geert Kersten,
CEL-SCI&#x2019;s Chief Executive and Principal Financial Officer,
evaluated the effectiveness of CEL-SCI&#x2019;s internal control
over financial reporting as of September 30, 2016 based on criteria
established in Internal Control - Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway
Commission, or the COSO Framework. Management&#x2019;s assessment
included an evaluation of the design of CEL-SCI&#x2019;s internal
control over financial reporting and testing of the operational
effectiveness of those controls.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">58</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In November 2017,
CEL-SCI discovered an error in the way it accounted for the lease
for its manufacturing facility. CEL-SCI initially recorded this
lease as an operating lease but later identified that it should
have accounted for it as a financing lease and capitalized an asset
and related liability. Accordingly, on November 17, 2017, the Audit
Committee of the Board of Directors of the Company concluded that
CEL-SCI&#x2019;s Management&#x2019;s Report on Internal Control over
Financial Reporting and the related Report of independent
Registered Public Accounting Firm on internal control over
financial reporting included in CEL-SCI&#x2019;s annual Report on
Form 10-K for the fiscal year ended September 30, 2016 should no
longer be relied upon. Based on this evaluation, Mr. Kersten
concluded that CEL-SCI&#x2019;s internal control over financial
reporting was not effective as of September 30,
2016.&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Management has
concluded that the correction of the error for this lease, the lack
of impairment assessment for the related asset, and the operating
effectiveness of the financial close process are control
deficiencies that constitute material weaknesses.</font>
<font style="font-family: Times New Roman; font-size: 13px">In
order to remediate these material weaknesses, the Company will
change certain control activities over financial reporting to
include the following:</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="margin-left: 96px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">All facility
leasing activities will be subject to a thorough review of capital
versus operating lease classification. Further, leases that include
construction activity prior to lease inception will be reviewed
against the build-to-suit lease guidance in ASC 840. In addition,
the Company will also engage outside financial reporting
specialists to assist it in the review process.</font> </div>
</div>
</div>
<div style="margin-left: 96px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">The Company will
enhance its policy for reviewing long-lived assets for impairments
by incorporating additional triggering event factors for
consideration as part of its control. This review will be carried
out by the Company and also be assisted by an outside financial
reporting specialist.</font> </div>
</div>
</div>
<div style="margin-left: 96px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">The financial
reporting process will be enhanced to include the use of monthly,
quarterly and annual closing checklists to capture routine and
non-routine transactions that require additional review. Further,
the Company will also augment its control process by expanding the
use of a financial reporting specialist to assist in the financial
close process.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;"> <font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">There was no change
in CEL-SCI&#x2019;s internal control over financial reporting that
occurred during the fiscal year ended September 30, 2016 that has
materially affected, or is reasonably likely to materially affect,
CEL-SCI&#x2019;s internal control over financial
reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
independent registered public accounting firm BDO USA, LLP has
issued an attestation report on CEL-SCI&#x2019;s internal control
over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">59</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
Report of Independent Registered Public Accounting
Firm</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Board
of Directors and Stockholders</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Vienna,
VA</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">We have audited CEL-SCI Corporation&#x2019;s (the
Company) internal control over financial reporting as of September
30, 2016, based on criteria established in</font> <font style="font-style: italic; color: #000000">Internal Control &#x2013;
Integrated Framework</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000">(2013)</font> <font style="color: #000000">issued by the Committee of Sponsoring
Organizations of the Treadway Commission (the COSO criteria). The
Company&#x2019;s management is responsible for maintaining effective
internal control over financial reporting and for its assessment of
the effectiveness of internal control over financial reporting,
included in the accompanying &#x201C;Item 9A, Management&#x2019;s
Report on Internal Control Over Financial Reporting&#x201D;. Our
responsibility is to express an opinion on the Company&#x2019;s
internal control over financial reporting based on our
audit.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">We
conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit
included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness
exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our
audit also included performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">A
company&#x2019;s internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles. A company&#x2019;s internal control
over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with
authorizations of management and directors of the company; and (3)
provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the
company&#x2019;s assets that could have a material effect on the
financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Because
of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
our report dated December 14, 2016, we expressed an unqualified
opinion on the effectiveness of internal control over financial
reporting as of September 30, 2016. Subsequent to December 14,
2016, CEL-SCI Corporation, Inc. identified a material misstatement
in its annual financial statements for 2016, 2015, and 2014,
requiring restatement of such financial statements. Management
revised its assessment of internal control over financial reporting
due to the identification of material weaknesses, described in the
following paragraph, in connection with the financial statement
restatement. Accordingly, our opinion on the effectiveness of
CEL-SCI Corporation, Inc.&#x2019;s internal control over financial
reporting as of September 30, 2016 expressed herein is different
from that expressed in our previous report.</font> </div>
<div> <font style="font-family: Times New Roman; font-size: 10">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">A
material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement
of the Company&#x2019;s annual or interim financial statements will
not be prevented or detected on a timely basis. Material weaknesses
regarding accounting for leases, assessment of impairment of
long-lived assets, and the financial close process have been
identified and described in management&#x2019;s revised assessment.
These material weaknesses were considered in determining the
nature, timing, and extent of audit tests applied in our audit of
the 2016, 2015, and 2014 financial statements (as
restated).</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">In our opinion, CEL-SCI Corporation did
not maintain, in all material respects, effective internal
control over financial reporting as of September 30, 2016, based on
the COSO criteria</font><font style="font-style: italic; color: #000000">.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
do not express an opinion or any other form of assurance on
management&#x2019;s statements referring to any corrective actions
to be taken by the Company after the date of management&#x2019;s
assessment.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">We
also have audited, in accordance with the standards of the Public
Company Accounting Oversight Board (United States), the balance
sheets of CEL-SCI Corporation as of September 30, 2016 and 2015,
and the related statements of operations, stockholders&#x2019;
(deficit) equity, and cash flows for each of the three years in the
period ended September 30, 2016 and our report dated December 14,
2016 expressed an unqualified opinion thereon that included an
explanatory paragraph regarding CEL-SCI Corporation&#x2019;s ability
to continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">/s/BDO
USA, LLP</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
McLean, Virginia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
December 14, 2016, except as to the effect of the material
weaknesses which is dated as of December 11,
2017</font> </div>

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">60</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
9B. OTHER INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;None.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Officers and Directors</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 29%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Name</font></div>
</td>
<td style="vertical-align: top; width: 13%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Age</font></div>
</td>
<td style="vertical-align: top; width: 59%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Position</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Geert
R. Kersten, Esq.</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">57</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Director,
Chief Executive Officer and Treasurer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Patricia
B. Prichep</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">65</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Senior
Vice President of Operations and Corporate Secretary</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Dr.
Eyal Talor</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">60</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Chief
Scientific Officer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Dr.
Daniel H. Zimmerman</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">75</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Senior
Vice President of Research, Cellular Immunology</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">John
Cipriano</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">74</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Senior
Vice President of Regulatory Affairs</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Alexander
G. Esterhazy (1)<br></font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">75</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Dr.
Peter R. Young</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">71</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Bruno
Baillavoine</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">64</font></div>
</td>
<td style="vertical-align: top; width: 59%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="display: table; margin-left: 47px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"> <font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">(1)</font>&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">Mr.
Esterhazy passed away on August 30, 2017.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The directors of
CEL-SCI serve in such capacity until the next annual meeting of
CEL-SCI's shareholders and until their successors have been duly
elected and qualified. The officers of CEL-SCI serve at the
discretion of CEL-SCI's directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
Mr. Maximilian de Clara resigned for personal health reasons,
effective immediately. The 87 year-old visionary funded the
original research of what has become CEL-SCI&#x2019;s
investigational drug Multikine at the Max Planck Institute in
Germany. Mr. de Cara by virtue of his former position as an officer
and director of CEL-SCI, was deemed to be the "parent" and
"founder" of CEL-SCI as those terms are defined under applicable
rules and regulations of the SEC.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">All of
CEL-SCI&#x2019;s directors have served as directors for a
significant period of time. Consequently, their long-standing
experience with CEL-SCI benefits both CEL-SCI and its
shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The principal
occupations of CEL-SCI's officers and directors, during the past
several years, are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Geert Kersten has
served in his current leadership role at CEL-SCI since 1995. Mr.
Kersten has been with CEL-SCI since 1987. He has been involved in
the pioneering field of cancer immunotherapy for over two decades
and has successfully steered CEL-SCI through many challenging
cycles in the biotechnology industry. Mr. Kersten also provides
CEL-SCI with significant expertise in the fields of finance and law
and has a unique vision of how CEL-SCI's Multikine product could
potentially change the way cancer is treated.&#xA0; Prior to
joining CEL-SCI, Mr. Kersten worked at the law firm of Finley &amp;
Kumble and worked at Source Capital, an investment banking firm
located in McLean, VA. He is a native of Germany, graduated from
Millfield School in England, and completed his studies in the US.
Mr. Kersten received his Undergraduate Degree in Accounting and an
M.B.A. from George Washington University, and a law degree (J.D.)
from American University in Washington, DC.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">61</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Patricia B. Prichep
joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President
of Operations since March 1994. Between December 1992 and March
1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep
became CEL-SCI's Corporate Secretary in May 2000. She is
responsible for all day-to-day operations of CEL-SCI, including
human resources and is the liaison with CEL-SCI&#x2019;s independent
registered public accounting firm for financial reporting. From
June 1990 to December 1992, Ms. Prichep was the Manager of Quality
and Productivity for the NASD&#x2019;s Management, Systems and
Support Department and was responsible for the internal auditing
and work flow analysis of operations. Between 1982 and 1990, Ms.
Prichep was Vice President and Operations Manager for Source
Capital, Ltd. She handled all operations and compliance for Source
Capital and was licensed as a securities broker. Ms. Prichep
received her B.A. from the University of Bridgeport in
Connecticut.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">Eyal Talor, Ph.D. joined CEL-SCI in October 1993.
In October 2009, Dr. Talor was promoted to Chief Scientific
Officer. Between this promotion and March of 1994 he was the Senior
Vice President of Research and Manufacturing.&#xA0; He is a
clinical immunologist with over 19 years of hands-on management of
clinical research and drug development for immunotherapy
application; pre-clinical to Phase III, in the biopharmaceutical
industry.&#xA0; His expertise includes; biopharmaceutical R&amp;D
and Biologics product development, GMP (Good Manufacturing
Practices) manufacture, Quality Control testing, and the design and
building of GMP manufacturing and testing facilities.&#xA0; He
served as Director of Clinical Laboratories (certified by the State
of Maryland) and has experience in the design of clinical trials
(Phase I &#x2013; III) and GCP (Good Clinical Practices)
requirements.&#xA0; He also has broad experience in the different
aspects of biological assay development, analytical methods
validation, raw material specifications, and QC (Quality Control)
tests development under FDA/GMP, USP, and ICH guidelines.&#xA0; He
has extensive experience in the preparation of documentation for
IND and other regulatory submissions.&#xA0; His scientific area of
expertise encompasses immune response assessment.&#xA0; He is the
author of over 25 publications and has published a number of
reviews on immune regulations in relation to clinical immunology.
Before coming to CEL-SCI, he was Director of R&amp;D and Clinical
Development at CBL, Inc., Principal Scientist - Project Director,
and Clinical Laboratory Director at SRA Technologies, Inc. Prior to
that he was a full time faculty member at The Johns Hopkins
University, Medical Institutions; School of Public Health.&#xA0; He
has invented technologies which are covered by</font> <font style="color: #000000">two US patents; one on Multikine&#x2019;s
composition of matter and method of use in cancer, and one on a
platform Peptide technology (&#x2018;Adapt&#x2019;) for the treatment
of autoimmune diseases, asthma, allergy, and transplantation
rejection.&#xA0; He also</font> is responsible for <font style="color: #000000">numerous product and process inventions as well as
a number of pending US and PCT patent applications.&#xA0; He
received his Ph.D. in Microbiology and Immunology from the
University of Ottawa, Ottawa, Ontario, Canada, and had
post-doctoral training in clinical and cellular immunology at The
John Hopkins University, Baltimore, Maryland, USA.&#xA0; He holds
an Adjunct Associate teaching position at the Johns Hopkins
University Medical Institutions.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">Daniel H. Zimmerman, Ph.D., was CEL-SCI's Senior
Vice President of Cellular Immunology between 1996 and December
2008 and again since November 2009.&#xA0; He joined CEL-SCI in
January 1996 as the Vice President of Research, Cellular
Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its
president from 1987-1995.&#xA0; From 1973-1987, Dr. Zimmerman
served in various positions at Electronucleonics, Inc. His
positions included: Scientist, Senior Scientist, Technical Director
and Program Manager. Dr Zimmerman held various teaching positions
at Montgomery College between 1987 and 1995. Dr. Zimmerman has
invented technologies which are covered by over a dozen US patents
as well as many foreign equivalent patents. He is the author of
over 40 scientific publications in the area of immunology and
infectious diseases. He has been awarded numerous grants from NIH
and DOD.&#xA0; From 1969-1973, Dr. Zimmerman was a Senior Staff
Fellow at NIH. For the following 25 years, he continued on at NIH
as a&#xA0;guest worker. Dr. Zimmerman received a Ph.D. in
Biochemistry in 1969, and a Masters in Zoology in 1966 from the
University of Florida as well as a B.S. in Biology from Emory and
Henry College in</font> 1963.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">62</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">John Cipriano, was
CEL-SCI&#x2019;s Senior Vice President of Regulatory Affairs between
March 2004 and December 2008 and again since October 2009. Mr.
Cipriano brings to CEL-SCI over 30 years of experience with both
biotech and pharmaceutical companies. In addition, he held
positions at the United States Food and Drug Administration (FDA)
as Deputy Director, Division of Biologics Investigational New
Drugs, Office of Biologics Research and Review and was the Deputy
Director, IND Branch, Division of Biologics Evaluation, Office of
Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the
Massachusetts College of Pharmacy in Boston, Massachusetts and his
M.S. in Pharmaceutical Chemistry from Purdue University in West
Lafayette, Indiana.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Alexander G.
Esterhazy has been a Director of CEL-SCI since December 1999 and
has been an independent financial advisor since November 1997.
Between July 1991 and October 1997, Mr. Esterhazy was a senior
partner of Corpofina S.A. Geneva, a firm engaged in mergers,
acquisitions and portfolio management. Between January 1988 and
July 1991, Mr. Esterhazy was a managing director of DG Bank in
Switzerland. During this period Mr. Esterhazy was in charge of the
Geneva, Switzerland branch of the DG Bank, founded and served as
Vice President of DG Finance (Paris) and was the President and
Chief Executive Officer of DG-Bourse, a securities brokerage
firm.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Peter R. Young,
Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young
has been a senior executive within the pharmaceutical industry in
the United States and Canada for most of his career, originally in
organizations that are now part of Sanofi S.A. Over the last 20
years he has primarily held positions of Chief Executive Officer or
Chief Financial Officer and has extensive experience with
acquisitions and equity financing. Since November 2001, Dr. Young
has been the President of Agnus Dei, LLC, which has acted as a
partner in an organization managing immune system clinics which
treats patients with diseases such as cancer, multiple sclerosis
and hepatitis. Dr. Young was also the President and Chief Executive
Officer of SRL Technology, Inc., a company involved in the
development of pharmaceutical drug delivery systems. Between 1998
and 2001, Dr. Young was the Chief Financial Officer of Adams
Laboratories, Inc., the developer of Mucinex&#xAE;. Dr. Young
received his Ph.D. in Organic Chemistry from the University of
Bristol, England after obtaining his Bachelor's degree in Honors
Chemistry, Mathematics and Economics. &#xA0;Subsequently, he
qualified as a Fellow of the Chartered Institute of Management
Accountants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Bruno Baillavoine
joined CEL-SCI&#x2019;s board of directors in June 2015. Since 2010,
Mr. Baillavoine has been a partner of Globomass Holdings Limited, a
London, England based developer of renewable energy projects from
concept through final operations. Since 2012 Mr. Baillavoine has
been the Executive Chairman of Globomass Holdings. Globomass
Holdings has subsidiaries in Ireland, Bulgaria, Croatia, Serbia,
and has recently acquired a 20% stake in a US based renewable
energy company. Between 1978 and 1982 he was the marketing manager
of Ravenhead Ltd., a manufacturer of glass tableware, and part of
United Distillers Group (later acquired by Grand Metropolitan).
During this time Mr. Baillavoine became the UK Business Manager
where he restored market share and profit for United Distillers.
From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and
Group Marketing Director for Prontaprint where he expanded the
number of shops to 500 locations in four years. Mr. Baillavoine
joined Grand Metropolitan Plc between 1986-1988 (now Diageo Plc),
an FTSE 100 beverage, food, hotel and leisure company, as director
in the Special Operations division. In this capacity, he developed
plans for Grand Met&#x2019;s trouble-shooting division for over
20,000 Grand Met retail outlets. From 1988-1991 he was the Managing
Director of Nutri Systems (UK) Ltd., a subsidiary of the US based
provider of professionally supervised weight loss programs. Between
1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a
multinational business support services group, and in 1992, was
promoted to the Managing Director for the manufacturing businesses.
The &#xA3;2.3 billion turnaround of BET during his tenure is one of
the most successful turnarounds of a top 100 FTSE company. Since
1995, Mr. Baillavoine has held a number of CEO positions across a
wide range of industries and geographical locations. Mr.
Baillavoine has European and American educations (US high school
and University of Wisconsin Eau Claire 1972-1976).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">63</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">All of CEL-SCI's
officers devote substantially all of their time to CEL-SCI's
business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
Board of Directors does not have a &#x201C;leadership
structure&#x201D;, as such, since each director is entitled to
introduce resolutions to be considered by the Board and each
director is entitled to one vote on any resolution considered by
the Board. CEL-SCI&#x2019;s Chief Executive Officer is not the
Chairman of CEL-SCI&#x2019;s Board of Directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
Board of Directors has the ultimate responsibility to evaluate and
respond to risks facing CEL-SCI. CEL-SCI&#x2019;s Board of Directors
fulfills its obligations in this regard by meeting on a regular
basis and communicating, when necessary, with CEL-SCI&#x2019;s
officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Alexander G.
Esterhazy, Dr. Peter R. Young and Bruno Baillavoine are independent
directors as that term is defined in section 803 of the listing
standards of the NYSE MKT.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has adopted
a Code of Ethics which is applicable to CEL-SCI&#x2019;S principal
executive, financial, and accounting officers and persons
performing similar functions. The Code of Ethics is available on
CEL-SCI&#x2019;s website, located at <font style="font-style: italic">www.cel-sci.com.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">If a violation of
this code of ethics act is discovered or suspected, any person
(anonymously, if desired) may send a detailed note, with relevant
documents, to CEL-SCI&#x2019;s Audit Committee, c/o Dr. Peter Young,
208 Hewitt Drive, Suite 103-143, Waco, TX 76712<font style="font-weight: bold">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">For purposes of
electing directors at its annual meeting, CEL-SCI has a nominating
committee that is made up of CEL-SCI&#x2019;s three independent
directors. The nominating committee selects the nominees to the
Board of Directors and they are approved by CEL-SCI&#x2019;s
shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">64</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI does not
have any policy regarding the consideration of director candidates
recommended by shareholders since a shareholder has never
recommended a nominee to the Board of Directors and under Colorado
law, any shareholder can nominate a person for election as a
director at the annual shareholders&#x2019; meeting. However,
CEL-SCI&#x2019;s Board of Directors will consider candidates
recommended by shareholders. To submit a candidate for the Board of
Directors the shareholder should send the name, address and
telephone number of the candidate, together with any relevant
background or biographical information, to CEL-SCI&#x2019;s Chief
Executive Officer, at the address shown on the cover page of this
report. The Board has not established any specific qualifications
or skills a nominee must meet to serve as a director. Although the
Board does not have any process for identifying and evaluating
director nominees, the Board does not believe there would be any
differences in the manner in which the Board evaluates nominees
submitted by shareholders as opposed to nominees submitted by any
other person.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI does not
have a policy with regard to Board member&#x2019;s attendance at
annual meetings. All Board members, with the exception of Mr. de
Clara and Mr. Esterhazy, attended the last annual
shareholder&#x2019;s meeting held on July 22, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Holders of
CEL-SCI&#x2019;s common stock can send written communications to
CEL-SCI&#x2019;s entire Board of Directors, or to one or more Board
members, by addressing the communication to &#x201C;the Board of
Directors&#x201D; or to one or more directors, specifying the
director or directors by name, and sending the communication to
CEL-SCI&#x2019;s offices in Vienna, Virginia. Communications
addressed to the Board of Directors as whole will be delivered to
each Board member. Communications addressed to a specific director
(or directors) will be delivered to the director (or directors)
specified.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Security holder
communications not sent to the Board of Directors as a whole are
not relayed to Board members.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
11. <font style="text-decoration: underline">EXECUTIVE
COMPENSATION</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Compensation
Discussion and Analysis</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">This Compensation
Discussion and Analysis (CD&amp;A) outlines CEL-SCI&#x2019;s
compensation philosophy, objectives and process for its executive
officers. <font style="color: #000000">This CD&amp;A includes
information on how compensation decisions are made, the overall
objectives of CEL-SCI&#x2019;s compensation program, a description
of the various components of compensation that are provided, and
additional information pertinent to understanding CEL-SCI&#x2019;s
executive officer compensation program.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The Compensation
Committee determines the compensation of CEL-SCI&#x2019;s Chief
Executive Officer and delegates to the Chief Executive Officer the
responsibility to determine the base salaries of all other
officers, other than himself, under the constraints of an overall
limitation on the total amount of compensation to be paid to
them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">65</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Compensation Philosophy</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
compensation philosophy extends to all employees, including
executive officers, and is designed to align employee and
shareholder interests. The philosophy&#x2019;s objective is to pay
fairly based upon the employee&#x2019;s position, experience and
individual performance. Employees may be rewarded through
additional compensation when CEL-SCI meets or exceeds targeted
business objectives. Generally, under CEL-SCI&#x2019;s compensation
philosophy, as an employee&#x2019;s level of responsibility
increases, a greater portion of his or her total potential
compensation becomes contingent upon annual
performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">A
substantial portion of an executive's compensation incorporates
performance criteria that support and reward achievement of
CEL-SCI&#x2019;s long term business goals.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 36px"><font style="font-size: 13px; font-family: Times New Roman">The fundamental
principles of CEL-SCI&#x2019;s compensation philosophy are described
below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Market-driven.</font> Compensation programs
are structured to be competitive both in their design and in the
total compensation that they offer.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Performance-based.</font> Certain officers
have some portion of their incentive compensation linked to
CEL-SCI&#x2019;s performance. The application of performance
measures as well as the form of the reward may vary depending on
the employee&#x2019;s position and responsibilities.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 36px"><font style="font-size: 13px; font-family: Times New Roman">Based on a review
of its compensation programs, CEL-SCI does not believe that such
programs encourage any of its employees to take risks that would be
likely to have a material adverse effect on
CEL-SCI.&#xA0;&#xA0;CEL-SCI reached this conclusion based on the
following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The salaries paid
to employees are consistent with the employees&#x2019; duties and
responsibilities.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Employees who have
high impact relative to the expectations of their job duties and
functions are rewarded.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI retains
employees who have skills critical to its long term
success.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Review
of Executive Officer Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
current policy is that the various elements of the compensation
package are not interrelated in that gains or losses from past
equity incentives are not factored into the determination of other
compensation.&#xA0;&#xA0;For instance, if options that are granted
in a previous year have an exercise price which is below the market
price of CEL-SCI&#x2019;s common stock, the Committee does not take
that circumstance into consideration in determining the amount of
the options or restricted stock to be granted the next
year.&#xA0;&#xA0;Similarly, if the options or restricted shares
granted in a previous year become extremely valuable, the Committee
does not take that into consideration in determining the options or
restricted stock to be awarded for the next
year.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI does not
have a policy with regard to the adjustment or recovery of awards
or payments if relevant performance measures upon which they are
based are restated or otherwise adjusted in a manner that would
reduce the size of an award or payment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">66</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Components
of Compensation&#x2014;Executive Officers</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
executive officers are compensated through the following three
components:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Base
Salary</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Long-Term
Incentives (&#x201C;LTIs&#x201D;) (stock options and/or grants of
stock)</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Benefits</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">These components
provide a balanced mix of base compensation and compensation that
is contingent upon each executive officer&#x2019;s individual
performance. A goal of the compensation program is to provide
executive officers with a reasonable level of security through base
salary and benefits. CEL-SCI wants to ensure that the compensation
programs are appropriately designed to encourage executive officer
retention and motivation to create shareholder value. <font style="color: #000000">The Compensation Committee believes that
CEL-SCI&#x2019;s stockholders are best served when CEL-SCI can
attract and retain talented executives by providing compensation
packages that are competitive but fair.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In past years, base
salaries, benefits and incentive compensation opportunities were
generally targeted near the median of general survey market data
derived from indices covering similar biotech/pharmaceutical
companies.&#xA0;&#xA0;The companies included Advaxis, Inc., Amicus
Therapeutics, Inc., Celsion Corp., CytRx Corporation, GERON Corp,
Idera Pharmaceuticals, Inc., Northwest Biotherapeutics, Inc.,
Oragenics, Inc., StemCells, Inc., TG Therapeutics, Inc., Venaxis,
Inc., Arrowhead Research Corp, CorMedix Inc., Fibrocell Science,
Inc., Hemispherx Biopharma, Inc., Opexa Therapeutics, Inc., Mateon
Therapeutics, Inc. (formerly OXiGENE, Inc.), Catalyst Bioscience,
Inc., Sorrento Therapeutics, Inc., Tenax Therapeutics, Inc.,
Trovagene, Inc. and ZIOPHARM Oncology, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During fiscal year
2014, CEL-SCI used a third party consultant to provide it with
recommendations for strategic long term incentive compensation for
certain key executives. The recommendation resulted in the
formation of the 2014 Incentive Stock Bonus Plan that was voted on
and passed by the shareholders at the annual meeting on July 22,
2014.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Base Salaries</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Base salaries
generally have been targeted to be competitive when compared to the
salary levels of persons holding similar positions in other
pharmaceutical companies and other publicly traded companies of
comparable size. Each executive officer&#x2019;s respective
responsibilities, experience, expertise and individual performance
are considered.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">A further
consideration in establishing compensation for the senior employees
is their long term history with CEL-SCI. Taken into consideration
are factors that have helped CEL-SCI survive in times when it was
financially weak, such as: willingness to accept salary cuts,
willingness not to be paid at all for extended time periods, and in
general an attitude that helped CEL-SCI survive during financially
difficult times.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">67</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Long-Term Incentives</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Stock grants and
option grants help to align the interests of CEL-SCI&#x2019;s
employees with those of its shareholders.&#xA0;&#xA0;Options and
stock grants are made under CEL-SCI&#x2019;s Stock Option, Incentive
Stock Bonus, Stock Bonus and Stock Compensation
Plans.&#xA0;&#xA0;Options are granted with exercise prices equal to
the closing price of CEL-SCI&#x2019;s common stock on the day
immediately preceding the date of grant, with pro rata vesting at
the end of each of the following three
years.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI believes
that grants of equity-based compensation:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Enhance the link
between the creation of shareholder value and long-term executive
incentive compensation;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Provide focus,
motivation and retention incentive; and</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 72px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Provide competitive
levels of total compensation.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI&#x2019;s
management believes that the pricing for biotechnology stocks is
highly inefficient until the time of product sales. As such, any
long term compensation tied to progress as measured by share price
is not as efficient as it should be. The plan approved by the
shareholders in July 2014, which covers senior and mid-level
employees, seeks to address this issue by rewarding employees for
meeting major operational milestones and significantly improved
share prices.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Benefits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In addition to cash
and equity compensation programs, executive officers participate in
the health and welfare benefit programs available to other
employees. In a few limited circumstances, CEL-SCI provides other
benefits to certain executive officers, such as car
allowances.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">All executive
officers are eligible to participate in CEL-SCI&#x2019;s 401(k) plan
on the same basis as its other employees. CEL-SCI matches 100% of
each employee&#x2019;s contribution up to 6% of his or her
salary.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">68</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following table
sets forth in summary form the compensation received by (i) the
Chief Executive and Financial Officer of CEL-SCI and (ii) by each
other executive officer of CEL-SCI who received in excess of
$100,000 during the three fiscal years ended September 30,
2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman">Name
and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman">Principal
Position</font></div>
</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Fiscal
Year</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Salary
(1)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Bonus
(2)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Restricted
Stock Awards (3)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Option
Awards (4)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">All
Other Compen-sation(5)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Total</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; font-weight: bold; vertical-align: bottom; display: inline-block; width: 10%; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman">$</font><font style="text-align: left; font-weight: bold; vertical-align: bottom; display: inline-block; width: 10%; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Maximilian de
Clara,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">345,618</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">46,352</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">40,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">431,970</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Former President
(6)</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">332,750</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">69,190</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">40,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">441,940</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td colspan="1" style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><br></font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">393,250</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">298,648</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">73,183</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">765,081</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R.
Kersten,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">558,432</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">15,900</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">54,981</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">629,314</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief
Executive</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">514,083</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">16,050</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">54,981</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">585,114</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Officer and
Treasurer</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">584,621</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">3,236,526</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">82,917</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">57,581</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">3,961,645</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Patricia B.
Prichep,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">245,804</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">14,725</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">9,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">269,559</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Senior Vice
President</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">235,702</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">14,128</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,906</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">256,736</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">of Operations
and</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">247,852</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,735,938</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">55,278</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,531</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">2,045,599</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Secretary</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Eyal Talor,
Ph.D.,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">303,597</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">9,600</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">319,227</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief Scientific
Officer</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">290,983</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">9,600</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">306,613</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td colspan="1" style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><br></font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">283,283</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,731,290</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">55,278</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">2,075,882</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Daniel Zimmerman,
Ph.D.,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">228,413</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">13,708</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">37,081</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">285,233</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Senior Vice
President of</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">219,026</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">13,148</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">52,003</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">290,209</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Research,
Cellular</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">213,231</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">13,274</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">227,319</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,031</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">459,855</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Immunology</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">John
Cipriano,</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2016</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">211,405</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">31</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">211,437</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Senior Vice
President of</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">202,718</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">31</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">202,749</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Regulatory
Affairs</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">197,354</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">--</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">888,614</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">41,549</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">31</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,127,458</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">69</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(1)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The dollar value of
base salary (cash and non-cash) earned. The officers of the Company
received stock in lieu of salary increases in FY 2016 and
2015.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The dollar value of
bonus (cash and non-cash) earned.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The fair value of
the shares of restricted stock issued during the periods covered by
the table is shown as compensation for services to the persons
listed in the table. For all persons listed in the table, the
shares were issued as CEL-SCI's contribution on behalf of the named
officer who participates in CEL-SCI's 401(k) retirement plan and,
by far the largest part, restricted shares issued from the 2014
Incentive Stock Bonus Plan that was voted on and passed by the
shareholders at the annual meeting on July 22, 2014. These shares
are not vested and are held in escrow. The shares will only be
earned upon the achievement of certain milestones leading to the
commercialization of CEL-SCI&#x2019;s Multikine technology, or
specified increases in the market price of CEL-SCI&#x2019;S stock.
If the performance or market criteria are not met as specified in
the Incentive Stock Bonus Plan, all or a portion of the awarded
shares will be forfeited. The value of all stock awarded during the
periods covered by the table is calculated according to ASC
718-10-30-3 which represented the grant date fair
value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(4)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The fair value of
all stock options granted during the periods covered by the table
are calculated on the grant date in accordance with ASC 718-10-30-3
which represented the grant date fair value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(5)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">All other
compensation received that CEL-SCI could not properly report in any
other column of the table including the dollar value of any
insurance premiums paid by, or on behalf of, CEL-SCI with respect
to term life insurance for the benefit of the named executive
officer and car allowances paid by CEL-SCI. Includes board of
directors fees for Mr. de Clara and Mr. Kersten.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(6)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
Mr. de Clara resigned as President for personal health
reasons.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">70</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Employee Pension, Profit Sharing or Other Retirement
Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has a
defined contribution retirement plan, qualifying under Section
401(k) of the Internal Revenue Code and covering substantially all
CEL-SCI&#x2019;s employees. CEL-SCI&#x2019;s contribution to the plan
is made in shares of CEL-SCI's common stock. Each participant's
contribution is matched by CEL-SCI with shares of common stock
which have a value equal to 100% of the participant's contribution,
not to exceed the lesser of $1,000 or 6% of the participant's total
compensation. CEL-SCI's contribution of common stock is valued each
quarter based upon the closing price of its common stock. The
fiscal 2016 expenses for this plan were $168,262. Other than the
401(k) Plan, CEL-SCI does not have a defined benefit, pension plan,
profit sharing or other retirement plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Compensation of Directors During Year Ended September 30,
2016</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Name</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Paid in Cash</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Stock Awards (1)</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Option Awards (2)</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Total</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Maximilian de Clara
(3)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">46,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">86,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Geert
Kersten</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Alexander Esterhazy
(4)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">45,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">46,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">91,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Peter R.
Young</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">50,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">46,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">96,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Bruno
Baillavoine</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">45,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">46,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">91,352</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(1)&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The fair value of
stock issued for services.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">The fair value of
options granted computed in accordance with ASC 718-10-30-3 on the
date of grant which represents their grant date fair
value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
Mr. de Clara resigned as President for personal health
reasons.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"> <font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">(4)</font>&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
August 30, 2017, Mr. Esterhazy passed away.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Directors&#x2019;
fees paid to Maximilian de Clara and Geert Kersten are included in
the Executive Compensation table.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016
Maximilian de Clara resigned as an officer and director of the
Company. In consideration for Mr. de Clara&#x2019;s past services to
the Company, the Company entered into a Termination Agreement with
Mr. de Clara which provided for the following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">1.</font></div>
<div style="text-align: justify; display: table-cell"> <font style="font-size: 13px; font-family: Times New Roman">The Company issued
26,000 restricted shares of its common stock to Mr. de
Clara. The first 13,000 shares were issued promptly
after August 31, 2016. Of the first 13,000 shares,
none of the shares may be sold prior to February 28, 2017. Starting
on February 28, 2017, each month the Company will remove the
restrictive legend on 2,600 shares. The
second 13,000 shares will be issued on August 31,
2017, but may not be sold prior to February 28, 2018. Starting on
February 28, 2018, each month the Company will remove the
restrictive legend on 2,600 shares. The
foregoing procedure will continue until the restricted legend has
been removed on all 26,000 shares.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">71</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">All options held by
Mr. de Clara vested as of August 31, 2016.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">3.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Mr. de
Clara&#x2019;s existing coverage under the Company&#x2019;s group
health plan ended on August 31, 2016. However, Mr. de Clara may be
eligible to elect temporary continuation coverage under the
Company&#x2019;s group health plan in accordance with the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(&#x201C;COBRA&#x201D;). Mr. de Clara did elect to receive COBRA
continuation coverage. Therefore, the Company will pay for COBRA
coverage (such payments will not include COBRA coverage with
respect to the Company&#x2019;s Section 125 health care
reimbursement plan) until February 28, 2018, or the maximum period
permitted under COBRA if such period is less than eighteen months.
If Mr. de Clara exhausts the applicable COBRA period prior to
February 28, 2018, the Company will reimburse Mr. de Clara for the
cost of an individual health insurance policy in an amount not to
exceed the amount of the monthly COBRA premium previously paid by
the Company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The Termination
Agreement was approved by the Company&#x2019;s Compensation
Committee.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Employment Contracts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Geert Kersten</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
CEL-SCI entered into a three-year employment agreement with Geert
Kersten, CEL-SCI&#x2019;s Chief Executive Officer. The employment
agreement with Mr. Kersten, which is essentially the same as Mr.
Kersten&#x2019;s prior employment agreement, as amended on August
30, 2013, provided that, during the term of the agreement, CEL-SCI
would pay Mr. Kersten an annual salary of $559,052, plus any
increases in proportion to salary increases granted to other senior
executive officers of CEL-SCI, as well any increases approved by
the Board of Directors during the period of the employment
agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the
employment term, Mr. Kersten will be entitled to receive any other
benefits which are provided to CEL-SCI's executive officers or
other full time employees in accordance with CEL-SCI's policies and
practices and subject to Mr. Kersten&#x2019;s satisfaction of any
applicable condition of eligibility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">If Mr. Kersten
resigns within ninety (90) days of the occurrence of any of the
following events: (i) a reduction in Mr. Kersten&#x2019;s salary
(ii) a relocation (or demand for relocation) of Mr. Kersten&#x2019;s
place of employment to a location more than ten (10) miles from his
current place of employment, (iii) a significant and material
reduction in Mr. Kersten&#x2019;s authority, job duties or level of
responsibility or the imposition of significant and material
limitations on the Mr. Kersten&#x2019;s autonomy in his position, or
(iv) a Change in Control, then the employment agreement will be
terminated and Mr. Kersten will be entitled to receive a lump-sum
payment from CEL-SCI equal to 24 months of salary ($1,118,104) and
the unvested portion of any stock options would vest immediately
($590,329). For purposes of the employment agreement a change in
the control of CEL-SCI means: (1) the merger of CEL-SCI with
another entity if after such merger the shareholders of CEL-SCI do
not own at least 50% of voting capital stock of the surviving
corporation; (2) the sale of substantially all of the assets of
CEL-SCI; (3) the acquisition by any person of more than 50% of
CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's
directors which has not been approved by the incumbent
directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">72</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The employment
agreement will also terminate upon the death of Mr. Kersten, Mr.
Kersten&#x2019;s physical or mental disability, willful misconduct,
an act of fraud against CEL-SCI, or a breach of the employment
agreement by Mr. Kersten.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">If the employment
agreement is terminated for any of the foregoing, Mr. Kersten, or
his legal representatives, as the case may be, will be paid the
salary provided by the employment agreement through the date of
termination, any options or bonus shares of CEL-SCI then held by
Mr. Kersten will become fully vested and the expiration date of any
options which would expire during the four year period following
his termination of employment will be extended to the date which is
four years after his termination of employment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Patricia B. Prichep / Eyal Talor, Ph.D.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
CEL-SCI entered into a three-year employment agreement with
Patricia B. Prichep, CEL-SCI&#x2019;s Senior Vice President of
Operations. The employment agreement with Ms. Prichep, which is
essentially the same as Ms. Prichep&#x2019;s prior employment
agreement entered into on August 30, 2013 provided that, during the
term of the agreement, CEL-SCI would pay Ms. Prichep an annual
salary of $245,804 plus any increases approved by the Board of
Directors during the period of the employment
agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On August 31, 2016,
CEL-SCI entered into a three-year employment agreement with Eyal
Talor, Ph.D., CEL-SCI&#x2019;s Chief Scientific Officer. The
employment agreement with Dr. Talor, which is essentially the same
as Dr. Talor&#x2019;s prior employment agreement entered into on
August 30, 2013, provided that, during the term of the agreement,
CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any
increases approved by the Board of Directors during the period of
the employment agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">If Ms. Prichep or
Dr. Talor resigns within ninety (90) days of the occurrence of any
of the following events: (i) a relocation (or demand for
relocation) of employee&#x2019;s place of employment to a location
more than ten (10) miles from the employee&#x2019;s current place of
employment, (ii) a significant and material reduction in the
employee&#x2019;s authority, job duties or level of responsibility
or (iii) the imposition of significant and material limitations on
the employee&#x2019;s autonomy in her or his position, the
employment agreement will be terminated and the employee will be
paid the salary provided by the employment agreement through the
date of termination and the unvested portion of any stock options
held by the employee will vest immediately.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In the event there
is a change in the control of CEL-SCI, the employment agreements
with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or Dr. Talor
(as the case may be) to resign from her or his position at CEL-SCI
and receive a lump-sum payment from CEL-SCI equal to 18 months of
salary ($368,706 and $455,180 respectively). In addition, the
unvested portion of any stock options held by the employee will
vest immediately ($108,010 and $108,010 respectively). For purposes
of the employment agreements, a change in the control of CEL-SCI
means: (1) the merger of CEL-SCI with another entity if after such
merger the shareholders of CEL-SCI do not own at least 50% of
voting capital stock of the surviving corporation; (2) the sale of
substantially all of the assets of CEL-SCI; (3) the acquisition by
any person of more than 50% of CEL-SCI's common stock; or (4) a
change in a majority of CEL-SCI's directors which has not been
approved by the incumbent directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">73</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The employment
agreements with Ms. Prichep and Dr. Talor will also terminate upon
the death of the employee, the employee&#x2019;s physical or mental
disability, willful misconduct, an act of fraud against CEL-SCI, or
a breach of the employment agreement by the employee. If the
employment agreement is terminated for any of these reasons the
employee, or her or his legal representatives, as the case may be,
will be paid the salary provided by the employment agreement
through the date of termination.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Compensation Committee Interlocks and Insider
Participation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has a
compensation committee comprised of Mr. Alexander Esterhazy, Mr.
Bruno Baillavoine and Dr. Peter Young, all of whom are independent
directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">During the year
ended September 30, 2016, no director of CEL-SCI was also an
executive officer of another entity, which had an executive officer
of CEL-SCI serving as a director of such entity or as a member of
the compensation committee of such entity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;<font style="text-decoration: underline">Loan
from Officer and Director</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Between December
2008 and June 2009, CEL-SCI&#x2019;s President, and a director,
Maximilian de Clara, loaned CEL-SCI $1,104,057.&#xA0;&#xA0;Between
July 2009 and July 2015, the loan from Mr. de Clara bore interest
at 15% per year. At Mr. de Clara&#x2019;s option, the loan was
convertible into shares of CEL-SCI&#x2019;s common stock, determined
by dividing the amount to be converted by
$100.00.&#xA0;&#xA0;In accordance with the loan
agreement, CEL-SCI issued Mr. de Clara warrants to purchase
6,593 shares of CEL-SCI&#x2019;s common stock at a
price of $100.00 per share.&#xA0;&#xA0;These warrants
expired on December 24, 2014.&#xA0;&#xA0;In consideration for an
extension of the due date, Mr. de Clara received warrants to
purchase 7,397 shares of CEL-SCI&#x2019;s common stock
at a price of $125.00 per share.&#xA0;&#xA0;These
warrants expired on January 6, 2015.&#xA0;&#xA0;In consideration of
Mr. de Clara&#x2019;s agreement to subordinate his note to the
convertible preferred shares and convertible debt as part of a
prior year settlement agreement, CEL-SCI extended the maturity date
of the note to July 6, 2015. &#xA0;&#xA0;In August 2014, the loan
was transferred to the de Clara Trust, of which CEL-SCI&#x2019;s
Chief Executive Officer, Geert Kersten, is the trustee and a
beneficiary.&#xA0;&#xA0;Mr. de Clara continued to receive the
interest payments.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">On June 29, 2015,
CEL-SCI extended the maturity date of the note to July 6, 2017,
lowered the interest rate to 9% per year and changed the conversion
price to $14.75, the closing stock price on the
previous trading day.&#xA0;&#xA0;&#xA0;The new terms were effective
July 7, 2015.&#xA0;&#xA0; Concurrently, CEL-SCI extended the
expiration date of the Series N warrants to August 18,
2017.&#xA0;&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">On October 11,
2015, at the request of Lake Whillans Vehicle I, LLC, the note was
extended for one year to July 6, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">On January 12,
2016, CEL-SCI owed the de Clara Trust $1,105,989, which amount
included accrued and unpaid interest. On January 13, 2016, the de
Clara Trust demanded payment on the note payable. At the same time
CEL-SCI sold 120,000 shares of its common stock and
120,000 Series X warrants to the de Clara Trust for
approximately $1,100,000. Each warrant allows the de Clara Trust to
purchase one share of CEL-SCI&#x2019;s common stock at a price of
$9.25 per share at any time on or before January 13,
2021.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">74</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Stock Option, Bonus and Compensation Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI has
Incentive Stock Option Plans, Non-Qualified Stock Option, Stock
Bonus, Stock Compensation Plans and an Incentive Stock Bonus Plan.
All Stock Option, Bonus and Compensation Plans have been approved
by the stockholders. A summary description of these Plans follows.
In some cases these Plans are collectively referred to as the
"Plans".</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Incentive Stock Option Plan</font>.
The Incentive Stock Option Plans authorize the issuance of shares
of CEL-SCI's common stock to persons who exercise options granted
pursuant to the Plans. Only CEL-SCI&#x2019;s employees may be
granted options pursuant to the Incentive Stock Option
Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Options may not be
exercised until one year following the date of grant. Options
granted to an employee then owning more than 10% of the common
stock of CEL-SCI may not be exercisable by its terms after five
years from the date of grant. Any other option granted pursuant to
the Plans may not be exercisable by its terms after ten years from
the date of grant.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The purchase price
per share of common stock purchasable under an option is determined
by the Committee but cannot be less than the fair market value of
the common stock on the date of the grant of the option (or 110% of
the fair market value in the case of a person owning more than 10%
of CEL-SCI's outstanding shares).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Non-Qualified Stock Option
Plans</font>. The Non-Qualified Stock Option Plans authorize the
issuance of shares of CEL-SCI's common stock to persons that
exercise options granted pursuant to the Plans. CEL-SCI's
employees, directors, officers, consultants and advisors are
eligible to be granted options pursuant to the Plans, provided
however that bona fide services must be rendered by such
consultants or advisors and such services must not be in connection
with sale a capital-raising transaction or promoting
CEL-SCI&#x2019;s common stock. The option exercise price is
determined by CEL-SCI&#x2019;s Board of Directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Stock Bonus Plan</font>. Under the
Stock Bonus Plans shares of CEL-SCI&#x2019;s common stock may be
issued to CEL-SCI's employees, directors, officers, consultants and
advisors, provided however that bona fide services must be rendered
by consultants or advisors and such services must not be in
connection with a capital-raising transaction or promoting
CEL-SCI&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Stock Compensation Plan</font>. Under
the Stock Compensation Plan, shares of CEL-SCI&#x2019;s common stock
may be issued to CEL-SCI&#x2019;s employees, directors, officers,
consultants and advisors in payment of salaries, fees and other
compensation owed to these persons. However, bona fide services
must be rendered by consultants or advisors and such services must
not be in connection with the offer or sale of securities in a
capital-raising transaction or promoting CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Incentive Stock Bonus Plan</font>.
Under the 2014 Incentive Stock Bonus Plan, shares of
CEL-SCI&#x2019;s common stock may be issued to executive officers
and other employees who contribute significantly to the success of
CEL-SCI, to participate in its future prosperity and growth and
aligns their interests with those of CEL-SCI&#x2019;s shareholders.
The purpose of the Plan is to provide long term incentive for
outstanding service to CEL-SCI and its shareholders and to assist
in recruiting and retaining people of outstanding ability and
initiative in executive and management positions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">75</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Other Information Regarding the
Plans</font>. The Plans are administered by CEL-SCI's Compensation
Committee (&#x201C;the Committee&#x201D;), each member of which is a
director of CEL-SCI. The members of the Committee were selected by
CEL-SCI's Board of Directors and serve for a one-year tenure and
until their successors are elected. A member of the Committee may
be removed at any time by action of the Board of Directors. Any
vacancies which may occur on the Committee will be filled by the
Board of Directors. The Committee is vested with the authority to
interpret the provisions of the Plans and supervise the
administration of the Plans. In addition, the Committee is
empowered to select those persons to whom shares or options are to
be granted, to determine the number of shares subject to each grant
of a stock bonus or an option and to determine when, and upon what
conditions, shares or options granted under the Plans will vest or
otherwise be subject to forfeiture and cancellation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">In the discretion
of the Committee, any option granted pursuant to the Plans may
include installment exercise terms such that the option becomes
fully exercisable in a series of cumulating portions. The Committee
may also accelerate the date upon which any option (or any part of
any options) is first exercisable. Any shares issued pursuant to
the Stock Bonus Plan or Stock Compensation Plan and any options
granted pursuant to the Incentive Stock Option Plan or the
Non-Qualified Stock Option Plans will be forfeited if the "vesting"
schedule established by the Committee administering the Plans at
the time of the grant is not met. For this purpose, vesting means
the period during which the employee must remain an employee of
CEL-SCI or the period of time a non-employee must provide services
to CEL-SCI. At the time an employee ceases working for CEL-SCI (or
at the time a non-employee ceases to perform services for CEL-SCI),
any shares or options not fully vested will be forfeited and
cancelled. At the discretion of the Committee payment for the
shares of common stock underlying options may be paid through the
delivery of shares of CEL-SCI's common stock having an aggregate
fair market value equal to the option price, provided such shares
have been owned by the option holder for at least one year prior to
such exercise. A combination of cash and shares of common stock may
also be permitted at the discretion of the Committee.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Options are
generally non-transferable except upon death of the option holder.
Shares issued pursuant to the Stock Bonus Plans will generally not
be transferable until the person receiving the shares satisfies the
vesting requirements imposed by the Committee when the shares were
issued.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The Board of
Directors of CEL-SCI may at any time, and from time to time, amend,
terminate, or suspend one or more of the Plans in any manner it
deems appropriate, provided that such amendment, termination or
suspension will not adversely affect rights or obligations with
respect to shares or options previously granted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Stock Options</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following
tables show information concerning the options granted during the
fiscal year ended September 30, 2016, to the persons named
below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">76</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Options Granted</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: center; text-align: center; padding-top: 0px; padding-bottom: 0px; margin-left: auto; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Name</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Grant
Date&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Options
Granted</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Price
Per Share</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Expiration
Date&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td rowspan="1" style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Daniel
Zimmerman</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/22/2016</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">4,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">11.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/21/2026</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Alexander Esterhazy
(1)</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/22/2016</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">5,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">11.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/21/2026</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Peter
Young</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/22/2016</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">5,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">11.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/21/2026</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Bruno
Baillavoine</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/22/2016</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">5,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">11.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/21/2026</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Maximilian de Clara
(2)</font></div>
</td>
<td style="width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/22/2016</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">5,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">11.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">7/21/2026</font></div>
</td>
</tr><tr>
<td style="width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 15%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 20px; padding-right: 8px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">(1)</font> </div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
August 30, 2017, Mr. Esterhazy passed away.</font> </div>
</div>
</div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 20px; padding-right: 8px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">(2)</font> </div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
August 31, 2016, Mr. de Clara resigned as President for personal
health reasons.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following
tables show information concerning the options cancelled and
exercised during the fiscal year ended September 30, 2016, to the
persons named below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Options Cancelled</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 23%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 29%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold">Weighted Average<br></font></font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;&#xA0;
Weighted Avergage<br></font></font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">Remaining
Contractual<br></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">Employee</font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 23%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">Total
Options<br></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 29%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold">Exercise Price<br></font></font></div>
</td>
<td style="vertical-align: bottom; width: 28%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold; font-family: Times New Roman">Term
(Years)<br></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 23%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">None</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Options Exercised</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 23%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;Date
of</font></font></div>
</td>
<td style="vertical-align: bottom; width: 29%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Shares
Acquired</font></font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;Value</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Name</font></font></div>
</td>
<td style="vertical-align: bottom; width: 23%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Exercise</font></font></div>
</td>
<td style="vertical-align: bottom; width: 29%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">On
Exercise</font></font></div>
</td>
<td style="vertical-align: bottom; width: 28%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Realized</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 23%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">None</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">77</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
following lists the outstanding options held by the persons named
below:</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold;">Shares underlying unexercised</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 90%; font-family: Times New Roman; font-weight: bold;">Option which are:</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Exercise</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Expiration</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Name</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Exercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Unexercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Date</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Maximilian
de Clara (3)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,745</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,888</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">08/05/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">08/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/21/25</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:80%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">11.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/21/26</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44,233</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">78</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold; font-family: Times New Roman">Shares
underlying unexercised</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 24%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Option
which are:</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Exercise</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman">Expiration</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman">Name</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Exercisable</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Unexercisable</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Price</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman">Date</font></font></div>
</td>
</tr></table>
</div>
<div style="margin-left: 0px; margin-right: 0px;">
<div style="null"></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Geert
R. Kersten</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,354</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,018</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,560</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,822</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:80%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,178</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,045</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patricia
B. Prichep</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,868</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,541</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,320</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,247</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,577</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,753</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,553</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">79</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold;">Shares underlying unexercised</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 90%; font-family: Times New Roman; font-weight: bold;">Option which are:</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Exercise</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Expiration</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Name</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Exercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Unexercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Date</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Eyal
Talor, Ph.D.</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">963</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(1)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,111</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,497</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,247</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,418</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,753</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,553</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Daniel
Zimmerman, Ph.D.</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,008</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,568</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">08/05/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">06/25/25</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,043</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">08/05/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/25/25</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/21/26</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,933</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">80</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold;">Shares underlying unexercised</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 24%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 90%; font-family: Times New Roman; font-weight: bold;">Option which are:</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Exercise</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Expiration</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Name</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Exercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Unexercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Date</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
John Cipriano</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">157.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/13/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">64</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">80.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/01/16</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/30/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,264</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Options awarded to
employees who did not collect a salary, or reduced or deferred
their salary between September 15, 2008 and June 30, 2009. For
example, Mr. Kersten and Ms. Prichep did not collect any salary
between September 30, 2008 and June 30, 2009.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Long-term
performance options: The Board of Directors has identified the
successful Phase III clinical trial for Multikine to be the most
important corporate event to create shareholder value. Therefore,
one third of the options can be exercised when the first 400
patients are enrolled in CEL-SCI's Phase III head and neck cancer
clinical trial. One third of the options can be exercised when all
of the patients have been enrolled in the Phase III clinical trial.
One third of the options can be exercised when the Phase III trial
is completed. The grant-date fair value of these options awarded to
the senior management of the Company amounts to $3.3 million in
total.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"> <font style="font-family: Times New Roman; font-size: 13px">(3)&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">On August 31, 2016,
Mr. de Clara resigned as President for personal health
reasons.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Summary</font>. The following shows
certain information as of September 30, 2016 concerning the stock
options and stock bonuses granted by CEL-SCI. Each option
represents the right to purchase one share of CEL-SCI's common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Name of
Plan</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Total
Shares Reserved Under Plans</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Shares
Reserved for Outstanding Options</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Shares
Issued</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Remaining
Options/Shares Under Plans</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incentive Stock
Option Plans</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">138,400</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">65,959</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">N/A</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">60,453</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Non-Qualified Stock
Option</font> <font style="font-size: 13px; font-family: Times New Roman">Plans</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">387,200</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">277,613</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">N/A</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">8<font style="color: rgb(0, 0, 0);">2,370</font></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Bonus
Plans</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">223,760</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">N/A</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">26,448</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">9<font style="color: rgb(0, 0, 0);">7,278</font></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Stock Compensation
Plan</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">134,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">N/A</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">79,401</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">53,276</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 44%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incentive Stock
Bonus Plan</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">640,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">N/A</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">624,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1<font style="color: rgb(0, 0, 0);">6</font>,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">Of the shares
issued pursuant to CEL-SCI's Stock Bonus Plans, 44,328
shares were issued as part of CEL-SCI's contribution to its 401(k)
plan.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">81</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following table
shows the weighted average exercise price of the outstanding
options granted pursuant to CEL-SCI&#x2019;s Incentive and
Non-Qualified Stock Option Plans as of September 30, 2016,
CEL-SCI&#x2019;s most recent fiscal year end. CEL-SCI's Incentive
and Non-Qualified Stock Option Plans have been approved by
CEL-SCI's shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Plan
category</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Number
of Securities to be Issued Upon Exercise of Outstanding Options
(a)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Weighted-Average
Exercise Price of Outstanding Options</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Number
of Securities Remaining Available For Future Issuance Under Equity
Compensation Plans, Excluding SecuritiesReflected in Column
(a)</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px"><font style="font-size: 13px; font-family: Times New Roman">Incentive Stock
Option Plans</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">65,959</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">74.25</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">60,453</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px"><font style="font-size: 13px; font-family: Times New Roman">Non-Qualified Stock
Option Plans</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">277,613</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">55.75</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">82,370</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman"><br>
</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Long Term Incentive Plans - Awards in Last Fiscal Year</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">See footnote 7 to
the financial statements included as part of this
report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: -96px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
12. <font style="text-decoration: underline">SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">The following table
shows, as of December 1, 2016, information with respect to the only
persons owning beneficially 5% or more of CEL-SCI&#x2019;s
outstanding common stock and the number and percentage of
outstanding shares owned by each director and officer of CEL-SCI
and by the officers and directors as a group. Unless otherwise
indicated, each owner has sole voting and investment powers over
his shares of common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="font-family: Times New Roman; font-weight: bold;">Name and
Address</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Number of Shares (1)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Percent of Class (2)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geert R.
Kersten</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">774,118</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">11.8</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">154,868</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.5</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Eyal Talor,
Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">149,295</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.4</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Daniel H.
Zimmerman, Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">20,366</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.3</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">82</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">70,973</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Alexander G.
Esterhazy</font> (4)</div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">20 Chemin du
Pre-Poiset</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">CH- 1253
Vandoeuvres</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geneve,
Switzerlan</font>d</div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,389</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Peter R. Young,
Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">208 Hewitt Drive,
Suite 103-143</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Waco, TX
76712</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,004</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.3</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,667</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">0.0</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">All Officers and
Directors</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">as a Group (8
persons)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,202,680</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">18.1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
</div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Includes shares
issuable prior to February 28, 2017 upon the exercise of options or
warrants granted to the following persons:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);">
<div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-family: Times New Roman;">Name</font></font></font></div>
</div>
</div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold;">Options or Warrants
Exercisable Prior to February 28, 2017</font></font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:86%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geert R. Kersten,
Esq.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">297,289</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,753</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Eyal Talor,
Ph.D.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19,595</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Daniel Zimmerman,
Ph.D.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,643</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,864</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Alexander G.
Esterhazy</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,456</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Peter R. Young,
Ph.D.</font></div>
</td>
<td colspan="1" style="width:14%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,813</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td colspan="1" style="width:14%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,667</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Amount includes
shares referred to in (1) above but excludes shares which may be
issued upon the exercise or conversion of other options, warrants
and other convertible securities previously issued by
CEL-SCI.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-size: 13px; font-family: Times New Roman">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Amount includes
shares held in trust for the benefit of Mr. Kersten's children and
warrants held in the de Clara Trust, of which Mr. Kersten is the
trustee and a beneficiary. Mr. Kersten is the stepson of Maximilian
de Clara, CEL-SCI&#x2019;s former president and
director.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"> <font style="font-family: Times New Roman; font-size: 13px">(4)&#xA0;</font> </div>
<div style="text-align: justify; display: table-cell"> <font style="font-family: Times New Roman; font-size: 13px">On August 30, 2017,
Mr. Esterhazy passed away.</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">83</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
13. <font style="text-decoration: underline">CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">See Item 7 of this
report for information concerning modifications to the terms of a
loan originally made by Maximilian de Clara, CEL-SCI&#x2019;s former
President and director, and subsequently transferred to the de
Clara Trust. Geert Kersten, CEL-SCI&#x2019;s Chief Executive Officer
and a director, is the trustee and a beneficiary of the de Clara
Trust.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
</font><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
14. <font style="text-decoration: underline">PRINCIPAL ACCOUNTING
FEES AND SERVICES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">BDO USA, LLP served
as CEL-SCI&#x2019;s independent registered public accountant for the
two years ended September 30, 2016. The following table shows the
aggregate fees billed to CEL-SCI for these years by BDO USA,
LLP:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">Year
Ended September 30,</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">2016</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">2015</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Audit
Fees</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">311,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">362,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Audit Related
Fees</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Tax
Fees</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">All Other
Fees</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Audit fees
represent amounts billed for professional services rendered for the
audit of CEL-SCI&#x2019;s annual financial statements and the
reviews of the financial statements included in CEL-SCI&#x2019;s
10-Q reports for the fiscal year and all regulatory filings. See
Note 1 to the financial statements included with this report for
more information.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Before BDO USA, LLP
was engaged by CEL-SCI to render audit or non-audit services, the
engagement was approved by CEL-SCI&#x2019;s audit committee.
CEL-SCI&#x2019;s Board of Directors is of the opinion that the Audit
Fees charged by BDO USA, LLP are consistent with BDO USA, LLP
maintaining its independence from CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">84</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 84px; margin-right: 0px; text-indent: -84px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ITEM
15. <font style="text-decoration: underline">EXHIBITS AND FINANCIAL
STATEMENT SCHEDULES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">See the Financial
Statements attached to this Report.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: middle; width: 10%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Exhibits</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3(a)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Articles of
Incorporation</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 3(a) of CEL-SCI's combined Registration
Statement on Form S-1 and Post-Effective Amendment ("Registration
Statement"), Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3(b)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Amended
Articles</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 3(a) of CEL-SCI's Registration Statement on
Form S-1, Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3(c)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Amended Articles
(Name change only)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Filed as Exhibit
3(c) to CEL-SCI's Registration Statement on Form S-1 Registration
Statement (No. 33-34878).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3(d)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Bylaws</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 3(b) of CEL-SCI's Registration Statement on
Form S-1, Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3(e)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Amended
Bylaws</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 3(ii) of CEL-SCI&#x2019;s report on Form 8-K
dated March 16, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Shareholders Rights
Agreement, as Amended</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 4&#xA0;filed with CEL-SCI&#x2019;s 10-K report
for the&#xA0;year ended September 30, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4(b)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incentive Stock
Option Plan</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 4 (b) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4(c)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Non-Qualified Stock
Option Plan</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 4 (b) filed on August 19, 2014 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-198244).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4(d)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Stock Bonus
Plan</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 4 (d) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4(e)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Stock Compensation
Plan</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 4 (e) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4(f)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2014 Incentive
Stock Bonus Plan</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Filed with this
Amendment No. 2 to the Company&#x2019;s annual report on Form 10-K
for the year ended September 30, 2014.</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">85</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(f)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities Purchase
Agreement (together&#xA0;with schedule required by Instruction 2
to&#xA0;Item 601 of Regulation S-K) pertaining to&#xA0;Series K
notes and warrants, together with the exhibits to the Securities
Purchase&#xA0;Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 to&#xA0;CEL-SCI&#x2019;s report on Form 8-K
dated&#xA0;August 4, 2006.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(g)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Subscription
Agreement (together with&#xA0;Schedule required by Instruction 2
toItem 601 of Regulation S-K) pertaining to&#xA0;April 2007 sale of
20,000,000 shares of&#xA0;CEL-SCI&#x2019;s common stock,
10,000,000&#xA0;Series L warrants and 10,000,000 Series
M&#xA0;Warrants</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 of&#xA0;CEL-SCI&#x2019;s report on Form 8-K
dated April&#xA0;18, 2007</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(h)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Warrant Adjustment
Agreement with&#xA0;Laksya Ventures</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(i) of&#xA0;CEL-SCI&#x2019;s report on Form
8-K dated August&#xA0;3, 2010</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(l)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">First Amendment to
Development Supply&#xA0;and Distribution Agreement with
Orient&#xA0;Europharma.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(m)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(m)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Exclusive License
and Distribution&#xA0;Agreement with Teva&#xA0;Pharmaceutical
Industries&#xA0;Ltd.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(n)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(n)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Lease
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(o)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(o)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Promissory Note
with Maximilian de&#xA0;Clara, together with Amendments 1 and
2</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(p)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(p)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Licensing Agreement
with Byron&#xA0;Biopharma</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(i) of&#xA0;CEL-SCI&#x2019;s report on Form
8-K dated March&#xA0;27, 2009</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(z)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Development, Supply
and Distribution&#xA0;Agreement with Orient Europharma</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit&#xA0;10(z)&#xA0;filed with CEL-SCI&#x2019;s
report on Form&#xA0;10-K for the year ended September 30,
2003.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(aa)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities Purchase
Agreement and&#xA0;form of the Series F warrants, which is&#xA0;and
exhibit to the Securities Purchase&#xA0;Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(aa)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated&#xA0;October 3, 2011.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(bb)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(bb)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated&#xA0;October 3, 2011.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(cc)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities&#xA0;&#xA0;Purchase
Agreement,&#xA0;&#xA0;together with&#xA0;&#xA0;the form of the
Series H warrant, which is an exhibit to the securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(cc) of CEL-SCI&#x2019;s report on Form 8-K
dated January 25, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(dd)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(dd)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated January 25, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">86</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(ee)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Warrant Amendment
Agreement, together with the form of the Series P warrant, which is
an exhibit to the Warrant Amendment Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ee)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated February 10, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(ff)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ff)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated February 10, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(gg)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities&#xA0;&#xA0;Purchase&#xA0;&#xA0;Agreement&#xA0;&#xA0;and
the form of the&#xA0;&#xA0;Series
Q&#xA0;&#xA0;&#xA0;warrant,&#xA0;&#xA0;which is
an&#xA0;&#xA0;exhibit to the Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(gg)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated June 18, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10(hh)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(hh)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated June 18, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ii)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities&#xA0;&#xA0;Purchase&#xA0;&#xA0;Agreement&#xA0;&#xA0;and
the form of the&#xA0;&#xA0;Series
R&#xA0;&#xA0;&#xA0;warrant,&#xA0;&#xA0;which is
an&#xA0;&#xA0;exhibit to the Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ii)&#xA0;of CEL-SCI&#x2019;s report on Form
8-K dated December 5, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(jj)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(jj)&#xA0;&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated December 5, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(nn)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Underwriting
Agreement, together with the form of Series S warrant which is an
exhibit to the underwriting agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated October 8, 2013.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(oo)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Underwriting
Agreement, together with the form of Series S warrant which is an
exhibit to the underwriting agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated December 19, 2013.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(pp)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Underwriting
Agreement, together with the form of Series T warrant which is an
exhibit to the warrant agent agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated April 15, 2014.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(qq)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Underwriting
Agreement, together with the form of Series S warrant which is an
exhibit to the warrant agent agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated October 23, 2014.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(rr)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Assignment and
Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and
GCP Clinical Studies, Ltd.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(rr) of CEL-SCI&#x2019;s report on Form
10-K/A report for the&#xA0;year ended September 30, 2014 dated
April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ss)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Service Agreement
with GCP Clinical Studies, Ltd., together with Amendment 1
thereto*</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ss) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(tt)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Joinder Agreement
with PLIVA Hrvatska d.o.o.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(tt) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(uu)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Master Service
Agreement with Ergomed Clinical Research, Ltd.,&#xA0;&#xA0;and
Clinical Trial Orders thereunder</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(uu) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">87</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(vv)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Co-Development and
Revenue Sharing Agreement with Ergomed Clinical Research Ltd.,
dated April 19, 2013, as amended</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(vv) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ww)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Co-Development and
Revenue Sharing Agreement II:&#xA0;&#xA0;Cervical Intraepithelial
Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical
Research Ltd., dated October 10, 2013, as amended</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ww) of CEL- first amendment to its Form
10-K report for the&#xA0;year ended September 30, 2014 dated April
17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(xx)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Co-Development and
Revenue Sharing Agreement III: Anal warts and anal intraepithelial
neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical
Research Ltd., dated October 24, 2013</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(xx) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(yy)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Master Services
Agreement with Aptiv Solutions, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(yy) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(zz)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Project Agreement
Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and
2 thereto*</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(zz) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(aaa)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Second Amendment to
Development Supply and Distribution Agreement with Orient
Europharma</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(aaa) of CEL-SCI&#x2019;s first amendment to
its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(bbb)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Amended and
Restated Promissory Note with Maximilian de Clara</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(bbb) of CEL-SCI&#x2019;s report on Form
10-K/A report for the&#xA0;year ended September 30, 2014 dated
April 17, 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ccc)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement dated May 22,</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2015 by and among
CEL-SCI Corporation and Dawson James Securities, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
filed on May 26, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ddd)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Warrant Agent
Agreement (as amended),</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series V
warrants</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 (ccc) of CEL-SCI&#x2019;s report on Form 8-K
filed on May 29, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(eee)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Assignment of
Proceeds and Investment Agreement between CEL-SCI Corporation and
Lake Whillans Vehicle 1.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 (ddd) of CEL-SCI&#x2019;s report on Form 8-K
filed on October 16, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(fff)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Placement Agent
Agreement dated October 22, 2015 by and among CEL-SCI Corporation
and Dawson James Securities, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
filed on October 23, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(ggg)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Warrant Agent
Agreement, Series W warrants</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 (eee) of CEL-SCI&#x2019;s report on Form 8-K
filed on October 23, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">88</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(iii)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Amendment to
Co-Development and Revenue</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Sharing Agreement
with Ergomed Clinical</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Research, Ltd.,
dated September 15, 2015</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10 (iii)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(jjj)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(jjj) of CEL-SCI&#x2019;s report on Form 8-K
dated May 19, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(kkk)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(kkk) of CEL-SCI&#x2019;s report on Form 8-K
dated August 24, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(lll)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Termination
Agreement with Maximilian de Clara</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(lll) of CEL-SCI&#x2019;s report on Form 8-K
dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(mmm)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Employment
Agreement with Geert Kersten (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(mmm) of CEL-SCI&#x2019;s report on Form 8-K
dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(nnn)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Employment
Agreement with Patricia Prichep (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(nnn) of CEL-SCI&#x2019;s report on Form 8-K
dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">10
(000)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Employment
Agreement with Eyal Taylor (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Incorporated by
reference to Exhibit 10(ooo) of CEL-SCI&#x2019;s report on Form 8-K
dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="cvm_ex231.htm"><font><font style="font-size: 13px; font-family: Times New Roman">23.1</font></font></a></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Consent of BDO USA,
LLP<br></font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="cvm_ex31.htm"><font style="font-size: 13px; font-family: Times New Roman">31</font></a></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Rule 13a-14(a)
Certifications</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0; <font style="font-size: 13px; font-family: Times New Roman"><br>
</font></font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 10%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="cvm_ex32.htm"><font style="font-size: 13px; font-family: Times New Roman">32</font></a></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Section 1350
Certifications</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">*&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Portions of this
exhibit have been omitted pursuant to a request for confidential
treatment filed with the Commission under Rule 24b-2 of the
Securities Exchange Act of 1934. The omitted confidential material
has been filed separately with the Commission. The location of the
omitted confidential information is indicated in the exhibit with
asterisks (*)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">89</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">TABLE
OF CONTENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; text-indent: 0px; width: 100%; height: 2px; background-color: #000000"><!--line--><br></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Page</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
2</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;FINANCIAL
STATEMENTS FOR THE YEARS</font> <font style="color: #000000; font-size: 13px; font-family: Times New Roman">ENDED
SEPTEMBER 30, 2016, 2015 and 2014:</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;Balance
Sheets</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
3</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;Statements
of Operations</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
4</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;Statements
of Stockholders&#x2019; (Deficit) Equity</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
5</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;Statements
of Cash Flows</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
6</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 87%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;
Notes to Financial Statements</font></div>
</td>
<td style="vertical-align: top; width: 13%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">F-
8</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-1</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; color: #000000; font-size: 13px; font-family: Times New Roman">
Report of Independent Registered Public Accounting
Firm</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Board
of Directors and Stockholders</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">CEL-SCI
Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Vienna,
Virginia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">We have audited the
accompanying balance sheets of CEL-SCI Corporation (the
&#x201C;Company&#x201D;) as of September 30, 2016 and 2015 and the
related statements of operations, stockholders&#x2019; (deficit)
equity, and cash flows for each of the three years in the period
ended September 30, 2016. These financial statements are the
responsibility of the Company&#x2019;s management. Our
responsibility is to express an opinion on these financial
statements based on our audits.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">We conducted our
audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In our opinion, the
financial statements referred to above present fairly, in all
material respects, the financial position of CEL-SCI Corporation at
September 30, 2016 and 2015, and the results of its operations and
its cash flows for each of the three years in the period ended
September 30, 2016, in conformity with accounting principles
generally accepted in the United States of America.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
discussed in Note 17 to the financial statements, the 2016, 2015,
and 2014 financial statements have been restated to correct certain
misstatements.</font> </div>
<div> <font style="font-family: Times New Roman; font-size: 10">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The accompanying
financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note <font style="color: #000000">2</font> to the financial statements, the Company
has a <font style="color: #000000">history of net</font> losses and
<font style="color: #000000">expects to incur substantial losses
for the foreseeable future</font> that raise substantial doubt
about its ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note
<font style="color: #000000">2</font>. The financial statements do
not include any adjustments that might result from the outcome of
this uncertainty.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">We also have
audited, in accordance with the standards of the Public Company
Accounting Oversight Board (United States), CEL-SCI
Corporation&#x2019;s internal control over financial reporting as of
September 30, 2016 based on criteria established in <font style="font-style: italic">Internal Control &#x2013; Integrated
Framework</font> <font style="font-style: italic">(2013)</font>
issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) and our report dated December <font style="color: #000000">14,</font> 2016, except as to the effect of
the material weaknesses which is dated December 11, 2017,
expressed an adverse opinion thereon.</font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">/s/
BDO USA, LLP</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">McLean,
Virginia</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="color: #000000; font-size: 13px; font-family: Times New Roman">December
14, 2016, except for the effects of the restatement discussed
in Note 17 which is as of December 11,
2017.<br></font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-2</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">BALANCE
SHEETS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">SEPTEMBER
30, 2016 and 2015</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">RESTATED</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ASSETS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CURRENT
ASSETS:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Cash
and cash equivalents</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,726,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Receivables</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">394,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">87,214</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Prepaid
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">981,677</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">979,655</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deposits
- current portion</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">154,995</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Inventory
used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,008,642</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,401,839</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,457,825</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,345,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">PROPERTY
AND EQUIPMENT, net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,350,836</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,945,831</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">PATENT
COSTS, net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">256,547</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">291,564</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">DEPOSITS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,820,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,970,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
ASSETS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">28,553,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LIABILITIES
AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CURRENT
LIABILITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accounts
payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,091,512</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,128,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accrued
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">378,672</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">88,575</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Due
to employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">538,278</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">365,131</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Notes
payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,104,057</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;Other
current liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,310</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">19,025</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Total
current liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,011,772</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,705,470</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Derivative
instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,394,934</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,686,587</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Lease
liability</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,011,023</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,783,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Deferred
revenue</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">125,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">126,639</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Other
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">22,609</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">14,026</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,565,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">33,315,972</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">COMMITMENTS
AND CONTINGENCIES</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">STOCKHOLDERS'
DEFICIT</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Preferred
stock, $.01 par value-200,000 shares authorized;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;-0-
shares issued and outstanding</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Common
stock, $.01 par value - 600,000,000 shares authorized;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;6,235,035
and 4,490,975 shares issued and
outstanding</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;at
September 30, 2016 and 2015, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62,350</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44,910</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Additional
paid-in capital</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">284,649,559</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">269,071,450</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accumulated
deficit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(285,391,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(273,878,630</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
stockholders' deficit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">28,553,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">See
notes to financial statements.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-3</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">STATEMENTS
OF OPERATIONS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">YEARS
ENDED SEPTEMBER 30, 2016, 2015 and 2014</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left:0px;font-size:13px;margin-top:0px;margin-bottom:0px;width:100%;margin-right:0px;font-family:Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:94%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">GRANT
INCOME AND OTHER</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">285,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">657,377</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">264,033</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">OPERATING
EXPENSES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Research
and development</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,191,750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,266,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;General
&amp; administrative</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,486,501</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">13,855,775</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">10,665,558</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">23,931,883</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">33,047,525</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,931,747</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">OPERATING
LOSS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(23,646,828</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(32,390,148</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(25,667,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">GAIN
ON DERIVATIVE INSTRUMENTS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">282,616</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">248,767</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LOSS
ON DEBT EXTINGUISHMENT</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">INTEREST
EXPENSE, NET</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,879,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,964,221</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,933,732</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
LOSS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ISSUANCE
OF ADDITIONAL SHARES DUE TO RESET PROVISIONS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,117,447</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
LOSS AVAILABLE TO COMMON SHAREHOLDERS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(28,470,126</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
LOSS PER COMMON SHARE</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;BASIC</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">WEIGHTED
AVERAGE COMMON SHARES</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;OUTSTANDING</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;BASIC
and DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,300,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,352,185</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px; font-family: Times New Roman">See
notes to financial statements.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-4</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">STATEMENTS
OF STOCKHOLDERS' (DEFICIT) EQUITY</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">YEARS
ENDED SEPTEMBER 30, 2016, 2015 and 2014</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: Times New Roman; margin: 0px auto 0px 0px; width: 100%; font-size: 13px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Additional</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Common</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Stock</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Paid-In</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Accumulated</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-size:11px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;font-weight:bold;vertical-align:bottom;display:inline-block;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Shares</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Amount</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Capital</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Deficit</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Total</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ORIGINALLY
REPORTED BALANCE, OCTOBER 1, 2013<br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,237,553</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">218,848,282</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(212,160,568</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,700,090</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ADJUSTMENT</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">326,827</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">326,827</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">RESTATED
BALANCE, OCTOBER 1, 2013</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,237,553</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">12,376</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">218,848,282</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(211,833,741</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7,026,917</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,270,220</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,434,544</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,447,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of warrants in connection with</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,791,448</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,791,448</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">401(k)
contributions paid</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;in
common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,591</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">66</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155,368</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155,434</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercise
of warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">106,740</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,067</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,279,251</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,280,318</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of warrant liability to equity</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,308,528</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,308,528</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued to nonemployees for service</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,199</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">232</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">626,886</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">627,118</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued for patents</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">348</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,999</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Modification
of options issued to consultants</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of restricted stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">628,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,280</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(6,280</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,958,637</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,958,637</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">36,752</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">36,752</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss - RESTATED</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2014</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,272,651</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">32,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">249,937,507</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(239,186,420</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,783,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,178,716</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,787</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,136,591</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,148,378</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of warrants in connection with</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,463,957</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,463,957</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">401(k)
contributions paid</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;in
common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,727</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">165,549</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">165,646</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued to nonemployees for service</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">29,599</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">296</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">533,680</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">533,976</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Modification
of warrants and extinguishment loss</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeiture
of unvested restricted stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(40</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">40</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,282</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">43</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,105,784</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,105,827</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss - RESTATED</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2015</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,490,975</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44,910</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">269,071,450</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(273,878,630</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,660,930</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,609</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,357,087</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,373,696</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of warrants in connection with</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">401(k)
contributions paid</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;in
common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,340</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">163</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,408</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued to nonemployees for service</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">49,953</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">689,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">690,313</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,837</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">168</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,012,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,012,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">79,359</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">79,359</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss - RESTATED</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2016</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,235,035</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">62,350</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">284,649,559</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(285,391,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px; font-family: Times New Roman">See
notes to financial statements.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-5</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">STATEMENTS
OF CASH FLOWS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">YEARS
ENDED SEPTEMBER 30, 2016, 2015 and 2014</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: Times New Roman; margin: 0px auto 0px 0px; width: 100%; font-size: 13px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 64%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 36%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:94%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Net
loss</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Adjustments
to reconcile net loss to</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;net
cash used in operating activities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Depreciation
and amortization</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">663,988</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">720,494</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">745,496</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Issuance
of common stock and options for services &#x2013;
non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">751,651</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">565,915</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">694,955</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Modification
of warrants issued to consultants</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Equity
based compensation</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,113,433</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,105,827</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,958,637</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Common
stock contributed to 401(k) plan</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">165,646</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155,434</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Impairment
loss on abandonment of patents</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,182</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Loss
on retired equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">248</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">313</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">268</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Gain
on derivative instruments</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(282,616</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(248,767</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Loss
on debt extinguishment</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Capitalized lease interest<br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">227,773</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">249,493</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">241,829</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;(Increase)/decrease
in assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Receivables</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,960</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(5,394</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,557</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Prepaid
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,999</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(68,268</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(158,088</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Inventory
used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">393,197</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50,181</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(435,392</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deposits</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145,005</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(200,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Increase/(decrease)
in liabilities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accounts
payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,389,931</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,981,886</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(751,971</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accrued
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">290,097</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(458,633</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">433,712</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deferred
revenue</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,639</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">48</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">46</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Due
to employees</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">72,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">57,170</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(78,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deferred
rent liability</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,896</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,358</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,739</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in operating activities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(23,082,493</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(23,833,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(22,928,019</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Purchases
of equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(31,405</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(73,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(103,977</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Expenditures
for patent costs</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,819</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(20,132</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,887</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in investing activities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,224</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(93,531</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(138,864</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Proceeds
from issuance of common stock and warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,420,301</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,148,378</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,428,641</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Payment
on related party loan</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,104,057</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Proceeds
from exercise of warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,118,387</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Payments
on obligations under capital lease</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,452</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,137</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash provided by financing activities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">20,308,031</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">21,139,926</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">31,538,891</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;NET
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,808,686</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,786,938</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,472,008</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, BEGINNING OF YEAR</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,726,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,513,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">41,612</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, END OF YEAR</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,726,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,513,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px; font-family: Times New Roman">See
notes to financial statements.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-6</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">STATEMENTS
OF CASH FLOWS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000; font-size: 13px; font-family: Times New Roman">YEARS
ENDED SEPTEMBER 30, 2016, 2015 and 2014</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:86%;">
<div><font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING
ACTIVITIES:</font><font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 2px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="3" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; vertical-align: bottom; width: 3%; font-size: 11px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; font-size: 11px; font-family: Times New Roman; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold;">RESTATED</font><br></font><font style="text-align: left; vertical-align: bottom; width: 3%; font-size: 11px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2014</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Receivable
due under the litigation funding arrangement offset by the same
amount</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;payable
to the legal firm providing the services</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">305,341</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Research
and office equipment included in accounts payable at year
end</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-<br></font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,345</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,074</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Capitalizable
patent costs included in accounts payable at year end.</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,685</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,474</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Patent
costs purchased with common stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,999</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Lease
payments included in accounts payable at year end</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">815</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">43</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,477</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Fair
value of warrant liabilities on the date of issuance reclassed to
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,463,957</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(5,320,989</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Financing
costs included in accounts payable at year end</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">46,605</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Forfeiture
of unvested restricted stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Stock
issued under an anti-dilution provision and cashless exercise of
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(16,375</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Prepaid
amount under consulting services paid with issuance of common
stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,021</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,861</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31,085</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;Cash
paid for interest expense</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,900,567<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,969,499<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,965,949<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">See
notes to financial statements.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-7</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">NOTES
TO FINANCIAL STATEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 37px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">ORGANIZATION</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI Corporation
(the Company) was incorporated on March 22, 1983, in the state of
Colorado, to finance research and development in biomedical science
and ultimately to engage in marketing and selling
products.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI is focused
on finding the best way to activate the immune system to fight
cancer and infectious diseases. The Company&#x2019;s lead
investigational therapy, Multikine (Leukocyte Interleukin,
Injection), is currently in a Phase 3 clinical trial as a potential
therapeutic agent directed at using the immune system to produce an
anti-tumor immune response for advanced primary head and neck
cancer. Data from Phase 1 and Phase 2 clinical trials suggest
Multikine has the potential to directly affect tumor cells. These
data also indicate that it appears to activate the patient&#x2019;s
own anti-tumor immune response. Multikine (Leukocyte Interleukin,
Injection) is the full name of this investigational therapy, which,
for simplicity, is referred to in the remainder of this document as
Multikine. Multikine is the trademark that the Company has
registered for this investigational therapy, and this proprietary
name is subject to FDA review in connection with the
Company&#x2019;s future anticipated regulatory submission for
approval. Multikine has not been licensed or approved by the FDA or
any other regulatory agency. Neither has its safety or efficacy
been established for any use. Further research is required, and
early-phase clinical trial results must be confirmed in the Phase 3
clinical trial of this investigational therapy that is in progress
and that is currently subject to a clinical hold on enrollment of
additional new patients.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Multikine has been
cleared by the regulators in twenty four countries around the
world, including the U.S. FDA, for a global Phase 3 clinical trial
in advanced primary (not yet treated) head and neck cancer
patients. On September 26, 2016, the Company received verbal notice
from the FDA that the Phase 3 clinical trial has been placed on
clinical hold. <font style="color: #000000">The FDA&#x2019;s partial
clinical hold letter identified the following specific
deficiencies: there is an unreasonable and significant risk of
illness or injury to human subjects; the investigator brochure is
misleading, erroneous, and materially incomplete; and that the plan
or protocol is deficient in design to meet its stated
objectives.</font> Pursuant to this communication from FDA,
patients currently receiving study treatments could continue to
receive treatment, and patients already enrolled in the study would
continue to be followed, but no additional patients could be
enrolled. On October 21, 2016, the Company announced it had
received the Partial Clinical Hold letter from the FDA. On November
21, 2016, the Company announced it has submitted what it believes
to be a complete response to the FDA<font style="color: #000000">.
On December 8, 2016, the FDA advised CEL-SCI that the agency was
denying CEL-SCI&#x2019;s request for a meeting at this time because
FDA&#x2019;s review of CEL-SCI&#x2019;s November 17, 2016 response
was ongoing. CEL-SCI was also advised that it will be receiving a
letter addressing CEL-SCI&#x2019;s response by December 18,
2016.</font></font> <font style="font-size: 13px; font-family: Times New Roman">Multikine is also
being used in a Phase 1 study at the University of California, San
Francisco (UCSF) in HIV/HPV co-infected men and women with
peri-anal warts.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-8</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman"><font style="color: #000000">
2</font><font style="color: #000000; font-family: Times New Roman">.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-weight: bold; font-size: 13px; font-family: Times New Roman">
OPERATIONS AND FINANCING</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
Company has incurred significant costs since its inception in
connection with the acquisition of certain patented and unpatented
proprietary technology and know-how relating to the human
immunological defense system, patent applications, research and
development, administrative costs, construction of laboratory
facilities, and clinical trials.&#xA0; The Company has funded such
costs with proceeds from loans and the public and private sale of
its common and preferred stock.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
Company is currently running a large multi-national Phase 3
clinical trial for head and neck cancer. The Company believes that
it has enough capital to support its operations as it believes that
it has ready access to new equity capital should the need arise.
During fiscal year 2016, the Company raised approximately $21.4
million in net proceeds through the sale of common stock and
warrants from public and private offerings. During fiscal year
2015, the Company raised $21.1 million net proceeds from public
offerings. To finance the study beyond the next 12 months, the
Company plans to raise additional capital in the form of corporate
partnerships, debt and/or equity financings. In addition, the
Company expects to receive proceeds from the arbitration against
its former clinical research organization, inVentiv. The Company
believes that it will be able to obtain additional financing
because it has done so consistently in the past, and because
Multikine is a product in the Phase 3 clinical trial stage.
However, there can be no assurance that the Company will be
successful in raising additional funds or that funds will be
available to the Company on acceptable terms or at all.&#xA0; If
the Company does not raise the necessary capital, the Company will
either have to slow or delay the Phase 3 clinical trial or even
significantly curtail its operations until such time as it is able
to raise the required funding. The financial statements have been
prepared assuming that the Company will continue as a going
concern, but due to the Company&#x2019;s future liquidity needs,
history of net losses, and the expectation that the Company will
incur losses for the foreseeable future, there is substantial doubt
about the Company&#x2019;s ability to continue as a going concern.
The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Since
the Company launched its Phase 3 clinical trial for Multikine, the
Company has spent approximately $34.5 million as of September 30,
2016 on direct costs for the Phase 3 clinical trial.&#xA0;
T</font><font style="color: #000000; font-size: 13px; font-family: Times New Roman">he
total remaining cash cost of the Phase 3 clinical trial, excluding
any costs that will be paid by CEL-SCI's partners, would be
approximately $12.1 million after September 30, 2016. This &#xED;s
based on the executed contract costs with the CROs only and does
not include other related costs, e.g. the manufacturing of the
drug. It should be noted that this estimate is based only on the
information currently available in the Company&#x2019;s contracts
with the Clinical Research Organizations responsible for managing
the Phase 3 clinical trial.&#xA0; This number can be affected by
the speed of enrollment, foreign currency exchange rates and many
other factors, some of which cannot be foreseen.&#xA0; The Company
has filed an amendment to the original Phase 3 protocol for it head
and neck cancer study with the FDA to allow for this expansion in
patient enrollment. Should the FDA allow the amended protocol filed
with them to proceed, the remaining cost of the Phase 3 clinical
trial will be higher. It is therefore possible that the cost of the
Phase 3 clinical trial will be higher than currently
estimated.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">On
September 26, 2016, the Company received verbal notice from the FDA
that the Phase 3 clinical trial has been placed on clinical hold.
Pursuant to this communication from FDA, patients currently
receiving study treatments could continue to receive treatment, and
patients already enrolled in the study would continue to be
followed, but no additional patients could be enrolled. On October
21, 2016, the Company announced it had received the Partial
Clinical Hold letter from the FDA. On November 21, 2016, the
Company announced it has submitted a complete response to the FDA
and will work diligently with the FDA to seek to have the partial
clinical hold lifted.</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-9</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0; <font style="font-size: 13px; font-family: Times New Roman"><br>
</font></font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 37px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Cash and Cash Equivalents</font> &#x2013; For
purposes of the statements of cash flows, cash and cash equivalents
consist principally of unrestricted cash on deposit and short-term
money market funds. The Company considers all highly liquid
investments with a maturity when purchased of less than three
months as cash and cash equivalents.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Prepaid Expenses</font> &#x2013; Prepaid
expenses are payments for future services to be rendered and are
expensed over the time period for which the service is rendered.
Prepaid expenses may also include payment for goods to be received
within one year of the payment date.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Inventory</font> &#x2013; Inventory consists of
manufacturing production advances and bulk purchases of laboratory
supplies to be consumed in the manufacturing of the Company&#x2019;s
product for clinical studies. Inventories are stated at the lower
of cost or market, where cost is determined using the first-in,
first out method applied on a consistent basis.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Deposits</font> &#x2013; The deposits are
required by the lease agreement for the manufacturing facility and
by the clinical research organization (CRO)
agreements.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Research and Office Equipment</font>&#x2013;
Research and office equipment is recorded at cost and depreciated
using the straight-line method over estimated useful lives of five
to seven years. Leasehold improvements are depreciated over the
shorter of the estimated useful life of the asset or the term of
the lease. Repairs and maintenance which do not extend the life of
the asset are expensed when incurred. The fixed assets are reviewed
on a quarterly basis to assess impairment, if any.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Patents</font> &#x2013; Patent expenditures are
capitalized and amortized using the straight-line method over the
shorter of the expected useful life or the legal life of the patent
(17 years). In the event changes in technology or other
circumstances impair the value or life of the patent, appropriate
adjustment to the asset value and period of amortization is made.
An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from
disposition, are less than the carrying value of the asset. The
amount of the impairment loss would be the difference between the
estimated fair value of the asset and its carrying
value.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Deferred Rent</font> &#x2013; Certain of the
Company&#x2019;s operating leases provide for minimum annual
payments that adjust over the life of the lease.&#xA0; The
aggregate minimum annual payments are expensed on a straight-line
basis over the minimum lease term. The Company recognizes a
deferred rent liability for rent escalations when the amount of
straight-line rent exceeds the lease payments, and reduces the
deferred rent liability when the lease payments exceed the
straight-line rent expense.&#xA0; For tenant improvement allowances
and rent holidays, the Company records a deferred rent liability
and amortizes the deferred rent over the lease term as a reduction
to rent expense.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Derivative Instruments</font> - The Company
has entered into financing arrangements that consist of
freestanding derivative instruments that contain embedded
derivative features, specifically, the settlement provisions in the
warrant agreements preclude the warrants from being treated as
equity. The Company accounts for these arrangements in accordance
with Accounting Standards Codification (ASC) 815, &#x201C;Accounting
for Derivative Instruments and Hedging Activities&#x201D;. In
accordance with accounting principles generally accepted in the
United States (U.S. GAAP), derivative instruments and hybrid
instruments are recognized as either assets or liabilities on the
balance sheet and are measured at fair value with gains or losses
recognized in earnings or other comprehensive income depending on
the nature of the derivative or hybrid instruments. The Company
determines the fair value of derivative instruments and hybrid
instruments based on available market data using appropriate
valuation models, giving consideration to all of the rights and
obligations of each instrument. The derivative liabilities are
re-measured at fair value at the end of each reporting
period as long as they are outstanding.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-10</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Grant Income</font> &#x2013; The Company's
grant arrangements are handled on a reimbursement basis. Grant
income under the arrangements is recognized when costs are
incurred.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Research and Development Costs</font> &#x2013;
Research and development expenditures are expensed as
incurred.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Leases &#x2013;</font> Leases are categorized
as either operating or capital leases at inception. Operating lease
costs are recognized on a straight-line basis over the term of the
lease. An asset and a corresponding liability for the capital lease
obligation are established for the cost of capital leases. The
capital lease obligation is amortized over the life of the lease.
For build-to-suit leases, the Company establishes an asset and
liability for the estimated construction costs incurred to the
extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement
of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for
sales recognition under the sale-leaseback accounting guidance. If
a lease does not meet the criteria to qualify for a sale-leaseback
transaction, the established asset and liability remain on the
Company's balance sheet.</font></font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Net Loss Per Common Share</font> &#x2013; The
Company calculates net loss per common share in accordance with ASC
260 &#x201C;Earnings Per Share&#x201D; (ASC 260). Basic and diluted
net loss per common share was determined by dividing net loss
applicable to common shareholders by the weighted average number of
common shares outstanding during the period. The Company&#x2019;s
potentially dilutive shares, which include outstanding common stock
options, restricted stock units, convertible preferred stock and
common stock warrants, have not been included in the computation of
diluted net loss per share for all periods as the result would be
anti-dilutive.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Concentration of Credit Risk</font> &#x2013;
Financial instruments, which potentially subject the Company to
concentrations of credit risk, consist of cash and cash
equivalents.&#xA0; The Company maintains its cash and cash
equivalents with high quality financial institutions.&#xA0; At
times, these accounts may exceed federally insured limits.&#xA0;
The Company has not experienced any losses in such bank
accounts.&#xA0; The Company believes it is not exposed to
significant credit risk related to cash and cash equivalents. All
non-interest bearing cash balances were fully insured&#xA0;up to
$250,000 at September 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Income Taxes</font> &#x2013; The Company uses
the asset and liability method of accounting for income taxes.
Under the asset and liability method, deferred tax assets and
liabilities are recognized for future tax consequences attributable
to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and
operating and tax loss carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. The Company
records a valuation allowance to reduce the deferred tax assets to
the amount that is more likely than not to be recognized. A full
valuation allowance was recorded against the deferred tax assets as
of September 30, 2016 and 2015.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-11</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Use of Estimates</font> &#x2013; The
preparation of financial statements in conformity U.S. GAAP
requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and the
accompanying disclosures. <font style="color: #000000">These
estimates are based on management&#x2019;s best knowledge of current
events and actions the Company may undertake in the future.
Estimates are used in accounting for, among other items, inventory
obsolescence, accruals, stock options, useful lives for
depreciation and amortization of long-lived assets, deferred tax
assets and the related valuation allowance, and the valuation of
derivative liabilities.</font><font style="color: #444444">&#xA0;</font>Actual results could differ from
estimates, although management does not generally believe such
differences would materially affect the financial statements in any
given year. However, in regard to the valuation of derivative
liabilities determined using various valuation techniques including
the Black-Scholes and binomial pricing methodologies, significant
fluctuations may materially affect the financial statements in a
given year. The Company considers such valuations to be significant
estimates.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Fair Value Measurements</font> &#x2013; The
Company evaluates financial assets and liabilities subject to fair
value measurements in accordance with a fair value hierarchy to
prioritize the inputs used to measure fair value. A financial
instrument&#x2019;s level within the fair value hierarchy is based
on the lowest level of input significant to the fair value
measurement, where Level 1 is the highest and Level 3 is the
lowest. See Note 12 for the definition of levels and the
classification of assets and liabilities in those
levels.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Stock-Based Compensation</font> &#x2013;
Compensation cost for all stock-based awards is measured at fair
value as of the grant date in accordance with the provisions of ASC
718, &#x201C;Compensation &#x2013; Stock Compensation.&#x201D; The
fair value of stock options is calculated using the Black-Scholes
option pricing model. The Black-Scholes model requires various
judgmental assumptions including volatility and expected option
life. The stock-based compensation cost is recognized on the
straight line allocation method as expense over the requisite
service or vesting period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Equity instruments
issued to non-employees are accounted for in accordance with ASC
505-50, &#x201C;Equity-Based Payments to Non-Employees.&#x201D;
Accordingly, compensation is recognized when goods or services are
received and may be measured using the Black-Scholes valuation
model, based on the type of award. The Black-Scholes model requires
various judgmental assumptions regarding the fair value of the
equity instruments at the measurement date and the expected life of
the options.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company has
Incentive Stock Option Plans, Non-Qualified Stock Options Plans, a
Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock
Bonus Plan. In some cases, these Plans are collectively referred to
as the &#x201C;Plans.&#x201D; All Plans have been approved by the
Company&#x2019;s stockholders.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company&#x2019;s
stock options are not transferable, and the actual value of the
stock options that an employee may realize, if any, will depend on
the excess of the market price on the date of exercise over the
exercise price. The Company has based its assumption for stock
price volatility on the variance of daily closing prices of the
Company&#x2019;s stock. The risk-free interest rate assumption was
based on the U.S. Treasury rate at date of the grant with term
equal to the expected life of the option. Historical data was used
to estimate option exercise and employee termination within the
valuation model. The expected term of options represents the period
of time that options granted are expected to be outstanding and has
been determined based on an analysis of historical exercise
behavior. If any of the assumptions used in the Black-Scholes model
change significantly, stock-based compensation expense for new
awards may differ materially in the future from that recorded in
the current period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-12</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Vesting of
restricted stock granted under the Incentive Stock Bonus Plan is
subject to service, performance or market conditions and meets the
classification of equity awards. These awards were measured at fair
market value on the grant-dates for issuances where the attainment
of performance criteria is probable and at fair value on the
grant-dates, using a Monte Carlo simulation for issuances where the
attainment of performance criteria is uncertain. The total
compensation cost will be expensed over the estimated requisite
service period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic">Reclassification</font> &#x2013; Certain prior
year items have been reclassified to conform to the current year
presentation.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-style: italic; color: #000000">Recent Accounting
Pronouncements</font> <font style="color: #000000; font-family: Times New Roman">&#x2013;</font>
<font style="color: #000000">In May 2014, the FASB issued
Accounting Standards Update (ASU) 2014-09,</font> <font style="font-style: italic; color: #000000">Revenue from Contracts with
Customers (Topic 606)</font> <font style="color: #000000">that will
supersede virtually all recognition guidance in US GAAP. For public
entities, the guidance is effective for annual and interim periods
beginning after December 15, 2017. Early adoption is permitted for
all entities for annual and interim periods beginning after
December 15, 2016. The FASB issued the following ASUs to amend the
new guidance: ASU 2015-14,</font> <font style="font-style: italic; color: #000000">Revenue from Contracts with
Customers (Topic 606): Deferral of the Effective Date,</font>
<font style="color: #000000">ASU 2016-08,</font> <font style="font-style: italic; color: #000000">Revenue from Contracts with
Customers (Topic 606): Principal versus Agent Considerations
(Reporting Revenue Gross versus Net),</font> <font style="color: #000000">ASU 2016-10</font><font style="font-style: italic; color: #000000">, Revenue from Contracts with
Customers (Topic 606): Identifying Performance Obligations and
Licensing, and</font> <font style="color: #000000">ASU
2016-12</font><font style="font-style: italic; color: #000000">,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope
Improvements and Practical Expedients.</font> <font style="color: #000000">Management does not expect the new standard or any
of the related updates to have a material effect on its financial
statements and related disclosures.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">In January 2016, the FASB issued Accounting
Standards Update (ASU) No. 2016-01,</font> <font style="font-style: italic; color: #000000">Financial Instruments &#x2013;
Overall (Subtopic 825-10): Recognition and Measurement of Financial
Assets and Financial Liabilities.</font> <font style="color: #000000">The new guidance is intended to improve the
recognition and measurement of financial instruments. The new
guidance is effective for fiscal years beginning after December 15,
2017, including interim periods within those fiscal years. Early
adoption is permitted for specific provisions within the guidance.
Management does not expect the new standard to have a material
effect on its financial statements and related
disclosures.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">In February 2016, the FASB issued</font> ASU
<font style="color: #000000">2016-02,&#xA0;</font><font style="font-style: italic; color: #000000">Leases</font><font style="color: #000000">, which will require most leases (with the
exception of leases with terms of less than one year) to be
recognized on the balance sheet as an asset and a lease liability.
Leases will be classified as an operating lease or a financing
lease. Operating leases are expensed using the straight-line method
whereas financing leases will be treated similarly to a capital
lease under the current standard. The new standard will be
effective for annual and interim periods, within those fiscal
years, beginning after December 15, 2018, but early adoption is
permitted. The new standard must be presented using the modified
retrospective method beginning with the earliest comparative period
presented. The Company is currently evaluating the effect of the
new standard on its financial statements and related
disclosures.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-13</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">In March 2016, the FASB issued ASU No.
2016-09,</font> <font style="font-style: italic; color: #000000">Compensation - Stock
Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting.</font> <font style="color: #000000">ASU 2016-09
simplifies several aspects of the accounting for share-based
payment award transactions, including income tax consequences,
classification of awards as either equity or liabilities and
classification on the statement of cash flows. The new standard
will be effective for annual and interim periods, within those
fiscal years, beginning after December 15, 2016 but early adoption
is permitted. The Company is currently evaluating the effect of the
new amendment on its financial statements and related
disclosures.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In August 2016, the
FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230):
Classification of Certain Cash Receipts and Cash Payments. ASU
2016-15 amends eight specific cash flow issues: 1.) Debt Prepayment
or Debt Extinguishment Costs, 2.) Settlement of Zero-Coupon Debt
Instruments or Other Debt Instruments with Coupon Interest Rates
That Are Insignificant in Relation to the Effective Interest Rate
of the Borrowing, 3.) Contingent Consideration Payments Made after
a Business Combination, 4.) Proceeds from the Settlement of
Insurance Claims, 5.) Proceeds from the Settlement of
Corporate-Owned Life Insurance Policies, including Bank-Owned Life
Insurance Policies, 6.) Distributions Received from Equity Method
Investees, 7.) Beneficial Interests in Securitization Transactions,
8.) Separately Identifiable Cash Flows and Application of the
Predominance Principle. Management does not expect the adoption of
the amendments in this Update to have a material effect on its
financial statements and related disclosures.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In November 2016,
the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230):
Restricted Cash. ASU 2016-18 requires that a statement of cash
flows explain the change during the period in the total of cash,
cash equivalents, and amounts generally described as restricted
cash or restricted cash equivalents. Therefore, amounts generally
described as restricted cash and restricted cash equivalents should
be included with cash and cash equivalents when reconciling the
beginning-of-period and end-of-period total amounts shown on the
statement of cash flows. The amendments in this Update are
effective for public business entities for fiscal years beginning
after December 15, 2017, and interim periods within those fiscal
years. Management does not expect the adoption of the amendments in
this Update to have a material effect on its financial statements
and related disclosures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
Company has considered all other recently issued accounting
pronouncements and does not believe the adoption of such
pronouncements will have a material impact on its financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">WARRANTS AND
NON-EMPLOYEE OPTIONS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The following chart
represents the warrants and non-employee options outstanding at
September 30, 2016:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-14</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; font-size: 13px; width: 100%; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px"><font style="font-family: Times New Roman; font-weight: bold">Warrant</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px"><font style="font-family: Times New Roman; font-weight: bold">Issue
Date</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Shares Issuable upon Exercise of
Warrant</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Exercise Price</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px"><font style="font-family: Times New Roman; font-weight: bold">Expiration
Date</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Refer-ence</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 29%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
R</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/6/12</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">105,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">100,00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/6/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
S</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/11/13
-10/24/14</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,037,120</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31.25</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/11/18</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
U</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">4/17/14</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,821</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">43.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/17/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
V</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/28/15</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">810,127</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/28/20</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
W</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/28/15</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">688,930</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/28/20</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
X</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">1/13/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">120,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9.25</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">1/13/21</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
Y</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2/15/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">26,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">12.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2/15/21</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
Z</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/23/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">264,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">11/23/21</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
ZZ</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/23/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">20,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/18/21</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
AA</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/26/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">200,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2/22/22</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
BB</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/26/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/22/21</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
N</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/18/08</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">113,785</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.18</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/18/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
P</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2/10/12</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">23,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">112.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">3/6/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Consultants</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/2/11-
7/1/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9.25- $87.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/27/16-
6/30/19</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The following chart
represents the warrants and non-employee options outstanding at
September 30, 2015:</font></div>
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; font-size: 13px; width: 100%; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-weight: bold">Warrants</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-weight: bold">Issue
Date</font></font></font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Shares Issuable upon Exercise of
Warrants</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Exercise Price</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px"><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-weight: bold">Expiration
Date</font></font></font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Refer-ence</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 29%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
N</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/18/08</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">113,785</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.18</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8/18/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
Q</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">6/21/12</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">48,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">125.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/22/15</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
R</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/6/12</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">105,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">100.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/6/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
S</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/11/13-
10/24/14</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,037,120</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31.25</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/11/18</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
U</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">4/17/14</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,821</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">43.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/17/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
V</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/28/15</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">810,127</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5/28/20</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series
P</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2/10/12</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">23,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">112.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">3/6/17</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 29%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Consultants</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/14/05 &#x2013;
7/1/15</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,520</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16.50 &#x2013; $500.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">10/14/15 -
6/30/18</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-15</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Warrant Liabilities</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The table below
presents the warrants accounted for as derivative liabilities at
September 30.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2016</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2015</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series S
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">3,111,361</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">7,363,555</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series U
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">44,551</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series V
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,620,253</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,278,481</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series W
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,799,858</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series Z
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">970,604</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series ZZ
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">70,609</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series AA
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">763,661</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series BB
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">58,588</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Total derivative
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">8,394,934</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">13,686,587</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The table below
presents the gains and (losses) on the warrant liabilities for the
years ended September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: -4px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman">Warrant
Series</font></font></div>
</div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">2016</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">2015</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 11px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-family: Times New Roman">2014</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series A -
E</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,105</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series F and
G</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">12,667</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
H</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">12,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">24,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
N</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">(1,404,027</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
Q</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">12,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">36,000</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
R</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">157,500</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">131,250</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
S</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">4,252,193</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">(1,705,466</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,098,787</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
T</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">276,122</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
U</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">44,552</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">75,738</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">73,967</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
V</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">4,658,228</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">1,724,739</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
W</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">3,260,913</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
Z</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">997,226</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
ZZ</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">75,229</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
AA</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">672,246</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Series
BB</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">53,139</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Net
gain</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">14,013,726</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">282,616</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">248,767</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-16</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company reviews
all outstanding warrants in accordance with the requirements of ASC
815. This topic provides that an entity should use a two-step
approach to evaluate whether an equity-linked financial instrument
(or embedded feature) is indexed to its own stock, including
evaluating the instrument&#x2019;s contingent exercise and
settlement provisions. The warrant agreements provide for
adjustments to the exercise price for certain dilutive events.
Under the provisions of ASC 815, the warrants are not considered
indexed to the Company&#x2019;s stock because future equity
offerings or sales of the Company&#x2019;s stock are not an input to
the fair value of a &#x201C;fixed-for-fixed&#x201D; option on equity
shares, and equity classification is therefore
precluded.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In accordance with
ASC 815, derivative liabilities must be measured at fair value upon
issuance and re-valued at the end of each reporting period through
expiration. Any change in fair value between the respective
reporting periods is recognized as a gain or loss in the statement
of operations.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Expired warrants</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">As of September 30,
2015, all Series A, B, C, E, F, G, H, and Q warrants had
expired.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Series R Warrants</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">On December 4,
2012, the Company sold 140,000 shares of its common
stock for $10,500,000, or $75.00 per share, in a
registered direct offering. The investors in this offering also
received Series R warrants which entitle the investors to purchase
up to 105,000 shares of the Company&#x2019;s common
stock. The Series R warrants may be exercised at any time before
December 6, 2016 at a price of $100.00 per share. The
fair value at issuance of the warrants of $4.2 million was recorded
as a warrant liability.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Series S Warrants</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 11, 2013, the Company closed a public offering of
713,043 units of common stock and warrants at a price
of $25.00 per unit for net proceeds of approximately
$16.4 million, net of underwriting discounts and commissions and
offering expenses of the Company. Each unit consisted of one share
of common stock and one Series S warrant to purchase one share of
common stock. The Series S warrants were immediately exercisable,
expire on October 11, 2018, and have an exercise price of
$31.25. In November 2013, the underwriters purchased
an additional 105,957 warrants pursuant to the
overallotment option, for which the Company received net proceeds
of $24,370. The fair value at issuance of the Series S warrants of
$6.1 million was recorded as a warrant liability.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
December 24, 2013, the Company closed a public offering of
190,476 units of common stock and warrants at a price
of $15.75 per unit for net proceeds of approximately
$2.8 million, net of underwriting discounts and commissions and
offering expenses of the Company. Each unit consisted of one share
of common stock and one Series S warrant to purchase one share of
common stock. The underwriters purchased an additional
19,048 units of common stock and warrants pursuant to
the overallotment option, for which the Company received net
proceeds of approximately $279,000. The fair value at issuance of
the Series S warrants of approximately $1.2 million was recorded as
a warrant liability. On February 7, 2014, the Series S warrants
began trading on the NYSE MKT under the symbol CVM WT.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-17</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 24, 2014, the Company closed an underwritten public
offering of 315,789 shares of common stock and
78,947 Series S warrants to purchase shares of common
stock. Additionally, on October 21, 2014, the Company sold
52,800 shares of common stock and 13,200
Series S warrants to purchase shares of common stock in a private
offering. The common stock and Series S warrants were sold at a
combined per unit price of $19.00 for net proceeds of
approximately $6.4 million, net of underwriting discounts and
commissions and offering expenses. The fair value at issuance of
the Series S warrants of approximately $461,000 was added to the
existing Series S warrant liability.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2016 and 2015, no Series S warrants
were exercised. During the year ended September 30, 2014,
83,551 Series S Warrants were exercised, and the
Company received proceeds of approximately $2.6
million.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series T and U Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
April 17, 2014, the Company closed a public offering of
285,129 shares of common stock at a price of
$35.00 and 71,282 Series T warrants to
purchase one share of common stock for net proceeds of
approximately $9.2 million, net of underwriting commissions and
offering expenses. The Series T warrants were immediately
exercisable and had an exercise price of $39.50. On
October 17, 2014, all of the Series T warrants expired. The
underwriters received 17,821 Series U warrants to
purchase one share of common stock. The Series U warrants were
exercisable beginning October 17, 2014, expire on October 17, 2017,
and have an exercise price of $43.75. The fair value
at issuance of the Series T and U warrants of approximately
$470,000 was recorded as a warrant liability.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series V Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On May
28, 2015, the Company closed an underwritten public offering of
810,127 shares of common stock and
810,127 Series V warrants to purchase shares of common
stock. The common stock and Series V warrants were sold at a
combined per unit price of $19.75 for net proceeds of
approximately $14.7 million, net of underwriting discounts and
commissions and offering expenses. The Series V warrants were
immediately exercisable at a price of $19.75 and
expire on May 28, 2020. The fair value at issuance of the Series V
warrants of approximately $8.0 million was recorded as a warrant
liability.</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series W Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, the Company closed an underwritten public
offering of 688,930 shares of common stock and
688,930 Series W warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $16.75 for net proceeds of approximately
$10.5 million, net of underwriting discounts and commissions and
offering expenses. The Series W warrants are immediately
exercisable at a price of $16.75 and expire on October
28, 2020. The fair value at issuance of the Series W warrants of
approximately $5.1 million was recorded as warrant
liability.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series Z and ZZ Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, the Company closed a registered direct offering of
400,000 shares of common stock and
264,000 Series Z warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $12.50 for net proceeds of approximately
$4.6 million, net of placement agent&#x2019;s commissions and
offering expenses. The Series Z warrants may be exercised at any
time on or after November 23, 2016 and on or before November 23,
2021 at a price of $13.75 per share. The Company also
issued 20,000 Series ZZ warrants to the placement
agent as part of its compensation. The Series ZZ warrants may be
exercised at any time on or after November 23, 2016 and on or
before May 18, 2021 at a price of $13.75 per share.
The fair value of the Series Z and Series ZZ warrants of
approximately $2.1 million on the date of issuance was recorded as
a warrant liability.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-18</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Series AA and BB Warrants</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px">On August 26, 2016,
the Company closed a registered direct offering
of&#xA0;400,000 shares of common stock and
200,000 Series AA warrants to purchase shares of
common stock. The common stock and warrants were sold at a combined
per unit price of $12.50 for proceeds of approximately
$4.5 million, net of placement agent&#x2019;s commissions and
offering expenses. The series AA warrants may be exercised at any
time after February 22, 2017 and on or before February 22, 2022 at
a price of $13.75 per share. The Company also issued
16,000 Series BB warrants to the placement agent as
part of its compensation. The Series BB warrants may be exercised
at any time on or after February 22, 2017 and on or before August
22, 2021 at a price of $13.75 per share. The fair
value of the Series AA and Series BB warrants of approximately $1.5
million on the date of issuance was recorded as a warrant
liability.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Equity Warrants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series X Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">In
January 2016, the Company sold 120,000 shares of its
common stock and 120,000 Series X warrants to the de
Clara Trust for approximately $1.1 million. The de Clara Trust is
controlled by Geert Kersten, the Company's Chief Executive Officer
and a director. Each Series X warrant allows the de Clara Trust to
purchase one share of the Company's common stock at a price of
$9.25 per share at any time on or before January 13,
2021. The Series X warrants qualify for equity treatment in
accordance with ASC 815. The relative fair value of the warrants
was calculated to be approximately $417,000.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series Y Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
February 15, 2016, the Company sold 52,000 shares of
its common stock and 26,000 Series Y warrants to a
private investor for $624,000. Each Series Y warrant allows the
holder to purchase one share of the Company's common stock at a
price of $12.00 per share at any time on or before
February 15, 2021. The Series Y warrants qualify for equity
treatment in accordance with ASC 815. The relative fair value on
the date of issuance of the warrants was calculated to be
approximately $144,000.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series N Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Series
N warrants were previously issued in connection with a financing.
On October 11, 2013 and December 24, 2013, in connection with
public offerings of common stock on those dates, the Company reset
the exercise price of the 20,751 outstanding Series N
warrants from $75.00 to $13.18 and issued
the Series N warrant holders 97,306 additional
warrants exercisable at $13.18, as required by the
warrant agreements. In January 2014, the Company offered the
investors the option to extend the Series N warrants by one year
and allow for cashless exercise in exchange for cancelling the
reset provision in the warrant agreement. One investor, holding
113,785 Series N warrants accepted this offer.
Accordingly, these warrants are no longer considered a derivative
liability due to the cancelation of the reset provision. The fair
value of the warrants on that date totaled approximately $1.3
million and was reclassified from derivative liabilities to
additional paid-in capital. On March 21, 2014, the other investor
exercised 4,272 Series N warrants. The Company
received cash proceeds of approximately $7,000 for 563
of the warrants exercised. The remaining 3,709
warrants were exercised in a cashless exercise. The fair value of
the warrants on the date of exercise was $137,000 and was
reclassified from derivative liabilities to additional paid-in
capital.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-19</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2014, the outstanding 113,785 Series N
Warrants were transferred to the de Clara Trust, of which the
Company&#x2019;s CEO, Geert Kersten, is the trustee and a
beneficiary. On June 29, 2015, the Company extended the expiration
date of the Series N warrants to August 18, 2017. The incremental
cost of this modification was approximately $475,000. The
modification was concurrent with the extinguishment and reissuance
of a note payable also held in the de Clara Trust, and was recorded
as a loss on debt extinguishment.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">As of
September 30, 2016, the remaining 113,785 Series N
warrants entitle the holder to purchase one share of the Company's
common stock at a price of $13.18 per share at any
time prior to August 18, 2017. On September 30, 2016 and 2015, no
derivative liability was recorded because the warrants no longer
were considered a liability for accounting purposes.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series L and Series M Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Series
L and Series M warrants were previously issued in connection with a
financing. In April 2014, 1,000 Series L warrants,
with an exercise price of $187.50, expired. In April
2015, the remaining 2,800 of the Series L warrants,
which had been repriced to $62.50 in April 2013,
expired.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2013, the Company reduced the exercise prices of the Series
M warrants from $85.00 to $25.00 in
exchange for a reduction in the number of warrants from
24,000 to 20,000. The additional cost of
$76,991 was recorded as non-employee stock expense. In March 2014,
20,000 Series M warrants were exercised at a price of
$25.00, and the Company received proceeds of
$500,000.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 24px;">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series P Warrants</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
February 10, 2012, the Company issued 23,600 Series P
warrants to purchase up to 23,600 shares of the
Company&#x2019;s common stock at a price of $112.50 per
share as an inducement for the exercise of previously issued
warrants. The Series P warrants are exercisable at any time prior
to March 6, 2017.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">3.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Options and Shares Issued to Consultants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The
Company typically enters into consulting arrangements in exchange
for common stock or stock options. During the years ended September
30, 2016 and 2015, the Company issued 49,953 and
29,599 shares of common stock, respectively, to
consultants, of which 31,360 and 7,200,
respectively, were restricted shares. Under these arrangements, the
common stock was issued with stock prices ranging between
$9.25 and $27.75 per share.</font> </div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Additionally,
during the years ended September 30, 2016 and 2015, the Company
issued to consultants 16,400 and 3,600
options, respectively, to purchase common stock with exercise
prices ranging from $9.25 to $25.50 per
share and fair values ranging from $3.00 to
$12.50 per share. The aggregate values of the
issuances of restricted common stock and common stock options are
recorded as prepaid expenses and are charged to general and
administrative expenses over the periods of service.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2016 and 2015, the Company recorded
total expense of approximately $752,000 and $566,000, respectively,
relating to these consulting agreements. At September 30, 2016 and
2015, approximately $48,000 and $30,000, respectively, are included
in prepaid expenses. As of September 30, 2016, 25,600
options issued to consultants as payment for services remained
outstanding, 17,600 of which are fully vested, and all
of which were issued from the Non-Qualified Stock Option
plans.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-20</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"> <font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">
PLANT, PROPERTY AND EQUIPMENT</font> </div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">Plant,
property and equipment consisted of the following at
September 30:</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">2016</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">2015</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Manufacturing
building</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">21,183,756</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">21,183,756</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Research
equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,158,633</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,268,757</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Furniture and
equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">133,499</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">141,347</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Leasehold
improvements</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">131,910</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">131,910</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,607,798</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,725,770</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Accumulated
depreciation and amortization</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(7,256,962</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(6,779,939</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net plant,
property and equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,350,836</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,945,831</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px">The Company
is not the legal owner of the manufacturing building, but is deemed
to be the owner for accounting purposes based on the accounting
guidance for build-to-suit leases. See Note 10, Commitments and
Contingencies &#x2013; Lease Obligations for additional information.
As of September 30, 2016 and 2015, accumulated depreciation on the
manufacturing building is approximately $4.1 million and $3.5
million, respectively. Depreciation
expense for the years ended September 30, 2016, 2015 and 2014
totaled approximately $626,000, $680,000 and
$703,000, respectively. Depreciation expense
includes depreciation on the leased manufacturing building of
approximately $514,000, which is included in research and
development costs on the Statement of Operations. One asset
is recorded under capital lease with a net book value of $0 and
approximately $8,000 on September 30, 2016 and 2015, respectively.
Amortization of the capital lease asset is included in general and
administrative expenses on the Statements of
Operations.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">6.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">PATENTS</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Patents consisted
of the following at September 30:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2016</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2015</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Patents</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">1,528,610</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">1,525,791</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td colspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Accumulated
amortization</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">(1,272,063.00</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">(1,234,227.00</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td colspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Net
Patents</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">256,547</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">291,564</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-21</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, 2016, 2015 there was no impairment of patent
costs and a nominal impairment charge in 2014. Amortization expense
for the years ended September 30, 2016, 2015 and 2014 totaled
approximately $38,000, $40,000 and $43,000, respectively. The total
estimated future amortization is as follows:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; border-bottom: 2px solid #000"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">
<font style="font-size: 11px">Years ending September
30,</font></font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">37,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">36,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">2019</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">35,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">2020</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">31,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">2021</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">28,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Thereafter</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">90,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td colspan="1" style="vertical-align: bottom; width: 86%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">257,000</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">7.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">INCOME
TAXES</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">At September 30,
2016 and 2015, the Company had federal net operating loss
carryforwards of approximately $170.8 million and
$156.8 million, respectively. The NOLs begin to expire
during the fiscal year ending September 30, 2019 and become fully
expired by the end of the fiscal year ended 2036. In addition, the
Company has a general business credit as a result of the credit for
increasing research activities (&#x201C;R&amp;D credit&#x201D;) of
approximately $1.2 million at September 30, 2016 and 2015. The
R&amp;D credit begins to expire during the fiscal year ending
September 30, 2020 and is fully expired during the fiscal year
ended 2029. Deferred taxes consisted of the following at September
30:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Net
operating loss carryforwards</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">64,366,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">61,363,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">R&amp;D
credit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,221,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,221,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Stock-based
compensation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,379,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,855,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Capitalized
R&amp;D</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,508,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,082,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Vacation
and other</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">179,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">114,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Loan
modification</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">57,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Total
deferred tax assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,653 ,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">83,692,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div>Fixed assets and intangibles<br></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(49,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)<br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(86,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">Total
deferred tax liabilities<br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(49,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)<br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(86,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)<br></font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Valuation
allowance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(90,604,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(83,606,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Net
deferred tax asset</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-22</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In assessing the
realization of deferred tax assets, management considered whether
it was more likely than not that some, or all, of the deferred tax
asset will be realized. The ultimate realization of the deferred
tax assets is dependent upon the generation of future taxable
income. Management has considered the history of the
Company&#x2019;s operating losses and believes that the realization
of the benefit of the deferred tax assets cannot be reasonably
assured. In addition, under Internal Revenue Code Section 382, the
Company&#x2019;s ability to utilize these net operating loss
carryforwards may be limited or eliminated in the event of future
changes in ownership.</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company has no
federal or state current or deferred tax expense or benefit. The
Company&#x2019;s effective tax rate differs from the applicable
federal statutory tax rate. The reconciliation of these rates is as
follows at September 30:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Federal
Rate</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">State
tax rate, net of federal benefit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3.92</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.15</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">State
tax rate change</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(22.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.15</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.93</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Other
adjustments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.03</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Adjustment
to deferreds</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19.13<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Permanent
differences (1)<br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44.90<br></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.71</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.43</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Change
in valuation allowance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(60.79</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(38.05</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(58.78</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Effective
tax rate</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">(1)
The 2016 amount is for the most part due to the
approximate $14 million gain on derivative instruments
from the change in fair value of the Company&#x2019;s warrant
liabilities during the period.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company applies
the provisions of ASC 740, <font style="font-style: italic">&#x201C;Accounting for Uncertainty in Income
Taxes,&#x201D;</font> which requires financial statement benefits to
be recognized for positions taken for tax return purposes when it
is more likely than not that the position will be sustained. The
Company has elected to reflect any tax penalties or interest
resulting from tax assessments on uncertain tax positions as a
component of tax expense. The Company has generated federal net
operating losses in tax years ending September 30, 1998 through
2015. These years remain open to examination by the major domestic
taxing jurisdictions to which the Company is subject.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">8.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">STOCK
COMPENSATION</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company
recognized the following expenses for options issued or vested and
restricted stock awarded during the year:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 42%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; font-weight: bold; width: 94%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman"><font style="font-size: 11px">Year
Ended September 30,</font></font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2016<br>
</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; font-size: 11px">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; border-bottom: 2px solid #000; font-size: 11px">2015<br>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; font-size: 11px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; color: #000; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2014</font><font style="text-align: left; color: #000; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td colspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Employees</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">2,113,433</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">5,105,827</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">3,958,637</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Non-employees</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">751,651</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">565,915</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; color: #000000; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">771,946</font><font style="text-align: left; color: #000000; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-23</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">Stock
Compensation is included in general and administrative
expenses. During the years ended September 30, 2016,
2015 and 2014, non-employee stock compensation excluded
approximately $48,000, $30,000 and $26,000, respectively, for
future services to be performed (Note 12).</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, the fair value of each option grant was
estimated on the date of grant using the Black-Scholes
option-pricing model with the following assumptions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: center; text-align: center; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2016</font><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2015</font><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2014</font><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Expected stock
price volatility</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">75.58
&#x2013; 80.9</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">73.38
&#x2013; 86.19</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">72.81
&#x2013; 86.87</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Risk-free interest
rate</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">0.71
&#x2013; 1.56</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">0.93
&#x2013; 2.35</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">0.59
&#x2013; 2.65</font><font style="font-size: 13px; font-family: Times New Roman">%</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Expected life of
options</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman"><font style="text-align: center; vertical-align: bottom; display: inline-block; font-size: 13px; font-family: Times New Roman">
3.0 &#x2013; 9.69 Years</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font>3.0 &#x2013; 9.76 Years</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>&#xA0;
<font style="font-size: 13px; font-family: Times New Roman">3.0
&#x2013; 9.76 Years</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 58%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Expected dividend
yield</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">-</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">-</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman">-</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Non-Qualified Stock Option
Plans</font>--At September 30, 2016, the Company has collectively
authorized the issuance of 387,200 shares of common
stock under its Non-Qualified Stock Option Plans. Options typically
vest over a three-year period and expire no later than ten years
after the grant date. Terms of the options are to be determined by
the Company&#x2019;s Compensation Committee, which administers the
plans. The Company&#x2019;s employees, directors, officers, and
consultants or advisors are eligible to be granted options under
the Non-Qualified Stock Option Plans.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Incentive Stock Option
Plans</font>--At September 30, 2016, the Company had collectively
authorized the issuance of 138,400 shares of common
stock under its Incentive Stock Option Plans. Options typically
vest over a three-year period and expire no later than ten years
after the grant date. Terms of the options were determined by the
Company&#x2019;s Compensation Committee, which administers the
plans. Only the Company&#x2019;s employees are eligible to be
granted options under the Incentive Stock Option
Plans.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Activity in the
Company&#x2019;s Non-Qualified and Incentive Stock Option Plans for
the two years ended September 30, 2016 is summarized as
follows:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-24</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font>&#xA0;<br></font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Non-Qualified and Incentive Stock Option Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:40%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:2%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:96%;font-size:13px;">Outstanding</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:2%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:40%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:2%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:96%;font-size:13px;">Exercisable</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:2%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Weighted</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Weighted</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Ave</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Ave</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Number of</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Weighted<br>
Average</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Remaining Contractual</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Aggregate<br>
Intrinsic</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Number of</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Weighted<br>
Average</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Remaining Contractual</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Aggregate<br>
Intrinsic</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Shares</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Exercise Price</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Term (Years)</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Value</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Shares</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Exercise Price</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Term (Years)</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Value</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at October 1, 2014</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">273,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">74.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6.55</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">137,755</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">85.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.49</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">46,134</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted
(a)</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,748</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">46.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,820</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">103.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,820</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">103.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cancelled</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at September 30, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">301,507</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">67.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.98</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">181,070</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">78.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.01</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">56,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted
(b)</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">48,544</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cancelled</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">343,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">59.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">232,898</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">66.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.76</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">(a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Includes 90,000
stock options granted to consultants</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">(b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Includes 410,000
stock options granted to consultants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">A summary of the
status of the Company&#x2019;s non-vested options for the two years
ended September 30, 2016 is presented below:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 408px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Number of<br>
Options</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">Weighted Average<br>
Grant Date<br>
Fair Value</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at October 1, 2014</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">135,491</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">53.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(46,134</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,748</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at September 30, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120,438</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">43.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(56,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">48,544</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">110,673</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">37.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 408px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-25</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 408px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Incentive Stock Bonus Plan</font>-- On
July 22, 2014 the Company's shareholders approved the 2014
Incentive Stock Bonus Plan, authorizing the issuance of up to
640,000 shares in the Company&#x2019;s Incentive Stock
Bonus Plan. The shares will only be earned upon the achievement of
certain milestones leading to the commercialization of the
Company&#x2019;s Multikine technology, or specified increases in the
market price of the Company&#x2019;s stock. If the performance or
market criteria are not met as specified in the Incentive Stock
Bonus Plan, all or a portion of the awarded shares will be
forfeited. The fair value of the shares on the grant date was
calculated using the market value on the grant-date for issuances
where the attainment of performance criteria is likely and using a
Monte Carlo simulation for issuances where the attainment of
performance criteria is uncertain. The grant date fair value of
shares issued that remain outstanding as of September 30, 2016 is
approximately $8.6 million. The total value of the shares, if
earned, is being expensed over the requisite service periods for
each milestone, provided the requisite service periods are
rendered, regardless of whether the market conditions are met. No
compensation cost is recognized for awards where the requisite
service period is not rendered. During the years ended September
30, 2016 and 2015, the Company recorded expense relating to the
issuance of restricted stock pursuant to the plan of approximately
$634,000 and $3.4 million, respectively. At September 30, 2016, the
Company has unrecognized compensation expense of approximately $3.1
million which is expected to be recognized over a weighted average
period of 5.03 years.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">A summary of the
status of the Company&#x2019;s restricted stock units issued from
the Incentive Stock Bonus Plan for the two years in the period
ended September 30, 2016 is presented below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">Number
of Shares</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="width: 14%; vertical-align: bottom">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">Weighted
Average Grant Date Fair Value</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Unvested at October
1, 2014</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">628,000</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">13.75</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Vested</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">(20,000</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Granted</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Forfeited</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">(4,000</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Unvested at
September 30, 2015</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">604,000</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">13.75</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Vested</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">-</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Unvested at
September 30, 2016</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">604,000</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; font-family: Times New Roman">13.75</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Bonus Plans</font> -- At
September 30, 2016, the Company was authorized to issue up to
223,760 shares of common stock under its Stock Bonus
Plans. All employees, directors, officers, consultants, and
advisors are eligible to be granted shares. During the year ended
September 30, 2016, 16,340 shares were issued to the
Company&#x2019;s 401(k) plan for a cost of approximately
$162,000<font style="font-family: Times New Roman">.</font> During
the year ended September 30, 2015, 9,727 shares were
issued to the Company&#x2019;s 401(k) plan for a cost of
approximately $166,000. During the year ended September 30, 2014,
6,591 shares were issued to the Company&#x2019;s 401(k)
plan for a cost of approximately $155,<font style="font-family: Times New Roman">000.</font> As of September 30,
2016, the Company has issued a total of 126,448 shares
of common stock from the Stock Bonus Plans.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Compensation Plans</font>-- At
September 30, 2016, 134,000 shares were authorized for
use in the Company&#x2019;s stock compensation plans. During the
years ended September 30, 2016<font style="font-family: Times New Roman">,</font> 2015 and 2014<font style="font-family: Times New Roman">,</font> 18,593, 8,733
and 16,399 shares, respectively, were issued from the
Stock Compensation Plans to consultants for payment of services at
a cost of approximately $234,000, $147,000 and $439,00<font style="font-family: Times New Roman">0</font>, respectively. During the
year ended September 30, 2016 and 2015, 3,837 and
4,282 shares, respectively, were issued to employees
from the Stock Compensation Plans as part of their compensation at
a cost of approximately $45,000 and $58,000, respectively. No
shares were issued to employees from the Stock Compensation Plans
during the year ended September 30, 2014. As of September 30, 2016,
the Company has issued 79,391 shares of common stock
from the Stock Compensation Plans<font style="font-family: Times New Roman">.</font></font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-26</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">9.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">EMPLOYEE
BENEFIT PLAN</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company
maintains a defined contribution retirement plan, qualifying under
Section 401(k) of the Internal Revenue Code, subject to the
Employee Retirement Income Security Act of 1974, as amended, and
covering substantially all Company employees. Each
participant&#x2019;s contribution is matched by the Company with
shares of common stock that have a value equal to 100% of the
participant&#x2019;s contribution, not to exceed the lesser of
$10,000 or 6% of the participant&#x2019;s total compensation. The
Company&#x2019;s contribution of common stock is valued each quarter
based upon the closing bid price of the Company&#x2019;s common
stock. Total expense, including plan maintenance, for the years
ended September 30, 2016, 2015 and 2014, in connection with this
Plan was approximately $168,000, $170,000 and $160,000,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">10.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
COMMITMENTS AND CONTINGENCIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; color: #000000; font-size: 13px; font-family: Times New Roman">
Clinical Research Agreements</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">In
March 2013, the Company entered into an agreement with Aptiv
Solutions to provide certain clinical research services in
accordance with a master service agreement. The Company will
reimburse Aptiv for costs incurred. The agreement required the
Company to make $600,000 in advance payments which are being
credited against future invoices in $150,000 annual increments
through December 2017. As of September 30, 2016, the total balance
advanced is $300,000, of which $150,000 is classified as a current
asset.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000">In April 2013, the Company entered into a
co-development and revenue sharing agreement with Ergomed. Under
the agreement, Ergomed will contribute up to $10 million towards
the study in the form of offering discounted clinical services in
exchange for a single digit percentage of milestone and royalty
payments, up to a specific maximum amount</font>. In October 2015,
the Company entered into a second <font style="color: #292929">co-development and revenue sharing agreement with
Ergomed</font> for an additional $2 million, for a total of $12
million. The Company accounted for the co-development and revenue
sharing agreement in accordance with ASC 808 &#x201C;Collaborative
Arrangements&#x201D;. The Company determined the payments to Ergomed
are within the scope of ASC 730 &#x201C;Research and
Development.&#x201D; Therefore, the Company records the discount on
the clinical services as a credit to research and development
expense on its Statements of Operations. Since the Company entered
into the co-development and revenue sharing agreement with Ergomed,
it has incurred research and development expenses of approximately
$19.2 million related to Ergomed&#x2019;s services. This amount is
net of Ergomed&#x2019;s discount of approximately $6.3 million.
During the years ended September 30, 2016, 2015 and 2014, the
Company recorded, approximately $7.2 million, $6.7 million and $4.4
million, respectively, as research and development expense related
to Ergomed&#x2019;s services. These amounts were net of
Ergomed&#x2019;s discount of approximately $2.1 million, $2.4
million and $1.5 million, respectively, over the comparable
periods.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In October 2013,
the Company entered into two co-development and profit sharing
agreements with Ergomed.&#xA0; One agreement supports the Phase 1
study being conducted at UCSF for the development of Multikine as a
potential treatment for peri-anal warts in HIV/HPV co-infected men
and women.&#xA0; The other agreement focuses on the development of
Multikine as a potential treatment for cervical dysplasia in
HIV/HPV co-infected women. Ergomed will assume up to $3 million in
clinical and regulatory costs for each study.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company is
currently involved in a pending arbitration proceeding, CEL-SCI
Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC)
and PharmaNet GmbH (f/k/a PharmaNet AG). On October 31, 2013,
<font style="color: #000000">the Company initiated the proceedings
against inVentiv Health Clinical, LLC, or inVentiv, the former
third-party CRO, and are seeking payment for damages related to
inVentiv&#x2019;s prior involvement in the ongoing Phase 3 clinical
trial of Multikine. The arbitration claim, initiated under the
Commercial Rules of the American Arbitration Association, alleges
(i) breach of contract, (ii) fraud in the inducement, and (iii)
common law fraud. The Company is seeking at least $50 million in
damages in its amended statement of claim. Based upon further
analysis, however, the Company believes that its damages (direct
and consequential) presently total over $150
million.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-27</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In an amended
statement of claim, the Company asserted the claims set forth above
as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In connection with
the pending arbitration proceedings, inVentiv has asserted
counterclaims against the Company for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for the Company&#x2019;s alleged use of
inVentiv&#x2019;s name in connection with publications and
promotions in violation of the parties&#x2019; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at
least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches
referenced in subsection (ii); and (iv) defamation, seeking at
least $1 million in damages for allegedly defamatory statements
made about inVentiv. The Company believes inVentiv&#x2019;s
counterclaims are meritless. However, if inVentiv successfully
asserts any of its counterclaims, such an adverse determination
could have a material adverse effect on the Company&#x2019;s
business, results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In October 2015 the
Company signed an arbitration funding agreement with a company
established by Lake Whillans Litigation Finance, LLC, a firm
specializing in funding litigation expenses. Pursuant to the
agreement, an affiliate of Lake Whillans provides the Company with
funding for litigation expenses to support its arbitration claims
against inVentiv. The funding is available to the Company to fund
the expenses of the ongoing arbitration and will only be repaid
when the Company receives proceeds from the arbitration. During the
year ended September 30, 2016, the Company recognized a gain of
approximately $1.1 million on the derecognition of legal fees to
record the transfer of the liability that existed prior to the
execution of the financing agreement from the Company to Lake
Whillans. The gain on derecognition of legal fees is recorded as a
reduction of general and administration expenses on the Statement
of Operations. All related legal fees are directly billed to and
paid by Lake Whillans. As part of the agreement with Lake Whillans,
the law firm agreed to cap its fees and expenses for the
arbitration at $5 million.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The arbitration
hearing on the merits (the &#x201C;trial&#x201D;) began on September
26, 2016.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Lease Agreements</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases a manufacturing facility near
Baltimore, Maryland under an operating lease (the San Tomas
lease). The building was remodeled in accordance with the
Company&#x2019;s specifications so that it can be used
by the Company to manufacture Multikine for the Company&#x2019;s
Phase 3 clinical trial and sales of the drug if approved by the
FDA. The lease is for a term of twenty years and requires annual
base rent to escalate each year at 3%. The Company is required to
pay all real estate and personal property taxes, insurance
premiums, maintenance expenses, repair costs and utilities. The
lease allows the Company, at its election, to extend the lease for
two ten-year periods or to purchase the building at the end of the
20-year lease. The Company contributed approximately $9.3
million towards the tenant-directed improvements, of which $3.2
million is being refunded during years six through twenty through
reduced rental payments. The landlord paid approximately $11.9
million towards the purchase of the building, land and the
tenant-directed improvements. The Company placed the building in
service in October 2008.</font> </div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
leased building is being depreciated using a straight line method
of the 20 year lease term to a residual value. The landlord
liability is being amortized over the 20 years using the effective
interest method.</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Lease
payments allocated to the landlord liability are accounted for as
debt service payments on that liability using the finance method of
accounting per ASC 840-40-55.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">The Company was
required to deposit the equivalent of one year of base rent in
accordance with the San Tomas lease. When the Company
meets the minimum cash balance required by the lease, the deposit
will be returned to the Company. The approximate $1.7 million
deposit is included in non-current assets on September 30, 2016 and
2015.</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px">Future
minimum lease payments under the San Tomas lease as of September
30, 2016 are as follows:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 11px">Years ending September
30,</font></font></font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,687,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,747,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,808,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,872,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,937,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 48px;"><font style="font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">15,762,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Total future
minimum lease obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,813,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Less imputed
interest on financing obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(11,802,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 4px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Net present value
of lease financing obligation</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,011,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company
subleases a portion of its rental space on a month to month term
lease, which requires a 30 day notice for termination. The sublease
rent for the years ended September 30, 2016, 2015 and 2014 was
approximately $67,000, $65,000 and $63,000, respectively, and is
recorded in grant income and other in the statements of
operations.</font></div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-28</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company leases
its research and development laboratory under a 60 month lease
which expires February 28, 2017. In September 2016, the lease was
extended through February 28, 2022. The operating lease includes
escalating rental payments. The Company is recognizing the related
rent expense on a straight line basis over the full 60 month term
of the lease at the rate of approximately $11,000 per month. As of
September 30, 2016 and 2015, the Company has recorded a deferred
rent liability of approximately $2,000 and $6,000,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company leases
its office headquarters under a 60 month lease which expires June
30, 2020. The operating lease includes escalating rental payments.
The Company is recognizing the related rent expense on a straight
line basis over the full 60 month term of the lease at the rate
approximately $8,000 per month. As of September 30, 2016 and 2015,
the Company has recorded a deferred rent liability of approximately
$18,000 and $13,000, respectively.</font></div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The Company leases
office equipment under a capital lease arrangement. The term of the
capital lease is 48 months and expired on September 30, 2016. The
monthly lease payment is $1,025. The lease bears interest at
approximately 6% per annum.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Approximate future minimum annual lease payments due under
non-cancelable operating leases, excluding the San Thomas, lease
for the years ending after September 30, 2016 are as
follows:</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">243,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">251,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">258,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">238,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">163,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">69,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
minimum lease payments:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,222,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Rent expense,
for the years ended September 30, 2016, 2015 and 2014, excluding
the rent paid on the San Tomas lease was approximately $300,000.
The Company&#x2019;s three leases expire between June 2020 and
October 2028.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">
Vendor Obligations</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Further, the
Company has contingent obligations with other vendors for work that
will be completed in relation to the Phase 3 trial. The timing of
these obligations cannot be determined at this time. The total
remaining cash cost of the Phase 3 clinical trial, excluding any
costs that will be paid by CEL-SCI's partners, would be
approximately $12.1 million after September 30, 2016. This is based
on the executed contract costs with the CROs only and does not
include other related costs, e.g. the manufacturing of the drug.
The Company has filed an amendment to the original Phase 3 protocol
for it head and neck cancer study with the FDA to allow for this
expansion in patient enrollment. Should the FDA allow the amended
protocol filed with them to proceed, the remaining cost of the
Phase 3 clinical trial will be higher.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-29</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">11.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
RELATED PARTY TRANSACTIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">Effective August
31, 2016, Maximilian de Clara, the Company&#x2019;s President and a
director, resigned for health reasons. In payment for past
services, the Company agreed to issue Mr. de Clara
26,000 shares of restricted stock; 13,000
shares upon his resignation and 13,000 on August 31,
2017. The market value of the shares granted, including the accrued
value of the shares to be issued in August 2017, totaled
$253,500.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">On January 13,
2016, the de Clara Trust demanded payment on the note payable, of
which the balance, including accrued and unpaid interest, was
$1,105,989. The de Clara Trust was established by Maximilian de
Clara, the Company&#x2019;s former President and a director. The
Company&#x2019;s Chief Executive Officer, Geert Kersten, is the
trustee and a beneficiary. When the de Clara Trust demanded payment
on the note, the Company sold 120,000 shares of its
common stock and 120,000 Series X warrants to the de
Clara Trust for approximately $1.1 million. Each warrant allows the
de Clara Trust to purchase one share of the Company's common stock
at a price of $9.25 per share at any time on or before
January 13, 2021.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">Prior to the
repayment, on June 29, 2015, the Company had extended the maturity
date of the note to July 6, 2017, lowered the interest rate from
15% to 9% and changed the conversion price from
$100.00 to $14.75, the closing stock
price on the previous trading day. The Company determined these
modifications to be substantive and accounted for the modification
as an extinguishment of the pre-modification note and issuance of
the post-modification note. The Company recorded an extinguishment
loss and a premium on the note payable of approximately $166,000,
which was credited to additional paid in capital. Concurrently, the
Company extended the expiration date of the Series N warrants to
August 18, 2017. The incremental cost of this modification was
approximately $475,000 and was included in debt extinguishment loss
on the note, for a total loss of approximately $620,000 during the
year ended September 30, 2015.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, 2016, 2015 and 2014, the Company paid
approximately $43,000, $146,000 and $179,000, respectively, in
interest expense to Mr. de Clara.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">12.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
STOCKHOLDERS&#x2019; EQUITY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">During the years
ended September 30, 2016 and 2015, no warrants were exercised.
During the year ended September 30, 2014, 107,822
Series M, N and S warrants were exercised. The Company issued
106,740 shares of common stock and received
approximately $3.1 million from the exercise of these warrants
since 3,709 Series N warrants were exercised in a
cashless exercise.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">On October 11,
2013, the Company closed a public offering of units of common stock
and Series S warrants at a price of $25.00 per unit
for net proceeds of $16.4 million, net of underwriting discounts
and commissions. Each unit consisted of one share of common stock
and a warrant to purchase one share of common stock. The warrants
were immediately exercisable and expire on October 11, 2018, and
have an exercise price of $31.25. In November 2013,
the underwriters purchased an additional 105,957
warrants pursuant to the overallotment option, for which the
Company received net proceeds of approximately
$24,000.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">On December 24,
2013, the Company closed a public offering of units of common stock
and Series S warrants at a price of $15.75 per unit
for net proceeds of approximately $2.8 million, net of underwriting
discounts and commissions. Each unit consisted of one share of
common stock and a warrant to purchase one share of common stock.
The warrants are immediately exercisable and expire on October 11,
2018, and have an exercise price of $31.25. The
underwriters exercised the option for the full 10% overallotment,
for which the Company received net proceeds of approximately
$279,000.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">The October and
December 2013 financings triggered the reset provision from the
August 2008 financing which resulted in the issuance of an
additional 62,523 shares of common stock. The cost of
additional shares issued was approximately $1.1 million. This cost
was recorded as a deemed a dividend.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-30</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 24, 2014, the Company closed an underwritten public
offering of 315,789 shares of common stock and
78,947 Series S warrants to purchase shares of common
stock. Additionally, in a related private offering on October 21,
2014, the Company sold 52,800 shares of common stock
and 13,200 Series S warrants to purchase shares of
common stock. The common stock and Series S warrants were sold at a
combined price of $19.00 for net proceeds of
approximately $6.4 million, net of offering expenses. The Series S
warrants trade of the NYSE MKT under the symbol CVM
WT.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
April 17, 2014, the Company closed a public offering of units
consisting of 285,129 shares of common stock and
Series T warrants to purchase an aggregate of 71,282
shares of common stock. The units were sold at a price of
$35.00 per unit. The Company received net proceeds of
approximately $9.1 million after deducting the underwriting
commissions and offering expenses. The common stock and warrants
separated immediately. The Series T warrants, with an exercise
price of $39.50 per share, expired on October 17,
2014. The underwriters in the offering received 17,821
Series U warrants to purchase one share of common stock. The Series
U warrants expire on October 17, 2017, and have an exercise price
of $43.75.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On May
28, 2015, the Company closed an underwritten public offering of
810,127 shares of common stock and
810,127 Series V warrants to purchase shares of common
stock. The common stock and Series V warrants were sold at a
combined per unit price of $19.75 for net proceeds of
approximately $14.7 million, net of underwriting discounts and
commissions and offering expenses. The Series V warrants are
immediately exercisable at a price of $19.75 and
expire on May 28, 2020.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, the Company closed an underwritten public
offering of 688,930 shares of common stock and
688,930 Series W warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined price
of $16.75 for net proceeds of approximately $10.5
million, net of underwriting commissions and offering expenses. The
warrants were immediately exercisable, expire October 28, 2020 and
have an exercise price of $16.75.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, the Company closed a registered direct offering of
400,000 shares of common stock and
264,000 Series Z warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $12.50 for net proceeds of approximately
$4.6 million, net of placement agent&#x2019;s commissions and
offering expenses. The Series Z warrants may be exercised at any
time on or after November 23, 2016 and on or before November 23,
2021 at a price of $13.75 per share. The Company also
issued 20,000 Series ZZ warrants to the placement
agent as part of its compensation. The Series ZZ warrants may be
exercised at any time on or after November 23, 2016 and on or
before May 18, 2021 at a price of $13.75 per
share.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On August 26, 2016, the Company closed a
registered direct offering of&#xA0;400,000 shares of
common stock and Series AA warrants to purchase up to
200,000 shares of common stock. Each share of common
stock was sold together with a Series AA warrant to purchase
one-half of a share of common stock for the combined purchase price
of $12.50. Each warrant can be exercised at any time
after February 22, 2017 and on or before February 22, 2022 at a
price of $13.75 per share.</font> The Company also
issued 16,000 Series BB warrants to the placement
agent as part of its compensation. The Series BB warrants may be
exercised at any time on or after February 22, 2017 and on or
before August 22, 2021 at a price of $13.75 per share.
The Company received proceeds from the sale of Series AA and Series
BB shares and warrants of approximately $4.5 million, net of
placement agent&#x2019;s commissions and offering
expenses</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">13.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
FAIR VALUE MEASUREMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In accordance with
the provisions of ASC 820, &#x201C;<font style="font-style: italic">Fair Value Measurements</font>,&#x201D; the
Company determines fair value as the price that would be received
to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
The Company generally applies the income approach to determine fair
value. This method uses valuation techniques to convert future
amounts to a single present amount. The measurement is based on the
value indicated by current market expectations about those future
amounts.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">ASC 820 establishes
a fair value hierarchy that prioritizes the inputs used to measure
fair value. The hierarchy gives the highest priority to active
markets for identical assets and liabilities (Level 1 measurement)
and the lowest priority to unobservable inputs (Level 3
measurement). The Company classifies fair value balances based on
the observability of those inputs. The three levels of the fair
value hierarchy are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Level 1 &#x2013;
Observable inputs such as quoted prices in active markets for
identical assets or liabilities</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Level 2 &#x2013;
Inputs other than quoted prices that are observable for the asset
or liability, either directly or indirectly. These include quoted
prices for similar assets or liabilities in active markets, quoted
prices for identical or similar assets or liabilities in markets
that are not active and amounts derived from valuation models where
all significant inputs are observable in active
markets</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 48px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px; font-family: Times New Roman">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Level 3 &#x2013;
Unobservable inputs that reflect management&#x2019;s
assumptions</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-31</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For disclosure
purposes, assets and liabilities are classified in their entirety
in the fair value hierarchy level based on the lowest level of
input that is significant to the overall fair value measurement.
The Company&#x2019;s assessment of the significance of a particular
input to the fair value measurement requires judgment and may
affect the placement within the fair value hierarchy
levels.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The table below
sets forth the liabilities measured at fair value on a recurring
basis, by input level, on the balance sheet at September 30,
2016:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: center; text-align: center; padding-top: 0px; padding-bottom: 0px; margin-left: auto; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Quoted
Prices in</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Significant</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Active
Markets for</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Other</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Significant</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Identical</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Observable</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Unobservable</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Liabilities
(Level 1)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Inputs
(Level 2)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Inputs
(Level 3)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Total</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 52%; border-bottom: 4px double #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="color: #000; font-family: Times New Roman">Derivative
Instruments</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="color: #000; font-family: Times New Roman">$
3,111,361</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="color: #000; font-family: Times New Roman">$
5,283,573</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="color: #000; font-family: Times New Roman">$
8,394,934</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The table below
sets forth the liabilities measured at fair value on a recurring
basis, by input level, on the balance sheet at September 30,
2015:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: 0px"></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: right; text-align: right; padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Quoted
Prices in</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Significant</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Active
Markets for</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Other</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Significant</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Identical</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Observable</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Unobservable</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%; border-bottom: 2px solid #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Liabilities
(Level 1)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Inputs
(Level 2)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Inputs
(Level 3)</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid #000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Total</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: top; width: 52%; border-bottom: 4px double #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">Derivative
Instuments<br></font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">$
7,365,555<br></font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">$
6,323,032<br></font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #000">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman">$
13,686,587<br></font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The following sets
forth the reconciliation of beginning and ending balances related
to fair value measurements using significant unobservable inputs
(Level 3), as of September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left: 0px; margin-right: 0px; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2016</font><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid #000; font-size: 13px; font-family: Times New Roman">2015</font><font style="text-align: left; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Beginning
balance</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">6,323,032</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">307,894</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;Issuances</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">8,722,073</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; font-size: 13px; font-family: Times New Roman">8,003,220</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: #ffffff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;Net realized
and unrealized derivative gain</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">(9,761,532</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid #000000; font-size: 13px; font-family: Times New Roman">(1,988,082</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-family: Times New Roman">)</font></div>
</td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 72%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Ending
balance</font></div>
</td>
<td style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">5,283,573<br>
</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: bottom; width: 14%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">
&#xA0;</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">$</font><font style="text-align: right; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 4px double #000000; font-size: 13px; font-family: Times New Roman">6,323,032<br>
</font><font style="text-align: left; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The fair values of
the Company&#x2019;s derivative instruments disclosed above under
Level 3 are primarily derived from valuation models where
significant inputs such as historical price and volatility of the
Company&#x2019;s stock as well as U.S. Treasury Bill rates are
observable in active markets. At September 30, 2016, the
Company&#x2019;s Level 3 derivative instruments have a weighted
average fair value of $0.10 per share and a weighted average
exercise price of $0.86 per share. Fair values were determined
using a weighted average risk free interest rate of 1.04% and 75%
volatility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-32</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">14.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
NET LOSS PER COMMON SHARE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Basic loss per
share is computed by dividing net loss available to common
shareholders by the weighted average number of common shares
outstanding during the period. The Company&#x2019;s potentially
dilutive shares, which include outstanding common stock options,
common stock warrants, restricted stock and shares issuable on
convertible debt, have not been included in the computation of
diluted net loss per share for all periods presented, as the result
would be anti-dilutive. For the years presented, the gain on
derivative instruments is not included in net loss available to
common shareholders for purposes of computing dilutive loss per
share because its effect is anti-dilutive.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The following table
provides a reconciliation of the numerators and denominators of the
basic and diluted per-share computations:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:13px;">2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss available to common shareholders &#x2013; Restated
(1)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(28,470,126</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Less:
Gain on derivative instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(248,767</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss available to common shareholders &#x2013; diluted
(restated)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(28,718,893</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
average number of shares - basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,300,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,352,185</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
per share &#x2013; basic (restated)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(12.10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
per share &#x2013; diluted (restated)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(12.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-family: Times New Roman; font-size: 13px;">(1) See Note
17 Restatement<br></font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For the years ended
September 30, 2016 and 2015, the gain on derivatives is not
excluded from the numerator in calculating diluted loss per share
because the gain relates to derivative warrants that were priced
higher than the average market price during the
period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In accordance with
the contingently issuable shares guidance of FASB ASC Topic 260,
<font style="font-style: italic">Earnings Per Share</font>, the
calculation of diluted net loss per share excludes the following
dilutive securities because their inclusion would have been
anti-dilutive as of September 30:</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:13px;">2016</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:13px;">2015</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:13px;">2014</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Options and
Warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,675,281</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,336,842</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,599,788</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Convertible
Debt</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">74,851</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">11,041</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested Restricted
Stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">604,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">604,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">628,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">4,279,281</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">3,015,693</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">2,238,829</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><a name="#jump_exp_1">&#xA0;</a>&#xA0;&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-33</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">15.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
SEGMENT REPORTING</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">ASC 280,
&#x201C;<font style="font-style: italic">Disclosure about Segments
of an Enterprise and Related Information</font>&#x201D; establishes
standards for reporting information regarding operating segments in
annual financial statements and requires selected information for
those segments to be presented in interim financial reports issued
to stockholders. This topic also establishes standards for related
disclosures about products and services and geographic areas.
Operating segments are identified as components of an enterprise
about which separate discrete financial information is available
for evaluation by the chief operating decision maker, or
decision-making group, in making decisions how to allocate
resources and assess performance. The Company&#x2019;s chief
decision maker, as defined under this topic, is the Chief Executive
Officer. To date, the Company has viewed its operations as
principally one segment, the research and development of certain
drugs and vaccines. As a result, the financial information
disclosed herein materially represents all of the financial
information related to the Company&#x2019;s principal operating
segment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">16.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
QUARTERLY INFORMATION (UNAUDITED)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">The following
quarterly data are derived from the Company&#x2019;s restated
statement of operations. See Note 17 for information concerning the
Restatement of the Company&#x2019;s financial
statements.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Financial
Data</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Fiscal
2016 (restated)</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Three months ended December 31,
2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Three months ended March 31, 2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Three months ended June 30, 2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Three months ended September 30,
2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Year ended<br>
September 30, 2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Grant
and other income</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,976</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">32,775</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">129,975</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">101,329</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">285,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,327,509</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,829,779</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,036,123</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,738,472</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,931,883</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Non-operating
(expenses) income, net</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(483,693</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(464,796</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(464,202</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(466,699</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,879,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Gain
(loss) on derivatives</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,122,960</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,593,730</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,508,744</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,975,752</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
income (loss) available to common shareholders</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,332,734</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,855,530</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,861,606</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,128,090</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">EPS
(LPS) - basic and diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1.87</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(0.78</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(0.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
average shares:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,390,740</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,736,809</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,965,300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,371,635</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,465,591</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,736,809</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,965,300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,371,635</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">F-34</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">Fiscal
2015 (restated)</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; font-size: 13px; width: 100%; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 35%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Three months ended December 31,
2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Three months ended March 31, 2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Three months ended June 30, 2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Three months ended September 30,
2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">Year ended<br>
September 30, 2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Grant
and other income</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">136,838</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">197,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">389,223</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(66,304</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">657,377</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,655,979</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,480,363</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,114,099</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,797,084</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,047,525</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Non-operating
(expenses) income, net</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(490,812</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(494,156</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(497,040</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(482,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,964,221</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Gain
(loss) on derivatives</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,162,970</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,782,796</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,428,780</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,526,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">282,616</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on debt extinguishment</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(620,457</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss available to common shareholders</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(7,846,983</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(12,559,695</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,413,593</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,871,939</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LPS
- basic</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.68</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4.14</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1.32</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.54</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LPS
- diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3.42</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4.14</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1.62</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.54</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
average shares:</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,930,431</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,033,915</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,351,852</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,881,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,300,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diluted</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,930,431</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,033,915</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,405,364</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,881,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,300,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has experienced large swings in its quarterly gains and
losses caused by the changes in the fair value of warrants each
quarter. The results of the restatement did not impact loss
per share for any of the periods presented except for the effects
of the 1:25 reverse stock split.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">17.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
RESTATEMENT</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The Company has
restated its previously issued 2016, 2015 and 2014 financial
statements to correct an error in the way it accounted for a lease
entered into in October 2008. In <font style="color: #000000">October 2008, the Company entered into a lease
arrangement whereby the Company leased a building owned by a third
party, but to which the owner made tenant-directed improvements.
Upon commencement of the lease, the Company accounted for the
arrangement as an operating lease under ASC 840,</font>
<font style="font-style: italic; color: #000000">Accounting for
Leases</font><font style="color: #000000">, whereby the total
minimum lease payment obligations under the leases were recognized
as monthly rent expense on a straight-line basis over the term of
the lease. The cost of the tenant improvements incurred were
capitalized as deferred rent and amortized over the 20-year lease
term.</font></font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">However, in November 2017, the Company discovered
an error in the way it accounted for the lease for the building
since it was determined that, as the terms of the original lease
required the Company to be responsible for possible cost overruns,
(but of which there were none), the Company was deemed to be the
owner of the leased building for accounting purposes only under ASC
840-40-55. In addition to the costs it incurred and capitalized for
the tenant improvements, the Company should have reflected an asset
on its balance sheet for the costs paid by the lessor to purchase
and improve the building, as well as a corresponding liability.
Upon completion of the improvements, the Company did not meet the
&#x201C;sale-leaseback&#x201D; criteria under ASC 840-40-25,</font>
<font style="font-style: italic; color: #000000">Accounting for
Leases, Sale-Leaseback Transactions</font> <font style="color: #000000">due to the Company&#x2019;s significant continuing
involvement with the facility which is considered to be other than
a normal leaseback as defined in ASC 840-40-25 and therefore should
have treated the lease as a financing obligation and the asset and
corresponding liability should not be
derecognized.</font></font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
correction to the historical financial statements to apply ASC
840-40-25 do not affect the total cash payments the Company has
made or is obligated to make under the lease agreement, nor does it
change the total expense to be recognized over the lease term.
However, the timing and nature of expense is different under this
treatment as compared to operating lease treatment. Specifically,
the Company should have recognized depreciation, expense on the
building it is deemed to own and interest expense on the associated
lease financing obligation, instead of rental
expense.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Accordingly, the
historical financial statements in this report have been restated.
The accompanying financial statements for the three years in the
period ended September 30, 2016 have been restated to reflect the
correction of the error for the lease accounting. Accumulated
deficit at October 1, 2013, was reduced by
$326,827.<br></font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On June 12, 2017,
the Company&#x2019;s shareholders approved a reverse split of the
Company&#x2019;s common stock which became effective on the NYSE
American on June 15, 2017. On that date, every twenty five issued
and outstanding shares of the Company&#x2019;s common stock
automatically converted into one outstanding share. As a result of
the reverse stock split, the number of the Company&#x2019;s
outstanding shares of common stock decreased from 230,127,331
(pre-split) shares to 9,201,645 (post-split) shares. In addition,
by reducing the number of the Company&#x2019;s outstanding shares,
the Company&#x2019;s loss per share in all prior periods will
increase by a factor of twenty five. The reverse stock split
affected all stockholders of the Company&#x2019;s common stock
uniformly, and did not affect any stockholder&#x2019;s percentage of
ownership interest. The par value of the Company&#x2019;s stock
remained unchanged at $0.01 per share and the number of authorized
shares of common stock remained the same after the reverse stock
split.</font> </div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">As the par value
per share of the Company&#x2019;s common stock remained unchanged at
$0.01 per share, a total of $2,204,938 was reclassified from common
stock to additional paid-in capital. In connection with this
reverse stock split, the number of shares of common stock reserved
for issuance under the Company&#x2019;s incentive and non-qualified
stock option plans, as well as the shares of common stock
underlying outstanding stock options and warrants, were also
proportionately reduced while the exercise prices of such stock
options and warrants were proportionately increased. All references
to shares of common stock and per share data for all periods
presented in the accompanying financial statements and notes
thereto have been adjusted to reflect the reverse stock split on a
retroactive basis.</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;<font style="font-size: 13px">F-35</font></font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The following is a
summary of the restatements for 2016:</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:94%;font-size:11px;">9/30/2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">PREVIOUSLY REPORTED</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">ADJUSTMENT</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,887,646</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(429,821</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,457,825</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,710,601</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,717,699</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,428,300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,598,247</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,287,878</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,554,315</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,011,023</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,565,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stockholders'
deficit, September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(956,068</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">276,855</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:94%;font-size:11px;">9/30/2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Balance
Sheet</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">PREVIOUSLY REPORTED</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">ADJUSTMENT</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,833,183</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(487,793</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,345,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,614,420</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,593,892</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,208,312</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,447,603</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,106,099</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,553,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,532,722</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,783,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,315,972</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stockholders'
deficit, September 30, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(5,085,119</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">322,855</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:94%;font-size:11px;">YEAR ENDED 9/30/2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">PREVIOUSLY REPORTED</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">ADJUSTMENT</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,351,779</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,838,280</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,931,883</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(25,553,225</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(23,646,828</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
income (expense), net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">73,001</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,952,391</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,879,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,466,498</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(45,994</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share, basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.36</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:94%;font-size:11px;">YEAR ENDED 9/30/2015</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">PREVIOUSLY REPORTED</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">ADJUSTMENT</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,098,147</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,191,750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34,953,922</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,047,525</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,296,545</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,906,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(32,390,148</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
income (expense), net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(40,260</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,923,961</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,964,221</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,674,646</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(17,564</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share, basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(10.51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:94%;font-size:11px;">YEAR ENDED 9/30/2014</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:3%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">PREVIOUSLY REPORTED</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">ADJUSTMENT</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">RESTATED</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,172,587</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,398</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,266,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27,838,145</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,906,398</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,931,747</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,574,112</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,906,398</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(25,667,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
income (expense), net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(40,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,892,812</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,933,732</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,366,265</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,586</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share, basic</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.11</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share, diluted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.22</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(12.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <br>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-36</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-size: 13px; font-weight: bold;">Accumulated</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-size: 13px; font-weight: bold;">Total Stockholders'</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 13px; font-weight: bold;">Deficit</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 13px; font-weight: bold;">Equity (Deficit)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">PREVIOUSLY
REPORTED, OCTOBER 1, 2013</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(212,160,568</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,700,090</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ADJUSTMENT</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">326,827</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">326,827</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">RESTATED
BALANCE, OCTOBER 1, 2013</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(211,833,741</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,026,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2014
equity transactions - unchanged</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31,109,575</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss &#x2013; RESTATED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(27,352,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2014</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(239,186,420</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,783,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2015
equity transactions - unchanged</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,146,127</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss - RESTATED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,692,210</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(273,878,630</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2016
equity transactions - unchanged</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,595,549</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss - RESTATED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(285,391,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">18.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;SUBSEQUENT
EVENTS</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">In accordance with
ASC 855, &#x201C;<font style="font-style: italic">Subsequent
Events</font>&#x201D;, the Company has reviewed subsequent events
through the date of the filing.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">On December 8,
2016, the Company sold 1,360,960 shares of common
stock and warrants to purchase common stock at a price of
$3.13 in a public offering. The warrants consist of
68,480 Series CC warrants to purchase 680,480 shares
of common stock, 1,360,960 Series DD warrants to
purchase 1,360,960 shares of common stock and
1,360,960 Series EE warrants to purchase
1,360,960 shares of common stock. The Series CC
warrants are immediately exercisable, expire in five-years and have
an exercise price of $5.00 per share. The Series DD
warrants are immediately exercisable, expire in six-months and have
an exercise price of $4.50 per share. The Series EE
warrants are immediately exercisable, expire in nine-months and
have an exercise price of $4.50 per share. In
addition, the Company issued 68,048 Series FF warrants
to purchase 68,048 shares of common stock to the
placement agent. The FF warrants are exercisable at any time on or
after June 8, 2017 and expire on December 1, 2021 and have an
exercise price $3.91. The net proceeds to CEL-SCI from
this offering was approximately $3.8 million, excluding any future
proceeds that may be received from the exercise of the
warrants.</font> </div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">On December 9,
2016, the Company reported on a communication received from the
staff of the NYSE MKT, its current listing exchange, that it
considered the Company to be noncompliant with certain listing
requirements based on its quarterly report for the period ended
June 30, 2016. The Company has been given the opportunity to
maintain its listing by submitting a plan of compliance by January
9, 2017. This plan must advise of actions the company has taken or
will take to regain compliance with the continued listing standards
by June 11, 2018. The Company intends to submit such a plan by
January 9, 2017. The communication and compliance plan has no
current effect on the listing of the Company's shares on the
exchange. If the plan is not acceptable or the Company does not
make sufficient progress under the plan or reestablish compliance
by June 11, 2018, then staff of the exchange may initiate
proceedings for delisting from the NYSE MKT. The Company may then
appeal a staff determination to initiate such proceedings in
accordance with the exchange's Company Guide.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-37</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; page-break-after: always; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"> <font style="font-size: 13px; font-family: Times New Roman">In accordance with
Section 13 or 15(a) of the Securities Exchange Act of 1934, the
Registrant has caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized on the 11th day
of December 2017.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" style="width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>CEL-SCI CORPORATION</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:</font></div>
</td>
<td style="width: 35%; border-bottom: 2px solid black">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-size: 13px; font-family: Times New Roman">Geert
R. Kersten</font></div>
</td>
<td style="width: 12%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R. Kersten,
Chief Executive Officer<br></font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Pursuant to the
requirements of the Securities Act of l934, this Report has been
signed below by the following persons on behalf of the Registrant
and in the capacities and on the dates indicated.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Signature</font></div>
</td>
<td style="text-indent: 0px; width: 32%; margin-left: 12px; margin-right: 0px">
<div style="text-align: left; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Title</font></div>
</td>
<td style="text-indent: 0px; width: 19%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Date</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Geert R.
Kersten</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief Executive,
Principal</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R.
Kersten</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Accounting,
Principal Financial</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Officer and a
Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">December 11,
2017<br></font></font></div>
</div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/Peter R.
Young</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">December 11,
2017<br></font></font></div>
</div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Dr. Peter R.
Young</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Bruno
Baillavoine</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">December
11,
2017<br></font></font></div>
</div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 300px"><font style="font-size: 13px; font-family: Times New Roman"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-38</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENTS OF EXPERTS AND COUNSEL
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">EXHIBIT
23.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Consent of
Independent Registered Public Accounting Firm</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">CEL-SCI
Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Vienna,
Virginia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
hereby consent to the incorporation by reference in the
Registration Statements on Form S&#xAC;3 (File numbers 333-162039,
333-161504, 333-162792, 333-184094, 333-186103, 333-196243 and
333-205444) and Form S&#xAC;8 (File numbers 333-117088, 333-140792,
333-162265, 333-179477, 333-184092 333-198244, 333-206538 and
333-214031) of CEL-SCI Corporation of our reports dated December
14, 2016 except for the effect of the restatement
discussed in Note 17 and the material
weaknesses, which are as of December 11, 2017, relating to the
financial statements, and the effectiveness of CEL-SCI
Corporation's internal control over financial reporting, which
appear in this Form 10-K/A. <font style="color: rgb(0, 0, 0);">Our report on the effectiveness of internal
control over financial reporting expresses an adverse
opinion on the effectiveness of the Company&#x2019;s
internal control over financial reporting as of September 30,
2016.</font> Our report on the financial statements contains an
explanatory paragraph regarding the Company&#x2019;s ability to
continue as a going concern.</font> </div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/BDO USA,
LLP</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">McLean,
Virginia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">December
11, 2017</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: #000"><!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>cvm_ex31.htm</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold">Exhibit
31</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CERTIFICATIONS</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I, Geert Kersten,
of CEL-SCI Corporation, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;I
have reviewed this annual report on Form 10-K/A of
CEL-SCI Corporation;</font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the
period covered by this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such
evaluation;&#xA0;&#xA0;and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of the internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">December
11, 2017</font></div>
</td>
<td style="width: 3%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:</font></div>
</td>
<td style="width: 35%; border-bottom: 2px solid black">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/&#xA0;Geert R.
Kersten</font></div>
</td>
<td style="width: 12%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R.
Kersten</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Principal Executive
Officer</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CERTIFICATIONS</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I, Geert Kersten,
of CEL-SCI Corporation, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;I
have reviewed this annual report on Form 10-K/A of
CEL-SCI Corporation;</font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the
period covered by this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such
evaluation;&#xA0;&#xA0;and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of the internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">December
11, 2017</font></div>
</td>
<td style="width: 3%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:</font></div>
</td>
<td style="width: 35%; border-bottom: 2px solid black">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Geert R.
Kersten</font></div>
</td>
<td style="width: 12%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R.
Kersten</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Principal Financial
Officer</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000"><!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>cvm_ex32.htm</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold">Exhibit
32</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"> <font style="font-size: 13px; font-family: Times New Roman">In connection with
the Annual Report of CEL-SCI Corporation (the
&#x201C;Company&#x201D;) on Form 10-K/A for the period
ending September 30, 2016 as filed with the Securities and Exchange
Commission (the &#x201C;Report&#x201D;), Geert Kersten, the Chief
Executive and Principal Financial Officer of the Company,
certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best
of his knowledge:</font> </div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: right; display: table-cell; width: 96px">
<font><font style="font-size: 13px; font-family: Times New Roman">(1)&#xA0;&#xA0;</font></font></div>
<div style="text-align: justify; display: table-cell"><font><font style="font-size: 13px; font-family: Times New Roman">The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</font></font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; display: table">
<div style="text-align: left; display: table-row">
<div style="text-align: right; display: table-cell; width: 96px">
<font><font style="font-size: 13px; font-family: Times New Roman">(2)&#xA0;&#xA0;</font></font></div>
<div style="text-align: justify; display: table-cell"><font><font style="font-size: 13px; font-family: Times New Roman">The information
contained in the Report fairly presents, in all material respects
the financial condition and results of the
Company.</font></font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">December
11, 2017</font></div>
</td>
<td style="width: 3%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:</font></div>
</td>
<td style="width: 35%; border-bottom: 2px solid black">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Geert R.
Kersten</font></div>
</td>
<td style="width: 12%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert Kersten,
Chief Executive and Principal</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Financial and
Accounting Officer</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><br>
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cvm_10k000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10k000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MQ6CI/^ME^@K*LER,Z,,Y.HKFM2TE+7">L%%%% !1110 4444 %%%% !1110
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M*&*G][R"#]*L_P!H:A_T#/\ R-_]:LSI-2BLO^T-0_Z!G_D7_P"M1_:&H?\
M0,_\B_\ UJ -2BLO^T-0_P"@9_Y&_P#K4OV_4/\ H&_^1O\ ZU &G169]OU#
M_H&?^1?_ *U'V_4/^@9_Y%_^M0!IT5E_VA?_ /0,/_?W_P"M2_VA?_\ 0,/_
M ']_^M0!IT5F?;]0_P"@9_Y&_P#K4?;[_P#Z!O\ Y%_^M0!IT5F?;]0_Z!G_
M )%_^M1]OU#_ *!G_D;_ .M0!IT5F?;]0_Z!G_D;_P"M2?VA?_\ 0,/_ ']_
M^M0!J45E_P!H7_\ T##_ -_?_K4?VAJ'_0,/_?W_ .M0!J45F?;]0_Z!A_[^
M_P#UJ/M^H?\ 0-_\B_\ UJ -.BLS[??_ /0-_P#(O_UJ/M^H?] S_P C?_6H
M TZ*S/M^H?\ 0,_\C?\ UJ/M^H?] S_R-_\ 6H TZ*S/[0U#OIG_ )&_^M2?
MVA?_ /0,/_?W_P"M0!J45F?VA?\ _0,/_?W_ .M1]OU#_H&'_O[_ /6H TZ*
MS/M^H?\ 0,_\B_\ UJ3[?J'_ $#/_(O_ -:@#4HK,^WZA_T#/_(W_P!:C^T-
M0_Z!G_D;_P"M0!IT5E_VAJ'_ $#/_(W_ -:JP\21PZK%87\!MFF7Y'+Y7.>
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M5_\ OHT?:)O^>K_]]5'10!)]HF_YZO\ G1Y\W_/5_P#OJHZ* )/M$W_/5_\
MOJJ=]:I?Q,DWS$CJ>M6*JWU]#86[2RL  * -3PYXAD@E32=4?Y_NV\['[X[*
MQ]?YUV->9>&O#]SXEO$U?4P\>FHVZW@)P9CV8_[/\Z]-H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N.U;5=7A\4?8[2YMUBW1%(WC.2#',6)P<D91
M?3!Q^/8TF%SD@9]<4 <EH?BN[U?6$MFL$AMVCW M*@<?(K!@N_<0<X^Z/7)K
M/'BK5K"S7SHHIS+(_ER\+Y:B:1?GW,JG@*!RO)[]^\"J&R% .,9Q1L4\;1CZ
M4 <)-XZNXKBW3[) WFQ9DC5P3&WE[\[@WS+[A2,?Q9XJ_;>(;B/0M0OYKJVG
M9+UH8I(US$1\H&.0._=@/5@*ZS8N<[1GUQ1Y:[=NT;?3'% '"6_C;49=-%^;
M"%HP ODH3O9S&[\$$C&4QWZ]>.;]MKU[_9>JW2SVEY)%J$5O"T8/E;6$*Y')
M/!=CU/-=;M7^Z/RI-B@8"@#TQ0!Q)\9:DEXD']FI-MWB3;(B&0K)(AV!GW?\
MLP<!6^]C/JK^*;U=4TU%FLYK>X0B:: YB@):/&[G.?FV]<98$XZ5VNQ<@[1D
M=#B@(@& J_E0 HI:** "BBB@ HHHH **** "BBB@ HHHH **** ."_X1'78]
MRPWMDB;B0"K$\FE_X13Q#_T$+/\ [Y;_  KO** .#_X13Q#_ -!"S_[X;_"D
M_P"$3\0_]!"S_P"^6_PKO:* ."_X1/Q#_P!!"S_[Y;_"C_A$_$/_ $$+/_OE
MJ[VB@#@_^$3\0?\ 00L_^^&_PI/^$3\0_P#01L_^^&KO<T4 <%_PB?B+MJ%G
M_P!\M_A2?\(GXC_Z"%E_WRW^%=]10!P(\)^(O^@C9_\ ?+?X4O\ PB?B'_H(
MV?\ WPU=[10!P1\)^(>VH6?_ 'RW^%'_  B?B+_H(67_ 'RW^%=[10!P7_")
M^(O^@A9?]\M_A2_\(GXA_P"@A9_]\-7>44 <'_PB?B'_ *"%G_WPU)_PB?B+
M/_(1L_\ OAJ[VB@#@O\ A$_$7_01L_\ OAJ7_A$_$/\ T$;/_OAJ[RB@#@_^
M$4\1?]!"R_[X:C_A$_$/_00L_P#OAJ[RB@#@O^$3\0]M1LO^^&H_X1/Q%_T$
M;/\ [X:N]HH X+_A$_$/_01L_P#OEO\ "E_X1/Q#_P!!&S_[X:N\HH X(^$_
M$6/^0A9?]\M1_P (GXB_Z"%E_P!\-7>T4 <%_P (GXB_Z"%E_P!\-2_\(GXA
M_P"@C9_]\-7>44 <%_PB?B+_ *"-G_WPU'_")^(O^@A9?]\-7>T4 <%_PB?B
M+_H(V?\ WPU%MX#NKK4XIM;NH;BUB&1!&" [?[6>U=[10 BJ$4*H 4#  [4M
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R.OZWJUC<ZRMDL+16M
ME%,K.^TQLQDR0-IW?='!(Z>]==7-:FF@R:N\-X]X+J0(K^7+<+& Q(0,5.P9
M((&>_P!: ,LZMXAD;4+FT:5X;.>?>'BCV,D;C")CYBQ4,#FMK2=8N-15;R.2
MV>RN[MDMMTFUC"J'E1@[R61CC(^4Y[8.,UUX9B=8HQK+.]P(&C62\#*S*S!B
MN<D'8W.,5>T^_P##VGO;V\,KB25P(U9YIEC.YHUY?(CR=RCIGH,T )X@\0W.
MGZS:Q6[.+:W"RWVV!GRKMM + $+@;WR2/NCUIK^,+B-9&DL[=5(E\@F=CO*3
M"+!PG!.01C/I[U8;Q;HK0K-$D\ZSM$AV6<A+B3(5L%<LO!Y&?2M"RO=+U4SP
M6\0E2(M&^ZW8(3G# $C#<CG&>10!F:!KT^LZJ2Z>2HMCNA#A@'69T)S_ ,!J
M >.5^W_8WLRC^8\ <N=OF1DF5<[?X4 8'ODCM5[3=7BDNK>&.QCABNA.;=X\
M<QQE1DC'&2Q('IBFZ?XFTF_CLSY;13W*)*$,+%4,BY +@;02,CKS0!3TWQA>
M:E/';1Z? L[S"/)G.S:8C)N'RY[8P0/Z4VS\67_V;3&O+:US=-MDECE8K'EM
MH!4*2">>O'O6E9ZUH4=JLL1@@7*YV0E0"T?F9'RCC9D[L8ZU%%K?AR62.2*-
M3,96V@63B16P"6QMRO!!W'''>@";4M:N;/5?L=O DKLL.T22[5R[NN>%)XVY
MJ"ZU^ZF\)PZG:1I'<O<Q0F-FRN?/6-AG'0\\X[]*6X\5:2EB=15)98@C."+:
M0.X0;LH"OS#GJ.*O6^K:9<;8$RK&81B%X&1@Y7S!\I (XYS_ %H PO[7U>74
M(X)KA+-VU1K4QQ%9!L^S[P,L@)^;!Z#KBF0^)=0N[*<(X%Q;Q+9R*%'-ZS[/
M3H,;OHWM6QJ.KZ-:7$JSQB2YMP9!BW9L.$W8#!2 Y4=,YQ4*:C%+I>FWTFGJ
M;RZF#00JI3]X5;D[@#PFXDD=!QGB@#._MK68+N2#]T]M'J\5GY[.-Y0HA(V[
M><DGG.>:IZ7XBUM=#T[7-0F<Z:T<$EV\\<:GYPP8IM_@!,9YYZ]:Z=]6M;62
M&'4K8VT\\H"A8VDC+E@JG>%P"20!NP:RI/%,!L+.!+*(O<R)#Y&UV6-6$G)
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M0312KYI:,J0"W'RB0#/'_35OTK;HH Q+7PQ9VLD3^=<RM"4\HR.#Y:)NVH,
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MX1_2/^@;:_\ ?L4?\(_H_P#T#+7_ +]B@#A_[8L/^?A/^^A1_;-C_P _$?\
MWT*[C_A'](_Z!MK_ -^Q2?\ "/:/_P! VU_[]B@#B/[8L?\ GXC_ .^J3^V;
M'_GXC_[Z%=Q_PCVC_P#0-M?^_8H_X1[1_P#H&6O_ '[% '$?VS8?\_"?]]4?
MVQ8_\_"?]]5W'_"/Z/\ ] VU_P"_8H_X1_1_^@;:_P#?L4 <-_;-A_S\1_\
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M_P#0/NOR'^-']K/_ - Z[_(?XU@?VA=_\_$GYT?VA=_\_#_G0!O_ -K/_P!
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M67</KTNQTGVF'_GJGYT?:8?^>J?G7-XHQ1]67</KTNQTGVF'_GJGYT?:8?\
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M$##S<B1(MV V4Z$MR.^ .A.98/#-P-?35;B=3*I8[E8$C<FP@97IQD#. <T
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MK4F*6B@ HHHH Y?2]:OM2A9_M-M$RL5*LOH>U7_/O_\ G^L_R_\ KUQ^E_\
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M$=9$5T8,K#((.010 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!/\ MFI/[5L_^>Z?]]5V4OAK1II6EDTZ!G<EF8CDD\TW_A%=#_Z!=O\ ]\T
M<?\ VI9_\]T_[ZH_M6R_Y[I_WU78?\(KH7_0+M_^^:3_ (130O\ H%V__?-
M'(?VK9?\]T_.C^U;/_GNG_?5=?\ \(IH7_0+M_\ OFC_ (130O\ H%V__?-
M'(?VK9_\]T_[ZJ.?6;.*!I/.4[1G@UV?_"*:%_T"[?\ [YH/A/02,'2K8_\
M : .(\.>'9_%-XNJZJC)IB-F" \><<_>/^S_ #KT]5"*%4 *!@ #I0J*B!54
M*H&  .!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>cvm_10k001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10k001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  @&!@<&
M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q
M-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %'
M B8# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T
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M9@UE;;46F2W1&=MP()P.@/\ @:]*Q3)((YAB1 P'J*Q5"*=T<T<#3C-2BVC
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MJ?S-6I/#4#RW#),\:S-;$( ,((&W*!]>AH D/BG2O+C823,S^9^[6WD9QY9
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MZ2NEQW!,\EQ/<3----( &<G@#CL   /04 :-%%% "5X)KY!\0:B0, W+X'_
MC7NE[<K9V4UR_P!V)"Y_ 5\^32F:>25NKL6/XUYF8RTBC"MT1T'@7_D;[+_@
M7_H)KVJO*/AMISSZS)?L/W5NA /^T?\ ZV:]7K; *U(JDO=%HHHKM-0HHHH
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M(CSR.S94!D&6!SCYAGI[UW-&.: ,_0+2:P\/Z=:7'^NAMHXWP<\A1FM&C%%
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M"I\S8^@YK+TS2+/6+._BO(RZK?RE<,1@\>E;FGZ/9:9;I%;P(-@QO*C<?J:
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MX8T:[OBRJ%)6X8 X]L\4_P#X16R_Y^K_ /\  IJ]$Y3=HK"_X16R_P"?J_\
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MZTFADC\F^F$9=2-R$Y!'J.:Z<5%-MP5S.BVX)O<****LT"BBDS0 M%)FC/-
M!@4UT1QAU4CW%.S36/% '+:MX\\-:3J1TZ[O<3@[7"(2$^I'2MA+&"[BCF2X
MD>)E#(RL,$'H<XYKR#Q-\,->N?%%U<6,:7%K=3&42M(!Y>3DA@>>,]LU[!X?
MTUM&T&RTYI/,:WB"%_4UA1G/G=U8]/'8;"4Z-.5&?,WNAPTPQG=#<2*Y[G!S
M3XC>QRJLJK(AZLIQBKU(:ZG-O<\A4TMB-9E.-V5/HPQ4N1ZU62]M9;AK>.XB
M>9?O1AP6'X5(L*+)O4;3C& >/RJ$:M-;F#XF\.IX@NM,\Y(9+>WG+31R?QH5
M(('OTJ2WLM"\&Z;*]M!%:0D_,%!+.>P]2:J:]XA;2O$MA;&14M?(EGN05R2!
M@*!]2:XW5=:EO[C[=>9S_P NUN3Q&/4^]8^ZI.2W.*OCO81E&+W>W0N:SKLV
MHGS+YGAL^L5HIP7]VKF[O4I;D"-<10C[L:]*K3323R&21BS&H_P-)Z[GA3G*
MI+FEJPHH_"B@D****!!1110 5'/&)864]Q4E!Z4#/0OA7K;WVAS:5.^Z;3G"
M*3U,;<K^6"/P%=_7CGPHD*^,=6B7[KVJLWX-Q_,UZU=WMM8P&:ZE2*,=V.*V
MB]#Z7#R<J2;,OPS_ *G4?^OZ7^E;M<C92:M!X?GN=.LO,FN[B29%<@%%/0X/
M4\59L8_$]U8PM-=6]J2N&!A)DR/7/%,V.EJ.6>&%=TLJ(H[LP%8W_"/W%P/]
M-UJ^E]5B81#]*DB\*Z/&VYK7SF]9G+_SH MP:QI]U<_9[>[BEEP3M1L]*O5!
M!9V]L,0011#_ &$ J?M0!X1X@O\ 6](^)GBC7=/FFGL],2!;NR#$AH)(\,RC
M/!4@&DT3Q?KMCX.\':3IK2^=J,,\CW1V/(2CMA!YK!<^N3G'2O:O[,TY)[JX
M^QVPENE"W$GEC,H P Q_B&/6JS^'=$FTR/39-)L7L(SF.V,"F-?HN,"E=7L!
MP.G^-O$7]H^$[357MH'NKNYMK[848.8U!3D$A6YY /6N<\0^(-;US28;@ZN8
M%MO%OV)'AC4#RP?E)/?'/!X.>:]AE\.:&^G16$NDV#6<+;XX&MTV(WJ!C -'
M_".Z')I\MB=)L#9S2>;) +==CO\ WB,8)]Z+K8#C;#6O$4WCS5-%.KI+:Z99
MP7!VVJ;K@D989'W<^V?:LC0?'OB&ZN_#-]<WMK<0:[=RV[Z='" UJ%)PP;J<
M8YSZUZ?9Z-I>FS--9V%K;2&-8B\404E%Z+QV%1V^@:-;7[ZA;:7917DF=UQ'
M H<YZ_,!FBZO8#RW0O'GB:9_#=Y<ZE;W4>J:G-8R60MU5E16(\P,.>.,]JSO
M"^N:SX>T;3KJVO8FL;OQ)+92VC0 DAG.6WYSGCBO3/"G@/1_"=JHCAAN+Q7D
M;[;)"HEPS$XW=<#-:Z:#HWD1P+IEEY,<_P!H1!"NU9<YW@8P&]^M%]0/%]>E
MW^'?&0$:1E/$T"Y0$;OG7D^_-=-!XUU]?B"MGJ4[6^F7%^UM9""V2:"91Q@R
M!MZOP<\8&.17HKZ!I$D<\;Z99NEQ*)YE:%2))!R'88Y;@<TV+P[HMOJ3:G#I
M-E'?,26N4@42$GK\V,TP-/%)@5GWVM66GG;-)F3^XHR:SD\7V+/@Q3*/7 /]
M:XZF.PU.7+.:3-X8:M-7C%V.B%+5:TO8+V/S+>0.O?':K%=4)1DKQ=T8M.+L
MQ:*3-+5""BBB@ KRGQUJ377BG[,#^[LH@ /]MN<_EBO5:\.UUR_C'6MW!$^/
MP XKLP*3JG-BF^0J4445[!Y@FD:@^A>.-)OXR1'<2"VG Z%6X_0X/X5[X,=Z
M^;M?8I!:NOWEN4*_7(KU#XSRS1?#"]>&62&0S0#?&Q!&9%[BO'QL4JEST\*V
MX';7NE:=J4MM+>V=O</;/YD#2H&\MO[PST-7.*^?+/6]6L_%7A+P?J\TYOM,
MU-0LX9@+JV9?D8\\XZ?A6]/\4_$ @O?$4%GIY\/6>I_V>UJY;[2_;?GH.O3%
M<9TGLK%57<Q  [DU5@T[3X+VXO[>U@2ZN@OG3H@#2XZ9/?%>.^-_%NO>(M/\
M9V&G1V,&CZ1#Y5SY^XSRDYY3' QCO5JY\>:Q81Z)X<T**!+B/1H+N6>>VFGW
M90814B!(/?)XH ]BXI1CM7D&K_$GQ3%H&BWL>BC3!<A_MUS=VTLL=LRMMP57
MY@#UR?6O1_"NJOK?AFQU&2>UGDGCRTEJ6\MCDC*[N1TZ'I0!L4444 %%%% &
M/>:TEAK=CI\\#+'>!@EQGY0X_A^I%:XZ5FZSHMOK=FEO<%T\N198Y(SAD93D
M$&KD=Q"97@$R-+&!O4-DKGID5*YKNY"YE)WVZ$]%)FEJBPK(\4RO;^%-7FC=
MHY([.5E=&P5(4\@^M:]073PQ6TLMP5$"(6D+]-H'.?;% 'FXO_$5@;*YN99<
MVEE<10*SEENRL6\2L ?F_A'/.0WK6CJ7B!]1N+:".XB:..XTZ0F%OXI';()!
MZ<#BNDBUW36L[6XOI(+)ITWQ17$BAMAX!]LC'YXJ83Z/;70L0]E%.1O$(VAN
M.<X_,T <M8W5Z+&P%QJ0N'?59HV7)1HP//P&PW/08!XZ5CZ'XAN[KPG8Q2,8
M##)8QK%(S++*K2J#-N!&4.2 /8Y]!V,_B+0;3S;E#!*@@DNI)X=C#" 9R<\M
MAQCZUH17FCW$"W$<UFT4<8<,"N$3/!SV&1^8H Y9O%6KVL?VN5+>ZCE6^\NW
MBC*L# 6V\Y.<@8/Z5J>$]:U+5'N5O5C9%CCDCD78I.[.1M5WX&!@YYS[5I2Z
MSH=K.T<M_8QR1%B5,B@IZ_3KS3X[S1K)X4CGLH'N\-&%*J9<]"/6@#4K.UV.
M\ET.]CL&*W;0.(2.S8XILGB'2(0_F:E:+Y;['S,ORMSP>>O!X]C5>[\10PSW
M$4-O)<F&S%X#$0=Z%B/EYY/!-)JZL5&7+)2['@7AC2O$'_"96B06UU'=Q7"F
M9F4C:,_,6/I_.OI7<5&2?K4=O-#=6T5S"P:*5 ZL.X(R#7/>/KZZL?"=R]G(
ML<LA6+<>H#'!Q[XK&G3]C%]3LS3,WB[5)1MRKH<5XEU6RUGQ"]["J/#:IY*R
M _ZPYS^0-<_-,\\ID<\G]*:$6WMX[=.B#GW--I+75GQ%2HZDG-]0KHO"OV"[
MU&WTZ[TR&<RLV9F9MP&,]!QVKG:T="U&/2M9M[V5&=(B257J<@BJ6Y5&2C43
M>QK/8VNL^(6T>SLX+'RY9!YR98L%SU!/M6?'H3/H]_J'V@!;.7RRFW[W(&<]
MNM.L-<6Q\4-JRQ%HVE=BA(SM;/ZU<N=?TS^Q-1T^RM+F/[7()-\C@C.03].E
M/0W7LI)M^?\ P"<>"@;N*T_M6+[3+#YT<9B/(]SG_/I5"Y\-F+2OMUO>Q76V
M802(B$;7)Q@$]>3Z5H#Q9:_\)#::C]GF\N&U\@KQDGU^E9\>NI%H=S9)&XFD
MO!<H_&T8(.#^5'NE2^KEMO!C^:]HFI0-J*1>:;;8>G^]52/P[$-%MM3N]22V
MCG8KM,18@@GCCZ5IGQ=8B\DU2.PF&IR0^429!Y8]_6LB\UF.Y\-6>F>6XE@E
M:1G.-ISGI^=#L*2H*[7]=C&.,G!R,\'UIKG:C'T%.K/U6Y:&VV1@M*YVJH&2
M2>@J3DBG)V1W/P>L6DN]:U9ONLR6R>^,L?YBO3;_ $ZTU.W,%W"LJ'IGJ#ZC
MT-8_@GP__P (YX6M;%SF=AYLY]7;DC\.!^%='6RV/IJ4.2"B8GAB61M,D@E<
MN;6=X YZD+T_2MNN.MHM5ETS4O[*N$BF%]+E64'=TZ'L:N6+^)K2RA6:UMKH
MA1G]\5?\<\9IFATM%87]OW,/_'UHM]&>YC D'Z5:L-=L=1G\B%I%F )*21LI
MX^M &G3<FH[HS+;2-;J'F"G8I. 36%X.N+ZXT8M>_,1*P1]V2>>?US0!E^)4
MU$W[,WF&WX\O;G'X^]3^%$U!;ABX<6I!SOZ9]JJZKX^NAXFN]!\/^'IM9NK&
M,/=L)UA2+/(7)!R?:J]]\0=4AUNQT?3?"LUU>7.GB^:&6Z6%XAG!4@@\CZUY
M$<JMBOK'.][V.]XZ]#V/*O4N^)UU$WI)$AM\#9MZ?C3_  LFH+>$D2"U*G=O
MZ9[8J30O'NFZOH.H:E=12Z<VFNT=];W/WH7';WST&.IXI/ _C4^,5U0MI<VG
MM8W/D&.9LN>,Y(Q\I]N:%E5L5]8YWWM_707UW]Q['E7J,\4+J!NP1O-J -NW
MIGWIGA=-1%_G$@ML'?OSCVQ[UT.NZU:^']*?4;U9&@1T0B-<G+,%'ZD5H@<<
M#K1_97^U?6.=][?UT#Z\_8>QY5ZG)^*TU!KA"@<VH7C9TSWS5'P^FH_VC&T(
MD$6?WA;[N*IZM\1/$.F>)K;0CX,,ES>-(;0_VD@\U4ZM]WY>.<$UV=_K,6C>
M&I=8U2(VRP0>;/$K!BAQ]T$=3GBIJ93SXGZQSOO8<,=RT?9<J]35!I'SY;;>
MN.*XSPWXSU?6Y[22[\*W.GZ9>(TD%X]PK@  D%U RN0.*U8?&6@W_P!I@TW5
M+6ZNH87E$2ORP4<D>H]Q7L-71P(XV\$PO)1<9\W<=V?6H*=9^+SXC_X0PWFF
M6R-KRW!E=&8&+R\XV^N<=ZW;%O!U[JBZ?;:O'<7;,56)9?O$=0"!@D8[5\?7
MR#$>T;@TTSZ"EFM)02DFF+X2%Q_:+%,^5L._T]JZ#7],O=4LC#9W[6K=P!P_
MU(Y%:5M:06<0C@C5%'H.M35]%EV$>$H*FW=GD8NNJ]5S2L<_;:+JT=K%&==F
M4J@!41(0,#UQS4O]D:M_T'Y_^_*5N45WG,8?]D:M_P!!^?\ [\I6Q CQVZ))
M(975<,Y&"Q]>*DHH 0UXKXPMFL?'E\K+A+I%F0^O&#^H->UUQ7Q"\.2:M817
M]FF;RSRP '+IW'O71AJGLZB;,JT.>%CS>BHXI1(OHPZJ>H-$\\=O$TLK!549
M.:]RZM<\FSO8J36S:KXCT328P6:>Z5G ZA <D_D#7N_B#0-/\3:1)I>IQM):
MR,K,J.5.5((Y'N*\[^%OAR>ZU&;Q5?Q-&K*8K%'&/E/5_P"@_&O6:\/%5.>I
M='J8>'+ P-1\':+JFMZ7J]U:LU]IG_'M*LA7'H#C[P^OOZUG3_#+PK<ZZVKR
MZ:3<-,)WC\UO):0?Q&/.TG\*["BN<W.,UGX7^%M>U*XU"]LI?/N0!/Y-P\:R
M8Z%E4X)JSJOP\\.ZQ#8I=6LBO90K!!-!,\<@C P%+*02/K7544 <9=_"_P ,
M7EG:VKV]VD=LC1J8[N16968L=QS\W))Y]:ZC3--M-'TV#3["!(+6!=D<:C@#
M_/>K=% !1110 4444 )7-ZWH5TVJ0ZSHLB0ZBF$E5^(YX\\AO<=C72TE3**D
MK,F45)68U3C )&XT^L/7=!?4WBN[.]FLM0MP?*F0Y4@_PLO0@XJU8W-U!I*S
M:T;:"=%)F:-_W8YZY-";O9H2D[V:-*J.LV)U/1KVQ5@IN('B#'H"P(JS%-'-
M&)(I%D1AD,I!!J6J+.#N-.U?5KN$I8) )])>SN'N<@0L6 .T#.[N1R >.:>O
M@FX@U!BLYN+5IQ<AI;B0%'"A1\@&&Z<'(Z]#7<T4 <<OA"X%E86WVB)!;Z/+
MI[E5/WW"?,/;Y3^=.U/0M:U%)F'V"*2[L?L<P+.RQX9B&7@9SN/!QCCK77T4
M <M'X8E6\AN&> ^7J,MX3MYVO$4 ^N2/RK-C\%ZC#I[6*7%LT=U;16]Q*P.Z
M(1DD&,=^O0D8//-=W10!QY\,:C!IT-O;W$)"W\]S-'O:,2J[,0"RC<"-P^N*
M;8Z%>^'K7[2 MY+#IHM4AA!R\@=B.O0?,.3Z5U^X9P3R>@KGM8N=>NKXZ9I%
ML+=-H,NH38VH#_<7NWUJ9245<F4E%!/+?>'O"]C:6=H]Y?"-+=%0?*'QC+'L
MHQ7(>,HKW3=!TRRO[U[NYGN6FF=N@('11V W<5Z7:Q/!:Q123--(BA6D88+$
M#J:X/XJV[_8],O%^Y%,R-_P(<?RI.-_>9S8F+=.4O(X,G)S24@.1FEK,^?"B
MBB@04444#"BBB@ HHIKR+&A9B !0 DLJPQEV(  K=^''AI]<UC_A(;V,_8K5
MO]$4_P#+20?Q?0?S^E9GAGPQ>>-+T.X>'1HF_>2]#+_LK_CVKW.VMH;*VCMK
M>-(H8U"HBC  %:1B>O@L+;WY$PZ4M-WKTR/SI&D1!EF"_4U9ZARVAZSI]E)?
MVUU=)#*U[(5#\9&?6NK&,<5Q,.GZ=-KDUEJ2DR?:6GM74_+(&QQD>A'2NF%Q
M<6<Q%U^\A8N_G*H584'(#<_K0!HTF!G..:;'*DL:R1L&1AE6'0BGT (:PO"(
M_P"*?3_KM+_Z&:WJB2)(DVQHJKG.%&!0!YY=>%_%.@^,]6UOPL^G7$&KA&N+
M>^9E\N11@,I4<CVJ'4O#OC2+QAI_B33UTFZNH]+%G<">1HU,A8LQ4 9QTKH=
M3\4RV]Y)!;Q+B,[2S@\GZ5?T+76U1GBEB"2J-V5Z$5Y\,SPTZWL(OWCJE@ZT
M:?M&M#C[3X7W5UHMTNK:S)#JM_J2ZE<RV2#8KKG:@#=0"<\]Q5[X?^"M6\+:
MSKUUJ.K2WD5[<%XPS ^9_P!-'X&'[<<5K:MXHDM;Q[:VB7Y#AF<=_I4VA^(G
MU"Y^RSQ@.02K)T.*4<UPLJWL5+78;P594_:VT,;XA?#NU\6VTES"K_VH?*1&
M:Z=(]BN"<J#C.,\XKI] \/V'AO3C9:<LJPES(1+,TIR0,\L2>W2J.M^(GT^Z
M^S01AG RS/T%-T7Q(]]=BUN(@&;.UE_K3_M3#>W]A?WMO+[Q?4JWL_:VT*6O
M>&+_ %+XC^&M>@,/V/38YEG#/ALNN!@8YK9\5:"GB?POJ&C/*8A=Q; ^,[3P
M0?S JOKGB%M-G%M#$#)C+,W05#HWB:2]O%MKB)07X5E]?I1+-,-&M[!RU!8.
MLZ7M;:&#IFA>.9]&_P"$>UB;2HM-6RDM3<VQ<S290HAP< 8X)^E9GAGX=ZKI
M=Q8B]L;5I+"VFMX[W^TII,AD*C9$1M0'//)Z<=J]8%([;49CV&:[V[*YRGEF
MC?#_ %G3X_! F:T_XDD=TMU^\)!\S.W;QSUYZ5'X3\#Z[H_B>RG6XALM*@:1
MY;..^:XB=CT\M&0&/DDYR3SC-:FIZU=W]R^)&2'.%0'''O6:KNK;E8@^H-?.
M5N(H1FXPA=>I[%/*92C>4K,]7S17(^&M8N9[@V<[F3(RC'J/:M_4=6L=)A\R
M\G6,'HO4M]!7LX/%PQ5+VD#S:]"5"?)(OT5F1>(-)EB207\"[E#;6< CZT_^
MW-*_Z"-M_P!_!768FA15*+6--FE6.*^@=V.%57!)J[0 4AQ2UGZQJUOH]A)=
MW!.U>%4=6/8"FDV[(3:2NS&UGP-I&JS-. UK,>6>+@'ZBLVQ^%^BQ7:W%[-/
MJ 0Y6.5L1CZ@=:Y#Q'XS96!U&261WY2TA;:D8]SW-9NG>([H#[;H]S+ ZGF)
MF)5O8@UV*#_A<_O=C-TJBIK$.F^1]3WE$2-%1%"JHP !@ 4^N;\'^*X/%&G-
M)M$5[ =EQ!G[I]1[&NDKC::=F:)W5T%%%%(84444 %%%% !1110 4444 %%%
M% "8!IDUO#<0O#-&LD;C:RL,@CT-244 8%AX5L])U$76G37%M"<[[1),PL2.
MNT]/PI=6U76-.O1]FT5KZRV L\4P$@/<;3UK=HQSFH<-+1T,_9I*T="CI^IB
M^T[[8UO/;+SN2X3:ZXZY%4K;Q?H%W(L<.K6S2,0H4M@DGM@UMXXQBJK:78O(
MLC65N9%.58Q#(/UQ0U/2PVIZ68MYJ-II\2R7ES% C' :1PH)].:AL=;TW4Y'
MCL;Z"X:, L(G#;0?I4]W8VU]&$NH(IE!R!(@;!]>:Y]TDTN9HX$CA![QH%W#
M\*SJU)4W?H7&,Y2TM8GU#Q7'9WTEE!INHWEQ'P1! =O_ 'T<"M%S>W^C9B+:
M?>2QY&]0YA;W'0XK&_M&ZS_KFK2TS43*?)F;YS]UCWK.%=2E9C=":NY/0K:3
MX86QO1J%[?W>H7P4JLLSX5 >H51P*W\>E+VHKIC%15D1&*BK(Y?QEXTM?"%G
M%)+$T\\Q(BA4XSCJ2?2LRRU:R^)OA"]ACB:"XC(!C8YV2=5(/<'_ !J[XZ\#
MIXPM( MP+>YMR?+<KD$'&01^ J3P/X,3PAI\T1N//N+APTK@8''0 ?G6?[SV
MG]T]*4<$\#_T]N>11^;;SR6=RACN(F*LK=014]>H>+O \'B!?M5JPM]00</C
MA_8UY;>VNI:++Y.IV<D6#@2!<J?QIN-CY#$825.5UL.HJ..>*091P?H:DR/4
M5)QV"BBFM(BC+,!]30"38ZBJWVQ9)!%;I)<2MP$B4L370Z;X$\1ZN0;A4TRV
M/5I.9"/9?\::39O3PU2;LD<[<7L=OA<EI#PJ*,DUU7AKX=7NM/'?>(0]M9\,
MEF#AW_WO0>W7Z5W/AWP+HWA\K-%$;B\QS<3_ #-^'85T]6HGJX?!1AK+5D-I
M:P6=K';6T2Q0QC:B(,!13;N(SVLD89E8@[2IP0?K6'XT\51^$M%^VM%YTLC^
M7%'G&YL9Y/IQ65X"\?\ _"72W%M/:"WN85#_ "-E67./S']:/:Q4^7J>Q'!5
MI4'7C'W$<1?76I07LUO/>7)>-RIS(W^-00S233HD]W*D;, SEB=H[G%=3X_T
MGR-5AO(U^6X&T@?WA_G]*1_A[J']FQW$<T9G*[F@88Q[9]:VE*YR)6.[T*'3
M8=-BBT^6.:-1G>IR6/<GWK3=%="K*&4\$$9!KP\-J.AZ@<&6TN8^HZ?_ *Q7
M7Z)\06WB'5T!4GB>->GU']:@H[-[6>WF,MFX(D=?,20DJJ ?P =#4UI>QW<:
ML \;,"?+E&U\ XSBI;>XANH%F@D62-QE64Y!H^S0_:?M/EKYVW9OQSCTH D-
M5K"^AU&V%Q!N\LL5^88Y!P:LFL+PB?\ BGT_ZZR?^AF@"S?:!87TWFR1E9#U
M9#C-6+'3+73D*V\>TM]YB<DUS\U]KNN:QJ%GHMW:6%KI\BPR3S0&9Y92H8@+
MN "@,.><FJ=W?>*I?$>G:'%J6GVMP]A+<SRK:&1'99%48!8$9#9ZGFN>.%HQ
MJ>T45S=S1UJCCR.3L=-?:%8W\GF2QD2=W4X)I^GZ/9:<2T$6'/!=CDUR%YXM
MUBST?4HKB&WCU/3KN*WGN41GB6*0 B<)G<1@_=SU'<5K^#M8OM5BOA=W%M>Q
M6T_EP7]LFQ;@;03\N3@J25//:A86BI^T45S=QNM4<>3F=C8O]'L]1(:>,[QT
M93@TW3]%LM.8O!%^\/&]CDU+J.IV^F0)+<;BKRQP@*!G+L%'X9-6L[T.PCIP
M>M'U6C[3VO*N;N+VU3EY+NQ3U#2+/4<&>/+C@.IP14=AHECIS^9#&?,Z;V.3
M7**_C%O%K:*?$-CM6T%WYG]F\G+E=OW_ &ZUTWB+5Y-#T5KJ*)9[EW2"",G:
M'E=@J@GL,GGVIO#474]IRKF[V#VU3EY+Z&O0>AKF[1/$>GS_ &O6-5TV>P$;
M/<*EJT1B !.5;<<@'U'3FHK;QK::@3!%:WUK)/;236<MS"%2<*N<KR3T(.&
M..U;F8S5/"KR3O/9,HW')C8XQ]*S%\+:FS8\M5'J7&*D\(Z_J>IW?A]+NY\Q
M;OP^MY,-@&Z;<@W<>S'BN[Q7CU<CPM2?/9KT/0IYGB(1Y=S%T70(],S+(_F3
MD8R!P/I6C>Z=9ZA"8KNW25/1AT^E6:6O2H4*=""ITU9''5JSJRYYN[*$>B:9
M'&J"PMR% 49C!/'O3O[(TW_H'VO_ 'Z7_"KM%;&95CTRPAD$D5E;HZ\AEC (
MJU110 5Y=X^U1KCQ%%8J?W=G'O8=B[?_ %L?G7J!Z5X?K\IF\8:R3G(F"#/H
M!BNO!1O5OV.;%2M YW6-)DU!UEB<"0#!#'@BIM)TXZ?;LKL&=SEL=*T*J:A=
M26=KYL4)E;<!CT]Z[98>A2J/$M:E0Q^,Q%".7Q=XWTZ?B6M U2Y\/^/+&X@5
M?(OF2VE#'AMS ?F.*]\1PPR"#]#7S7JL[BST^[VF.59XW"]P<BO:)]#OK#6)
M=9T]O-0D.;/<1NR/FQVSGD5P8J*53F3WU-83O!0<4G'33KZG7452TW5+;5(/
M-@8@KP\;##(?0CM5VN8H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!*IW]FMW#@<2+]TU=HJ914E9C3:.-="C%6&"#2 E2"#@BN@U33_/7SHQ^\
M'4>M<\00<$<UYE2FZ;L=49*2.CTW4!<*(Y#B0#\ZT:XQ6*,&4D$>E=%IVH+<
MH(Y#B4#\ZZJ%>_NR,JE.VJ-&BDI:ZS$0]#7,Z=X<O8==U2[U#4C>V-W@Q6DB
MY6+\^.G'%=/5#6=6M=#TJ?4;UBL$*Y;:,D]@![DU,DMWT-*<IZPBK\VA@7_P
MY\.WS%Q;-;N>\#;:YS6OA[I&BZ7=:C+J.H""!-Y1,,WX5WNA:Y9^(=*BU&Q+
MF&3(PXP5(/((K1DC26-DD561A@JPR#19-71C+#4XU+5([/5'D_ACP5HWB?24
MU*&]U)(F8J8Y"H((]QG-='_PKSPQIEK)=7%O-<K"A=O-<MD 9Z"NSM[>&UA6
M&WB2*->B(H 'X"I& 88/0]:(QLM=QRI4/:-PC9=CD? NLZ-KFGS3:3I@LE@D
M\LJ8U!/?.15WQ1HFHZU!:)IVK/I[13"1R@/SCTX__56U;6EO:(4MH(H5)R5C
M4*,_A5BERMQM(Z/:QA5YZ*LNBW,37O$FF^&+!;G4IBH8[451EG/L*;X;\5Z7
MXIMY)=-E8F,XDC<89?3(K ^)/@R[\5VMK)82H+FU+8CD;"N&QGGL>*@^&?@B
M^\+_ &NZU%T$]PJHL4;9"@<\GUJ.:I[2UM#L5#!_4O:.?[R^QTWBGPS:>*M)
M:PNF9,-OCD7JC>M9?@OP):>$/M$J7#W-U, K2,NW"CL!_P#7KL:*MPBY<SW.
M2.*K1HN@I>Z^A6N+.WNS$9XP_E.)%SV8=#5FBBK.<SM5T2QUF#R[N!6(^ZXX
M9?H:\L\0>&+S0I=Q!FM6^[,HZ>Q]#7LE0W-M%=V[P3H'C<8(- 'C>A^(;W0I
M]T#;X6/SPL?E;_ UZSH^L6VM62W-LX_VT)^9#Z&O+O$_AR70;X;27M923$^.
M1_LGWJKH.MSZ'J*W$66C;B6//#K_ (T >RW=NMW:RP.2%D4J2#@BLCPOHKZ)
MISQ3.6F>0LQW9 &>/\?QK8M;F*\M8[B%@T<BAE(]*D)]J .7NM#UNRUF\U#P
M_?V427Q5[BVO86=/,"A=ZE6!!( !'M56?P_XF76-/U>WU+39KZ&SDM9VN+=P
MC[G#955;C& .2:?K^M7]OJ#V\3&&->A Y;WJ?PUK%[>79MYR94VD[R.5KRHY
MM1EB?JZ3O>QVO 5%1]M=6*C^"[XV#SKJD;ZY)?)?R7,D&86=%VJGEYR$"].<
M@\]:T_#>A7>FW>HW^H3V[WFH2*TB6L1CB0*NT8!))/J3_2NBHKU3B.8\4>"=
M*\2M'-<6D#72R1$S."28U<,5X/<9'XUMZ=IEEI%BEG86Z6]NA)6->@R<FK9K
ME/$FL7MI=BW@)B3;G>!RU<N+Q4,+2=2>QM0H2KSY(FFND2#Q<^M><OEM8BU\
MO'((<MG/IS4VO:.FNZ/+8O*T+,5>*9!EHI%(96'T(%87A_6K^XOTMIF,T;#E
MB.5]ZZ\=*6#QD,73]I!6]1XC#RH3Y)'*+I'B;48I++6]3TU]/D@DAE6UM762
M;<I7)+,0O7/ K(T#X>SZ/>*[IHVV*!X4N(;:19WW*5RQ+E1UYP.?:O0Z*ZS
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MZ9K%[]D33Y=.O;O[5))-(XFCR%#*%"D-]W@[AC/3BJA\+:C!X?T"&TDLVO\
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M0]6JY711H<OO2W,ZE2^B%HHHKJ,@HHHH **** "BBB@ HHHH **** "BBB@
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M=:V(88X$"1J%%2T5V0I1AL8RDY;A1116A(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 &*:T:M]Y0?J*=10!4DTVUEZQ ?3BJ
MCZ'"?N2,OUYK6HK.5*#W12G)=3"?0I!G9*I],\5 VC72] I_&NC_  HK-X:!
M2JR.5;3[I#S"WX"F&TG'6)A^%==44[F*WDD !*J2,^PK-X1=&5[9G*>1*/\
MEFWY4>3+_P \V_*KNF^*(G\$V'B+4P((YX(Y91&I8(7('UP">O:I]1\5:1I3
MW2W=PR_9(XI)RL;,$61MJ9P.I/;TYI?5%W#VS[&7Y,O_ #S;\J46TQZ1L?PI
MK?$KPW''(\DM[&8C^^1K&8-$O7>XVY5/]H\5;U/QUH6DWDEI<3W#2Q1I-)Y-
MK)*J1MDAR5! 7CK3^J+N'MGV(!9W!Z0O_P!\TY=/NF'$3?E5:[\>6>F>(KRU
MO9&:Q2T@N(9+>!Y3A]^YF*Y 0!5Y..M:>J^,]$T>:&*XN)7:2(3$V\#S!(ST
M=RH.U?<^AI_5(]Q>V9&ND7;=5 ^IJ9=#F_BD45'J?C;1-*F6&:>>61H%N5%M
M;O,#$Q(#Y0'C@TMUXST6TN+>#SYIY+B%+B%;6W>;?&Q(##:#QQ5+"P0>UD6T
MT*/^.4GZ"K,>DVB=4+?[QK+A\::)<:R-+CN9?-:0PI*8'$+R#JBR$;2PYX![
M5F:?XNN91:FZ:!3/JMY9A%C<LZ1>9@+C/S83)SUK148+9$.<GU.Q2"*/[B*O
MT%25Y[X;^(2WNE7&KZM+)% \WE6UI'I\HD)W, %/)E.%R=H&.:WF\<:%'IEO
M?M<S>3<3&W1?L[^8)0"2A3&X-QT(K1)+8DZ2BN9N?'&E68@>YAU.*.6,2^8V
MGS;(U.>7.W"XQSGI4)\;6Q\37^B+:W7F6\2/'<"WD:)BRLW+ 8"X YSSSCI3
M ZRBN>T7Q39:C86\DMS'YS:>E^[(C*AB;/S+N&<<'@\CC/6H[KQUHEI;6D[R
M73K=0"Y58K221DB/1W"@E!]<4 =+14<$\5S!'/#(LD4BAT=3D,#R"*DH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1+P1 0M*,Y ).2!M(SC&172< 8&!0!P%EX7UZ%++0I18_P!BV=X+I;P2,9Y
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M'H1QCKS7H-% %#1;$:;HUG9"*.(00K'LC9F5<#H"W)'UJ_110 4444 %%%%
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6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cvm_10k002.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10k002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M"U_[\K_A7*:5XUN9_#EWKU]_9[6<,/F".TD9I$;^XX/>GR^(?$UEX?N]8O\
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M[4+?5-.@O[5BUO.F^-F4J2#[&B47%V8U)/83^RM._P"?"U_[\K_A1_96G?\
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M<@U9?QE;?\)(-'CAF;?;"9+@1L5)/(Z#[N.<_A2Y)=A\\3;_ +*T[_GPM?\
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MH61@K'"M@C)!/>IKCQ#$?"UWK5DC2)%$\B"5"F[;GL><4N5E<R+_ /96G?\
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MW(&!U.3BH/MC?\^LOYK_ (T^\_U _P!]?_0A3*:0FP^V-_SZS?FO^-'VQO\
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M:FHS0,AVW7]^'_O@_P"-&VZ_OP_]\'_&IJ,T 0[;K^_#_P!\'_&C;=?WX?\
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M1MNO[\/_ 'P?\:FS1F@"';=?WX?^^#_C1MNO[\/_ 'P?\:FHS0!#MNO[\/\
MWP?\:-MU_?A_[X/^-39HS18"';=?WX?^^#_C1MNO[\/_ 'P?\:FS1GWHL!#M
MNO[\/_?!_P :LVOF;6\PH3GC:#3,U-#T/UJ9; B0T4&BI**FE?\ ((LO^N"?
M^@BKE4]*_P"019?]<$_]!%7* ,[7=+.LZ1-8"Y>W$N,NB@\ @D8/!!Q@^QKD
MM \!7VD7>F-/?P3Q6GENS+$5<ND;1A1VVX;/KQ7;WETMG:R7#H[K&N2(UR3]
M!6)8>-=&U*^L[2VEE:2\B66(F)@,%2P!]#A30!LW@S;8Y&77I_O"H?)_Z:R_
M]]U/>?Z@?[Z_^A"F9'K5(3(O)_Z:R_\ ?='D_P#367_ONI<CUHR/6J)(O)_Z
M:R_]]T>3_P!-9?\ ONI<CUHR/6@"+R?^FDO_ 'W1Y/\ TTE_[[J7(]:,CUI7
M B\G_II+_P!]T>3_ --)?^^ZER/6C(]:8$7D_P#367_ONCR?^FDO_?=2Y'K1
MD>M $7D_]-9?^^Z/)_Z:R_\ ?=2Y'K1D>M*X$7D_]-9?^^Z/)_Z:2_\ ?=2Y
M'K1D>M $7D_]-)?^^Z/)_P"FLO\ WW4N1ZT9'K3 B\G_ *:R_P#?='D_]-)?
M^^ZER/6C(]: (O)_Z:R_]]T>3_TUE_[[J7(]:,CUI7 B\G_II+_WW1Y/_327
M_ONI<CUHR/6G<"+R?^FLO_?='D?]-)?^^ZER/6C(]: (O)_Z:2_]]T>3_P!-
M)?\ ONI<CUHR/6@"+R?^FLO_ 'W1Y/\ TTE_[[J7(]:,CUH B\G_ *:R_P#?
M='D_]-9?^^ZER/6C(]: (O)_Z:2_]]T>1_TUE_[[J7(]:,CUH B\C_II+_WW
M1Y'_ $UE_P"^ZER/6C(]: (O)_Z:2_\ ?='D_P#327_ONI<CUHR/6E<"+R?^
MFLO_ 'W1Y/\ TTE_[[J7(]:,CUHN!%Y/_367_ONCR?\ II)_WW4N1ZT9'K3
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M_GA'_P!\T?9;;_GA'_WS1]IB_P!O_OAO\*/M,7^W_P!\-_A1< ^RVW_/"/\
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M/^>7_CPH DHJ/?)_SR_\>%&^3_GE_P"/"@"2BH]\G_/+_P >%&^3_GE_X\*
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MVCGE7N3<./9<?T#5V.LQ>?H>H1?W[:0?^.FN+C9M4^,<K^7E=,LMN-W1F_\
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M(O\ OV?\:8B:BH=MS_STB_[]G_&C;<_\](O^_9_QH FHJ';<_P#/2+_OV?\
M&C;<_P#/2'_OV?\ &@":BH=MS_STB_[]G_&C;<_\](O^_9_QH FHJ';<_P#/
M2+_OV?\ &C;<_P#/2'_OV?\ &@";-%0[;G_GI%_W[/\ C1MN?^>D7_?L_P"-
M $U%0[;G_GI%_P!^S_C1MN?^>D7_ '[/^- $U%0[;G_GI%_W[/\ C1MN?^>D
M7_?L_P"- $U%0[;G_GI%_P!^S_C1MN?^>D7_ '[/^- $U%0[;G_GI%_W[/\
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M.6X(Z\5W06Y_YZ0_]^S_ (TY2YG<<J?LFX7O;JCB/AI^Z;Q%:=/)U%L#Z_\
MZJ[VO/?!0FA\9^+;97C#?:%D.4/<M[^]=YMNO^>D/_?L_P"-55^(RI_"345Y
MS\4M0UC3M/L#9ZBML))6#^62A8@9'.>E=/X6OKK5/#.GW;7<,SO$ [["<L.#
MGGK6=GO8W<$HJ7,KOIU-_-%0[;G_ )Z1?]^S_C1MN?\ GI%_W[/^-!!-14.V
MY_YZ1?\ ?L_XT;;G_GI%_P!^S_C0!-14.VY_YZ1?]^S_ (T;;G_GI%_W[/\
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M%]F@_P">,?\ WR*/LT'_ #QC_P"^13 ER/449'J*B^S0?\\8_P#OD4?9H/\
MGC'_ -\BA@2Y'J*,CU%1?9H/^>,?_?(H^S0?\\8_^^12 ER/449'J*B^S0?\
M\8_^^11]F@_YXQ_]\TP)<CU%&1ZBHOLT'_/&/_OD4?9H/^>,?_?(H ER/449
M'J*B^S0?\\8_^^11]F@_YXQ_]\BBX$N1ZBC(]147V:#_ )XQ_P#?(H^S0?\
M/&/_ +Y% $N1ZBC(]147V:#_ )XQ_P#?(H^S0?\ /&/_ +Y% $N1ZBC(]147
MV:#_ )XQ_P#?(H^S0?\ /&/_ +Y% $N1ZBC(]147V:#_ )XQ_P#?(H^S0?\
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MNQ)1&-RKSP#^)_.B6X1V)[UMMMN/9UZ#/\0JO]JB]7_[]M_A5F\_U _WU_\
M0A3:$-D'VF+U?_OVW^%'VF+U?_OVW^%3T55A$'VF+_;_ ._;?X4?:8O5_P#O
MVW^%3T46 @^U1>K_ /?MO\*/M47J_P#W[;_"IZ*+ 0?:8O5_^_;?X4?:HO5_
M^_;?X5/118"#[3%ZO_W[;_"C[5%ZO_W[;_"IZ*+ 0?:8O5_^_;?X4?:8O5_^
M_;?X5/118"#[3%ZO_P!^V_PH^U1>K_\ ?MO\*GHHL!!]JB]7_P"_;?X4?:HO
M5_\ OVW^%3T46 @^TQ>K_P#?MO\ "C[3%ZO_ -^V_P *GHHL!!]IB]7_ ._;
M?X4?:HO5_P#OVW^%3T46 @^TQ>K_ /?MO\*/M,7J_P#W[;_"IZ*+ 0?:8O\
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MB@"'?/\ \\%_[^?_ %J-\_\ SP7_ +^?_6J:B@"'?/\ \\%_[^?_ %J-\_\
MSP7_ +^?_6J:BC4"'?/_ ,\%_P"_G_UJ-\__ #P7_OY_]:IJ*-0(=\__ #P7
M_OY_]:C?/_SP7_OY_P#6J:BC4"'?/_SP7_OY_P#6HWS_ //!?^_G_P!:IJ*
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MQXNU[6LY&R*%3^'/_H-=$?X?-V,'\=CT#;=?\]HO^_1_^*HVW7_/:'_OT?\
MXJIZ*YSH(-MU_P ]H?\ OT?_ (JC;=?\]H?^_1_^*J>B@"#;=?\ /:'_ +]'
M_P"*HVW7_/:'_OT?_BJGHHL!!MNO^>T/_?H__%4;;K_GM#_WZ/\ \54]%%@(
M-MU_SVA_[]'_ .*HVW7_ #VA_P"_1_\ BJGHH @VW7_/:'_OT?\ XJC;=?\
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M%'FQ_P#/1/\ OH4[@,^SI_?E_P"_AK@_%,(@^)7A.8,^'\R(G><_G_P*N_\
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M181P2<$(6 _"J>G>-3?Z[96#VX@CGMX7+D,<R21F0(#C P >3UI2W".QU%X
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M]_/_ *U&^X_YXI_W\_\ K4 <-\1C_:6I^'?#PZ7=V))/]U>/ZG\J[X *  ,
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MX_YXI_W\_P#K4;Y_^>*_]_/_ *U $U%0[[C_ )XK_P!_/_K4;Y_^>*_]_/\
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M!%!)/)) RI'&P5F)'&"2,<^]<II>FZJWB/0KBZTRZMEL[ 13W'G(QED*X*N
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MH=MQ_P ]8_\ OV?\:-MQ_P ]8_\ OV?\:+@345#MN/\ GK'_ -^S_C1MN/\
MGK'_ -^S_C1<":BH=MQ_SUC_ ._9_P :-MQ_SUC_ ._9_P :+C)J*AVW'_/6
M/_OV?\:-MQ_SUC_[]G_&BXB:BH=MQ_SUC_[]G_&C;<?\]8_^_9_QHN!-14.V
MX_YZQ_\ ?L_XT;;C_GK'_P!^S_C1<":BH=MQ_P ]8_\ OV?\:-MQ_P ]8_\
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M'D\-:;+KZ:RR2?:T(88<[=P4J#CUVDB@"_>D+;9)P ZY)_WA4/GP_P#/6/\
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ME&X?(3T'U]A4%SXHT>"_T^RCGBN+B^E1$2%E)564L'/MA?UH V//A_Y[1_\
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M#\L>!DY]..:AC\1:%+)&D>I6;-*F] ''S+SS^A_(T :7GP_\]8_^^A1Y\/\
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M/M"?W9/^_;?X5-118"'[0G]V3_OVW^%'VA/[LG_?MO\ "IJ*+ 0_:$_NR?\
M?MO\*/M"?W9/^_;?X5-118"'[0G]V3_OVW^%'VE/[LG_ '[;_"IJJZC?0Z7I
MMS?W!Q#;QF1OH*:0F[:G!^*YAXG\::7X=CWM9VQ^TWN%/;H/R_G7?^?%MVA)
M-N,8\INGY5QGPWL)IK6]\1WHS=:I*74GM&#Q^O\ (5W5:5-/=70B&JYNYXWX
MTLV\&R7<NE2O'INKHT4MKL("/W*YX'&?U%>@^#)[9/!VEK DH00#K&>O<\>]
M;5[I]GJ,'DWMM%<1 [@DB!AFIXXHX8UCB1411A548 %2Y2EHS6U-022U[W(_
MM*?W9/\ OVW^%'VA/[LG_?MO\*FHJ;"(?M"?W9/^_;?X5'<-!=6TMO-'*T4J
M&-QY;<@C![>AJU45PXBMI9-Q78C-E5W$8'8=_I2L!R#^#+:>VA@NM1O)UM;<
M6MIFWV^5'N4\X'S,=BC/%::Z+%%I-[817#[;NYDG<S6GF*=[9*E3P17*1^*/
M%SQ:48XHY/M.]W>2U9!_K %B8 ?*VPY)'<^U377B'Q7;Z>+ERJ^;)=>5MT]G
M*F,D11$ _P >,[N.G'6D&I:@^'^FV1A:WGN9/*@6,)-"2"R!MC#^[C=Z'@#&
M*-'\$K9V=C)<ZC<-J-N+?]XL&4 B4J$Q@9&&;GZ4_P 0^)-;LM;L[*RC42R6
M<5P;86YE+R&4(R;A]T!23GVK(F\1>)[^XF53=VEM;WULWF?8R'\MG97##N
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M(MFS,$"%$)X"L26'&>E3:;X@\3R^#]6U":SCFOX(U:VB6)E)8KEE*XYVGTH
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M U"\=YK80-M@*9( 'F''5^.M9_A*^UC4O$EU=:H)QFQ4&$V[1I$XEDR@SPQ
MQSZ&LVU\4>*[^Z:"&&2"-[E566:P.Y4,<A((Z<,BCKWH W-.\)6]CH6L:8^H
M7MQ_::%)9Y8B7'[O9GW.!GZTMSX/T^XUAM0:24ET16B>WWIE$*JP!X'!Y!!_
M6L/3M:\0ZOX@T!KZ*6V03(\EO';.JE6M6)=G]-[%=I[J*DU!_$,FO7<"WUR
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MX66#6)VPL,6# @S%&6(0_7=R>O%=30!#ON<8\E,?]=?_ *U&^XSGR4_[^_\
MUJFHI@1;[G_GBG_?W_ZU)ON?^>"?]_/_ *U344 0E[G&/)3_ +^__6H$ES_S
MQ3_O[_\ 6J:B@"'?<_\ /%/^_O\ ]:CS+G.?)3/_ %U_^M4U% $.^Y_YX)_W
M]_\ K4>9<Y_U*?\ ?W_ZU344 0[[C_GBG_?W_P"M2A[D?\L4_P"_O_UJEHH
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M;/\ 2F5-#T-9/8T1)WHH-%245-*_Y!%E_P!<$_\ 015RJ>E?\@BR_P"N"?\
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MY% '5_8H?^FG_?UO\:/L4/\ TT_[^M_C5BB@"O\ 8H?^FG_?UO\ &D^QP?\
M33_OZW^-6#7!/XEUZUN;W983W,,MS(+4O;OT#QJ!P!A=ID.3Z47 [7['!_TT
M_P"_K?XT?8H/^FG_ '];_&N+N=0UJU\!EV2_CO8RI295WR2GS#E2N"P&WN15
MS0=2UJY\8:A%=V\QL3O,+E658T&W9P1@E@2>N1@YHN!U/V*'_II_W];_ !I/
ML4'_ $T_[^M_C5FB@#%UWP];ZUHMUIQEEB\]-N\.QQ^!-<YX=^&&DZ5IS0:C
MC4)2Y8.2R!1Z  UWAKS(:UXOL+LDVMU=QYN9E+0DJ%\T(%; R=@RP Y8&CK<
MOVDN1T^CZ$^N_";3]2U&UGL+EK&&/_61#+9YSD$G@UZ#;V\=M&$0N0!CYF)_
MG7':9XD\27-]:V]QH_[N<2.LRQ,@*(T@).X_*7Q$5![.?2JNLZOKJ7NK)9_;
M4?[/;LL;0EEA)?$NUE7YB%(/&?:CK<)5)2BHMZ+8] -%9GA^>ZN= LIKR"2&
MX:/YTD8EASP3D \C!YYYHH(+&E?\@BR_ZX)_Z"*N53TK_D$67_7!/_015R@
MHHHH 3%&*6B@!,4M%% !1110 4F*6B@ Q1110 4444 )BC%+10 F*,4M% !1
M110 4F*6B@!,48I:* "BBB@ I,4M% "8HQ2T4 %%%% !28%+10 F*,4M% "8
MI:** "DQ2T4 )BC%+10 F*6BB@ HHHH 3%&*6B@ HHHH **** $Q1BEHH 3%
M+110 4444 )BC%+10 F*,4M% !1110 4F*6B@!,4M%% !1110 4F*6B@!,4M
M%% "&B@T4 5-*/\ Q*++_K@G_H(JWD444 &11D444 &11D444 &11D444 &1
M1D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D44
M4 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &1
M1D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D44
M4 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &1
>1D444 &11D444 &11D444 &11D444 !-%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cvm_10k003.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10k003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M  (1 Q$ /P#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH ;H1A1C'85[]0M!;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@>W6O*$BN]!\2>)O&VGK)*MGK,EOJELN3YMGY43%@/[R$ENW!/-;/AO1M/\
M&W@CQ!;K/^ZN-;O)[2[BY:)_,W1RH?4<'MD$CO0!Z-<ZE96=U:VL]U#'<7;%
M;>)G :4@9.T=3@<FLF7QUX6@U=M*FU_3TO58HT33CY6'&TGH#[$YKF/AU:WV
MO._B[Q#+%-J,8;3[98L[(4C;;(P&!\SNK$GTP!CI7.PV%YHWP\NA96VC>*?
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MO4DC+ ;1MX'K67I.L^(O&.K:5 NM3Z5:S^'HK^<6<41+3M(R\%U8A3CIZ 4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;NKZ=>&2"X$K;0 Q7((P?6BX'5-X%T%KNZNDCOX);N9IY_L^J7,*O(>K;4D
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M>P'3BM#6=$TWQ#I<NFZK:)<VDN-T;Y'(Z$$<@^XKSJX^,4<!N+\#1O[-@NC
MULVH 7SH'V&58L8]PI.2!71?%*X:'P#<2(TX!N;4-]G+!V4SH"%V\Y()''K0
MP-+3O!.AZ9J\>K)%<7&H1QF*.YO;N6X>-#GY5,C':.3T]3ZFH5^'_AI;U;E;
M*7"71O%MS=RF!9R<^8(MVS/X8K@1+92^,=$T[PC9Z_8:G%=QW-^M]-.B&R!(
MDW),YW9R ,+U[BNBT[PYI_B'Q5XLDU)KYW@OXXH?+OYX@B_9XFP C@=23TH
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M\\DC2E%55)9F+;@%7D'.1G.>:YX^*AH\GB66#3GN+R"XL;:*+[2?]*FEBC"
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MB6^F1Z?<C2);BTUBR272FB8[IKA\;8'&,*3N!W9Q@'TKN[)[E[&![R...Y9
M94C8LJMCD GJ >],#+N_"FC7UEJ-I/:L8=1G6XN0LSJ6D79M8$'*D>6GW<=*
MS[SX=>&[YYC/;WF+E$2Z5-0G47(484R@/\Y&.IY)Y)-=710!G:EHFG:OI?\
M9E]:B2SRC")6* ;&#+]TCH5''M4$OAG29M/U.PDM2UMJ<C27:>8P\QF #'.<
MC(4=,5L44 <WJO@70-:NYKF[MK@23PBWN/(NY81/&,X60(P#@9/7FEG\#:#,
ME@$@N;:2PMQ:VTUI=RPRI",83>C!F7@<,3^IKHZ* ,*R\&Z!ITFFR6FGK$VF
M1R1V?[QR(0_WR 3C<W=C\QSUJ[HVB:?H%B;'2[?[/:^8TBPAV94+')V@D[1D
MD[1@#)P*T** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGG1SHGW6V[U*L"2>IZXKM:* .#3X=-;QZ"]MJSF\TRYN+B>>XMQ)]K,^?-W
M$;2<G!YQ[TNE^!M6TM=.L%\2NVCZ?,)(HEM MPZ*<K$\N[!3L<*,CBN[HH X
M;_A!]5B:>QM?$LUOHD]Z;QK>*#;<)N?S&C28,-J%L_PYP2,U9F\$F7PEJ6A?
M;\?;;Z2\\[R?N;Y_.V[=W./NYS[^U=A10!R\WA(RV7BNW^V8_M_?\WE?ZC=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** . \1_%"WT'Q0NA
MP:-J.HR1E!=O:H&,6]"RA5ZN<*21QQGD]*T==^(>B:%KVEZ))(UQJ-_<Q0""
M'!:$2$ ._P#=&2..O.<5YM\4;'4I/']M+IF@ZI;:M( ECJNF2\W)\IOE?H$V
MM@'/)0-V KL?'&B74P\(W$.G>?J U^PFU":UM\DJBL"[D#.T>IX'%" N>(/B
MAIGA_5[ZQETW4;B+3?)^WW4$:F.V\W&S.6!.<CH*77?BAI.@:W<Z?/97\T5D
M8A?WD,0,5H9?N!CG)SD'@=^YXKSOXB^&]4OO&FO2CP_JMY=W0LUT:XM8%:V&
MS'F>>>AYS_K >!V&*F\8Z%XA.H>+M'CT.]NY/$K6#6UW;Q[H(S'M\SS&_@Y!
MQF@#W8'(R#D51OS_ *;I?_7TW_HF2K<*&.%(R<[5 S69<V:P:GIL@FG<M<L-
MKRE@/W4G0&@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH+N
M]M;"V>YO+F&VMT^_+,X15^I/ K)T/QCH'B6]N[31M2CO9;0 S&)6*+DD##8V
MMT/0F@#=HKDM?N/'DNJ/:>'=/T:&S"@B^OYW8L3U C09!'OD'BLO_A!/%&I<
MZY\0=4(/2/2HDLPOJ-PR3^- 'H#.J*S,P55&22< "N5O_B;X)T[_ %_B;3B1
MU$,OG?\ H&:W=/TN#3](ATT237,,4?EEKJ0R.X_VB>M0V/AK0M,_X\-%TZU_
MZX6J)_(4 <Y8?%7PYJ^H6]GI2:E?^?*L8F@L)/+0DXRS,!@#N>U=!XAUF?0]
M,6[M](OM4D:0)Y%D@9QD$[CDCCCK[BM; Q@"EH X#_A//$[C=%\.=7*_[=Q$
MA_+-;7ASQ%J^LW4T.H^%K[2$1-RRW$J,KG/W1M.<]ZZ6B@#E_$7C&7P[?QP'
MPSKVI0O&'-QIMJ)E4Y(VD;@<\9_$5Q^K?%C3[B]MK*5M;T"U*/+<W$VG,)N"
M J*"& !R<M@XP ,$Y'K&*RM6T2/4I+>XBNKBRO;?=Y-U;E=RAL;E(8%64X7(
M(/0'@@$ '/\ A3Q!'?:A:PV&L2:QI5_:S7%M<SQ[)8VADC1T/RKN!\U<9&1M
M/)!&.S5T<$HP8 D$@YY%9.E: FGWDU]<7=Q?W\J",W%QM!5 <[%5 %49Y.!D
MG&2<#'.7?PF\/&[DO-(GU/0KR1B[S:9>-'DG_9.5Q[ "@#NZ*X*STOXC:)=P
MQQ:WIFO:=O4/]OA,$Z)GLR9#''=JZW6-=TO0+:*YU:^ALX)91"DDQPI<@D#/
M;@'D\<4 :%%1PSPW,*302I+%(NY)$8,K#U!'45)0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 TA203U'2EQ7CWC7QWXCT[XCQ:)9ZEIFD6T:H\+ZE$1!=!D8L7D_A4,
MH"XY/6MSQ?XT\0Z3XIT/3K+2S#IMQJ=K:7&H2X*S&7DI&.N ,Y;U&/J >C4G
M&<UY!XM^)FJ:?XZU#0[/4]*TN/3E@"G4+>61;J23:3O= 1$BAL9/?'8_+)XI
M^(?B/3M3\17>G?81I?AQK1;B"2,L]UYV,D-D;=N>./KGI0!ZY5"__P"/W2_^
MOIO_ $3)5R-Q)&KCHPR,UEW.H65SJ>FPP7<$LJW+%DCD#$8BD'(% &O1110
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MQEU&/49+.!KZ)#''<-&#(BGJ W4"K=%% !1110 4444 %%%% !1110 4444
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M5F$#0(,X9E&2<XZ<$9KJDBCB0)&BH@Z*HP!3L 4 <E=Z=XWU70[%!KMAHFI
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M<ZY811VTTN8[9#DLJ)V)*J6//(H ].N_$.BV%_%87FKV-O>38\JWFN$21\G
MVJ3DY((&.XIUSKVD66H0Z?=:I907L^/*MY9U623)P-JDY.2,<5XY\3QX5OO$
MUWX>MH]-MM<U+R'U/5[^<(MI&FW;L+GARNT;4QD'GU&)XZ73OMGQ&^TM ^JJ
MVF?V:TA!FVX3)B)YZ8SMI(#Z.S5"_P#^/W2_^OIO_1,E6X=WD)O^_M&[ZUEW
M#7IU/31<1P+%]I;:4D)8GRI,9! [4P-BBBB@ HJM?ZA::992WE]<Q6UM$NZ2
M65MJJ/K67X;\2VGB[2Y;ZR@O([,RM%')/$8O/4 ?.G?:<D \'(- &+XB\?&#
M5#X>\+V8UGQ 0=T2-^YM/]J9^P_V<Y/3C(S9\)>$;S2;R;6M<U:;5->NHA'-
M+N*PQ)G/EQ)T"@XY(R>O&2*V- \-:/X8T_[%H]A%:PEBS;<LSGU9B26/U)K6
MH ***0D#K0 M%9\^NZ1:W\-A<:G9Q7DS;8K=YU$CGT"YR:P[3XA:/J/B/^Q-
M.M]2NYDE>*>>*S?R;=ESG>YQ@9&,C- '645RFEZSXPO=?\B\\*P:=I2LX:YD
MU!))& SM(1!QDXX)Z'K3=(TCQJNMK?:UXHM9+-2P.G6=@JHP((4^8Q+@@X./
M;% '6%@!DG%8'B3Q&FEVOV;3YK276;AA':V\TG&3R7<#G8JAF8^B^XJGHG@.
M#1M3^WR:]XAU*4(R!-0U!I(QNZG:  ?Q_F!7.Z3X5TSPCXROKO3?!M[]GC@6
M"U>VV2!]PW2/F23</X4 [;6_O4 ='X?^(?ASQ!:Q^1J5O]L%J;F>U1][1!?O
MC(&&P?3KU'%)HOQ'\->(YKB'1KJYO)+>!IW"64P^4=AN49// ZFJWA:S^P^)
M[\67AN?2]+NX5F/F111B.9<*54(QX9=IQT!1CU:NTP* .2T?QXNL-=!/#'B:
MU%O;O<!KO3_+$VW'R(=W+G/ XS1I'CF35OM8'A3Q-:&VMGN/],L5B\W;_P L
MTRW+G/ XZ=:ZW Q1@>E ')Z1XVFU=;O'A3Q):&VMVG_TRS6+SB.B)E^7/8<#
MCJ*72?&=WJ<=Z[^$_$%G]F@,P6YMT0S$?P)\W+GL.GO75X%&!^= '*:5XUFU
M2WOICX4\1V9LX#-LNK14,Q'\$?S?,QQTI-+\<2:G;7\W_"*^)+7[' 9MEU9"
M-I\?P1C=\S>U=9@>E+@4 <GI?C=]3L]0N/\ A%O$MI]BA\WR[NQ$;S]?EB&[
MYFXZ?2C3?&[ZG8ZC=#PKXDM?L40D\JZLA')<=?EB&[YFXZ>X]:ZO ]*,"@#D
M]-\;2ZG8ZA<KX5\1VILXPXAN[-8Y)\YXC!;YCQT]Q2Z=XMU74M,U"Z3PAJUO
M+;(&@@NS'$UR3V&6XQWS_P#6KJ\#THP* .2L/$/BVZTK49[GP4;2\@53:6S:
MI$WVG).X;@,(0.>1SFN6\1^(?%.H:8^A:E8Z'H=YJ/*)>:EN3[,O^M$C*!][
M*( O)#-TVYKU; %136MO<8\Z"*7'3>@./SH \EMM2\1+JDJW/BOPQ97>N-':
MQS:*/M @G3E)&21L'>@:(G&<B$5V5KX,OY/#]]INL^*]6OY;UE:2XB9;8QX/
M(C"CY0>A&2,?C73+862NKK:0*RG*L(P"#[58H YK2O /A?1]*FTRWT>"2SGE
M$TT5UFX#N!@,?,)YXKH88(;>)8H8DCC085$4 */0 5)10 4444 %%%% !111
M0 4444 %%%% !1C-%% '(:[\-/#6MW?V[[&VGZF#N2_TZ0V\ZL3DME>&;W8'
MJ:=X;T7Q9HFIFWO_ !##K.B^6?+>Y@V7<3 _*NY>'&.K-R3V%=;10!@:QXV\
M.>']7M],U?5([*YN$\R/ST98RN2.9,;!T/4_SK:AN(;F&.:":.6*1=R.C!E8
M'N".M1WUA9ZG:M:W]I!=6[_>BGC#H?J#Q7$S_"NRL9FNO">K:AX;NF.XK:R&
M2W=O5X7.#QQC( XXH [^BLW35U&PT",:M<K?WT,1,TUO!L\TC/1!GDC' ZGL
M.E8FB?$KPMKD_P!DCU$6=^#M:ROU,$RM_=PW!/T)H ZVBD!!Z&EH *3:/2EH
MH J3:5I]P+@36-M(+E/+GW1*?-7^ZW'(]C6+;> /"MC:ZE;VFBP00ZC%Y-TD
M19?,3G@8/R]3TQ^@KI:* /)?"_AG3-%T34K27P9KB?VMN6[@CFW*(MS;(P?-
M!^53@GJ3NYP0*T_!'@'1K;P_K.GW&A75I!>S/#(L]PX:X@!W1D@.=I <IP1G
M:3WKT>C'.: .4TWX;>$=)T_4+"ST=4M=054NHWGDD$@4DK]YCC!)Z8J_8^#/
M#.FV,]C::#I\=K< ">+R%83 '(WY'S8/3.:W** *EAI6G:5 8-.L+6SA)R8[
M>%8USZX4 5:P/2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,;4O"VB:OJ=GJ-_IEK<75HV8I)(E8]",'
M(Y R2!V.#UK0NM/L[[R/M=I!<>1*LT/G1A_+D7[KKGHPR<$<UQ7B+XGV^A>*
M%T2#1M1U*2)D%V]J@8Q;T9E"KU=L*3CC@'GM6CKOQ#T30M?TO1))'N-2U"XB
M@$$6,PB0@!WST'(XZ\YQ0!J7GA'PUJ%W)=WOA[2;FYE.7FGLHW=N,<DC)X%3
MW/A_1KR^@OKK2;&:[MP!#/);JSQX.1M8C(P>GI7,>(/B?I7A_6[K3YK'4)XK
M 1'4+N"(&*T\W&S<2<G.0> >O<Y -=^*&E:%K=QI\ME?SPV7DB_O(8P8;3S?
MN;B3DYR.@_,\4 =SC%4+_P#X_=+_ .OIO_1,E.U;4H])T2^U1T:2.TMI+AE4
M\L$4L0/RKS75_BK/:/I=U=>&+R"W+_: [7"<1M'(JLPZJ#AR,\G8>* /5ZS=
M=U*;2-&N;ZVT^YU&:)1LM+89>0D@ #VYR3V )YQBO-+_ .*%WXCLHE\.RVVB
M6$J#[1K>K,J)&<#<D*$_O'7./3/U!KI[CQI:^'])TFWAM]9\237%JCPSV-H9
M3., ;V;A03U/<=Q0!1L?!6J>*;Z+6/'TD<PC??:Z)"V;:W]#)_ST?Z\=>H.!
MZ$JI&BHBA548"@8 %<EJ]YXXNOL8\.Z=I=K%/;K)-+JDC%X'/5-B=P,<Y(S2
MZSX.U#Q#<6\E]XGU2S@2!4FM=,D$"22#[S;N6P?0GIWH V]4\0Z-H@4ZIJME
M9;ONBXG5"?H">:QM5\=P6&O_ -BVNBZUJ5XK()#:6A,488 @L[$#&#VK0E\'
M^'[G5!J=WH]G<WX14^T7$8D;"C Y;//OUK;P!VH Y6ZE\<S^)EBLK?1K70XI
MDWS3R/)/-'P6V@8"GJ.::W@R[N?$W]KWOBG6I88IQ-!80RB&! #D(P4?..W/
M4=<UUM% &#9^"_#=AJLVJ6^BV:ZA-*9WN6C#2;R22P)R5R2>F*W<#TI:* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(USPQH?B.W\G5]+M;Q0
M,*TJ#<H_V6ZK^!%:]% '&Z'X"?PUK$,^D>(-3CTI<B32KB3SXL8(4(6Y0 D'
MOG%:'B?Q6OA;[-+<:5J=W:2;O-GLH/-%OC'+C.<'/4#L:Z*DP* ,/0/&7AWQ
M/&#H^K6UT^,F(-MD7ZH<,/RK=KF-?^'WACQ'(9[[2HEN\[EN[?,4P/KO7!/X
MYK0\/Z*^@:4+!M3OM15')6:^D$D@4]%W8&0* ->BN#'Q1L=.OS9>*-+U#P_(
M7*QS74>^WE]-LJ9'3GT'K7:6=_::C:K<V-U#<V[_ '98'#JWT(XH L45"]W;
M1W"6[W$2SN,I&7 9A[#J:FH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \'^*=EJ,GCVVETO0
M-4MM6D 2QU739CFY/E-\K] FUNN>2@;G&*[+QQHEU.OA&XATX3WZZ_83:A-:
MP9)"*P+N0,[1ZG@9%>BE0>PXZ<4<>E 'AWCS1==.M>,]-L]"O[S_ (286'V*
MY@C#0QF':'$K9PG0XS47C#0-=34/%VB6FAWUX/$9L/L=W#%F&/RMN_S6S\G0
MXS7N])@>E 7,'Q="3\/]>@!&3I=P@)( _P!4PZG@5X)K.H:?XD\');7TKC5[
MJ[$\K+JMHL058W6)<-,2 JE200#G<,C-?3/M6??HGVW2_D7_ (^CV_Z8R4 >
M.>%_A?;^*O"FCWW_  E%VYM8VA6*6.&YCMY%.'5"005W+P02,8(KLX_ 7BF&
M-8XOB+J*1J JJ+&'  Z"O0  !@ "EH X#_A!O%O?XD:E^%E$*/\ A O$Q^_\
M1M8/^[!$O]*[^B@#@?\ A7NM-]_XA^(C_NLB_P!*/^%<:D>OQ \4_A<H/_9:
M[ZB@#@/^%;7_ /T4#Q7_ .!:_P#Q-'_"M]1'3X@>*OQNE/\ [+7?T4 <"? /
MB*/_ (]OB)K:X_Y[1QR_S%)_PB?Q"BXB^)(=1T$NB0D_B0:[^B@#@#IOQ3LO
M^/;7_#VI>HO;-X?_ $632?VS\3M/.;KPKHVJCN-/U PD?]_17H%% 'GQ^)=[
M8977/ _B.R<<L]O +J)1ZET/]*R](\9>%_$VK:M++XSN+-?M(%K"UXUH/*\J
M/HKXYW^9[\>F*]5KC=9^'6GZU?7EQ<7LVRZE\YH7M;654?8J$J9(69<A!WH
MN^'#)!K6L6/V^YN[>'R'A:XE\P@.A)P?2NEKS"Q^#%KH0EE\.^*=>TRZ<[@R
MS(T1(Z;XPH#@<\>YJX=0^(_ACG4-.LO%-@F<W%@?L]T%')9HC\K'&<*G)]:
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ML?:3G:1RKC/.&! /(P>:GTK2+72(9$MQ(TDS^9---(TDDKX RS,23P  .@
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MT9R>@6_B.?\ QZ@#=HJ"WO+:[C\RVN(IT_O1N&'Z5/0 4444 %%%% !1110
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M%% !1110 4444 %%%% !0>1BBB@#G(/ ^D6MM%;6\^L101($CC36;M510,
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MN">$R6>E6]OYA@5GF>XF+;(U4=<@+_WU0!T?]B:3_P! NR_\!U_PH_L32?\
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MK3XC3KI?BD:OI2V6J^'HA)-;K/YD<@9"T>UL#KC&/<?@ =C_ &)I/_0+LO\
MP'7_  H_L32?^@79?^ Z_P"%<9/\2Q;^)="\/'3G>_NVB2_?#+%:N\8?8"1\
MS8.<>E7?%_Q"MO#7B'1-#BMQ=7VHW,4;KOP((W?;O/N3T'?!]J .F_L32?\
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M%']B:3_T"[+_ ,!U_P *OT4 4/[$TG_H%V7_ (#K_A1_8FD_] NR_P# =?\
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M% '(_#7P[?>&/!5KINHE!<[Y)6BC;<L.]BP0'OC/YY^M==110 4444 %%%%
M!1110 4444 %>-_$7P/KGB#Q#?C3="A>/4888_[134&A5-I&3/%G]YC'RX''
M'7%>R44 <=X0\/W6EZWKMY=PM&C_ &>SM-S*VZ""( , "<;F9S@\^U<O)X"U
MK4? GCC19(H[:YU77)[VS,D@*O'OC=2=I.-VPCGD=Q7K-% (\U^'GAK5[#Q)
MJ^M7NAVWAZWNK>"W33+:5'5F0<RG9P.I [\G/J?2J** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^*^ORZ-I>MWNGV$&GRZV^FWZJCEK=#MV,&W8R,MDD8/& * /8J*X[PCXJO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUD;E@.I ZX'<]JAN/%WAZUFL8IM8LUDOU5K11*#YX8X4ICJ"?2LC5[/5M/\
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M$(S!CGJ3C SQBK^G>%-0AT[PW%-8*)+37KJ]N?G3Y8V-R4?@\GYXN!DCCT.
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>cvm-20160930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:CVM="http://cel-sci.com/20160930">
    <link:schemaRef xlink:href="cvm-20160930.xsd" xlink:type="simple" />
    <xbrli:context id="From2014-10-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_Level1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_Level1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_Level2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_Level2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_Level3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_Level3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:Level3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_TotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">CVM:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesAThroughEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAThroughEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesAThroughEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAThroughEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesFAndGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFAndGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesFAndGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFAndGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SeriesQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesAThroughEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAThroughEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesFAndGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFAndGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2015-10-01to2016-09-30">CEL SCI CORP</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-10-01to2016-09-30">0000725363</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2015-10-01to2016-09-30">10-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2015-10-01to2016-09-30">2016-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2015-10-01to2016-09-30">true</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-10-01to2016-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2015-10-01to2016-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2015-10-01to2016-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2015-10-01to2016-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2015-10-01to2016-09-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2015-10-01to2016-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2015-10-01to2016-09-30">2016</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2917996</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5726682</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">41612</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">8513620</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">394515</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">87214</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">981677</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">979655</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">154995</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">150000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1008642</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1401839</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">5457825</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">8345390</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">5887646</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-429821</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">8833183</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-487793</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">256547</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">291564</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1820917</us-gaap:DepositAssets>
    <us-gaap:DepositAssets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1970917</us-gaap:DepositAssets>
    <us-gaap:Assets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24886125</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">28553702</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">11598247</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13287878</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">15447603</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13106099</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3091512</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5128682</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">378672</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">88575</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">538278</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">365131</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1104057</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">4011772</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6705470</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">8394934</us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">13686587</us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">125000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">126639</us-gaap:DeferredRevenue>
    <us-gaap:Liabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">25565338</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">33315972</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">12554315</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13011023</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">20532722</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">12783250</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">62350</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">44910</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">284649559</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">269071450</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-285391122</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-273878630</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">-211833741</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-239186420</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-679213</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-4762270</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">6700090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">10783813</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12376</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">32726</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">218848282</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">249937507</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-212160568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-239186420</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">44910</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">269071450</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-273878630</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">62350</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">284649559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-285391122</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-956068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">276855</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-5085119</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">322850</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24886125</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">28553702</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">6235035</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">4490975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">6235035</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-09-30" unitRef="Shares" decimals="INF">4490975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherIncome contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">657377</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">285055</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">101329</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-66304</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">264033</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="0">20976</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">32775</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">129975</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">136838</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">197620</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">389223</us-gaap:OtherIncome>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">19191750</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">17445382</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">15266189</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30_us-gaap_CollaborativeArrangementMember" unitRef="USD" decimals="0">7200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-10-01to2015-09-30_us-gaap_CollaborativeArrangementMember" unitRef="USD" decimals="0">6700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-10-01to2014-09-30_us-gaap_CollaborativeArrangementMember" unitRef="USD" decimals="0">4400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">19351779</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906397</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">21098147</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906397</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">17172587</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906398</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">13855775</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">6486501</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">10665558</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">33047525</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">23931883</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">6738472</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">7797084</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">25931747</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="0">5327509</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">5829779</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">6036123</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">9655979</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">7480363</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">8114099</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">25838280</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906397</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">34953922</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906397</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">27838145</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1906398</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-32390148</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-23646828</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-25667714</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">282616</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">14013726</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">248767</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-620457</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-620457</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-34692210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-27352679</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-27352679</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-34692210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-11466498</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-45994</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-34674646</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-17564</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-27366265</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13586</us-gaap:NetIncomeLoss>
    <CVM:IssuanceOfAdditionalShares contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</CVM:IssuanceOfAdditionalShares>
    <CVM:IssuanceOfAdditionalShares contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:IssuanceOfAdditionalShares>
    <CVM:IssuanceOfAdditionalShares contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">1117447</CVM:IssuanceOfAdditionalShares>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-34692210</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-1128090</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-9871939</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-28470126</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="0">2332734</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-8855530</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-3861606</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">-7846983</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-12559695</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-4413593</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2014-10-01to2015-09-30" unitRef="USDPShares" decimals="INF">-10.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-2.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2013-10-01to2014-09-30" unitRef="USDPShares" decimals="INF">-12.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2014-10-01to2014-12-31" unitRef="USDPShares" decimals="INF">-2.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" decimals="INF">-4.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-04-01to2015-06-30" unitRef="USDPShares" decimals="INF">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USDPShares" decimals="INF">-12.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="From2014-10-01to2015-09-30" unitRef="USDPShares" decimals="INF">-10.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-2.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2013-10-01to2014-09-30" unitRef="USDPShares" decimals="INF">-12.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2014-10-01to2014-12-31" unitRef="USDPShares" decimals="INF">-3.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" decimals="INF">-4.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-04-01to2015-06-30" unitRef="USDPShares" decimals="INF">-1.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USDPShares" decimals="INF">-12.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">3300761</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-10-01to2014-09-30" unitRef="Shares" decimals="INF">2352185</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued contextRef="AsOf2013-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1237533</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3272651</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4490975</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6235035</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">21148378</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">21373696</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">28447246</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12702</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">28434544</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">11787</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">21136591</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">16609</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">21357087</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1270220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1178716</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1660930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-8463957</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-8722073</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-7791448</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7791448</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-8463957</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-8722073</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">165646</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">161571</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">155434</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">66</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">155368</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">97</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">165549</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">163</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">161408</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6591</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9727</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16340</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <CVM:ExerciseOfWarrants contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">4280318</CVM:ExerciseOfWarrants>
    <CVM:ExerciseOfWarrants contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1067</CVM:ExerciseOfWarrants>
    <CVM:ExerciseOfWarrants contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4279251</CVM:ExerciseOfWarrants>
    <CVM:ExerciseOfWarrants contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</CVM:ExerciseOfWarrants>
    <CVM:ConversionOfWarrantLiabilityToEquity contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">1308528</CVM:ConversionOfWarrantLiabilityToEquity>
    <CVM:ConversionOfWarrantLiabilityToEquity contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1308528</CVM:ConversionOfWarrantLiabilityToEquity>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">533976</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">690313</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">627118</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">232</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">626886</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">296</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">533680</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">689813</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">23199</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">29599</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49953</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">9999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9996</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">76991</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">76991</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <CVM:ModificationToWarrants contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">620457</CVM:ModificationToWarrants>
    <CVM:ModificationToWarrants contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">0</CVM:ModificationToWarrants>
    <CVM:ModificationToWarrants contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">620457</CVM:ModificationToWarrants>
    <CVM:ModificationToWarrants contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</CVM:ModificationToWarrants>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6280</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-6280</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4282</CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions>
    <CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16837</CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">35800</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">79359</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">36752</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36752</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">0</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">35800</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">79359</CVM:EquityBasedCompensationNonemployees>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">-40</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">40</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">5105827</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2012683</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">3958637</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-10-01to2014-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3958637</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">43</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-10-01to2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5105784</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-10-01to2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">168</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2012515</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">565915</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">751651</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">694955</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">5105827</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2113433</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">3958637</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">1182</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">313</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">248</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">268</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-5394</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1960</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-7557</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-68268</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">15999</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-158088</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">50181</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">393197</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-435392</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">150000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">145005</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-200000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">3981886</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-2389931</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-751971</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-458633</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">290097</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">433712</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">48</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1639</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">46</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">57170</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">72397</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-78376</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">6358</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">1896</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-3739</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-23833333</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-23082493</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-22928019</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">73399</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">31405</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">103977</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">20132</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2819</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">34887</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-93531</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-34224</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-138864</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">21148378</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">21420301</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">28428641</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">3118387</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">8452</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">8213</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">8137</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">21139926</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">20308031</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">31538891</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-2786938</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-2808686</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">8472008</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <CVM:DecreaseIncreaseInResearchAndOfficeEquipment contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-2345</CVM:DecreaseIncreaseInResearchAndOfficeEquipment>
    <CVM:DecreaseIncreaseInResearchAndOfficeEquipment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:DecreaseIncreaseInResearchAndOfficeEquipment>
    <CVM:DecreaseIncreaseInResearchAndOfficeEquipment contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-1074</CVM:DecreaseIncreaseInResearchAndOfficeEquipment>
    <CVM:DecreaseIncreaseInPatentCosts contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-11685</CVM:DecreaseIncreaseInPatentCosts>
    <CVM:DecreaseIncreaseInPatentCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:DecreaseIncreaseInPatentCosts>
    <CVM:DecreaseIncreaseInPatentCosts contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">4474</CVM:DecreaseIncreaseInPatentCosts>
    <CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-8463957</CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants>
    <CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-8722073</CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants>
    <CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-5320989</CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants>
    <CVM:IncreaseInPrepaidServices contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">3861</CVM:IncreaseInPrepaidServices>
    <CVM:IncreaseInPrepaidServices contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">18021</CVM:IncreaseInPrepaidServices>
    <CVM:IncreaseInPrepaidServices contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">31085</CVM:IncreaseInPrepaidServices>
    <us-gaap:InterestPaidNet contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">1969499</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">1900567</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">1965949</us-gaap:InterestPaidNet>
    <us-gaap:FixturesAndEquipmentGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3158633</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">3268757</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">133499</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">141347</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">131910</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">131910</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24607798</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">24725770</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">7256962</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6779939</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">680000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">626000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">703000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1258610</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1525791</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1272063</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1234227</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">40471</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">42785</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">5105827</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2113433</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">3958637</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">565915</CVM:NonemployeesShareBasedCompensation>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">751651</CVM:NonemployeesShareBasedCompensation>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">771946</CVM:NonemployeesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.7338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">.7558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.7281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.8619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">.809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.8687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.0235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">.0156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <CVM:ExpectedLifeOfOptionsMin1 contextRef="From2014-10-01to2015-09-30">P3Y</CVM:ExpectedLifeOfOptionsMin1>
    <CVM:ExpectedLifeOfOptionsMin1 contextRef="From2015-10-01to2016-09-30">P3Y</CVM:ExpectedLifeOfOptionsMin1>
    <CVM:ExpectedLifeOfOptionsMin1 contextRef="From2013-10-01to2014-09-30">P3Y</CVM:ExpectedLifeOfOptionsMin1>
    <CVM:ExpectedLifeOfOptionsMax contextRef="From2014-10-01to2015-09-30">P9Y9M4D</CVM:ExpectedLifeOfOptionsMax>
    <CVM:ExpectedLifeOfOptionsMax contextRef="From2015-10-01to2016-09-30">P9Y8M8D</CVM:ExpectedLifeOfOptionsMax>
    <CVM:ExpectedLifeOfOptionsMax contextRef="From2013-10-01to2014-09-30">P9Y9M4D</CVM:ExpectedLifeOfOptionsMax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <CVM:WeightedAverageGrantDateFairValueBeginning contextRef="From2014-10-01to2015-09-30" unitRef="USDPShares" decimals="INF">53.75</CVM:WeightedAverageGrantDateFairValueBeginning>
    <CVM:WeightedAverageGrantDateFairValueBeginning contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">43.00</CVM:WeightedAverageGrantDateFairValueBeginning>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2014-10-01to2015-09-30" unitRef="USDPShares" decimals="INF">43.00</CVM:WeightedAverageGrantDateFairValueEnding>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">37.00</CVM:WeightedAverageGrantDateFairValueEnding>
    <us-gaap:RestrictedStockExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">3400000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">634000</us-gaap:RestrictedStockExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">170000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">168000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">160000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">300000</us-gaap:LeaseAndRentalExpense>
    <CVM:RDDeferredRentLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2000</CVM:RDDeferredRentLiability>
    <CVM:RDDeferredRentLiability contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6000</CVM:RDDeferredRentLiability>
    <CVM:DeferredRentLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">18000</CVM:DeferredRentLiability>
    <CVM:DeferredRentLiability contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">13000</CVM:DeferredRentLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_Level1Member" unitRef="USD" decimals="0">3111361</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-09-30_Level1Member" unitRef="USD" decimals="0">7363555</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_Level2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-09-30_Level2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_Level3Member" unitRef="USD" decimals="0">5283573</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-09-30_Level3Member" unitRef="USD" decimals="0">6323032</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_TotalMember" unitRef="USD" decimals="0">8394934</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-09-30_TotalMember" unitRef="USD" decimals="0">13686587</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">5283573</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6323032</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">307894</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-1988082</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-9761532</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">248767</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-34692210</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-28718893</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <CVM:OptionsAndWarrantsExcludedFromEarningsPerShare contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">2336842</CVM:OptionsAndWarrantsExcludedFromEarningsPerShare>
    <CVM:OptionsAndWarrantsExcludedFromEarningsPerShare contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">3675281</CVM:OptionsAndWarrantsExcludedFromEarningsPerShare>
    <CVM:OptionsAndWarrantsExcludedFromEarningsPerShare contextRef="From2013-10-01to2014-09-30" unitRef="Shares" decimals="INF">1599788</CVM:OptionsAndWarrantsExcludedFromEarningsPerShare>
    <CVM:AntidilutiveConvertibleDebt contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">74851</CVM:AntidilutiveConvertibleDebt>
    <CVM:AntidilutiveConvertibleDebt contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">0</CVM:AntidilutiveConvertibleDebt>
    <CVM:AntidilutiveConvertibleDebt contextRef="From2013-10-01to2014-09-30" unitRef="Shares" decimals="INF">11041</CVM:AntidilutiveConvertibleDebt>
    <CVM:AntidilutiveUnvestedRestrictedStock contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">604000</CVM:AntidilutiveUnvestedRestrictedStock>
    <CVM:AntidilutiveUnvestedRestrictedStock contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">604000</CVM:AntidilutiveUnvestedRestrictedStock>
    <CVM:AntidilutiveUnvestedRestrictedStock contextRef="From2013-10-01to2014-09-30" unitRef="Shares" decimals="INF">628000</CVM:AntidilutiveUnvestedRestrictedStock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">3015693</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4279281</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-10-01to2014-09-30" unitRef="Shares" decimals="INF">2238829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-1964221</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1879390</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">-466699</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-482213</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="0">-483693</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-464796</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-464202</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">-490812</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-494156</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-497040</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">282616</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">14013726</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesAThroughEWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesAThroughEWarrantsMember" unitRef="USD" decimals="0">6105</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesNMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesNMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesFAndGWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesFAndGWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesQMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesQMember" unitRef="USD" decimals="0">12000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesRMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesRMember" unitRef="USD" decimals="0">157500</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_SeriesHMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_SeriesHMember" unitRef="USD" decimals="0">12000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-07-01to2016-09-30" unitRef="USD" decimals="0">5975752</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="0">-1526338</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">4252193</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">-1705466</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">248767</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesTMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">44552</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="0">8122960</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-2593730</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">2508744</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">2162970</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-4782796</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">4428780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesAThroughEWarrantsMember" unitRef="USD" decimals="0">1</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesNMember" unitRef="USD" decimals="0">-1404027</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesFAndGWarrantsMember" unitRef="USD" decimals="0">12667</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesHMember" unitRef="USD" decimals="0">24000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesQMember" unitRef="USD" decimals="0">36000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">4658228</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesRMember" unitRef="USD" decimals="0">131250</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">1098787</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesTMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesTMember" unitRef="USD" decimals="0">276122</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">75738</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">73967</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">1724739</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">3260913</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">997226</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">75229</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">672246</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">53139</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2014-10-01to2015-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2013-10-01to2014-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">3300761</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-07-01to2016-09-30" unitRef="Shares" decimals="INF">5371635</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-07-01to2015-09-30" unitRef="Shares" decimals="INF">3881600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-10-01to2015-12-31" unitRef="Shares" decimals="INF">4390740</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">4736809</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-04-01to2016-06-30" unitRef="Shares" decimals="INF">4965300</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-10-01to2014-12-31" unitRef="Shares" decimals="INF">2930431</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">3033915</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-04-01to2015-06-30" unitRef="Shares" decimals="INF">3351852</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">3300761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2016-07-01to2016-09-30" unitRef="Shares" decimals="INF">5371635</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-07-01to2015-09-30" unitRef="Shares" decimals="INF">3881600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-10-01to2015-12-31" unitRef="Shares" decimals="INF">4465591</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">4736809</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2016-04-01to2016-06-30" unitRef="Shares" decimals="INF">4965300</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2014-10-01to2014-12-31" unitRef="Shares" decimals="INF">2930431</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">3033915</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-04-01to2015-06-30" unitRef="Shares" decimals="INF">3405364</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">720494</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">663988</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">745496</us-gaap:DepreciationAndAmortization>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1104057</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">305341</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</CVM:IncreaseInDirectFinancingCosts>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">46605</CVM:IncreaseInDirectFinancingCosts>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">0</CVM:IncreaseInDirectFinancingCosts>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-12-09" unitRef="Shares" decimals="INF">7548976</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">60807407</dei:EntityPublicFloat>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt; &amp;#8211; For&#13;purposes of the statements of cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term&#13;money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months&#13;as cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Prepaid Expenses&lt;/i&gt; &amp;#8211; Prepaid expenses&#13;are payments for future services to be rendered and are expensed over the time period for which the service is rendered. Prepaid&#13;expenses may also include payment for goods to be received within one year of the payment date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Inventory&lt;/i&gt; &amp;#8211; Inventory consists&#13;of manufacturing production advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&amp;#8217;s&#13;product for clinical studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in,&#13;first out method applied on a consistent basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deposits&lt;/i&gt; &amp;#8211; The deposits are required&#13;by the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Research and Office Equipment&lt;/i&gt;&amp;#8211;&#13;Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of&#13;five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term&#13;of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are&#13;reviewed on a quarterly basis to assess impairment, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Patents&lt;/i&gt; &amp;#8211; Patent expenditures are&#13;capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the&#13;patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate&#13;adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted&#13;cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The&#13;amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deferred Rent &lt;/i&gt; &amp;#8211; Certain of the Company&amp;#8217;s operating leases&#13;provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate minimum annual payments are expensed&#13;on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when&#13;the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed&#13;the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays, the Company records a deferred rent&#13;liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Derivative Instruments&lt;/i&gt; - The Company&#13;has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features,&#13;specifically, the settlement provisions in the warrant agreements preclude the warrants from being treated as equity. The Company&#13;accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting for Derivative&#13;Instruments and Hedging Activities&amp;#8221;. In accordance with accounting principles generally accepted in the United States (U.S.&#13;GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are&#13;measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the&#13;derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based&#13;on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each&#13;instrument. The derivative liabilities are re-measured at fair value at the end of each reporting period as long as they are outstanding.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Grant Income&lt;/i&gt; &amp;#8211; The Company's grant&#13;arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt; &amp;#8211;&#13;Research and development expenditures are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Leases &amp;#8211; &lt;/i&gt;Leases are&#13;categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over&#13;the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of&#13;capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes&#13;an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural&#13;improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit&#13;leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.&#13;If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on&#13;the Company's balance sheet.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt; &amp;#8211; The&#13;Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (ASC 260). Basic and diluted&#13;net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number&#13;of common shares outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common&#13;stock options, restricted stock units, convertible preferred stock and common stock warrants, have not been included in the computation&#13;of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt; &amp;#8211;&#13;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&amp;#160;&#13;The Company maintains its cash and cash equivalents with high quality financial institutions.&amp;#160; At times, these accounts may&#13;exceed federally insured limits.&amp;#160; The Company has not experienced any losses in such bank accounts.&amp;#160; The Company believes&#13;it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were&#13;fully insured&amp;#160;up to $250,000 at September 30, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt; &amp;#8211; The Company uses&#13;the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities&#13;are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing&#13;assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities&#13;are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are&#13;expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized&#13;in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax&#13;assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred&#13;tax assets as of September 30, 2016 and 2015.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt; &amp;#8211; The preparation&#13;of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported&#13;in the financial statements and the accompanying disclosures. These estimates are based on management&amp;#8217;s best knowledge of&#13;current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory&#13;obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets&#13;and the related valuation allowance, and the valuation of derivative liabilities.&lt;font style="color: #444444"&gt;&amp;#160;&lt;/font&gt;Actual&#13;results could differ from estimates, although management does not generally believe such differences would materially affect the&#13;financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using various&#13;valuation techniques including the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect&#13;the financial statements in a given year. The Company considers such valuations to be significant estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt; &amp;#8211; The Company&#13;evaluates financial assets and liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize&#13;the inputs used to measure fair value. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest&#13;level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 12 for&#13;the definition of levels and the classification of assets and liabilities in those levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#8211; Compensation&#13;cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &amp;#8220;Compensation&#13;&amp;#8211; Stock Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model.&#13;The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based&#13;compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments issued to non-employees are&#13;accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non-Employees.&amp;#8221; Accordingly, compensation is&#13;recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of&#13;award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the&#13;measurement date and the expected life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has Incentive Stock Option Plans,&#13;Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,&#13;these Plans are collectively referred to as the &amp;#8220;Plans.&amp;#8221; All Plans have been approved by the Company&amp;#8217;s stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock options are not transferable,&#13;and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price&#13;on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance&#13;of daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate&#13;at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise&#13;and employee termination within the valuation model. The expected term of options represents the period of time that options granted&#13;are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions&#13;used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in&#13;the future from that recorded in the current period.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vesting of restricted stock granted under the&#13;Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.&#13;These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is&#13;probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Reclassification&lt;/i&gt; &amp;#8211; Certain prior&#13;year items have been reclassified to conform to the current year presentation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt; &amp;#8211;&#13;In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, &lt;i&gt;Revenue from Contracts with Customers (Topic 606)&lt;/i&gt;&#13;that will supersede virtually all recognition guidance in US GAAP. For public entities, the guidance is effective for annual and&#13;interim periods beginning after December 15, 2017. Early adoption is permitted for all entities for annual and interim periods&#13;beginning after December 15, 2016. The FASB issued the following ASUs to amend the new guidance: ASU 2015-14, &lt;i&gt;Revenue from Contracts&#13;with Customers (Topic 606): Deferral of the Effective Date,&lt;/i&gt; ASU 2016-08, &lt;i&gt;Revenue from Contracts with Customers (Topic 606):&#13;Principal versus Agent Considerations (Reporting Revenue Gross versus Net),&lt;/i&gt; ASU 2016-10&lt;i&gt;, Revenue from Contracts with Customers&#13;(Topic 606): Identifying Performance Obligations and Licensing, and&lt;/i&gt; ASU 2016-12&lt;i&gt;, Revenue from Contracts with Customers (Topic&#13;606): Narrow-Scope Improvements and Practical Expedients.&lt;/i&gt; Management does not expect the new standard or any of the related&#13;updates to have a material effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, the FASB issued Accounting&#13;Standards Update (ASU) No. 2016-01, &lt;i&gt;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of&#13;Financial Assets and Financial Liabilities.&lt;/i&gt; The new guidance is intended to improve the recognition and measurement of financial&#13;instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within&#13;those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new&#13;standard to have a material effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;,&#13;which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance&#13;sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases&#13;are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current&#13;standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December&#13;15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning&#13;with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial&#13;statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2016, the FASB issued ASU No. 2016-09,&#13;&lt;i&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&lt;/i&gt; ASU 2016-09 simplifies&#13;several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification&#13;of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective&#13;for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The&#13;Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 amends eight specific&#13;cash flow issues: 1.) Debt Prepayment or Debt Extinguishment Costs, 2.) Settlement of Zero-Coupon Debt Instruments or Other Debt&#13;Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing, 3.)&#13;Contingent Consideration Payments Made after a Business Combination, 4.) Proceeds from the Settlement of Insurance Claims, 5.)&#13;Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned Life Insurance Policies, 6.) Distributions&#13;Received from Equity Method Investees, 7.) Beneficial Interests in Securitization Transactions, 8.) Separately Identifiable Cash&#13;Flows and Application of the Predominance Principle. Management does not expect the adoption of the amendments in this Update to&#13;have a material effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2016, the FASB issued ASU 2016-18,&#13;Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during&#13;the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.&#13;Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash&#13;equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The&#13;amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim&#13;periods within those fiscal years. Management does not expect the adoption of the amendments in this Update to have a material&#13;effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has considered all other recently&#13;issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and office equipment consisted of the&#13;following at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Manufacturing building&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,183,756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,783,756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Research equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,158,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,268,757&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;133,499&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;141,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,607,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,725,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,256,962&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(6,779,939&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net plant, property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,350,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,945,831&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The Company is&#13;not the legal owner of the manufacturing building, but is deemed to be the owner for accounting purposes based on the&#13;accounting guidance for build-to-suit leases. See Note 10, Commitments and Contingencies &amp;#8211; Lease Obligations for&#13;additional information. As of September 30, 2016 and 2015, accumulated depreciation on the manufacturing building&#13;is approximately $4.1 million and $3.5 million, respectively. Depreciation expense for the years ended September 30, 2016,&#13;2015 and 2014 totaled approximately $626,000, $680,000 and $703,000, respectively. Depreciation expense includes depreciation&#13;on the leased manufacturing building of approximately $514,000, which is included in research and development costs on&#13;the Statement of Operations. One asset is recorded under capital lease with a net book value of $0 and approximately $8,000&#13;on September 30, 2016 and 2015, respectively. Amortization of the capital lease asset is included in general and&#13;administrative expenses on the Statements of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents consisted of the following at September&#13;30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,528,610&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,525,791&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,272,063.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,234,227.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;256,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;291,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2016, 2015&#13;there was no impairment of patent costs and a nominal impairment charge in 2014. Amortization expense for the years ended September&#13;30, 2016, 2015 and 2014 totaled approximately $38,000, $40,000 and $43,000, respectively. The total estimated future amortization&#13;is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Years ending September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;37,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;36,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;257,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;At September 30, 2016 and 2015, the&#13;Company had federal net operating loss carryforwards of approximately $170.8 million and $156.8 million, respectively. The NOLs&#13;begin to expire during the fiscal year ending September 30, 2019 and become fully expired by the end of the fiscal year ended 2036.&#13;In addition, the Company has a general business credit as a result of the credit for increasing research activities (&amp;#8220;R&amp;#38;D&#13;credit&amp;#8221;) of approximately $1.2 million at September 30, 2016 and 2015. The R&amp;#38;D credit begins to expire during the fiscal&#13;year ending September 30, 2020 and is fully expired during the fiscal year ended 2029. Deferred taxes consisted of the following&#13;at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;64,366,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;61,363,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;R&amp;#38;D credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,379,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,855,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Capitalized R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,508,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,082,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vacation and other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;179,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;114,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Loan modification&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;57,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,653 ,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,692,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets and intangibles&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(49,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(86,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(49,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(86,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(90,604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(83,606,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all,&#13;of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation&#13;of future taxable income. Management has considered the history of the Company&amp;#8217;s operating losses and believes that the&#13;realization of the benefit of the deferred tax assets cannot be reasonably assured. In addition, under Internal Revenue Code Section&#13;382, the Company&amp;#8217;s ability to utilize these net operating loss carryforwards may be limited or eliminated in the event of&#13;future changes in ownership.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company has no federal or state current or deferred tax expense or benefit. The Company&amp;#8217;s effective tax rate differs from&#13;the applicable federal statutory tax rate. The reconciliation of these rates is as follows at September 30:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font-size: 8pt"&gt;Federal Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Other adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Adjustment to deferreds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Permanent differences (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44.90&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(60.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(38.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(58.78&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effective tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;(1) The 2016 amount is&#13;for the most part due to the approximate $14 million gain on derivative instruments from the change in fair value of the Company&amp;#8217;s&#13;warrant liabilities during the period.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company applies the provisions of ASC 740, &lt;i&gt;&amp;#8220;Accounting for Uncertainty in Income Taxes,&amp;#8221;&lt;/i&gt; which requires financial&#13;statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position&#13;will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain&#13;tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September&#13;30, 1998 through 2015. These years remain open to examination by the major domestic taxing jurisdictions to which the Company&#13;is subject.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The Company recognized&#13;the following expenses for options issued or vested and restricted stock awarded during the year:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year&#13;    Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,113,433&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,105,827&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,958,637&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;751,651&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;565,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;771,946&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Stock compensation&#13;is included in general and administrative expense. During the years ended September 30, 2016, 2015 and 2014, non-employee stock&#13;compensation excluded approximately $48,000, $30,000 and $26,000, respectively, for future services to be performed (Note 12).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;During the years&#13;ended September 30, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing&#13;model with the following assumptions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-bottom: 1.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 58%; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected&#13;    stock price volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 75.58&amp;#160;&amp;#8211;&amp;#160;80.9%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 73.38 &amp;#8211; 86.19%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 72.81 &amp;#8211; 86.87%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 0.71 &amp;#8211; 1.56%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 0.93 &amp;#8211; 2.35%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; 0.59 &amp;#8211; 2.65%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected&#13;    life of options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;3.0&#13;    &amp;#8211; 9.69 Years&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3.0&#13;    &amp;#8211; 9.76 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3.0&#13;    &amp;#8211; 9.76 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected&#13;    dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Non-Qualified&#13;Stock Option Plans&lt;/u&gt;--At September 30, 2016, the Company has collectively authorized the issuance of 387,200 shares of common&#13;stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten&#13;years after the grant date. Terms of the options are to be determined by the Company&amp;#8217;s Compensation Committee, which administers&#13;the plans. The Company&amp;#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options&#13;under the Non-Qualified Stock Option Plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Incentive Stock&#13;Option Plans&lt;/u&gt;--At September 30, 2016, the Company had collectively authorized the issuance of 138,400 shares of common stock&#13;under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after&#13;the grant date. Terms of the options were determined by the Company&amp;#8217;s Compensation Committee, which administers the plans.&#13;Only the Company&amp;#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Activity in the&#13;Company&amp;#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2016 is summarized as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&lt;u&gt;Non-Qualified&#13;and Incentive Stock Option Plans&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="15" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&#13;    Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&#13;    Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&lt;br /&gt;&#13;    &lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&#13;    Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Term&#13;    (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&#13;    Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Term&#13;    (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;273,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;74.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.55&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;137,755&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;85.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;62.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;35,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;54,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,820&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;103.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,820&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;103.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;301,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;67.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;181,070&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;78.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;31.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted (b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;21.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;343,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;59.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;232,898&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;66.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding: 0.75pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="12" style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Includes&#13;    90,000 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="21"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 72px; padding: 0.75pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Includes&#13;    410,000 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;A summary of the&#13;status of the Company&amp;#8217;s non-vested options for the two years in the period ended September 30, 2016 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.25in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Grant&#13;    Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;    Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;134,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;53.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(46,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;35,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(4,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;120,438&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;43.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;110,673&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;37.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.25in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Incentive Stock&#13;Bonus Plan&lt;/u&gt;-- On July 22, 2014 the Company's shareholders approved the 2014 Incentive Stock Bonus Plan, authorizing the issuance&#13;of up to 640,000 shares in the Company&amp;#8217;s Incentive Stock Bonus Plan. The shares will only be earned upon the achievement&#13;of certain milestones leading to the commercialization of the Company&amp;#8217;s Multikine technology, or specified increases in&#13;the market price of the Company&amp;#8217;s stock. If the performance or market criteria are not met as specified in the Incentive&#13;Stock Bonus Plan, all or a portion of the awarded shares will be forfeited. The fair value of the shares on the grant date was&#13;calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using&#13;a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of&#13;shares issued that remain outstanding as of September 30, 2016 is approximately $8.6 million. The total value of the shares, if&#13;earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered,&#13;regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service&#13;period is not rendered. During the years ended September 30, 2016 and 2015, the Company recorded expense relating to the issuance&#13;of restricted stock pursuant to the plan of approximately $634,000 and $3.4 million, respectively. At September 30, 2016, the&#13;Company has unrecognized compensation expense of approximately $3.1 million which is expected to be recognized over a weighted&#13;average period of 5.03 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;A summary of the&#13;status of the Company&amp;#8217;s restricted stock units issued from the Incentive Stock Bonus Plan for the two years in the period&#13;ended September 30, 2016 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested&#13;    at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;628,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(4,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested at September&#13;    30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested at September&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Stock Bonus&#13;Plans&lt;/u&gt; -- At September 30, 2016, the Company was authorized to issue up to 223,760 shares of common stock under its Stock Bonus&#13;Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares. During the year ended&#13;September 30, 2016, 16,340 shares were issued to the Company&amp;#8217;s 401(k) plan for a cost of approximately $162,000. During&#13;the year ended September 30, 2015, 9,727 shares were issued to the Company&amp;#8217;s 401(k) plan for a cost of approximately $166,000.&#13;During the year ended September 30, 2014, 6,591 shares were issued to the Company&amp;#8217;s 401(k) plan for a cost of approximately&#13;$155,000. As of September 30, 2016, the Company has issued a total of 126,448 shares of common stock from the Stock Bonus Plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Stock Compensation&#13;Plans&lt;/u&gt;-- At September 30, 2016, 134,000 shares were authorized for use in the Company&amp;#8217;s stock compensation plans. During&#13;the years ended September 30, 2016, 2015 and 2014, 18,593, 8,733 and 16,399 shares, respectively, were issued from the Stock Compensation&#13;Plans to consultants for payment of services at a cost of approximately $234,000, $147,000 and $439,000, respectively. During&#13;the year ended September 30, 2016 and 2015, 3,837 and 4,282 shares, respectively, were issued to employees from the Stock Compensation&#13;Plans as part of their compensation at a cost of approximately $45,000 and $58,000, respectively. No shares were issued to employees&#13;from the Stock Compensation Plans during the year ended September 30, 2014. As of September 30, 2016, the Company has issued 79,391&#13;shares of common stock from the Stock Compensation Plans.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a defined contribution&#13;retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security&#13;Act of 1974, as amended, and covering substantially all Company employees. Each participant&amp;#8217;s contribution is matched by&#13;the Company with shares of common stock that have a value equal to 100% of the participant&amp;#8217;s contribution, not to exceed&#13;the lesser of $10,000 or 6% of the participant&amp;#8217;s total compensation. The Company&amp;#8217;s contribution of common stock is&#13;valued each quarter based upon the closing bid price of the Company&amp;#8217;s common stock. Total expense, including plan maintenance,&#13;for the years ended September 30, 2016, 2015 and 2014, in connection with this Plan was approximately $168,000, $170,000 and $160,000,&#13;respectively.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Effective August 31, 2016, Maximilian&#13;de Clara, the Company&amp;#8217;s President and a director, resigned for health reasons. In payment for past services, the Company&#13;agreed to issue Mr. de Clara 26,000 shares of restricted stock; 13,000 shares upon his resignation and 13,000 on August 31, 2017.&#13;The market value of the shares granted, including the accrued value of the shares to be issued in August 2017, totaled $253,500.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On January 13, 2016, the de Clara&#13;Trust demanded payment on the note payable, of which the balance, including accrued and unpaid interest, was $1,105,989. The de&#13;Clara Trust was established by Maximilian de Clara, the Company&amp;#8217;s former President and a director. The Company&amp;#8217;s Chief&#13;Executive Officer, Geert Kersten, is the trustee and a beneficiary. When the de Clara Trust demanded payment on the note, the Company&#13;sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each&#13;warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per share at any time&#13;on or before January 13, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Prior to the repayment, on June 29,&#13;2015, the Company had extended the maturity date of the note to July 6, 2017, lowered the interest rate from 15% to 9% and changed&#13;the conversion price from $100.00 to $14.75, the closing stock price on the previous trading day. The Company determined these&#13;modifications to be substantive and accounted for the modification as an extinguishment of the pre-modification note and issuance&#13;of the post-modification note. The Company recorded an extinguishment loss and a premium on the note payable of approximately $166,000,&#13;which was credited to additional, paid in capital. Concurrently, the Company extended the expiration date of the Series N warrants&#13;to August 18, 2017. The incremental cost of this modification was approximately $475,000 and was included in debt extinguishment&#13;loss on the note, for a total loss of approximately $620,000 during the year ended September 30, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;During the years ended September&#13;30, 2016, 2015 and 2014, the Company paid approximately $43,000, $146,000 and $179,000, respectively, in interest expense to Mr.&#13;de Clara.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <CVM:StockholdersEquityTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;During the years ended September&#13;30, 2016 and 2015, no warrants were exercised. During the year ended September 30, 2014, 107,822 Series M, N and S warrants were&#13;exercised. The Company issued 106,740 shares of common stock and received approximately $3.1 million from the exercise of these&#13;warrants since 3,709 Series N warrants were exercised in a cashless exercise.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;On October 11, 2013, the Company&#13;closed a public offering of units of common stock and Series S warrants at a price of $25.00 per unit for net proceeds of $16.4&#13;million, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to purchase&#13;one share of common stock. The warrants were immediately exercisable and expire on October 11, 2018, and have an exercise price&#13;of $31.25. In November 2013, the underwriters purchased an additional 105,957 warrants pursuant to the overallotment option, for&#13;which the Company received net proceeds of approximately $24,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;On December 24, 2013, the Company&#13;closed a public offering of units of common stock and Series S warrants at a price of $15.75 per unit for net proceeds of approximately&#13;$2.8 million, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to&#13;purchase one share of common stock. The warrants are immediately exercisable and expire on October 11, 2018, and have an exercise&#13;price of $31.25. The underwriters exercised the option for the full 10% overallotment, for which the Company received net proceeds&#13;of approximately $279,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;The October and December 2013 financings&#13;triggered the reset provision from the August 2008 financing which resulted in the issuance of an additional 62,523 shares of common&#13;stock. The cost of additional shares issued was approximately $1.1 million. This cost was recorded as a deemed a dividend.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;On October 24, 2014, the Company&#13;closed an underwritten public offering of 315,789 shares of common stock and 78,947 Series S warrants to purchase shares of common&#13;stock. Additionally, in a related private offering on October 21, 2014, the Company sold 52,800 shares of common stock and 13,200&#13;Series S warrants to purchase shares of common stock. The common stock and Series S warrants were sold at a combined price of $19.00&#13;for net proceeds of approximately $6.4 million, net of offering expenses. The Series S warrants trade of the NYSE MKT under the&#13;symbol CVM WT.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;On April 17, 2014, the Company closed&#13;a public offering of units consisting of 285,129 shares of common stock and Series T warrants to purchase an aggregate of 71,282&#13;shares of common stock. The units were sold at a price of $35.00 per unit. The Company received net proceeds of approximately $9.1&#13;million after deducting the underwriting commissions and offering expenses. The common stock and warrants separated immediately.&#13;The Series T warrants, with an exercise price of $39.50 per share, expired on October 17, 2014. The underwriters in the offering&#13;received 17,821 Series U warrants to purchase one share of common stock. The Series U warrants expire on October 17, 2017, and&#13;have an exercise price of $43.75.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On May 28, 2015, the Company closed&#13;an underwritten public offering of 810,127 shares of common stock and 810,127 Series V warrants to purchase shares of common stock.&#13;The common stock and Series V warrants were sold at a combined per unit price of $19.75 for net proceeds of approximately $14.7&#13;million, net of underwriting discounts and commissions and offering expenses. The Series V warrants are immediately exercisable&#13;at a price of $19.75 and expire on May 28, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On October 28, 2015, the Company&#13;closed an underwritten public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common&#13;stock. The common stock and warrants were sold at a combined price of $16.75 for net proceeds of approximately $10.5 million, net&#13;of underwriting commissions and offering expenses. The warrants were immediately exercisable, expire October 28, 2020 and have&#13;an exercise price of $16.75.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On May 23, 2016, the Company closed&#13;a registered direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock.&#13;The common stock and warrants were sold at a combined per unit price of $12.50 for net proceeds of approximately $4.6 million,&#13;net of placement agent&amp;#8217;s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after&#13;November 23, 2016 and on or before November 23, 2021 at a price of $13.75 per share. The Company also issued 20,000 Series ZZ warrants&#13;to the placement agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23,&#13;2016 and on or before May 18, 2021 at a price of $13.75 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On August 26, 2016, the Company closed&#13;a registered direct offering of&amp;#160;400,000 shares of common stock and Series AA warrants to purchase up to 200,000 shares of&#13;common stock. Each share of common stock was sold together with a Series AA warrant to purchase one-half of a share of common stock&#13;for the combined purchase price of $12.50. Each warrant can be exercised at any time after February 22, 2017 and on or before February&#13;22, 2022 at a price of $13.75 per share. The Company also issued 16,000 Series BB warrants to the placement agent as part of its&#13;compensation. The Series BB warrants may be exercised at any time on or after February 22, 2017 and on or before August 22, 2021&#13;at a price of $13.75 per share. The Company received proceeds from the sale of Series AA and Series BB shares and warrants of approximately&#13;$4.5 million, net of placement agent&amp;#8217;s commissions and offering expenses&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</CVM:StockholdersEquityTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares&#13;outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common stock options,&#13;common stock warrants, restricted stock and shares issuable on convertible debt, have not been included in the computation of&#13;diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain&#13;on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss&#13;per share because its effect is anti-dilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -20pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders &amp;#8211; Restated (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(28,470,126)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Less:&amp;#160;&amp;#160;Gain&#13;    on derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(248,767)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders &amp;#8211; diluted (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(28,718,893)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average number of shares - basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,866,204&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,300,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,352,185&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    per share &amp;#8211; basic (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.10)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    per share &amp;#8211; diluted (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.21)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1)&#13;See Note 17 &lt;/font&gt;Restatement&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;For&#13;the years ended September 30, 2016 and 2015, the gain on derivatives is not excluded from the numerator in calculating diluted&#13;loss per share because the gain relates to derivative warrants that were priced higher than the average market price during the&#13;period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;accordance with the contingently issuable shares guidance of FASB ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, the calculation of&#13;diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as&#13;of September 30:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2016&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2015&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2014&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options&#13;    and Warrants &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,675,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,336,842&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,599,788&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible&#13;    Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;74,851&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,041&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested&#13;    Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;628,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,279,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,015,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,238,829&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 280, &amp;#8220;&lt;i&gt;Disclosure about Segments&#13;of an Enterprise and Related Information&lt;/i&gt;&amp;#8221; establishes standards for reporting information regarding operating segments&#13;in annual financial statements and requires selected information for those segments to be presented in interim financial reports&#13;issued to stockholders. This topic also establishes standards for related disclosures about products and services and geographic&#13;areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is&#13;available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources&#13;and assess performance. The Company&amp;#8217;s chief decision maker, as defined under this topic, is the Chief Executive Officer.&#13;To date, the Company has viewed its operations as principally one segment, the research and development of certain drugs and vaccines.&#13;As a result, the financial information disclosed herein materially represents all of the financial information related to the Company&amp;#8217;s&#13;principal operating segment.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following quarterly data are derived from the Company&amp;#8217;s restated statement of operations. See Note 17 for information concerning&#13;the Restatement of the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Financial&#13;Data&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fiscal&#13;2016 (restated)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended December 31, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended March 31, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended June 30, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended September 30, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 18.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Year&#13;    ended September 30, 2016 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Grant&#13;    and other income&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,976&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;32,775&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;129,975&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;101,329&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;285,055&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,327,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,829,779&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,036,123&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,738,472&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,931,883&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-operating&#13;    (expenses) income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(483,693)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(464,796)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(464,202)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(466,699)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,879,390)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    (loss) on derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,122,960&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2,593,730)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,508,744&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,975,752&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;14,013,726&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    income (loss) available to common shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;2,332,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (8,855,530)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (3,861,606)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (1,128,090)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;EPS&#13;    (LPS) - basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.87)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(0.78)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(0.21)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average shares:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,390,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,736,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,965,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,371,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,866,204&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,465,591&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,736,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,965,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,371,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,866,204&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fiscal&#13;2015 (restated)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended December 31, 2014 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended March 31, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended June 30, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended September 30, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Year&#13;    ended September 30, 2015 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Grant&#13;    and other income&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;136,838&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;197,620&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;389,223&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(66,304)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;657,377&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;9,655,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,480,363&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,114,099&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,797,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,047,525&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-operating&#13;    (expenses) income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(490,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(494,156)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(497,040)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(482,213)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,964,221)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    (loss) on derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,162,970&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,782,796)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,428,780&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,526,338)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;282,616&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    on debt extinguishment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(620,457)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(620,457)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,846,983)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12,559,695)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,413,593)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(9,871,939)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;LPS&#13;    - basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.68)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4.14)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.32)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.54)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;LPS&#13;    - diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(3.42)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4.14)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.62)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.54)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average shares:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,930,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,033,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,351,852&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,881,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,300,761&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,930,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,033,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,405,364&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,881,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,300,761&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company has experienced large swings in its quarterly gains and losses caused by the changes in the fair value of&#13;warrants each quarter. The results of the restatement did not impact loss per share for any of the periods presented except&#13;for the effects of the 1:25 reverse stock split.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;For purposes of the statements of&#13;cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The&#13;Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Prepaid expenses are payments for future services to be rendered and are expensed&#13;over the time period for which the service is rendered. Prepaid expenses may also include payment for goods to be received within&#13;one year of the payment date.&lt;/font&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Inventory consists of manufacturing production advances and bulk purchases of&#13;laboratory supplies to be consumed in the manufacturing of the Company&amp;#8217;s product for clinical studies. Inventories are stated&#13;at the lower of cost or market, where cost is determined using the first-in, first out method applied on a consistent basis.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <CVM:Deposits2 contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The deposits are required by the lease agreement for the manufacturing facility&#13;and by the clinical research organization (CRO) agreements.&lt;/font&gt;&lt;/p&gt;</CVM:Deposits2>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and office equipment is recorded at&#13;cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements&#13;are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which&#13;do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to assess impairment,&#13;if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Patent expenditures are capitalized and amortized using the straight-line method&#13;over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or&#13;other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization&#13;is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the&#13;asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference&#13;between the estimated fair value of the asset and its carrying value.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Certain of the Company&amp;#8217;s operating&#13;leases provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate minimum annual payments&#13;are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations&#13;when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments&#13;exceed the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays, the Company records a deferred&#13;rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/font&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into financing arrangements&#13;that consist of freestanding derivative instruments that contain embedded derivative features, specifically, the settlement provisions&#13;in the warrant agreements preclude the warrants from being treated as equity. The Company accounts for these arrangements in accordance&#13;with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting for Derivative Instruments and Hedging Activities&amp;#8221;. In&#13;accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments&#13;are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized&#13;in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines&#13;the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models,&#13;giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are re-measured at fair&#13;value at the end of each reporting period as long as they are outstanding.&lt;/p&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <CVM:GrantIncomePolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The Company's grant arrangements are handled on a reimbursement basis. Grant&#13;income under the arrangements is recognized when costs are incurred.&lt;/font&gt;&lt;/p&gt;</CVM:GrantIncomePolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The Company calculates net loss per common share in accordance with ASC 260&#13;&amp;#8220;Earnings Per Share&amp;#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable&#13;to common shareholders by the weighted average number of common shares outstanding during the period. The Company&amp;#8217;s potentially&#13;dilutive shares, which include outstanding common stock options, restricted stock units, convertible preferred stock and common&#13;stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be&#13;anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Financial instruments, which potentially subject the Company to concentrations&#13;of credit risk, consist of cash and cash equivalents.&amp;#160; The Company maintains its cash and cash equivalents with high quality&#13;financial institutions.&amp;#160; At times, these accounts may exceed federally insured limits.&amp;#160; The Company has not experienced&#13;any losses in such bank accounts.&amp;#160; The Company believes it is not exposed to significant credit risk related to cash and&#13;cash equivalents. All non-interest bearing cash balances were fully insured&amp;#160;up to $250,000 at September 30, 2016.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the asset and liability method&#13;of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future&#13;tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using&#13;enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered&#13;or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that&#13;includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is&#13;more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September&#13;30, 2016 and 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The preparation of financial statements in conformity U.S. GAAP requires management&#13;to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#13;These estimates are based on management&amp;#8217;s best knowledge of current events and actions the Company may undertake in the&#13;future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives&#13;for depreciation and amortization of long-lived assets, deferred tax assets and the related valuation allowance, and the valuation&#13;of derivative liabilities.&lt;font style="color: #444444"&gt;&amp;#160;&lt;/font&gt;Actual results could differ from estimates, although management&#13;does not generally believe such differences would materially affect the financial statements in any given year. However, in regard&#13;to the valuation of derivative liabilities determined using various valuation techniques including the Black-Scholes and binomial&#13;pricing methodologies, significant fluctuations may materially affect the financial statements in a given year. The Company considers&#13;such valuations to be significant estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;The Company evaluates financial assets and liabilities subject to fair value&#13;measurements in accordance with a fair value hierarchy to prioritize the inputs used to measure fair value. A financial instrument&amp;#8217;s&#13;level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level&#13;1 is the highest and Level 3 is the lowest. See Note 12 for the definition of levels and the classification of assets and liabilities&#13;in those levels.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation cost for all stock-based awards&#13;is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &amp;#8220;Compensation &amp;#8211; Stock&#13;Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes&#13;model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost&#13;is recognized on the straight line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments issued to non-employees are&#13;accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non-Employees.&amp;#8221; Accordingly, compensation is&#13;recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of&#13;award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the&#13;measurement date and the expected life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has Incentive Stock Option Plans,&#13;Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,&#13;these Plans are collectively referred to as the &amp;#8220;Plans.&amp;#8221; All Plans have been approved by the Company&amp;#8217;s stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock options are not transferable,&#13;and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on&#13;the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of&#13;daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at&#13;date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and&#13;employee termination within the valuation model. The expected term of options represents the period of time that options granted&#13;are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions&#13;used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in&#13;the future from that recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vesting of restricted stock granted under the&#13;Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.&#13;These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is&#13;probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Certain prior year items have been reclassified to conform to the current year&#13;presentation.&lt;/font&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued Accounting Standards&#13;Update (ASU) 2014-09, &lt;i&gt;Revenue from Contracts with Customers (Topic 606)&lt;/i&gt; that will supersede virtually all recognition guidance&#13;in US GAAP. For public entities, the guidance is effective for annual and interim periods beginning after December 15, 2017. Early&#13;adoption is permitted for all entities for annual and interim periods beginning after December 15, 2016. The FASB issued the following&#13;ASUs to amend the new guidance: ASU 2015-14, &lt;i&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&lt;/i&gt;&#13;ASU 2016-08, &lt;i&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross&#13;versus Net),&lt;/i&gt; ASU 2016-10&lt;i&gt;, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#13;and&lt;/i&gt; ASU 2016-12&lt;i&gt;, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.&lt;/i&gt;&#13;Management does not expect the new standard or any of the related updates to have a material effect on its financial statements&#13;and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, the FASB issued Accounting&#13;Standards Update (ASU) No. 2016-01, &lt;i&gt;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of&#13;Financial Assets and Financial Liabilities.&lt;/i&gt; The new guidance is intended to improve the recognition and measurement of financial&#13;instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within&#13;those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new&#13;standard to have a material effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;,&#13;which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance&#13;sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases&#13;are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current&#13;standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December&#13;15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning&#13;with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial&#13;statements and related disclosures.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2016, the FASB issued ASU No. 2016-09,&#13;&lt;i&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&lt;/i&gt; ASU 2016-09 simplifies&#13;several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification&#13;of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective&#13;for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The&#13;Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 amends eight specific&#13;cash flow issues: 1.) Debt Prepayment or Debt Extinguishment Costs, 2.) Settlement of Zero-Coupon Debt Instruments or Other Debt&#13;Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing, 3.)&#13;Contingent Consideration Payments Made after a Business Combination, 4.) Proceeds from the Settlement of Insurance Claims, 5.)&#13;Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned Life Insurance Policies, 6.) Distributions&#13;Received from Equity Method Investees, 7.) Beneficial Interests in Securitization Transactions, 8.) Separately Identifiable Cash&#13;Flows and Application of the Predominance Principle. Management does not expect the adoption of the amendments in this Update to&#13;have a material effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2016, the FASB issued ASU 2016-18,&#13;Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during&#13;the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.&#13;Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash&#13;equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The&#13;amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim&#13;periods within those fiscal years. Management does not expect the adoption of the amendments in this Update to have a material&#13;effect on its financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has considered all other recently&#13;issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <CVM:DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;following chart represents the warrants and non-employee options outstanding at September 30, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrant&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Issue&#13;    &lt;u&gt;Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares&#13;    Issuable upon Exercise of &lt;u&gt;Warrant&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    &lt;u&gt;Price&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Expiration&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Refer-ence&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;105,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$100.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/13&#13;    -10/24/14 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,037,010&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1/13/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1/13/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/15/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/15/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11/23/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/18/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/22/22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/22/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$4,112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/2/11-&#13;    7/1/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$9.25-&amp;#160;&amp;#160;$87.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/27/16-&#13;    6/30/19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;following chart represents the warrants and non-employee options outstanding at September 30, 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Issue&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares&#13;    Issuable upon Exercise of &lt;u&gt;Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    &lt;u&gt;Price&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Expiration&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Refer-ence&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Q&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6/21/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$125.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/22/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,625,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$100..00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/13-&#13;    10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,928,010&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;445,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,253,164&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;590,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;$112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/14/05&#13;    &amp;#8211; 7/1/15 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$16.50&#13;    &amp;#8211; $500.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/14/15&#13;    - 6/30/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</CVM:DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,363,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44,551&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,620,253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,278,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,799,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;970,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;70,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;763,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;58,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Total derivative liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,394,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,686,587&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant Series&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font-size: 8pt"&gt;Series A - E&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,105&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series F and G&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series H&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,404,027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Q&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;36,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;157,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;131,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,252,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,705,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,098,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series T&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;276,122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,738&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;73,967&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,658,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,724,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,260,913&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;997,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;672,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;53,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Net gain&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,013,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;282,616&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;248,767&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,528,610&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,525,791&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,272,063.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,234,227.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;256,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;291,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Years ending September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;37,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;36,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;257,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <CVM:ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Year Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 8pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,113,433&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,105,827&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,958,637&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;751,651&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;565,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;771,946&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 58%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 75.58&amp;#160;&amp;#8211;&amp;#160;80.9%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 73.38 &amp;#8211; 86.19%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 72.81 &amp;#8211; 86.87%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 0.71 &amp;#8211; 1.56%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 0.93 &amp;#8211; 2.35%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; 0.59 &amp;#8211; 2.65%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected life of options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;3.0 &amp;#8211; 9.69 Years&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.0 &amp;#8211; 9.76 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.0 &amp;#8211; 9.76 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &amp;#160; -&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;273,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;74.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6.55&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;137,755&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;62.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;54,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,820&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;103.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,820&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;103.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;301,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;67.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;181,070&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;78.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;31.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;343,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;59.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;232,898&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;66.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="12" style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Includes 90,000 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="21"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 72px; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;(b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Includes 410,000 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <CVM:ScheduleOfNonvestedOptionsTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;134,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;53.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(46,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,438&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;43.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;110,673&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;37.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleOfNonvestedOptionsTableTextBlock>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at October 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;628,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(4,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Courier New, Courier, Monospace; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2016&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2015&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2014&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options&#13;    and Warrants &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,675,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,336,842&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,599,788&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible&#13;    Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;74,851&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,041&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested&#13;    Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;628,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,279,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,015,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,238,829&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Fiscal 2016&#13;(restated)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended December 31, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended March 31, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended June 30, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended September 30, 2016 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 18.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Year&#13;    ended September 30, 2016 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Grant&#13;    and other income&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,976&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;32,775&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;129,975&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;101,329&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;285,055&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,327,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,829,779&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,036,123&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,738,472&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,931,883&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-operating&#13;    (expenses) income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(483,693)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(464,796)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(464,202)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(466,699)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,879,390)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    (loss) on derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,122,960&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2,593,730)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,508,744&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,975,752&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;14,013,726&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    income (loss) available to common shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;2,332,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (8,855,530)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (3,861,606)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (1,128,090)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&#13;    (11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;EPS&#13;    (LPS) - basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.87)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(0.78)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(0.21)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average shares:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,390,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,736,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,965,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,371,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,866,204&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,465,591&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,736,809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,965,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,371,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,866,204&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Fiscal 2015&#13;(restated)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended December 31, 2014 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended March 31, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended June 30, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Three&#13;    months ended September 30, 2015 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Year&#13;    ended September 30, 2015 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Grant&#13;    and other income&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;136,838&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;197,620&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;389,223&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(66,304)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;657,377&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;9,655,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,480,363&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,114,099&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,797,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,047,525&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-operating&#13;    (expenses) income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(490,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(494,156)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(497,040)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(482,213)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,964,221)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    (loss) on derivatives&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,162,970&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,782,796)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,428,780&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,526,338)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;282,616&#13;    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    on debt extinguishment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(620,457)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(620,457)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,846,983)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12,559,695)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,413,593)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(9,871,939)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;LPS&#13;    - basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.68)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4.14)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.32)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.54)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;LPS&#13;    - diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(3.42)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4.14)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1.62)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.54)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average shares:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,930,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,033,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,351,852&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,881,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,300,761&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,930,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,033,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,405,364&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,881,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,300,761&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <CVM:FullyInsuredAmountOfNoninterestBearingCashBalances contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">250000</CVM:FullyInsuredAmountOfNoninterestBearingCashBalances>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesNMember">2017-08-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_SeriesNMember">2017-08-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_SeriesQMember">2015-12-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesRMember">2016-12-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_SeriesRMember">2016-12-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesPMember">2017-03-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_SeriesPMember">2017-03-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2018-10-11</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_custom_SeriesSMember">2018-10-11</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember">2017-10-17</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember">2020-05-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_custom_SeriesUMember">2017-10-17</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2014-10-01to2015-09-30_custom_SeriesVMember">2020-05-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember">2020-10-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesXMember">2021-01-13</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesYMember">2021-02-15</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember">2021-11-23</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember">2021-05-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember">2022-02-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember">2021-08-22</CVM:ExpirationDate1>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesNMember">2008-08-18</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_SeriesNMember">2008-08-18</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_SeriesQMember">2012-06-21</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesRMember">2012-12-06</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_SeriesRMember">2012-12-06</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesPMember">2012-02-10</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_SeriesPMember">2012-02-10</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember">2014-04-17</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember">2015-05-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_custom_SeriesUMember">2014-04-17</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2014-10-01to2015-09-30_custom_SeriesVMember">2015-05-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember">2015-10-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesXMember">2016-01-13</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesYMember">2016-02-15</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember">2016-08-26</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember">2016-08-26</CVM:Issuedate2>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesNMember" unitRef="Shares" decimals="INF">113785</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesQMember" unitRef="Shares" decimals="INF">48000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesPMember" unitRef="Shares" decimals="INF">23600</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="Shares" decimals="INF">25600</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesRMember" unitRef="Shares" decimals="INF">105000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_SeriesNMember" unitRef="Shares" decimals="INF">113785</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_custom_SeriesQMember" unitRef="Shares" decimals="INF">48000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_SeriesRMember" unitRef="Shares" decimals="INF">105000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_ConsultantsMember" unitRef="Shares" decimals="INF">9520</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesSMember" unitRef="Shares" decimals="INF">1037120</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesUMember" unitRef="Shares" decimals="INF">17821</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesVMember" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesWMember" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesXMember" unitRef="Shares" decimals="INF">120000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesYMember" unitRef="Shares" decimals="INF">26000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesZMember" unitRef="Shares" decimals="INF">264000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesZZMember" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesAAMember" unitRef="Shares" decimals="INF">200000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesBBMember" unitRef="Shares" decimals="INF">16000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_custom_SeriesSMember" unitRef="Shares" decimals="INF">1037120</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_custom_SeriesUMember" unitRef="Shares" decimals="INF">17821</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_custom_SeriesVMember" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2015-09-30_custom_SeriesPMember" unitRef="Shares" decimals="INF">23600</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesNMember" unitRef="USDPShares" decimals="INF">13.18</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesQMember" unitRef="USDPShares" decimals="INF">125.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesPMember" unitRef="USDPShares" decimals="INF">112.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesRMember" unitRef="USDPShares" decimals="INF">100.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_SeriesNMember" unitRef="USDPShares" decimals="INF">13.18</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_custom_SeriesQMember" unitRef="USDPShares" decimals="INF">125.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_SeriesRMember" unitRef="USDPShares" decimals="INF">100.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesSMember" unitRef="USDPShares" decimals="INF">31.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesUMember" unitRef="USDPShares" decimals="INF">43.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesVMember" unitRef="USDPShares" decimals="INF">19.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesWMember" unitRef="USDPShares" decimals="INF">16.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesXMember" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesYMember" unitRef="USDPShares" decimals="INF">12.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesZMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesZZMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesAAMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesBBMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_custom_SeriesSMember" unitRef="USDPShares" decimals="INF">31.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_custom_SeriesUMember" unitRef="USDPShares" decimals="INF">43.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_custom_SeriesVMember" unitRef="USDPShares" decimals="INF">19.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2015-09-30_custom_SeriesPMember" unitRef="USDPShares" decimals="INF">112.50</CVM:ExercisePrice>
    <CVM:ExercisePriceMinimum contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePriceMinimum>
    <CVM:ExercisePriceMinimum contextRef="AsOf2015-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">16.50</CVM:ExercisePriceMinimum>
    <CVM:ExercisePriceMaximum contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">87.50</CVM:ExercisePriceMaximum>
    <CVM:ExercisePriceMaximum contextRef="AsOf2015-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">500.00</CVM:ExercisePriceMaximum>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">37000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">36000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">35000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">31000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">28000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30_OutstandingMember" unitRef="Shares" decimals="INF">301507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_OutstandingMember" unitRef="Shares" decimals="INF">343571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30_ExercisableMember" unitRef="Shares" decimals="INF">181070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_ExercisableMember" unitRef="Shares" decimals="INF">232898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">273246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">137755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="Shares" decimals="INF">48544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">35748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <CVM:NumberOfStocksExpired contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="Shares" decimals="INF">4240</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2015-10-01to2016-09-30_ExercisableMember" unitRef="Shares" decimals="INF">4240</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">2820</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">2820</CVM:NumberOfStocksExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">67.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">59.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">78.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">66.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">74.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">85.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">16.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">46.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">145.00</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2015-10-01to2016-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">145.00</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">103.75</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">103.75</CVM:WeightedAverageExercisePriceExpired>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-10-01to2016-09-30_OutstandingMember">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-10-01to2016-09-30_ExercisableMember">P5Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember">P5Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2015-10-01to2016-09-30_OutstandingMember">P5Y4M6D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2015-10-01to2016-09-30_ExercisableMember">P4Y9M4D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember">P5Y11M23D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember">P5Y4D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2015-09-30_OutstandingMember" unitRef="USD" decimals="0">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2016-09-30_OutstandingMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2015-09-30_ExercisableMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2016-09-30_ExercisableMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2014-09-30_custom_OutstandingMember" unitRef="USD" decimals="0">3600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2014-09-30_custom_ExercisableMember" unitRef="USD" decimals="0">3600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <CVM:NumberOfStockVested contextRef="From2015-10-01to2016-09-30_ExercisableMember" unitRef="Shares" decimals="INF">56069</CVM:NumberOfStockVested>
    <CVM:NumberOfStockVested contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">46134</CVM:NumberOfStockVested>
    <CVM:WeightedAverageExercisePriceVested contextRef="From2015-10-01to2016-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">31.75</CVM:WeightedAverageExercisePriceVested>
    <CVM:WeightedAverageExercisePriceVested contextRef="From2014-10-01to2015-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">62.00</CVM:WeightedAverageExercisePriceVested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2015-10-01to2016-09-30">P5Y11D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">243000</us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">251000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">258000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">238000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">163000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">69000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1222000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-10-01to2015-09-30" unitRef="USDPShares" decimals="INF">-10.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2016-09-30" unitRef="USDPShares" decimals="INF">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2015-12-31" unitRef="USDPShares" decimals="INF">0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="USDPShares" decimals="INF">-1.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="USDPShares" decimals="INF">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USDPShares" decimals="INF">-2.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USDPShares" decimals="INF">-10.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <CVM:ExpirationStartDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2016-10-27</CVM:ExpirationStartDate>
    <CVM:ExpirationStartDate contextRef="From2014-10-01to2015-09-30_ConsultantsMember">2015-10-14</CVM:ExpirationStartDate>
    <CVM:ExpirationEndDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2019-06-30</CVM:ExpirationEndDate>
    <CVM:ExpirationEndDate contextRef="From2014-10-01to2015-09-30_ConsultantsMember">2018-06-30</CVM:ExpirationEndDate>
    <CVM:IssueStartDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2011-12-02</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2014-10-01to2015-09-30_ConsultantsMember">2005-10-14</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2013-10-11</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2014-10-01to2015-09-30_custom_SeriesSMember">2013-10-11</CVM:IssueStartDate>
    <CVM:IssueEndDate1 contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2016-07-01</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2014-10-01to2015-09-30_ConsultantsMember">2015-07-01</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2014-10-24</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2014-10-01to2015-09-30_custom_SeriesSMember">2014-10-24</CVM:IssueEndDate1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;CEL-SCI&#13;Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in&#13;biomedical science and ultimately to engage in marketing and selling products.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;CEL-SCI&#13;is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company&amp;#8217;s&#13;lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently in a Phase 3 clinical trial as a potential&#13;therapeutic agent directed at using the immune system to produce an anti-tumor immune response for advanced primary head and neck&#13;cancer. Data from Phase 1 and Phase 2 clinical trials suggest Multikine has the potential to directly affect tumor cells. These&#13;data also indicate that it appears to activate the patient&amp;#8217;s own anti-tumor immune response. Multikine (Leukocyte Interleukin,&#13;Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this document&#13;as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary&#13;name is subject to FDA review in connection with the Company&amp;#8217;s future anticipated regulatory submission for approval. Multikine&#13;has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established&#13;for any use. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial&#13;of this investigational therapy that is in progress and that is currently subject to a clinical hold on enrollment of additional&#13;new patients.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Multikine&#13;has been cleared by the regulators in twenty four countries around the world, including the U.S. FDA, for a global Phase 3 clinical&#13;trial in advanced primary (not yet treated) head and neck cancer patients. On September 26, 2016, the Company received verbal&#13;notice from the FDA that the Phase 3 clinical trial has been placed on clinical hold. The FDA&amp;#8217;s partial clinical hold letter&#13;identified the following specific deficiencies: there is an unreasonable and significant risk of illness or injury to human subjects;&#13;the investigator brochure is misleading, erroneous, and materially incomplete; and that the plan or protocol is deficient in design&#13;to meet its stated objectives. Pursuant to this communication from FDA, patients currently receiving study treatments could continue&#13;to receive treatment, and patients already enrolled in the study would continue to be followed, but no additional patients could&#13;be enrolled. On October 21, 2016, the Company announced it had received the Partial Clinical Hold letter from the FDA. On November&#13;21, 2016, the Company announced it has submitted what it believes to be a complete response to the FDA. On December 8, 2016, the&#13;FDA advised CEL-SCI that the agency was denying CEL-SCI&amp;#8217;s request for a meeting at this time because FDA&amp;#8217;s review&#13;of CEL-SCI&amp;#8217;s November 17, 2016 response was ongoing. CEL-SCI was also advised that it will be receiving a letter addressing&#13;CEL-SCI&amp;#8217;s response by December 18, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Multikine&#13;is also being used in a Phase 1 study at the University of California, San Francisco (UCSF) in HIV/HPV co-infected men and women&#13;with peri-anal warts.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <CVM:OperationsAndFinancingTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented&#13;proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development,&#13;administrative costs, construction of laboratory facilities, and clinical trials.&amp;#160; The Company has funded such costs with&#13;proceeds from loans and the public and private sale of its common and preferred stock.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer. The Company believes that&#13;it has enough capital to support its operations as it believes that it has ready access to new equity capital should the need&#13;arise. During fiscal year 2016, the Company raised approximately $21.4 million in net proceeds through the sale of common stock&#13;and warrants from public and private offerings. During fiscal year 2015, the Company raised $21.1 million net proceeds from public&#13;offerings. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate&#13;partnerships, debt and/or equity financings. In addition, the Company expects to receive proceeds from the arbitration against&#13;its former clinical research organization, inVentiv. The Company believes that it will be able to obtain additional financing&#13;because it has done so consistently in the past, and because Multikine is a product in the Phase 3 clinical trial stage. However,&#13;there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the&#13;Company on acceptable terms or at all.&amp;#160; If the Company does not raise the necessary capital, the Company will either have&#13;to slow or delay the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise&#13;the required funding. The financial statements have been prepared assuming that the Company will continue as a going concern,&#13;but due to the Company&amp;#8217;s future liquidity needs, history of net losses, and the expectation that the Company will incur&#13;losses for the foreseeable future, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&#13;The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;Since&#13;the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $34.5 million as&#13;of September 30, 2016 on direct costs for the Phase 3 clinical trial. The total remaining cash cost of the Phase 3 clinical&#13;trial, excluding any costs that will be paid by CEL-SCI&amp;#8217;s partners, would approximately be $12.1 million&#13;after September 30, 2016. This is based on the executed contract costs with the CROs only and does not include other related&#13;cost, e.g. the manufacturing of the drug. It should be noted that this estimate is based only on the information currently&#13;available in the Company&amp;#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3&#13;clinical trial.&amp;#160; This number can be affected by the speed of enrollment, foreign currency exchange rates and many other&#13;factors, some of which cannot be foreseen.&amp;#160; The Company has filed an amendment to the original Phase 3 protocol for it&#13;head and neck cancer study with the FDA to allow for this expansion in patient enrollment. Should the FDA allow the amended&#13;protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be higher. It is therefore&#13;possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;September 26, 2016, the Company received verbal notice from the FDA that the Phase 3 clinical trial has been placed on clinical&#13;hold. Pursuant to this communication from FDA, patients currently receiving study treatments could continue to receive treatment,&#13;and patients already enrolled in the study would continue to be followed, but no additional patients could be enrolled. On October&#13;21, 2016, the Company announced it had received the Partial Clinical Hold letter from the FDA. On November 21, 2016, the Company&#13;announced it has submitted a complete response to the FDA and will work diligently with the FDA to seek to have the partial clinical&#13;hold lifted.&lt;/font&gt;&lt;/p&gt;</CVM:OperationsAndFinancingTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;following chart represents the warrants and non-employee options outstanding at September 30, 2016:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrant&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Issue&#13;    &lt;u&gt;Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares&#13;    Issuable upon Exercise of &lt;u&gt;Warrant&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    &lt;u&gt;Price&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Expiration&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Refer-ence&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;105,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$100.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/13&#13;    -10/24/14 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,037,010&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1/13/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1/13/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/15/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/15/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11/23/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/18/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/22/22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/22/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$4,112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/2/11-&#13;    7/1/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$9.25-&amp;#160;&amp;#160;$87.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/27/16-&#13;    6/30/19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;following chart represents the warrants and non-employee options outstanding at September 30, 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Issue&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares&#13;    Issuable upon Exercise of &lt;u&gt;Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    &lt;u&gt;Price&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Expiration&#13;    Date&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Refer-ence&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$13.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Q&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6/21/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$125.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/22/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,625,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$100..00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/13-&#13;    10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,928,010&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;445,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;20,253,164&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;590,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;$112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/14/05&#13;    &amp;#8211; 7/1/15 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$16.50&#13;    &amp;#8211; $500.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10/14/15&#13;    - 6/30/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;1.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;u&gt;Warrant&#13;                                         Liabilities&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;table below presents the warrants accounted for as derivative liabilities at September 30.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 52%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle; width: 23%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2016&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle; width: 23%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2015&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&amp;#9;&#13;    3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&amp;#9;&#13;    7,363,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;44,551&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;1,620,253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;6,278,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    W warrants&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;1,799,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Z warrants&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;970,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: middle; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;70,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: middle; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;763,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    BB warrants&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&amp;#9;58,588&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&amp;#9;-&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.5pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&#13;    derivative liabilities&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;u&gt;$&amp;#9;8,394,934&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; text-decoration: underline; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;u&gt;$&amp;#9;13,686,587&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The&#13;table below presents the gains and (losses) on the warrant liabilities for the years ended September 30:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 18%; padding-right: -4.5pt; padding-left: 5.4pt; text-decoration: underline"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrant&#13;    Series&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 22%; padding-right: -49.5pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;u&gt;2016&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: -4.5pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;u&gt;2015&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;u&gt;2014&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    A - E&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&amp;#9;6,105&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&amp;#9;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    F and G&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;12,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    H&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;12,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;24,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;(1,404,027)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Q&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;12,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;36,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    R&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;157,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;131,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    S&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,252,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,705,466)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;1,098,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    T&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-decoration: none; padding-right: 5.4pt; padding-left: 27pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 0.25in; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;276,122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: center; text-indent: 35pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    U&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;44,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 0.9pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;75,738&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 27pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;73,967&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: center; text-indent: 39.5pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;4,658,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;1,724,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;3,260,913&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;997,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;75,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;672,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series&#13;    BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;53,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    gain &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;u&gt;$&amp;#9;14,013,726&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;u&gt;$&amp;#9;282,616&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&lt;u&gt;$&amp;#9;248,767&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 8.1pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;The&#13;Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should&#13;use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own&#13;stock, including evaluating the instrument&amp;#8217;s contingent exercise and settlement provisions. The warrant agreements provide&#13;for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered&#13;indexed to the Company&amp;#8217;s stock because future equity offerings or sales of the Company&amp;#8217;s stock are not an input to&#13;the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option on equity shares, and equity classification is therefore precluded.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;In&#13;accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each&#13;reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain&#13;or loss in the statement of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;i&gt;Expired&#13;warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;As&#13;of September 30, 2015, all Series A, B, C, E, F, G, H, and Q warrants had expired. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;i&gt;Series&#13;R Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;On&#13;December 4, 2012, the Company sold 140,000 shares of its common stock for $10,500,000, or $75.00 per share, in a registered direct&#13;offering. The investors in this offering also received Series R warrants which entitle the investors to purchase up to 105,000&#13;shares of the Company&amp;#8217;s common stock. The Series R warrants may be exercised at any time before December 6, 2016 at a price&#13;of $4,100.00 per share. The fair value at issuance of the warrants of $4.2 million was recorded as a warrant liability. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;S Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;October 11, 2013, the Company closed a public offering of  713,043 units of common stock and warrants at a price of $25.00 per&#13;unit for net proceeds of approximately $16.4 million, net of underwriting discounts and commissions and offering expenses of&#13;the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock.&#13;The Series S warrants were immediately exercisable, expire on October 11, 2018, and have an exercise price of $31.25. In&#13;November 2013, the underwriters purchased an additional  105,957 warrants pursuant to the overallotment option, for which&#13;the Company received net proceeds of $24,370. The fair value at issuance of the Series S warrants of $6.1 million was&#13;recorded as a warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;December 24, 2013, the Company closed a public offering of  190,746 units of common stock and warrants at a price of $15.75&#13;per unit for net proceeds of approximately $2.8 million, net of underwriting discounts and commissions and offering expenses&#13;of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common&#13;stock. The underwriters purchased an additional  19,048 units of common stock and warrants pursuant to the overallotment&#13;option, for which the Company received net proceeds of approximately $279,000. The fair value at issuance of the Series S&#13;warrants of approximately $1.2 million was recorded as a warrant liability. On February 7, 2014, the Series S warrants began&#13;trading on the NYSE MKT under the symbol CVM WT.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;October 24, 2014, the Company closed an underwritten public offering of  315,789 shares of common stock and  78,947 Series&#13;S warrants to purchase shares of common stock. Additionally, on October 21, 2014, the Company sold 52,800 shares of common&#13;stock and 13,200 Series S warrants to purchase shares of common stock in a private offering. The common stock and Series S&#13;warrants were sold at a combined per unit price of $19.00 for net proceeds of approximately $6.4 million, net of underwriting&#13;discounts and commissions and offering expenses. The fair value at issuance of the Series S warrants of approximately&#13;$461,000 was added to the existing Series S warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;During&#13;the years ended September 30, 2016 and 2015, no Series S warrants were exercised. During the year ended September 30, 2014, 83,551&#13;Series S Warrants were exercised, and the Company received proceeds of approximately $2.6 million.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;T and U Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;April 17, 2014, the Company closed a public offering of  285,129 shares of common stock at a price of $35.00 and 71,282&#13;Series T warrants to purchase one share of common stock for net proceeds of approximately $9.2 million, net of underwriting&#13;commissions and offering expenses. The Series T warrants were immediately exercisable and had an exercise price of $39.50. On&#13;October 17, 2014, all of the Series T warrants expired. The underwriters received  17,821 Series U warrants to purchase one&#13;share of common stock. The Series U warrants were exercisable beginning October 17, 2014, expire on October 17, 2017, and&#13;have an exercise price of $43.75. The fair value at issuance of the Series T and U warrants of approximately $470,000 was&#13;recorded as a warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;V Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;May 28, 2015, the Company closed an underwritten public offering of  810,127 shares of common stock and  810,127 Series V&#13;warrants to purchase shares of common stock. The common stock and Series V warrants were sold at a combined per unit price of&#13;$19.75 for net proceeds of approximately $14.7 million, net of underwriting discounts and commissions and offering expenses.&#13;The Series V warrants were immediately exercisable at a price of $19.75 and expire on May 28, 2020. The fair value at issuance&#13;of the Series V warrants of approximately $8.0 million was recorded as a warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;W Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;October 28, 2015, the Company closed an underwritten public offering of  688,930 shares of common stock and 688,930 Series&#13;W warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $16.75&#13;for net proceeds of approximately $10.5 million, net of underwriting discounts and commissions and offering expenses. The&#13;Series W warrants are immediately exercisable at a price of $16.75 and expire on October 28, 2020. The fair value at issuance&#13;of the Series W warrants of approximately $5.1 million was recorded as warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;Z and ZZ Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On May&#13;23, 2016, the Company closed a registered direct offering of 400,000 shares of common stock and 264,000 Series Z warrants&#13;to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $12.50 for net proceeds&#13;of approximately $4.6 million, net of placement agent&amp;#8217;s commissions and offering expenses. The Series Z warrants may be&#13;exercised at any time on or after November 23, 2016 and on or before November 23, 2021 at a price of $13.75 per share. The Company&#13;also issued 20,000 Series ZZ warrants to the placement agent as part of its compensation. The Series ZZ warrants may be exercised&#13;at any time on or after November 23, 2016 and on or before May 18, 2021 at a price of $13.75 per share. The fair value of the Series&#13;Z and Series ZZ warrants of approximately $2.1 million on the date of issuance was recorded as a warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;AA and BB Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;August 26, 2016, the Company closed a registered direct offering of&amp;#160; 400,000 shares of common stock and 200,000 Series AA&#13;warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $12.50&#13;for proceeds of approximately $4.5 million, net of placement agent&amp;#8217;s commissions and offering expenses. The series AA&#13;warrants may be exercised at any time after February 22, 2017 and on or before February 22, 2022 at a price of $13.75 per&#13;share. The Company also issued 16,000 Series BB warrants to the placement agent as part of its compensation. The Series BB&#13;warrants may be exercised at any time on or after February 22, 2017 and on or before August 22, 2021 at a price of $13.75 per&#13;share. The fair value of the Series AA and Series BB warrants of approximately $1.5 million on the date of issuance was&#13;recorded as a warrant liability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Equity&#13;                                         Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;X Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In&#13;January 2016, the Company sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for&#13;approximately $1.1 million. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a director.&#13;Each Series X warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per share&#13;at any time on or before January 13, 2021. The Series X warrants qualify for equity treatment in accordance with ASC 815. The&#13;relative fair value of the warrants was calculated to be approximately $417,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;Y Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;February 15, 2016, the Company sold 52,000 shares of its common stock and 26,000 Series Y warrants to a private investor for&#13;$624,000. Each Series Y warrant allows the holder to purchase one share of the Company's common stock at a price of $12.00 per&#13;share at any time on or before February 15, 2021. The Series Y warrants qualify for equity treatment in accordance with ASC 815.&#13;The relative fair value on the date of issuance of the warrants was calculated to be approximately $144,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;i&gt;Series&#13;N Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Series&#13;N warrants were previously issued in connection with a financing. On October 11, 2013 and December 24, 2013, in&#13;connection with public offerings of common stock on those dates, the Company reset the exercise price of the  120,751&#13;outstanding Series N warrants from $75.00 to $13.18 and issued the Series N warrant holders  97,306 additional warrants&#13;exercisable at $13.18, as required by the warrant agreements. In January 2014, the Company offered the investors the option to&#13;extend the Series N warrants by one year and allow for cashless exercise in exchange for cancelling the reset provision in&#13;the warrant agreement. One investor, holding 113,785 Series N warrants accepted this offer. Accordingly, these warrants are&#13;no longer considered a derivative liability due to the cancelation of the reset provision. The fair value of the warrants on&#13;that date totaled approximately $1.3 million and was reclassified from derivative liabilities to additional paid-in capital.&#13;On March 21, 2014, the other investor exercised  4,272 Series N warrants. The Company received cash proceeds of&#13;approximately $7,000 for  563 of the warrants exercised. The remaining  3,709 warrants were exercised in a cashless&#13;exercise. The fair value of the warrants on the date of exercise was $137,000 and was reclassified from derivative&#13;liabilities to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;On&#13;October 28, 2014, the outstanding  113,785 Series N Warrants were transferred to the de Clara Trust, of which the&#13;Company&amp;#8217;s CEO, Geert Kersten, is the trustee and a beneficiary. On June 29, 2015, the Company extended the expiration&#13;date of the Series N warrants to August 18, 2017. The incremental cost of this modification was approximately $475,000. The&#13;modification was concurrent with the extinguishment and reissuance of a note payable also held in the de Clara Trust, and was&#13;recorded as a loss on debt extinguishment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;As&#13;of September 30, 2016, the remaining  113,785 Series N warrants entitle the holder to purchase one share of the Company's&#13;common stock at a price of $13.18 per share at any time prior to August 18, 2017. On September 30, 2016 and 2015, no&#13;derivative liability was recorded because the warrants no longer were considered a liability for accounting&#13;purposes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Series&#13;L and Series M Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Series L and Series M warrants were&#13;previously issued in connection with a financing. In April 2014, 1,000 Series L warrants, with an exercise price of $187.50, expired.&#13;In April 2015, the remaining 2,800 of the Series L warrants, which had been repriced to $62.50 in April 2013, expired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;In October 2013, the Company reduced&#13;the exercise prices of the Series M warrants from $85.00 to $25.00 in exchange for a reduction in the number of warrants from 24,000&#13;to 20,000. The additional cost of $76,991 was recorded as non-employee stock expense. In March 2014, 20,000 Series M warrants&#13;were exercised at a price of $25.00, and the Company received proceeds of $500,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;i&gt;Series&#13;P Warrants &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify"&gt;On February 10, 2012, the Company&#13;issued 23,600 Series P warrants to purchase up to 23,600 shares of the Company&amp;#8217;s common stock at a price of $112.50 per share&#13;as an inducement for the exercise of previously issued warrants. The Series P warrants are exercisable at any time prior to March&#13;6, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;3.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;&lt;u&gt;Options&#13;                                         and Shares Issued to Consultants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify"&gt;The Company typically enters into&#13;consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2016 and 2015, the&#13;Company issued 49,953 and 29,599 shares of common stock, respectively, to consultants, of which 31,360 and 7,200, respectively,&#13;were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $9.25 and $27.75&#13;per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify"&gt;Additionally, during the years&#13;ended September 30, 2016 and 2015, the Company issued to consultants 16,400 and 3,600 options, respectively, to purchase common&#13;stock with exercise prices ranging from $9.25 to $25.50 per share and fair values ranging from $3.00 to $12.50 per share. The aggregate&#13;values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to&#13;general and administrative expenses over the periods of service.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;During the years ended September&#13;30, 2016 and 2015, the Company recorded total expense of approximately $752,000 and $566,000, respectively, relating to these consulting&#13;agreements. At September 30, 2016 and 2015, approximately $48,000 and $30,000, respectively, are included in prepaid expenses.&#13;As of September 30, 2016, 25,600 options issued to consultants as payment for services remained outstanding, 17,600 of which are&#13;fully vested, and all of which were issued from the Non-Qualified Stock Option plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;307,894&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,722,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,003,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Net realized and unrealized derivative gain&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(9,761,532&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,988,082&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders &amp;#8211; Restated (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(28,470,126)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Less:&amp;#160;&amp;#160;Gain&#13;    on derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(248,767)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    loss available to common shareholders &amp;#8211; diluted (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;(28,718,893)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    average number of shares - basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,866,204&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,300,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,352,185&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    per share &amp;#8211; basic (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.10)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Loss&#13;    per share &amp;#8211; diluted (restated)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.21)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1)&#13;See Note 16 Restatement&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <CVM:NumberOfUnvestedOptionsBeginning contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">135491</CVM:NumberOfUnvestedOptionsBeginning>
    <CVM:NumberOfUnvestedOptionsBeginning contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">120438</CVM:NumberOfUnvestedOptionsBeginning>
    <CVM:VestedOptions contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">-46134</CVM:VestedOptions>
    <CVM:VestedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">-56069</CVM:VestedOptions>
    <CVM:GrantedOptions contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">35748</CVM:GrantedOptions>
    <CVM:GrantedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">48544</CVM:GrantedOptions>
    <CVM:ForfeitedOptions contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">-4667</CVM:ForfeitedOptions>
    <CVM:ForfeitedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">-2240</CVM:ForfeitedOptions>
    <CVM:NumberOfUnvestedOptionsEnding contextRef="From2014-10-01to2015-09-30" unitRef="Shares" decimals="INF">120438</CVM:NumberOfUnvestedOptionsEnding>
    <CVM:NumberOfUnvestedOptionsEnding contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">110673</CVM:NumberOfUnvestedOptionsEnding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">8003220</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">8722073</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <CVM:IncreaseInPatentCosts contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</CVM:IncreaseInPatentCosts>
    <CVM:IncreaseInPatentCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:IncreaseInPatentCosts>
    <CVM:IncreaseInPatentCosts contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">9999</CVM:IncreaseInPatentCosts>
    <CVM:ForfeitureOfUnvestedRestrictedStock contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">1000</CVM:ForfeitureOfUnvestedRestrictedStock>
    <CVM:ForfeitureOfUnvestedRestrictedStock contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:ForfeitureOfUnvestedRestrictedStock>
    <CVM:ForfeitureOfUnvestedRestrictedStock contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">0</CVM:ForfeitureOfUnvestedRestrictedStock>
    <CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">0</CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants>
    <CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants>
    <CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-16375</CVM:StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">43</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">815</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">3477</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities measured&#13;at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 56%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Active Markets for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Identical Assets or&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Liabilities&amp;#160;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;$3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;$5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;$8,394,934&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities measured&#13;at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 55%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Active&amp;#160;Markets&amp;#160;for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Identical Assets or&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Liabilities&amp;#160;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;$7,365,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;$6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$13,686,587&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <CVM:NumberOfUnvestedSharesBeginning contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesBeginning>
    <CVM:NumberOfUnvestedSharesBeginning contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">628000</CVM:NumberOfUnvestedSharesBeginning>
    <CVM:VestedShares contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">20000</CVM:VestedShares>
    <CVM:VestedShares contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">20000</CVM:VestedShares>
    <CVM:GrantedShares contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">0</CVM:GrantedShares>
    <CVM:GrantedShares contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">0</CVM:GrantedShares>
    <CVM:ForfeitedShares contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">0</CVM:ForfeitedShares>
    <CVM:ForfeitedShares contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">4000</CVM:ForfeitedShares>
    <CVM:NumberOfUnvestedSharesEnding contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesEnding>
    <CVM:NumberOfUnvestedSharesEnding contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesEnding>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the provisions of&#13;ASC 820, &amp;#8220;&lt;i&gt;Fair Value Measurements&lt;/i&gt;,&amp;#8221; the Company determines fair value as the price that would be received to&#13;sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The&#13;Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future&#13;amounts to a single present amount. The measurement is based on the value indicated by current market expectations about those&#13;future amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 820 establishes a fair value hierarchy&#13;that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical&#13;assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company&#13;classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 &amp;#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 &amp;#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 &amp;#8211; Unobservable inputs that reflect management&amp;#8217;s assumptions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For disclosure purposes, assets and liabilities&#13;are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the&#13;overall fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement&#13;requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities&#13;measured at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 60%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 10%; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted Prices in&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 7%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 10%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Active Markets for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Identical Assets or&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Liabilities&amp;#160;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$8,394,934&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities&#13;measured at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 59%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 7%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Active&amp;#160;Markets&amp;#160;for&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Identical Assets or&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Liabilities&amp;#160;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$7,365,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$13,686,587&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following sets forth the reconciliation&#13;of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September&#13;30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;307,894&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,722,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,003,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;Net realized and unrealized derivative gain&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(9,761,532&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,988,082&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of the Company&amp;#8217;s&#13;derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such&#13;as historical price and volatility of the Company&amp;#8217;s stock as well as U.S. Treasury Bill rates are observable in active markets.&#13;At September 30, 2016, the Company&amp;#8217;s Level 3 derivative instruments have a weighted average fair value of $0.10 per share&#13;and a weighted average exercise price of $0.86 per share. Fair values were determined using a weighted average risk free interest&#13;rate of 1.04% and 75% volatility.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <dei:AmendmentDescription contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;October 2008, the Company entered into an agreement whereby the Company leased a building owned by a third party. The Company accounted&#13;for the arrangement as an operating lease under ASC 840, &lt;i&gt;Accounting for Leases&lt;/i&gt;. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;November 2017, the Company determined that the lease should have been treated as a financing obligation rather than an operating&#13;lease. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;Accordingly,&#13;this amended 10-K is filed to correct the manner in which the Company accounted for the lease. See &lt;u&gt;Note 17. Restatement, &lt;/u&gt;in&#13;the financial statements enclosed herein, for further information&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;addition: &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol; letter-spacing: -0.1pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;per share data, including earnings per share&#13;amounts, in this amended 10-K have been adjusted to reflect a 1 for 25 reverse stock split which became effective on the NYSE American&#13;on June 15, 2017;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol; letter-spacing: -0.1pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;management&amp;#8217;s report on internal control&#13;over financial reporting and its conclusion on disclosure controls and procedures have been revised to address the material weaknesses&#13;in internal control over financial reporting; and &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol; letter-spacing: -0.1pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt; letter-spacing: -0.1pt"&gt;the opinion of BDO USA, LLP on the effectiveness&#13;of the Company&amp;#8217;s internal control over financial reporting as of September 30, 2016 has been amended.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;Except for the above, no other&#13;information included in the 10-K report filed on December 15, 2016 is amended by this Form 10-K/A.&lt;/font&gt;&lt;/p&gt;</dei:AmendmentDescription>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">17350836</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">17945831</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3310</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">19025</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">22609</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">14026</us-gaap:OtherLiabilitiesNoncurrent>
    <CVM:ExerciseOfWarrantsShares contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">106740</CVM:ExerciseOfWarrantsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">348</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2013-10-01to2014-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">628000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="From2014-10-01to2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-4000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:BuildingsAndImprovementsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">21183756</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">21183756</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;accordance with ASC 855, &amp;#8220;&lt;i&gt;Subsequent Events&lt;/i&gt;&amp;#8221;, the Company has reviewed subsequent events through the date of&#13;the filing.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;December 8, 2016, the Company sold 1,360,960 shares of common stock and warrants to purchase common stock at a price of $3.13&#13;in a public offering. The warrants consist of 68,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960Series&#13;DD warrants to purchase 1,360,960shares of common stock and 1,360,960Series EE warrants to purchase 1,360,960shares of common&#13;stock. The Series CC warrants are immediately exercisable, expire in five-years and have an exercise price of $5.00 per share.&#13;The Series DD warrants are immediately exercisable, expire in six-months and have an exercise price of $4.50 per share. The Series&#13;EE warrants are immediately exercisable, expire in nine-months and have an exercise price of $4.50 per share. In addition, the&#13;Company issued 68,048 Series FF warrants to purchase 68,048 shares of common stock to the placement agent. The FF warrants are&#13;exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $3.91. The net proceeds&#13;to CEL-SCI from this offering &amp;#160;was approximately $3.8 million, excluding any future proceeds that may be received from the&#13;exercise of the warrants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;December 9, 2016, the Company reported on a communication received from the staff of the NYSE MKT, its current listing exchange,&#13;that it considered the Company to be noncompliant with certain listing requirements based on its quarterly report for the period&#13;ended June 30, 2016. The Company has been given the opportunity to maintain its listing by submitting a plan of compliance by&#13;January 9, 2017. This plan must advise of actions the company has taken or will take to regain compliance with the continued listing&#13;standards by June 11, 2018. The Company intends to submit such a plan by January 9, 2017. The communication and compliance plan&#13;has no current effect on the listing of the Company's shares on the exchange. If the plan is not acceptable or the Company does&#13;not make sufficient progress under the plan or reestablish compliance by June 11, 2018, then staff of the exchange may initiate&#13;proceedings for delisting from the NYSE MKT. The Company may then appeal a staff determination to initiate such proceedings in&#13;accordance with the exchange's Company Guide.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <CVM:FairValueOfSeriesSWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3111361</CVM:FairValueOfSeriesSWarrants>
    <CVM:FairValueOfSeriesSWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">7363555</CVM:FairValueOfSeriesSWarrants>
    <CVM:FairvalueofSeriesUWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesUWarrants>
    <CVM:FairvalueofSeriesUWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">44551</CVM:FairvalueofSeriesUWarrants>
    <CVM:FairvalueofSeriesVWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1620253</CVM:FairvalueofSeriesVWarrants>
    <CVM:FairvalueofSeriesVWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6278481</CVM:FairvalueofSeriesVWarrants>
    <CVM:FairvalueofSeriesWWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1779858</CVM:FairvalueofSeriesWWarrants>
    <CVM:FairvalueofSeriesWWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesWWarrants>
    <CVM:FairvalueofSeriesZWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">970604</CVM:FairvalueofSeriesZWarrants>
    <CVM:FairvalueofSeriesZWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesZWarrants>
    <CVM:FairvalueofSeriesZZWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">70609</CVM:FairvalueofSeriesZZWarrants>
    <CVM:FairvalueofSeriesZZWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesZZWarrants>
    <CVM:FairvalueofSeriesAAWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">763661</CVM:FairvalueofSeriesAAWarrants>
    <CVM:FairvalueofSeriesAAWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesAAWarrants>
    <CVM:FairvalueofSeriesBBWarrants contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">58588</CVM:FairvalueofSeriesBBWarrants>
    <CVM:FairvalueofSeriesBBWarrants contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</CVM:FairvalueofSeriesBBWarrants>
    <CVM:TotalFairvalueofDerivativeLiabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">8394934</CVM:TotalFairvalueofDerivativeLiabilities>
    <CVM:TotalFairvalueofDerivativeLiabilities contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">13686587</CVM:TotalFairvalueofDerivativeLiabilities>
    <us-gaap:RestatementOfPriorYearIncomeNetOfTax contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">326827</us-gaap:RestatementOfPriorYearIncomeNetOfTax>
    <us-gaap:RestatementOfPriorYearIncomeNetOfTax contextRef="From2013-10-01to2014-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">326827</us-gaap:RestatementOfPriorYearIncomeNetOfTax>
    <us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">7026917</us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax>
    <us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax contextRef="AsOf2013-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12376</us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax>
    <us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax contextRef="AsOf2013-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">218848282</us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax>
    <us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax contextRef="AsOf2013-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-211833741</us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax>
    <us-gaap:OtherAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">19428300</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">20208312</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">5710601</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13717699</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">6614420</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">13593892</us-gaap:OtherAssets>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-1964221</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1879390</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-1933732</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">73001</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1952391</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-40260</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1923961</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-40920</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">-1892812</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-32390148</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-23646828</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-25667714</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2015-10-01to2016-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-25553225</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2015-10-01to2016-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">1906397</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2014-10-01to2015-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-34296545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2014-10-01to2015-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">1906397</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2013-10-01to2014-09-30_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="0">-27574112</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="From2013-10-01to2014-09-30_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="0">1906398</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EquityFairValueAdjustment contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">19146127</us-gaap:EquityFairValueAdjustment>
    <us-gaap:EquityFairValueAdjustment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">15595549</us-gaap:EquityFairValueAdjustment>
    <us-gaap:EquityFairValueAdjustment contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">31109575</us-gaap:EquityFairValueAdjustment>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-679213</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-4762270</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">6700090</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">10783813</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <CVM:RestatementOfPriorYearIncomeNet contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">326827</CVM:RestatementOfPriorYearIncomeNet>
    <CVM:NetLoss contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">-34692210</CVM:NetLoss>
    <CVM:NetLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</CVM:NetLoss>
    <CVM:NetLoss contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">-27352679</CVM:NetLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2015-10-01to2016-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;Research and development expenditures are expensed as incurred.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LeasePolicyTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;&lt;/i&gt;Leases are&#13;categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over&#13;the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of&#13;capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes&#13;an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural&#13;improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit&#13;leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.&#13;If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on&#13;the Company's balance sheet.&lt;/p&gt;</us-gaap:LeasePolicyTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">13011000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24813000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">15762000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1937000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1872000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1808000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1747000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1687000</us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 4.5pt 0 0 0.25in; text-align: justify; background-color: white"&gt;The&#13;Company has restated its previously issued 2016, 2015 and 2014 financial statements to correct an error in the way it accounted&#13;for a lease entered into in October 2008. In October 2008, the Company entered into a lease arrangement whereby the Company leased&#13;a building owned by a third party, but to which the owner made tenant-directed improvements. Upon commencement of the lease, the&#13;Company accounted for the arrangement as an operating lease under ASC 840, &lt;i&gt;Accounting for Leases&lt;/i&gt;, whereby the total minimum&#13;lease payment obligations under the leases were recognized as monthly rent expense on a straight-line basis over the term of the&#13;lease. The cost of the tenant improvements incurred were capitalized as deferred rent and amortized over the 20-year lease term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"&gt;However,&#13;in November 2017, the Company discovered an error in the way it accounted for the lease for the building since it was determined&#13;that, as the terms of the original lease required the Company to be responsible for possible cost overruns, (but of which there&#13;were none), the Company was deemed to be the owner of the leased building for accounting purposes only under ASC 840-40-55. In&#13;addition to the costs it incurred and capitalized for the tenant improvements, the Company should have reflected an asset on its&#13;balance sheet for the costs paid by the lessor to purchase and improve the building, as well as a corresponding liability. Upon&#13;completion of the improvements, the Company did not meet the &amp;#8220;sale-leaseback&amp;#8221; criteria under ASC 840-40-25, &lt;i&gt;Accounting&#13;for Leases, Sale-Leaseback Transactions&lt;/i&gt; due to the Company&amp;#8217;s significant continuing involvement with the facility which&#13;is considered to be other than a normal leaseback as defined in ASC 840-40-25 and therefore should have treated the lease as a&#13;financing obligation and the asset and corresponding liability should not be derecognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"&gt;The correction&#13;to the historical financial statements to apply ASC 840-40-25 do not affect the total cash payments the Company has made or is&#13;obligated to make under the lease agreement, nor does it change the total expense to be recognized over the lease term. However,&#13;the timing and nature of expense is different under this treatment as compared to operating lease treatment. Specifically, the&#13;Company should have recognized depreciation, expense on the building it is deemed to own and interest expense on the associated&#13;lease financing obligation, instead of rental expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Accordingly, the historical financial&#13;statements in this report have been restated. The accompanying financial statements for the three years in the period ended September&#13;30, 2016 have been restated to reflect the correction of the error for the lease accounting. Accumulated deficit at October 1,&#13;2013, was reduced by $326,827.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On June 12, 2017, the Company&amp;#8217;s&#13;shareholders approved a reverse split of the Company&amp;#8217;s common stock which became effective on the NYSE American on June 15,&#13;2017. On that date, every twenty five issued and outstanding shares of the Company&amp;#8217;s common stock automatically converted&#13;into one outstanding share. As a result of the reverse stock split, the number of the Company&amp;#8217;s outstanding shares of common&#13;stock decreased from 230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. In addition, by reducing the number of the&#13;Company&amp;#8217;s outstanding shares, the Company&amp;#8217;s loss per share in all prior periods will increase by a factor of twenty&#13;five. The reverse stock split affected all stockholders of the Company&amp;#8217;s common stock uniformly, and did not affect any stockholder&amp;#8217;s&#13;percentage of ownership interest. The par value of the Company&amp;#8217;s stock remained unchanged at $0.01 per share and the number&#13;of authorized shares of common stock remained the same after the reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;As the par value per share of the&#13;Company&amp;#8217;s common stock remained unchanged at $0.01 per share, a total of $2,204,938 was reclassified from common stock to&#13;additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance&#13;under the Company&amp;#8217;s incentive and non-qualified stock option plans, as well as the shares of common stock underlying outstanding&#13;stock options and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were&#13;proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying&#13;financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The following is a summary of the&#13;restatements for 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;9/30/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;PREVIOUSLY REPORTED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,887,646 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(429,821)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,457,825 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,710,601 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,717,699 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,428,300 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;11,598,247 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,287,878 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,886,125 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;12,554,315 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,011,023 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,565,338 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stockholders' deficit, September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(956,068)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;276,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(679,213)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;9/30/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Balance Sheet&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,833,183 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(487,793)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,345,390 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,614,420 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,593,892 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,208,312 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,447,603 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,106,099 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;28,553,702 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,532,722 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;12,783,250 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,315,972 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stockholders' deficit, September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(5,085,119)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;322,850 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,762,270)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 21%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,351,779 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;17,445,382 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,838,280 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;23,931,883 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(25,553,225)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,397&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(23,646,828)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;73,001 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,952,391)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,879,390)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,466,498)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(45,994)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.36)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;21,098,147 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,191,750 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;34,953,922 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,047,525 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,296,545)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,397&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(32,390,148)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(40,260) &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,923,961)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,964,221)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,674,646)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(17,564)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;17,172,587 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,398)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,266,189 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;27,838,145 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,398)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,931,747 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,574,112)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(25,667,714)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(40,920)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,892,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,933,732)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,366,265)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,586&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.11)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.10)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.22)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.21)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total Stockholders' &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deficit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Equity (Deficit)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;PREVIOUSLY REPORTED, OCTOBER 1, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(212,160,568)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,700,090 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;326,827 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;326,827 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;RESTATED BALANCE, OCTOBER 1, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(211,833,741)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,026,917 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;31,109,575 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss &amp;#8211; RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(239,186,420)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10,783,813 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,146,127 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss - RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(273,878,630)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,762,270)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,595,549 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss - RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(285,391,122)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(679,213)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">11802000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2015-10-01to2016-09-30_OutstandingMember" unitRef="Shares" decimals="INF">2240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2014-10-01to2015-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">54667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:DebtAndCapitalLeaseObligations contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">13011023</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">12783250</us-gaap:DebtAndCapitalLeaseObligations>
    <CVM:CapitalizedLeaseInterest contextRef="From2014-10-01to2015-09-30" unitRef="USD" decimals="0">249493</CVM:CapitalizedLeaseInterest>
    <CVM:CapitalizedLeaseInterest contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">227773</CVM:CapitalizedLeaseInterest>
    <CVM:CapitalizedLeaseInterest contextRef="From2013-10-01to2014-09-30" unitRef="USD" decimals="0">241829</CVM:CapitalizedLeaseInterest>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Manufacturing building&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,183,756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,783,756&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Research equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,158,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,268,757&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;133,499&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;141,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,607,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,725,770&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,256,962&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(6,779,939&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net plant, property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,350,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,945,831&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <CVM:RestrictedStockAwardWeightedAverageGrantDateFairValueEnding contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="USDPShares" decimals="INF">13.75</CVM:RestrictedStockAwardWeightedAverageGrantDateFairValueEnding>
    <CVM:RestrictedStockAwardWeightedAverageGrantDateFairValueEnding contextRef="From2014-10-01to2015-09-30_custom_RestrictedStockAwardsMember" unitRef="USDPShares" decimals="INF">13.75</CVM:RestrictedStockAwardWeightedAverageGrantDateFairValueEnding>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr&gt;&lt;td style="vertical-align: top; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;9/30/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;PREVIOUSLY REPORTED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,887,646 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(429,821)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,457,825 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;5,710,601 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,717,699 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,428,300 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;11,598,247 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,287,878 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,886,125 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;12,554,315 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,011,023 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,565,338 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stockholders' deficit, September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(956,068)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;276,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(679,213)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;9/30/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Balance Sheet&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,833,183 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(487,793)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;8,345,390 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,614,420 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,593,892 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,208,312 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,447,603 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,106,099 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;28,553,702 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;20,532,722 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;12,783,250 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,315,972 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stockholders' deficit, September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(5,085,119)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;322,850 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,762,270)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 21%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,351,779 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;17,445,382 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,838,280 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;23,931,883 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(25,553,225)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,397&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(23,646,828)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;73,001 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,952,391)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,879,390)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,466,498)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(45,994)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.36)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2.37)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;21,098,147 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,191,750 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;34,953,922 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,397)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33,047,525 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,296,545)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,397&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(32,390,148)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(40,260) &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,923,961)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,964,221)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,674,646)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(17,564)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(10.51)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;YEAR ENDED 9/30/2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;PREVIOUSLY&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;REPORTED&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;RESTATED&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;17,172,587 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,398)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,266,189 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total operating expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;27,838,145 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,906,398)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,931,747 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,574,112)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,906,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(25,667,714)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Interest income (expense), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(40,920)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,892,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,933,732)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,366,265)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,586&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.11)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.10)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss per common share, diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.22)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(12.21)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total Stockholders' &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deficit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Equity (Deficit)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;PREVIOUSLY REPORTED, OCTOBER 1, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(212,160,568)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,700,090 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;ADJUSTMENT&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;326,827 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;326,827 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;RESTATED BALANCE, OCTOBER 1, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(211,833,741)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;7,026,917 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;31,109,575 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss &amp;#8211; RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(27,352,679)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(239,186,420)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;10,783,813 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;19,146,127 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss - RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(34,692,210)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(273,878,630)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(4,762,270)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016 equity transactions - unchanged&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;15,595,549 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net loss - RESTATED&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(11,512,492)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;BALANCE, SEPTEMBER 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(285,391,122)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(679,213)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2015-10-01to2016-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Clinical Research Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2013, the Company entered into an agreement&#13;with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will&#13;reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited&#13;against future invoices in $150,000 annual increments through December 2017. As of September 30, 2016, the total balance advanced&#13;is $300,000, of which $150,000 is classified as a current asset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2013, the Company entered into a co-development&#13;and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in&#13;the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments,&#13;up to a specific maximum amount. In October 2015, the Company entered into a second &lt;font style="color: #292929"&gt;co-development&#13;and revenue sharing agreement with Ergomed&lt;/font&gt; for an additional $2 million, for a total of $12 million. The Company accounted&#13;for the co-development and revenue sharing agreement in accordance with ASC 808 &amp;#8220;Collaborative Arrangements&amp;#8221;. The Company&#13;determined the payments to Ergomed are within the scope of ASC 730 &amp;#8220;Research and Development.&amp;#8221; Therefore, the Company&#13;records the discount on the clinical services as a credit to research and development expense on its Statements of Operations.&#13;Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development&#13;expenses of approximately $19.2 million related to Ergomed&amp;#8217;s services. This amount is net of Ergomed&amp;#8217;s discount of&#13;approximately $6.3 million. During the years ended September 30, 2016, 2015 and 2014, the Company recorded, approximately $7.2&#13;million, $6.7 million and $4.4 million, respectively, as research and development expense related to Ergomed&amp;#8217;s services.&#13;These amounts were net of Ergomed&amp;#8217;s discount of approximately $2.1 million, $2.4 million and $1.5 million, respectively,&#13;over the comparable periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2013, the Company entered into two&#13;co-development and profit sharing agreements with Ergomed.&amp;#160; One agreement supports the Phase 1 study being conducted at UCSF&#13;for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.&amp;#160; The other&#13;agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women.&#13;Ergomed will assume up to $3 million in clinical and regulatory costs for each study.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is currently involved in a pending&#13;arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet&#13;AG). On October 31, 2013, the Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former&#13;third-party CRO, and are seeking payment for damages related to inVentiv&amp;#8217;s prior involvement in the ongoing Phase 3 clinical&#13;trial of Multikine. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges&#13;(i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. The Company is seeking at least $50 million in&#13;damages in its amended statement of claim. Based upon further analysis, however, the Company believes that its damages (direct&#13;and consequential) presently total over $150 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In an amended statement of claim, the Company&#13;asserted the claims set forth above as well as an additional claim for professional malpractice.&amp;#160;&amp;#160;The arbitrator subsequently&#13;granted inVentiv&amp;#8217;s motion to dismiss the professional malpractice claim based on the &amp;#8220;economic loss doctrine&amp;#8221;&#13;which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim&#13;alongside a claim for breach of contract.&amp;#160;&amp;#160;The arbitrator denied the remainder of inVentiv&amp;#8217;s motion, which had&#13;sought to dismiss certain other aspects of the amended statement of claim.&amp;#160;&amp;#160;In particular, the arbitrator rejected inVentiv&amp;#8217;s&#13;argument that several aspects of the amended statement of claim were beyond the arbitrator&amp;#8217;s jurisdiction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the pending arbitration proceedings,&#13;inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for&#13;services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Company&amp;#8217;s&#13;alleged use of inVentiv&amp;#8217;s name in connection with publications and promotions in violation of the parties&amp;#8217; contract;&#13;(iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits&#13;allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking&#13;at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&amp;#8217;s counterclaims&#13;are meritless. However, if inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material&#13;adverse effect on the Company&amp;#8217;s business, results, financial condition and liquidity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2015 the Company signed an arbitration&#13;funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation&#13;expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with funding for litigation expenses to&#13;support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration&#13;and will only be repaid when the Company receives proceeds from the arbitration. During the year ended September 30, 2016, the&#13;Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability&#13;that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of&#13;legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal&#13;fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap&#13;its fees and expenses for the arbitration at $5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The arbitration hearing on the merits (the &amp;#8220;trial&amp;#8221;)&#13;began on September 26, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Lease Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases a manufacturing facility&#13;near Baltimore, Maryland under an operating lease (the San Tomas lease). The building was remodeled in accordance with the Company&amp;#8217;s&#13;specifications so that it can be used by the Company to manufacture Multikine for the Company&amp;#8217;s Phase 3 clinical trial and&#13;sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each&#13;year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses,&#13;repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase&#13;the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements,&#13;of which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately&#13;$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building&#13;in service in October 2008.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The leased building is being depreciated using&#13;a straight line method of the 20 year lease term to a residual value. The landlord liability is being amortized over the 20 years&#13;using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Lease payments allocated to the landlord liability&#13;are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company was required to deposit the equivalent&#13;of one year of base rent in accordance with the San Tomas lease. When the Company meets the minimum cash balance required by the&#13;lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets on September&#13;30, 2016 and 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future minimum lease payments under the San&#13;Tomas lease as of September 30, 2016 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Years ending September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,687,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,747,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,808,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,872,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,937,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,762,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,813,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(11,802,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,011,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company subleases a portion of its rental&#13;space on a month to month term lease, which requires a 30 day notice for termination. The sublease rent for the years ended September&#13;30, 2016, 2015 and 2014 was approximately $67,000, $65,000 and $63,000, respectively, and is recorded in grant income and other&#13;in the statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its research and development&#13;laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28,&#13;2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight&#13;line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of September 30, 2016 and&#13;2015, the Company has recorded a deferred rent liability of approximately $2,000 and $6,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its office headquarters under&#13;a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing&#13;the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per&#13;month. As of September 30, 2016 and 2015, the Company has recorded a deferred rent liability of approximately $18,000 and $13,000,&#13;respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases office equipment under a&#13;capital lease arrangement. The term of the capital lease is 48 months and expired on September 30, 2016. The monthly lease payment&#13;is $1,025. The lease bears interest at approximately 6% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Approximate future minimum annual lease payments&#13;due under non-cancelable operating leases, excluding the San Thomas, lease for the years ending after September 30, 2016 are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;243,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;251,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;258,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;163,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total minimum lease payments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,222,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160; &amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense, for the years ended September&#13;30, 2016, 2015 and 2014, excluding the rent paid on the San Tomas lease was approximately $300,000. The Company&amp;#8217;s three leases&#13;expire between June 2020 and October 2028.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Vendor Obligations&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, the Company has contingent obligations&#13;with other vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be&#13;determined at this time. The total remaining cash cost of the Phase 3 clinical trial, excluding any costs that will be paid by&#13;CEL-SCI's partners, would be approximately $12.1 million after September 30, 2016. This is based on the executed contract costs&#13;with the CROs only and does not include other related costs, e.g. the manufacturing of the drug. The Company has filed an amendment&#13;to the original Phase 3 protocol for it head and neck cancer study with the FDA to allow for this expansion in patient enrollment.&#13;Should the FDA allow the amended protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be&#13;higher.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Years ending September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,687,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,747,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,808,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,872,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,937,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,762,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,813,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(11,802,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,011,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;243,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;251,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;258,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;163,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total minimum lease payments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,222,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;64,366,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;61,363,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;R&amp;#38;D credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,379,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,855,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Capitalized R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,508,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,082,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vacation and other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;179,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;114,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Loan modification&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;57,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,653 ,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,692,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets and intangibles&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(49,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(86,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(49,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(86,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(90,604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(83,606,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2015-10-01to2016-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font-size: 8pt"&gt;Federal Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Other adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Adjustment to deferreds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Permanent differences (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44.90&lt;/font&gt;&lt;br /&gt;&#13;&lt;br /&gt;&#13;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(60.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(38.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(58.78&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effective tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">6379000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5855000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">64366000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">61363000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">18508000</CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">15082000</CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <CVM:LoanModification contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</CVM:LoanModification>
    <CVM:LoanModification contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">57000</CVM:LoanModification>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">179000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">114000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90653000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">83692000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-49000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-86000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-49000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-86000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90604000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">83606000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.0512</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0392</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0515</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">-0.0015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.220</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0093</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">-0.0021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.0000</CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds>
    <CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0000</CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds>
    <CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.1913</CVM:EffectiveTaxRateReconciliationAdjustmentToDeferreds>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">-0.0071</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.4490</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">-0.0043</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">-0.3805</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.6079</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">-0.5878</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2014-10-01to2015-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-10-01to2014-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cvm-20160930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9aQ5w7xRiXgen8uOanNMSaGDicPtwZB66YlBvml/ffkaHy0iVtbUwiRYu4ImQRQF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:CVM="http://cel-sci.com/20160930" elementFormDefault="qualified" targetNamespace="http://cel-sci.com/20160930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - 1. ORGANIZATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OperationsFinancing" id="OperationsFinancing">
	  <link:definition>00000008 - Disclosure - 2. OPERATIONS, FINANCING</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" id="DerivativesLiabilitiesWarrantsAndOtherOptions">
	  <link:definition>00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" id="ResearchAndOfficeEquipment">
	  <link:definition>00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/Patents" id="Patents">
	  <link:definition>00000012 - Disclosure - 6. PATENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - 7. INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensation" id="StockCompensation">
	  <link:definition>00000014 - Disclosure - 8. STOCK COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000015 - Disclosure - 9. EMPLOYEE BENEFIT PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000017 - Disclosure - 11. RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000018 - Disclosure - 12. STOCKHOLDERS EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000019 - Disclosure - 13. FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
	  <link:definition>00000020 - Disclosure - 14. NET LOSS PER COMMON SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SegmentReporting" id="SegmentReporting">
	  <link:definition>00000021 - Disclosure - 15. SEGMENT REPORTING</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/QuarterlyInformation" id="QuarterlyInformation">
	  <link:definition>00000022 - Disclosure - 16. QUARTERLY INFORMATION (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/Restatement" id="Restatement">
	  <link:definition>00000023 - Disclosure - 17. RESTATEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000024 - Disclosure - 18. SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000025 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" id="DerivativesLiabilitiesWarrantsAndOtherOptionsTables">
	  <link:definition>00000026 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" id="ResearchAndOfficeEquipmentTables">
	  <link:definition>00000027 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsTables" id="PatentsTables">
	  <link:definition>00000028 - Disclosure - 6. PATENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000029 - Disclosure - 7. INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationTables" id="StockCompensationTables">
	  <link:definition>00000030 - Disclosure - 8. STOCK COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000031 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000032 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
	  <link:definition>00000033 - Disclosure - 14. NET LOSS PER COMMON SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/QuarterlyInformationTables" id="QuarterlyInformationTables">
	  <link:definition>00000034 - Disclosure - 16. QUARTERLY INFORMATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RestatementTables" id="RestatementTables">
	  <link:definition>00000035 - Disclosure - 17. RESTATEMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000036 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" id="WarrantsAndNon-employeeOptionsDetails">
	  <link:definition>00000037 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" id="WarrantsAndNon-employeeOptionsDetails1">
	  <link:definition>00000038 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" id="WarrantsAndNon-employeeOptionsDetails2">
	  <link:definition>00000039 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" id="WarrantsAndNon-employeeOptionsDetailsNarrative">
	  <link:definition>00000040 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" id="PlantPropertyAndEquipmentDetails">
	  <link:definition>00000041 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" id="PlantPropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000042 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetails" id="PatentsDetails">
	  <link:definition>00000043 - Disclosure - 6. PATENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetails1" id="PatentsDetails1">
	  <link:definition>00000044 - Disclosure - 6. PATENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
	  <link:definition>00000045 - Disclosure - 6. PATENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" id="IncomeTaxesNetDeferredTaxAssetDetails">
	  <link:definition>00000046 - Disclosure - 7. INCOME TAXES Net deferred tax asset (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="IncomeTaxesReconciliationOfEffectiveTaxRateDetails">
	  <link:definition>00000047 - Disclosure - 7. INCOME TAXES Reconciliation of effective tax rate (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" id="StockCompensationAwardsDetails">
	  <link:definition>00000048 - Disclosure - 8. STOCK COMPENSATION Awards (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" id="StockCompensationAssumptionsDetails">
	  <link:definition>00000049 - Disclosure - 8. STOCK COMPENSATION Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" id="StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails">
	  <link:definition>00000050 - Disclosure - 8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" id="StockCompensationNonvestedOptionsDetails">
	  <link:definition>00000051 - Disclosure - 8. STOCK COMPENSATION Nonvested Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" id="StockCompensationRsuDetails">
	  <link:definition>00000052 - Disclosure - 8. STOCK COMPENSATION RSU (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
	  <link:definition>00000053 - Disclosure - 8. STOCK COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" id="EmployeeBenefitPlanDetailNarrative">
	  <link:definition>00000054 - Disclosure - 9. EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000055 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000056 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>00000058 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
	  <link:definition>00000059 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" id="NetLossPerCommonShareDetails">
	  <link:definition>00000060 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" id="NetLossPerCommonShareDetails1">
	  <link:definition>00000061 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/QuarterlyInformationDetails" id="QuarterlyInformationDetails">
	  <link:definition>00000062 - Disclosure - 16. QUARTERLY INFORMATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RestatementDetails" id="RestatementDetails">
	  <link:definition>00000063 - Disclosure - 17. RESTATEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RestatementDetails1" id="RestatementDetails1">
	  <link:definition>00000064 - Disclosure - 17. RESTATEMENT (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RestatementDetails2" id="RestatementDetails2">
	  <link:definition>00000065 - Disclosure - 17. RESTATEMENT (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="CVM_IssuanceOfAdditionalShares" name="IssuanceOfAdditionalShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExerciseOfWarrants" name="ExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConversionOfWarrantLiabilityToEquity" name="ConversionOfWarrantLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ModificationToWarrants" name="ModificationToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" name="AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EquityBasedCompensationNonemployees" name="EquityBasedCompensationNonemployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DecreaseIncreaseInResearchAndOfficeEquipment" name="DecreaseIncreaseInResearchAndOfficeEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DecreaseIncreaseInPatentCosts" name="DecreaseIncreaseInPatentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" name="IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInPrepaidServices" name="IncreaseInPrepaidServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonemployeesShareBasedCompensation" name="NonemployeesShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpectedLifeOfOptionsMin1" name="ExpectedLifeOfOptionsMin1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpectedLifeOfOptionsMax" name="ExpectedLifeOfOptionsMax" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageGrantDateFairValueBeginning" name="WeightedAverageGrantDateFairValueBeginning" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageGrantDateFairValueEnding" name="WeightedAverageGrantDateFairValueEnding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RDDeferredRentLiability" name="RDDeferredRentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentLiability" name="DeferredRentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" name="OptionsAndWarrantsExcludedFromEarningsPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AntidilutiveConvertibleDebt" name="AntidilutiveConvertibleDebt" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AntidilutiveUnvestedRestrictedStock" name="AntidilutiveUnvestedRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInDirectFinancingCosts" name="IncreaseInDirectFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityTextBlock" name="StockholdersEquityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Deposits2" name="Deposits2" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" name="DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" name="ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleOfNonvestedOptionsTableTextBlock" name="ScheduleOfNonvestedOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" name="FullyInsuredAmountOfNoninterestBearingCashBalances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationDate1" name="ExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Issuedate2" name="Issuedate2" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMinimum" name="ExercisePriceMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMaximum" name="ExercisePriceMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStocksExpired" name="NumberOfStocksExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceExpired" name="WeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" name="WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStockVested" name="NumberOfStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceVested" name="WeightedAverageExercisePriceVested" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationStartDate" name="ExpirationStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationEndDate" name="ExpirationEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IssueStartDate" name="IssueStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IssueEndDate1" name="IssueEndDate1" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OperationsAndFinancingTextBlock" name="OperationsAndFinancingTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedOptionsBeginning" name="NumberOfUnvestedOptionsBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_VestedOptions" name="VestedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantedOptions" name="GrantedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ForfeitedOptions" name="ForfeitedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedOptionsEnding" name="NumberOfUnvestedOptionsEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInPatentCosts" name="IncreaseInPatentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ForfeitureOfUnvestedRestrictedStock" name="ForfeitureOfUnvestedRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" name="StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" name="LeasePaymentsIncludedInAccountsPayableAtYearEnd" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedSharesBeginning" name="NumberOfUnvestedSharesBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_VestedShares" name="VestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantedShares" name="GrantedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ForfeitedShares" name="ForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedSharesEnding" name="NumberOfUnvestedSharesEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExerciseOfWarrantsShares" name="ExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesSWarrants" name="FairValueOfSeriesSWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesUWarrants" name="FairvalueofSeriesUWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesVWarrants" name="FairvalueofSeriesVWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesWWarrants" name="FairvalueofSeriesWWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesZWarrants" name="FairvalueofSeriesZWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesZZWarrants" name="FairvalueofSeriesZZWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesAAWarrants" name="FairvalueofSeriesAAWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofSeriesBBWarrants" name="FairvalueofSeriesBBWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_TotalFairvalueofDerivativeLiabilities" name="TotalFairvalueofDerivativeLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestatementOfPriorYearIncomeNet" name="RestatementOfPriorYearIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NetLoss" name="NetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CapitalizedLeaseInterest" name="CapitalizedLeaseInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" name="RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" name="DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LoanModification" name="LoanModification" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" name="EffectiveTaxRateReconciliationAdjustmentToDeferreds" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesNMember" name="SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CSchleuningSeriesAMember" name="CSchleuningSeriesAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesCMember" name="SeriesCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesEMember" name="SeriesEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFMember" name="SeriesFMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesGMember" name="SeriesGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHMember" name="SeriesHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQMember" name="SeriesQMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLMember" name="SeriesLMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLRepricedMember" name="SeriesLRepricedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModifiedMember" name="SeriesMModifiedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesPMember" name="SeriesPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorsMember" name="PrivateInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WarrantsHeldbyOfficerAndDirectorMember" name="WarrantsHeldbyOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKwarrantsMember" name="SeriesKwarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Financings2009WarrantsSeriesAToEMember" name="Financings2009WarrantsSeriesAToEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Warrants2008SeriesNMember" name="Warrants2008SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFAndGWarrantsMember" name="SeriesFAndGWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQWarrantsMember" name="SeriesQWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConvertibleNotesSettlementMember" name="ConvertibleNotesSettlementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncentiveStockOptionPlansMember" name="IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonQualifiedStockOptionPlansMember" name="NonQualifiedStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockBonusPlansMember" name="StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesRMember" name="SeriesRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModififedMember" name="SeriesMModififedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOMember" name="SeriesOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Level1Member" name="Level1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Level2Member" name="Level2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Level3Member" name="Level3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_TotalMember" name="TotalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OutstandingMember" name="OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisableMember" name="ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAThroughEWarrantsMember" name="SeriesAThroughEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentLiabilityMember" name="DeferredRentLiabilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrantsMember" name="PrivateInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants1Member" name="PrivateInvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants2Member" name="PrivateInvestorWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants3Member" name="PrivateInvestorWarrants3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesSMember" name="SeriesSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesTMember" name="SeriesTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesUMember" name="SeriesUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_BasicEpsMember" name="BasicEpsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DilutiveEpsMember" name="DilutiveEpsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativeLiabilitiesGainMember" name="DerivativeLiabilitiesGainMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_BasicAndDilutiveEPSMember" name="BasicAndDilutiveEPSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKAndLWarrantsMember" name="SeriesKAndLWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKAndSeriesAThroughEWarrantsMember" name="SeriesKAndSeriesAThroughEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesVMember" name="SeriesVMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesWMember" name="SeriesWMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesXMember" name="SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesYMember" name="SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZMember" name="SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZZMember" name="SeriesZZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAAMember" name="SeriesAAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesBBMember" name="SeriesBBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NetLossRestatedMember" name="NetLossRestatedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EquityTransactionsMember" name="EquityTransactionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExerciseOfWarrantsAndStockOptions" name="ExerciseOfWarrantsAndStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExerciseOfWarrantsAndStockOptionsShares" name="ExerciseOfWarrantsAndStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExerciseOfDerivativeLiabilities" name="ExerciseOfDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ModificationOfOptionsIssuedToEmployees" name="ModificationOfOptionsIssuedToEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ModificationOfStockOptionsIssuedToEmployees" name="ModificationOfStockOptionsIssuedToEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DepositsHeld" name="DepositsHeld" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestatementAbstract" name="RestatementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsTablesAbstract" name="PatentsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsTablesAbstract" name="FairValueMeasurementsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NetLossPerCommonShareTablesAbstract" name="NetLossPerCommonShareTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestatementTablesAbstract" name="RestatementTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" name="DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" name="DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" name="FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" name="EmployeeBenefitPlanDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndOfficeEquipmentDetailsAbstract" name="ResearchAndOfficeEquipmentDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" name="ResearchAndOfficeEquipmentDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsAbstract" name="PatentsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsNarrativeAbstract" name="PatentsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" name="IncomeTaxesNetDeferredTaxAssetDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" name="IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityDetails1Abstract" name="StockholdersEquityDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetailsAbstract" name="StockCompensationDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetails3Abstract" name="StockCompensationDetails3Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStocksCancelled" name="NumberOfStocksCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceCancelled" name="WeightedAverageExercisePriceCancelled" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" name="WeightedAverageRemainingContractualLifeInYearsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationNonvestedOptionsDetailsAbstract" name="StockCompensationNonvestedOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationRsuDetailsAbstract" name="StockCompensationRsuDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetailsNarrativeAbstract" name="StockCompensationDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesDetailsAbstract" name="CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" name="CommitmentsAndContingenciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetailsAbstract" name="FairValueMeasurementsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsAbstract" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetails1Abstract" name="FairValueMeasurementsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsAbstract" name="I.EarningsPerShareDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsNarrativeAbstract" name="I.EarningsPerShareDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_QuarterlyInformationDetailsAbstract" name="QuarterlyInformationDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_QuarterlyInformationDetails1Abstract" name="QuarterlyInformationDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_QuarterlyInformationDetails2Abstract" name="QuarterlyInformationDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cvm-20160930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20160930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20160930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20160930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20160930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20160930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20160930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20160930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SegmentReporting" xlink:href="cvm-20160930.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformation" xlink:href="cvm-20160930.xsd#QuarterlyInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Restatement" xlink:href="cvm-20160930.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20160930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20160930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationTables" xlink:href="cvm-20160930.xsd#QuarterlyInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementTables" xlink:href="cvm-20160930.xsd#RestatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20160930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20160930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20160930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20160930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20160930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:href="cvm-20160930.xsd#QuarterlyInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails" xlink:href="cvm-20160930.xsd#RestatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails1" xlink:href="cvm-20160930.xsd#RestatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails2" xlink:href="cvm-20160930.xsd#RestatementDetails2" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDebtAndCapitalLeaseObligations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssuanceOfAdditionalShares" xlink:label="loc_CVMIssuanceOfAdditionalShares" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_CVMIssuanceOfAdditionalShares" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfStockOptionsIssuedToEmployees" xlink:label="loc_CVMModificationOfStockOptionsIssuedToEmployees" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CVMModificationOfStockOptionsIssuedToEmployees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DepositsHeld" xlink:label="loc_CVMDepositsHeld" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CVMDepositsHeld" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS, FINANCING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - 7. INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 8. STOCK COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000015 - Disclosure - 9. EMPLOYEE BENEFIT PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 11. RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - 12. STOCKHOLDERS EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000019 - Disclosure - 13. FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000020 - Disclosure - 14. NET LOSS PER COMMON SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SegmentReporting" xlink:title="00000021 - Disclosure - 15. SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformation" xlink:title="00000022 - Disclosure - 16. QUARTERLY INFORMATION (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Restatement" xlink:title="00000023 - Disclosure - 17. RESTATEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - 18. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000026 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000027 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000028 - Disclosure - 6. PATENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - 7. INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000030 - Disclosure - 8. STOCK COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000032 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000033 - Disclosure - 14. NET LOSS PER COMMON SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationTables" xlink:title="00000034 - Disclosure - 16. QUARTERLY INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementTables" xlink:title="00000035 - Disclosure - 17. RESTATEMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000037 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000038 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:title="00000039 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:title="00000040 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000043 - Disclosure - 6. PATENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000044 - Disclosure - 6. PATENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000045 - Disclosure - 6. PATENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000046 - Disclosure - 7. INCOME TAXES Net deferred tax asset (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000047 - Disclosure - 7. INCOME TAXES Reconciliation of effective tax rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000048 - Disclosure - 8. STOCK COMPENSATION Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000049 - Disclosure - 8. STOCK COMPENSATION Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000050 - Disclosure - 8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000051 - Disclosure - 8. STOCK COMPENSATION Nonvested Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000052 - Disclosure - 8. STOCK COMPENSATION RSU (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000053 - Disclosure - 8. STOCK COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000054 - Disclosure - 9. EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000056 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000058 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000059 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000060 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000061 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:title="00000062 - Disclosure - 16. QUARTERLY INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails" xlink:title="00000063 - Disclosure - 17. RESTATEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails1" xlink:title="00000064 - Disclosure - 17. RESTATEMENT (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails2" xlink:title="00000065 - Disclosure - 17. RESTATEMENT (Details 2)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cvm-20160930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20160930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20160930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20160930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20160930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20160930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20160930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20160930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SegmentReporting" xlink:href="cvm-20160930.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformation" xlink:href="cvm-20160930.xsd#QuarterlyInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Restatement" xlink:href="cvm-20160930.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20160930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20160930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationTables" xlink:href="cvm-20160930.xsd#QuarterlyInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementTables" xlink:href="cvm-20160930.xsd#RestatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20160930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20160930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20160930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20160930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20160930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:href="cvm-20160930.xsd#QuarterlyInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails" xlink:href="cvm-20160930.xsd#RestatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails1" xlink:href="cvm-20160930.xsd#RestatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails2" xlink:href="cvm-20160930.xsd#RestatementDetails2" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:label="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:label="loc_us-gaapImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptions" xlink:label="loc_CVMExerciseOfWarrantsAndStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsAndStockOptions_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptionsShares" xlink:label="loc_CVMExerciseOfWarrantsAndStockOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsAndStockOptionsShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrants" xlink:label="loc_CVMExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrants_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsShares" xlink:label="loc_CVMExerciseOfWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsShares_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConversionOfWarrantLiabilityToEquity" xlink:label="loc_CVMConversionOfWarrantLiabilityToEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMConversionOfWarrantLiabilityToEquity_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfDerivativeLiabilities" xlink:label="loc_CVMExerciseOfDerivativeLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfDerivativeLiabilities_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationToWarrants" xlink:label="loc_CVMModificationToWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMModificationToWarrants_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfOptionsIssuedToEmployees" xlink:label="loc_CVMModificationOfOptionsIssuedToEmployees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMModificationOfOptionsIssuedToEmployees_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="loc_CVMEquityBasedCompensationNonemployees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMEquityBasedCompensationNonemployees_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS, FINANCING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - 7. INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 8. STOCK COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000015 - Disclosure - 9. EMPLOYEE BENEFIT PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 11. RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - 12. STOCKHOLDERS EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000019 - Disclosure - 13. FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000020 - Disclosure - 14. NET LOSS PER COMMON SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SegmentReporting" xlink:title="00000021 - Disclosure - 15. SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformation" xlink:title="00000022 - Disclosure - 16. QUARTERLY INFORMATION (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Restatement" xlink:title="00000023 - Disclosure - 17. RESTATEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - 18. SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000026 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000027 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000028 - Disclosure - 6. PATENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - 7. INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000030 - Disclosure - 8. STOCK COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000032 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000033 - Disclosure - 14. NET LOSS PER COMMON SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationTables" xlink:title="00000034 - Disclosure - 16. QUARTERLY INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementTables" xlink:title="00000035 - Disclosure - 17. RESTATEMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000037 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQMember" xlink:label="loc_CVMSeriesQMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesPMember" xlink:label="loc_CVMSeriesPMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Issuedate2" xlink:label="loc_CVMIssuedate2_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMIssuedate2_470" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant_470" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExercisePrice_470" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationDate1" xlink:label="loc_CVMExpirationDate1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExpirationDate1_470" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueStartDate" xlink:label="loc_CVMIssueStartDate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMIssueStartDate_470" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueEndDate1" xlink:label="loc_CVMIssueEndDate1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMIssueEndDate1_470" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationStartDate" xlink:label="loc_CVMExpirationStartDate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExpirationStartDate_470" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationEndDate" xlink:label="loc_CVMExpirationEndDate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExpirationEndDate_470" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExercisePriceMinimum_470" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_470" xlink:to="loc_CVMExercisePriceMaximum_470" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000038 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:title="00000039 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAThroughEWarrantsMember" xlink:label="loc_CVMSeriesAThroughEWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAThroughEWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesFAndGWarrantsMember" xlink:label="loc_CVMSeriesFAndGWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFAndGWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesHMember" xlink:label="loc_CVMSeriesHMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesTMember" xlink:label="loc_CVMSeriesTMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesTMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQMember" xlink:label="loc_CVMSeriesQMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_490" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:title="00000040 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000043 - Disclosure - 6. PATENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000044 - Disclosure - 6. PATENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000045 - Disclosure - 6. PATENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000046 - Disclosure - 7. INCOME TAXES Net deferred tax asset (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000047 - Disclosure - 7. INCOME TAXES Reconciliation of effective tax rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000048 - Disclosure - 8. STOCK COMPENSATION Awards (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000049 - Disclosure - 8. STOCK COMPENSATION Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000050 - Disclosure - 8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OutstandingMember" xlink:label="loc_CVMOutstandingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMOutstandingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisableMember" xlink:label="loc_CVMExercisableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMExercisableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStockVested" xlink:label="loc_CVMNumberOfStockVested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStockVested_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfOptionsExercised" xlink:label="loc_CVMNumberOfOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfOptionsExercised_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksExpired" xlink:label="loc_CVMNumberOfStocksExpired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksExpired_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksCancelled" xlink:label="loc_CVMNumberOfStocksCancelled_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksCancelled_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="loc_CVMWeightedAverageExercisePriceVested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceVested_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="loc_CVMWeightedAverageExercisePriceExpired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceExpired_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="loc_CVMWeightedAverageExercisePriceCancelled_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceCancelled_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000051 - Disclosure - 8. STOCK COMPENSATION Nonvested Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000052 - Disclosure - 8. STOCK COMPENSATION RSU (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="loc_CVMRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="loc_CVMNumberOfUnvestedSharesBeginning_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesBeginning_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_VestedShares" xlink:label="loc_CVMVestedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMVestedShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantedShares" xlink:label="loc_CVMGrantedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMGrantedShares_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitedShares" xlink:label="loc_CVMForfeitedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMForfeitedShares_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="loc_CVMNumberOfUnvestedSharesEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesEnding_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMRestrictedStockAwardWeightedAverageGrantDateFairValueEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRestrictedStockAwardWeightedAverageGrantDateFairValueEnding_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000053 - Disclosure - 8. STOCK COMPENSATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000054 - Disclosure - 9. EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000056 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaapGainContingenciesByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGainContingenciesByNatureAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RDDeferredRentLiability" xlink:label="loc_CVMRDDeferredRentLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRDDeferredRentLiability_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredRentLiability" xlink:label="loc_CVMDeferredRentLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentLiability_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000058 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level1Member" xlink:label="loc_CVMLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level2Member" xlink:label="loc_CVMLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level3Member" xlink:label="loc_CVMLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_TotalMember" xlink:label="loc_CVMTotalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMTotalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="loc_CVMFairValueMeasurementsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMFairValueMeasurementsAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CVMFairValueMeasurementsAbstract_90" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000059 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000060 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000061 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:title="00000062 - Disclosure - 16. QUARTERLY INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails" xlink:title="00000063 - Disclosure - 17. RESTATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaapScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaapRestatementAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapRestatementAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssets_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails1" xlink:title="00000064 - Disclosure - 17. RESTATEMENT (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaapScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaapRestatementAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapRestatementAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails2" xlink:title="00000065 - Disclosure - 17. RESTATEMENT (Details 2)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cvm-20160930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class Of Warrant Or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesNMember" xlink:label="CVM_SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesNMember_lbl" xml:lang="en-US">Series N [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQMember" xlink:label="CVM_SeriesQMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQMember" xlink:to="CVM_SeriesQMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesQMember_lbl" xml:lang="en-US">Series Q [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesPMember" xlink:label="CVM_SeriesPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPMember" xlink:to="CVM_SeriesPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesPMember_lbl" xml:lang="en-US">Series P [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConsultantsMember" xlink:label="CVM_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesRMember" xlink:label="CVM_SeriesRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRMember" xlink:to="CVM_SeriesRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesRMember_lbl" xml:lang="en-US">SeriesRMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">FairValueByFairValueHierarchyLevel [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level1Member" xlink:label="CVM_Level1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level1Member" xlink:to="CVM_Level1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Level1Member_lbl" xml:lang="en-US">Level1</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level2Member" xlink:label="CVM_Level2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level2Member" xlink:to="CVM_Level2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Level2Member_lbl" xml:lang="en-US">Level2</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level3Member" xlink:label="CVM_Level3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level3Member" xlink:to="CVM_Level3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Level3Member_lbl" xml:lang="en-US">Level3</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_TotalMember" xlink:label="CVM_TotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalMember" xlink:to="CVM_TotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_TotalMember_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OutstandingMember" xlink:label="CVM_OutstandingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OutstandingMember" xlink:to="CVM_OutstandingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OutstandingMember_lbl" xml:lang="en-US">Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisableMember" xlink:label="CVM_ExercisableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisableMember" xlink:to="CVM_ExercisableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisableMember_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAThroughEWarrantsMember" xlink:label="CVM_SeriesAThroughEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesAThroughEWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesAThroughEWarrantsMember_lbl" xml:lang="en-US">Series A through E warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesFAndGWarrantsMember" xlink:label="CVM_SeriesFAndGWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFAndGWarrantsMember" xlink:to="CVM_SeriesFAndGWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesFAndGWarrantsMember_lbl" xml:lang="en-US">SeriesFAndGWarrantsMember</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesHMember" xlink:label="CVM_SeriesHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHMember" xlink:to="CVM_SeriesHMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesHMember_lbl" xml:lang="en-US">Series H [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesSMember" xlink:label="CVM_SeriesSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesSMember_lbl" xml:lang="en-US">Series S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesUMember" xlink:label="CVM_SeriesUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesUMember" xlink:to="CVM_SeriesUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesUMember_lbl" xml:lang="en-US">Series U [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesTMember" xlink:label="CVM_SeriesTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesTMember" xlink:to="CVM_SeriesTMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesTMember_lbl" xml:lang="en-US">Series T [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Ergomed Collaborative Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesVMember" xlink:label="CVM_SeriesVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesVMember" xlink:to="CVM_SeriesVMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesVMember_lbl" xml:lang="en-US">Series V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesWMember" xlink:label="CVM_SeriesWMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesWMember" xlink:to="CVM_SeriesWMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesWMember_lbl" xml:lang="en-US">Series W [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesXMember" xlink:label="CVM_SeriesXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesXMember" xlink:to="CVM_SeriesXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesXMember_lbl" xml:lang="en-US">Series X [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesYMember" xlink:label="CVM_SeriesYMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesYMember" xlink:to="CVM_SeriesYMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesYMember_lbl" xml:lang="en-US">Series Y [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZMember" xlink:label="CVM_SeriesZMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZMember" xlink:to="CVM_SeriesZMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZMember_lbl" xml:lang="en-US">Series Z [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZZMember" xlink:label="CVM_SeriesZZMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZZMember" xlink:to="CVM_SeriesZZMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZZMember_lbl" xml:lang="en-US">Series ZZ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAAMember" xlink:label="CVM_SeriesAAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAAMember" xlink:to="CVM_SeriesAAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesAAMember_lbl" xml:lang="en-US">Series AA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesBBMember" xlink:label="CVM_SeriesBBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesBBMember" xlink:to="CVM_SeriesBBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesBBMember_lbl" xml:lang="en-US">Series BB [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesWMember" xlink:to="CVM_SeriesWMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_SeriesWMember_2_lbl" xml:lang="en-US">Series V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="CVM_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestrictedStockAwardsMember" xlink:to="CVM_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementAdjustmentMember" xlink:to="us-gaap_RestatementAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestatementAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="CVM_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DocumentAndEntityInformationAbstract" xlink:to="CVM_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">PATENT COSTS, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">DEPOSITS - net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndCapitalLeaseObligations" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.01 par value - 600,000,000 shares authorized; 6,235,035 and 4,490,975 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">GRANT INCOME AND OTHER</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General &amp; administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US">GAIN ON DERIVATIVE INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">LOSS ON DEBT EXTINGUISHMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">INTEREST EXPENSE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssuanceOfAdditionalShares" xlink:label="CVM_IssuanceOfAdditionalShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssuanceOfAdditionalShares" xlink:to="CVM_IssuanceOfAdditionalShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CVM_IssuanceOfAdditionalShares_lbl" xml:lang="en-US">ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS AVAILABLE TO COMMON SHAREHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">BASIC and DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_2_lbl" xml:lang="en-US">Adjustments for Error Corrections [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">BALANCE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">BALANCE, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:label="us-gaap_RestatementOfPriorYearIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:to="us-gaap_RestatementOfPriorYearIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestatementOfPriorYearIncomeNetOfTax_lbl" xml:lang="en-US">Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:label="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:to="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_lbl" xml:lang="en-US">Restated Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Issuance of warrants in connection with sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">401(k) contributions paid in common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">401(k) contributions paid in common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptions" xlink:label="CVM_ExerciseOfWarrantsAndStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfWarrantsAndStockOptions" xlink:to="CVM_ExerciseOfWarrantsAndStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US">Exercise of warrants and stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptionsShares" xlink:label="CVM_ExerciseOfWarrantsAndStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfWarrantsAndStockOptionsShares" xlink:to="CVM_ExerciseOfWarrantsAndStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExerciseOfWarrantsAndStockOptionsShares_lbl" xml:lang="en-US">Exercise of warrants and stock options, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrants" xlink:label="CVM_ExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfWarrants" xlink:to="CVM_ExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsShares" xlink:label="CVM_ExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfWarrantsShares" xlink:to="CVM_ExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExerciseOfWarrantsShares_lbl" xml:lang="en-US">Exercise of warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConversionOfWarrantLiabilityToEquity" xlink:label="CVM_ConversionOfWarrantLiabilityToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConversionOfWarrantLiabilityToEquity" xlink:to="CVM_ConversionOfWarrantLiabilityToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ConversionOfWarrantLiabilityToEquity_lbl" xml:lang="en-US">Conversion of warrant liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued to nonemployees for service</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued to nonemployees for service, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock issued for patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued for patents, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfDerivativeLiabilities" xlink:label="CVM_ExerciseOfDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfDerivativeLiabilities" xlink:to="CVM_ExerciseOfDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExerciseOfDerivativeLiabilities_lbl" xml:lang="en-US">Exercise of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_lbl" xml:lang="en-US">Modification of options issued to consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationToWarrants" xlink:label="CVM_ModificationToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationToWarrants" xlink:to="CVM_ModificationToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ModificationToWarrants_lbl" xml:lang="en-US">Modification of warrants and extinguishment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeiture of unvested restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeiture of unvested restricted stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfOptionsIssuedToEmployees" xlink:label="CVM_ModificationOfOptionsIssuedToEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfOptionsIssuedToEmployees" xlink:to="CVM_ModificationOfOptionsIssuedToEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ModificationOfOptionsIssuedToEmployees_lbl" xml:lang="en-US">Modification of options issued to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Equity based compensation - employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:to="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_lbl" xml:lang="en-US">Equity based compensation - employees, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="CVM_EquityBasedCompensationNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EquityBasedCompensationNonemployees" xlink:to="CVM_EquityBasedCompensationNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EquityBasedCompensationNonemployees_lbl" xml:lang="en-US">Equity based compensation - non-employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">BALANCE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">BALANCE, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt premium</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of common stock and options for services - non-employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_2_lbl" xml:lang="en-US">Modification of warrants issued to consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfStockOptionsIssuedToEmployees" xlink:label="CVM_ModificationOfStockOptionsIssuedToEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfStockOptionsIssuedToEmployees" xlink:to="CVM_ModificationOfStockOptionsIssuedToEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ModificationOfStockOptionsIssuedToEmployees_lbl" xml:lang="en-US">Modification of stock options issued to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xml:lang="en-US">Impairment loss on abandonment of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on retired equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_2_lbl" xml:lang="en-US">Gain on derivative instruments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="CVM_CapitalizedLeaseInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CapitalizedLeaseInterest" xlink:to="CVM_CapitalizedLeaseInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CapitalizedLeaseInterest_lbl" xml:lang="en-US">Capitalized lease interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DepositsHeld" xlink:label="CVM_DepositsHeld" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DepositsHeld" xlink:to="CVM_DepositsHeld_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DepositsHeld_lbl" xml:lang="en-US">Deposits held</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditures for patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xml:lang="en-US">Payment on related party loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payments on convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on obligations under capital lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DecreaseIncreaseInResearchAndOfficeEquipment" xlink:label="CVM_DecreaseIncreaseInResearchAndOfficeEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DecreaseIncreaseInResearchAndOfficeEquipment" xlink:to="CVM_DecreaseIncreaseInResearchAndOfficeEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DecreaseIncreaseInResearchAndOfficeEquipment_lbl" xml:lang="en-US">Research and office equipment included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DecreaseIncreaseInPatentCosts" xlink:label="CVM_DecreaseIncreaseInPatentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DecreaseIncreaseInPatentCosts" xlink:to="CVM_DecreaseIncreaseInPatentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DecreaseIncreaseInPatentCosts_lbl" xml:lang="en-US">Capitalizable patent costs included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInPatentCosts" xlink:label="CVM_IncreaseInPatentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInPatentCosts" xlink:to="CVM_IncreaseInPatentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInPatentCosts_lbl" xml:lang="en-US">Patent costs purchased with common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:to="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xml:lang="en-US">Lease payments included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:to="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_lbl" xml:lang="en-US">Fair value of warrant liabilities on the date of issuance reclassed to liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="CVM_IncreaseInDirectFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDirectFinancingCosts" xlink:to="CVM_IncreaseInDirectFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInDirectFinancingCosts_lbl" xml:lang="en-US">Financing costs included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitureOfUnvestedRestrictedStock" xlink:label="CVM_ForfeitureOfUnvestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitureOfUnvestedRestrictedStock" xlink:to="CVM_ForfeitureOfUnvestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_ForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US">Forfeiture of unvested restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" xlink:label="CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" xlink:to="CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Stock issued under an anti-dilution provision and cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInPrepaidServices" xlink:label="CVM_IncreaseInPrepaidServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInPrepaidServices" xlink:to="CVM_IncreaseInPrepaidServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInPrepaidServices_lbl" xml:lang="en-US">Prepaid amount under consulting services paid with issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="CVM_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NotesToFinancialStatementsAbstract" xlink:to="CVM_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">1. ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OperationsAndFinancingTextBlock" xlink:label="CVM_OperationsAndFinancingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OperationsAndFinancingTextBlock" xlink:to="CVM_OperationsAndFinancingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OperationsAndFinancingTextBlock_lbl" xml:lang="en-US">2. OPERATIONS, FINANCING</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="CVM_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">4. WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">5. PLANT, PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">6. PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">7. INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">8. STOCK COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">9. EMPLOYEE BENEFIT PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">10. COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">11. RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockholdersEquityTextBlock" xlink:label="CVM_StockholdersEquityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityTextBlock_lbl" xml:lang="en-US">12. STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">13. FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">14. NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">15. SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">16. QUARTERLY INFORMATION (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementAbstract" xlink:label="CVM_RestatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestatementAbstract" xlink:to="CVM_RestatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestatementAbstract_lbl" xml:lang="en-US">Restatement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">RESTATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">18. SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Deposits2" xlink:label="CVM_Deposits2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_Deposits2_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xml:lang="en-US">Research and Office Equipment and Leasehold Improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantIncomePolicyTextBlock" xlink:label="CVM_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantIncomePolicyTextBlock" xlink:to="CVM_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:label="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:to="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding_lbl" xml:lang="en-US">Derivative liabilities, warrants and other options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Research and office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsTablesAbstract" xlink:label="CVM_PatentsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsTablesAbstract" xlink:to="CVM_PatentsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsTablesAbstract_lbl" xml:lang="en-US">Patents Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:to="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_lbl" xml:lang="en-US">Employees and non-employees stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Assumptions for Option Pricing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock Option Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:to="CVM_ScheduleOfNonvestedOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of non-vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesTablesAbstract" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesTablesAbstract" xlink:to="CVM_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum lease payments under the San Tomas lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum annual rental payments due under non-cancelable operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="CVM_FairValueMeasurementsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsTablesAbstract" xlink:to="CVM_FairValueMeasurementsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsTablesAbstract_lbl" xml:lang="en-US">Fair Value Measurements Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NetLossPerCommonShareTablesAbstract" xlink:label="CVM_NetLossPerCommonShareTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLossPerCommonShareTablesAbstract" xlink:to="CVM_NetLossPerCommonShareTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NetLossPerCommonShareTablesAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Quarterly information</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementTablesAbstract" xlink:label="CVM_RestatementTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestatementTablesAbstract" xlink:to="CVM_RestatementTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestatementTablesAbstract_lbl" xml:lang="en-US">Restatement Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Restatements</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Details</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:to="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_lbl" xml:lang="en-US">Fully Insured Amount of non-interest bearing cash balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Issuedate2" xlink:label="CVM_Issuedate2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Issuedate2" xlink:to="CVM_Issuedate2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Issuedate2_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePrice" xlink:label="CVM_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationDate1" xlink:label="CVM_ExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate1" xlink:to="CVM_ExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationDate1_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueStartDate" xlink:label="CVM_IssueStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueStartDate" xlink:to="CVM_IssueStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssueStartDate_lbl" xml:lang="en-US">Issue Start date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueEndDate1" xlink:label="CVM_IssueEndDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueEndDate1" xlink:to="CVM_IssueEndDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssueEndDate1_lbl" xml:lang="en-US">Issue End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationStartDate" xlink:label="CVM_ExpirationStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationStartDate" xlink:to="CVM_ExpirationStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationStartDate_lbl" xml:lang="en-US">Expiration start date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationEndDate" xlink:label="CVM_ExpirationEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationEndDate" xlink:to="CVM_ExpirationEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationEndDate_lbl" xml:lang="en-US">Expiration end date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMinimum" xlink:label="CVM_ExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMinimum_lbl" xml:lang="en-US">Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMaximum" xlink:label="CVM_ExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMaximum_lbl" xml:lang="en-US">Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:label="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract_lbl" xml:lang="en-US">Forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueOfSeriesSWarrants" xlink:label="CVM_FairValueOfSeriesSWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesSWarrants" xlink:to="CVM_FairValueOfSeriesSWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesSWarrants_lbl" xml:lang="en-US">Series S warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesUWarrants" xlink:label="CVM_FairvalueofSeriesUWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesUWarrants" xlink:to="CVM_FairvalueofSeriesUWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesUWarrants_lbl" xml:lang="en-US">Series U warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesVWarrants" xlink:label="CVM_FairvalueofSeriesVWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesVWarrants" xlink:to="CVM_FairvalueofSeriesVWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesVWarrants_lbl" xml:lang="en-US">Series V warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesWWarrants" xlink:label="CVM_FairvalueofSeriesWWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesWWarrants" xlink:to="CVM_FairvalueofSeriesWWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesWWarrants_lbl" xml:lang="en-US">Series W warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesZWarrants" xlink:label="CVM_FairvalueofSeriesZWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesZWarrants" xlink:to="CVM_FairvalueofSeriesZWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesZWarrants_lbl" xml:lang="en-US">Series Z warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesZZWarrants" xlink:label="CVM_FairvalueofSeriesZZWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesZZWarrants" xlink:to="CVM_FairvalueofSeriesZZWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesZZWarrants_lbl" xml:lang="en-US">Series ZZ warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesAAWarrants" xlink:label="CVM_FairvalueofSeriesAAWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesAAWarrants" xlink:to="CVM_FairvalueofSeriesAAWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesAAWarrants_lbl" xml:lang="en-US">Series AA warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesBBWarrants" xlink:label="CVM_FairvalueofSeriesBBWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesBBWarrants" xlink:to="CVM_FairvalueofSeriesBBWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofSeriesBBWarrants_lbl" xml:lang="en-US">Series BB warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_TotalFairvalueofDerivativeLiabilities" xlink:label="CVM_TotalFairvalueofDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalFairvalueofDerivativeLiabilities" xlink:to="CVM_TotalFairvalueofDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_TotalFairvalueofDerivativeLiabilities_lbl" xml:lang="en-US">Total derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Derivative Gain on Derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" xlink:label="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" xlink:to="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract_lbl" xml:lang="en-US">Warrants And Non-employee Options Details Narrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_3_lbl" xml:lang="en-US">Gain on warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:to="CVM_ResearchAndOfficeEquipmentDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsAbstract_lbl" xml:lang="en-US">Plant Property And Equipment Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xml:lang="en-US">Manufacturing building</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FixturesAndEquipmentGross" xlink:to="us-gaap_FixturesAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FixturesAndEquipmentGross_lbl" xml:lang="en-US">Research equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net plant, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:to="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract_lbl" xml:lang="en-US">Plant Property And Equipment Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsDetailsAbstract" xlink:label="CVM_PatentsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsAbstract" xlink:to="CVM_PatentsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsAbstract_lbl" xml:lang="en-US">Patents Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="CVM_PatentsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsNarrativeAbstract" xlink:to="CVM_PatentsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsNarrativeAbstract_lbl" xml:lang="en-US">Patents Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:label="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract_lbl" xml:lang="en-US">Income Taxes Net Deferred Tax Asset Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl" xml:lang="en-US">Capitalized R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Vacation and other</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_LoanModification" xlink:label="CVM_LoanModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LoanModification" xlink:to="CVM_LoanModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LoanModification_lbl" xml:lang="en-US">Loan modification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Fixed assets and intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:label="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract_lbl" xml:lang="en-US">Income Taxes Reconciliation Of Effective Tax Rate Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">State tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:to="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_lbl" xml:lang="en-US">Adjustment to Deferreds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockholdersEquityDetails1Abstract" xlink:label="CVM_StockholdersEquityDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityDetails1Abstract" xlink:to="CVM_StockholdersEquityDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityDetails1Abstract_lbl" xml:lang="en-US">Stock Compensation Awards Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="CVM_NonemployeesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NonemployeesShareBasedCompensation_lbl" xml:lang="en-US">Non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetailsAbstract" xlink:label="CVM_StockCompensationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsAbstract" xlink:to="CVM_StockCompensationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationDetailsAbstract_lbl" xml:lang="en-US">Stock Compensation Assumptions Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected stock price volatility, min</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected stock price volatility, max</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, min</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, max</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpectedLifeOfOptionsMin1" xlink:label="CVM_ExpectedLifeOfOptionsMin1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMin1" xlink:to="CVM_ExpectedLifeOfOptionsMin1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpectedLifeOfOptionsMin1_lbl" xml:lang="en-US">Expected life of options, min</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpectedLifeOfOptionsMax" xlink:label="CVM_ExpectedLifeOfOptionsMax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMax" xlink:to="CVM_ExpectedLifeOfOptionsMax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpectedLifeOfOptionsMax_lbl" xml:lang="en-US">Expected life of options, max</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStockVested" xlink:label="CVM_NumberOfStockVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStockVested" xlink:to="CVM_NumberOfStockVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStockVested_lbl" xml:lang="en-US">Number of Options Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfOptionsExercised" xlink:label="CVM_NumberOfOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CVM_NumberOfOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksExpired" xlink:label="CVM_NumberOfStocksExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksExpired" xlink:to="CVM_NumberOfStocksExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStocksExpired_lbl" xml:lang="en-US">Number of Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksCancelled" xlink:label="CVM_NumberOfStocksCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksCancelled" xlink:to="CVM_NumberOfStocksCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStocksCancelled_lbl" xml:lang="en-US">Number of Options Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="CVM_WeightedAverageExercisePriceVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceVested" xlink:to="CVM_WeightedAverageExercisePriceVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceVested_lbl" xml:lang="en-US">Weighted Average Exercise Price Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="CVM_WeightedAverageExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceExpired" xlink:to="CVM_WeightedAverageExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="CVM_WeightedAverageExercisePriceCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceCancelled" xlink:to="CVM_WeightedAverageExercisePriceCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceCancelled_lbl" xml:lang="en-US">Weighted Average Exercise Price Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years) granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:to="CVM_StockCompensationNonvestedOptionsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract_lbl" xml:lang="en-US">Stock Compensation Nonvested Options Details</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedOptionsBeginning" xlink:label="CVM_NumberOfUnvestedOptionsBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedOptionsBeginning" xlink:to="CVM_NumberOfUnvestedOptionsBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedOptionsBeginning_lbl" xml:lang="en-US">Number of unvested options, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_VestedOptions" xlink:label="CVM_VestedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedOptions" xlink:to="CVM_VestedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_VestedOptions_lbl" xml:lang="en-US">Vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantedOptions" xlink:label="CVM_GrantedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedOptions" xlink:to="CVM_GrantedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantedOptions_lbl" xml:lang="en-US">Granted options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitedOptions" xlink:label="CVM_ForfeitedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedOptions" xlink:to="CVM_ForfeitedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ForfeitedOptions_lbl" xml:lang="en-US">Forfeited options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedOptionsEnding" xlink:label="CVM_NumberOfUnvestedOptionsEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedOptionsEnding" xlink:to="CVM_NumberOfUnvestedOptionsEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedOptionsEnding_lbl" xml:lang="en-US">Number of unvested options, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageGrantDateFairValueBeginning" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueBeginning" xlink:to="CVM_WeightedAverageGrantDateFairValueBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueEnding" xlink:to="CVM_WeightedAverageGrantDateFairValueEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="CVM_NumberOfUnvestedSharesBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesBeginning" xlink:to="CVM_NumberOfUnvestedSharesBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedSharesBeginning_lbl" xml:lang="en-US">Number of unvested shares, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_VestedShares" xlink:label="CVM_VestedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedShares" xlink:to="CVM_VestedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_VestedShares_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantedShares" xlink:label="CVM_GrantedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedShares" xlink:to="CVM_GrantedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantedShares_lbl" xml:lang="en-US">Granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitedShares" xlink:label="CVM_ForfeitedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedShares" xlink:to="CVM_ForfeitedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_ForfeitedShares_lbl" xml:lang="en-US">Forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="CVM_NumberOfUnvestedSharesEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesEnding" xlink:to="CVM_NumberOfUnvestedSharesEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedSharesEnding_lbl" xml:lang="en-US">Number of unvested shares, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:label="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:to="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetailsNarrativeAbstract" xlink:label="CVM_StockCompensationDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsNarrativeAbstract" xlink:to="CVM_StockCompensationDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationDetailsNarrativeAbstract_lbl" xml:lang="en-US">Stock Compensation Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Expense relating to the restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US">Employee Benefits and Share-based Compensation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Expense for Company's contribution to employee benefit plan</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Total future minimum lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less imputed interest on financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Net present value of lease financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingenciesByNatureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingenciesByNatureAxis_lbl" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RDDeferredRentLiability" xlink:label="CVM_RDDeferredRentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RDDeferredRentLiability" xlink:to="CVM_RDDeferredRentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RDDeferredRentLiability_lbl" xml:lang="en-US">R &amp; D deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredRentLiability" xlink:label="CVM_DeferredRentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_DeferredRentLiability_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="CVM_FairValueMeasurementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsAbstract" xlink:to="CVM_FairValueMeasurementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="CVM_FairValueMeasurementsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsDetails1Abstract" xlink:to="CVM_FairValueMeasurementsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsDetails1Abstract_lbl" xml:lang="en-US">Fair Value Measurements Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xml:lang="en-US">Net realized and unrealized derivative (gain)/loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="CVM_I.EarningsPerShareDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_I.EarningsPerShareDetailsAbstract" xlink:to="CVM_I.EarningsPerShareDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_I.EarningsPerShareDetailsAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Details</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss - available to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="us-gaap_GainOnDerivativeInstrumentsPretax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax_lbl" xml:lang="en-US">Less: Gain on derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted average number of shares - basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">EPS (LPS) - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:label="CVM_I.EarningsPerShareDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:to="CVM_I.EarningsPerShareDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_I.EarningsPerShareDetailsNarrativeAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:label="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:to="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare_lbl" xml:lang="en-US">Options and warrants excluded from earnings per share due to anti-dilutive effect</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AntidilutiveConvertibleDebt" xlink:label="CVM_AntidilutiveConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AntidilutiveConvertibleDebt" xlink:to="CVM_AntidilutiveConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AntidilutiveConvertibleDebt_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AntidilutiveUnvestedRestrictedStock" xlink:label="CVM_AntidilutiveUnvestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AntidilutiveUnvestedRestrictedStock" xlink:to="CVM_AntidilutiveUnvestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AntidilutiveUnvestedRestrictedStock_lbl" xml:lang="en-US">Unvested Restricted Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetailsAbstract" xlink:label="CVM_QuarterlyInformationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_QuarterlyInformationDetailsAbstract" xlink:to="CVM_QuarterlyInformationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_QuarterlyInformationDetailsAbstract_lbl" xml:lang="en-US">Quarterly Information Details</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncome_2_lbl" xml:lang="en-US">Grant income and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Non-operating (expense) income, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Gain (loss) on derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3_lbl" xml:lang="en-US">Net loss available to common shareholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net income (loss) per share-basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_3_lbl" xml:lang="en-US">Net loss per share-basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_3_lbl" xml:lang="en-US">Net loss per share-diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares-basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares-diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpenses_3_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_3_lbl" xml:lang="en-US">Net loss per common share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetails2Abstract" xlink:label="CVM_QuarterlyInformationDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_QuarterlyInformationDetails2Abstract" xlink:to="CVM_QuarterlyInformationDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_QuarterlyInformationDetails2Abstract_lbl" xml:lang="en-US">Restatement Details 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated Deficit, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_3_lbl" xml:lang="en-US">Accumulated Deficit, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders equity, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NetLoss" xlink:label="CVM_NetLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLoss" xlink:to="CVM_NetLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_NetLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementOfPriorYearIncomeNet" xlink:label="CVM_RestatementOfPriorYearIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestatementOfPriorYearIncomeNet" xlink:to="CVM_RestatementOfPriorYearIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_RestatementOfPriorYearIncomeNet_lbl" xml:lang="en-US">Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="us-gaap_EquityFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueAdjustment_lbl" xml:lang="en-US">Equity transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Stockholders equity, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_BasicAndDilutiveEPSMember" xlink:label="CVM_BasicAndDilutiveEPSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_BasicAndDilutiveEPSMember" xlink:to="CVM_BasicAndDilutiveEPSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_BasicAndDilutiveEPSMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_BasicEpsMember" xlink:label="CVM_BasicEpsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_BasicEpsMember" xlink:to="CVM_BasicEpsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_BasicEpsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CSchleuningSeriesAMember" xlink:label="CVM_CSchleuningSeriesAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CSchleuningSeriesAMember" xlink:to="CVM_CSchleuningSeriesAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CSchleuningSeriesAMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:label="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesTablesAbstract" xlink:to="CVM_CommitmentsAndContingenciesTablesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConsultantsMember_doc" xml:lang="en-US">Consultants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConvertibleNotesSettlementMember" xlink:label="CVM_ConvertibleNotesSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConvertibleNotesSettlementMember" xlink:to="CVM_ConvertibleNotesSettlementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConvertibleNotesSettlementMember_doc" xml:lang="en-US">Convertible Notes Settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentLiability_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredRentLiabilityMember" xlink:label="CVM_DeferredRentLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiabilityMember" xlink:to="CVM_DeferredRentLiabilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentLiabilityMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Deposits2_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DepositsHeld" xlink:to="CVM_DepositsHeld_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DepositsHeld_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DerivativeLiabilitiesGainMember" xlink:label="CVM_DerivativeLiabilitiesGainMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DerivativeLiabilitiesGainMember" xlink:to="CVM_DerivativeLiabilitiesGainMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DerivativeLiabilitiesGainMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DilutiveEpsMember" xlink:label="CVM_DilutiveEpsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DilutiveEpsMember" xlink:to="CVM_DilutiveEpsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DilutiveEpsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:to="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisableMember" xlink:to="CVM_ExercisableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisableMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExerciseOfDerivativeLiabilities" xlink:to="CVM_ExerciseOfDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExerciseOfDerivativeLiabilities_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMaximum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMinimum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMax" xlink:to="CVM_ExpectedLifeOfOptionsMax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpectedLifeOfOptionsMax_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMin1" xlink:to="CVM_ExpectedLifeOfOptionsMin1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpectedLifeOfOptionsMin1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate1" xlink:to="CVM_ExpirationDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationDate1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationEndDate" xlink:to="CVM_ExpirationEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationEndDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationStartDate" xlink:to="CVM_ExpirationStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationStartDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsAbstract" xlink:to="CVM_FairValueMeasurementsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FairValueMeasurementsAbstract_doc" xml:lang="en-US">Fair Value Measurements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesSWarrants" xlink:to="CVM_FairValueOfSeriesSWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FairValueOfSeriesSWarrants_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofSeriesUWarrants" xlink:to="CVM_FairvalueofSeriesUWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FairvalueofSeriesUWarrants_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Financings2009WarrantsSeriesAToEMember" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Financings2009WarrantsSeriesAToEMember" xlink:to="CVM_Financings2009WarrantsSeriesAToEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember_doc" xml:lang="en-US">Financings 2009 Warrants Series A To E.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedShares" xlink:to="CVM_ForfeitedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ForfeitedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:to="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedShares" xlink:to="CVM_GrantedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_GrantedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncentiveStockOptionPlansMember" xlink:label="CVM_IncentiveStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockOptionPlansMember" xlink:to="CVM_IncentiveStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncentiveStockOptionPlansMember_doc" xml:lang="en-US">Incentive Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:to="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_doc" xml:lang="en-US">Increase In Derivative Liabilities From Issuance Of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssuanceOfAdditionalShares" xlink:to="CVM_IssuanceOfAdditionalShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssuanceOfAdditionalShares_doc" xml:lang="en-US">Issuance Of Additional Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueEndDate1" xlink:to="CVM_IssueEndDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssueEndDate1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueStartDate" xlink:to="CVM_IssueStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssueStartDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Issuedate2" xlink:to="CVM_Issuedate2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Issuedate2_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level1Member" xlink:to="CVM_Level1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Level1Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level2Member" xlink:to="CVM_Level2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Level2Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Level3Member" xlink:to="CVM_Level3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Level3Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfOptionsIssuedToEmployees" xlink:to="CVM_ModificationOfOptionsIssuedToEmployees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ModificationOfOptionsIssuedToEmployees_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfStockOptionsIssuedToEmployees" xlink:to="CVM_ModificationOfStockOptionsIssuedToEmployees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ModificationOfStockOptionsIssuedToEmployees_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLossPerCommonShareTablesAbstract" xlink:to="CVM_NetLossPerCommonShareTablesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NetLossPerCommonShareTablesAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NonQualifiedStockOptionPlansMember" xlink:label="CVM_NonQualifiedStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonQualifiedStockOptionPlansMember" xlink:to="CVM_NonQualifiedStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonQualifiedStockOptionPlansMember_doc" xml:lang="en-US">Non Qualified Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonemployeesShareBasedCompensation_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfOptionsExercised_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStockVested" xlink:to="CVM_NumberOfStockVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStockVested_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksCancelled" xlink:to="CVM_NumberOfStocksCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStocksCancelled_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksExpired" xlink:to="CVM_NumberOfStocksExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStocksExpired_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesBeginning" xlink:to="CVM_NumberOfUnvestedSharesBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfUnvestedSharesBeginning_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesEnding" xlink:to="CVM_NumberOfUnvestedSharesEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfUnvestedSharesEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OperationsAndFinancingTextBlock" xlink:to="CVM_OperationsAndFinancingTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_OperationsAndFinancingTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OutstandingMember" xlink:to="CVM_OutstandingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_OutstandingMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PrivateInvestorWarrants1Member" xlink:label="CVM_PrivateInvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants1Member" xlink:to="CVM_PrivateInvestorWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants1Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PrivateInvestorWarrants2Member" xlink:label="CVM_PrivateInvestorWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants2Member" xlink:to="CVM_PrivateInvestorWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants2Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PrivateInvestorWarrants3Member" xlink:label="CVM_PrivateInvestorWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants3Member" xlink:to="CVM_PrivateInvestorWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants3Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PrivateInvestorWarrantsMember" xlink:label="CVM_PrivateInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrantsMember" xlink:to="CVM_PrivateInvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PrivateInvestorsMember" xlink:label="CVM_PrivateInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorsMember" xlink:to="CVM_PrivateInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorsMember_doc" xml:lang="en-US">Private Investors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RDDeferredRentLiability" xlink:to="CVM_RDDeferredRentLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_RDDeferredRentLiability_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:to="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:to="CVM_ScheduleOfNonvestedOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesAThroughEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesAThroughEWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesCMember" xlink:label="CVM_SeriesCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesCMember" xlink:to="CVM_SeriesCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesCMember_doc" xml:lang="en-US">Series C.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesEMember" xlink:label="CVM_SeriesEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesEMember" xlink:to="CVM_SeriesEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesEMember_doc" xml:lang="en-US">Series E.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFAndGWarrantsMember" xlink:to="CVM_SeriesFAndGWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFAndGWarrantsMember_doc" xml:lang="en-US">Series F And G Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesFMember" xlink:label="CVM_SeriesFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFMember" xlink:to="CVM_SeriesFMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFMember_doc" xml:lang="en-US">Series F.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesGMember" xlink:label="CVM_SeriesGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesGMember" xlink:to="CVM_SeriesGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesGMember_doc" xml:lang="en-US">Series G.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHMember" xlink:to="CVM_SeriesHMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesHMember_doc" xml:lang="en-US">Series H.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesKAndLWarrantsMember" xlink:label="CVM_SeriesKAndLWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKAndLWarrantsMember" xlink:to="CVM_SeriesKAndLWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKAndLWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesKAndSeriesAThroughEWarrantsMember" xlink:label="CVM_SeriesKAndSeriesAThroughEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKAndSeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesKAndSeriesAThroughEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKAndSeriesAThroughEWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesKwarrantsMember" xlink:label="CVM_SeriesKwarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKwarrantsMember" xlink:to="CVM_SeriesKwarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKwarrantsMember_doc" xml:lang="en-US">Series K warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesLMember" xlink:label="CVM_SeriesLMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLMember" xlink:to="CVM_SeriesLMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesLMember_doc" xml:lang="en-US">Series L.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesLRepricedMember" xlink:label="CVM_SeriesLRepricedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLRepricedMember" xlink:to="CVM_SeriesLRepricedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesLRepricedMember_doc" xml:lang="en-US">Series L Repriced.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesMModifiedMember" xlink:label="CVM_SeriesMModifiedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModifiedMember" xlink:to="CVM_SeriesMModifiedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModifiedMember_doc" xml:lang="en-US">Series M Modified.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesMModififedMember" xlink:label="CVM_SeriesMModififedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModififedMember" xlink:to="CVM_SeriesMModififedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModififedMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesNMember_doc" xml:lang="en-US">Series N.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesOMember" xlink:label="CVM_SeriesOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOMember" xlink:to="CVM_SeriesOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesOMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPMember" xlink:to="CVM_SeriesPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesPMember_doc" xml:lang="en-US">Series P.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQMember" xlink:to="CVM_SeriesQMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQMember_doc" xml:lang="en-US">Series Q.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQWarrantsMember" xlink:label="CVM_SeriesQWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQWarrantsMember" xlink:to="CVM_SeriesQWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQWarrantsMember_doc" xml:lang="en-US">Series Q Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRMember" xlink:to="CVM_SeriesRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesRMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesSMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesTMember" xlink:to="CVM_SeriesTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesTMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesUMember" xlink:to="CVM_SeriesUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesUMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_doc" xml:lang="en-US">Shares Issuable Upon Exercise Of warrant.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockBonusPlansMember" xlink:label="CVM_StockBonusPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockBonusPlansMember" xlink:to="CVM_StockBonusPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockBonusPlansMember_doc" xml:lang="en-US">Stock Bonus Plans.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetails3Abstract" xlink:label="CVM_StockCompensationDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetails3Abstract" xlink:to="CVM_StockCompensationDetails3Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationDetails3Abstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsAbstract" xlink:to="CVM_StockCompensationDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:to="CVM_StockCompensationNonvestedOptionsDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityDetails1Abstract" xlink:to="CVM_StockholdersEquityDetails1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockholdersEquityDetails1Abstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockholdersEquityTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalFairvalueofDerivativeLiabilities" xlink:to="CVM_TotalFairvalueofDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_TotalFairvalueofDerivativeLiabilities_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalMember" xlink:to="CVM_TotalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_TotalMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedShares" xlink:to="CVM_VestedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_VestedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Warrants2008SeriesNMember" xlink:label="CVM_Warrants2008SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Warrants2008SeriesNMember" xlink:to="CVM_Warrants2008SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Warrants2008SeriesNMember_doc" xml:lang="en-US">Warrants 2008 Series N.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:to="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xml:lang="en-US">Warrants Held by Officer And Director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceCancelled" xlink:to="CVM_WeightedAverageExercisePriceCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceCancelled_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceExpired" xlink:to="CVM_WeightedAverageExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceExpired_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceVested" xlink:to="CVM_WeightedAverageExercisePriceVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceVested_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueBeginning" xlink:to="CVM_WeightedAverageGrantDateFairValueBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueEnding" xlink:to="CVM_WeightedAverageGrantDateFairValueEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssuanceOfAdditionalShares" xlink:to="CVM_IssuanceOfAdditionalShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssuanceOfAdditionalShares_3_lbl" xml:lang="en-US">IssuanceOfAdditionalShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_3_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:to="us-gaap_RestatementOfPriorYearIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestatementOfPriorYearIncomeNetOfTax_2_lbl" xml:lang="en-US">Restatement of Prior Year Income, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:to="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax_2_lbl" xml:lang="en-US">Impact of Restatement on Opening Retained Earnings, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Officers and Stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitureOfUnvestedRestrictedStock" xlink:to="CVM_ForfeitureOfUnvestedRestrictedStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ForfeitureOfUnvestedRestrictedStock_2_lbl" xml:lang="en-US">ForfeitureOfUnvestedRestrictedStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Deposits2_3_lbl" xml:lang="en-US">Deposits2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_2_lbl" xml:lang="en-US">Finite-Lived Patents, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfOptionsExercised_3_lbl" xml:lang="en-US">NumberOfOptionsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedShares" xlink:to="CVM_ForfeitedShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ForfeitedShares_3_lbl" xml:lang="en-US">Forfeited shares [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:to="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding_2_lbl" xml:lang="en-US">RestrictedStockAwardWeightedAverageGrantDateFairValueEnding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DeferredRentLiability_3_lbl" xml:lang="en-US">DeferredRentLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="us-gaap_GainOnDerivativeInstrumentsPretax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOnDerivativeInstrumentsPretax_2_lbl" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLoss" xlink:to="CVM_NetLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NetLoss_2_lbl" xml:lang="en-US">NetLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestatementOfPriorYearIncomeNet" xlink:to="CVM_RestatementOfPriorYearIncomeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestatementOfPriorYearIncomeNet_2_lbl" xml:lang="en-US">RestatementOfPriorYearIncomeNet</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cvm-20160930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 171826 09302016 10KA.xfr; Date: 2017%2D12%2D08T20:33:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8002000E -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20160930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20160930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20160930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20160930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20160930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20160930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20160930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20160930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20160930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20160930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20160930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SegmentReporting" xlink:href="cvm-20160930.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformation" xlink:href="cvm-20160930.xsd#QuarterlyInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Restatement" xlink:href="cvm-20160930.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20160930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20160930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20160930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20160930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20160930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20160930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20160930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationTables" xlink:href="cvm-20160930.xsd#QuarterlyInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementTables" xlink:href="cvm-20160930.xsd#RestatementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20160930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:href="cvm-20160930.xsd#WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20160930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20160930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20160930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20160930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20160930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20160930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20160930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20160930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20160930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20160930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20160930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20160930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20160930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:href="cvm-20160930.xsd#QuarterlyInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails" xlink:href="cvm-20160930.xsd#RestatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails1" xlink:href="cvm-20160930.xsd#RestatementDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RestatementDetails2" xlink:href="cvm-20160930.xsd#RestatementDetails2" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="loc_CVMDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDebtAndCapitalLeaseObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssuanceOfAdditionalShares" xlink:label="loc_CVMIssuanceOfAdditionalShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_CVMIssuanceOfAdditionalShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:label="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:label="loc_us-gaapImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpactOfRestatementOnOpeningRetainedEarningsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptions" xlink:label="loc_CVMExerciseOfWarrantsAndStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsAndStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsAndStockOptionsShares" xlink:label="loc_CVMExerciseOfWarrantsAndStockOptionsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsAndStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrants" xlink:label="loc_CVMExerciseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfWarrantsShares" xlink:label="loc_CVMExerciseOfWarrantsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConversionOfWarrantLiabilityToEquity" xlink:label="loc_CVMConversionOfWarrantLiabilityToEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMConversionOfWarrantLiabilityToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExerciseOfDerivativeLiabilities" xlink:label="loc_CVMExerciseOfDerivativeLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMExerciseOfDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationToWarrants" xlink:label="loc_CVMModificationToWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMModificationToWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfOptionsIssuedToEmployees" xlink:label="loc_CVMModificationOfOptionsIssuedToEmployees" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMModificationOfOptionsIssuedToEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="loc_CVMEquityBasedCompensationNonemployees" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMEquityBasedCompensationNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ModificationOfStockOptionsIssuedToEmployees" xlink:label="loc_CVMModificationOfStockOptionsIssuedToEmployees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CVMModificationOfStockOptionsIssuedToEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfIntangibleAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DepositsHeld" xlink:label="loc_CVMDepositsHeld" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_CVMDepositsHeld" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DecreaseIncreaseInResearchAndOfficeEquipment" xlink:label="loc_CVMDecreaseIncreaseInResearchAndOfficeEquipment" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMDecreaseIncreaseInResearchAndOfficeEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DecreaseIncreaseInPatentCosts" xlink:label="loc_CVMDecreaseIncreaseInPatentCosts" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMDecreaseIncreaseInPatentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInPatentCosts" xlink:label="loc_CVMIncreaseInPatentCosts" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInPatentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:label="loc_CVMIncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="loc_CVMIncreaseInDirectFinancingCosts" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInDirectFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitureOfUnvestedRestrictedStock" xlink:label="loc_CVMForfeitureOfUnvestedRestrictedStock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMForfeitureOfUnvestedRestrictedStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" xlink:label="loc_CVMStockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMStockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncreaseInPrepaidServices" xlink:label="loc_CVMIncreaseInPrepaidServices" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInPrepaidServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS, FINANCING">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OperationsAndFinancingTextBlock" xlink:label="loc_CVMOperationsAndFinancingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_CVMOperationsAndFinancingTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_CVMSummaryOfSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - 7. INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000014 - Disclosure - 8. STOCK COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000015 - Disclosure - 9. EMPLOYEE BENEFIT PLAN">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 11. RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - 12. STOCKHOLDERS EQUITY">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockholdersEquityTextBlock" xlink:label="loc_CVMStockholdersEquityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_CVMStockholdersEquityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000019 - Disclosure - 13. FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000020 - Disclosure - 14. NET LOSS PER COMMON SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SegmentReporting" xlink:title="00000021 - Disclosure - 15. SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformation" xlink:title="00000022 - Disclosure - 16. QUARTERLY INFORMATION (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Restatement" xlink:title="00000023 - Disclosure - 17. RESTATEMENT">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementAbstract" xlink:label="loc_CVMRestatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMRestatementAbstract" xlink:to="loc_us-gaapAccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - 18. SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Deposits2" xlink:label="loc_CVMDeposits2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_CVMDeposits2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaapPropertyPlantAndEquipmentImpairment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantIncomePolicyTextBlock" xlink:label="loc_CVMGrantIncomePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_CVMGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="loc_us-gaapLeasePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapLeasePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000026 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:label="loc_CVMDerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_CVMDerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000027 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000028 - Disclosure - 6. PATENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsTablesAbstract" xlink:label="loc_CVMPatentsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsTablesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsTablesAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - 7. INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000030 - Disclosure - 8. STOCK COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:label="loc_CVMScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CVMScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:label="loc_CVMScheduleOfNonvestedOptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CVMScheduleOfNonvestedOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000032 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="loc_CVMFairValueMeasurementsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000033 - Disclosure - 14. NET LOSS PER COMMON SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NetLossPerCommonShareTablesAbstract" xlink:label="loc_CVMNetLossPerCommonShareTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationTables" xlink:title="00000034 - Disclosure - 16. QUARTERLY INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementTables" xlink:title="00000035 - Disclosure - 17. RESTATEMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementTablesAbstract" xlink:label="loc_CVMRestatementTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMRestatementTablesAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_CVMDisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:label="loc_CVMFullyInsuredAmountOfNoninterestBearingCashBalances" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_CVMFullyInsuredAmountOfNoninterestBearingCashBalances" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000037 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:label="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQMember" xlink:label="loc_CVMSeriesQMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesPMember" xlink:label="loc_CVMSeriesPMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Issuedate2" xlink:label="loc_CVMIssuedate2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssuedate2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationDate1" xlink:label="loc_CVMExpirationDate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueStartDate" xlink:label="loc_CVMIssueStartDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssueStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IssueEndDate1" xlink:label="loc_CVMIssueEndDate1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssueEndDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationStartDate" xlink:label="loc_CVMExpirationStartDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpirationEndDate" xlink:label="loc_CVMExpirationEndDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMaximum" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000038 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:label="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueOfSeriesSWarrants" xlink:label="loc_CVMFairValueOfSeriesSWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesSWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesUWarrants" xlink:label="loc_CVMFairvalueofSeriesUWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesUWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesVWarrants" xlink:label="loc_CVMFairvalueofSeriesVWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesVWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesWWarrants" xlink:label="loc_CVMFairvalueofSeriesWWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesWWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesZWarrants" xlink:label="loc_CVMFairvalueofSeriesZWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesZWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesZZWarrants" xlink:label="loc_CVMFairvalueofSeriesZZWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesZZWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesAAWarrants" xlink:label="loc_CVMFairvalueofSeriesAAWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesAAWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairvalueofSeriesBBWarrants" xlink:label="loc_CVMFairvalueofSeriesBBWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairvalueofSeriesBBWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_TotalFairvalueofDerivativeLiabilities" xlink:label="loc_CVMTotalFairvalueofDerivativeLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMTotalFairvalueofDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2" xlink:title="00000039 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" xlink:label="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAThroughEWarrantsMember" xlink:label="loc_CVMSeriesAThroughEWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAThroughEWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesFAndGWarrantsMember" xlink:label="loc_CVMSeriesFAndGWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFAndGWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesHMember" xlink:label="loc_CVMSeriesHMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesTMember" xlink:label="loc_CVMSeriesTMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesTMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesQMember" xlink:label="loc_CVMSeriesQMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative" xlink:title="00000040 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" xlink:label="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:label="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaapBuildingsAndImprovementsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapBuildingsAndImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaapFixturesAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapFixturesAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000042 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:label="loc_CVMResearchAndOfficeEquipmentDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000043 - Disclosure - 6. PATENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000044 - Disclosure - 6. PATENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsDetailsAbstract" xlink:label="loc_CVMPatentsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000045 - Disclosure - 6. PATENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="loc_CVMPatentsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsNarrativeAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000046 - Disclosure - 7. INCOME TAXES Net deferred tax asset (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:label="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="loc_CVMDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_CVMDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_LoanModification" xlink:label="loc_CVMLoanModification" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_CVMLoanModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000047 - Disclosure - 7. INCOME TAXES Reconciliation of effective tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:label="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:label="loc_CVMEffectiveTaxRateReconciliationAdjustmentToDeferreds" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_CVMEffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000048 - Disclosure - 8. STOCK COMPENSATION Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockholdersEquityDetails1Abstract" xlink:label="loc_CVMStockholdersEquityDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails1Abstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="loc_CVMNonemployeesShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails1Abstract" xlink:to="loc_CVMNonemployeesShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000049 - Disclosure - 8. STOCK COMPENSATION Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetailsAbstract" xlink:label="loc_CVMStockCompensationDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpectedLifeOfOptionsMin1" xlink:label="loc_CVMExpectedLifeOfOptionsMin1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_CVMExpectedLifeOfOptionsMin1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExpectedLifeOfOptionsMax" xlink:label="loc_CVMExpectedLifeOfOptionsMax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_CVMExpectedLifeOfOptionsMax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000050 - Disclosure - 8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetails3Abstract" xlink:label="loc_CVMStockCompensationDetails3Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetails3Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OutstandingMember" xlink:label="loc_CVMOutstandingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMOutstandingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ExercisableMember" xlink:label="loc_CVMExercisableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMExercisableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStockVested" xlink:label="loc_CVMNumberOfStockVested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStockVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfOptionsExercised" xlink:label="loc_CVMNumberOfOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksExpired" xlink:label="loc_CVMNumberOfStocksExpired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfStocksCancelled" xlink:label="loc_CVMNumberOfStocksCancelled" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="loc_CVMWeightedAverageExercisePriceVested" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="loc_CVMWeightedAverageExercisePriceExpired" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="loc_CVMWeightedAverageExercisePriceCancelled" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000051 - Disclosure - 8. STOCK COMPENSATION Nonvested Options (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:label="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedOptionsBeginning" xlink:label="loc_CVMNumberOfUnvestedOptionsBeginning" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMNumberOfUnvestedOptionsBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_VestedOptions" xlink:label="loc_CVMVestedOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMVestedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantedOptions" xlink:label="loc_CVMGrantedOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMGrantedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitedOptions" xlink:label="loc_CVMForfeitedOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMForfeitedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedOptionsEnding" xlink:label="loc_CVMNumberOfUnvestedOptionsEnding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMNumberOfUnvestedOptionsEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageGrantDateFairValueBeginning" xlink:label="loc_CVMWeightedAverageGrantDateFairValueBeginning" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMWeightedAverageGrantDateFairValueBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMWeightedAverageGrantDateFairValueEnding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMWeightedAverageGrantDateFairValueEnding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000052 - Disclosure - 8. STOCK COMPENSATION RSU (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationRsuDetailsAbstract" xlink:label="loc_CVMStockCompensationRsuDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationRsuDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="loc_CVMRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="loc_CVMNumberOfUnvestedSharesBeginning" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_VestedShares" xlink:label="loc_CVMVestedShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMVestedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_GrantedShares" xlink:label="loc_CVMGrantedShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMGrantedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_ForfeitedShares" xlink:label="loc_CVMForfeitedShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMForfeitedShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="loc_CVMNumberOfUnvestedSharesEnding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMRestrictedStockAwardWeightedAverageGrantDateFairValueEnding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRestrictedStockAwardWeightedAverageGrantDateFairValueEnding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000053 - Disclosure - 8. STOCK COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_StockCompensationDetailsNarrativeAbstract" xlink:label="loc_CVMStockCompensationDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000054 - Disclosure - 9. EMPLOYEE BENEFIT PLAN (Detail Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000055 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000056 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaapGainContingenciesByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGainContingenciesByNatureAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RDDeferredRentLiability" xlink:label="loc_CVMRDDeferredRentLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRDDeferredRentLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_DeferredRentLiability" xlink:label="loc_CVMDeferredRentLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000058 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsDetailsAbstract" xlink:label="loc_CVMFairValueMeasurementsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level1Member" xlink:label="loc_CVMLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level2Member" xlink:label="loc_CVMLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_Level3Member" xlink:label="loc_CVMLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_TotalMember" xlink:label="loc_CVMTotalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_CVMTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="loc_CVMFairValueMeasurementsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMFairValueMeasurementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000059 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="loc_CVMFairValueMeasurementsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000060 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax" xlink:label="loc_us-gaapGainOnDerivativeInstrumentsPretax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapGainOnDerivativeInstrumentsPretax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000061 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:label="loc_CVMOptionsAndWarrantsExcludedFromEarningsPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMOptionsAndWarrantsExcludedFromEarningsPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AntidilutiveConvertibleDebt" xlink:label="loc_CVMAntidilutiveConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMAntidilutiveConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_AntidilutiveUnvestedRestrictedStock" xlink:label="loc_CVMAntidilutiveUnvestedRestrictedStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMAntidilutiveUnvestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/QuarterlyInformationDetails" xlink:title="00000062 - Disclosure - 16. QUARTERLY INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetailsAbstract" xlink:label="loc_CVMQuarterlyInformationDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails" xlink:title="00000063 - Disclosure - 17. RESTATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetails1Abstract" xlink:label="loc_CVMQuarterlyInformationDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails1Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaapScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaapRestatementAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails1" xlink:title="00000064 - Disclosure - 17. RESTATEMENT (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetails1Abstract" xlink:label="loc_CVMQuarterlyInformationDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails1Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaapAdjustmentsForErrorCorrectionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="loc_us-gaapAdjustmentsForErrorCorrectionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaapScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaapRestatementAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForErrorCorrectionDomain" xlink:to="loc_us-gaapRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RestatementDetails2" xlink:title="00000065 - Disclosure - 17. RESTATEMENT (Details 2)">
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_QuarterlyInformationDetails2Abstract" xlink:label="loc_CVMQuarterlyInformationDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementOfPriorYearIncomeNetOfTax" xlink:label="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapRestatementOfPriorYearIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_NetLoss" xlink:label="loc_CVMNetLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_CVMNetLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20160930.xsd#CVM_RestatementOfPriorYearIncomeNet" xlink:label="loc_CVMRestatementOfPriorYearIncomeNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_CVMRestatementOfPriorYearIncomeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaapEquityFairValueAdjustment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapEquityFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMQuarterlyInformationDetails2Abstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804509552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 09, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL SCI CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="letter-spacing: -0.1pt">In
October 2008, the Company entered into an agreement whereby the Company leased a building owned by a third party. The Company accounted
for the arrangement as an operating lease under ASC 840, <i>Accounting for Leases</i>. </font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="letter-spacing: -0.1pt">In
November 2017, the Company determined that the lease should have been treated as a financing obligation rather than an operating
lease. </font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">Accordingly,
this amended 10-K is filed to correct the manner in which the Company accounted for the lease. See <u>Note 17. Restatement, </u>in
the financial statements enclosed herein, for further information</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="letter-spacing: -0.1pt">In
addition: </font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol; letter-spacing: -0.1pt">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">per share data, including earnings per share
amounts, in this amended 10-K have been adjusted to reflect a 1 for 25 reverse stock split which became effective on the NYSE American
on June 15, 2017;</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol; letter-spacing: -0.1pt">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">management&#8217;s report on internal control
over financial reporting and its conclusion on disclosure controls and procedures have been revised to address the material weaknesses
in internal control over financial reporting; and </font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol; letter-spacing: -0.1pt">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">the opinion of BDO USA, LLP on the effectiveness
of the Company&#8217;s internal control over financial reporting as of September 30, 2016 has been amended.</font></td></tr></table>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.1pt">Except for the above, no other
information included in the 10-K report filed on December 15, 2016 is amended by this Form 10-K/A.</font></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,548,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,807,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808435584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,917,996<span></span>
</td>
<td class="nump">$ 5,726,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">394,515<span></span>
</td>
<td class="nump">87,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">981,677<span></span>
</td>
<td class="nump">979,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits - current portion</a></td>
<td class="nump">154,995<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">1,008,642<span></span>
</td>
<td class="nump">1,401,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,457,825<span></span>
</td>
<td class="nump">8,345,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, net</a></td>
<td class="nump">17,350,836<span></span>
</td>
<td class="nump">17,945,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">PATENT COSTS, net</a></td>
<td class="nump">256,547<span></span>
</td>
<td class="nump">291,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">DEPOSITS - net of current portion</a></td>
<td class="nump">1,820,917<span></span>
</td>
<td class="nump">1,970,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">24,886,125<span></span>
</td>
<td class="nump">28,553,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,091,512<span></span>
</td>
<td class="nump">5,128,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">378,672<span></span>
</td>
<td class="nump">88,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to employees</a></td>
<td class="nump">538,278<span></span>
</td>
<td class="nump">365,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">19,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,011,772<span></span>
</td>
<td class="nump">6,705,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent', window );">Derivative instruments</a></td>
<td class="nump">8,394,934<span></span>
</td>
<td class="nump">13,686,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Lease liability</a></td>
<td class="nump">13,011,023<span></span>
</td>
<td class="nump">12,783,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">126,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">22,609<span></span>
</td>
<td class="nump">14,026<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,565,338<span></span>
</td>
<td class="nump">33,315,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 600,000,000 shares authorized; 6,235,035 and 4,490,975 shares issued and outstanding</a></td>
<td class="nump">62,350<span></span>
</td>
<td class="nump">44,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">284,649,559<span></span>
</td>
<td class="nump">269,071,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(285,391,122)<span></span>
</td>
<td class="num">(273,878,630)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(679,213)<span></span>
</td>
<td class="num">(4,762,270)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</a></td>
<td class="nump">$ 24,886,125<span></span>
</td>
<td class="nump">$ 28,553,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability arising from contracts that meet the criteria of being accounted for as derivative instruments, financial instrument or contract used to mitigate a specified risk (hedge), energy marketing activities (trading activities), expected to be settled after one year or beyond the normal operating cycle, if longer. Examples of energy marketing activities include, but are not limited to, trading of electricity, coal, natural gas and oil using financial instruments, including, but not limited to, forward contracts, options and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804415616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Shares Authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">6,235,035<span></span>
</td>
<td class="nump">4,490,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock Shares Outstanding</a></td>
<td class="nump">6,235,035<span></span>
</td>
<td class="nump">4,490,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810779536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">GRANT INCOME AND OTHER</a></td>
<td class="nump">$ 285,055<span></span>
</td>
<td class="nump">$ 657,377<span></span>
</td>
<td class="nump">$ 264,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,445,382<span></span>
</td>
<td class="nump">19,191,750<span></span>
</td>
<td class="nump">15,266,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">6,486,501<span></span>
</td>
<td class="nump">13,855,775<span></span>
</td>
<td class="nump">10,665,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,931,883<span></span>
</td>
<td class="nump">33,047,525<span></span>
</td>
<td class="nump">25,931,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(23,646,828)<span></span>
</td>
<td class="num">(32,390,148)<span></span>
</td>
<td class="num">(25,667,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">GAIN ON DERIVATIVE INSTRUMENTS</a></td>
<td class="nump">14,013,726<span></span>
</td>
<td class="nump">282,616<span></span>
</td>
<td class="nump">248,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">LOSS ON DEBT EXTINGUISHMENT</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(620,457)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">INTEREST EXPENSE, NET</a></td>
<td class="num">(1,879,390)<span></span>
</td>
<td class="num">(1,964,221)<span></span>
</td>
<td class="num">(1,933,732)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(11,512,492)<span></span>
</td>
<td class="num">(34,692,210)<span></span>
</td>
<td class="num">(27,352,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssuanceOfAdditionalShares', window );">ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,117,447)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON SHAREHOLDERS</a></td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (28,470,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC</a></td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="num">$ (12.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED</a></td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="num">$ (12.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC and DILUTED</a></td>
<td class="nump">4,866,204<span></span>
</td>
<td class="nump">3,300,761<span></span>
</td>
<td class="nump">2,352,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssuanceOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Additional Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssuanceOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811611536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2013</a></td>
<td class="nump">$ 12,376<span></span>
</td>
<td class="nump">$ 218,848,282<span></span>
</td>
<td class="num">$ (212,160,568)<span></span>
</td>
<td class="nump">$ 6,700,090<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2013</a></td>
<td class="nump">1,237,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestatementOfPriorYearIncomeNetOfTax', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,827<span></span>
</td>
<td class="nump">326,827<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax', window );">Restated Balance at Sep. 30, 2013</a></td>
<td class="nump">$ 12,376<span></span>
</td>
<td class="nump">218,848,282<span></span>
</td>
<td class="num">(211,833,741)<span></span>
</td>
<td class="nump">7,026,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock</a></td>
<td class="nump">$ 12,702<span></span>
</td>
<td class="nump">28,434,544<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,447,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock, Shares</a></td>
<td class="nump">1,270,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Issuance of warrants in connection with sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,791,448)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,791,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">155,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="nump">6,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="nump">4,279,251<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,280,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExerciseOfWarrantsShares', window );">Exercise of warrants, Shares</a></td>
<td class="nump">106,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ConversionOfWarrantLiabilityToEquity', window );">Conversion of warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">626,886<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">627,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, Shares</a></td>
<td class="nump">23,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued for patents</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued for patents, Shares</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Modification of options issued to consultants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">76,991<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">$ 6,280<span></span>
</td>
<td class="num">(6,280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, Shares</a></td>
<td class="nump">628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation - employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,958,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,958,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EquityBasedCompensationNonemployees', window );">Equity based compensation - non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,352,679)<span></span>
</td>
<td class="num">(27,352,679)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2014</a></td>
<td class="nump">$ 32,726<span></span>
</td>
<td class="nump">249,937,507<span></span>
</td>
<td class="num">(239,186,420)<span></span>
</td>
<td class="nump">10,783,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2014</a></td>
<td class="nump">3,272,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock</a></td>
<td class="nump">$ 11,787<span></span>
</td>
<td class="nump">21,136,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,148,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock, Shares</a></td>
<td class="nump">1,178,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Issuance of warrants in connection with sale of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(8,463,957)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,463,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">165,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">165,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="nump">9,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">533,680<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">533,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, Shares</a></td>
<td class="nump">29,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Modification of options issued to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ModificationToWarrants', window );">Modification of warrants and extinguishment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">620,457<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">620,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of unvested restricted stock</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeiture of unvested restricted stock, Shares</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation - employees</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">5,105,784<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,105,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions', window );">Equity based compensation - employees, Shares</a></td>
<td class="nump">4,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EquityBasedCompensationNonemployees', window );">Equity based compensation - non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">35,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,692,210)<span></span>
</td>
<td class="num">(34,692,210)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2015</a></td>
<td class="nump">$ 44,910<span></span>
</td>
<td class="nump">269,071,450<span></span>
</td>
<td class="num">(273,878,630)<span></span>
</td>
<td class="num">(4,762,270)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2015</a></td>
<td class="nump">4,490,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock</a></td>
<td class="nump">$ 16,609<span></span>
</td>
<td class="nump">21,357,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,373,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock, Shares</a></td>
<td class="nump">1,660,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Issuance of warrants in connection with sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,722,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,722,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">161,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">161,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="nump">16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">689,813<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">690,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, Shares</a></td>
<td class="nump">49,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Modification of options issued to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation - employees</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">2,012,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,012,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions', window );">Equity based compensation - employees, Shares</a></td>
<td class="nump">16,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EquityBasedCompensationNonemployees', window );">Equity based compensation - non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,512,492)<span></span>
</td>
<td class="num">(11,512,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2016</a></td>
<td class="nump">$ 62,350<span></span>
</td>
<td class="nump">$ 284,649,559<span></span>
</td>
<td class="num">$ (285,391,122)<span></span>
</td>
<td class="num">$ (679,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2016</a></td>
<td class="nump">6,235,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ConversionOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ConversionOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_EquityBasedCompensationNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_EquityBasedCompensationNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ModificationToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ModificationToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of cumulative effect of restatement on the opening retained earnings of the earliest year presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestatementOfPriorYearIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Resulting effect of restatement to correct an error, after tax effects, on the net income of prior periods for the year in which any adjustments are first made. In statements containing more than one period, discloses the effects for each period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestatementOfPriorYearIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeitures of stock or other type of equity issued of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810478960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (27,352,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">663,988<span></span>
</td>
<td class="nump">720,494<span></span>
</td>
<td class="nump">745,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock and options for services - non-employees</a></td>
<td class="nump">751,651<span></span>
</td>
<td class="nump">565,915<span></span>
</td>
<td class="nump">694,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Modification of warrants issued to consultants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">2,113,433<span></span>
</td>
<td class="nump">5,105,827<span></span>
</td>
<td class="nump">3,958,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">161,571<span></span>
</td>
<td class="nump">165,646<span></span>
</td>
<td class="nump">155,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Impairment loss on abandonment of patents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on retired equipment</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on derivative instruments</a></td>
<td class="num">(14,013,726)<span></span>
</td>
<td class="num">(282,616)<span></span>
</td>
<td class="num">(248,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">620,457<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CapitalizedLeaseInterest', window );">Capitalized lease interest</a></td>
<td class="nump">227,773<span></span>
</td>
<td class="nump">249,493<span></span>
</td>
<td class="nump">241,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(1,960)<span></span>
</td>
<td class="num">(5,394)<span></span>
</td>
<td class="num">(7,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">15,999<span></span>
</td>
<td class="num">(68,268)<span></span>
</td>
<td class="num">(158,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">393,197<span></span>
</td>
<td class="nump">50,181<span></span>
</td>
<td class="num">(435,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Deposits</a></td>
<td class="nump">145,005<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,389,931)<span></span>
</td>
<td class="nump">3,981,886<span></span>
</td>
<td class="num">(751,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">290,097<span></span>
</td>
<td class="num">(458,633)<span></span>
</td>
<td class="nump">433,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,639)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to employees</a></td>
<td class="nump">72,397<span></span>
</td>
<td class="nump">57,170<span></span>
</td>
<td class="num">(78,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent liability</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="num">(3,739)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,082,493)<span></span>
</td>
<td class="num">(23,833,333)<span></span>
</td>
<td class="num">(22,928,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(31,405)<span></span>
</td>
<td class="num">(73,399)<span></span>
</td>
<td class="num">(103,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(2,819)<span></span>
</td>
<td class="num">(20,132)<span></span>
</td>
<td class="num">(34,887)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(34,224)<span></span>
</td>
<td class="num">(93,531)<span></span>
</td>
<td class="num">(138,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">21,420,301<span></span>
</td>
<td class="nump">21,148,378<span></span>
</td>
<td class="nump">28,428,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Payment on related party loan</a></td>
<td class="num">(1,104,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,118,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under capital lease</a></td>
<td class="num">(8,213)<span></span>
</td>
<td class="num">(8,452)<span></span>
</td>
<td class="num">(8,137)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,308,031<span></span>
</td>
<td class="nump">21,139,926<span></span>
</td>
<td class="nump">31,538,891<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(2,808,686)<span></span>
</td>
<td class="num">(2,786,938)<span></span>
</td>
<td class="nump">8,472,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">5,726,682<span></span>
</td>
<td class="nump">8,513,620<span></span>
</td>
<td class="nump">41,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">2,917,996<span></span>
</td>
<td class="nump">5,726,682<span></span>
</td>
<td class="nump">8,513,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</a></td>
<td class="nump">305,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DecreaseIncreaseInResearchAndOfficeEquipment', window );">Research and office equipment included in accounts payable at year end</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,345)<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DecreaseIncreaseInPatentCosts', window );">Capitalizable patent costs included in accounts payable at year end</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,685)<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInPatentCosts', window );">Patent costs purchased with common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd', window );">Lease payments included in accounts payable at year end</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants', window );">Fair value of warrant liabilities on the date of issuance reclassed to liabilities</a></td>
<td class="num">(8,722,073)<span></span>
</td>
<td class="num">(8,463,957)<span></span>
</td>
<td class="num">(5,320,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInDirectFinancingCosts', window );">Financing costs included in accounts payable at year end</a></td>
<td class="nump">46,605<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants', window );">Stock issued under an anti-dilution provision and cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInPrepaidServices', window );">Prepaid amount under consulting services paid with issuance of common stock</a></td>
<td class="nump">18,021<span></span>
</td>
<td class="nump">3,861<span></span>
</td>
<td class="nump">31,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">$ 1,900,567<span></span>
</td>
<td class="nump">$ 1,969,499<span></span>
</td>
<td class="nump">$ 1,965,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CapitalizedLeaseInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CapitalizedLeaseInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DecreaseIncreaseInPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DecreaseIncreaseInPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DecreaseIncreaseInResearchAndOfficeEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DecreaseIncreaseInResearchAndOfficeEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Derivative Liabilities From Issuance Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInDirectFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInDirectFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockIssuedUnderAntidilutionProvisionAndCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6477933&amp;loc=d3e60009-112784<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800618608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">1. ORGANIZATION</a></td>
<td class="text"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">CEL-SCI
Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in
biomedical science and ultimately to engage in marketing and selling products.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"><font style="font-size: 8pt">CEL-SCI
is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company&#8217;s
lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently in a Phase 3 clinical trial as a potential
therapeutic agent directed at using the immune system to produce an anti-tumor immune response for advanced primary head and neck
cancer. Data from Phase 1 and Phase 2 clinical trials suggest Multikine has the potential to directly affect tumor cells. These
data also indicate that it appears to activate the patient&#8217;s own anti-tumor immune response. Multikine (Leukocyte Interleukin,
Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this document
as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary
name is subject to FDA review in connection with the Company&#8217;s future anticipated regulatory submission for approval. Multikine
has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established
for any use. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial
of this investigational therapy that is in progress and that is currently subject to a clinical hold on enrollment of additional
new patients.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"><font style="font-size: 8pt">Multikine
has been cleared by the regulators in twenty four countries around the world, including the U.S. FDA, for a global Phase 3 clinical
trial in advanced primary (not yet treated) head and neck cancer patients. On September 26, 2016, the Company received verbal
notice from the FDA that the Phase 3 clinical trial has been placed on clinical hold. The FDA&#8217;s partial clinical hold letter
identified the following specific deficiencies: there is an unreasonable and significant risk of illness or injury to human subjects;
the investigator brochure is misleading, erroneous, and materially incomplete; and that the plan or protocol is deficient in design
to meet its stated objectives. Pursuant to this communication from FDA, patients currently receiving study treatments could continue
to receive treatment, and patients already enrolled in the study would continue to be followed, but no additional patients could
be enrolled. On October 21, 2016, the Company announced it had received the Partial Clinical Hold letter from the FDA. On November
21, 2016, the Company announced it has submitted what it believes to be a complete response to the FDA. On December 8, 2016, the
FDA advised CEL-SCI that the agency was denying CEL-SCI&#8217;s request for a meeting at this time because FDA&#8217;s review
of CEL-SCI&#8217;s November 17, 2016 response was ongoing. CEL-SCI was also advised that it will be receiving a letter addressing
CEL-SCI&#8217;s response by December 18, 2016.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.25in; text-align: justify"><font style="font-size: 8pt">Multikine
is also being used in a Phase 1 study at the University of California, San Francisco (UCSF) in HIV/HPV co-infected men and women
with peri-anal warts.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790754128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. OPERATIONS, FINANCING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_OperationsAndFinancingTextBlock', window );">2. OPERATIONS, FINANCING</a></td>
<td class="text"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">The
Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented
proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development,
administrative costs, construction of laboratory facilities, and clinical trials.&#160; The Company has funded such costs with
proceeds from loans and the public and private sale of its common and preferred stock.&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">The
Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer. The Company believes that
it has enough capital to support its operations as it believes that it has ready access to new equity capital should the need
arise. During fiscal year 2016, the Company raised approximately $21.4 million in net proceeds through the sale of common stock
and warrants from public and private offerings. During fiscal year 2015, the Company raised $21.1 million net proceeds from public
offerings. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate
partnerships, debt and/or equity financings. In addition, the Company expects to receive proceeds from the arbitration against
its former clinical research organization, inVentiv. The Company believes that it will be able to obtain additional financing
because it has done so consistently in the past, and because Multikine is a product in the Phase 3 clinical trial stage. However,
there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the
Company on acceptable terms or at all.&#160; If the Company does not raise the necessary capital, the Company will either have
to slow or delay the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise
the required funding. The financial statements have been prepared assuming that the Company will continue as a going concern,
but due to the Company&#8217;s future liquidity needs, history of net losses, and the expectation that the Company will incur
losses for the foreseeable future, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.
The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">Since
the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $34.5 million as
of September 30, 2016 on direct costs for the Phase 3 clinical trial. The total remaining cash cost of the Phase 3 clinical
trial, excluding any costs that will be paid by CEL-SCI&#8217;s partners, would approximately be $12.1 million
after September 30, 2016. This is based on the executed contract costs with the CROs only and does not include other related
cost, e.g. the manufacturing of the drug. It should be noted that this estimate is based only on the information currently
available in the Company&#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3
clinical trial.&#160; This number can be affected by the speed of enrollment, foreign currency exchange rates and many other
factors, some of which cannot be foreseen.&#160; The Company has filed an amendment to the original Phase 3 protocol for it
head and neck cancer study with the FDA to allow for this expansion in patient enrollment. Should the FDA allow the amended
protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be higher. It is therefore
possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><font style="font-size: 8pt">On
September 26, 2016, the Company received verbal notice from the FDA that the Phase 3 clinical trial has been placed on clinical
hold. Pursuant to this communication from FDA, patients currently receiving study treatments could continue to receive treatment,
and patients already enrolled in the study would continue to be followed, but no additional patients could be enrolled. On October
21, 2016, the Company announced it had received the Partial Clinical Hold letter from the FDA. On November 21, 2016, the Company
announced it has submitted a complete response to the FDA and will work diligently with the FDA to seek to have the partial clinical
hold lifted.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_OperationsAndFinancingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_OperationsAndFinancingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800560608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash and Cash Equivalents</i> &#8211; For
purposes of the statements of cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term
money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months
as cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Prepaid Expenses</i> &#8211; Prepaid expenses
are payments for future services to be rendered and are expensed over the time period for which the service is rendered. Prepaid
expenses may also include payment for goods to be received within one year of the payment date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Inventory</i> &#8211; Inventory consists
of manufacturing production advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&#8217;s
product for clinical studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in,
first out method applied on a consistent basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Deposits</i> &#8211; The deposits are required
by the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Office Equipment</i>&#8211;
Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of
five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term
of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are
reviewed on a quarterly basis to assess impairment, if any.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Patents</i> &#8211; Patent expenditures are
capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the
patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate
adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The
amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Deferred Rent </i> &#8211; Certain of the Company&#8217;s operating leases
provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate minimum annual payments are expensed
on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when
the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed
the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays, the Company records a deferred rent
liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative Instruments</i> - The Company
has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features,
specifically, the settlement provisions in the warrant agreements preclude the warrants from being treated as equity. The Company
accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &#8220;Accounting for Derivative
Instruments and Hedging Activities&#8221;. In accordance with accounting principles generally accepted in the United States (U.S.
GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are
measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the
derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based
on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each
instrument. The derivative liabilities are re-measured at fair value at the end of each reporting period as long as they are outstanding.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grant Income</i> &#8211; The Company's grant
arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development Costs</i> &#8211;
Research and development expenditures are expensed as incurred.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Leases &#8211; </i>Leases are
categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over
the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of
capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes
an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.
If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on
the Company's balance sheet.</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net Loss Per Common Share</i> &#8211; The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted
net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number
of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common
stock options, restricted stock units, convertible preferred stock and common stock warrants, have not been included in the computation
of diluted net loss per share for all periods as the result would be anti-dilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Concentration of Credit Risk</i> &#8211;
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160;
The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may
exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes
it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were
fully insured&#160;up to $250,000 at September 30, 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income Taxes</i> &#8211; The Company uses
the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities
are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax
assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred
tax assets as of September 30, 2016 and 2015.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Use of Estimates</i> &#8211; The preparation
of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of
current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory
obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets
and the related valuation allowance, and the valuation of derivative liabilities.<font style="color: #444444">&#160;</font>Actual
results could differ from estimates, although management does not generally believe such differences would materially affect the
financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using various
valuation techniques including the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect
the financial statements in a given year. The Company considers such valuations to be significant estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fair Value Measurements</i> &#8211; The Company
evaluates financial assets and liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize
the inputs used to measure fair value. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest
level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 12 for
the definition of levels and the classification of assets and liabilities in those levels.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock-Based Compensation</i> &#8211; Compensation
cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &#8220;Compensation
&#8211; Stock Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model.
The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based
compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments issued to non-employees are
accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non-Employees.&#8221; Accordingly, compensation is
recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of
award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the
measurement date and the expected life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has Incentive Stock Option Plans,
Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,
these Plans are collectively referred to as the &#8220;Plans.&#8221; All Plans have been approved by the Company&#8217;s stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock options are not transferable,
and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price
on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance
of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate
at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise
and employee termination within the valuation model. The expected term of options represents the period of time that options granted
are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions
used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in
the future from that recorded in the current period.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vesting of restricted stock granted under the
Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.
These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is
probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reclassification</i> &#8211; Certain prior
year items have been reclassified to conform to the current year presentation.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recent Accounting Pronouncements</i> &#8211;
In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>
that will supersede virtually all recognition guidance in US GAAP. For public entities, the guidance is effective for annual and
interim periods beginning after December 15, 2017. Early adoption is permitted for all entities for annual and interim periods
beginning after December 15, 2016. The FASB issued the following ASUs to amend the new guidance: ASU 2015-14, <i>Revenue from Contracts
with Customers (Topic 606): Deferral of the Effective Date,</i> ASU 2016-08, <i>Revenue from Contracts with Customers (Topic 606):
Principal versus Agent Considerations (Reporting Revenue Gross versus Net),</i> ASU 2016-10<i>, Revenue from Contracts with Customers
(Topic 606): Identifying Performance Obligations and Licensing, and</i> ASU 2016-12<i>, Revenue from Contracts with Customers (Topic
606): Narrow-Scope Improvements and Practical Expedients.</i> Management does not expect the new standard or any of the related
updates to have a material effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, the FASB issued Accounting
Standards Update (ASU) No. 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities.</i> The new guidance is intended to improve the recognition and measurement of financial
instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within
those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new
standard to have a material effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases</i>,
which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance
sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases
are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December
15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning
with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial
statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No. 2016-09,
<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> ASU 2016-09 simplifies
several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification
of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective
for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The
Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 amends eight specific
cash flow issues: 1.) Debt Prepayment or Debt Extinguishment Costs, 2.) Settlement of Zero-Coupon Debt Instruments or Other Debt
Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing, 3.)
Contingent Consideration Payments Made after a Business Combination, 4.) Proceeds from the Settlement of Insurance Claims, 5.)
Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned Life Insurance Policies, 6.) Distributions
Received from Equity Method Investees, 7.) Beneficial Interests in Securitization Transactions, 8.) Separately Identifiable Cash
Flows and Application of the Predominance Principle. Management does not expect the adoption of the amendments in this Update to
have a material effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during
the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.
Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash
equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The
amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim
periods within those fiscal years. Management does not expect the adoption of the amendments in this Update to have a material
effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has considered all other recently
issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial
statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779523904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">4. WARRANTS AND NON-EMPLOYEE OPTIONS</a></td>
<td class="text"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">The
following chart represents the warrants and non-employee options outstanding at September 30, 2016:</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"><font style="font: 8pt Times New Roman, Times, Serif"><u>Warrant</u></font></td>
    <td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Issue
    <u>Date</u></font></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Shares
    Issuable upon Exercise of <u>Warrant</u></font></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    <u>Price</u></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Expiration
    Date</u></font></td>
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Refer-ence</u></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    R</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">105,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$100.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/13
    -10/24/14 </font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,037,010</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$31.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4/17/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,821</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$3.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/17/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">810,127</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$19.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    W</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">688,930</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$16.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    X</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1/13/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">120,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$9.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1/13/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Y</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/15/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">26,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$12.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/15/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Z</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/23/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">264,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11/23/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    ZZ</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/23/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/18/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    AA</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/26/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/22/22</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    BB</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/26/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">16,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/22/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    N</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/08</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">113,785</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$0.53</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    P</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/10/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,600</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$4,112.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3/6/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Consultants</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/2/11-
    7/1/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,600</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$9.25-&#160;&#160;$87.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/27/16-
    6/30/19</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">The
following chart represents the warrants and non-employee options outstanding at September 30, 2015:</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"><font style="font: 8pt Times New Roman, Times, Serif"><u>Warrants</u></font></td>
    <td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Issue
    Date</u></font></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Shares
    Issuable upon Exercise of <u>Warrants</u></font></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    <u>Price</u></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Expiration
    Date</u></font></td>
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Refer-ence</u></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    N</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/08</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">113,785</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Q</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6/21/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,200,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$125.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/22/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    R</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,625,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$100..00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/13-
    10/24/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,928,010</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$31.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4/17/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">445,514</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$43.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/17/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,253,164</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$19.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    P</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/10/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">590,001</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;$112.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3/6/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Consultants</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/14/05
    &#8211; 7/1/15 </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">238,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$16.50
    &#8211; $500.00</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/14/15
    - 6/30/18</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><font style="font-size: 8pt; letter-spacing: -0.1pt">1.</font></td><td style="text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><u>Warrant
                                         Liabilities</u></font></td></tr></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font-size: 8pt">The
table below presents the warrants accounted for as derivative liabilities at September 30.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 52%">&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle; width: 23%"><font style="font: 8pt Times New Roman, Times, Serif"><u>2016</u></font></td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif"><u></u></font></td>
    <td style="text-align: center; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle; width: 23%"><font style="font: 8pt Times New Roman, Times, Serif"><u>2015</u></font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S warrants</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">$&#9;
    3,111,361</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">$&#9;
    7,363,555</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U warrants</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;44,551</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V warrants</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;1,620,253</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;6,278,481</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    W warrants&#160;&#160;</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;1,799,858</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Z warrants&#160;&#160;</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;970,604</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: middle; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    ZZ warrants</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; vertical-align: middle; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;70,609</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: middle; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    </tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    AA warrants</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;763,661</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    </tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    BB warrants&#160;&#160;</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><u>&#9;58,588</u></font></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 8.1pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif"><u>&#9;-</u></font></td>
    </tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><u>&#160;</u></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.5pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    </tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Total
    derivative liabilities&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
    <td style="text-align: right; padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"><u>$&#9;8,394,934</u></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</font></td>
    <td style="text-align: right; padding-right: 5.5pt; padding-left: 8.1pt; text-decoration: underline; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"><u>$&#9;13,686,587</u></font></td>
    </tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify"><font style="font-size: 8pt">The
table below presents the gains and (losses) on the warrant liabilities for the years ended September 30:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 18%; padding-right: -4.5pt; padding-left: 5.4pt; text-decoration: underline"><font style="font: 8pt Times New Roman, Times, Serif"><u>Warrant
    Series</u></font></td>
    <td style="width: 22%; padding-right: -49.5pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;<u>2016</u></font></td>
    <td style="width: 3%; padding-right: -4.5pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;<u>2015</u></font></td>
    <td style="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>2014</u></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    A - E</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">$&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">$&#9;6,105</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">$&#9;1</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    F and G</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;12,667</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    H</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;12,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;24,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    N</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;(1,404,027)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Q</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;12,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;36,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    R&#160;&#160;</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;157,500</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;131,250</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S&#160;&#160;</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">4,252,193</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,705,466)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#9;1,098,787</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    T&#160;&#160;</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-decoration: none; padding-right: 5.4pt; padding-left: 27pt; text-align: right"><font style="font-size: 8pt">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 0.25in; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">276,122</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: center; text-indent: 35pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U&#160;&#160;</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;44,552</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 0.9pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">75,738</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: right; text-indent: 27pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">73,967</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-align: center; text-indent: 39.5pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;4,658,228</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;1,724,739</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    W</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;3,260,913</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Z</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;997,226</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    ZZ</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;75,229</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    AA</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;672,246</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">Series
    BB</font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;53,139</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: none; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9;-</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; text-decoration: none">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: -0.05in; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif; text-decoration: none"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Net
    gain </font></td>
    <td style="padding-right: -0.05in; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"><u>$&#9;14,013,726</u></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"><u>$&#9;282,616</u></font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt; text-decoration: underline; text-align: right; vertical-align: middle"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double"><u>$&#9;248,767</u></font></td>
    <td style="padding-right: 5.4pt; padding-left: 8.1pt"><font style="font: 8pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">The
Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should
use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own
stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide
for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered
indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to
the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">In
accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each
reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain
or loss in the statement of operations.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><i>Expired
warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><b>&#160;</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">As
of September 30, 2015, all Series A, B, C, E, F, G, H, and Q warrants had expired. </font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><i>&#160;</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><i>Series
R Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">On
December 4, 2012, the Company sold 140,000 shares of its common stock for $10,500,000, or $75.00 per share, in a registered direct
offering. The investors in this offering also received Series R warrants which entitle the investors to purchase up to 105,000
shares of the Company&#8217;s common stock. The Series R warrants may be exercised at any time before December 6, 2016 at a price
of $4,100.00 per share. The fair value at issuance of the warrants of $4.2 million was recorded as a warrant liability. </font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>&#160;</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
S Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
October 11, 2013, the Company closed a public offering of  713,043 units of common stock and warrants at a price of $25.00 per
unit for net proceeds of approximately $16.4 million, net of underwriting discounts and commissions and offering expenses of
the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock.
The Series S warrants were immediately exercisable, expire on October 11, 2018, and have an exercise price of $31.25. In
November 2013, the underwriters purchased an additional  105,957 warrants pursuant to the overallotment option, for which
the Company received net proceeds of $24,370. The fair value at issuance of the Series S warrants of $6.1 million was
recorded as a warrant liability.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
December 24, 2013, the Company closed a public offering of  190,746 units of common stock and warrants at a price of $15.75
per unit for net proceeds of approximately $2.8 million, net of underwriting discounts and commissions and offering expenses
of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common
stock. The underwriters purchased an additional  19,048 units of common stock and warrants pursuant to the overallotment
option, for which the Company received net proceeds of approximately $279,000. The fair value at issuance of the Series S
warrants of approximately $1.2 million was recorded as a warrant liability. On February 7, 2014, the Series S warrants began
trading on the NYSE MKT under the symbol CVM WT.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
October 24, 2014, the Company closed an underwritten public offering of  315,789 shares of common stock and  78,947 Series
S warrants to purchase shares of common stock. Additionally, on October 21, 2014, the Company sold 52,800 shares of common
stock and 13,200 Series S warrants to purchase shares of common stock in a private offering. The common stock and Series S
warrants were sold at a combined per unit price of $19.00 for net proceeds of approximately $6.4 million, net of underwriting
discounts and commissions and offering expenses. The fair value at issuance of the Series S warrants of approximately
$461,000 was added to the existing Series S warrant liability.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">During
the years ended September 30, 2016 and 2015, no Series S warrants were exercised. During the year ended September 30, 2014, 83,551
Series S Warrants were exercised, and the Company received proceeds of approximately $2.6 million.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
T and U Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
April 17, 2014, the Company closed a public offering of  285,129 shares of common stock at a price of $35.00 and 71,282
Series T warrants to purchase one share of common stock for net proceeds of approximately $9.2 million, net of underwriting
commissions and offering expenses. The Series T warrants were immediately exercisable and had an exercise price of $39.50. On
October 17, 2014, all of the Series T warrants expired. The underwriters received  17,821 Series U warrants to purchase one
share of common stock. The Series U warrants were exercisable beginning October 17, 2014, expire on October 17, 2017, and
have an exercise price of $43.75. The fair value at issuance of the Series T and U warrants of approximately $470,000 was
recorded as a warrant liability.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
V Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
May 28, 2015, the Company closed an underwritten public offering of  810,127 shares of common stock and  810,127 Series V
warrants to purchase shares of common stock. The common stock and Series V warrants were sold at a combined per unit price of
$19.75 for net proceeds of approximately $14.7 million, net of underwriting discounts and commissions and offering expenses.
The Series V warrants were immediately exercisable at a price of $19.75 and expire on May 28, 2020. The fair value at issuance
of the Series V warrants of approximately $8.0 million was recorded as a warrant liability.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
W Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
October 28, 2015, the Company closed an underwritten public offering of  688,930 shares of common stock and 688,930 Series
W warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $16.75
for net proceeds of approximately $10.5 million, net of underwriting discounts and commissions and offering expenses. The
Series W warrants are immediately exercisable at a price of $16.75 and expire on October 28, 2020. The fair value at issuance
of the Series W warrants of approximately $5.1 million was recorded as warrant liability.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
Z and ZZ Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On May
23, 2016, the Company closed a registered direct offering of 400,000 shares of common stock and 264,000 Series Z warrants
to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $12.50 for net proceeds
of approximately $4.6 million, net of placement agent&#8217;s commissions and offering expenses. The Series Z warrants may be
exercised at any time on or after November 23, 2016 and on or before November 23, 2021 at a price of $13.75 per share. The Company
also issued 20,000 Series ZZ warrants to the placement agent as part of its compensation. The Series ZZ warrants may be exercised
at any time on or after November 23, 2016 and on or before May 18, 2021 at a price of $13.75 per share. The fair value of the Series
Z and Series ZZ warrants of approximately $2.1 million on the date of issuance was recorded as a warrant liability.</font></p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt"><i>Series
AA and BB Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">On
August 26, 2016, the Company closed a registered direct offering of&#160; 400,000 shares of common stock and 200,000 Series AA
warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $12.50
for proceeds of approximately $4.5 million, net of placement agent&#8217;s commissions and offering expenses. The series AA
warrants may be exercised at any time after February 22, 2017 and on or before February 22, 2022 at a price of $13.75 per
share. The Company also issued 16,000 Series BB warrants to the placement agent as part of its compensation. The Series BB
warrants may be exercised at any time on or after February 22, 2017 and on or before August 22, 2021 at a price of $13.75 per
share. The fair value of the Series AA and Series BB warrants of approximately $1.5 million on the date of issuance was
recorded as a warrant liability.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><font style="font-size: 8pt">2.</font></td><td style="text-align: justify"><font style="font-size: 8pt"><u>Equity
                                         Warrants</u></font></td></tr></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt"><i>Series
X Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">In
January 2016, the Company sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for
approximately $1.1 million. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a director.
Each Series X warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per share
at any time on or before January 13, 2021. The Series X warrants qualify for equity treatment in accordance with ASC 815. The
relative fair value of the warrants was calculated to be approximately $417,000.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt"><i>Series
Y Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">On
February 15, 2016, the Company sold 52,000 shares of its common stock and 26,000 Series Y warrants to a private investor for
$624,000. Each Series Y warrant allows the holder to purchase one share of the Company's common stock at a price of $12.00 per
share at any time on or before February 15, 2021. The Series Y warrants qualify for equity treatment in accordance with ASC 815.
The relative fair value on the date of issuance of the warrants was calculated to be approximately $144,000.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><i>&#160;</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt"><i>Series
N Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">Series
N warrants were previously issued in connection with a financing. On October 11, 2013 and December 24, 2013, in
connection with public offerings of common stock on those dates, the Company reset the exercise price of the  120,751
outstanding Series N warrants from $75.00 to $13.18 and issued the Series N warrant holders  97,306 additional warrants
exercisable at $13.18, as required by the warrant agreements. In January 2014, the Company offered the investors the option to
extend the Series N warrants by one year and allow for cashless exercise in exchange for cancelling the reset provision in
the warrant agreement. One investor, holding 113,785 Series N warrants accepted this offer. Accordingly, these warrants are
no longer considered a derivative liability due to the cancelation of the reset provision. The fair value of the warrants on
that date totaled approximately $1.3 million and was reclassified from derivative liabilities to additional paid-in capital.
On March 21, 2014, the other investor exercised  4,272 Series N warrants. The Company received cash proceeds of
approximately $7,000 for  563 of the warrants exercised. The remaining  3,709 warrants were exercised in a cashless
exercise. The fair value of the warrants on the date of exercise was $137,000 and was reclassified from derivative
liabilities to additional paid-in capital.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">On
October 28, 2014, the outstanding  113,785 Series N Warrants were transferred to the de Clara Trust, of which the
Company&#8217;s CEO, Geert Kersten, is the trustee and a beneficiary. On June 29, 2015, the Company extended the expiration
date of the Series N warrants to August 18, 2017. The incremental cost of this modification was approximately $475,000. The
modification was concurrent with the extinguishment and reissuance of a note payable also held in the de Clara Trust, and was
recorded as a loss on debt extinguishment.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">As
of September 30, 2016, the remaining  113,785 Series N warrants entitle the holder to purchase one share of the Company's
common stock at a price of $13.18 per share at any time prior to August 18, 2017. On September 30, 2016 and 2015, no
derivative liability was recorded because the warrants no longer were considered a liability for accounting
purposes.</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt"><i>Series
L and Series M Warrants</i></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt"></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Series L and Series M warrants were
previously issued in connection with a financing. In April 2014, 1,000 Series L warrants, with an exercise price of $187.50, expired.
In April 2015, the remaining 2,800 of the Series L warrants, which had been repriced to $62.50 in April 2013, expired.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">In October 2013, the Company reduced
the exercise prices of the Series M warrants from $85.00 to $25.00 in exchange for a reduction in the number of warrants from 24,000
to 20,000. The additional cost of $76,991 was recorded as non-employee stock expense. In March 2014, 20,000 Series M warrants
were exercised at a price of $25.00, and the Company received proceeds of $500,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="letter-spacing: -0.1pt"><i>Series
P Warrants </i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">On February 10, 2012, the Company
issued 23,600 Series P warrants to purchase up to 23,600 shares of the Company&#8217;s common stock at a price of $112.50 per share
as an inducement for the exercise of previously issued warrants. The Series P warrants are exercisable at any time prior to March
6, 2017.</p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt; letter-spacing: -0.1pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><font style="font-size: 8pt; letter-spacing: -0.1pt">3.</font></td><td><font style="font-size: 8pt; letter-spacing: -0.1pt"><u>Options
                                         and Shares Issued to Consultants</u></font></td></tr></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify">The Company typically enters into
consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2016 and 2015, the
Company issued 49,953 and 29,599 shares of common stock, respectively, to consultants, of which 31,360 and 7,200, respectively,
were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $9.25 and $27.75
per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify">Additionally, during the years
ended September 30, 2016 and 2015, the Company issued to consultants 16,400 and 3,600 options, respectively, to purchase common
stock with exercise prices ranging from $9.25 to $25.50 per share and fair values ranging from $3.00 to $12.50 per share. The aggregate
values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to
general and administrative expenses over the periods of service.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">During the years ended September
30, 2016 and 2015, the Company recorded total expense of approximately $752,000 and $566,000, respectively, relating to these consulting
agreements. At September 30, 2016 and 2015, approximately $48,000 and $30,000, respectively, are included in prepaid expenses.
As of September 30, 2016, 25,600 options issued to consultants as payment for services remained outstanding, 17,600 of which are
fully vested, and all of which were issued from the Non-Qualified Stock Option plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0">&#160;</p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 5pt 0 0 0.25in; text-align: justify"><font style="font-size: 8pt"></font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779688384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">5. PLANT, PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and office equipment consisted of the
following at September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Manufacturing building&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">21,183,756&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">21,783,756&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Research equipment</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt"></font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,158,633</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt"></font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,268,757</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Furniture and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">133,499</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">141,347</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leasehold improvements</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">131,910</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">131,910</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,607,798</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,725,770</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation and amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,256,962</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(6,779,939</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net plant, property and equipment</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,350,836</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,945,831</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The Company is
not the legal owner of the manufacturing building, but is deemed to be the owner for accounting purposes based on the
accounting guidance for build-to-suit leases. See Note 10, Commitments and Contingencies &#8211; Lease Obligations for
additional information. As of September 30, 2016 and 2015, accumulated depreciation on the manufacturing building
is approximately $4.1 million and $3.5 million, respectively. Depreciation expense for the years ended September 30, 2016,
2015 and 2014 totaled approximately $626,000, $680,000 and $703,000, respectively. Depreciation expense includes depreciation
on the leased manufacturing building of approximately $514,000, which is included in research and development costs on
the Statement of Operations. One asset is recorded under capital lease with a net book value of $0 and approximately $8,000
on September 30, 2016 and 2015, respectively. Amortization of the capital lease asset is included in general and
administrative expenses on the Statements of Operations.</p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0">&#160;</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6644271072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">6. PATENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents consisted of the following at September
30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Patents</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,528,610</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,525,791</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,272,063.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,234,227.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net Patents</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">256,547</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">291,564</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2016, 2015
there was no impairment of patent costs and a nominal impairment charge in 2014. Amortization expense for the years ended September
30, 2016, 2015 and 2014 totaled approximately $38,000, $40,000 and $43,000, respectively. The total estimated future amortization
is as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Years ending September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">37,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">36,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">31,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">28,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">257,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6627977984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">7. INCOME TAXES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">At September 30, 2016 and 2015, the
Company had federal net operating loss carryforwards of approximately $170.8 million and $156.8 million, respectively. The NOLs
begin to expire during the fiscal year ending September 30, 2019 and become fully expired by the end of the fiscal year ended 2036.
In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&#38;D
credit&#8221;) of approximately $1.2 million at September 30, 2016 and 2015. The R&#38;D credit begins to expire during the fiscal
year ending September 30, 2020 and is fully expired during the fiscal year ended 2029. Deferred taxes consisted of the following
at September 30:</p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Net operating loss carryforwards</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">64,366,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">61,363,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">R&#38;D credit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,221,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,221,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock-based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6,379,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,855,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Capitalized R&#38;D</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,508,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,082,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vacation and other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">179,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">114,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Loan modification</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">57,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">90,653 ,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,692,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets and intangibles</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(49,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(86,000</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax liabilities</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(49,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(86,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(90,604,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(83,606,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net deferred tax asset</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all,
of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation
of future taxable income. Management has considered the history of the Company&#8217;s operating losses and believes that the
realization of the benefit of the deferred tax assets cannot be reasonably assured. In addition, under Internal Revenue Code Section
382, the Company&#8217;s ability to utilize these net operating loss carryforwards may be limited or eliminated in the event of
future changes in ownership.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company has no federal or state current or deferred tax expense or benefit. The Company&#8217;s effective tax rate differs from
the applicable federal statutory tax rate. The reconciliation of these rates is as follows at September 30:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>



<p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 61%"><font style="font-size: 8pt">Federal Rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3.92</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.12</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.15</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate change</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(22.00</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.15</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.93</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Other adjustments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.03</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.21</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Adjustment to deferreds</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">19.13</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Permanent differences (1)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44.90</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.71</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.43</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(60.79</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(38.05</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(58.78</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Effective tax rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1) The 2016 amount is
for the most part due to the approximate $14 million gain on derivative instruments from the change in fair value of the Company&#8217;s
warrant liabilities during the period.&#160;</p>

<p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company applies the provisions of ASC 740, <i>&#8220;Accounting for Uncertainty in Income Taxes,&#8221;</i> which requires financial
statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position
will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain
tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September
30, 1998 through 2015. These years remain open to examination by the major domestic taxing jurisdictions to which the Company
is subject.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800559008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">8. STOCK COMPENSATION</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">The Company recognized
the following expenses for options issued or vested and restricted stock awarded during the year:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Year
    Ended September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%"><font style="font: 8pt Times New Roman, Times, Serif">Employees</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 0%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,113,433</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 0%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5,105,827</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 0%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,958,637</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Non-employees</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">751,651</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">565,915</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">771,946</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Stock compensation
is included in general and administrative expense. During the years ended September 30, 2016, 2015 and 2014, non-employee stock
compensation excluded approximately $48,000, $30,000 and $26,000, respectively, for future services to be performed (Note 12).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">During the years
ended September 30, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing
model with the following assumptions.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1.5pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;<b>2016</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; width: 58%; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Expected
    stock price volatility</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 75.58&#160;&#8211;&#160;80.9%</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 73.38 &#8211; 86.19%</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 72.81 &#8211; 86.87%</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Risk-free
    interest rate</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 0.71 &#8211; 1.56%</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 0.93 &#8211; 2.35%</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; 0.59 &#8211; 2.65%</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Expected
    life of options</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;3.0
    &#8211; 9.69 Years&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3.0
    &#8211; 9.76 Years</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3.0
    &#8211; 9.76 Years</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Expected
    dividend yield</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; -&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; -&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    &#160; -&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><u>Non-Qualified
Stock Option Plans</u>--At September 30, 2016, the Company has collectively authorized the issuance of 387,200 shares of common
stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten
years after the grant date. Terms of the options are to be determined by the Company&#8217;s Compensation Committee, which administers
the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options
under the Non-Qualified Stock Option Plans.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><u>Incentive Stock
Option Plans</u>--At September 30, 2016, the Company had collectively authorized the issuance of 138,400 shares of common stock
under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after
the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee, which administers the plans.
Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Activity in the
Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2016 is summarized as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b><u>Non-Qualified
and Incentive Stock Option Plans</u></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="15" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Outstanding</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Exercisable</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ave</b></font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ave</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Remaining
    Contractual</b></font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Intrinsic</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Average</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Remaining
    Contractual</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font><font style="font-size: 8pt"><br />
    <font style="font-family: Times New Roman, Times, Serif"><b>Intrinsic</b></font></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Shares</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Exercise
    Price</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Term
    (Years)</b></font></td>
    <td colspan="2" style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Shares</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Exercise
    Price</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Term
    (Years)</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at October 1, 2014</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">273,246</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">74.50</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.55</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,600</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">137,755</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">85.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.49</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,600</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">16,134</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">62.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Granted (a)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">35,748</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">16.50</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">54,667</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,820</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">103.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,820</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">103.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at September 30, 2015</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">301,507</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">67.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.98</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">50</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">181,070</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">78.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.01</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">56,069</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">31.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Granted (b)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">48,544</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,240</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">21.50</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,240</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">145.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,240</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">145.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">343,571</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">59.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5.35</font></td>
    <td colspan="2"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">232,898</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">66.25</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4.76</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding: 0.75pt"><font style="font: 8pt Times New Roman, Times, Serif">(a)</font></td>
    <td colspan="12" style="padding: 0.75pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Includes
    90,000 stock options granted to consultants</font></td>
    <td colspan="21"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 3px"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 3px"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<table cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; width: 72px; padding: 0.75pt"><font style="font: 8pt Times New Roman, Times, Serif">(b)</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Includes
    410,000 stock options granted to consultants</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">A summary of the
status of the Company&#8217;s non-vested options for the two years in the period ended September 30, 2016 is presented below:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.25in"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Grant
    Date</b></font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Options</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Fair
    Value</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font: 8pt Times New Roman, Times, Serif">Unvested at October 1, 2014</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">134,491</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">53.75</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(46,134</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">35,748</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(4,667</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Unvested at September 30, 2015</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">120,438</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">43.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Vested</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(56,069</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">48,544</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(2,240</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 8pt Times New Roman, Times, Serif">Unvested at September 30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">110,673</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">37.00</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 4.25in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><u>Incentive Stock
Bonus Plan</u>-- On July 22, 2014 the Company's shareholders approved the 2014 Incentive Stock Bonus Plan, authorizing the issuance
of up to 640,000 shares in the Company&#8217;s Incentive Stock Bonus Plan. The shares will only be earned upon the achievement
of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in
the market price of the Company&#8217;s stock. If the performance or market criteria are not met as specified in the Incentive
Stock Bonus Plan, all or a portion of the awarded shares will be forfeited. The fair value of the shares on the grant date was
calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using
a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of
shares issued that remain outstanding as of September 30, 2016 is approximately $8.6 million. The total value of the shares, if
earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered,
regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service
period is not rendered. During the years ended September 30, 2016 and 2015, the Company recorded expense relating to the issuance
of restricted stock pursuant to the plan of approximately $634,000 and $3.4 million, respectively. At September 30, 2016, the
Company has unrecognized compensation expense of approximately $3.1 million which is expected to be recognized over a weighted
average period of 5.03 years.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">A summary of the
status of the Company&#8217;s restricted stock units issued from the Incentive Stock Bonus Plan for the two years in the period
ended September 30, 2016 is presented below:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Grant Date Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Unvested
    at October 1, 2014</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">628,000</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 1%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">13.75</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(20,000</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;Granted</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;Forfeited</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(4,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Unvested at September
    30, 2015</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">13.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Unvested at September
    30, 2016</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">13.75</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><u>Stock Bonus
Plans</u> -- At September 30, 2016, the Company was authorized to issue up to 223,760 shares of common stock under its Stock Bonus
Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares. During the year ended
September 30, 2016, 16,340 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $162,000. During
the year ended September 30, 2015, 9,727 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $166,000.
During the year ended September 30, 2014, 6,591 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately
$155,000. As of September 30, 2016, the Company has issued a total of 126,448 shares of common stock from the Stock Bonus Plans.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><u>Stock Compensation
Plans</u>-- At September 30, 2016, 134,000 shares were authorized for use in the Company&#8217;s stock compensation plans. During
the years ended September 30, 2016, 2015 and 2014, 18,593, 8,733 and 16,399 shares, respectively, were issued from the Stock Compensation
Plans to consultants for payment of services at a cost of approximately $234,000, $147,000 and $439,000, respectively. During
the year ended September 30, 2016 and 2015, 3,837 and 4,282 shares, respectively, were issued to employees from the Stock Compensation
Plans as part of their compensation at a cost of approximately $45,000 and $58,000, respectively. No shares were issued to employees
from the Stock Compensation Plans during the year ended September 30, 2014. As of September 30, 2016, the Company has issued 79,391
shares of common stock from the Stock Compensation Plans.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt">&#160;</font></p>



<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777552048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">9. EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a defined contribution
retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security
Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by
the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed
the lesser of $10,000 or 6% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is
valued each quarter based upon the closing bid price of the Company&#8217;s common stock. Total expense, including plan maintenance,
for the years ended September 30, 2016, 2015 and 2014, in connection with this Plan was approximately $168,000, $170,000 and $160,000,
respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800548464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">10. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i>Clinical Research Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2013, the Company entered into an agreement
with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will
reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited
against future invoices in $150,000 annual increments through December 2017. As of September 30, 2016, the total balance advanced
is $300,000, of which $150,000 is classified as a current asset.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2013, the Company entered into a co-development
and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in
the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments,
up to a specific maximum amount. In October 2015, the Company entered into a second <font style="color: #292929">co-development
and revenue sharing agreement with Ergomed</font> for an additional $2 million, for a total of $12 million. The Company accounted
for the co-development and revenue sharing agreement in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company
determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company
records the discount on the clinical services as a credit to research and development expense on its Statements of Operations.
Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development
expenses of approximately $19.2 million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of
approximately $6.3 million. During the years ended September 30, 2016, 2015 and 2014, the Company recorded, approximately $7.2
million, $6.7 million and $4.4 million, respectively, as research and development expense related to Ergomed&#8217;s services.
These amounts were net of Ergomed&#8217;s discount of approximately $2.1 million, $2.4 million and $1.5 million, respectively,
over the comparable periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2013, the Company entered into two
co-development and profit sharing agreements with Ergomed.&#160; One agreement supports the Phase 1 study being conducted at UCSF
for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.&#160; The other
agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women.
Ergomed will assume up to $3 million in clinical and regulatory costs for each study.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently involved in a pending
arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet
AG). On October 31, 2013, the Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former
third-party CRO, and are seeking payment for damages related to inVentiv&#8217;s prior involvement in the ongoing Phase 3 clinical
trial of Multikine. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges
(i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. The Company is seeking at least $50 million in
damages in its amended statement of claim. Based upon further analysis, however, the Company believes that its damages (direct
and consequential) presently total over $150 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an amended statement of claim, the Company
asserted the claims set forth above as well as an additional claim for professional malpractice.&#160;&#160;The arbitrator subsequently
granted inVentiv&#8217;s motion to dismiss the professional malpractice claim based on the &#8220;economic loss doctrine&#8221;
which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#160;&#160;The arbitrator denied the remainder of inVentiv&#8217;s motion, which had
sought to dismiss certain other aspects of the amended statement of claim.&#160;&#160;In particular, the arbitrator rejected inVentiv&#8217;s
argument that several aspects of the amended statement of claim were beyond the arbitrator&#8217;s jurisdiction.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the pending arbitration proceedings,
inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for
services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Company&#8217;s
alleged use of inVentiv&#8217;s name in connection with publications and promotions in violation of the parties&#8217; contract;
(iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking
at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&#8217;s counterclaims
are meritless. However, if inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material
adverse effect on the Company&#8217;s business, results, financial condition and liquidity.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2015 the Company signed an arbitration
funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation
expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with funding for litigation expenses to
support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration
and will only be repaid when the Company receives proceeds from the arbitration. During the year ended September 30, 2016, the
Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability
that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of
legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal
fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap
its fees and expenses for the arbitration at $5 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The arbitration hearing on the merits (the &#8220;trial&#8221;)
began on September 26, 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Lease Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases a manufacturing facility
near Baltimore, Maryland under an operating lease (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s
specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and
sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each
year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses,
repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase
the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements,
of which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately
$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building
in service in October 2008.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The leased building is being depreciated using
a straight line method of the 20 year lease term to a residual value. The landlord liability is being amortized over the 20 years
using the effective interest method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease payments allocated to the landlord liability
are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was required to deposit the equivalent
of one year of base rent in accordance with the San Tomas lease. When the Company meets the minimum cash balance required by the
lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets on September
30, 2016 and 2015.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future minimum lease payments under the San
Tomas lease as of September 30, 2016 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Years ending September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,687,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,747,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,808,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,872,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,937,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">15,762,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,813,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less imputed interest on financing obligation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(11,802,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net present value of lease financing obligation</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">13,011,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company subleases a portion of its rental
space on a month to month term lease, which requires a 30 day notice for termination. The sublease rent for the years ended September
30, 2016, 2015 and 2014 was approximately $67,000, $65,000 and $63,000, respectively, and is recorded in grant income and other
in the statements of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its research and development
laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28,
2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight
line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of September 30, 2016 and
2015, the Company has recorded a deferred rent liability of approximately $2,000 and $6,000, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its office headquarters under
a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing
the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per
month. As of September 30, 2016 and 2015, the Company has recorded a deferred rent liability of approximately $18,000 and $13,000,
respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases office equipment under a
capital lease arrangement. The term of the capital lease is 48 months and expired on September 30, 2016. The monthly lease payment
is $1,025. The lease bears interest at approximately 6% per annum.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Approximate future minimum annual lease payments
due under non-cancelable operating leases, excluding the San Thomas, lease for the years ending after September 30, 2016 are as
follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">243,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">251,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">258,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">238,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">163,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">69,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total minimum lease payments:</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">1,222,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160; &#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense, for the years ended September
30, 2016, 2015 and 2014, excluding the rent paid on the San Tomas lease was approximately $300,000. The Company&#8217;s three leases
expire between June 2020 and October 2028.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vendor Obligations</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, the Company has contingent obligations
with other vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be
determined at this time. The total remaining cash cost of the Phase 3 clinical trial, excluding any costs that will be paid by
CEL-SCI's partners, would be approximately $12.1 million after September 30, 2016. This is based on the executed contract costs
with the CROs only and does not include other related costs, e.g. the manufacturing of the drug. The Company has filed an amendment
to the original Phase 3 protocol for it head and neck cancer study with the FDA to allow for this expansion in patient enrollment.
Should the FDA allow the amended protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be
higher.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790807248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">11. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Effective August 31, 2016, Maximilian
de Clara, the Company&#8217;s President and a director, resigned for health reasons. In payment for past services, the Company
agreed to issue Mr. de Clara 26,000 shares of restricted stock; 13,000 shares upon his resignation and 13,000 on August 31, 2017.
The market value of the shares granted, including the accrued value of the shares to be issued in August 2017, totaled $253,500.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On January 13, 2016, the de Clara
Trust demanded payment on the note payable, of which the balance, including accrued and unpaid interest, was $1,105,989. The de
Clara Trust was established by Maximilian de Clara, the Company&#8217;s former President and a director. The Company&#8217;s Chief
Executive Officer, Geert Kersten, is the trustee and a beneficiary. When the de Clara Trust demanded payment on the note, the Company
sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each
warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per share at any time
on or before January 13, 2021.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Prior to the repayment, on June 29,
2015, the Company had extended the maturity date of the note to July 6, 2017, lowered the interest rate from 15% to 9% and changed
the conversion price from $100.00 to $14.75, the closing stock price on the previous trading day. The Company determined these
modifications to be substantive and accounted for the modification as an extinguishment of the pre-modification note and issuance
of the post-modification note. The Company recorded an extinguishment loss and a premium on the note payable of approximately $166,000,
which was credited to additional, paid in capital. Concurrently, the Company extended the expiration date of the Series N warrants
to August 18, 2017. The incremental cost of this modification was approximately $475,000 and was included in debt extinguishment
loss on the note, for a total loss of approximately $620,000 during the year ended September 30, 2015.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">During the years ended September
30, 2016, 2015 and 2014, the Company paid approximately $43,000, $146,000 and $179,000, respectively, in interest expense to Mr.
de Clara.</p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0">&#160;</p>



<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788554880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityTextBlock', window );">12. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">During the years ended September
30, 2016 and 2015, no warrants were exercised. During the year ended September 30, 2014, 107,822 Series M, N and S warrants were
exercised. The Company issued 106,740 shares of common stock and received approximately $3.1 million from the exercise of these
warrants since 3,709 Series N warrants were exercised in a cashless exercise.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">On October 11, 2013, the Company
closed a public offering of units of common stock and Series S warrants at a price of $25.00 per unit for net proceeds of $16.4
million, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to purchase
one share of common stock. The warrants were immediately exercisable and expire on October 11, 2018, and have an exercise price
of $31.25. In November 2013, the underwriters purchased an additional 105,957 warrants pursuant to the overallotment option, for
which the Company received net proceeds of approximately $24,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">On December 24, 2013, the Company
closed a public offering of units of common stock and Series S warrants at a price of $15.75 per unit for net proceeds of approximately
$2.8 million, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to
purchase one share of common stock. The warrants are immediately exercisable and expire on October 11, 2018, and have an exercise
price of $31.25. The underwriters exercised the option for the full 10% overallotment, for which the Company received net proceeds
of approximately $279,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">The October and December 2013 financings
triggered the reset provision from the August 2008 financing which resulted in the issuance of an additional 62,523 shares of common
stock. The cost of additional shares issued was approximately $1.1 million. This cost was recorded as a deemed a dividend.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">On October 24, 2014, the Company
closed an underwritten public offering of 315,789 shares of common stock and 78,947 Series S warrants to purchase shares of common
stock. Additionally, in a related private offering on October 21, 2014, the Company sold 52,800 shares of common stock and 13,200
Series S warrants to purchase shares of common stock. The common stock and Series S warrants were sold at a combined price of $19.00
for net proceeds of approximately $6.4 million, net of offering expenses. The Series S warrants trade of the NYSE MKT under the
symbol CVM WT.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">On April 17, 2014, the Company closed
a public offering of units consisting of 285,129 shares of common stock and Series T warrants to purchase an aggregate of 71,282
shares of common stock. The units were sold at a price of $35.00 per unit. The Company received net proceeds of approximately $9.1
million after deducting the underwriting commissions and offering expenses. The common stock and warrants separated immediately.
The Series T warrants, with an exercise price of $39.50 per share, expired on October 17, 2014. The underwriters in the offering
received 17,821 Series U warrants to purchase one share of common stock. The Series U warrants expire on October 17, 2017, and
have an exercise price of $43.75.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On May 28, 2015, the Company closed
an underwritten public offering of 810,127 shares of common stock and 810,127 Series V warrants to purchase shares of common stock.
The common stock and Series V warrants were sold at a combined per unit price of $19.75 for net proceeds of approximately $14.7
million, net of underwriting discounts and commissions and offering expenses. The Series V warrants are immediately exercisable
at a price of $19.75 and expire on May 28, 2020.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On October 28, 2015, the Company
closed an underwritten public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common
stock. The common stock and warrants were sold at a combined price of $16.75 for net proceeds of approximately $10.5 million, net
of underwriting commissions and offering expenses. The warrants were immediately exercisable, expire October 28, 2020 and have
an exercise price of $16.75.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On May 23, 2016, the Company closed
a registered direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock.
The common stock and warrants were sold at a combined per unit price of $12.50 for net proceeds of approximately $4.6 million,
net of placement agent&#8217;s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after
November 23, 2016 and on or before November 23, 2021 at a price of $13.75 per share. The Company also issued 20,000 Series ZZ warrants
to the placement agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23,
2016 and on or before May 18, 2021 at a price of $13.75 per share.</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On August 26, 2016, the Company closed
a registered direct offering of&#160;400,000 shares of common stock and Series AA warrants to purchase up to 200,000 shares of
common stock. Each share of common stock was sold together with a Series AA warrant to purchase one-half of a share of common stock
for the combined purchase price of $12.50. Each warrant can be exercised at any time after February 22, 2017 and on or before February
22, 2022 at a price of $13.75 per share. The Company also issued 16,000 Series BB warrants to the placement agent as part of its
compensation. The Series BB warrants may be exercised at any time on or after February 22, 2017 and on or before August 22, 2021
at a price of $13.75 per share. The Company received proceeds from the sale of Series AA and Series BB shares and warrants of approximately
$4.5 million, net of placement agent&#8217;s commissions and offering expenses</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0">&#160;</p>



<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790753040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">13. FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the provisions of
ASC 820, &#8220;<i>Fair Value Measurements</i>,&#8221; the Company determines fair value as the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The
Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future
amounts to a single present amount. The measurement is based on the value indicated by current market expectations about those
future amounts.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 establishes a fair value hierarchy
that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical
assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company
classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as
follows:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">o</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">o</font></td>
    <td colspan="2" style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">o</font></td>
    <td colspan="2" style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For disclosure purposes, assets and liabilities
are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the
overall fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy levels.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities
measured at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; width: 60%; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Quoted Prices in</b></font></td>
    <td style="width: 13%; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Significant</b></font></td>
    <td style="vertical-align: top; width: 7%; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; width: 10%; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Active Markets for</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Other</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Significant</b></font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Identical Assets or</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Observable</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Unobservable</b></font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Liabilities&#160;(Level&#160;1)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Inputs&#160;(Level&#160;2)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Inputs&#160;(Level&#160;3)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td></tr>
<tr>
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Derivative Instruments</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$3,111,361</font></td>
    <td style="vertical-align: top; border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">-&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$5,283,573</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$8,394,934</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities
measured at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2015:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="vertical-align: top; width: 59%; line-height: 107%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Quoted&#160;Prices&#160;in</b></font></td>
    <td style="width: 11%; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Significant</b></font></td>
    <td style="vertical-align: top; width: 13%; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; width: 7%; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Active&#160;Markets&#160;for</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Other</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Significant</b></font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Identical Assets or</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Observable</b></font></td>
    <td style="text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Unobservable</b></font></td>
    <td style="vertical-align: top; line-height: 107%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Liabilities&#160;(Level&#160;1)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Inputs&#160;(Level&#160;2)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Inputs&#160;(Level&#160;3)</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td></tr>
<tr>
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Derivative Instruments</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$7,365,555</font></td>
    <td style="vertical-align: top; border-bottom: black 1.5pt double; text-align: right; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$6,323,032</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;$13,686,587</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following sets forth the reconciliation
of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September
30:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Beginning balance</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">6,323,032</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">307,894</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;Issuances</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">8,722,073</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">8,003,220</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Net realized and unrealized derivative gain</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">(9,761,532</font></td>
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">(1,988,082</font></td>
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Ending balance</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">5,283,573</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$6,323,032</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of the Company&#8217;s
derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such
as historical price and volatility of the Company&#8217;s stock as well as U.S. Treasury Bill rates are observable in active markets.
At September 30, 2016, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $0.10 per share
and a weighted average exercise price of $0.86 per share. Fair values were determined using a weighted average risk free interest
rate of 1.04% and 75% volatility.</p>

<p style="font: 8pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790889440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">14. NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Basic
loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares
outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
common stock warrants, restricted stock and shares issuable on convertible debt, have not been included in the computation of
diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain
on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss
per share because its effect is anti-dilutive.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -20pt"><font style="font: 8pt Times New Roman, Times, Serif">The
following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:</font></p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2016</font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2015</font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders &#8211; Restated (1)</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(28,470,126)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Less:&#160;&#160;Gain
    on derivative instruments</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(248,767)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders &#8211; diluted (restated)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(28,718,893)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average number of shares - basic and diluted</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,866,204</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,300,761</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,352,185</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    per share &#8211; basic (restated)</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.10)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    per share &#8211; diluted (restated)</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.21)</font></td></tr>
</table>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">(1)
See Note 17 </font>Restatement&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For
the years ended September 30, 2016 and 2015, the gain on derivatives is not excluded from the numerator in calculating diluted
loss per share because the gain relates to derivative warrants that were priced higher than the average market price during the
period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <i>Earnings Per Share</i>, the calculation of
diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as
of September 30:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><u>2016</u></font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><u>2015</u></font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><u>2014</u></font></td></tr>
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Options
    and Warrants &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">3,675,281</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2,336,842</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,599,788</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Convertible
    Debt</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">74,851</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">11,041</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Unvested
    Restricted Stock</font></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">628,000</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td>
    <td style="border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,279,281</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,015,693</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,238,829</font></td></tr>
</table>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800552304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>15. SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">15. SEGMENT REPORTING</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 280, &#8220;<i>Disclosure about Segments
of an Enterprise and Related Information</i>&#8221; establishes standards for reporting information regarding operating segments
in annual financial statements and requires selected information for those segments to be presented in interim financial reports
issued to stockholders. This topic also establishes standards for related disclosures about products and services and geographic
areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is
available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources
and assess performance. The Company&#8217;s chief decision maker, as defined under this topic, is the Chief Executive Officer.
To date, the Company has viewed its operations as principally one segment, the research and development of certain drugs and vaccines.
As a result, the financial information disclosed herein materially represents all of the financial information related to the Company&#8217;s
principal operating segment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641974144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. QUARTERLY INFORMATION (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">16. QUARTERLY INFORMATION (UNAUDITED)</a></td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
following quarterly data are derived from the Company&#8217;s restated statement of operations. See Note 17 for information concerning
the Restatement of the Company&#8217;s financial statements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>Financial
Data</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>Fiscal
2016 (restated)</b></font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended December 31, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended March 31, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended June 30, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended September 30, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 18.5pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Year
    ended September 30, 2016 </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Grant
    and other income</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,976
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32,775
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;129,975
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;101,329
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;285,055
    </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating
    expenses</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,327,509</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,829,779</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;6,036,123</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;6,738,472</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,931,883</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Non-operating
    (expenses) income, net</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(483,693)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(464,796)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(464,202)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(466,699)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(1,879,390)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    (loss) on derivatives</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;8,122,960
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;(2,593,730)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;2,508,744
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,975,752
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;14,013,726
    </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    income (loss) available to common shareholders</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;2,332,734</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (8,855,530)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (3,861,606)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (1,128,090)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (11,512,492)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">EPS
    (LPS) - basic and diluted</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.53</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.87)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.78)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.21)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average shares:</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Basic</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,390,740</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,736,809</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,965,300</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,371,635</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,866,204</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Diluted</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,465,591</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,736,809</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,965,300</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,371,635</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,866,204</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>Fiscal
2015 (restated)</b></font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended December 31, 2014 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended March 31, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended June 30, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended September 30, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Year
    ended September 30, 2015 </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Grant
    and other income</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;136,838
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;197,620
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;389,223
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(66,304)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;657,377
    </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating
    expenses</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,655,979</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,480,363</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,114,099</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,797,084</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,047,525</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Non-operating
    (expenses) income, net</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(490,812)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(494,156)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(497,040)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(482,213)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,964,221)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    (loss) on derivatives</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,162,970
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,782,796)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,428,780
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,526,338)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;282,616
    </font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    on debt extinguishment</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(620,457)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(620,457)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,846,983)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;(12,559,695)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,413,593)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,871,939)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">LPS
    - basic</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.68)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4.14)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.32)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.54)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">LPS
    - diluted</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3.42)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4.14)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.62)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.54)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average shares:</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Basic</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,930,431</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,033,915</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,351,852</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,881,600</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,300,761</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Diluted</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,930,431</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,033,915</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,405,364</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,881,600</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,300,761</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company has experienced large swings in its quarterly gains and losses caused by the changes in the fair value of
warrants each quarter. The results of the restatement did not impact loss per share for any of the periods presented except
for the effects of the 1:25 reverse stock split.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790725456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. RESTATEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RestatementAbstract', window );"><strong>Restatement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">RESTATEMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 4.5pt 0 0 0.25in; text-align: justify; background-color: white">The
Company has restated its previously issued 2016, 2015 and 2014 financial statements to correct an error in the way it accounted
for a lease entered into in October 2008. In October 2008, the Company entered into a lease arrangement whereby the Company leased
a building owned by a third party, but to which the owner made tenant-directed improvements. Upon commencement of the lease, the
Company accounted for the arrangement as an operating lease under ASC 840, <i>Accounting for Leases</i>, whereby the total minimum
lease payment obligations under the leases were recognized as monthly rent expense on a straight-line basis over the term of the
lease. The cost of the tenant improvements incurred were capitalized as deferred rent and amortized over the 20-year lease term.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">However,
in November 2017, the Company discovered an error in the way it accounted for the lease for the building since it was determined
that, as the terms of the original lease required the Company to be responsible for possible cost overruns, (but of which there
were none), the Company was deemed to be the owner of the leased building for accounting purposes only under ASC 840-40-55. In
addition to the costs it incurred and capitalized for the tenant improvements, the Company should have reflected an asset on its
balance sheet for the costs paid by the lessor to purchase and improve the building, as well as a corresponding liability. Upon
completion of the improvements, the Company did not meet the &#8220;sale-leaseback&#8221; criteria under ASC 840-40-25, <i>Accounting
for Leases, Sale-Leaseback Transactions</i> due to the Company&#8217;s significant continuing involvement with the facility which
is considered to be other than a normal leaseback as defined in ASC 840-40-25 and therefore should have treated the lease as a
financing obligation and the asset and corresponding liability should not be derecognized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">The correction
to the historical financial statements to apply ASC 840-40-25 do not affect the total cash payments the Company has made or is
obligated to make under the lease agreement, nor does it change the total expense to be recognized over the lease term. However,
the timing and nature of expense is different under this treatment as compared to operating lease treatment. Specifically, the
Company should have recognized depreciation, expense on the building it is deemed to own and interest expense on the associated
lease financing obligation, instead of rental expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Accordingly, the historical financial
statements in this report have been restated. The accompanying financial statements for the three years in the period ended September
30, 2016 have been restated to reflect the correction of the error for the lease accounting. Accumulated deficit at October 1,
2013, was reduced by $326,827.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On June 12, 2017, the Company&#8217;s
shareholders approved a reverse split of the Company&#8217;s common stock which became effective on the NYSE American on June 15,
2017. On that date, every twenty five issued and outstanding shares of the Company&#8217;s common stock automatically converted
into one outstanding share. As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common
stock decreased from 230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. In addition, by reducing the number of the
Company&#8217;s outstanding shares, the Company&#8217;s loss per share in all prior periods will increase by a factor of twenty
five. The reverse stock split affected all stockholders of the Company&#8217;s common stock uniformly, and did not affect any stockholder&#8217;s
percentage of ownership interest. The par value of the Company&#8217;s stock remained unchanged at $0.01 per share and the number
of authorized shares of common stock remained the same after the reverse stock split.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">As the par value per share of the
Company&#8217;s common stock remained unchanged at $0.01 per share, a total of $2,204,938 was reclassified from common stock to
additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance
under the Company&#8217;s incentive and non-qualified stock option plans, as well as the shares of common stock underlying outstanding
stock options and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were
proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying
financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The following is a summary of the
restatements for 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">9/30/2016</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">PREVIOUSLY REPORTED</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total current assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,887,646 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(429,821)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,457,825 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Other assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,710,601 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,717,699 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,428,300 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11,598,247 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,287,878 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,886,125 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total liabilities</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,554,315 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,011,023 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,565,338 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Stockholders' deficit, September 30, 2016</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(956,068)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;276,855</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(679,213)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">9/30/2015</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Balance Sheet</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total current assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,833,183 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(487,793)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,345,390 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Other assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,614,420 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,593,892 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,208,312 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,447,603 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,106,099 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28,553,702 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total liabilities</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,532,722 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,783,250 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,315,972 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Stockholders' deficit, September 30, 2015</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5,085,119)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;322,850 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,762,270)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2016</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 21%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,351,779 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,445,382 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,838,280 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,931,883 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,553,225)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,397</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(23,646,828)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;73,001 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,952,391)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,879,390)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,466,498)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(45,994)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic and diluted</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.36)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2015</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,098,147 </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,191,750 </font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;34,953,922 </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,047,525 </font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,296,545)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,397</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(32,390,148)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(40,260) </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,923,961)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,964,221)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,674,646)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(17,564)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic and diluted</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2014</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,172,587 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,398)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,266,189 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27,838,145 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,398)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,931,747 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,574,112)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,398</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,667,714)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(40,920)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,892,812)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,933,732)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,366,265)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,586</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.11)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.10)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, diluted</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.22)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.21)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Accumulated</font></td>
    <td nowrap="nowrap" style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Total Stockholders' </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Deficit</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Equity (Deficit)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">PREVIOUSLY REPORTED, OCTOBER 1, 2013</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(212,160,568)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,700,090 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;326,827 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;326,827 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">RESTATED BALANCE, OCTOBER 1, 2013</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(211,833,741)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,026,917 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2014 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;31,109,575 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss &#8211; RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2014</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(239,186,420)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,783,813 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2015 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,146,127 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss - RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2015</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(273,878,630)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,762,270)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2016 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,595,549 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss - RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2016</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(285,391,122)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(679,213)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RestatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RestatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 6.G.2.b(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e31034-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 1.N.Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e30840-122693<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641976768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>18. SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">18. SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
accordance with ASC 855, &#8220;<i>Subsequent Events</i>&#8221;, the Company has reviewed subsequent events through the date of
the filing.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
December 8, 2016, the Company sold 1,360,960 shares of common stock and warrants to purchase common stock at a price of $3.13
in a public offering. The warrants consist of 68,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960Series
DD warrants to purchase 1,360,960shares of common stock and 1,360,960Series EE warrants to purchase 1,360,960shares of common
stock. The Series CC warrants are immediately exercisable, expire in five-years and have an exercise price of $5.00 per share.
The Series DD warrants are immediately exercisable, expire in six-months and have an exercise price of $4.50 per share. The Series
EE warrants are immediately exercisable, expire in nine-months and have an exercise price of $4.50 per share. In addition, the
Company issued 68,048 Series FF warrants to purchase 68,048 shares of common stock to the placement agent. The FF warrants are
exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $3.91. The net proceeds
to CEL-SCI from this offering &#160;was approximately $3.8 million, excluding any future proceeds that may be received from the
exercise of the warrants.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
December 9, 2016, the Company reported on a communication received from the staff of the NYSE MKT, its current listing exchange,
that it considered the Company to be noncompliant with certain listing requirements based on its quarterly report for the period
ended June 30, 2016. The Company has been given the opportunity to maintain its listing by submitting a plan of compliance by
January 9, 2017. This plan must advise of actions the company has taken or will take to regain compliance with the continued listing
standards by June 11, 2018. The Company intends to submit such a plan by January 9, 2017. The communication and compliance plan
has no current effect on the listing of the Company's shares on the exchange. If the plan is not acceptable or the Company does
not make sufficient progress under the plan or reestablish compliance by June 11, 2018, then staff of the exchange may initiate
proceedings for delisting from the NYSE MKT. The Company may then appeal a staff determination to initiate such proceedings in
accordance with the exchange's Company Guide.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811046160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">For purposes of the statements of
cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The
Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Prepaid expenses are payments for future services to be rendered and are expensed
over the time period for which the service is rendered. Prepaid expenses may also include payment for goods to be received within
one year of the payment date.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Inventory consists of manufacturing production advances and bulk purchases of
laboratory supplies to be consumed in the manufacturing of the Company&#8217;s product for clinical studies. Inventories are stated
at the lower of cost or market, where cost is determined using the first-in, first out method applied on a consistent basis.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Deposits2', window );">Deposits</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">The deposits are required by the lease agreement for the manufacturing facility
and by the clinical research organization (CRO) agreements.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Research and Office Equipment and Leasehold Improvements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and office equipment is recorded at
cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements
are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which
do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to assess impairment,
if any.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Patent expenditures are capitalized and amortized using the straight-line method
over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or
other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization
is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the
asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference
between the estimated fair value of the asset and its carrying value.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><p style="margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Certain of the Company&#8217;s operating
leases provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate minimum annual payments
are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations
when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments
exceed the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays, the Company records a deferred
rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into financing arrangements
that consist of freestanding derivative instruments that contain embedded derivative features, specifically, the settlement provisions
in the warrant agreements preclude the warrants from being treated as equity. The Company accounts for these arrangements in accordance
with Accounting Standards Codification (ASC) 815, &#8220;Accounting for Derivative Instruments and Hedging Activities&#8221;. In
accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments
are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized
in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines
the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models,
giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are re-measured at fair
value at the end of each reporting period as long as they are outstanding.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">The Company's grant arrangements are handled on a reimbursement basis. Grant
income under the arrangements is recognized when costs are incurred.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Research and development expenditures are expensed as incurred.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i></i>Leases are
categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over
the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of
capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes
an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.
If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on
the Company's balance sheet.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">The Company calculates net loss per common share in accordance with ASC 260
&#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable
to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially
dilutive shares, which include outstanding common stock options, restricted stock units, convertible preferred stock and common
stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be
anti-dilutive.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Financial instruments, which potentially subject the Company to concentrations
of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality
financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced
any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and
cash equivalents. All non-interest bearing cash balances were fully insured&#160;up to $250,000 at September 30, 2016.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method
of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that
includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is
more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September
30, 2016 and 2015.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">The preparation of financial statements in conformity U.S. GAAP requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.
These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the
future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives
for depreciation and amortization of long-lived assets, deferred tax assets and the related valuation allowance, and the valuation
of derivative liabilities.<font style="color: #444444">&#160;</font>Actual results could differ from estimates, although management
does not generally believe such differences would materially affect the financial statements in any given year. However, in regard
to the valuation of derivative liabilities determined using various valuation techniques including the Black-Scholes and binomial
pricing methodologies, significant fluctuations may materially affect the financial statements in a given year. The Company considers
such valuations to be significant estimates.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">The Company evaluates financial assets and liabilities subject to fair value
measurements in accordance with a fair value hierarchy to prioritize the inputs used to measure fair value. A financial instrument&#8217;s
level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level
1 is the highest and Level 3 is the lowest. See Note 12 for the definition of levels and the classification of assets and liabilities
in those levels.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation cost for all stock-based awards
is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &#8220;Compensation &#8211; Stock
Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes
model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost
is recognized on the straight line allocation method as expense over the requisite service or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments issued to non-employees are
accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non-Employees.&#8221; Accordingly, compensation is
recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of
award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the
measurement date and the expected life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has Incentive Stock Option Plans,
Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,
these Plans are collectively referred to as the &#8220;Plans.&#8221; All Plans have been approved by the Company&#8217;s stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock options are not transferable,
and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on
the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of
daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at
date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and
employee termination within the valuation model. The expected term of options represents the period of time that options granted
are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions
used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in
the future from that recorded in the current period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vesting of restricted stock granted under the
Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.
These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is
probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued Accounting Standards
Update (ASU) 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i> that will supersede virtually all recognition guidance
in US GAAP. For public entities, the guidance is effective for annual and interim periods beginning after December 15, 2017. Early
adoption is permitted for all entities for annual and interim periods beginning after December 15, 2016. The FASB issued the following
ASUs to amend the new guidance: ASU 2015-14, <i>Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,</i>
ASU 2016-08, <i>Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross
versus Net),</i> ASU 2016-10<i>, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,
and</i> ASU 2016-12<i>, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.</i>
Management does not expect the new standard or any of the related updates to have a material effect on its financial statements
and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, the FASB issued Accounting
Standards Update (ASU) No. 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities.</i> The new guidance is intended to improve the recognition and measurement of financial
instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within
those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new
standard to have a material effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases</i>,
which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance
sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases
are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December
15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning
with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial
statements and related disclosures.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No. 2016-09,
<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> ASU 2016-09 simplifies
several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification
of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective
for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The
Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 amends eight specific
cash flow issues: 1.) Debt Prepayment or Debt Extinguishment Costs, 2.) Settlement of Zero-Coupon Debt Instruments or Other Debt
Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing, 3.)
Contingent Consideration Payments Made after a Business Combination, 4.) Proceeds from the Settlement of Insurance Claims, 5.)
Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned Life Insurance Policies, 6.) Distributions
Received from Equity Method Investees, 7.) Beneficial Interests in Securitization Transactions, 8.) Separately Identifiable Cash
Flows and Application of the Predominance Principle. Management does not expect the adoption of the amendments in this Update to
have a material effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during
the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.
Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash
equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The
amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim
periods within those fiscal years. Management does not expect the adoption of the amendments in this Update to have a material
effect on its financial statements and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has considered all other recently
issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial
statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="margin: 0"><font style="font-size: 8pt">Certain prior year items have been reclassified to conform to the current year
presentation.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_Deposits2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_Deposits2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65670824&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750999248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding', window );">Derivative liabilities, warrants and other options outstanding</a></td>
<td class="text"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">The
following chart represents the warrants and non-employee options outstanding at September 30, 2016:</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"><font style="font: 8pt Times New Roman, Times, Serif"><u>Warrant</u></font></td>
    <td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Issue
    <u>Date</u></font></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Shares
    Issuable upon Exercise of <u>Warrant</u></font></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    <u>Price</u></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Expiration
    Date</u></font></td>
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Refer-ence</u></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    R</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">105,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$100.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/13
    -10/24/14 </font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,037,010</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$31.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4/17/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">17,821</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$3.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/17/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">810,127</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$19.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    W</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">688,930</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$16.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    X</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1/13/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">120,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$9.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1/13/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Y</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/15/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">26,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$12.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/15/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Z</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/23/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">264,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11/23/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    ZZ</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/23/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/18/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    AA</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/26/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/22/22</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    BB</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/26/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">16,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/22/21</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    N</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/08</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">113,785</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$0.53</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    P</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/10/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,600</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$4,112.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3/6/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Consultants</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/2/11-
    7/1/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,600</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$9.25-&#160;&#160;$87.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/27/16-
    6/30/19</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="font-size: 8pt">The
following chart represents the warrants and non-employee options outstanding at September 30, 2015:</font></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"><font style="font: 8pt Times New Roman, Times, Serif"><u>Warrants</u></font></td>
    <td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Issue
    Date</u></font></td>
    <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Shares
    Issuable upon Exercise of <u>Warrants</u></font></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    <u>Price</u></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Expiration
    Date</u></font></td>
    <td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>Refer-ence</u></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    N</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/08</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">113,785</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$13.18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8/18/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    Q</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6/21/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,200,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$125.00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/22/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    R</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,625,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$100..00</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">12/6/16</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    S</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/13-
    10/24/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,928,010</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$31.25</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/11/18</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    U</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4/17/14</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">445,514</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$43.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/17/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    V</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/15</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">20,253,164</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$19.75</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5/28/20</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">1</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Series
    P</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2/10/12</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">590,001</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;$112.50</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3/6/17</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Consultants</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/14/05
    &#8211; 7/1/15 </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">238,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">$16.50
    &#8211; $500.00</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">10/14/15
    - 6/30/18</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">3</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,111,361</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">7,363,555</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44,551</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,620,253</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6,278,481</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,799,858</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">970,604</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">70,609</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">763,661</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">58,588</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Total derivative liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">8,394,934</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">13,686,587</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Warrant Series</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 61%"><font style="font-size: 8pt">Series A - E</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">6,105</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series F and G</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">12,667</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series H</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">12,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series N</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(1,404,027</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Q</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">12,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">36,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series R</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">157,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">131,250</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series S</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,252,193</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(1,705,466</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,098,787</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series T</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">276,122</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44,552</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">75,738</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">73,967</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,658,228</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,724,739</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3,260,913</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">997,226</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">75,229</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">672,246</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">53,139</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Net gain</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">14,013,726</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">282,616</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">248,767</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800443280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Research and office equipment</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Manufacturing building&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">21,183,756&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">21,783,756&#160;</font></td>
    <td><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Research equipment</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt"></font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,158,633</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt"></font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,268,757</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Furniture and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">133,499</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">141,347</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leasehold improvements</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">131,910</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">131,910</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,607,798</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,725,770</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation and amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,256,962</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(6,779,939</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net plant, property and equipment</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,350,836</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,945,831</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750999248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsTablesAbstract', window );"><strong>Patents Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Patents</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Patents</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,528,610</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,525,791</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,272,063.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,234,227.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net Patents</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">256,547</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">291,564</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Years ending September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">37,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">36,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">31,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">28,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">257,000</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752991344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Net deferred tax asset</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Net operating loss carryforwards</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">64,366,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">61,363,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">R&#38;D credit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,221,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,221,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock-based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6,379,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,855,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Capitalized R&#38;D</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,508,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,082,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vacation and other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">179,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">114,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Loan modification</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">57,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">90,653 ,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,692,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets and intangibles</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(49,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(86,000</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax liabilities</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(49,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(86,000</font></td>
    <td><font style="font-size: 8pt">)</font><br />
<br />
</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(90,604,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(83,606,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net deferred tax asset</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of effective tax rate</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 61%"><font style="font-size: 8pt">Federal Rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 8pt">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3.92</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.12</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.15</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate change</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(22.00</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.15</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.93</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Other adjustments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.03</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.21</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Adjustment to deferreds</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">19.13</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Permanent differences (1)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44.90</font><br />
<br />
</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.71</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(0.43</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(60.79</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(38.05</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(58.78</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Effective tax rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">0.00</font></td>
    <td><font style="font-size: 8pt">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783953104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock', window );">Employees and non-employees stock compensation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Year Ended September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%"><font style="font-size: 8pt">Employees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,113,433</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,105,827</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,958,637</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-employees</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">751,651</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">565,915</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">771,946</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Pricing</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">&#160;<font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><font style="font: 8pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; width: 58%; text-align: justify"><font style="font-size: 8pt">Expected stock price volatility</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; 75.58&#160;&#8211;&#160;80.9%</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font-size: 8pt">&#160; &#160; 73.38 &#8211; 86.19%</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right"><font style="font-size: 8pt">&#160; &#160; 72.81 &#8211; 86.87%</font></td>
    <td style="width: 1%">&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 8pt">Risk-free interest rate</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; 0.71 &#8211; 1.56%</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; 0.93 &#8211; 2.35%</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; 0.59 &#8211; 2.65%</font></td>
    <td>&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 8pt">Expected life of options</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160;3.0 &#8211; 9.69 Years&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.0 &#8211; 9.76 Years</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3.0 &#8211; 9.76 Years</font></td>
    <td>&#160;</td>
    </tr>
<tr>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 8pt">Expected dividend yield</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; -&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; -&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">&#160; &#160; -&#160;</font></td>
    <td>&#160;</td>
    </tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Plans</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="15" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Outstanding</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercisable</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font><br />
<font style="font-size: 8pt"><b>Average</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font><br />
<font style="font-size: 8pt"><b>Intrinsic</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font><br />
<font style="font-size: 8pt"><b>Average</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font><br />
<font style="font-size: 8pt"><b>Intrinsic</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Outstanding at October 1, 2014</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">273,246</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">74.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6.55</font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3,600</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">137,755</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">85.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.49</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3,600</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,134</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">62.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (a)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,748</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">16.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">54,667</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">6.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,820</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">103.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,820</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">103.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Outstanding at September 30, 2015</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">301,507</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">67.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.98</font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">181,070</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">78.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.01</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">0</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">56,069</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">31.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (b)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">48,544</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,240</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">21.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">145.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">145.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Outstanding at September 30, 2016</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">343,571</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">59.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5.35</font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">0</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">232,898</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">66.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4.76</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">0</font></td>
    <td>&#160;</td></tr>
<tr>
    <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 8pt">(a)</font></td>
    <td colspan="12" style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt">Includes 90,000 stock options granted to consultants</font></td>
    <td colspan="21">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="width: 3px">&#160;</td>
    <td style="width: 3px">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 72px; padding: 0.75pt"><font style="font-size: 8pt">(b)</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt">Includes 410,000 stock options granted to consultants</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleOfNonvestedOptionsTableTextBlock', window );">Schedule of non-vested options</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Weighted Average</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Grant Date</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Unvested at October 1, 2014</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">134,491</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">53.75</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(46,134</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,748</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(4,667</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2015</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">120,438</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">43.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(56,069</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">48,544</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(2,240</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">110,673</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">37.00</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock units</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Number of Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Grant Date Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%; text-align: justify"><font style="font-size: 8pt">Unvested at October 1, 2014</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">628,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">13.75</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(20,000</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(4,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2015</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">13.75</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">13.75</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleOfNonvestedOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleOfNonvestedOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790722960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future minimum lease payments under the San Tomas lease</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Years ending September 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,687,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,747,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,808,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,872,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,937,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">15,762,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,813,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less imputed interest on financing obligation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(11,802,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net present value of lease financing obligation</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">13,011,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum annual rental payments due under non-cancelable operating leases</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">243,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">251,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">258,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">238,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">163,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">69,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total minimum lease payments:</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">1,222,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6627563376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsTablesAbstract', window );"><strong>Fair Value Measurements Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities measured
at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 56%">&#160;</td>
    <td style="width: 11%; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in</b></font></td>
    <td style="width: 14%; text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Significant</b></font></td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 11%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Active Markets for</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Other</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Significant</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Identical Assets or</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Observable</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Unobservable</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Liabilities&#160;(Level&#160;1)</b></font></td>
    <td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"><font style="font-size: 8pt"><b>Inputs&#160;(Level&#160;2)</b></font></td>
    <td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"><font style="font-size: 8pt"><b>Inputs&#160;(Level&#160;3)</b></font></td>
    <td style="text-align: center; border-bottom: Black 1pt solid; vertical-align: middle"><font style="font-size: 8pt"><b>Total</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: middle"><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">$3,111,361</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-&#160;</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">$5,283,573</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">$8,394,934</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities measured
at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 55%">&#160;</td>
    <td style="width: 10%; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Quoted&#160;Prices&#160;in</b></font></td>
    <td style="width: 13%; text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Significant</b></font></td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 7%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Active&#160;Markets&#160;for</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Other</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Significant</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Identical Assets or</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Observable</b></font></td>
    <td style="text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Unobservable</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Liabilities&#160;(Level&#160;1)</b></font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Inputs&#160;(Level&#160;2)</b></font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Inputs&#160;(Level&#160;3)</b></font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"><font style="font-size: 8pt"><b>Total</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: middle"><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">$7,365,555</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">$6,323,032</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; vertical-align: middle"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;$13,686,587</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Beginning balance</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">6,323,032</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">307,894</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;Issuances</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,722,073</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,003,220</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Net realized and unrealized derivative gain</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(9,761,532</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,988,082</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending balance</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">$6,323,032</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800640880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NetLossPerCommonShareTablesAbstract', window );"><strong>Net Loss Per Common Share Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings per share</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2016</font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2015</font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="width: 15%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">2014</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders &#8211; Restated (1)</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(28,470,126)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Less:&#160;&#160;Gain
    on derivative instruments</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(248,767)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders &#8211; diluted (restated)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;(28,718,893)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average number of shares - basic and diluted</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,866,204</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,300,761</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,352,185</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    per share &#8211; basic (restated)</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.10)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    per share &#8211; diluted (restated)</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.21)</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin-top: 0; margin-bottom: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(1)
See Note 16 Restatement</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Courier New, Courier, Monospace; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>2016</u></font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>2015</u></font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><u>2014</u></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Options
    and Warrants &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,675,281</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,336,842</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,599,788</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Convertible
    Debt</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">74,851</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,041</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Unvested
    Restricted Stock</font></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">628,000</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td>
    <td style="border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">4,279,281</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">3,015,693</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">2,238,829</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NetLossPerCommonShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NetLossPerCommonShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790820080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. QUARTERLY INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly information</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b>Fiscal 2016
(restated)</b></font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended December 31, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended March 31, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended June 30, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 11%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended September 30, 2016 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 18.5pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Year
    ended September 30, 2016 </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Grant
    and other income</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,976
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32,775
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;129,975
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;101,329
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;285,055
    </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating
    expenses</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,327,509</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,829,779</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;6,036,123</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;6,738,472</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,931,883</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Non-operating
    (expenses) income, net</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(483,693)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(464,796)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(464,202)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(466,699)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(1,879,390)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    (loss) on derivatives</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;8,122,960
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;(2,593,730)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;2,508,744
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,975,752
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;14,013,726
    </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    income (loss) available to common shareholders</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;2,332,734</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (8,855,530)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (3,861,606)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (1,128,090)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$
    (11,512,492)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">EPS
    (LPS) - basic and diluted</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.53</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.87)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.78)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(0.21)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average shares:</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Basic</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,390,740</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,736,809</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,965,300</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,371,635</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,866,204</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Diluted</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,465,591</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,736,809</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;4,965,300</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;5,371,635</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,866,204</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b>&#160;</b></font></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b>Fiscal 2015
(restated)</b></font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended December 31, 2014 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended March 31, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended June 30, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Three
    months ended September 30, 2015 </font></td>
    <td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td style="width: 12%; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Year
    ended September 30, 2015 </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Grant
    and other income</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;136,838
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;197,620
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;389,223
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(66,304)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;657,377
    </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating
    expenses</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,655,979</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,480,363</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,114,099</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,797,084</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,047,525</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Non-operating
    (expenses) income, net</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(490,812)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(494,156)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(497,040)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(482,213)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,964,221)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    (loss) on derivatives</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,162,970
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,782,796)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,428,780
    </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,526,338)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;282,616
    </font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Loss
    on debt extinguishment</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(620,457)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(620,457)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net
    loss available to common shareholders</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,846,983)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;(12,559,695)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,413,593)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,871,939)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">LPS
    - basic</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.68)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4.14)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.32)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.54)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">LPS
    - diluted</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3.42)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4.14)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1.62)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.54)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 2.25pt double; font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    average shares:</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Basic</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,930,431</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,033,915</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,351,852</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,881,600</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,300,761</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Diluted</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,930,431</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,033,915</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,405,364</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,881,600</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 8pt">&#160;</font></td>
    <td nowrap="nowrap" style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,300,761</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></p>



<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771592656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. RESTATEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RestatementTablesAbstract', window );"><strong>Restatement Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Restatements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: top; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">9/30/2016</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">PREVIOUSLY REPORTED</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total current assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,887,646 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(429,821)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,457,825 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Other assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,710,601 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,717,699 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,428,300 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11,598,247 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,287,878 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,886,125 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total liabilities</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,554,315 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,011,023 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,565,338 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Stockholders' deficit, September 30, 2016</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(956,068)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;276,855</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(679,213)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">9/30/2015</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Balance Sheet</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total current assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,833,183 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(487,793)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,345,390 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Other assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,614,420 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,593,892 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,208,312 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total assets</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,447,603 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,106,099 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28,553,702 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total liabilities</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,532,722 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,783,250 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,315,972 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Stockholders' deficit, September 30, 2015</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5,085,119)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;322,850 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,762,270)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2016</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 21%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,351,779 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,445,382 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,838,280 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,931,883 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,553,225)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,397</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(23,646,828)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;73,001 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,952,391)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,879,390)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,466,498)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(45,994)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic and diluted</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.36)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2.37)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2015</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,098,147 </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,191,750 </font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;34,953,922 </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,397)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,047,525 </font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,296,545)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,397</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(32,390,148)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(40,260) </font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,923,961)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,964,221)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,674,646)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(17,564)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic and diluted</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(10.51)</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">YEAR ENDED 9/30/2014</font></td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">PREVIOUSLY</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORTED</p></td>
    <td nowrap="nowrap" style="vertical-align: bottom; width: 19%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="vertical-align: top; width: 18%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">RESTATED</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Research and development expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,172,587 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,398)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,266,189 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Total operating expenses</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27,838,145 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,906,398)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,931,747 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,574,112)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,906,398</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(25,667,714)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Interest income (expense), net</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(40,920)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,892,812)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,933,732)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,366,265)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,586</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, basic</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.11)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.10)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss per common share, diluted</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.22)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(12.21)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Accumulated</font></td>
    <td nowrap="nowrap" style="width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Total Stockholders' </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Deficit</font></td>
    <td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Equity (Deficit)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">PREVIOUSLY REPORTED, OCTOBER 1, 2013</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(212,160,568)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,700,090 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">ADJUSTMENT</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;326,827 </font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;326,827 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">RESTATED BALANCE, OCTOBER 1, 2013</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(211,833,741)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,026,917 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2014 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;31,109,575 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss &#8211; RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,352,679)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2014</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(239,186,420)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,783,813 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2015 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19,146,127 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss - RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(34,692,210)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2015</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(273,878,630)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,762,270)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">2016 equity transactions - unchanged</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,595,549 </font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">Net loss - RESTATED</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,512,492)</font></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">BALANCE, SEPTEMBER 30, 2016</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(285,391,122)</font></td>
    <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(679,213)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RestatementTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RestatementTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641974144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract', window );"><strong>Summary Of Significant Accounting Policies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FullyInsuredAmountOfNoninterestBearingCashBalances', window );">Fully Insured Amount of non-interest bearing cash balances</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FullyInsuredAmountOfNoninterestBearingCashBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FullyInsuredAmountOfNoninterestBearingCashBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812052880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 18,  2008<span></span>
</td>
<td class="text">Aug. 18,  2008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">113,785<span></span>
</td>
<td class="nump">113,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.18<span></span>
</td>
<td class="nump">$ 13.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 18,  2017<span></span>
</td>
<td class="text">Aug. 18,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember', window );">Series Q [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 125.00<span></span>
</td>
<td class="nump">$ 125.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 22,  2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember', window );">SeriesRMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Dec.  06,  2012<span></span>
</td>
<td class="text">Dec.  06,  2012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 100.00<span></span>
</td>
<td class="nump">$ 100.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Dec.  06,  2016<span></span>
</td>
<td class="text">Dec.  06,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">1,037,120<span></span>
</td>
<td class="nump">1,037,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="nump">$ 31.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 11,  2018<span></span>
</td>
<td class="text">Oct. 11,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">Oct. 11,  2013<span></span>
</td>
<td class="text">Oct. 11,  2013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">Oct. 24,  2014<span></span>
</td>
<td class="text">Oct. 24,  2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember', window );">Series U [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Apr. 17,  2014<span></span>
</td>
<td class="text">Apr. 17,  2014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">17,821<span></span>
</td>
<td class="nump">17,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 43.75<span></span>
</td>
<td class="nump">$ 43.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 17,  2017<span></span>
</td>
<td class="text">Oct. 17,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 28,  2015<span></span>
</td>
<td class="text">May 28,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">810,127<span></span>
</td>
<td class="nump">810,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 19.75<span></span>
</td>
<td class="nump">$ 19.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">May 28,  2020<span></span>
</td>
<td class="text">May 28,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember', window );">Series P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Feb. 10,  2012<span></span>
</td>
<td class="text">Feb. 10,  2012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">23,600<span></span>
</td>
<td class="nump">23,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 112.50<span></span>
</td>
<td class="nump">$ 112.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Mar.  06,  2017<span></span>
</td>
<td class="text">Mar.  06,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">9,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">Dec.  02,  2011<span></span>
</td>
<td class="text">Oct. 14,  2005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">Jul.  01,  2016<span></span>
</td>
<td class="text">Jul.  01,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationStartDate', window );">Expiration start date</a></td>
<td class="text">Oct. 27,  2016<span></span>
</td>
<td class="text">Oct. 14,  2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationEndDate', window );">Expiration end date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">Jun. 30,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMinimum', window );">Exercise Price Minimum</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 16.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMaximum', window );">Exercise Price Maximum</a></td>
<td class="nump">$ 87.50<span></span>
</td>
<td class="nump">$ 500.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Oct. 28,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">810,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Jan. 13,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Jan. 13,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Feb. 15,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 23,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Nov. 23,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 23,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">May 18,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 26,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 22,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 26,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 22,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssueEndDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssueEndDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssueStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssueStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_Issuedate2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_Issuedate2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issuable Upon Exercise Of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6601496992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract', window );"><strong>Forfeited shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesSWarrants', window );">Series S warrants</a></td>
<td class="nump">$ 3,111,361<span></span>
</td>
<td class="nump">$ 7,363,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesUWarrants', window );">Series U warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesVWarrants', window );">Series V warrants</a></td>
<td class="nump">1,620,253<span></span>
</td>
<td class="nump">6,278,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesWWarrants', window );">Series W warrants</a></td>
<td class="nump">1,779,858<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesZWarrants', window );">Series Z warrants</a></td>
<td class="nump">970,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesZZWarrants', window );">Series ZZ warrants</a></td>
<td class="nump">70,609<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesAAWarrants', window );">Series AA warrants</a></td>
<td class="nump">763,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofSeriesBBWarrants', window );">Series BB warrants</a></td>
<td class="nump">58,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_TotalFairvalueofDerivativeLiabilities', window );">Total derivative liabilities</a></td>
<td class="nump">$ 8,394,934<span></span>
</td>
<td class="nump">$ 13,686,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesSWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesSWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesAAWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesAAWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesBBWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesBBWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesUWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesUWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesVWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesVWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesWWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesWWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesZWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesZWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofSeriesZZWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofSeriesZZWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_TotalFairvalueofDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_TotalFairvalueofDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811714160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="nump">$ 5,975,752<span></span>
</td>
<td class="nump">$ 2,508,744<span></span>
</td>
<td class="num">$ (2,593,730)<span></span>
</td>
<td class="nump">$ 8,122,960<span></span>
</td>
<td class="num">$ (1,526,338)<span></span>
</td>
<td class="nump">$ 4,428,780<span></span>
</td>
<td class="num">$ (4,782,796)<span></span>
</td>
<td class="nump">$ 2,162,970<span></span>
</td>
<td class="nump">$ 14,013,726<span></span>
</td>
<td class="nump">$ 282,616<span></span>
</td>
<td class="nump">$ 248,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAThroughEWarrantsMember', window );">Series A through E warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,105<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,404,027)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFAndGWarrantsMember', window );">SeriesFAndGWarrantsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHMember', window );">Series H [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesTMember', window );">Series T [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">276,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember', window );">Series Q [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember', window );">SeriesRMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">157,500<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,252,193<span></span>
</td>
<td class="num">(1,705,466)<span></span>
</td>
<td class="nump">1,098,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember', window );">Series U [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,552<span></span>
</td>
<td class="nump">75,738<span></span>
</td>
<td class="nump">73,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,658,228<span></span>
</td>
<td class="nump">1,724,739<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,260,913<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,229<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,246<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,139<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAThroughEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAThroughEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFAndGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFAndGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800470288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EmployeeBenefitPlanDetailsNarrativeAbstract', window );"><strong>Warrants And Non-employee Options Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on warrants</a></td>
<td class="nump">$ 14,013,726<span></span>
</td>
<td class="nump">$ 282,616<span></span>
</td>
<td class="nump">$ 248,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_EmployeeBenefitPlanDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_EmployeeBenefitPlanDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811919728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ResearchAndOfficeEquipmentDetailsAbstract', window );"><strong>Plant Property And Equipment Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Manufacturing building</a></td>
<td class="nump">$ 21,183,756<span></span>
</td>
<td class="nump">$ 21,183,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Research equipment</a></td>
<td class="nump">3,158,633<span></span>
</td>
<td class="nump">3,268,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">133,499<span></span>
</td>
<td class="nump">141,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">131,910<span></span>
</td>
<td class="nump">131,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross</a></td>
<td class="nump">24,607,798<span></span>
</td>
<td class="nump">24,725,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(7,256,962)<span></span>
</td>
<td class="num">(6,779,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net plant, property and equipment</a></td>
<td class="nump">$ 17,350,836<span></span>
</td>
<td class="nump">$ 17,945,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ResearchAndOfficeEquipmentDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ResearchAndOfficeEquipmentDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753212592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract', window );"><strong>Plant Property And Equipment Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 626,000<span></span>
</td>
<td class="nump">$ 680,000<span></span>
</td>
<td class="nump">$ 703,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783320176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>6. PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 1,258,610<span></span>
</td>
<td class="nump">$ 1,525,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,272,063)<span></span>
</td>
<td class="num">(1,234,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Patents</a></td>
<td class="nump">$ 256,547<span></span>
</td>
<td class="nump">$ 291,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811545760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>6. PATENTS (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsAbstract', window );"><strong>Patents Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2017</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2018</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2019</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2020</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2021</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 256,547<span></span>
</td>
<td class="nump">$ 291,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750528752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsNarrativeAbstract', window );"><strong>Patents Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 40,471<span></span>
</td>
<td class="nump">$ 42,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798512064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>7. INCOME TAXES Net deferred tax asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract', window );"><strong>Income Taxes Net Deferred Tax Asset Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,366,000<span></span>
</td>
<td class="nump">$ 61,363,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit</a></td>
<td class="nump">1,221,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,379,000<span></span>
</td>
<td class="nump">5,855,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd', window );">Capitalized R&amp;D</a></td>
<td class="nump">18,508,000<span></span>
</td>
<td class="nump">15,082,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation and other</a></td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LoanModification', window );">Loan modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">90,653,000<span></span>
</td>
<td class="nump">83,692,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Fixed assets and intangibles</a></td>
<td class="num">(49,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(49,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(90,604,000)<span></span>
</td>
<td class="num">(83,606,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LoanModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LoanModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798227392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. INCOME TAXES Reconciliation of effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract', window );"><strong>Income Taxes Reconciliation Of Effective Tax Rate Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">5.12%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State tax rate change</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(0.15%)<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.03%)<span></span>
</td>
<td class="num">(0.21%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds', window );">Adjustment to Deferreds</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">19.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">44.90%<span></span>
</td>
<td class="num">(0.71%)<span></span>
</td>
<td class="num">(0.43%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(60.79%)<span></span>
</td>
<td class="num">(38.05%)<span></span>
</td>
<td class="num">(58.78%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798017536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION Awards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityDetails1Abstract', window );"><strong>Stock Compensation Awards Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employees</a></td>
<td class="nump">$ 2,113,433<span></span>
</td>
<td class="nump">$ 5,105,827<span></span>
</td>
<td class="nump">$ 3,958,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NonemployeesShareBasedCompensation', window );">Non-employees</a></td>
<td class="nump">$ 751,651<span></span>
</td>
<td class="nump">$ 565,915<span></span>
</td>
<td class="nump">$ 771,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NonemployeesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NonemployeesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751294992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationDetailsAbstract', window );"><strong>Stock Compensation Assumptions Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, min</a></td>
<td class="nump">75.58%<span></span>
</td>
<td class="nump">73.38%<span></span>
</td>
<td class="nump">72.81%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, max</a></td>
<td class="nump">80.90%<span></span>
</td>
<td class="nump">86.19%<span></span>
</td>
<td class="nump">86.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, min</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, max</a></td>
<td class="nump">1.56%<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpectedLifeOfOptionsMin1', window );">Expected life of options, min</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpectedLifeOfOptionsMax', window );">Expected life of options, max</a></td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
<td class="text">9 years 9 months 4 days<span></span>
</td>
<td class="text">9 years 9 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpectedLifeOfOptionsMax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpectedLifeOfOptionsMax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpectedLifeOfOptionsMin1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpectedLifeOfOptionsMin1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797599168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">301,507<span></span>
</td>
<td class="nump">273,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">48,544<span></span>
</td>
<td class="nump">35,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Forfeited</a></td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">54,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStocksExpired', window );">Number of Options Expired</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">343,571<span></span>
</td>
<td class="nump">301,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 67.75<span></span>
</td>
<td class="nump">$ 74.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">12.00<span></span>
</td>
<td class="nump">16.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">21.50<span></span>
</td>
<td class="nump">46.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">145.00<span></span>
</td>
<td class="nump">103.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 59.25<span></span>
</td>
<td class="nump">$ 67.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</a></td>
<td class="text">5 years 4 months 6 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">181,070<span></span>
</td>
<td class="nump">137,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStockVested', window );">Number of Options Vested</a></td>
<td class="nump">56,069<span></span>
</td>
<td class="nump">46,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStocksExpired', window );">Number of Options Expired</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">232,898<span></span>
</td>
<td class="nump">181,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 78.75<span></span>
</td>
<td class="nump">$ 85.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceVested', window );">Weighted Average Exercise Price Vested</a></td>
<td class="nump">31.75<span></span>
</td>
<td class="nump">62.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">145.00<span></span>
</td>
<td class="nump">103.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 66.25<span></span>
</td>
<td class="nump">$ 78.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</a></td>
<td class="text">5 years 4 days<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</a></td>
<td class="text">4 years 9 months 4 days<span></span>
</td>
<td class="text">5 years 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfStocksExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfStocksExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800455136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION Nonvested Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationNonvestedOptionsDetailsAbstract', window );"><strong>Stock Compensation Nonvested Options Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedOptionsBeginning', window );">Number of unvested options, Beginning</a></td>
<td class="nump">120,438<span></span>
</td>
<td class="nump">135,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_VestedOptions', window );">Vested options</a></td>
<td class="num">(56,069)<span></span>
</td>
<td class="num">(46,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GrantedOptions', window );">Granted options</a></td>
<td class="nump">48,544<span></span>
</td>
<td class="nump">35,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ForfeitedOptions', window );">Forfeited options</a></td>
<td class="num">(2,240)<span></span>
</td>
<td class="num">(4,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedOptionsEnding', window );">Number of unvested options, Ending</a></td>
<td class="nump">110,673<span></span>
</td>
<td class="nump">120,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueBeginning', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 43.00<span></span>
</td>
<td class="nump">$ 53.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 37.00<span></span>
</td>
<td class="nump">$ 43.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ForfeitedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ForfeitedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedOptionsBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedOptionsBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedOptionsEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedOptionsEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationNonvestedOptionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationNonvestedOptionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_VestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_VestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageGrantDateFairValueBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageGrantDateFairValueBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageGrantDateFairValueEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageGrantDateFairValueEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6642091104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION RSU (Details) - Restricted Stock Awards [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedSharesBeginning', window );">Number of unvested shares, Beginning</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">628,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_VestedShares', window );">Vested shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GrantedShares', window );">Granted shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ForfeitedShares', window );">Forfeited shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedSharesEnding', window );">Number of unvested shares, Ending</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GrantedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GrantedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RestrictedStockAwardWeightedAverageGrantDateFairValueEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790963184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. STOCK COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationDetailsNarrativeAbstract', window );"><strong>Stock Compensation Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Expense relating to the restricted stock</a></td>
<td class="nump">$ 634,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">5 years 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790751840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefits and Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense for Company's contribution to employee benefit plan</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789450096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>10. COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesDetailsAbstract', window );"><strong>Commitments And Contingencies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2017</a></td>
<td class="nump">$ 1,687,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2018</a></td>
<td class="nump">1,747,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2019</a></td>
<td class="nump">1,808,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2020</a></td>
<td class="nump">1,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2021</a></td>
<td class="nump">1,937,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15,762,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Total future minimum lease obligation</a></td>
<td class="nump">24,813,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less imputed interest on financing obligation</a></td>
<td class="num">(11,802,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Net present value of lease financing obligation</a></td>
<td class="nump">$ 13,011,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785944656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>10. COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesDetailsAbstract', window );"><strong>Commitments And Contingencies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2017</a></td>
<td class="nump">$ 243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2018</a></td>
<td class="nump">251,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2019</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2020</a></td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2021</a></td>
<td class="nump">163,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments:</a></td>
<td class="nump">$ 1,222,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800529728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 17,445,382<span></span>
</td>
<td class="nump">$ 19,191,750<span></span>
</td>
<td class="nump">$ 15,266,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RDDeferredRentLiability', window );">R &amp; D deferred rent liability</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DeferredRentLiability', window );">Deferred rent liability</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Ergomed Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RDDeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RDDeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800468224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>13. FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level1Member', window );">Level1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 3,111,361<span></span>
</td>
<td class="nump">$ 7,363,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level2Member', window );">Level2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level3Member', window );">Level3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">5,283,573<span></span>
</td>
<td class="nump">6,323,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_TotalMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 8,394,934<span></span>
</td>
<td class="nump">$ 13,686,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_Level3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=CVM_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811372704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsDetails1Abstract', window );"><strong>Fair Value Measurements Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 6,323,032<span></span>
</td>
<td class="nump">$ 307,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">8,722,073<span></span>
</td>
<td class="nump">8,003,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Net realized and unrealized derivative (gain)/loss</a></td>
<td class="num">(9,761,532)<span></span>
</td>
<td class="num">(1,988,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 5,283,573<span></span>
</td>
<td class="nump">$ 6,323,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808536512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. NET LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_I.EarningsPerShareDetailsAbstract', window );"><strong>Net Loss Per Common Share Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss - available to common shareholders</a></td>
<td class="num">$ (1,128,090)<span></span>
</td>
<td class="num">$ (3,861,606)<span></span>
</td>
<td class="num">$ (8,855,530)<span></span>
</td>
<td class="nump">$ 2,332,734<span></span>
</td>
<td class="num">$ (9,871,939)<span></span>
</td>
<td class="num">$ (4,413,593)<span></span>
</td>
<td class="num">$ (12,559,695)<span></span>
</td>
<td class="num">$ (7,846,983)<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (28,470,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Less: Gain on derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(248,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss - diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (28,718,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
<td class="nump">3,300,761<span></span>
</td>
<td class="nump">2,352,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="num">$ (12.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(10.51)<span></span>
</td>
<td class="num">$ (12.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">EPS (LPS) - Basic and Diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_I.EarningsPerShareDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_I.EarningsPerShareDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800553648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. NET LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_I.EarningsPerShareDetailsNarrativeAbstract', window );"><strong>Net Loss Per Common Share Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_OptionsAndWarrantsExcludedFromEarningsPerShare', window );">Options and warrants excluded from earnings per share due to anti-dilutive effect</a></td>
<td class="nump">3,675,281<span></span>
</td>
<td class="nump">2,336,842<span></span>
</td>
<td class="nump">1,599,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AntidilutiveConvertibleDebt', window );">Convertible Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,851<span></span>
</td>
<td class="nump">11,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AntidilutiveUnvestedRestrictedStock', window );">Unvested Restricted Stock</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">628,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,279,281<span></span>
</td>
<td class="nump">3,015,693<span></span>
</td>
<td class="nump">2,238,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AntidilutiveConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AntidilutiveConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AntidilutiveUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AntidilutiveUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_I.EarningsPerShareDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_I.EarningsPerShareDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_OptionsAndWarrantsExcludedFromEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_OptionsAndWarrantsExcludedFromEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798491376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. QUARTERLY INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_QuarterlyInformationDetailsAbstract', window );"><strong>Quarterly Information Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Grant income and other</a></td>
<td class="nump">$ 101,329<span></span>
</td>
<td class="nump">$ 129,975<span></span>
</td>
<td class="nump">$ 32,775<span></span>
</td>
<td class="nump">$ 20,976<span></span>
</td>
<td class="num">$ (66,304)<span></span>
</td>
<td class="nump">$ 389,223<span></span>
</td>
<td class="nump">$ 197,620<span></span>
</td>
<td class="nump">$ 136,838<span></span>
</td>
<td class="nump">$ 285,055<span></span>
</td>
<td class="nump">$ 657,377<span></span>
</td>
<td class="nump">$ 264,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">6,738,472<span></span>
</td>
<td class="nump">6,036,123<span></span>
</td>
<td class="nump">5,829,779<span></span>
</td>
<td class="nump">5,327,509<span></span>
</td>
<td class="nump">7,797,084<span></span>
</td>
<td class="nump">8,114,099<span></span>
</td>
<td class="nump">7,480,363<span></span>
</td>
<td class="nump">9,655,979<span></span>
</td>
<td class="nump">23,931,883<span></span>
</td>
<td class="nump">33,047,525<span></span>
</td>
<td class="nump">25,931,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Non-operating (expense) income, net</a></td>
<td class="num">(466,699)<span></span>
</td>
<td class="num">(464,202)<span></span>
</td>
<td class="num">(464,796)<span></span>
</td>
<td class="num">(483,693)<span></span>
</td>
<td class="num">(482,213)<span></span>
</td>
<td class="num">(497,040)<span></span>
</td>
<td class="num">(494,156)<span></span>
</td>
<td class="num">(490,812)<span></span>
</td>
<td class="num">(1,879,390)<span></span>
</td>
<td class="num">(1,964,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivatives</a></td>
<td class="nump">5,975,752<span></span>
</td>
<td class="nump">2,508,744<span></span>
</td>
<td class="num">(2,593,730)<span></span>
</td>
<td class="nump">8,122,960<span></span>
</td>
<td class="num">(1,526,338)<span></span>
</td>
<td class="nump">4,428,780<span></span>
</td>
<td class="num">(4,782,796)<span></span>
</td>
<td class="nump">2,162,970<span></span>
</td>
<td class="nump">14,013,726<span></span>
</td>
<td class="nump">282,616<span></span>
</td>
<td class="nump">248,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(620,457)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(620,457)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (1,128,090)<span></span>
</td>
<td class="num">$ (3,861,606)<span></span>
</td>
<td class="num">$ (8,855,530)<span></span>
</td>
<td class="nump">$ 2,332,734<span></span>
</td>
<td class="num">$ (9,871,939)<span></span>
</td>
<td class="num">$ (4,413,593)<span></span>
</td>
<td class="num">$ (12,559,695)<span></span>
</td>
<td class="num">$ (7,846,983)<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (28,470,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) per share-basic and diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share-basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(10.51)<span></span>
</td>
<td class="num">$ (12.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share-diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="num">$ (12.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares-basic</a></td>
<td class="nump">5,371,635<span></span>
</td>
<td class="nump">4,965,300<span></span>
</td>
<td class="nump">4,736,809<span></span>
</td>
<td class="nump">4,390,740<span></span>
</td>
<td class="nump">3,881,600<span></span>
</td>
<td class="nump">3,351,852<span></span>
</td>
<td class="nump">3,033,915<span></span>
</td>
<td class="nump">2,930,431<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
<td class="nump">3,300,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares-diluted</a></td>
<td class="nump">5,371,635<span></span>
</td>
<td class="nump">4,965,300<span></span>
</td>
<td class="nump">4,736,809<span></span>
</td>
<td class="nump">4,465,591<span></span>
</td>
<td class="nump">3,881,600<span></span>
</td>
<td class="nump">3,405,364<span></span>
</td>
<td class="nump">3,033,915<span></span>
</td>
<td class="nump">2,930,431<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
<td class="nump">3,300,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_QuarterlyInformationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_QuarterlyInformationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798931168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>17. RESTATEMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">$ 5,457,825<span></span>
</td>
<td class="nump">$ 8,345,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">19,428,300<span></span>
</td>
<td class="nump">20,208,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,886,125<span></span>
</td>
<td class="nump">28,553,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,565,338<span></span>
</td>
<td class="nump">33,315,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="num">(679,213)<span></span>
</td>
<td class="num">(4,762,270)<span></span>
</td>
<td class="nump">$ 10,783,813<span></span>
</td>
<td class="nump">$ 6,700,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,887,646<span></span>
</td>
<td class="nump">8,833,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">5,710,601<span></span>
</td>
<td class="nump">6,614,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,598,247<span></span>
</td>
<td class="nump">15,447,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,554,315<span></span>
</td>
<td class="nump">20,532,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="num">(956,068)<span></span>
</td>
<td class="num">(5,085,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="num">(429,821)<span></span>
</td>
<td class="num">(487,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">13,717,699<span></span>
</td>
<td class="nump">13,593,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,287,878<span></span>
</td>
<td class="nump">13,106,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,011,023<span></span>
</td>
<td class="nump">12,783,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="nump">$ 276,855<span></span>
</td>
<td class="nump">$ 322,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812020848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. RESTATEMENT (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,445,382<span></span>
</td>
<td class="nump">$ 19,191,750<span></span>
</td>
<td class="nump">$ 15,266,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 6,738,472<span></span>
</td>
<td class="nump">$ 6,036,123<span></span>
</td>
<td class="nump">$ 5,829,779<span></span>
</td>
<td class="nump">$ 5,327,509<span></span>
</td>
<td class="nump">$ 7,797,084<span></span>
</td>
<td class="nump">$ 8,114,099<span></span>
</td>
<td class="nump">$ 7,480,363<span></span>
</td>
<td class="nump">$ 9,655,979<span></span>
</td>
<td class="nump">23,931,883<span></span>
</td>
<td class="nump">33,047,525<span></span>
</td>
<td class="nump">25,931,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,646,828)<span></span>
</td>
<td class="num">(32,390,148)<span></span>
</td>
<td class="num">(25,667,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,879,390)<span></span>
</td>
<td class="num">(1,964,221)<span></span>
</td>
<td class="num">(1,933,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
<td class="num">$ (34,692,210)<span></span>
</td>
<td class="num">$ (27,352,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(10.51)<span></span>
</td>
<td class="num">$ (12.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (4.14)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="num">$ (12.21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,351,779<span></span>
</td>
<td class="nump">$ 21,098,147<span></span>
</td>
<td class="nump">$ 17,172,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,838,280<span></span>
</td>
<td class="nump">34,953,922<span></span>
</td>
<td class="nump">27,838,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,553,225)<span></span>
</td>
<td class="num">(34,296,545)<span></span>
</td>
<td class="num">(27,574,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,001<span></span>
</td>
<td class="num">(40,260)<span></span>
</td>
<td class="num">(40,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,466,498)<span></span>
</td>
<td class="num">$ (34,674,646)<span></span>
</td>
<td class="num">$ (27,366,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (10.51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,906,397)<span></span>
</td>
<td class="num">$ (1,906,397)<span></span>
</td>
<td class="num">$ (1,906,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,906,397)<span></span>
</td>
<td class="num">(1,906,397)<span></span>
</td>
<td class="num">(1,906,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,906,397<span></span>
</td>
<td class="nump">1,906,397<span></span>
</td>
<td class="nump">1,906,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,952,391)<span></span>
</td>
<td class="num">(1,923,961)<span></span>
</td>
<td class="num">(1,892,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,994)<span></span>
</td>
<td class="num">$ (17,564)<span></span>
</td>
<td class="nump">$ 13,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799542608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. RESTATEMENT (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_QuarterlyInformationDetails2Abstract', window );"><strong>Restatement Details 2</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit, beginning</a></td>
<td class="num">$ (273,878,630)<span></span>
</td>
<td class="num">$ (239,186,420)<span></span>
</td>
<td class="num">$ (211,833,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,512,492)<span></span>
</td>
<td class="num">(34,692,210)<span></span>
</td>
<td class="num">(27,352,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestatementOfPriorYearIncomeNetOfTax', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit, ending</a></td>
<td class="num">(285,391,122)<span></span>
</td>
<td class="num">(273,878,630)<span></span>
</td>
<td class="num">(239,186,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity, beginning</a></td>
<td class="num">(4,762,270)<span></span>
</td>
<td class="nump">10,783,813<span></span>
</td>
<td class="nump">6,700,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NetLoss', window );">Net loss</a></td>
<td class="num">(11,512,492)<span></span>
</td>
<td class="num">(34,692,210)<span></span>
</td>
<td class="num">(27,352,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RestatementOfPriorYearIncomeNet', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity transactions</a></td>
<td class="nump">15,595,549<span></span>
</td>
<td class="nump">19,146,127<span></span>
</td>
<td class="nump">31,109,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity, ending</a></td>
<td class="num">$ (679,213)<span></span>
</td>
<td class="num">$ (4,762,270)<span></span>
</td>
<td class="nump">$ 10,783,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_QuarterlyInformationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_QuarterlyInformationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RestatementOfPriorYearIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RestatementOfPriorYearIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestatementOfPriorYearIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Resulting effect of restatement to correct an error, after tax effects, on the net income of prior periods for the year in which any adjustments are first made. In statements containing more than one period, discloses the effects for each period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestatementOfPriorYearIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]-V'IM#N8?&U\%^PY^W47_!5!+ P04    " "HA(M+F5R<(Q &  "<)P
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M>)N$$?P]!S!T9M,):/ '0L,(_K9#F#D5V,,D"2-07P7 S%B$P%8GH9-IZJL
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M.@>M/N1PS_7BX?AA53^VW=N0WV\//Q([?&B;E_X'<)/CK_!N_P=02P,$%
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MCIK904.GFC?%M/3^=@E"EYB1:D[G%YAK!0M)HR7181,,Q\G[]GPVSLHH'.S
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M1QH D5A/M9:5##"J7:)EDY@XUGQCG! HM/0BT;6135EF'4 5V*NIUJH)1ZY
MD##!"!1:>KH!=(A-(H7F.98F'OY)_TA*F9*QM3%@G%$"X:G"%<)<(5 ..9GI
M$B !E\1116>@B\R2G0W265.6<87FC,G"@"Q>YKR,2)#D0<@<RHQ5ISI(QRZE
MFG/,%0;ED"S?9ZP+F7(I(B>M UTNG)8\1[I2A*50.Y;"0&/2B\Y70C-7CK9
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MOVSL?X7HP$M)KOP(-?Z#S8:$RH7C9W\VXYB-AL-N^D%L_L;Y7U!+ P04
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M@'0&[&,>-B:*RA^XXT5F<"!F['W'PQ,GA]3WI@S.V(IXY\5;[[T4R?XZ8Y=
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M@RV&A,:'XPV>[31FD^%-/_\@MGSC\B=02P,$%     @ J(2+2ZANTAZT 0
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M73C>^;,9QVPT'';3#V+S-RY^ 5!+ P04    " "HA(M+,+XQ];4!  #2 P
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M#L]N'+/1"+:;?A";OW'Q"U!+ P04    " "HA(M+?56Y#+0!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q]4]MNVS ,_15!'U E2M8%@6V@
MZ3"TP 8$';8]*S9M"]7%E>2X^_M1LNMYF[<72:1X#@\I*ANL>_8M0""O6AF?
MTS:$[LB8+UO0PM_8#@S>U-9I$=!T#?.= U$ED%:,;S:W3 MI:)$EW]D5F>V#
MD@;.COA>:^%^G$#9(:=;^N9XDDT;HH,562<:^ +A:W=V:+&9I9(:C)?6$ =U
M3N^VQ],^QJ> ;Q(&OSB36,G%VN=H/%8YW41!H* ,D4'@=H5[4"H2H8R7B9/.
M*2-P>7YC_YAJQUHNPL.]5=]E%=J<'BBIH!:]"D]V>("IGG>43,5_@BLH#(]*
M,$=IE4\K*7L?K)Y84(H6K^,N3=J'\69WF&#K #X!^ PXI#QL3)24?Q!!%)FS
M W%C[SL1GWA[Y-B;,CI3*](=BO?HO1;XH!F[1J(IYC3&\$7,=HY@R#ZGX&LI
M3OPO.%^'[U85[A)\]YO"?^3?KQ+L$\'^OR6NQ?RIDBUZJL$U:9H\*6UOTB0O
MO// WO'T)K_"QVG_+%PCC2<7&_!E4_]K:P.@E,T-CE"+'VPV%-0A'M_CV8UC
M-AK!=M,/8O,W+GX"4$L#!!0    ( *B$BTN2%J!WM0$  -(#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;&U3VV[<(!#]%<0'!"]V+EK9EK*IHE1J
MI56BML^L/;91N#B U^G?![#7<5._ #.<<^;"D(_:O-H.P*%W*90M<.=<OR?$
M5AU(9J]T#\K?--I(YKQI6F)[ ZR.)"D(39(;(AE7N,RC[VC*7 ].< 5'@^P@
M)3-_#R#T6. =OCB>>=NYX"!EWK,67L#]ZH_&6V11J;D$9;E6R$!3X/O=_I %
M? 3\YC#:U1F%2DY:OP;C>UW@)"0$ BH7%)C?SO  0@0AG\;;K(F7D(&X/E_4
M'V/MOI83L_"@Q1]>NZ[ =QC5T+!!N&<]/L%<SS5&<_$_X S"PT,F/D:EA8TK
MJ@;KM)Q5?"J2O4\[5W$?IYOT0MLFT)E %\)=)) I4,S\&W.LS(T>D9EZW[/P
MQ+L]];VI@C.V(M[YY*WWGDN:I#DY!Z$9<Y@P=(79+0CBU9<0="O$@?Y'I]OT
M=#/#--+3=?3;=%L@VQ3(HD#V3XG9EQ*W,-=?@I!53R68-DZ3194>5)SDE7<9
MV'L:W^03/DW[3V9:KBPZ:>=?-O:_T=J!3R6Y\B/4^0^V& (:%XZW_FRF,9L,
MI_OY!Y'E&Y<?4$L#!!0    ( *B$BTL+OOY#M0$  -(#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;'U386_<( S]*X@?4')<UIY.2:1>JVF3-NG4
M:>MG+G$25(@S()?NWP](FF9;M"^ C=_SLS'9B.;%M@".O&K5V9RVSO5'QFS9
M@A;V!GOH_$V-1@OG3=,PVQL0501IQ7B2W#(M9$>++/K.ILAP<$IV<#;$#EH+
M\^L$"L><[NB;XTDVK0L.5F2]:. ;N._]V7B++2R5U-!9B1TQ4.?T?G<\I2$^
M!OR0,-K5F81*+H@OP?A<Y30)@D!!Z0*#\-L5'D"I0.1E_)PYZ9(R -?G-_:/
ML79?RT58>$#U+"O7YO1 206U&)1[PO$3S/5\H&0N_@M<0?GPH,3G*%'9N))R
ML [US.*E:/$Z[;*+^SC=[-,9M@W@,X O@$/,PZ9$4?FC<*+(#([$3+WO17CB
MW9'[WI3!&5L1[[QXZ[W7@B>W&;L&HCGF-,7P5<QNB6">?4G!MU*<^#]PO@W?
M;RK<1_C^#X5WVP3I)D$:"=+_EK@5<_@K"5OU5(-IXC194N+0Q4E>>9>!O>?Q
M3=[#IVG_*DPC.TLNZ/S+QO[7B Z\E.3&CU#K/]AB**A=.-[YLYG&;#(<]O,/
M8LLW+GX#4$L#!!0    ( *B$BTL2XI\<M@$  -(#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;'U3VV[<(!#]%<0'!)O=)MN5;2F;JFJE1%JE:OO,
MVF,;!3PNX'7R]P7LN%9K]068X9PS%X9L1/-B6P!'7K7J;$Y;Y_HC8[9L00M[
M@SUT_J9&HX7SIFF8[0V(*I*T8CQ);ID6LJ-%%GUG4V0X."4[.!MB!ZV%>3N!
MPC&G*7UW/,NF=<'!BJP7#7P#][T_&V^Q1:62&CHKL2,&ZIS>I\?3/N CX(>$
MT:[.)%1R07P)QM<JITE("!24+B@(OUWA 90*0CZ-7[,F74(&XOK\KOXYUNYK
MN0@+#ZA^RLJU.3U04D$M!N6><?P"<ST?*)F+?X0K* \/F?@8)2H;5U(.UJ&>
M57PJ6KQ.N^SB/DXWNW2F;1/X3. +X1#CL"E0S/R3<*+(#([$3+WO17CB],A]
M;\K@C*V(=SYYZ[W7@B<?,W8-0C/F-&'X"I,N".;5EQ!\*\2)_T/GV_3=9H:[
M2-^MHQ]NMP7VFP+[*+#_;XD;F#3Y*PA;]52#:>(T65+BT,5)7GF7@;WG\4W^
MP*=I?Q*FD9TE%W3^96/_:T0'/I7DQH]0ZS_88BBH73C>^;.9QFPR'/;S#V++
M-RY^ U!+ P04    " "HA(M+^AQ:U[0!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q]4V%OW" ,_2N('U NW*WM3DFD7J=JDS;IU&GM9RYQ
M$E0(&9!+]^]G2)JF;;8O@(W?\[,QZ6#LDVL /'G6JG49;;SO]HRYH@$MW(7I
MH,6;RE@M/)JV9JZS(,H(THKQS>:2:2%;FJ?1=[1Y:GJO9 M'2UROM;!_#J#,
MD-&$OCCN9=WXX&!YVHD:?H+_U1TM6FQF*:6&UDG3$@M51F^2_6$7XF/ @X3!
M+<XD5'(RYBD8W\J,;H(@4%#XP"!P.\,M*!6(4,;OB9/.*0-P>7YAOXNU8RTG
MX>#6J$=9^B:CUY244(E>^7LS?(6IGD^43,5_AS,H# ]*,$=AE(LK*7KGC9Y8
M4(H6S^,NV[@/XPW_/,'6 7P"\!EP=1UK&1-%Y5^$%WEJS4#LV/M.A"=.]AQ[
M4P1G;$6\0_$.O>><)TG*SH%HBCF,,7P1\QK!D'U.P==2'/@'.%^';U<5;B-\
M^T;A/PAVJP2[2+#[;XEK,=MW2=BBIQIL':?)D<+T;9SDA7<>V!L>W^0U?)SV
M'\+6LG7D9#R^;.Q_98P'E+*YP!%J\(/-AH+*A^,5GNTX9J/A33?](#9_X_PO
M4$L#!!0    ( *B$BTMH? :NM0$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;'U386_<( S]*X@?4"Y<KJM.2:1>JVF3-NG4:>MG+G$25 @9
MD$OW[V=(FF9;M"^ C=_SLS'9:.R+:P$\>=6J<SEMO>^/C+FR!2W<C>FAPYO:
M6"T\FK9AKK<@J@C2BO'=[I9I(3M:9-%WMD5F!J]D!V=+W*"UL+].H,R8TX2^
M.9YDT_K@8$76BP:^@?_>GRU:;&&II(;.2=,1"W5.[Y/C*0WQ,>"'A-&MSB14
M<C'F)1B?JYSN@B!04/K ('"[P@,H%8A0QL^9DRXI W!]?F/_&&O'6B["P8-1
MS[+R;4[O**F@%H/R3V;\!',]!TKFXK_ %12&!R68HS3*Q964@_-&SRPH18O7
M:9==W,?IYI#.L&T GP%\ =S%/&Q*%)4_"B^*S)J1V*GWO0A/G!PY]J8,SMB*
M>(?B'7JO!4_2C%T#T1QSFF+X*B99(ABR+RGX5HH3_P?.M^'[387["-__H?"P
M39!N$J21(/UOB5LQMW\E8:N>:K!-G"9'2C-T<9)7WF5@[WE\D_?P:=J_"MO(
MSI&+\?BRL?^U,1Y0RNX&1ZC%#[88"FH?CA_P;*<QFPQO^OD'L>4;%[\!4$L#
M!!0    ( *B$BTL\C<QKMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;&U3VV[<(!#]%<0'!)O=)MN5;2F;JFJE5EJE:OK,VF,;A8L+>)W^
M?0$3UTG] LPPY\R982@F;9YM#^#0BQ3*EKAW;C@28NL>)+,W>@#E;UIM)'/>
M-!VQ@P'61) 4A&;9+9&,*UP5T7<V5:%')[B"LT%VE)*9/R<0>BIQCE\=C[SK
M77"0JAA8!S_ _1S.QEMD86FX!&6Y5LA 6^+[_'C:A_@8\,1ALJLS"I5<M'X.
MQM>FQ%D0! )J%QB8WZ[P $($(B_C=^+$2\H 7)]?V3_'VGTM%V;A08M?O'%]
MB0\8-="R4;A'/7V!5,\'C%+QW^ *PH<')3Y'K86-*ZI'Z[1,+%Z*9"_SSE7<
MIW1SFV#; )H = $<8AXR)XK*/S''JL+H"9FY]P,+3YP?J>]-'9RQ%?'.B[?>
M>ZUH?E>0:R!*,:<YAJYB\B6">/8E!=U*<:+_P>DV?+>I<!?ANS<*#]L$^TV"
M?238OR'X^*[$C1B:O4M"5CV58+HX31;5>E1QDE?>96#O:7R3?^'SM']GIN/*
MHHMV_F5C_UNM'7@IV8T?H=Y_L,40T+IPO/-G,X_9;#@]I!]$EF]<_0502P,$
M%     @ J(2+2WCPL=:T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL?5/;;MLP#/T501]0)4K6=8%MH.DP;, *!!VV/2LV;0O5Q97DN/W[
M4;+K>INW%TFD> X/*2H;K'OT+4 @SUH9G],VA.[ F"];T,)?V0X,WM36:1'0
M= WSG0-1)9!6C&\VUTP+:6B1)=_)%9GM@Y(&3H[X7FOA7HZ@[)#3+7UU/,BF
M#='!BJP3#7R#\+T[.;38S%))#<9+:XB#.J>WV\-Q'^-3P \)@U^<2:SD;.UC
M-+Y4.=U$0:"@#)%!X':!.U J$J&,IXF3SBDC<'E^9?^4:L=:SL+#G54_917:
MG-Y04D$M>A4>[/ 9IGK>43(5_Q4NH# \*L$<I54^K:3L?;!Z8D$I6CR/NS1I
M'\8;_F&"K0/X!. SX";E86.BI/RC"*+(G!V(&WO?B?C$VP/'WI31F5J1[E"\
M1^^EX'R;L4LDFF*.8PQ?Q+Q%,&2?4_"U%$?^%YROPW>K"G<)OOM-X3\(]JL$
M^T2P_V^):S&[/Y*P14\UN"9-DR>E[4V:Y(5W'MA;GM[D+7R<]GOA&FD\.=N
M+YOZ7UL; *5LKG"$6OQ@LZ&@#O'X'L]N'+/1"+:;?A";OW'Q"U!+ P04
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M<6'[SN_-])8GP^E^'E.R_"O*WU!+ P04    " "HA(M+>X<:?[@!  #2 P
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MN7#<^[,9QVPT'';3#V+S-\[? %!+ P04    " "HA(M+#0#1C\0!   W!
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M7-@^^+V9WO(4.-W/8TJ6_XKR+U!+ P04    " "HA(M+'*A_1<,!   W!
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M(!3]%<('%$?'=CI1DTZ;9C?932;=;/O,Z%5)02S@V/W[!;363GD1N)Q[SKG
M-1NE>M4M@$'O@G<ZQZTQ_9X07;8@J+Z2/71VIY9*4&.7JB&Z5T KGR0XB:/H
MF@C*.EQD/G94128'PUD'1X7T( 15_P[ Y9CC#?X(/+&F-2Y BJRG#?P!\[<_
M*KLB"TO%!'2:R0XIJ'-\M]D?4H?W@&<&HU[-D:OD).6K6_RL<APY0\"A-(Z!
MVN$,]\"Y([(VWF9.O$BZQ/7\@_W1UVYK.5$-]Y*_L,JT.=YA5$%-!VZ>Y/@#
MYGI2C.;B?\$9N(4[)U:CE%S[+RH';:286:P50=^GD75^'*>=Y'9."R?$<T*\
M).R\#IF$O/,':FB1*3DB-9U]3]T5;_:Q/9O2!?U1^#UK7MOHN4BB;4;.CFC&
M'"9,O,)L%@2Q[(M$')(XQ-_2XW!Z$G28^/3DB\,T3+ -$FP]P?8+P?5%B2',
M35@D#8JD 8+=A4@(<WLA0E87)T U_LEJ5,JA\^VRBBY=<1?[B_^$3RWUFZJ&
M=1J=I+'/QU]R+:4!:R6ZLEY:V\7+@D-MW/3&SM7TEJ>%D?W<IF3Y5Q3_ 5!+
M P04    " "HA(M+T7;4"[8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6QM4]N.G# ,_94H'[ !AFE7(T#:V:IJI58:;=7V.0,&HLV%)F'8
M_GV=P%*ZY26)'9_C8\<I)F.?70_@R8N2VI6T]WXX,>;J'A1W=V8 C3>ML8I[
M-&W'W&"!-Q&D),N2Y!U37&A:%=%WL55A1B^%AHLE;E2*V]]GD&8J:4I?'4^B
MZWUPL*H8> ??P'\?+A8MMK(T0H%VPFABH2WI0WHZYR$^!OP0,+G-F81*KL8\
M!^-S4](D" ()M0\,'+<;/(*4@0AE_%HXZ9HR +?G5_:/L7:LY<H=/!KY4S2^
M+^D])0VT?)3^R4R?8*GG2,E2_!>X@<3PH 1SU$:ZN))Z=-ZHA06E*/XR[T+'
M?9IOCOD"VP=D"R!; ?<Q#YL31>4?N.=58<U$[-S[@8<G3D\9]J8.SMB*>(?B
M'7IOU2%-"G8+1$O,>8[)-C'I&L&0?4V1[:4X9__!LWWX85?A(<(/6WAZW"?(
M=PGR2)#_4V+ZIL2]F+<JV::G"FP7I\F1VHPZ3O+&NP[L0Q;?Y&_X/.U?N>V$
M=N1J/+YL[']KC >4DMSA"/7XP59#0NO#\3V>[3QFL^'-L/P@MG[CZ@]02P,$
M%     @ J(2+2R&6U8JW 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL;5/;;MP@$/T5Q >$-?:FT<JVE$T5I5(CK1*U?6;ML8W"Q06\3OX^
M@!W72?T"S##GS)EAR$=M7FP'X-"K%,H6N'.N/Q!BJPXDLU>Z!^5O&FTD<]XT
M+;&] 59'D!2$[G;71#*N<)E'W\F4N1Z<X I.!ME!2F;>CB#T6. $?SB>>-NY
MX"!EWK,6GL']ZD_&6V1AJ;D$9;E6R$!3X-OD<,Q"? SXS6&TJS,*E9RU?@G&
MC[K NR (!%0N,#"_7> .A A$7L;?F1,O*0-P??Y@OX^U^UK.S,*=%G]X[;H"
MWV!40\,&X9[T^ !S/7N,YN)_P@6$#P]*?(Y*"QM75 W6:3FS>"F2O4X[5W$?
MIQNZGV'; #H#Z *XB7G(E"@J_\X<*W.C1V2FWO<L/'%RH+XW57#&5L0[+]YZ
M[Z5,DS0GET TQQRG&+J*298(XMF7%'0KQ9'^!Z?;\'1381KAZ2>%V39!MDF0
M18+L$\'^2XE;,==?DI!53R68-DZ3194>5)SDE7<9V%L:W^1?^#3MC\RT7%ET
MULZ_;.Q_H[4#+V5WY4>H\Q]L,00T+AR_^;.9QFPRG.[G'T26;UR^ U!+ P04
M    " "HA(M+PG&/%Z !  != P  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6QMD]MNXR 0AE\%\0#%P9L>(MM2T]5J5]J5HJZVO2;V.$;EX 42MV_?
M 5PKK9*+P S_?', 5Y-U+WX ".15*^-K.H0P;ACS[0!:^"L[@L&3WCHM IKN
MP/SH0'0I2"O&B^*::2$-;:KDV[FFLL>@I(&=(_ZHM7!O6U!VJNF*?C@>Y6$(
MT<&::A0'^ OAW[AS:+&%TDD-QDMKB(.^IO>KS;:,^B1XDC#YLSV)G>RM?8G&
MKZZF12P(%+0A$@0N)W@ I2((R_@_,^F2,@:>[S_H/U+OV,M>>'BPZEEV8:CI
M+24=].*HPJ.=?L+<SYJ2N?G?< *%\E@)YFBM\NF?M$<?K)XI6(H6KWF5)JU3
M/EG?S6&7 _@<P)< GGO)B5+EWT403>7L1%R>_2CB%:\V'&?31F<:13K#XCUZ
M3TVYNJG8*8)FS39K^"?-[:)AR%^2\(M)> *4GP!WEP'E14"9 -_. ;SX4F76
M7">-21J^+O#W)0\[FTQ\>'^$.TCCR=X&''(:16]M $065WB; [[UQ5#0A[B]
MP;W+-YZ-8,?Y,;/EBVK> 5!+ P04    " "HA(M+T&)Q9HL&  "C*@  &0
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M;DB$RV@/$>TAFI!P-)KP*!';!*!PC>5Z 297/)^(UJ&%X%HU84+&'324,H&
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MG=IS.W?6D&QP3PJ:WK7B/U!+ P04    " "HA(M+XXT&^O !  #Z!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q]5-&.G" 4_17C>Q=%T=V)FG1M
MFC9ID\DV;9\9O8YF42PPX_;O"^A:UZ%]&;B7<P[G,$@V<?$L6P#EO?1LD+G?
M*C4>$))5"SV5=WR$0:\T7/14Z5*<D1P%T-J2>H9P$"2HI]W@%YGM'461\8MB
MW0!'X<E+WU/Q^Q$8GW(_]%\;3]VY5::!BFRD9_@&ZOMX%+I"JTK=]3#(C@^>
M@";WWX>'DAB\!?SH8)*;N6>2G#A_-L7G.O<#8P@85,HH4#U<H03&C)"V\6O1
M]-<M#7$[?U7_:+/K+"<JH>3L9U>K-O?O?:^&AEZ8>N+3)UCR$-];PG^!*S -
M-T[T'A5GTOYZU44JWB\JVDI/7^:Q&^PXS2MQNM#<!+P0\$H(X_\2HH40[0AH
M=F:C?J"*%IG@DR?F/VNDYDZ$AT@?9F6:]NSLFDXK=?=:Q#C,T-4(+9C'&8,W
M&/P64=XBHK\0I VL+K#3!;;\Z(V+?PA$3H'("L1;BQ'9Q9@QB<4,%A-B<I^$
MP2Z, T<P21]"MZ'8:2B^,13C:&=HQI#-1N]"G.(@V0%+)S#21Y2Z+1&G)>*P
M%.\LD9OLF"0D3G>&'+"'D"3QS@[:W$+S*GREXMP-TCMQI2^TO78-YPJT9'"G
M-5O]$*T%@T:9::KG8OX<YT+Q<7EIT/K<%7\ 4$L#!!0    ( *B$BTM;2AVV
M% (  $0&   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;'V5T8Z;,!!%
M?P7Q 6O 0" B2%VJJI5:*=JJ[;,#0T!K,+6=L/W[VH:E"3A]B3WVG7MFB#'9
MR/BK: "D\];17AS<1LIACY H&^B(>&(#]&JG9KPC4H7\C,3 @50FJ:,H\+P8
M=:3MW3PS:T>>9^PB:=O#D3OBTG6$_WD&RL:#Z[OO"R_MN9%Z >790,[P'>2/
MX<A5A!:7JNV@%RWK'0[UP?W@[XM4ZXW@9PNCN)D[NI,38Z\Z^%(=7$\7!!1*
MJ1V(&JY0 *7:2)7Q>_9T%Z1.O)V_NW\RO:M>3D1 P>BOMI+-P4U<IX*:7*A\
M8>-GF/N)7&=N_BM<@2JYKD0Q2D:%^77*BY"LFUU4*1UYF\:V-^,X[6 \I]D3
M@CDA6!+\\+\)>$[ JP0T569:_4@DR3/.1H=/?]9 ])GP]U@]S%(OFF=G]E2W
M0JU>\S"(,G351K/F>=($-YK@7E%L%?B?!*D"EBH":Q6!R<=W5<1V VPUP,8@
M,@;]5*+G[U9]3*+X1H1WGN?9.:&5$]HXR8JS%>'X(2>R<B(;)UUQMB(</>3$
M5DYLX03>BK,58?\A9V?E[&P<?\6QB)*'G,3*28Q%>'>0UL<@V6!2[R$FM6+2
M#29=4]+-80NB. I7LL(B2_TH#E?5H)OW6=^OWP@_M[UP3DRJJ\&\P#5C$I2E
M]Z1::]25O@04:JFG.S7GT\4V!9(-\YV-E@]'_A=02P,$%     @ J(2+2UU(
M&+?S 0  X 0  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL?53;;J,P
M$/T5Q ?47-PD&P%2DVC5E7:EJ*OM/CLP7%0;4]N$[M^O+Y12@OJ"/>-SSESP
M.!FX>)$U@/+>&&UEZM=*=7N$9%X#(_*.=]#JDY(+1I0V185D)X 4EL0HBH)@
M@QAI6C]+K.\LLH3WBC8MG(4G>\:(^'< RH?4#_UWQU-3U<HX4)9TI(+?H/YT
M9Z$M-*D4#8-6-KSU!)2I_Q#N3]C@+>"Y@4'.]IZIY,+YBS%^%*D?F(2 0JZ,
M M'+%8Y J1'2:;R.FOX4TA#G^W?U[[9V7<N%2#AR^K<I5)WZ.]\KH"0]54]\
M>(2QGGO?&XO_"5>@&FXRT3%R3J7]>GDO%6>CBDZ%D3>W-JU=!W>"PY&V3HA&
M0C01PLV7A'@DQ!\$_"4!CP2\("!7BNW-B2B2)8(/GG!_MR/F$H5[K+N?&Z=M
MMCW3[9':>\UPM$O0U0B-F(/#1#-,."&05I]"1&LA#M$-/?H<X'B+B!>0TRUD
MB]>3B%?KC"T__E3GMW4!O"J K0">"\3!HE$.L[&8UM6Q"X(%ZGB+P@'>AHN"
M5U#1=G>_2!G-_C,#4=D9DE[.^U:9=LV\TY@^1.:>+/P'/;YNVCYDW.S_(J)J
M6NE=N-*WT-Z5DG,%.LG@3@]4K9^;R:!0*K/=ZKUP0^<,Q;OQ/4'3HY;]!U!+
M P04    " "HA(M+C?#?*XX"  "#"0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6R-EMN.VC 0AE\ERGTW/L1.@@"I2U6U4BNMMFI[;<! M$F<Q@:V
M;U_;R5*()[0W^/3/S#<V&7M^5MV+/DAIHM>Z:O0B/AC3SI)$;PZR%OI!M;*Q
M*SO5U<+88;=/=-M)L?5&=940A'A2B[*)EW,_]]0MY^IHJK*13UVDCW4MNM^/
MLE+G18SCMXGG<G\P;B)9SENQE]^D^=X^=7:47+QLRUHVNE1-U,G=(GZ/9RM,
MG8%7_"CE65_U(Y?*6JD7-_B\7<3($<E*;HQS(6QSDBM95<Z3Y?@U.(TO,9WA
M=?_-^T>?O$UF+;1<J>IGN36'19S'T5;NQ+$RS^K\20X)L3@:LO\B3[*R<D=B
M8VQ4I?UOM#EJH^K!BT6IQ6O?EHUOS_T**P8SV( ,!N1B@-.[!G0PH".#I"?S
MJ7X01BSGG3I'77]:K7!_"CRC=C,W;M+OG5^SV6H[>UJF%,^3DW,T:!Y[#;G2
MD%O%*E30OY+$ EPH"$A!O#V]H9AP0$$'U#M(;QS041J]AGM-XS4\I9PCA$;9
M $),.;T6WB"E(%(*(*4CI%[#KB)A0G!(]&_=#1 #@1@ Q$9 + C$:5:$0*&.
MY8Q- G$0B - ? 3$P\QSAO*0"!!:'9E$RD"D#$#*1DA9& G:(D"&TTF<',3)
M 9Q\A),'<<8DH8)EDR %"%( (,4(I C"%(@S&NY,*,PI+Z:/"B.X=*$0*D7C
MVH6"8.]2X+0@7<ZGD2:J*0:0@G**_Q,)T-U#@DLK)@ 2&2.1,)0]/)0"5(#4
M'A^Z P:7;!S6;)*-OS4<UN( Z)ZD!TFN;D/W//DJNGW9Z&BMC+U8_?6W4\I(
MZPX]V,P.]D5T&51R9UPWL_VN?Q;T Z/:X<F37-Y=RS]02P,$%     @ J(2+
M2XA@ P9] @  H D  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC9;;
MCILP%$5_!?$!8VXA%Y%(DZ"JE5HIFJK39X><!#2 J>V$Z=_7-@R3.(<T+X#-
M.MO;9@L[:1E_$SF =-ZKLA9+-Y>R61 BLAPJ*IY8 [5Z<V"\HE(U^9&(A@/=
MFZ*J)('GQ:2B1>VN$M.WY:N$G619U+#ECCA5%>5_UU"R=NGZ[D?'2W',I>X@
MJZ2A1_@)\E>SY:I%!I5]44$M"E8[' Y+]]E?I+XI,,1K :VX>';T5':,O>G&
MM_W2];0C*"&36H*JVQDV4)9:2?GXTXNZPYBZ\/+Y0_V+F;R:S(X*V+#R=[&7
M^=*=N<X>#O14RA?6?H5^0A/7Z6?_'<Y0*EP[46-DK!3FZF0G(5G5JR@K%7WO
M[D5M[FWW)@[[,KP@Z N"H<"/[Q:$?4'X61#=+8CZ@L@J(-U4S-JD5-)5PEGK
M\.[S-E2GR%]$:O4SW6D6V[Q3RR-4[WD516%"SEJH9]8=$UPP_D 0I3X,$6!#
MK(.;\N!Z@,TM$5I(>HM,(]Q$B,XS-/7AU3Q'!")4(#("T97 Q%HHC(FMN3[
MI/>9*[,3U.P$$9A:9C%F9IG%F+EE%F$F'FXV1LW&B(!OF<48.T488T4YQ9B1
M&$Q1LU-$P(X!QM@QP!CK"Z48,\/-SE"S,T3 ^GQKC+%C\ "3(DP\$H,Y:G:.
M"-@QP!@[!AACQP!C1F+@>_A_TT,D[""@D)T$%+*C@$(C6?!'_O0^(F&G 8-N
MXO (E/X'ZAR3BVVJ GXT1P#A9.Q42_VWO^@=CAG/@=[FK/ZU/GZ8[>]3ICN[
M_*#\6-3"V3&I-E&SU1T8DZ \>D_JWY6KX]+0*.$@]>-4/?/NS- U)&OZ\Q 9
M#F6K?U!+ P04    " "HA(M+%("3W1H"  "<!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q]5-%NFS 4_17$!]08;$@J@E0239NT25&G=<\.N0FH
M!C/;"=W?SS:4)L#Z@NW+.<?G&'/33LA750)H[ZWFC=KXI=;M(T*J**%FZD&T
MT)@W)R%KILU2GI%J);"C(]4<A4$0HYI5C9^EKK:762HNFE<-[*6G+G7-Y-\<
MN.@V/O;?"\_5N=2V@+*T96?X"?I7NY=FA4:58U5#HRK1>!).&_\)/^ZHQ3O
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M5==)NH61;=\EDZ%5K_\"4$L#!!0    ( *B$BTM3Z?SS-0(  -T&   9
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M(MKK4G*N0&<9/.B9JO6+,QD42F6V6[T7;NZ<H7@W/BEH>M>R_U!+ P04
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MS&]0781D[>A%26GQLWTVG7D.]@3!D>8G)",AF0@Q^I"0CH3TE?!Q!#@2X((
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M'U&"M&::-FF3HD[K?CO)34 UF-E.Z-Y^MJ&,@-O\B7WM<P[G..:R[KAXD26
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M3.VY'5G6D*P;IG$P_B64_P!02P,$%     @ J(2+2R3_K%:C P  #P\  !D
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M;W)K<VAE971S+W-H965T-C,N>&ULC5=M;],P$/XK4;ZS^/SNJ:W$NB&00)I
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M658ZK][7X.%@[=+5\6#KGLOJK?;O\^8)?7-09H?VUX?Q\2>0Z?]02P,$%
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M>/,?_WL:PP\ES/64%Q6.DR$N;^'&+X'(%?E: 6X4^CCA:WX2=XZ$,ZM*?!"
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M=;!%?D;A'EG9C2D4<Q.R9I.!+H,6Q&="">/BJ')]!XL4XPZ1-.EQ5^)S5P!
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M^,>TV- 0, "(MG#R7HH(0"IEI981CO$35X4\0G N;*[>**]?2,PL02+$25;
M/)[W00VQ\0MP68?KP<D Q82C7=>)%"9\K9F(DYS#1 O/2+9-:U:LYK'BJST!
MC%HVP\7D2+DI/$]HEBTH[:O<;5C;:SLJ(P"3A8S$(\H<2HMMJ% (7NV,,-AA
M=%AGL+X5WD(DF' _07@CU@976/O"-7>CM!ZZAGS#VA=% H3B]TP2#OP+5RXE
M^/#,H56R0,;%6%"2HE?Y#NG#7;ZK6I?MA OMV7U/=4)YE1-6B4&>K!:)&PR
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MTAGS KZ":?IP&-$@G$Q'P:M^;S3@;P'R9D=7N,D^8D$\",<XXC",8/>C?C!
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MI%&$<=\U6RQ\PW;3H%:#6"SR2.A\"0Q%+]9DU**I M9OMNE:A:IDB!$%P\$
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MF=+V[!ZPP&6??&BX-[V'H7P;#0E@_I\O[F$,@NT@'$V(NY$O?@04!E<:Q .
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M2PL'<KZS$HG/#@T[:ARRA^\*91#DX!7:<WK!>\W:,HL>V.L5T+;DT$J^-V7
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M&S9#A3:'_1/X[VA4<U E/K$ \.=E)E<(O@;HH7T_O[<U$N&S)4H=Q+I&\'O
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M-HF/-0PZ6Y,#A5BDN90B+@4D,G,J_:#YPP+"2']61F*26X@V7M<.&<&1EM,
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M"!C;WJ)CX5JKM56_/O9N@+(6A 3/P1N,^N7>2R_QVYYJ[=G8'B2I0= !-ZD
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M0,]BA"E(E+1W@$.T2RGOM)245.[M2U_((RA#+/E7.0U8V DOS#FNLM$G#DN
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MGO1<MWID2*^\V1-04N,;,O-KEG@R/_-F?K"ZB7'+]XSJ\?6C'E6KZJ8CG:\
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M_IS/QO^A+=X 4$L! A0#%     @ J(2+2Q\CSP/     $P(   L
M     ( !     %]R96QS+RYR96QS4$L! A0#%     @ J(2+2V;S"V""
ML0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "HA(M+='AB6.X    K @  $0              @ &9 0  9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "HA(M+F5R<(Q &  "<)P  $P
M        @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *B$
MBTNWK1[5IP(   4*   8              "  ?<(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "HA(M+5Q(8JD,$   Q$P  &
M        @ '4"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ J(2+2\2W&;T^ @  J <  !@              ( !31   'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *B$BTM=;5!$O@,  "8/   8
M              "  <$2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " "HA(M+)X7=^QT'  "1)P  &               @ &U%@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ J(2+2TJ0_%;E!@
M720  !@              ( !"!X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( *B$BTLB3[7^LP$  -(#   8              "  2,E
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "HA(M+I]M+
MNK0!  #2 P  &               @ $,)P  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ J(2+2WXZ !VU 0  T@,  !@
M ( !]B@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( *B$
MBTN3YJL6LP$  -(#   9              "  >$J  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ J(2+2XY4C*>T 0  T@,  !D
M         ( !RRP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " "HA(M+67:PD+0!  #2 P  &0              @ &V+@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *B$BTM7FT)FM@$  -(#
M   9              "  :$P  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ J(2+2V/>;I2T 0  T@,  !D              ( !CC(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "HA(M+J&[2
M'K0!  #2 P  &0              @ %Y-   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( *B$BTLPOC'UM0$  -(#   9
M  "  60V  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MJ(2+2WU5N0RT 0  T@,  !D              ( !4#@  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " "HA(M+DA:@=[4!  #2 P  &0
M            @ $[.@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( *B$BTL+OOY#M0$  -(#   9              "  2<\  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ J(2+2Q+BGQRV 0
MT@,  !D              ( !$SX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " "HA(M+^AQ:U[0!  #2 P  &0              @ $
M0   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *B$BTMH
M? :NM0$  -(#   9              "  >M!  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ J(2+2SR-S&NW 0  T@,  !D
M     ( !UT,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *B$BTL- -&/Q $  #<$   9              "
M 7E.  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ J(2+
M2S&Z-%_' 0  -P0  !D              ( !=%   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " "HA(M+*9+MQNX!  !F!0  &0
M        @ %R4@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( *B$BTNJ0NUCP0$  #<$   9              "  9=4  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ J(2+2QRH?T7# 0  -P0
M !D              ( !CU8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " "HA(M+,U C"\4!   W!   &0              @ &)6
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( *B$BTO1=M0+
MM@$  -(#   9              "  85:  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ J(2+2R&6U8JW 0  T@,  !D
M ( !<EP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "H
MA(M+PG&/%Z !  != P  &0              @ %@7@  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *B$BTO08G%FBP8  *,J   9
M          "  3=@  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#
M%     @ J(2+2^Q^<Y1T @  /@@  !D              ( !^68  'AL+W=O
M<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "HA(M+W=\4 9($  !*
M%P  &0              @ &D:0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;%!+ 0(4 Q0    ( *B$BTNYLI'K]@$  .4$   9              "  6UN
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ J(2+2]?"
M1(A5 @  0@<  !D              ( !FG   'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6Q02P$"% ,4    " "HA(M+6K(9/_(!  #C!   &0
M    @ $F<P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M *B$BTOCC0;Z\ $  /H$   9              "  4]U  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ J(2+2UM*';84 @  1 8  !D
M             ( !=G<  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " "HA(M+74@8M_,!  #@!   &0              @ '!>0  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *B$BTN-\-\KC@(
M (,)   9              "  >M[  !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ J(2+2XA@ P9] @  H D  !D              ( !
ML'X  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "HA(M+
M%("3W1H"  "<!0  &0              @ %D@0  >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( *B$BTMZ6]I];@(  .X(   9
M      "  ;6#  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ J(2+2_<AT9OX P  C!(  !D              ( !6H8  'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "HA(M+,!L '78"  "V!P
M&0              @ &)B@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( *B$BTM3Z?SS-0(  -T&   9              "  3:-  !X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ J(2+2]<^<N'\
M 0  -P4  !D              ( !HH\  'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " "HA(M+DT/_ZNX!  #C!   &0
M@ '5D0  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( *B$
MBTOD%";T+ (  +<&   9              "  ?J3  !X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ J(2+2TYAO)L  @  T@4  !D
M         ( !798  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M    " "HA(M+LQ3'Y%0"  !P!P  &0              @ &4F   >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *B$BTO-9_8!&0(  #X&
M   9              "  1^;  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL
M4$L! A0#%     @ J(2+2Z$YR7$T @  '@8  !D              ( !;YT
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "HA(M+)/^L
M5J,#   /#P  &0              @ ':GP  >&PO=V]R:W-H965T<R]S:&5E
M=#8P+GAM;%!+ 0(4 Q0    ( *B$BTO+DJ0P5@(   ,'   9
M  "  ;2C  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
MJ(2+2WA/$"M]!0  JQD  !D              ( !0:8  'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " "HA(M+@OWAU5P#   N#0  &0
M            @ 'UJP  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( *B$BTN.F*N72 4   X9   9              "  8BO  !X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ J(2+2P&VD>OB @
M/PH  !D              ( !![4  'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6Q02P$"% ,4    " "HA(M+R(NFO0>)  "C[@$ %               @ $@
MN   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "HA(M+D=GE0#8"
M   A"@  #0              @ %900$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( *B$BTNY_5\S"@4  %LJ   /              "  ;I# 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "HA(M+VKGW5R\"   X)P  &@
M    @ 'Q2 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "HA(M+,&^I3/4!  "/)@  $P              @ %82P$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     2@!* #@4  !^30$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 1. ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>1. ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 2. OPERATIONS, FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OperationsFinancing</Role>
      <ShortName>2. OPERATIONS, FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/ResearchAndOfficeEquipment</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 6. PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/Patents</Role>
      <ShortName>6. PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 7. INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxes</Role>
      <ShortName>7. INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 8. STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensation</Role>
      <ShortName>8. STOCK COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 9. EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/EmployeeBenefitPlan</Role>
      <ShortName>9. EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingencies</Role>
      <ShortName>10. COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 11. RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RelatedPartyTransactions</Role>
      <ShortName>11. RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 12. STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockholdersEquity</Role>
      <ShortName>12. STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 13. FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurements</Role>
      <ShortName>13. FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 14. NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShare</Role>
      <ShortName>14. NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 15. SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SegmentReporting</Role>
      <ShortName>15. SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 16. QUARTERLY INFORMATION (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/QuarterlyInformation</Role>
      <ShortName>16. QUARTERLY INFORMATION (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 17. RESTATEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/Restatement</Role>
      <ShortName>17. RESTATEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 18. SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SubsequentEvents</Role>
      <ShortName>18. SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 6. PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsTables</Role>
      <ShortName>6. PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/Patents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 7. INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesTables</Role>
      <ShortName>7. INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 8. STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationTables</Role>
      <ShortName>8. STOCK COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>10. COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsTables</Role>
      <ShortName>13. FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 14. NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>14. NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 16. QUARTERLY INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/QuarterlyInformationTables</Role>
      <ShortName>16. QUARTERLY INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/QuarterlyInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 17. RESTATEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RestatementTables</Role>
      <ShortName>17. RESTATEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/Restatement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails2</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetailsNarrative</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PlantPropertyAndEquipmentDetails</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - 6. PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetails</Role>
      <ShortName>6. PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - 6. PATENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetails1</Role>
      <ShortName>6. PATENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - 6. PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetailsNarrative</Role>
      <ShortName>6. PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 7. INCOME TAXES Net deferred tax asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails</Role>
      <ShortName>7. INCOME TAXES Net deferred tax asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - 7. INCOME TAXES Reconciliation of effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>7. INCOME TAXES Reconciliation of effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - 8. STOCK COMPENSATION Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationAwardsDetails</Role>
      <ShortName>8. STOCK COMPENSATION Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - 8. STOCK COMPENSATION Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationAssumptionsDetails</Role>
      <ShortName>8. STOCK COMPENSATION Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - 8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails</Role>
      <ShortName>8. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - 8. STOCK COMPENSATION Nonvested Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails</Role>
      <ShortName>8. STOCK COMPENSATION Nonvested Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - 8. STOCK COMPENSATION RSU (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationRsuDetails</Role>
      <ShortName>8. STOCK COMPENSATION RSU (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - 8. STOCK COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>8. STOCK COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - 9. EMPLOYEE BENEFIT PLAN (Detail Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative</Role>
      <ShortName>9. EMPLOYEE BENEFIT PLAN (Detail Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>10. COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>10. COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - 10. COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>10. COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>13. FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - 13. FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>13. FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>14. NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - 14. NET LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareDetails1</Role>
      <ShortName>14. NET LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - 16. QUARTERLY INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/QuarterlyInformationDetails</Role>
      <ShortName>16. QUARTERLY INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/QuarterlyInformationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - 17. RESTATEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RestatementDetails</Role>
      <ShortName>17. RESTATEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/RestatementTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - 17. RESTATEMENT (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RestatementDetails1</Role>
      <ShortName>17. RESTATEMENT (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/RestatementTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cvm-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - 17. RESTATEMENT (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RestatementDetails2</Role>
      <ShortName>17. RESTATEMENT (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/RestatementTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20160930.xml</File>
    <File>cvm-20160930.xsd</File>
    <File>cvm-20160930_cal.xml</File>
    <File>cvm-20160930_def.xml</File>
    <File>cvm-20160930_lab.xml</File>
    <File>cvm-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2016-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001654954-17-011495-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-17-011495-xbrl.zip
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MA+ASH]L(T4XFO[K^@@"45+,5YB^>XKZ24-+2'P1%*$W(V)NY?OS'5S<?WX-
M&Z'-46_2YD UC@LJF^AJD3R&D?<?(+]*V%P#GHJZ05X'X/)4^P.VBKM6 +L.
M9[,P."015IBQ(2#W(+_]@&R4\$R9_U,*78W];93J]H3*C1_!@</_PRX 3ZZ/
M#M]5<NU&T0MH((KHRG0G H>RV%$LQS$%P*K,UAB(I52W!*)AJ:9IJ\<"4:L
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M:!,B_CE>Q$DX^^?/Y(GX2I4[ !5%T4Q%%#/5@&@2^/02K\I06YJI&>(]+,>
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M26,*@6N"A'M<@,UKV"3039] C6RP!7G"&^ACP1E,R4>DL'AQ_R\R3@K*@O*
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M$"^8+V"8!?>I^-C""-1>*'&5"U+;QZ.4M%)AZ3PVA\"+<_&?\!SV. W(X@#
M<!2> I%QMBQ'0)KO_C-]7\$I\&'TAPG/W64_:>E/;-(1[#N1L'I54E24SQE"
M0.9Z/)Y+JW[@Y5S7C7W8J3SS &W'\IVC:$";E@UP6?Q!"_>&;^A6(^63(&;6
MS9K<-_$1JNWQ'"6->U&].F1TXU*OA9JZ:PZ^LYHT>BQ+K>\R%J'&>Y[T N]@
M]-12[$(*R0I@(M1TD0781V(X]LM*4D+!0, U9*%A,1.WJ!G8T[E.P%2#418J
M*CY+?\R-0:Z18(<F#\@I3,IDYE^NCYY"S*'+4L0R-XO/C:=03$,(.\&W*5][
M5G!2/*<3D^ D>E*'!@KGGK3<)$X/6_.C+[J*&.ROK+(*J &K]?($AHM@J7<T
MCZJ0K>+!)C)9C=$K\)C]\(4(;C(W:'G08LW)@B$;0T,N$#N;BG/M798[&H*0
M#(;OTFD*-'Y%1X8MP92R C5X,;<(BWD+K+Z-^NN\]H['65BE&RL]0.-O.=:P
MRAE+^3>#HF9)7N:9[T"%!J/@?1B&&8E9"=5*PC-9W2HW-TL%E<6$4JI1,G83
M3WNYD+@($E^.']_0J#H:W$S"WC(Q=.>[ 4]E1(+\*ST/]6A"7?Y4S!\#$VA5
M/-/?!OR'-V&PX$\S9RQ8F3A_A.;_Q1CW&=-CX]16 (G%1Z 5=[[/ G$^QGA2
MQRU,#VP$5J,O%3D)%!T;BAX=T6,CFFWV1+)JL+*#,"J2^0'<I5'+*B(RY8K[
M06-?># ..X$!R$'!<W:IVUKDX.(8+#Z"J;5,]%')%!%:2).6(('UZ<'.L>3&
M5/;@V4F<V2$\BQ U.$ES#*F9B4* 1GM)-/9$W9=]0]\9K1RP,$%'*PXS\<02
M$BC\]"U1J?,)4;RA$LB.'%T/"!6#-3R%=9P7]*_%,(,&3UF&F*,L98<G$95I
M.3S/[I*M3\-57R(J!E_HXVP_D@P3N=7&3#3,WR%XII6GGJP5E>#/>S'6RF*U
M),W81 !2IR9U4U.3)L5P1A'9'C.OGHD+P9M94C8\S)S%HWFF49AIBCEK#!&+
M06*$%^O'*5VEC]+U<G,JS3H38MSBX35-7D6LHFP03^M3+&.63^#Z+S03:@HN
M4(:0C*+N"8@7< %!H%'Z%8IU4CU'04F#8ZMJE^E,'BX7O#2T $1+O6 -I.8=
M$FD S,_->&0H'B42 AA>GI3"3UQX012@+0M-IR?I/"R86H07%6K^E9O#L(<K
MZ0N<KO*,))[TOD[#H>4N!!NX>39 Q&*\F1J/68TYAH@F'I>T:+(1PDE]U3WF
M5A';\<QSP2-G1@-XO+KJS/%YN'0.<M$PG+# "5JV0+/\B)9& "@=)WABGB:)
MB<!GN51>5C=U3X^EJ/(O^)"K\PW2_&_I _9ND:[=R,?CY]F"51_5AX?Y3SE,
ML%%C5@'&9$L2HOFYZF!1=7-?UILB3^);]9TNR&$24H2+Q+BE[HY&QBAHM,<&
MC?P+MEB4C<;S"M@Y3):>R.40?7<N= 6Z.)PC%H3*F[LH#,(%3]S<E)@-!O8'
M4 ?8PHJE,+Z_^OPF]75+2X!^F5/#X;NKS[]\+_'65P-)@.6)! NN/*Y#S-,9
MI]DRU_36 PQQ?_<EG'MCR93-[X66 4S_N)S=X@7P#_ :F %>A%8C1ME]OY#Y
MF69UHF+ZY3,]EF/)NG/:1 J+P&A<D*TM?SKFA]6T7@L#7JS$$M;(C]]00,RR
MW*][ GL14%$TQ8+LMX!P>NR*M4^  VLDO7.Q>MZ=<%/'HZED,R]) P((>0K-
MTI32TG04A&U3FDQ@B=M%57>(!U&THNKS+ZR.?Y9V#D 3($7!:_Q=8BVP]*W;
M1R%:OX6O>3J#FQ7<O,NP^Q:(92 0()_6',KV/E3SFH)TES:QDD <QZ!3KQY8
M-8)0"@2O?<IJ<-)Y?HHP)X._])$DWY>"J,@9@ .I$H@4J@)F;B:XZU-Z2'LG
M*,9;H0Z)1LM!802H[>@!8BDT:EUH.,(H4 R:CVX4A<]@589S(MT4^ET #'<X
M"+5<L=_3Q,N;FS!0/I0<'3++.:.OF,L)B5)X9NCR U-FY,Z9,0&T206]FUFA
M0@8)NEEK3[_3XU?QT/L2!#X(Z_]U06I$5&";FP0V!62-T/X8CC@+*@(+YFF9
M8HVFJ+-OG^@AL?3=Y\5]0DG<5K&#'M#5)T$FXPX)QW-I.# ?_RH_NLF__'GI
M5)R3W)<EN<4*'[ 9"C,(>%4#)[(B$+,"$#DY<1&_5."X/$M104P]K'GGZ5-;
MU<% "/,OZQ+FWG)=AR=5XM#;]4A:3RP>HP@><U;F4(%9>4(V9]B>'7=@Q_?D
M/MK$CYFR4P=%((4BKIS:6:B,9>91$XC'R,'[C].*(^F[[" - U[S_,"4_IJ%
M<.)B[\2TB]WW*WEI2T7*C"A8H7(LN<7*+58QDV5W\N9)<>8>"<8Z>WFI=P;5
M"D(Q/B\ENBWKL%$H!MS2,8=Z?FZ\/'(.6%HB#[ZCYU,.0\MHJ3 L+R/B?D6!
M07(ID;%,YA6NL267>7^0<^HRXP_6"A4*!!<L8#+=+Q*L_5XG(TJ@G"UHDG7J
M'Q6P.:/U_-1Y3< D2C-:.5HSD'+[C](=3.]A\)'FGT4L2X='V[))BO%3/'5E
M. 7 >2)&"D,J9:8E1L22Y$DWI)<^"?/<L*1VO>C)%;TSR(#AI1M"A&-8=FC#
MC5A+L=&(%2U%X)ST6))50Q7/+@4C9%1J]SO(A7-ZBL0X'=NQ1?34#^DO"X8O
M99W3JAP>Y4Q[<-)@EEB&%Q<U;YJG7D@<'RR%R]+ /(^,Y>6S/(:VU-.!5C4L
MQ=O2 _<TO;S0C;>*X& I=,T+C\Q;K"0W*!2[L2SU,MG:>VMA';]>+1Y0%F^Q
M%6#+4NL])R?:*?H];5W&.5/5T/"^7HG\II$U^@;M"C_GF*??I!D&(W%"MGU(
M^)@ODIJ8+%B:TC&#,WXM*:/O@;[N$]9GES$B;?0"7[W[BC2R\.+'O"T $""\
M\3GO>@- _H-$X? Z7& -,7U1]#E@L%O*@/@+CU+EOS(7E[UZDQZ#?:(>Y1>,
M'5U%M$^0D,@&R*!W(_"^(,7X1&&(E*+?A.@F4V=<&WW/V8**HI7P0IZR\<&=
M$,Y^KO0&=2Q:7\!.]_QD:R#I@(B[*&1]L+)^<T74W&"E$W5"8&\]S(,V. C;
MWKP.(RSC2,CP]AE/J'[&X[I\N+0CNB@BW[C![]N>-G&_O9@5VV1'59_2Y!$*
M#,^7^<#LAAO:X)O@RQ:\_(8$!+:"N98,VS11[S,9+VA6)$/DEX(8MRG-4/,"
M#_9Y&,6C9P=(R,RGI R!M'W%RF13)D#D 'E.PIG'NFG>I:V"MCI&F7A,U5 J
MV7ARH9=YTTE(@>B]IKIR\"/:$JB=MDE"NX8D_)2?Q>$CHGRS\V0CEEVP3E4C
M'?AN>LC)#EM9>71V-LKM7/X,.R_B8PQ6JAT':<$!K?#(L^PG)!X#.S$W::7Q
M?K3R5:%TE9_E103L!3*H.SHCO;7#8\]17MF<E4]3B5NHZ&3YU&(Q[",[K D#
M; '!K83,*!F&TV':_0A/_8.)\ U#8;H*F/ZYDD'%?,2UO$F]QX);QD\$[E/!
M7 C&UPWO"/89.]8L!'=*3+1&Q<YRH(9M1R]VZJ2[I>46R"78*(P:'!$]2/-9
MO0"71H5^<^*I&FOTD&YE6CBSO)>TF&/I16K^+ZL-; 1;LG]++N_Q]RJ_C&B?
MVUB6;W8!VP9X*'G!I(@$1LDZBK_-Z+1#-[EL;F:>MNZ?B%WV\H.YI5+UUT??
MT>*TK)YZ3'P_!H($@/&B'OKWW)U,TK\+H"GJ=MB>O4GR"(_*\K>O\DEQOB@=
MC';\ (F9PGT?)DDXRY]&@J%O3$I6PK\L/I>.S"$?LA'1A3'F21D^RD<9AXB+
MX(^OU&SA]Y@/%64#WF.REJ0 &F+L%%O$_YBV(LV.[,5Z/_P\C+W_$+J_V2/W
M^ $IF0)UGWZ=%?^UON(3QYMQ,+S1C]'!"'H?U*]#;8/3=@Z\)K=G.PE^*-PL
M0KN?H>M07L"[93D5"+ZE<;^IR3+BQM%&JU4Y5E4&BJT-+,,\-12= ^JMHZ.^
M(>9,W^ 6AJ5_6Q4+F1E'"O?75,=_:M1\6UNS+KU93;WM )G\;5&GUJ(2;: 8
M]L#4M&.AY?P0JIHV<)W5 D(/J^K>+Z* =NUE$9V:_-.X/;&O/%0T;: [SI'
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MCQ59*9"'/7')+.M<0UOST)=I-8&0N[2(\ *'8G<@.G/))4GTY;+[KL3VG?*
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MX?Q':>Y.T&%Z+<DCRYCOCX;OW*H]"7(;2%%?I5,M@?.CU$8JWDTP]A<3$F<
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MJLQ>0@BRDPL*(GZDC8K2[UL3=5OWO'U9MQ4$<,"R*GOF$VNK)CYR)#U8G2_
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M:F^)Y\7+==O))%^F* GJYC5%:KATN^?7OW, <-':I$1)%(6;5*Y:(H&S;S@
M2K=QE9K?^'TUFSNMYV%"LXU1$\_GK=;9IE9Q+1+OU5NX[VO!4_&EOYBL^+=2
MJ6WE2AZT#J4E']X<&8B.U(0==("-@82O3N)>IQ&EP4+CH'!?0&E7;$7BW6*(
MABA0+K&&-1#Z?G[!5WY-#]L\)I;'4C]1'L+4Q[M[%.Q$[66$Z2MO%W82E5['
M+V]=<8\>]EA2ME"!U/0"0#UEFP6S6[O*6%07"[;/)(WF89R')8 [+[4(SN%
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M+I/+2^0Z9)ZVYA!G:+3?$W59KB1N$C>)F\2M\6O?+B4G^%/T-N88K/8XBN[
MWFK_4.MRV$-<5SD@CF417=V\'MEEU>D2)PUBJ"JQ+4UR\LPYJ1/#U(GF;&X0
M:8O)[[*L2-PD;A(WB9L,OG==@,]VB2#TQ4Z1<M6=Q]Q-U]P7VP/UOFX"O),P
M'?G56[M;5(X[[J=G>M_8L@#595V60G80@<(S3_;NN)02)26JD"B]OVU!2OKD
M?7SRH5;"I7A+KRQM:%N$3'IE*5'->V5]BT2M\<I7;/-N\55WMD*W$7[<]H3
MW5 \_"RABF8K"YB(#5*S_+B='-=S0._<V?-67 7R]!7"I?N*L@-!%O<QY">
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M4B6<LED?W"AR QB2NN.[;-R^ D I$8U3'WX)I^Q=^#-Q$XH'T"H3#\U.HG@
M\CCAQR(!Q+Q_!$QEI" FXD5$)9S  S "O S T>]C.N>G*N&S^!"=3NFXF$Q[
MKILP(^2_,>">A.-O2CSWO:3?&G;S>7^Y2N/>K>O.G_\K8\E;+W"#L>?Z[P)
M;N8F7AA\@8%>^H#%/__S/]!R_Y*]]<J-[ZZ#"?[?F_]-/6 -4"C^%/K>^#%_
M21D#&O#'9SK]QP]OHW"FJYK9T]2>JB4A?+9ZZK!GJ#_\<P'W'*6])?0M\&B>
M1O,0Y4LP*)>%.).D,>"@3/WP =YEGU$HV0=:8(:HQ%Z<@#!X0*2YZ_M,3M(
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M4YF"A##P@+0"'VY)$%K" &6/P(#,F .(A#&Z'+$CVZ/H$?F;I;T%RER= 4<
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M4R..J4L)N%@)<!R-6/)2Y0N6 $-5B6UMC@,N(>)\W<B*J)0U&7-*"9 QIY2
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M#ZCV+O@WFS#X&<0C5L9I% &O@8G .E?Y= <0*(8R!J8QCB>1!_\%47.5>9C
MD_ G@X-/2=/$&RO >:#BQ(O8 HKB)DH:9[19(0&7!)0A^#?Q>DDZ"Z/L,9#%
M.1@_"I0&^DSND5 3> 4D+7I4[A!WI%I Q]\8%)R2?07,@ZM,0;<%!AI[C'_6
ME[")E3B]O466%=2"!QFT.8X(*4<(2.-.D4D*AW0,$LUY%%,&PP3GAF%#!45B
MS'D/-/ 2Q9W/L;5D12[FP#B8I\Q<)7S81I#^TZQEP!3L1>[B7-/4]Y7 G3$#
MD-QY\6;I>;CSQG>$T3[V9G.TH\DC$Y.(3FF$;<%)F!F5B+733$".LW$GH!UH
M.!@@0- <XC+P JH$S!!%4\%I5;)LC!<1O?5BO+YYPJ#9#C:RFCT!H@6B0L'Q
M/S(8&-8>\GOT;\; 4'G[^EK!U ',". !GB'@Y%(>O.2N#,8";Z:L=L/8,_;F
MS-H"A*GO)B&()0P_\^(81V%B.P<X[EV_A#6#!O$*P@2L!0T4H"T>* 2F)'L!
M/H\>&00((WX-M @1R?)<J&KCQS[808_]A(-Z":#H3FGRB*_1*7K$\2.?!RCF
MCGPOOJ,3!L14#)RB2+U-(S&^\ ",T_^;8J\U)RM\[3_VYDR/EFP"O 3HQ<H,
M+"K,A;2<>A%XBDQ UML2!L43DBCT!W]'GM["5+'@,O^^L%HEUKK%3'>ASXPT
M#:+0]YDS@RG=R<3C$W'I !D0BGAN;FE5L!BSQ^ <HD*.<K%AA$P> -%'D%!6
M,D]Q+1L =R/X.&&//X21/\&88>RGN6O[VK_IHT!RJ^ JMWXX @(O\Y:[!"87
MZ$>6#?<SE/M'"FR**&K/SXNF/'.(.3>4CP$0<)ZPH%#1+:)@G$86S 389HK'
M=BGW-!IE+ T3W!K$'$&F2;E]V>#;<NK-?7?,??N"''%W#",M6(0Y)!?X]J+(
M^30!H\6CA0DZDJE'.7&G((?A U(UGM,Q!JT0:DT]%D\!'YXST6?&"OQB&@"9
M8A#4D<]CK;@(=)7(B[^A-'N^'Z!>H*\(_IU&+/JX2T$&,Z6(7V2>NJ1H\/@H
M"L=W*9\-#!=&%  84<#"AP&%4(3K/@9W2"$6&XR!ZH =?5'H(7-D/DP'0X*6
M)N$X]''(#"\,(.$/A)W#$2HS2A-NKA(>LC(X@8O \D]I%*>((#S'C -,"2X0
M'2JSK,A3)HB9E)2L )<%1MTDG3QR,9OQA\+4YU4F+TAI!H@0GN)!CG(^M.O#
M#S 0-R"%3>/#/RR,B0"/,@ZCX1RE"1CZDKDI@8QO\JB:YH,S<?\X3D(F[-HZ
M87># /04Q1.BBCMW4D@_DVPAC*\R8?RM$,8%96 S?0!?@WK%P*@T7<Q=7((L
M>Q"AS8CZ'N0*L<#>53()*6(XQLABWM< ,M-GIS0E P+5%&R&A_Y01-R%B'&/
MQ](=4*E'9'(6E9<5$OT6QG3<3*&@L10DX;($J0J&Z6,7_-Z*+O-X('-,ZP;/
M2*9H-H>]0!+A"H/;$&;KY\#CERPBS+#* L('T%HD5R&P;L8G$!?T<_ =3_S6
MXB@F!0.?4U,3Y#QK%^8)>HTHTH3E6*5\1!-Z)R3B:P"2'\4>QCO +Y@?F!YX
M+D ,UNAM!,[$B\>A\NSKJYNW/^- O[W[X^JW3W^ C/9XP@7C@]8SG7^ [)8;
M*!8"S@'IGHM*^P!:M3$P*#6@52I"E,LE8F$0.'D=3-ZR+!Q[%4Y4KY@G:_DH
MOL0('P=6!=LJ</:+T.IR/ \.)&7Y0]F3C<,878&'%05T"OB!->5M"LW=,<2F
M,3.JR'D(&1(70T07DS;*XXDTR/YD0)12 D!H?!>$?GC[R)[\%H0/O;OP =3*
M9^NTF<'B3I0E8/@TLZC@U#!>%WDL$7-BZ.X+#P4$WE1)X:F9.YF!>8X3Y#U;
M(0?L">()7Z7C#"G?'6$]!V/]J3OV?,"6"H>\E,;VN6W0+/5%N6+ Z#V%H ZI
MG0(PG,Q(Q(PB8THG,7<,?N@&66P-[CR%7&',76'$T]78]5GFZ"7<(X>!^#G+
M"&/L[2O!<G S=""Q/7\,EA5O(5&*TB 0_@; H)"V@?WM!5GFM2$X1F^Z+E1?
MJ%&58@%P<]R>\["!0AAQ"Q+HSKV$UU3B=([+=4R<PMP.*BR+71PG"SUX(.:.
MQQCLP@B8MF&."M8_&S>^8P$92G! A>*[$"=#BOLZC1#K*3@$>/ 1U'-=*N$R
M)\WR\.]94?-'7>L/(#[V?6&1 HA=<^5)[B*&&@L*A8H(]6 *P6% ]\(OAA+J
MMD;!PBDH$BX^;@+67 LL@J?EX"W 5II)!#7Y#%^*LF\1SH[H8QADY/N>@"PK
M,]8RMS@QQOJ, PR"<GB;\4$$R2 T,TX/49OF=@?<:0!N^\Z;P\ 3.DJ0#%=8
ML>#<G&:>$.!\%^3C+P)!69<V!T/$\(MX,S\1C;Q$%,W=6W 1<2:5,0,.S_W,
MY#RWV6%TZP;BN&?,@O_ _.U^BZ"7XSF6J0%,X8AYI!)M<JQ$U,]#4"';DQ!+
MHZRG,,9Z5U:(Y37"6&0EV4L+130W*ZEO+[=@IG4+>O ;I"80-)&\=DM1DQ%T
MS%3B.(V$4"P5XS($P9.@ DY3QF64 &9,2GB"QV')*!N"_Y53Y][U_(Q$R9*5
M0AZ-T?'S!V@T8\/ ()!ZEGW<N^D"9).0\GH:%T<NO0@CNGHAD605E[QN=I\G
M@S'D;3CE!.* QVVT1%F]A["Q%,0 O\#& M/]99.&@:#//3#+/KB)0\X)0C"X
M\PP]J[LQTK%D @5/2 _G8\+/T6&PBY)%1.>LXH,<G/&:S3H&YJDJ*^2S9 6_
M T,NRL:8LD[2/&7;4@/U/8!S@OJ*IA8T&=(K%JV PJ,5\L,XS@(6'(HK+-?%
M]<"QV)"O;;!W1<67V1%03LKHQ6<G19D$,E+<H,'RWDF8HC49A6FR$7QWA+$4
M*Y)LH4:?P;&1\I.021POD5%62'4GZ+?YSPR_&5OBX=71PB0!:. >BAH\9M<L
M>DT>=TO<-(@W,/4911Y1?L,VYP0$DJ5 <>]8(1,\,EH3.XUR1,XPBKK!-"17
MRTQ2?1<X=L<*(O&V8"FWT8NFA]50YB)C* <9QJ!OYE[<C;,B1%'\-%11<8#?
M^8*4".@S+5D/##<?"?;^BY4:)N5NS/,!+H>K+Q=U7 *:FQ6"$0,^*9/PS*S/
M78_5FM>5*C)O3T2Q;!%M>/E'32_B%QXM8?/N&LP1%5P+B!5V9((2!L*PT''>
M08;;N4N)#J?]YX]8FO%YMI>[BTQYLZ45W\UR17P?T.Z#[<7W0?;2*6X39T&9
M(-@D2N'G=TD6<S('FM"\) I08J$5\2Q#[#]F8'L!1B#<'N;1.<<_]Y+"HZ\S
M8QFR93PSQG_.0IF/I5 FKQIYS(R"T !>[FU6WQ<"P/%?E*"%]!)P"<2)Z3QL
MX&NBQ6(#2#=B.BVMN; U PI:*1 =8_@VOL.->0J&A;$H,V?K7'R!"I +46YB
M82[9HB3.RM?.,J\0;$U_/9^5 Q07X)BP]1_AV<+( ]Q+"4]>N4;2>#Q.7+LX
M(4J_&=79TD*(,0H$#_D:)7@[L+\B81!5WQ)%^LI-D:JPJB=[G<6L"&E1M! P
M,3RR.;/E<XQV26D-EONOS4HMS%.FMG?@H#"#>Y>(Q5A(Y8&F?&;PP$Q0<E==
M>V!\M23:N3I,#E^@E)6!#1A\Y!:VYI*:TO!R&M<MMJ1VE,4>9>U"3YZ9'V>Q
M1]FPT%-]]:61Q9[UZTJ"%AL7>[:OZO#R.2K_0QA]@^@$I)6S:-E*@KW^QI8G
M,7/AR>WB\FDN&I!?3+?8"MX4^$0!?;E-\#5EI1:@X#M6:V6R F_^1B?H!Z]Q
M!9*565][\1AR$$@T3E2,UR$:W*#\=8N Q8(S>-P($Y(Y^DV>IM"B+,7<7!CT
MJ-A:"BDL#QO"8@<\)N.K<=GS2M:0I_6L:6KN(IMPLQ3[>XXZ(_ZNG]L\>)/D
M#IY5U9]>**,PFM"H!R[3=^<Q4"/[]$,!$,(291.!@<,A_8S(HS!)PEGQ-,H/
M>V.2O2'FTX<PG8"\%V&J]UPQ^P-D6O:M3Z?%EXR3$SH6/9S/%2S,1R#U="-#
M&2^WRTW^;HH?_N2\9!Q(UZ=>R>1IU+3!#J@)^HUQQ27:&R76[;L )<,'FW_W
MQLX^.79\,TH.)B++E",%PZID^_4QUFJ<L^;)<<_06V4N.Z!@;PRMIM3R(-CG
MR!;;37)\FA#NQHS28;'_C&N&/>P@KX P^Q@MV>\MI%AOTFO0I8ET8"NSEB%,
MPOG.:EDS*I P2Y@/#G-MC:ME;>I#O:\%J<>#_<,#MA,JA^WS:;G!'M\;)TV_
MLJXTO1.HJ"915?6$>MT,'C]J["KV3K"$29?5:K-5&9>.FK&;3@B:>J5I5YJ1
MP]R#;_3!E390.H$>40V;J%HGC,*/AM;7S2Y@(J3.D?:MQ?;M:Q<D#2R9#<:L
M"ZAH-G'TS<)V-E$:7HS3"7ZH3+9L:<1:;,3^Z(*DF5>Z<Z5U0FD<326:OJ_.
MM,"*:<..F#$F7/J) V1IQ;9:L3^[(&B86';%C%F.0X9&%TIF5D?,&)<N:<=:
M;<?^NQ.2=J49)Z_--E5F5KM1^1]VI3"&LK5WDM\.([9Y;>R\C=A?71 T'0*Q
MCA@QW>J&#=/TCBQ>,MF21JS51NSO+@@:2%E7(C'=&G3$BG6FO*^A='7$C'4U
MH?Q;VK%VH=*5A+(S9@RB?$=:L79;L>OK+D@:B-GI>Q:E%>ND%=.O=/Q76K$6
M6[&7+[L@:1VR8EI7"F-=L6(.LV(R%FNS%?O0#4&#H%\]<7MU4V48@]C.ONK?
M BN&5Y)V@2%,MCK2]=K5ZOZG+@B:?H4=UIW88:D;Q*H=B9W67 V(INE]LQ,+
MD@9NII06JU46JW03:!=$3(/ _DK3>CG,]I76D312-\_.>&$[6*]TCD+^Z4?'
M[HA-PWY7D#&KD#CKR@!_.>R$F=L<*:\Q<U?L)+:%K]IP7MVQ#]<\IR/V3'G$
M7E7%.LX1>]P)'_N,O1.<U+5X$-^EG[^W/]OE 7PM$6QY )\\@.^L#UF3,$N8
M3Y.57-H!?'*-JUVH=&:-2S/ZIS[422YR7<I*_;^Z(&C6E:YU9)%+([K:E;Y)
MW>S(7CR-=4Z>^M -:<GD@<AGA(I.++U#1R)WQY2=OC.W=9;L9$:K4\<?%ZNH
MV?''7< .C-A0=^3QQVW#1!Y_W"Y3)D\Z;ADJ Y.8W4#EQT%7-J_(XX[/().4
MQQVW"Q5=);II$,W:UYBU(964)QY+0R9WL-31_N[L8#&'6-JONW7UI""OZ_\N
M=8++[2TM-&<UM[?LWI%[#AM=3A[N#ZY4LX"-J8ZC:]H+OKG%5,X)']UP=JCH
MGSCBLM!"K6/ C^8N5QVV0*"T0J!Z8L=*W3+8A>],4?NZZ06[MN6]4'R: !UZ
M8D/%<Z6G]K7==JP4NS/*NS&6=VLL=5.S+1<"=ZTJ[CT(1@'__$]NW^&;'./-
MO@!>7=K(L=SB7(Q28N7J4XSN^Y)8ZV^3GV+20W#77^S]S]6KTO]^]]R1YWL)
M!NE^G0[K-6K0A"ZT00$:T.4]5)D]DNW8XKHXHG[XH&S8JS4>ARF8P EH7Z2X
ML3(!B.[=Q+NGBE\P=WF[UAIY?9H23YK254+8^U)B9^/5AJUE!ZP$"8!,_:=U
M9-KJ:5?=9[69'52H%\HRY#-O,O%I#I%N_-3<_@]=%9T!NVQUV17/10KK/VU"
MN3DT#XNBV196FO5<S!G6MVYRP[P'(QG4#:CD_ID*MRK# FB#:)I&#.NX]Y4>
M?%]*%>K7U:(#4-\&RAO$-*N5Z\]8C;YV2HTR/O:DTAR-UH,!Z$DU*W7&>O)'
M)_5$(Q9?8)7Z<C2:6T2W'3)P.J\R?Q8JLVXAJ5-J9 ^'Q#'W[4>4:M2TBS]C
M]?G[8M1G:*O$4H_;X-/DXOA^<&>5@!JJ=:BE_DO0JK_;%,AE"SG5"SS[,IBI
MVKY'W-6MH!X7R9;HY/%YNZOR[C3G>D)67KTXF0&XOCZ- 3BZHEL&L6I7#UO(
MOYV5>G=<SLGS7I3ROGS9GJ#X: KM9TM70E),AY@.3S5W6<AJ(9>[KN++'.S5
M9%[UOLV%7IU5>M7M_*IP#N%3308[$BD7AEU$?)\VO0-GNSL(^8[8-,:8QN!>
MHW-MY\(1,]W#<.]+F+A^#N_ZCJ7M??Y/?#JFR]UFDYJ7%S%?/D>/O?Y<F83I
MJ#0R,U#Y"K)#C.& #(W!SL:K95)4A0JG*3"?@31HD(,Y%H1K]IX>O]D^:/;L
MD=HG;UTOX.?</_/#.*;QSTH8E!LK%WHGL;,2?WND;A0K%(@]66BFK';JO6RF
M/,PY_4]$E]EDSNJ)U[W!4][_.*?T%^UC/+'<U4AG;7OZ.E2'%2.=IH[P?M)!
M[]_@*? U=N'LP;#=C66[G,=^*H95:>/<CNTN9^\?%=OC?BK1=O<(K=2NW!K2
M;L+@)-6#QFOV2D]YLU_VV5/[*O/I51=O#MUJ6K=%L3UM(743MN/2U2*:6O>0
MC79C=(@S YR%36W[2THGS,Q;EJ;\V@U#(^W,V9'U9,AH.K&LNN=?2#.SHYGY
M31H8:6"JZ.1A3MLX&4;ZX) 822M#][JB2%J92[0RG0ICGFEDH(*1T>V?I94Y
MCI6I>X60M#*7:&6Z%\L8EHQECF=E/C?0>2(MST5:'M,F9K=,CV9H1*]][JJT
M/3O:GIONVIX!R)%.M&'=W?_2]IQ\P1M2'5LUR<"R#I;JG,2V$77H$-N1M>@C
M6;<O)[%NY5ZO(%S>4=#JW9,[M>57!&<#=4[7,K4?W-6Z8W2[WJ:;M8IZ[$(6
M^\H+)A3IDYTG?&(NZ[9%-+WN70D[TB$[ 7&!$(9Y0&%OV$ W >6YVX7EH^"D
M+U@XT^P0JM0.QI\HWEZRFL,64,(VB6T<XOS\BE3@WN_41##(\'#M'U4<A^B8
MEZ[C7"S(\NF(%^HFB&4Z1-</> ''I7B*5O)7([8^  =1][RD3B!_P(RJ_4(M
M'4#-LSXOTP$81+=4,M0.5D$_.9\OVP$<NJIT:4BW7YBEX:]YGN9E&O[AT(:X
MWY)F7UI B;0T^Y=G]B_4[MLFF/U#E /:P65I]B72TNQ+L[_Q(([KRS3[EJT3
M?2##?6D")=+2[E^>W7_Y\C+MOFD0[2"K?^W@LC3[$FEI]MMD]BL(CCB(]@QN
M5:KF!#8? =]^@6J&WSLRMBMX7R:WC[8'[9BR>W(C?N#[4!K&]@,M#J3&<]*5
MHT;9&RYT.9A@BFEJGJ _(*IF$%O?_>SJTS&Y"L:G",'/@O.ZHQ-KCR/+NT^@
M@4-LJ^[-$DUNFCV:"JRQ^<W>B,'O?5C=BUC]UH<7BD^3A$8]<8$#,\=:A2T'
M3]]?T2)$LNL^7H6SN1L\*A&]]^A#K+B^KX1I$B=N@-*3W]*G@%-SQZ!8$S<8
M4^7!2^[8_1X1_=_4B^B,71,23I7KFU>*HYE]Y<N=%Z/7]L;*/ KOO0G%:T3<
M1'$#!1[VDD<EO@M3?\+ 2&.JN$KR$()8T;GBSN$==PQ3A J]=_W436#..PHS
M1FP F#1Y[($<?J,39>H% )3G^@!DG$0I J,\"R,%+QN9X,TC4^HF:41_5CQ$
M9$*_PW<PM(<P/P0,@C@)Q]\(_#KV4X:YF!<_(J+%T%P&'%VS7\3*&$@.C^",
M,&HT]A"1 %032.\SLG#T8S!',5*EN"[%O8VH()R@$ ,$;TYQ)\AF_AO B?/G
MH\\C#QB 3XW!?&&P,?'\E%T%1>_QC;[R%964O57,76(.*=_: BR/*$3>":(2
M Q 1Y2PIT0D?%X*R@#RCF3*B8Q?Y-TV1QH(W,-T4!#JXA8DAJ'-]RB#8/E(&
M"7#8"^9I G,S4/"MJ>M%"K*$XCBNDKVNJR^F'L#9 XKTV*?\%^V%$L[1#^!%
M-0*L^ XF 6U#'HFOQKX;Q]X4' %[UF/7W404QD/Z490'.NF?N;YWQG"]X^JZ
M;(MRT5Y_,YHR@]E!4I49=6.0THD"EJ@D4NF<<3Y.V8@H'!'ML9_8DTP!X4N0
M/ IFB4$0T7D8,?,PARE#4)2[*$QO[T!3YQZ//_K*-9C6\9T+!@(-:&G"$4T>
M* V$#8WG=,Q 7AXT1G$$&0QO Z .P +JRC(,!@)H%E[%A$/C.&"T$VYR ,X0
M!F! Q%)TVX((O.KAAS<H(<+,+MQA[:V/_LX.R]$:OHTZ@-LU7TD#]2K?9484
MO.&'L-B)K[<IUT1Y29171'E#E+=$^94HOW&?\Z_"[]ZY$VXKP+NL*1B<%6%R
MT5YB>E<$VEM:2_VL_-DYO>V*F?W(G>-K.N8*.F#ZJ9-R\*G$H3]1M(&*IW^*
MH!"])F8$XW V@VB AZ089_^HJ7CV(#Y*,)K]T3;[\!8X6/XF8<D1N.E;#[(7
M#"XFH-3C1-@*'@?SV-\+[BD,' F?[<5YG S6(P[1U5.( R:9'?E<F(N'.P\2
M(I8Z^52D)-E@$*//TP@"C1A#&?Q34TUVL"E+;7+T-H7?990YH*OSS]Q'#*"R
M/(3%14C)!'@,/[!P.:>YQ6ANL6=XQI(9SA\'1%/5!?KQ&4O!$;R5QV("ZAP,
M-D1?5V:>[V.X_N#R "F:9.'1\G64C^=@7;M@13=:RYNSM)9G9Q7+UN_C. E1
M$36-::*Q:/W&D#:@NH#5&/G>N#!"H%V*#4^K T-) X_KVX)!Q""F*!WDZLWT
M4L_L(J_IP/O,?@:4%4'&E$[8>*RZ\]V;0;;B/X)UM?J#3)T)>QB>877&A\AC
MN=#$B\=ARB:$V1$<, ^LJ.&RI$P #\$4#6)FZ?*R@<"XK[S!<A(#B=4YP%"S
M="X,*#=":Q'%7X4EO,GM2MG8;GR]SR H6=*;DB4''Z%XLQF=>)P$PJ9B'92(
MD!!+%DL\='@$>>?>4U8#6RP((?T-K0\L4$2*_"&\Y\:XX'].50I.(T-B@J-A
ML1BS1==7F.\8FG8!,#R)UCC):D$P< 3!;ICP9)/56 AC-7-2R\0OO-JR)/RH
M#XAAJU4<P"H9\7VKKY4]@4C,MWN#G119/8DA/>,\:FTHI@]J6R-MJ!)[8.U@
MC32S;YML?HPTJEHCO>\T:HRRN.<TQJ@H;7,=JV@ AN  G"HDWVH9..K+UD&I
M9!F6N6(/,9RM8R@6JBOKW$[=(/)CH+REHRAUHT?%9G(\(!M,TXC>NISV2>2R
MU01Q5?J'OV[>*.__OR^<$;QJ]S@;A;[RZH_WRI]?SJ!6UXFP2!BBP7I#%!1Z
MDM!@K5DR-)/8SK"4.JXHB6([9#BPE85 .!>1LN*N'Z2O7.<ZZ3^2<D2@:^O
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MI]:N&BEX/Y)-JF19WGC/MGR6DUSVERN0!"5<0( !0,G:O_[KGAD\"9(  3Y
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MBB7JZ/Q^('@!@!SFBM6A_>$LU?QZ%B9P:G&+B2V.E7?C3%5:X"JW7^;>2Q
MA*>'8!S$-EI.2V:7DCK]F%>:7C7Q$G-8BA!9=$61,E11,MZ;V^[D O>N/7=A
M+G8^TVMCT#I**6 !K8R8:C69\U10B6S(RS0H.GK3.&MDE+P?O,JRI-8(91I!
MTY4E3.4R8)@R,;-=&DTM #N(UJI\&996EC!JX2ZV!G$*RDG*Y(A\V*4,X#K4
MH-,VH,A@#>S$&B@%FR4\GA/]R\*EF"\5PW,$8B7,\NR*7@>"C)+F(]-9JPKC
M7-_<DK)GA!6(A"E@&,?A+I"1XSM3=^R">*<'ZC\7(!-EJRI8CLEP+NRS8H$4
MAH2%JP4\K(3?:+"K=<E(J@J-60E6X-%Q$,5L!(!S%DRRPI8T\["</*"E:=5T
M_J4?@)P=+P"-0+:TYBLL &BP<*,'=MU#JR7F+0(;JWC"*6X_L[,2KY$>'&^2
M%"HLDX)OS8J;$%K>$$"9.*.X-.^P^[K>?6NJVW%[/"?,5Y_N^1)5C6QEKEJN
ML9>I.I?Z^0JV,KP5A)4[!';CAF1.MO6JE(A"I$A2Z+9P]F0J"14\!;TD&X<6
M]1W3V,\D30L0,@]HT'Q?^*.'+%UEPW[(7^%^[*E!VV>"- 6T1FWZ9G!RVI<8
MH:"8LBW:V)0&(X^EGC*U1<K[(C^D,Q#^R\H<0<DT+C61I%F1%)+\N%I9%K.*
M#T6MH3 957,P>7.$)8=#ATY&%:.7.@W(='/#*[FINZ=/?>;9F<.F<W9ZGPNG
M7RIN!'A<C'D\Y;*/(RJ1[6/9EV&FO@Q67*ULM]ML E:YG&E7_H*>=*C?%L9B
M#NXDYI?=,C+],6?B).KC2T,GEB4MA4KZ@7_AS.9>\.PX_)#F(4V4^;EM2IF_
M>(_YL>A+*1E_587D:I8Z>,E+<P[<6@TN_Q#+^>-X:Z)0&OJ"/V<V5[NS\X0I
M0O\%)=30UD56Y2M+26)%N5H*2A(.KA ]VU:?JQ.C6!%8_FJS^J]+2C>+V2_=
MKD>L20/*-FH$HBPJB#<,D%PZ/HO>I^4EV*54_$H%G\H8"H7.5?P&A*L=G?UB
M5YK4,5QA#(%WS5&L; C(Z^"VC8;1W5*'?]:RN=8_5)%EV_P]O^D(8*?[T<*+
MCR9*[X"V3@.9#9*ZEM:7]Y_'SW-D7$S#]&GA$M?G%S9C1@-:X!N%W#WO^+-T
M_U*X+0N3!\8+2[6D:A6I*ODU$QFL6L32V 6?;!'-6E7KAN3ZDM KF4 89PR5
M\Y\J$E%T7@4'J\J5?IBI>_!Q#,<*7ORP*7.=BK!M4@X_[/0K( 4UT>080>N)
M?<JU:/PE(BAIJ\(BPA"DE[*1+P/*@KP/QS7%DGZ3$EG9M4<MT@HELA;)@^'Z
M*K_T8$H 9Z4*JJ9*PU*E0(KGLL&2H)K9)Q3/W#S):PETYNS*IOPS);VA+2H7
MW!ZYOP^=>SMF_,L'X.I+XF>F'^0X:BD0J+BCV.JI@I$W9T!%P4N=K'0T]>:C
M'P^@N:=HI3#<.SX6-F5?3V9@=\/$S%F859U^3)IN.:QU#P 8.>$C8&T7MDD]
MCTQ1:AX @DV2BP*R@<53BM%+UP3C%2D7!H\1HQM?TW76LJ'(\2RZ"4$*N.#)
M9#33;7.7]E?Q^HU8OD\QL^D5L6IVFK;OLYYB> B4&9"Y>ZXH\U1YX64MOYM7
M;'Z:>O.<ZN6<"2/N,L):P]E5&L$*5CKS'S%YGNCXTP4>:'BCG)0=Y%6\V&NL
MH N;GVYJ6M\V\"_^F\:?X>WJ'=U[3*'!_*"D%U5?-D)#8V']%%VI475/FNV=
ML7__?A%=W-OV_(>WZ9W(^[3]873E3WYQ)BC,KY"MZ47Y6S?"7,%%Z'P%<-YX
M0/>?__,_4#/]>S+6.S@,?D-1_B&[7__(N['=^E\<O&:$,=_8D1O]Z@<CY%K4
M0=]C)T#X.O#'\"MZ,YG.04/8X8\OSO2G%^^ "7%77DCBA2C% 6Z8"]&Z4,07
M/Q>-GKR14S:"&M,E9QZ5K)65A@TS@K*WLY:N%7Q4J_5K8E9)EUJUOEP]RCA
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MX2E8>!-AY*"'WP&%>@*Z/(4K<CQ/L&$5Z!\1@E"8VRY^*<0@4:*I$PIV>H.
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MPI]8W'\!8UD-S1+6$$7X'ZP@R\MOPI;.UWNEN2E %8:ZR/9H/U'*EQ3N+,L
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M@]68KD@OV,O$A3S">2W[=HW26TFK'<B:HY=N_5QS1Y;OX3/Q6*>R\0*44QC
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M+FWF84*O2H2WTF[TP(39![P.^_T!.-@&P? !D'W/:/N.$L'AYI<-1 EG[!X
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MY2O?+;E'L]"C %W/: C 9S"D0[5_)N%!/:9>*( :GC%3Q_Z&+ 5:R2)D 4E
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M+\3FI.4W^*^!!]BU.+U497?!^4$H%& HR8SWRE$9_(H@2B((V-USQ15R(7Z
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M!G[71WQS +H%O<7!?FC0=Z8BK@#][]]_&X6>^P/^+_SY_P%02P,$%     @
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M=XT5,CP@8E@?@MA,6RO3^6JE0!"(K'H^4U:?U:56HS6@&ZQ6F*GB_0^47&A
MA*P^Q*R5]@GK$XQX,5^N:TV$OH0PR)!G/TV<C>MMZ=YW0 2M/D2M+U<POK3E
M]!M$BO%\>1EY8.7-U4R]&DU@_-5X)SHD!^GU4,4,$_&L_P[[A>>+I.K,+J]]
M]#W$EV/?4T?6@ AG?1S/KBY6,/HQ^MK7>L?47I,.9FH\( )?J=18>9/^5J/9
ME,J2U[MW2^S(2@1,D5Q9>1-W6>^XH"3-+&F((,I+G1N0),FA66P3H?0EDVZ
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M+6PG^$/;NK<=.T!=?+,@1'W[2+HC--G T1//9%"K+2%43( /+#A_Q'TL$=\
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M]\0)ETWLTI3/8>S^F_VGH+2E&F8?F59"K[XR+10'PV0UQL9S/24-=F#.*>G
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MZ?$LNKV[^"]GM__K)=OVW3E^LB5=,5L)A4K!2\P6O?3Y=U"P2[XZ<#GS<FG
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M4NN$SQ]J*5IYOV89DPEH^PB+H',7$GD1?('.Q^\FTRE=4YQ=H<_CT>+K#"K
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MVF#*;J*)A*TV8<)[:'Q)ZYS1@B=*;YZM@L7.$W*8$E06!<'FB^MY-,6?WCY
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MFXE_=#V1F8150]3.MZL;8GMF:L6/::WP6<XH::ZK'GRI5XMK'$7(W>T3>A3
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M_F*4]J8,%)/67(WKC4+3/%LZ3#N5:D"9!'LJ^O,731;5Y0QSA@^SQI OX/G
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MFP2.'Z0/$_>6_XK#-*O3%(4[""Z><O_("GK+WH;D5&>O+]1\S; )D+4L40-
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M)$^&*@,[\+!,A)^$F40XYJR4U>16[-H)'A )_3UJAM9D4IJBK1]$M #JLU)
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MK)@DQD7B(1B%HQNTN4-!]<18**(['!I@*OGPQ2K]U$28)E_ZQ$?RDR"2RN*
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M,>MYP#I+.C.ZKFY[.H^_5)->'8'7&=*GOHLE6/=6$0ID&T!UVSI/NE0N_1E
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M9 :#3&LL)OH25=&(_M;'FTS[SL\60P>!>83RZNE.>U/3<HN'VB!TS A]F6*
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MRWYASM5)6$T34AMU+LV4""DO::9:X(0"+IN!:^/23 V"P _Z/EX0+7;!#Y/
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M$0 0              "  0    !C=FTM,C Q-C Y,S N>&UL4$L! A0#%
M  @ J(2+2^'L;_#Y%   WOX  !               ( !2#0! &-V;2TR,#$V
M,#DS,"YX<V102P$"% ,4    " "HA(M+O/2/2U(2  ":UP  %
M    @ %O20$ 8W9M+3(P,38P.3,P7V-A;"YX;6Q02P$"% ,4    " "HA(M+
M54"^/$H;  #UD0$ %               @ 'S6P$ 8W9M+3(P,38P.3,P7V1E
M9BYX;6Q02P$"% ,4    " "HA(M+^B!2/FMB  "5S04 %
M@ %O=P$ 8W9M+3(P,38P.3,P7VQA8BYX;6Q02P$"% ,4    " "HA(M+/5HS
M_IT]   B!P0 %               @ $,V@$ 8W9M+3(P,38P.3,P7W!R92YX
8;6Q02P4&      8 !@"$ 0  VQ<"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
